PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ozaki, M; Wada-Katsumata, A; Fujikawa, K; Iwasaki, M; Yokohari, F; Satoji, Y; Nisimura, T; Yamaoka, R				Ozaki, M; Wada-Katsumata, A; Fujikawa, K; Iwasaki, M; Yokohari, F; Satoji, Y; Nisimura, T; Yamaoka, R			Ant nestmate and non-nestmate discrimination by a chemosensory sensillum	SCIENCE			English	Article							KIN RECOGNITION; HYMENOPTERA; INSECTS; ODOR	In animal societies, chemical communication plays an important role in conflict and cooperation. For ants, cuticular hydrocarbon (CHC) blends produced by non-nestmates elicit overt aggression. We describe a sensory sensillum on the antennae of the carpenter ant Camponotus japonicus that functions in nestmate discrimination. This sensillum is multiporous and responds only to non-nestmate CHC blends. This suggests a role for a peripheral recognition mechanism in detecting colony-specific chemical signals.	Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan; Fukuoka Univ, Fac Sci, Dept Earth Syst Sci, Fukuoka 8140180, Japan	Kyoto Institute of Technology; Fukuoka University	Ozaki, M (corresponding author), Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.	mamiko@kit.ac.jp		Wada-Katsumata, Ayako/0000-0002-2895-1102				[Anonymous], 1971, INSECT SOC; Breed M.D., 1987, P243; CROZIER RH, 1979, BEHAV ECOL SOCIOBIOL, V4, P217, DOI 10.1007/BF00297645; GETZ WM, 1987, INT J NEUROSCI, V32, P963, DOI 10.3109/00207458709043353; GETZ WM, 1994, BEHAV NEURAL BIOL, V61, P191, DOI 10.1016/S0163-1047(05)80075-5; GETZ WM, 1982, J THEOR BIOL, V99, P585, DOI 10.1016/0022-5193(82)90212-0; Holldobler B., 1980, Evolution of social behaviour: hypotheses and empirical tests, P35; HOWARD RW, 1993, INSECT LIPIDS: CHEMISTRY, BIOCHEMISTRY AND BIOLOGY, P179; Isidoro N, 2001, MICROSC RES TECHNIQ, V55, P350, DOI 10.1002/jemt.1183; LACY RC, 1983, AM NAT, V121, P489, DOI 10.1086/284078; Lahav S, 1999, NATURWISSENSCHAFTEN, V86, P246, DOI 10.1007/s001140050609; OBIN MS, 1989, ANIM BEHAV, V38, P430, DOI 10.1016/S0003-3472(89)80036-3; Tegoni M, 2004, TRENDS BIOCHEM SCI, V29, P257, DOI 10.1016/j.tibs.2004.03.003; Vander Meer Robert K., 1998, P79; VANDERMEER RK, 1989, J CHEM ECOL, V15, P2115, DOI 10.1007/BF01207442; YAMAOKA R, 1990, PHYSL ECOL JPN, V27, P3152	16	307	332	3	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2005	309	5732					311	314		10.1126/science.1105244	http://dx.doi.org/10.1126/science.1105244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	944SP	15947139				2022-12-28	WOS:000230449800049
J	Que, LG; Liu, LM; Yan, Y; Whitehead, GS; Gavett, SH; Schwartz, DA; Stamler, JS				Que, LG; Liu, LM; Yan, Y; Whitehead, GS; Gavett, SH; Schwartz, DA; Stamler, JS			Protection from experimental asthma by an endogenous bronchodilator	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN S-NITROSYLATION; AIRWAY HYPERRESPONSIVENESS; CYSTIC-FIBROSIS; NITROGEN-OXIDES; EXHALED AIR; NITROSOTHIOLS; DISEASE; INFLAMMATION; INHIBITION	Mechanisms that protect against asthma remain poorly understood. S-nitrosoglutathione (GSNO), an endogenous bronchodilator, is depleted from asthmatic airways, suggesting a protective role. We report that, following allergen challenge, witd-type mice exhibiting airway hyperresponsivity have increased airway levels of the enzyme GSNO reductase (GSNOR) and are depleted of lung S-nitrosothiols (SNOs). In contrast, mice with genetic deletion of GSNOR exhibit increases in lung SNOs and are protected from airway hyperresponsivity. Our results indicate that endogenous SNOs, governed by GSNOR, are critical regulators of airway responsivity and may provide new therapeutic approaches to asthma.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; US EPA, Expt Toxicol Div, Res Triangle Pk, NC 27711 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; United States Environmental Protection Agency	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	STAML001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [K08 HL004171-05, K08 HL004171, HL004171] Funding Source: Medline; NIEHS NIH HHS [ES012496, P01 ES012496-010004, P01 ES012496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES012496, Z01ES101945] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALVING K, 1993, EUR RESPIR J, V6, P1368; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; QUE LG, UNPUB; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/ajrccm.165.7.2105032; Whalen EJ, 2000, HYPERTENSION, V36, P376, DOI 10.1161/01.HYP.36.3.376; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xiong YL, 1999, J IMMUNOL, V162, P445	25	246	264	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1618	1621		10.1126/science.1108228	http://dx.doi.org/10.1126/science.1108228			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15919956	Green Accepted			2022-12-28	WOS:000229827000054
J	Granich, RM; Oh, P; Lewis, B; Porco, TC; Flood, J				Granich, RM; Oh, P; Lewis, B; Porco, TC; Flood, J			Multidrug resistance among persons with tuberculosis in California, 1994-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; UNITED-STATES; TRANSMISSION; OUTBREAK; INFECTIONS; OUTCOMES	Context Between 1994 and 2003, tuberculosis (TB) cases in California declined 33% (4834 to 3224). However, in 2003 California reported the largest number of cases in the nation, and over the past decade the proportion of cases with multidrug-resistant tuberculosis (MDR-TB) has not decreased. Objective To describe the magnitude, trends, geographic distribution, clinical characteristics, risk factors, and outcomes of MDR-TB cases reported to the California registry of Reports of Verified Cases of TB. Design, Setting, and Cases Analysis of 38 291 TB cases reported from all 61 local health jurisdictions in California during 1994-2003. Multidrug-resistant TB was defined as resistance to at least isoniazid and rifampin. Main Outcome Measures Results of univariate and multivariable analyses of MDR-TB magnitude, trends, geographic distribution, clinical characteristics, associated factors, and outcomes. Results Of 38 291 reported TB cases, 28 712 (75%) were tested for resistance to at least isoniazid and rifampin; of these, 407 MDR-TB cases (1.4%) were reported from 38 of 61 California health jurisdictions (62%); the proportion of MDR-TB cases did not significantly change over the study period (P=.87). Cases of MDR-TB were twice as likely to have cavitary lesions compared with non-MDR-TB cases (P<.001) and were 7 times more likely to have reported previous treatment for TB (P<.001). Of MDR-TB cases with outcomes, 231 (67%) completed therapy, and those with MDR-TB were significantly less likely to complete therapy than those without MDR-TB (P<.001). Multivariate analysis identified previous TB diagnosis, positive acid-fast bacilli sputum smear results, Asian/Pacific Islander ethnicity, time in the United States less than 5 years at the time of diagnosis, and outcomes of "died" and "moved" as factors associated with MDR-TB. Conclusions Multidrug-resistant TB, an airborne disease with limited, costly treatment options, persists in 1% to 2 % of all cases despite California's control efforts. Local and global TB control efforts are needed to prevent the further development and spread of MDR-TB.	Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA; Calif Dept Hlth Serv, TB Control Branch, Sacramento, CA USA	Centers for Disease Control & Prevention - USA; California Department of Health Care Services	Granich, RM (corresponding author), Off US Global AIDS Coordinator, 2100 Penn Ave NW, Washington, DC 20522 USA.	granichrm@state.gov	Lewis, Bryan/AGI-2140-2022	Lewis, Bryan/0000-0003-0793-6082				Agerton T, 1997, JAMA-J AM MED ASSOC, V278, P1073, DOI 10.1001/jama.278.13.1073; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; *CA DEP HLTH SERV, 2001, REP TUB CAL 2000; *CDCP, 1993, JAMA-J AM MED ASSOC, V269, P978; *CDCP, 1990, JAMA-J AM MED ASSOC, V264, P173; Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-1159OC; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Granich RM, 2001, INT J TUBERC LUNG D, V5, P53; KOO D, 1995, WESTERN J MED, V163, P441; Lobato MN, 1998, PEDIATR INFECT DIS J, V17, P407, DOI 10.1097/00006454-199805000-00012; Lockman S, 2001, CLIN INFECT DIS, V32, P373, DOI 10.1086/318489; MILLER A, 2003, SUBSET SELECTION REG; Moore M, 1997, JAMA-J AM MED ASSOC, V278, P833, DOI 10.1001/jama.278.10.833; NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Peter CR, 1998, WESTERN J MED, V169, P208; Rajbhandary SS, 2004, INT J TUBERC LUNG D, V8, P1012; Raviglione MC, 2001, ANN NY ACAD SCI, V953, P88, DOI 10.1111/j.1749-6632.2001.tb11364.x; Ridzon R, 1997, J PEDIATR-US, V131, P863, DOI 10.1016/S0022-3476(97)70034-9; RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282; *STAT CA DEP FIN, 2003, CAL CURR POP SURV RE; *STAT CA DEP FIN, 2002, REV HIST CIT COUNT S; Viallefont V, 2001, STAT MED, V20, P3215, DOI 10.1002/sim.976.abs; BAYESIAN MODEL AVERI; 1991, MMWR MORB MORTAL WKL, V40, P649	30	59	63	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2732	2739		10.1001/jama.293.22.2732	http://dx.doi.org/10.1001/jama.293.22.2732			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941802	Bronze			2022-12-28	WOS:000229643700021
J	Alexapoulos, GS				Alexapoulos, GS			Depression in the elderly	LANCET			English	Review							LATE-LIFE DEPRESSION; PRIMARY-CARE PATIENTS; RECURRENT MAJOR DEPRESSION; LATE-ONSET DEPRESSION; GERIATRIC DEPRESSION; EXECUTIVE DYSFUNCTION; WHITE-MATTER; RISK-FACTORS; SUICIDAL IDEATION; HEALTH-CARE	In elderly people, depression mainly affects those with chronic medical illnesses and cognitive impairment, causes suffering, family disruption, and disability, worsens the outcomes of many medical illnesses, and increases mortality. Ageing-related and disease-related processes, including arteriosclerosis and inflammatory, endocrine, and immune changes compromise the integrity of frontostriatal pathways, the amygdala, and the hippocampus, and increase vulnerability to depression. Heredity factors might also play a part. Psychosocial adversity-economic impoverishment, disability, isolation, relocation, caregiving, and bereavement-contributes to physiological changes, further increasing susceptibility to depression or triggering depression in already vulnerable elderly individuals. Treatment with antidepressants is well tolerated by elderly people and is, overall, as effective as in young adults. Evidence-based guidelines for prevention of new episodes of depression are available as are care-delivery systems that increase the likelihood of diagnosis, and improve the treatment of, late-life depression. However, in North America at least, public insurance covers these services inadequately.	Cornell Univ, Weill Med Coll, White Plains, NY 10605 USA; Weill Cornell Inst Geriatr Psychiat, White Plains, NY 10605 USA	Cornell University	Alexapoulos, GS (corresponding author), Cornell Univ, Weill Med Coll, 21 Bloomingdale Rd, White Plains, NY 10605 USA.	gsalexop@med.cornell.edu		Alexopoulos, George/0000-0001-5677-7001	NIMH NIH HHS [R01 MH65653, P30 MH68638] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH068638, R01MH065653] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aizenstein HJ, 2002, INT J GERIATR PSYCH, V17, P664, DOI 10.1002/gps.685; Alexopoulos G S, 2001, Postgrad Med, VSpec No Pharmacotherapy, P1; ALEXOPOULOS GS, 1993, BIOL PSYCHIAT, V34, P141, DOI 10.1016/0006-3223(93)90383-O; Alexopoulos GS, 2005, AM J PSYCHIAT, V162, P718, DOI 10.1176/appi.ajp.162.4.718; ALEXOPOULOS GS, 1993, AM J PSYCHIAT, V150, P1693; Alexopoulos GS, 2004, NEUROPSYCHOPHARMACOL, V29, P2278, DOI 10.1038/sj.npp.1300557; Alexopoulos GS, 1997, AM J PSYCHIAT, V154, P562; Alexopoulos GS, 2002, AM J PSYCHIAT, V159, P1929, DOI 10.1176/appi.ajp.159.11.1929; Alexopoulos GS, 1997, ARCH GEN PSYCHIAT, V54, P915; Alexopoulos GS, 2002, AM J GERIAT PSYCHIAT, V10, P98, DOI 10.1176/appi.ajgp.10.1.98; Alexopoulos GS, 2000, ARCH GEN PSYCHIAT, V57, P285, DOI 10.1001/archpsyc.57.3.285; Alexopoulos GS, 2002, BIOL PSYCHIAT, V52, P543, DOI 10.1016/S0006-3223(02)01468-3; Alexopoulos GS, 2002, AM J GERIAT PSYCHIAT, V10, P687, DOI 10.1176/appi.ajgp.10.6.687; Alexopoulos GS, 2001, INT J GERIATR PSYCH, V16, P553, DOI 10.1002/gps.464; Alexopoulos GS, 2001, AM J PSYCHIAT, V158, P835, DOI 10.1176/appi.ajp.158.6.835; ALEXOPOULOS GS, 1992, BIOL PSYCHIAT, V31, P591, DOI 10.1016/0006-3223(92)90245-U; Alexopoulos GS, 1999, ARCH GEN PSYCHIAT, V56, P1048, DOI 10.1001/archpsyc.56.11.1048; Alexopoulos GS, 2002, BIOL PSYCHIAT, V52, P164, DOI 10.1016/S0006-3223(02)01381-1; ALEXOPOULOS GS, 1990, AM PSYCHIAT PRESS RE, P249; Alexopoulos GS, 2005, CLIN GERIATRIC PSYCH, P233; Alexopoulos GS, 2004, COMPREHENSIVE TXB GE, V3rd, P609; ANSTEY K, 1995, INT J GERIATR PSYCH, V10, P265, DOI 10.1002/gps.930100403; Armer J M, 1993, Issues Ment Health Nurs, V14, P157, DOI 10.3109/01612849309031614; Ballmaier M, 2004, AM J PSYCHIAT, V161, P99, DOI 10.1176/appi.ajp.161.1.99; Bartels SJ, 2003, PSYCHIAT CLIN N AM, V26, P971, DOI 10.1016/S0193-953X(03)00072-8; Bartels SJ, 2000, AM J GERIAT PSYCHIAT, V8, P160, DOI 10.1176/appi.ajgp.8.2.160; BAUMGARTEN M, 1992, J CLIN EPIDEMIOL, V45, P61, DOI 10.1016/0895-4356(92)90189-T; Beautrais AL, 2002, SUICIDE LIFE-THREAT, V32, P1, DOI 10.1521/suli.32.1.1.22184; BERGER AK, 1999, AM J PSYCHIAT, V156, P1239; BLAZER D, 1987, GERONTOLOGIST, V27, P281, DOI 10.1093/geront/27.3.281; Blazer DG, 2000, AM J PSYCHIAT, V157, P1915, DOI 10.1176/appi.ajp.157.12.1915; Blazer DG, 2002, AGING MENT HEALTH, V6, P315, DOI 10.1080/1360786021000006938; Blazer DG, 2002, AM J GERIAT PSYCHIAT, V10, P515, DOI 10.1176/appi.ajgp.10.5.515; Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249; Brodaty H, 2001, J AFFECT DISORDERS, V66, P225, DOI 10.1016/S0165-0327(00)00317-7; Brown ES, 2004, BIOL PSYCHIAT, V55, P1, DOI 10.1016/S0006-3223(03)00473-6; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Butters MA, 2004, AM J GERIAT PSYCHIAT, V12, P387, DOI 10.1176/appi.ajgp.12.4.387; Butters MA, 2000, AM J PSYCHIAT, V157, P1949, DOI 10.1176/appi.ajp.157.12.1949; CALLAHAN CM, 1992, J GEN INTERN MED, V7, P26, DOI 10.1007/BF02599097; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Carney RM, 2003, BIOL PSYCHIAT, V54, P241, DOI 10.1016/S0006-3223(03)00111-2; CASTEN JR, 2004, CURR OPIN OPHTHALMOL, V15, P181; Charney DS, 2003, ARCH GEN PSYCHIAT, V60, P664, DOI 10.1001/archpsyc.60.7.664; Clyburn LD, 2000, J GERONTOL B-PSYCHOL, V55, pS2, DOI 10.1093/geronb/55.1.s2; COLLINS C, 1994, NURS RES, V43, P221; CONWELL Y, 1989, J AFFECT DISORDERS, V17, P189, DOI 10.1016/0165-0327(89)90042-6; Conwell Y, 1998, AM J GERIAT PSYCHIAT, V6, P122; Conwell Y, 2002, BIOL PSYCHIAT, V52, P193, DOI 10.1016/S0006-3223(02)01347-1; Conwell Y, 1996, AM J PSYCHIAT, V153, P1001; Cramer JA, 1998, PSYCHIATR SERV, V49, P196, DOI 10.1176/ps.49.2.196; Davidson RJ, 2001, ANN NY ACAD SCI, V935, P191, DOI 10.1111/j.1749-6632.2001.tb03481.x; Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175; Draper BM, 2001, AUST NZ J PSYCHIAT, V35, P626, DOI 10.1046/j.1440-1614.2001.00930.x; Drevets WC, 1999, ANN NY ACAD SCI, V877, P614, DOI 10.1111/j.1749-6632.1999.tb09292.x; Drevets WC, 2003, ANN NY ACAD SCI, V985, P420, DOI 10.1111/j.1749-6632.2003.tb07098.x; Duberstein P R, 1995, Int Psychogeriatr, V7, P183, DOI 10.1017/S1041610295001967; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Elderkin-Thompson V, 2003, ARCH CLIN NEUROPSYCH, V18, P529, DOI 10.1016/S0887-6177(03)00022-2; Erickson K, 2003, NEUROSCI BIOBEHAV R, V27, P233, DOI 10.1016/S0149-7634(03)00033-2; Farran CJ, 1997, J AGING HEALTH, V9, P316, DOI 10.1177/089826439700900303; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; Frodl T, 2003, BIOL PSYCHIAT, V53, P338, DOI 10.1016/S0006-3223(02)01474-9; Frodl T, 2002, AM J PSYCHIAT, V159, P1112, DOI 10.1176/appi.ajp.159.7.1112; GALLO JJ, 1994, J GERONTOL, V49, pP251, DOI 10.1093/geronj/49.6.P251; GATZ M, 1992, J ABNORM PSYCHOL, V101, P701, DOI 10.1037/0021-843X.101.4.701; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; GREENWALD BS, 1988, J AFFECT DISORDERS, V15, P61, DOI 10.1016/0165-0327(88)90010-9; Harman JS, 2004, J AM GERIATR SOC, V52, P809, DOI 10.1111/j.1532-5415.2004.52224.x; Harman JS, 2001, INT J PSYCHIAT MED, V31, P239, DOI 10.2190/Q3VY-T8V9-30MA-VC5C; HICKIE I, 1995, BIOL PSYCHIAT, V37, P151, DOI 10.1016/0006-3223(94)00174-2; Hickie I, 2001, PSYCHOL MED, V31, P1403, DOI 10.1017/S0033291701004731; JACOBY RJ, 1980, BRIT J PSYCHIAT, V136, P270, DOI 10.1192/bjp.136.3.270; Jansson M, 2003, AM J MED GENET B, V120B, P79, DOI 10.1002/ajmg.b.20016; Jorm AF, 2001, AUST NZ J PSYCHIAT, V35, P776, DOI 10.1046/j.1440-1614.2001.00967.x; KALAYAM B, 1995, BIOL PSYCHIAT, V38, P649, DOI 10.1016/0006-3223(95)00175-1; Kalayam B, 1999, ARCH GEN PSYCHIAT, V56, P713, DOI 10.1001/archpsyc.56.8.713; Kalayam B, 2003, AM J PSYCHIAT, V160, P2054, DOI 10.1176/appi.ajp.160.11.2054; KATON W, 1994, J AFFECT DISORDERS, V31, P81, DOI 10.1016/0165-0327(94)90111-2; Koder DA, 1996, INT J GERIATR PSYCH, V11, P97, DOI 10.1002/(SICI)1099-1166(199602)11:2<97::AID-GPS310>3.0.CO;2-W; KRAL VA, 1989, CAN J PSYCHIAT, V34, P445, DOI 10.1177/070674378903400515; Krishnan KRR, 1997, AM J PSYCHIAT, V154, P497; Krishnan KRR, 2002, BIOL PSYCHIAT, V52, P185, DOI 10.1016/S0006-3223(02)01349-5; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Kumar A, 2004, PSYCHIAT RES-NEUROIM, V130, P131, DOI 10.1016/j.pscychresns.2003.12.002; LEDOUX JE, 1993, ANN NY ACAD SCI, V702, P149, DOI 10.1111/j.1749-6632.1993.tb17246.x; Llewellyn-Jones RH, 1999, BMJ-BRIT MED J, V319, P676, DOI 10.1136/bmj.319.7211.676; Lockwood KA, 2002, AM J PSYCHIAT, V159, P1119, DOI 10.1176/appi.ajp.159.7.1119; Luber MP, 2001, AM J GERIAT PSYCHIAT, V9, P169, DOI 10.1176/appi.ajgp.9.2.169; Lynch TR, 1999, J AFFECT DISORDERS, V56, P49, DOI 10.1016/S0165-0327(99)00023-3; Lyness JM, 1999, J AM GERIATR SOC, V47, P647, DOI 10.1111/j.1532-5415.1999.tb01584.x; Lyness JM, 2002, AM J GERIAT PSYCHIAT, V10, P275, DOI 10.1176/appi.ajgp.10.3.275; LYNESS JM, 1995, J AM GERIATR SOC, V43, P216, DOI 10.1111/j.1532-5415.1995.tb07325.x; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Mayberg H, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P177; McEwen BS, 2003, BIOL PSYCHIAT, V54, P200, DOI 10.1016/S0006-3223(03)00177-X; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; Miller DB, 2003, METABOLISM, V52, P17, DOI 10.1053/S0026-0495(03)00296-8; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; MORRIS PLP, 1992, AUST NZ J PSYCHIAT, V26, P208, DOI 10.3109/00048679209072029; MURPHY CF, 2003, AM J GERIAT PSYCHIAT, V11, P1; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; Nebes RD, 2003, J PSYCHIATR RES, V37, P99, DOI 10.1016/S0022-3956(02)00085-7; O'Brien J, 1998, BMJ-BRIT MED J, V317, P982, DOI 10.1136/bmj.317.7164.982; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; Olin JT, 2002, AM J GERIAT PSYCHIAT, V10, P125; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290; OXMAN TE, 1990, PSYCHOSOMATICS, V31, P174, DOI 10.1016/S0033-3182(90)72191-3; Oxman TE, 2001, J GERONTOL B-PSYCHOL, V56, pP35, DOI 10.1093/geronb/56.1.P35; Palsson SP, 2001, PSYCHOL MED, V31, P1159, DOI 10.1017/S0033291701004524; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Reynolds CF, 1999, JAMA-J AM MED ASSOC, V281, P39, DOI 10.1001/jama.281.1.39; Robinson RG, 2003, BIOL PSYCHIAT, V54, P376, DOI 10.1016/S0006-3223(03)00423-2; Roeloffs C, 2003, GEN HOSP PSYCHIAT, V25, P311, DOI 10.1016/S0163-8343(03)00066-5; Romanelli J, 2002, J AM GERIATR SOC, V50, P817, DOI 10.1046/j.1532-5415.2002.50205.x; Rybarczyk B, 1999, BEHAV MED, V24, P181; Sackeim HA, 2001, JAMA-J AM MED ASSOC, V285, P1299, DOI 10.1001/jama.285.10.1299; Sajatovic M, 1997, PSYCHIATR SERV, V48, P1461; Salzman C, 2002, BIOL PSYCHIAT, V52, P265, DOI 10.1016/S0006-3223(02)01337-9; SALZMAN C, 2005, CLIN GERIATRIC PSYCH, P305; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Schulberg HC, 1998, ARCH GEN PSYCHIAT, V55, P1121, DOI 10.1001/archpsyc.55.12.1121; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; Sheline YI, 2000, BIOL PSYCHIAT, V48, P791, DOI 10.1016/S0006-3223(00)00994-X; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; SHULMAN KI, 1992, AM J PSYCHIAT, V149, P341; Simpson S, 1998, PSYCHOL MED, V28, P1015, DOI 10.1017/S003329179800693X; Sirey JA, 2005, AM J PSYCHIAT, V162, P184, DOI 10.1176/appi.ajp.162.1.184; Sirey JA, 2001, AM J PSYCHIAT, V158, P479, DOI 10.1176/appi.ajp.158.3.479; Sobin C, 1997, AM J PSYCHIAT, V154, P4; Teresi J, 2001, SOC PSYCH PSYCH EPID, V36, P613, DOI 10.1007/s127-001-8202-7; Unutzer J, 2003, J AM GERIATR SOC, V51, P505, DOI 10.1046/j.1532-5415.2003.51159.x; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; Waern M, 2002, AM J PSYCHIAT, V159, P450, DOI 10.1176/appi.ajp.159.3.450; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; West CG, 1998, J AM GERIATR SOC, V46, P49, DOI 10.1111/j.1532-5415.1998.tb01012.x; Whyte EM, 2001, AM J PSYCHIAT, V158, P2074, DOI 10.1176/appi.ajp.158.12.2074; Wiener P, 1997, AM J GERIAT PSYCHIAT, V5, P116; Wilson KCM, 1999, BRIT J PSYCHIAT, V175, P549, DOI 10.1192/bjp.175.6.549; WRAGG RE, 1989, AM J PSYCHIAT, V146, P577; Yaffe K, 1999, ARCH GEN PSYCHIAT, V56, P425, DOI 10.1001/archpsyc.56.5.425; YOUNG RJC, 2003, POSTCOLONIALISM VERY, P34; ZISOOK S, 1994, DIAGNOSIS TREATMENT, P419	144	1020	1071	5	170	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1961	1970		10.1016/S0140-6736(05)66665-2	http://dx.doi.org/10.1016/S0140-6736(05)66665-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	932XJ	15936426				2022-12-28	WOS:000229587800033
J	Nelson, MR; Liew, D; Bertram, M; Vos, T				Nelson, MR; Liew, D; Bertram, M; Vos, T			Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged >= 70	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COST-EFFECTIVENESS; RISK; EVENTS; PANEL	Objective To investigate the routine use of low dose aspirin in people aged ! 70 without overt cardiovascular disease. Design Epidemiological modelling in a hypothetical population. Setting Reference populations of men and women in the year 2000 from the state of Victoria, Australia. Subjects 10 000 men and 10 000 women aged 70-74 with no cardiovascular disease. Main outcome measures First ever myocardial infarction or unstable angina, ischaemic or haemorrhagic stroke, and major gastrointestinal haemorrhage. Health adjusted years of life lived. Results The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (- 389 in men, - 321 in women) and ischaemic stroke (- 19 in men and - 35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding. The results in health adjusted years of life lived (which take into account length and quality of life) are equivocal for aspirin causing net harm or net benefit. Conclusion Epidemiological modelling suggests that any benefits of low dose aspirin on risk of cardiovascular disease in people aged ! 70 are offset by adverse events. These findings are tempered by wide confidence intervals, indicating that the overall outcome could be beneficial or adverse.	Univ Tasmania, Sch Med, Discipline Gen Practice, Hobart, Tas 7001, Australia; Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; WHO, CH-1211 Geneva, Switzerland; Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia	University of Tasmania; Florey Institute of Neuroscience & Mental Health; Monash University; World Health Organization; University of Queensland	Nelson, MR (corresponding author), Univ Tasmania, Sch Med, Discipline Gen Practice, Hobart, Tas 7001, Australia.	Mark.Nelson@utas.edu.au	matt, peter/AFR-0434-2022; Vos, Theo/F-3324-2010	matt, peter/0000-0002-6855-3440; Liew, Danny/0000-0002-0131-623X				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Bonita R, 1997, STROKE, V28, P1898, DOI 10.1161/01.STR.28.10.1898; Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006; D'Agostino RB, 2000, AM HEART J, V139, P272, DOI 10.1016/S0002-8703(00)90236-9; *DEP HUM SERV VICT, 2000, VICT ADM EV DAT; Dunstan DW, 2002, DIABETES RES CLIN PR, V57, P119, DOI 10.1016/S0168-8227(02)00025-6; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hart RG, 2000, ARCH NEUROL-CHICAGO, V57, P326, DOI 10.1001/archneur.57.3.326; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Liew D, 2002, MED J AUSTRALIA, V177, P364, DOI 10.5694/j.1326-5377.2002.tb04839.x; Lilford RJ, 1998, BMJ-BRIT MED J, V317, P405; MATHERS C, 1999, 17 AIHW PHE; MCELDUFF P, 2000, 11 AIHW CVD; Meade TW, 1998, LANCET, V351, P233; Nelson MR, 2003, DRUG AGING, V20, P897, DOI 10.2165/00002512-200320120-00004; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; ROSS R, 1999, NEW ENGL J MED, V143, P683; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; *STEER COMM PHYS H, 1980, NEW ENGL J MED, V321, P129; Sturmer T, 1996, AM J EPIDEMIOL, V143, P683; Thrift AG, 2000, STROKE, V31, P2087, DOI 10.1161/01.STR.31.9.2087; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Unal B, 2004, CIRCULATION, V109, P1101, DOI 10.1161/01.CIR.0000118498.35499.B2; *VICT DEP HUM SERV, 1999, VICT BURD DIS STUD M; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1996, JAMA-J AM MED ASSOC, V276, P1353	31	44	44	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1306	1308A		10.1136/bmj.38456.676806.8F	http://dx.doi.org/10.1136/bmj.38456.676806.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15908442	Green Published, Bronze			2022-12-28	WOS:000229655700024
J	Aguzzi, A				Aguzzi, A			Prion toxicity: All sail and no anchor	SCIENCE			English	Editorial Material							ALZHEIMERS-DISEASE; SCRAPIE; PROTEIN		Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Heikenwalder M, 2005, SCIENCE, V307, P1107, DOI 10.1126/science.1106460; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; Prinz M, 2003, NATURE, V425, P957, DOI 10.1038/nature02072; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273	10	30	31	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1420	1421		10.1126/science.1114168	http://dx.doi.org/10.1126/science.1114168			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933188				2022-12-28	WOS:000229619300037
J	Rosenberg, R				Rosenberg, R			A medical mystery - Bradycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Connecticut, Ctr Hlth, Avon, CT 06001 USA	University of Connecticut	Rosenberg, R (corresponding author), Univ Connecticut, Ctr Hlth, Avon, CT 06001 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2337	2337		10.1056/NEJMicm040547	http://dx.doi.org/10.1056/NEJMicm040547			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930424				2022-12-28	WOS:000229446400010
J	James, RF				James, RF			Rectus sheath haematoma	LANCET			English	Editorial Material									Bexhill Hosp, Irvine Unit, E Sussex TN40 2DZ, England		James, RF (corresponding author), Bexhill Hosp, Irvine Unit, E Sussex TN40 2DZ, England.							BROTZMAN GL, 1991, J FAM PRACTICE, V33, P194; CASEY RG, 2000, IRISH MED J, P90; CERVANTES J, 1983, AM SURGEON, V49, P542; GALLEGS A, 1997, BJS, V849, P1295; Hecker R B, 1990, Tex Med, V86, P68	5	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1824	1824		10.1016/S0140-6736(05)66587-7	http://dx.doi.org/10.1016/S0140-6736(05)66587-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910957				2022-12-28	WOS:000229291600029
J	MacMillan, HL; Thomas, BH; Jamieson, E; Walsh, HA; Boyle, MH; Shannon, HS; Gafni, A				MacMillan, HL; Thomas, BH; Jamieson, E; Walsh, HA; Boyle, MH; Shannon, HS; Gafni, A			Effectiveness of home visitation by public-health nurses in prevention of the recurrence of child physical abuse and neglect: a randomised controlled trial	LANCET			English	Article							SURVIVAL ANALYSIS; MALTREATMENT; REABUSE; SAMPLE; CARE	Background Recurrence of child maltreatment is a major problem, yet little is known about approaches to reduce this risk in families referred to child protection agencies. Since home visitation by nurses for disadvantaged first-time mothers has proven effective in prevention of child abuse and neglect, we aimed to investigate whether this approach might reduce recidivism. Methods We enrolled in a randomised controlled trial 163 families with a history of one index child being exposed to physical abuse or neglect to compare standard treatment with a programme of home visitation by nurses in addition to standard treatment. The main outcome was recurrence of child physical abuse and neglect based on a standardised review of child protection records. Analysis was by intention to treat. Findings At 3-years' follow-up, records were available for 160 of 163 (98%) families randomised. 139 (85%) completed follow-up. Recurrence of child physical abuse (31 [43%] in the control group vs 29 [33%] in the intervention group) and neglect (37 [51%] vs 41 [47%]) did not differ between groups. However, hospital records showed significantly higher recurrence of either physical abuse or neglect in the intervention group than in the control group (21 [24%] vs 8 [11%]). There were no differences between groups for the other secondary outcome measures. Interpretation Despite the positive results of home visitation by nurses as an early prevention strategy, this visit-based strategy does not seem to be effective in prevention of recidivism of physical abuse and neglect in families associated with the child protection system. Much more effort needs to be directed towards prevention before a pattern of abuse or neglect is established in a family.	McMaster Univ, Offord Ctr Child Studies, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Sch Nursing, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Publ Hlth Res Educ & Dev Program, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University; McMaster University	MacMillan, HL (corresponding author), McMaster Univ, Offord Ctr Child Studies, Dept Psychiat & Behav Neurosci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	macmilnh@mcmaster.ca	MacMillan, Harriet/B-4530-2016	MacMillan, Harriet/0000-0002-1223-706X				Bavolek S.J., 1989, EARLY CHILD DEV CARE, V42, P99, DOI [10.1080/0300443890420107, DOI 10.1080/0300443890420107]; BAVOLEK SJ, 1989, RES VALIDATION REPOR; Boyle MH, 2001, J CHILD PSYCHOL PSYC, V42, P141, DOI 10.1111/1469-7610.00706; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Caldwell B., 1984, HOME OBSERVATION MEA; Cutrona C.E., 1987, ADV PERSONAL RELATIO, V1, P37; CUTRONA CE, 1984, J ABNORM PSYCHOL, V93, P378, DOI 10.1037/0021-843X.93.4.378; DePanfilis D, 2002, CHILD ABUSE NEGLECT, V26, P187, DOI 10.1016/S0145-2134(01)00316-7; DePanfilis D., 1998, CHILD MALTREATMENT, V3, P27, DOI [10.1177/1077559598003001003, DOI 10.1177/1077559598003001003]; FERLEGER N, 1988, CHILD ABUSE NEGLECT, V12, P41, DOI 10.1016/0145-2134(88)90006-3; FRYER GE, 1994, CHILD ABUSE NEGLECT, V18, P1063, DOI 10.1016/0145-2134(94)90132-5; HEGAR RL, 1994, J INTERPERS VIOLENCE, V9, P170, DOI 10.1177/088626094009002002; HERRENKOHL RC, 1979, CHILD ABUSE NEGLECT, V3, P67; LEVY HB, 1995, CHILD ABUSE NEGLECT, V19, P1363, DOI 10.1016/0145-2134(95)00095-P; MacMillan HL, 2000, CAN MED ASSOC J, V163, P1451; MACMILLAN HL, 1994, J CHILD PSYCHOL PSYC, V35, P835, DOI 10.1111/j.1469-7610.1994.tb02298.x; MACMILLAN HL, 1993, CAN J PSYCHIAT, V38, P436, DOI 10.1177/070674379303800610; Marshall D. B., 1999, CHILD MALTREATMENT, V4, P287, DOI DOI 10.1177/1077559599004004002; Milner J., 1986, CHILD ABUSE POTENTIA; Milner JS, 1989, EARLY CHILD DEV CARE, V42, P85; MURPHY JM, 1992, CHILD ABUSE NEGLECT, V16, P485, DOI 10.1016/0145-2134(92)90065-Y; Nelson G, 2001, CAN J BEHAV SCI, V33, P1, DOI 10.1037/h0087123; OLDS D, 1995, PEDIATRICS, V95, P365; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Olds DL., 1998, FUTURE CHILD, V3, P53, DOI [DOI 10.2307/1602543, 10.2307/1602543]; Quay H.C., 1987, REVISED BEHAV PROBLE; SINGER JD, 1991, PSYCHOL BULL, V110, P268, DOI 10.1037/0033-2909.110.2.268; WOLFE DA, 1993, CLIN PSYCHOL REV, V13, P473, DOI 10.1016/0272-7358(93)90043-L	30	106	107	0	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1786	1793		10.1016/S0140-6736(05)66388-X	http://dx.doi.org/10.1016/S0140-6736(05)66388-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	928SI	15910951				2022-12-28	WOS:000229291600023
J	Meinzer, U; Hugot, JP				Meinzer, U; Hugot, JP			Nod2 and Crohn's disease: many connected highways	LANCET			English	Editorial Material							RECEPTOR AGONISTS; IMMUNE-RESPONSES; INNATE; PATHWAYS		Hop Robert Debre, INSERM, Dept Paediat Gastroenterol, U458, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Hugot, JP (corresponding author), Hop Robert Debre, INSERM, Dept Paediat Gastroenterol, U458, F-75019 Paris, France.	jean-pierre.hugot@rdb.ap-hop-paris.fr	Meinzer, Ulrich/N-4282-2019; Hugot, Jean-Pierre/F-6594-2012	Hugot, Jean-Pierre/0000-0002-8446-6056				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432; Netea MG, 2004, EUR J IMMUNOL, V34, P2052, DOI 10.1002/eji.200425229; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Stehlik C, 2003, J BIOL CHEM, V278, P31941, DOI 10.1074/jbc.M300009200; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092	12	6	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2005	365	9473					1752	1754		10.1016/S0140-6736(05)66562-2	http://dx.doi.org/10.1016/S0140-6736(05)66562-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910938				2022-12-28	WOS:000229291600007
J	Sladden, MJ; Johnston, GA				Sladden, MJ; Johnston, GA			More common skin infections in children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ERYTHEMA MULTIFORME; HEAD LICE; ACYCLOVIR; MALATHION		Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Dept Dermatol, Leicester LE1 5WW, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester	Sladden, MJ (corresponding author), Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Dept Dermatol, Leicester LE1 5WW, Leics, England.	m.sladden@doctors.org.uk	Johnston, Graham/Y-2348-2019	Johnston, Graham/0000-0001-7494-0765				[Anonymous], COCHRANE DATABASE SY; ASTON R, 1998, HEAD LICE REPORT CON; Burgess Ian F., 1995, Advances in Parasitology, V36, P271, DOI 10.1016/S0065-308X(08)60493-5; BURGESS IF, 1994, CLIN THER, V16, P57; BURGESS IF, 1996, MATERNAL CHILD  JUN, P142; BURNS DA, 2004, ROOKS TEXTBOOK DERMA; CLORE ER, 1990, J SCHOOL HEALTH, V60, P212, DOI 10.1111/j.1746-1561.1990.tb05917.x; Develoux M, 2004, ANN DERMATOL VENER, V131, P561, DOI 10.1016/S0151-9638(04)93668-X; DODD CS, 2001, DATABASE SYST REV; FAWCETT HA, 1983, BRIT MED J, V287, P798, DOI 10.1136/bmj.287.6395.798-a; FREEDBERG IM, 2004, FITZPATRICKS DERMATO; HARPER J, 2000, TEXTBOOK PEDIAT DERM; Johnston GA, 2002, CLIN EXP DERMATOL, V27, P661, DOI 10.1046/j.1365-2230.2002.01098.x; Johnston Graham A, 2004, Expert Rev Anti Infect Ther, V2, P439, DOI 10.1586/14787210.2.3.439; Kane KS, 2002, COLOR ATLAS SYNOPSIS; Katz Joseph, 1999, Pediatric Dentistry, V21, P359; Ko CJ, 2004, J AM ACAD DERMATOL, V50, P1, DOI 10.1016/S0190-9622(03)02729-4; Maunder J W, 1993, Health Visit, V66, P317; McCarthy JS, 2004, POSTGRAD MED J, V80, P382, DOI 10.1136/pgmj.2003.014563; Meinking TL, 2002, J PEDIATR-US, V141, P665, DOI 10.1067/mpd.2002.129031; Nash B, 2003, BRIT MED J, V326, P1256, DOI 10.1136/bmj.326.7401.1256; ROBERTS C, 1988, PHARM UPDATE     JUL, P240; Roberts RJ, 2000, LANCET, V356, P540, DOI 10.1016/S0140-6736(00)02578-2; *ROY COLL PAED CHI, 2003, MED CHILDR; Royal College of Paediatrics and Child Health and Neonatal and Paediatric Pharmacists Group, 2003, MED CHILDR; SCHOFIELD JK, 1993, BRIT J DERMATOL, V128, P542, DOI 10.1111/j.1365-2133.1993.tb00232.x; Sladden MJ, 2004, BMJ-BRIT MED J, V329, P95, DOI 10.1136/bmj.329.7457.95; Strong M, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000320.pub2; Stulberg DL, 2002, AM FAM PHYSICIAN, V66, P119; TAPLIN D, 1982, JAMA-J AM MED ASSOC, V247, P3103, DOI 10.1001/jama.247.22.3103; Taplin D, 1986, Pediatr Dermatol, V3, P344, DOI 10.1111/j.1525-1470.1986.tb00538.x; TATNALL FM, 1995, BRIT J DERMATOL, V132, P267; Usha V, 2000, J AM ACAD DERMATOL, V42, P236, DOI 10.1016/S0190-9622(00)90131-2; Walker G.J.A., 2000, COCHRANE DB SYST REV, V3; WALKER GJA, 2002, DRUG THER B, V40, P43; Whitley Richard J, 2002, Semin Pediatr Infect Dis, V13, P6, DOI 10.1053/spid.2002.29752; Williams HC, 2003, EVIDENCE BASED DERMA; WOHLFAHRT DJ, 1982, MED J AUSTRALIA, V1, P512, DOI 10.5694/j.1326-5377.1982.tb124157.x; WORRALL G, CLIN EVIDENCE HERPES; 2002, DRUG THER B, V40, P43	40	11	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2005	330	7501					1194	1198		10.1136/bmj.330.7501.1194	http://dx.doi.org/10.1136/bmj.330.7501.1194			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905257	Green Published			2022-12-28	WOS:000229320500023
J	Brown, M; Pasvol, G				Brown, M; Pasvol, G			Chromoblastomycosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Brown, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.		Pasvol, Geoffrey/B-7113-2009						0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					E19	E19		10.1056/NEJMicm040848	http://dx.doi.org/10.1056/NEJMicm040848			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901855	Green Accepted			2022-12-28	WOS:000229180100010
J	Escolar, ML; Poe, MD; Provenzale, JM; Richards, KC; Allison, J; Wood, S; Wenger, DA; Pietryga, D; Wall, D; Champagne, M; Morse, R; Krivit, W; Kurtzberg, J				Escolar, ML; Poe, MD; Provenzale, JM; Richards, KC; Allison, J; Wood, S; Wenger, DA; Pietryga, D; Wall, D; Champagne, M; Morse, R; Krivit, W; Kurtzberg, J			Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOBOID-CELL LEUKODYSTROPHY; BONE-MARROW TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; PLACENTAL-BLOOD; STORAGE DISEASES; UNRELATED DONORS; TWITCHER MOUSE; RECONSTITUTION; RECIPIENTS	BACKGROUND: Infantile Krabbe's disease produces progressive neurologic deterioration and death in early childhood. We hypothesized that transplantation of umbilical-cord blood from unrelated donors before the development of symptoms would favorably alter the natural history of the disease among newborns in whom the disease was diagnosed because of a family history. We compared the outcomes among these newborns with the outcomes among infants who underwent transplantation after the development of symptoms and with the outcomes in an untreated cohort of affected children. METHODS: Eleven asymptomatic newborns (age range, 12 to 44 days) and 14 symptomatic infants (age range, 142 to 352 days) with infantile Krabbe's disease underwent transplantation of umbilical-cord blood from unrelated donors after myeloablative chemotherapy. Engraftment, survival, and neurodevelopmental function were evaluated longitudinally for four months to six years. RESULTS: The rates of donor-cell engraftment and survival were 100 percent and 100 percent, respectively, among the asymptomatic newborns (median follow-up, 3.0 years) and 100 percent and 43 percent, respectively, among the symptomatic infants (median follow-up, 3.4 years). Surviving patients showed durable engraftment of donor-derived hematopoietic cells with restoration of normal blood galactocerebrosidase levels. Infants who underwent transplantation before the development of symptoms showed progressive central myelination and continued gains in developmental skills, and most had age-appropriate cognitive function and receptive language skills, but a few had mild-to-moderate delays in expressive language and mild-to-severe delays in gross motor function. Children who underwent transplantation after the onset of symptoms had minimal neurologic improvement. CONCLUSIONS: Transplantation of umbilical-cord blood from unrelated donors in newborns with infantile Krabbe's disease favorably altered the natural history of the disease. Transplantation in babies after symptoms had developed did not result in substantive neurologic improvement.	Univ N Carolina, Clin Ctr Study Dev & Learning, Program Neurodev Funct Rare Disorders, Chapel Hill, NC 27599 USA; Univ N Carolina, Frank Porter Graham Child Dev Inst, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Pediat Blood & Marrow Transplant Program, Durham, NC USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; DeVos Childrens Hosp, Pediat Blood & Bone Marrow Transplantat Program, Grand Rapids, MI USA; Texas Transplant Inst, San Antonio, TX USA; Hop St Justine, Montreal, PQ H3T 1C5, Canada; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Jefferson University; Universite de Montreal; University of Minnesota System; University of Minnesota Twin Cities	Escolar, ML (corresponding author), Univ N Carolina, Clin Ctr Study Dev & Learning, Program Neurodev Funct Rare Disorders, Box 7255, Chapel Hill, NC 27599 USA.	maria.escolar@cdl.unc.edu	Poe, Michele/K-6615-2012; Escolar, Maria/J-3721-2016	Poe, Michele/0000-0001-9693-3638; 	NIDDK NIH HHS [DK 38795] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK038795, R01DK038795] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayley N, 1993, BAYLEY SCALES INFANT; Bruininks RH., 1996, SCALES INDEPENDENT B; deCasperi R, 2000, BONE MARROW TRANSPL, V25, P541, DOI 10.1038/sj.bmt.1702185; Elliott C, 1990, DIFFERENTIAL ABILITI; Folio M.R., 2000, PEABODY DEV MOTOR SC, V2nd ed.; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; HOON AH, 1993, J PEDIATR-US, V123, pS1, DOI 10.1016/S0022-3476(05)81587-2; ICHIOKA T, 1987, P NATL ACAD SCI USA, V84, P4259, DOI 10.1073/pnas.84.12.4259; Jacobson P, 2001, BONE MARROW TRANSPL, V27, P855, DOI 10.1038/sj.bmt.1703010; KRIVIT W, 1995, CELL TRANSPLANT, V4, P385, DOI 10.1016/0963-6897(95)00021-O; Krivit W, 1998, NEW ENGL J MED, V338, P1119, DOI 10.1056/NEJM199804163381605; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Mullen EM, 1995, CIRCLE PINES; Nine G., 1994, J CLIN NEUROPHYSIOL, V11, P40, DOI DOI 10.1097/00004691-199401000-00010.PUBMED:8195426; Rossetti LM., 1990, ROSSETTI INFANT TODD; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201; RUBINSTEIN P, 1993, BLOOD, V81, P1679; Scriver C.R., 2001, METABOLIC MOL BASES, P3669; Staba SL, 2004, NEW ENGL J MED, V350, P1960, DOI 10.1056/NEJMoa032613; TOYOSHIMA E, 1986, J NEUROL SCI, V74, P307, DOI 10.1016/0022-510X(86)90116-4; WENGER DA, 1991, TECHNIQUES DIAGNOSTI, P587; Zimmerman I., 1992, PRESCHOOL LANGUAGE S	25	480	494	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2069	2081		10.1056/NEJMoa042604	http://dx.doi.org/10.1056/NEJMoa042604			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901860				2022-12-28	WOS:000229180100005
J	Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Ockene, JK; Petitti, DB; Siu, AL; Teutsch, SM; Yawn, BP				Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Ockene, JK; Petitti, DB; Siu, AL; Teutsch, SM; Yawn, BP		US Preventive Serv Task Force	Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							CONJUGATED EQUINE ESTROGENS; RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; REPLACEMENT THERAPY; BREAST-CANCER; ESTROGEN/PROGESTIN REPLACEMENT; PLUS PROGESTIN; OVARIAN-CANCER; FOLLOW-UP; RISK	This statement summarizes the U.S. Preventive Services Task Force recommendations on hormone therapy for the prevention of chronic conditions in postmenopausal women and the supporting scientific evidence, and updates the Task Force's 2002 recommendations on hormone replacement therapy. The updated statement is based on the results of the Women's Health Initiative randomized, controlled trial, as well as the information in the 2002 summary of the evidence on this topic, which is available on the USPSTF Web site (www.preventiveservices.ahrq.gov).	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Agency for Healthcare Research & Quality	Johnson, MS (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							Abramson B, 2004, CAN MED ASSOC J, V170, P1388, DOI 10.1053/cmaj.1030755; *ACOG TASK FORC HO, 2004, OBSTET GYNECOL S, V104, pS1; *AM CANC SOC, CANC FACTS FIG 2004; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; HUMPHREY L, 2002, SYSTEMATIC EVIDENCE; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LEBLANC E, 2002, SYSTEMATIC EVIDENCE; Linfante A, 2004, CIRCULATION, V110, P664; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Miller J, 2002, SYSTEMATIC EVIDENCE, V11; North American Menopause Society, 2004, Menopause, V11, P589; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Sheridan SL, 2004, AM J PREV MED, V26, P56, DOI 10.1016/j.amepre.2003.09.011; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Wathen CN, 2004, CAN MED ASSOC J, V170, P1535, DOI 10.1503/cmaj.1030756	30	96	97	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					855	860		10.7326/0003-4819-142-10-200505170-00011	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897536				2022-12-28	WOS:000229099600007
J	Murata, Y; Iwasaki, H; Sasaki, M; Inaba, K; Okamura, Y				Murata, Y; Iwasaki, H; Sasaki, M; Inaba, K; Okamura, Y			Phosphoinositide phosphatase activity coupled to an intrinsic voltage sensor	NATURE			English	Article							ASCIDIAN CIONA-INTESTINALIS; RECTIFYING K+ CHANNELS; ION CHANNELS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POTASSIUM CHANNELS; TUMOR-SUPPRESSOR; PTEN; ACTIVATION; IDENTIFICATION; PERSPECTIVE	Changes in membrane potential affect ion channels and transporters, which then alter intracellular chemical conditions. Other signalling pathways coupled to membrane potential have been suggested(1-3) but their underlying mechanisms are unknown. Here we describe a novel protein from the ascidian Ciona intestinalis that has a transmembrane voltage-sensing domain homologous to the S1 - S4 segments of voltage-gated channels and a cytoplasmic domain similar to phosphatase and tensin homologue. This protein, named C. intestinalis voltage-sensor-containing phosphatase (Ci-VSP), displays channel-like 'gating' currents and directly translates changes in membrane potential into the turnover of phosphoinositides. The activity of the phosphoinositide phosphatase in Ci-VSP is tuned within a physiological range of membrane potential. Immunocytochemical studies show that Ci-VSP is expressed in Ciona sperm tail membranes, indicating a possible role in spermfunction or morphology. Our data demonstrate that voltage sensing can function beyond channel proteins and thus more ubiquitously than previously realized.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Sect Dev Neurophysiol, Aichi 4448787, Japan; Natl Inst Nat Sci, Natl Inst Physiol Sci, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Okazaki, Aichi 4448585, Japan; Univ Tsukuba, Grad Sch Life & Environm Sci, Shimoda Marine Res Ctr, Shizuoka 4150025, Japan; Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Tsukuba, Ibaraki 3058566, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Okamura, Y (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Sect Dev Neurophysiol, Higashiyama 5-1,Myodaiji Cho, Aichi 4448787, Japan.	yokamura@nips.ac.jp		Murata, Yoshimichi/0000-0002-2070-7949; Iwasaki, Hirohide/0000-0002-7432-5938				BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Dong XY, 2003, BRIT J CANCER, V89, P291, DOI 10.1038/sj.bjc.6601062; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Horn R, 2002, J GEN PHYSIOL, V120, P449, DOI 10.1085/jgp.20028658; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Izumi H, 1999, DEV BIOL, V213, P246, DOI 10.1006/dbio.1999.9367; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Padma P, 2003, MOL BIOL CELL, V14, P774, DOI 10.1091/mbc.02-06-0089; Reymond A, 2002, NATURE, V420, P582, DOI 10.1038/nature01178; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; Tapparel C, 2003, GENE, V323, P189, DOI 10.1016/j.gene.2003.09.038; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Yoshida M, 2002, P NATL ACAD SCI USA, V99, P14831, DOI 10.1073/pnas.242470599; Zhang C, 2004, NEURON, V42, P225, DOI 10.1016/S0896-6273(04)00189-8; Zhang C, 2002, NAT NEUROSCI, V5, P425, DOI 10.1038/nn845; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	29	524	541	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1239	1243		10.1038/nature03650	http://dx.doi.org/10.1038/nature03650			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15902207				2022-12-28	WOS:000230140500045
J	Pichichero, ME; Rennels, MB; Edwards, KM; Blatter, MM; Marshall, GS; Bologa, M; Wang, E; Mills, E				Pichichero, ME; Rennels, MB; Edwards, KM; Blatter, MM; Marshall, GS; Bologa, M; Wang, E; Mills, E			Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CONTROLLED-TRIAL; EPIDEMIOLOGY; INFANTS	Context Increasing reports of pertussis among US adolescents, adults, and their infant contacts have stimulated vaccine development for older age groups. Objective To assess the immunogenicity and reactogenicity of a tetanus-diphtheria 5-component (pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3) acellular pertussis vaccine (Tdap) in adolescents and adults. Design, Setting, and Participants A prospective, randomized, modified double-blind, comparative trial was conducted in healthy adolescents and adults aged 11 through 64 years from August 2001 to August 2002 at 39 US clinical centers. Interventions A single 0.5-mL intramuscular dose of either Tdap or tetanus-diphtheria vaccine (Td). Main Outcome Measures Antibody titers to diphtheria and tetanus toxoids for Tdap and Td were measured in sera collected from subsets of adolescents and adults, before and 28 days after vaccination. For pertussis antigens, titers in sera from Tdap vaccinees were assessed vs those from infants who received analogous pediatric diphtheria-tetanus-acellular pertussis vaccine (DTaP) in a previous efficacy trial, Safety was assessed via solicited local and systemic reactions for 14 days and adverse events for 6 months following vaccination. Results A total of 4480 participants were enrolled. For both Tdap and Td, more than 94% and nearly 100% of vaccinees had protective antibody concentrations of at least 0.1 IU/mL for diphtheria and tetanus, respectively. Geometric mean antibody titers to pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3 exceeded (by 2.1 to 5.4 times) levels in infants following immunization at 2, 4, and 6 months with DTaP. The incidence of solicited local and systemic reactions and adverse events was generally similar between the Tdap and Td groups. Conclusions This Tdap vaccine elicited robust immune responses in adolescents and adults to pertussis, tetanus, and diphtheria antigens, while exhibiting an overall safety profile similar to that of a licensed Td vaccine. These data support the potential routine use of this Tdap vaccine in adolescents and adults.	Univ Rochester, Med Ctr, Elmwood Pediat Grp, Rochester, NY 14642 USA; Univ Maryland, Baltimore, MD 21201 USA; Vanderbilt Univ, Nashville, TN USA; Primary Phys Res, Pittsburgh, PA USA; Univ Louisville, Louisville, KY 40292 USA; Sanofi Pasteur Ltd, Toronto, ON, Canada	University of Rochester; University System of Maryland; University of Maryland Baltimore; Vanderbilt University; University of Louisville; Sanofi-Aventis	Pichichero, ME (corresponding author), Univ Rochester, Med Ctr, Elmwood Pediat Grp, 601 Elmwood Ave, Rochester, NY 14642 USA.	michael_pichichero@urmc.rochester.edu	Pichichero, Michael E/AID-7886-2022					[Anonymous], 1993, IMMUNOLOGICAL BASIS; Beyer WEP, 1996, EUR J CLIN MICROBIOL, V15, P65, DOI 10.1007/BF01586187; Bisgard KM, 2004, PEDIATR INFECT DIS J, V23, P985, DOI 10.1097/01.inf.0000145263.37198.2b; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P73; *CDCP, 2005, MMWR-MORBID MORTAL W, V53, P1213; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; CHERRY JD, 1989, WESTERN J MED, V150, P319; De Serres G, 2000, J INFECT DIS, V182, P174, DOI 10.1086/315648; DEEN JL, 1995, CLIN INFECT DIS, V21, P1211, DOI 10.1093/clinids/21.5.1211; GENTILI G, 1984, J BIOL STAND, V12, P167, DOI 10.1016/S0092-1157(84)80050-5; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; *NACI, 2002, CAN IMM GUID, P169; Skowronski DM, 2002, J INFECT DIS, V185, P1448, DOI 10.1086/340280; Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; *US FDA CTR BIOL E, 1997, VACC REL BIOL PROD A; Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012; von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8; WHARTON M, 2004, VACCINES, P211; Yih WK, 2000, J INFECT DIS, V182, P1409, DOI 10.1086/315863	21	99	111	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 22	2005	293	24					3003	3011		10.1001/jama.293.24.3003	http://dx.doi.org/10.1001/jama.293.24.3003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937SG	15933223	Bronze			2022-12-28	WOS:000229945200015
J	Quinn, TC; Overbaugh, J				Quinn, TC; Overbaugh, J			HIV/AIDS in women: An expanding epidemic	SCIENCE			English	Review							HIV-1 INFECTION; TRANSMISSION; POPULATION	More than 20 years into the human immunodeficiency virus-type 1 (HIV-1) epidemic, women account for nearly half of the 40 million people living with HIV-1 worldwide, with an even higher proportion existing in developing countries. Social determinants of female vulnerability to HIV-1 include gender disparities, poverty, cultural and sexual norms, lack of education, and violence. Women ire also more susceptible to HIV-1 because of hormonal changes, vaginal microbial ecology and physiology, and a higher prevalence of sexually transmitted diseases. Prevention strategies must address the wide range of gender inequalities that promote the dissemination of HIV-1.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Int Hlth, Baltimore, MD 21205 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Fred Hutchinson Cancer Center	Quinn, TC (corresponding author), NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	tquinn@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000361, Z01AI000361] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*CDC, 2004, HIV AIDS SURV REP 20, V15; Gilbert PB, 2005, J INFECT DIS, V191, P666, DOI 10.1086/428405; GRAY RH, IN PRESS LANCET; Kiddugavu M, 2003, AIDS, V17, P233, DOI 10.1097/00002030-200301240-00014; Lavreys L, 2004, AIDS, V18, P695, DOI 10.1097/00002030-200403050-00017; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Montefiori DC, 2004, J INFECT DIS, V190, P1962, DOI 10.1086/425518; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; *PREM GEND DEV GRO, 2004, INT GEND ISS HIV AID; Sagar M, 2004, AIDS, V18, P615, DOI 10.1097/00002030-200403050-00005; *UNAIDS UN POP FUN, 2004, WOM HIV AIDS CONFR C; *UNAIDS UN POP FUN, 2005, AIDS EP UPD DEC 2004	12	283	293	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1582	1583		10.1126/science.1112489	http://dx.doi.org/10.1126/science.1112489			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947174				2022-12-28	WOS:000229827000041
J	Shao, ZP; Haile, SM; Ahn, J; Ronney, PD; Zhan, ZL; Barnett, SA				Shao, ZP; Haile, SM; Ahn, J; Ronney, PD; Zhan, ZL; Barnett, SA			A thermally self-sustained micro solid-oxide fuel-cell stack with high power density	NATURE			English	Article							PERFORMANCE; ANODE; TEMPERATURE; OXIDATION; CATHODE	High energy efficiency and energy density, together with rapid refuelling capability, render fuel cells highly attractive for portable power generation(1,2). Accordingly, polymer-electrolyte direct-methanol fuel cells are of increasing interest as possible alternatives to Li ion batteries(3). However, such fuel cells face several design challenges and cannot operate with hydrocarbon fuels of higher energy density. Solid-oxide fuel cells (SOFCs) enable direct use of higher hydrocarbons(4-6), but have not been seriously considered for portable applications because of thermal management difficulties at small scales, slow start-up and poor thermal cyclability. Here we demonstrate a thermally self-sustaining micro-SOFC stack with high power output and rapid start-up by using single chamber operation on propane fuel. The catalytic oxidation reactions supply sufficient thermal energy to maintain the fuel cells at 500 - 600 degrees C. A power output of similar to 350 mW( at 1.0 V) was obtained from a device with a total cathode area of only 1.42 cm(2).	CALTECH, Pasadena, CA 91125 USA; Univ So Calif, Dept Aerosp & Mech Engn, Los Angeles, CA 90089 USA; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA	California Institute of Technology; University of Southern California; Northwestern University	Haile, SM (corresponding author), CALTECH, Pasadena, CA 91125 USA.	smhaile@caltech.edu	Shao, Zongping/AAY-8177-2020; Barnett, Scott A/B-7502-2009; Ronney, Paul/B-4007-2009; shao, zongping/B-5250-2013; Haile, Sossina M/I-3448-2015	Ronney, Paul/0000-0002-2779-6438; Ahn, Jeongmin/0000-0002-9041-6100; shao, zongping/0000-0002-4538-4218				Dyer CK, 2002, J POWER SOURCES, V106, P31, DOI 10.1016/S0378-7753(01)01069-2; DYER CK, 1990, NATURE, V343, P547, DOI 10.1038/343547a0; Heinzel A, 2002, J POWER SOURCES, V105, P250, DOI 10.1016/S0378-7753(01)00948-X; Hibino T, 2000, SCIENCE, V288, P2031, DOI 10.1126/science.288.5473.2031; Hibino T, 1996, SOLID STATE IONICS, V91, P69, DOI 10.1016/S0167-2738(96)00437-7; Hibino T, 2001, J ELECTROCHEM SOC, V148, pA544, DOI 10.1149/1.1368098; Koh JH, 2001, ELECTROCHEM SOLID ST, V4, pA12, DOI 10.1149/1.1339237; Liu H, 2004, ENVIRON SCI TECHNOL, V38, P2281, DOI 10.1021/es034923g; McGrath KM, 2004, J IND ENG CHEM, V10, P1063; Murray EP, 1999, NATURE, V400, P649, DOI 10.1038/23220; Napporn TW, 2004, ELECTROCHEM SOLID ST, V7, pA60, DOI 10.1149/1.1645352; Park SD, 2000, NATURE, V404, P265, DOI 10.1038/35005040; Ronney PD, 2003, COMBUST FLAME, V135, P421, DOI 10.1016/j.combustflame.2003.07.003; Shao ZP, 2004, NATURE, V431, P170, DOI 10.1038/nature02863; Shao ZP, 2004, SOLID STATE IONICS, V175, P39, DOI 10.1016/j.ssi.2004.09.018; Shukla AK, 2002, ELECTROCHIM ACTA, V47, P3401, DOI 10.1016/S0013-4686(02)00276-1; Stefan IC, 2004, ELECTROCHEM SOLID ST, V7, pA198, DOI 10.1149/1.1739311; Suzuki T, 2004, J ELECTROCHEM SOC, V151, pA1473, DOI 10.1149/1.1782141; Tao SW, 2003, NAT MATER, V2, P320, DOI 10.1038/nmat871; Thomas SC, 2002, ELECTROCHIM ACTA, V47, P3741, DOI 10.1016/S0013-4686(02)00344-4	20	558	580	5	461	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					795	798		10.1038/nature03673	http://dx.doi.org/10.1038/nature03673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944699	Green Accepted			2022-12-28	WOS:000229638700045
J	Turner, PC; Sylla, A; Gong, YY; Diailo, MS; Sutcliffe, AE; Hall, AJ; Wild, CP				Turner, PC; Sylla, A; Gong, YY; Diailo, MS; Sutcliffe, AE; Hall, AJ; Wild, CP			Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study	LANCET			English	Article							HEPATOCELLULAR-CARCINOMA; PRIMARY PREVENTION; DIETARY AFLATOXIN; YOUNG-CHILDREN; LIVER-CANCER; BENIN; RISK; INFECTION; GROWTH; TOGO	Background Aflatoxins are fungal metabolites that frequently contaminate staple foods in much of sub-Saharan Africa, and are associated with increased risk of liver cancer and impaired growth in young children. We aimed to assess whether postharvest measures to restrict aflatoxin contamination of groundnut crops could reduce exposure in west African villages. Methods We undertook an intervention study at subsistence farms in the lower Kindia region of Guinea. Farms from 20 villages were included, ten of which implemented a package of postharvest measures to restrict aflatoxin contamination of the groundnut crop; ten controls followed usual postharvest practices. We measured the concentrations of blood aflatoxin-albumin adducts from 600 people immediately after harvest and at 3 months and 5 months postharvest to monitor the effectiveness of the intervention. Findings In control villages mean aflatoxin-albumin concentration increased postharvest (from 5.5 pg/mg [95% CI 4.7-6.1] immediately after harvest to 18.7 pg/mg [17.0-20.6] 5 months later). By contrast, mean aflatoxin-albumin concentration in intervention villages after 5 months of groundnut storage was much the same as that immediately postharvest (7.2 pg/mg [6.2-8.4] vs 8.0 pg/mg [7.0-9.2]). At 5 months, mean adduct concentration in intervention villages was less than 50% of that in control villages (8.0 pg/mg [7.2-9.2] vs 18.7 pg/mg [17.0-20.6], p<0.0001). About a third of the number of people had non-detectable aflatoxin-albumin concentrations at harvest. At 5 months, five (2%) people in the control villages had non-detectable adduct concentrations compared with 47 (20%) of those in the intervention group (p<0.0001). Mean concentrations of aflatoxin B1 in groundnuts in household stores in intervention and control villages were consistent with measurements of aflatoxin-albumin adducts. Interpretation Use of low-technology approaches at the subsistence-farm level in sub-Saharan Africa could substantially reduce the disease burden caused by aflatoxin exposure.	Univ Leeds, Ctr Biostat & Epidemiol, Leeds Inst Genet Hlth & Therpaeut, Mol Epidemiol Unit, Leeds LS2 9JT, W Yorkshire, England; Univ London, London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London, England; Inst Pasteur Guinee, Kindia, Guinea	University of Leeds; University of London; London School of Hygiene & Tropical Medicine	Wild, CP (corresponding author), Univ Leeds, Ctr Biostat & Epidemiol, Leeds Inst Genet Hlth & Therpaeut, Mol Epidemiol Unit, Leeds LS2 9JT, W Yorkshire, England.	c.p.wild@leeds.ac.uk	Gong, Yun Yun/L-7094-2016; Turner, Paul C/A-6152-2011; Gong, Yun Yun/C-8412-2018; Turner, Paul C/B-8131-2013; Wild, Christopher/ABC-6260-2020	Gong, Yun Yun/0000-0003-4927-5526; Gong, Yun Yun/0000-0003-4927-5526; Wild, Christopher/0000-0003-0249-8669	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006052] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06052] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN SJ, 1992, T ROY SOC TROP MED H, V86, P426, DOI 10.1016/0035-9203(92)90253-9; *ASS OFF AN CHEM, 1990, OFF METH AN AOAC NAT, P1184; Chapot B., 1991, TECHNIQUES DIAGNOSTI, P135; CROMPTON JAF, 1993, TROP SCI, V33, P283; Diallo Mamadou S., 1995, Natural Toxins, V3, P6, DOI 10.1002/nt.2620030103; Egner PA, 2001, P NATL ACAD SCI USA, V98, P14601, DOI 10.1073/pnas.251536898; Gong YY, 2004, ENVIRON HEALTH PERSP, V112, P1334, DOI 10.1289/ehp.6954; Gong YY, 2003, INT J EPIDEMIOL, V32, P556, DOI 10.1093/ije/dyg109; Gong YY, 2002, BRIT MED J, V325, P20, DOI 10.1136/bmj.325.7354.20; Hall AJ, 2003, BRIT MED J, V326, P994, DOI 10.1136/bmj.326.7397.994; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2002, IARC Monogr Eval Carcinog Risks Hum, V82, P1; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; RAISUDDIN S, 1993, MYCOPATHOLOGIA, V124, P189, DOI 10.1007/BF01103737; Sylla A, 1999, MUTAT RES-FUND MOL M, V428, P187, DOI 10.1016/S1383-5742(99)00046-0; Turner PC, 2002, J GASTROEN HEPATOL, V17, pS441, DOI 10.1046/j.1440-1746.17.s4.7.x; Turner PC, 2003, ENVIRON HEALTH PERSP, V111, P217, DOI 10.1289/ehp.5753; Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5&lt;620::AID-IJC5&gt;3.0.CO;2-W; *WHO, 1998, FOOD ADDITIVES SERIE, P359; *WHO INT AG RES CA, 2003, IARC SCI PUBL, V153, P299; Wild CP, 2002, MUTAGENESIS, V17, P471, DOI 10.1093/mutage/17.6.471; Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2	22	190	195	2	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1950	1956		10.1016/S0140-6736(05)66661-5	http://dx.doi.org/10.1016/S0140-6736(05)66661-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936422				2022-12-28	WOS:000229587800029
J	Bowerman, B				Bowerman, B			Advocating asymmetry and the POP-1 paradox: Noncanonical Wnt signaling in C-elegans	CELL			English	Editorial Material							CELL POLARITY; GONADOGENESIS; PATHWAY	In this issue of Cell, Kidd and colleagues (Kidd et al., 2005) describe their identification of a novel beta-catenin that functions in noncanonical C. elegans Writ signaling pathways to specify the different fates of daughter cells produced by asymmetric cell division.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Bowerman, B (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.							Herman MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1530, DOI 10.2741/1306; Herman MA, 2001, DEVELOPMENT, V128, P581; Kidd AR, 2005, CELL, V121, P761, DOI 10.1016/j.cell.2005.03.029; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Miskowski J, 2001, DEV BIOL, V230, P61, DOI 10.1006/dbio.2000.9998; Siegfried KR, 2002, DEVELOPMENT, V129, P443; Thorpe CJ, 2004, DEVELOPMENT, V131, P2899, DOI 10.1242/dev.01171	7	1	5	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 3	2005	121	5					662	664		10.1016/j.cell.2005.05.020	http://dx.doi.org/10.1016/j.cell.2005.05.020			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935751	Bronze			2022-12-28	WOS:000229658000003
J	Kim, MG; da Cunha, L; McFall, AJ; Belkhadir, Y; DebRoy, S; Dangl, JL; Mackey, D				Kim, MG; da Cunha, L; McFall, AJ; Belkhadir, Y; DebRoy, S; Dangl, JL; Mackey, D			Two Pseudomonas syringae type III effectors inhibit RIM-regulated basal defense in Arabidopsis	CELL			English	Article							DISEASE-RESISTANCE; HYPERSENSITIVE RESPONSE; SECRETION SYSTEM; GENOMEWIDE IDENTIFICATION; CALLOSE SYNTHASE; GENE-PRODUCT; BACTERIAL; AVRRPT2; VIRULENCE; PROTEINS	Plant cells have two defense systems that detect bacterial pathogens. One is a basal defense system that recognizes complex pathogen-associated molecular patterns (PAMPs). A second system uses diseaseresistance (R) proteins to recognize type III effector proteins that are delivered into the plant cell by the pathogen's type III secretion system. Here we show that these two pathways are linked. We find that two Pseudomonas syringae type III effectors, AvrRpt2 and AvrRpm1, inhibit PAMP-induced signaling and thus compromise the host's basal defense system. RIN4 is an Arabidopsis protein targeted by AvrRpt2 and AvrRpm1 for degradation and phosphorylation, respectively. We find that RIN4 is itself a regulator of PAMP signaling. The R proteins, RPS2 and RPM1, sense type III effector-induced perturbations of RIN4. Thus, R proteins guard the plant against type III effectors that inhibit PAMP signaling and provide a mechanistic link between the two plant defense systems.	Ohio State Univ, Dept Hort & Crop Sci, Columbus, OH 43210 USA; Ohio State Univ, Dept Plant Cellular & Mol Biol, Columbus, OH 43210 USA; Ohio State Univ, Program Plant Mol Biol & Biotechnol, Program Mol Cellular & Dev Biol, Columbus, OH 43210 USA; Michigan State Univ, Dept Energy, Plant Res Lab, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Univ N Carolina, Carolina Ctr Genome Sci, Curriculum Genet, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Curriculum Genet, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Michigan State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mackey, D (corresponding author), Ohio State Univ, Dept Hort & Crop Sci, Room 306C Kottman Hall, Columbus, OH 43210 USA.	mackey.86@osu.edu	Belkhadir, Youssef/GXM-6743-2022	Belkhadir, Youssef/0000-0001-7149-7139				Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Asai T, 2000, PLANT CELL, V12, P1823, DOI 10.1105/tpc.12.10.1823; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Axtell MJ, 2003, MOL MICROBIOL, V49, P1537, DOI 10.1046/j.1365-2958.2003.03666.x; Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; Belkhadir Y, 2004, PLANT CELL, V16, P2822, DOI 10.1105/tpc.104.024117; Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; Chang JH, 2004, CURR OPIN MICROBIOL, V7, P11, DOI 10.1016/j.mib.2003.12.006; Chen ZY, 2000, MOL PLANT MICROBE IN, V13, P1312, DOI 10.1094/MPMI.2000.13.12.1312; Chen ZY, 2004, PLANT J, V37, P494, DOI 10.1111/j.1365-313X.2003.01984.x; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Collmer A, 2000, P NATL ACAD SCI USA, V97, P8770, DOI 10.1073/pnas.97.16.8770; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Deng WL, 1998, J BACTERIOL, V180, P4523, DOI 10.1128/JB.180.17.4523-4531.1998; Espinosa A, 2004, CELL MICROBIOL, V6, P1027, DOI 10.1111/j.1462-5822.2004.00452.x; Fellbrich G, 2002, PLANT J, V32, P375, DOI 10.1046/j.1365-313X.2002.01454.x; Fouts DE, 2002, P NATL ACAD SCI USA, V99, P2275, DOI 10.1073/pnas.032514099; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; Govrin EM, 2000, CURR BIOL, V10, P751, DOI 10.1016/S0960-9822(00)00560-1; Guttman DS, 2002, SCIENCE, V295, P1722, DOI 10.1126/science.295.5560.1722; Hauck P, 2003, P NATL ACAD SCI USA, V100, P8577, DOI 10.1073/pnas.1431173100; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jacobs AK, 2003, PLANT CELL, V15, P2503, DOI 10.1105/tpc.016097; JAKOBEK JL, 1993, PLANT CELL, V5, P57, DOI 10.1105/tpc.5.1.57; Jin P, 2003, PLANT PHYSIOL, V133, P1072, DOI 10.1104/pp.103.025999; Jones DA, 2004, CURR OPIN IMMUNOL, V16, P48, DOI 10.1016/j.coi.2003.11.016; Keshavarzi M, 2004, MOL PLANT MICROBE IN, V17, P805, DOI 10.1094/MPMI.2004.17.7.805; Kliebenstein DJ, 1999, MOL PLANT MICROBE IN, V12, P1022, DOI 10.1094/MPMI.1999.12.11.1022; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; Lehmann Przemyslaw, 2002, Journal of Applied Genetics, V43, P403; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Maleck K, 2000, NAT GENET, V26, P403, DOI 10.1038/82521; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; Mudgett MB, 1999, MOL MICROBIOL, V32, P927, DOI 10.1046/j.1365-2958.1999.01403.x; Navarro L, 2004, PLANT PHYSIOL, V135, P1113, DOI 10.1104/pp.103.036749; Newman MA, 2002, PLANT J, V29, P487, DOI 10.1046/j.0960-7412.2001.00233.x; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Nimchuk Z, 2003, ANNU REV GENET, V37, P579, DOI 10.1146/annurev.genet.37.110801.142628; Nishimura MT, 2003, SCIENCE, V301, P969, DOI 10.1126/science.1086716; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Petnicki-Ocwieja T, 2002, P NATL ACAD SCI USA, V99, P7652, DOI 10.1073/pnas.112183899; Qureshi ST, 2003, GENES IMMUN, V4, P87, DOI 10.1038/sj.gene.6363937; RITTER C, 1995, MOL PLANT MICROBE IN, V8, P444, DOI 10.1094/MPMI-8-0444; Rohmer L, 2003, MOL MICROBIOL, V47, P1545, DOI 10.1046/j.1365-2958.2003.03402.x; Ron M, 2004, PLANT CELL, V16, P1604, DOI 10.1105/tpc.022475; Shao F, 2003, SCIENCE, V301, P1230, DOI 10.1126/science.1085671; Tao Y, 2003, PLANT CELL, V15, P317, DOI 10.1105/tpc.007591; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	54	360	376	3	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					749	759		10.1016/j.cell.2005.03.025	http://dx.doi.org/10.1016/j.cell.2005.03.025			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935761	Bronze			2022-12-28	WOS:000229658000013
J	Schweitzer, MH; Wittmeyer, JL; Horner, JR				Schweitzer, MH; Wittmeyer, JL; Horner, JR			Gender-specific reproductive tissue in ratites and Tyrannosaurus rex	SCIENCE			English	Article							MALE JAPANESE QUAIL; MEDULLARY BONE; AVIAN BONE; ESTROGEN; EVOLUTION; CALCIUM; BIRDS; OSTEOGENESIS; ORIGIN; MODEL	Unambiguous indicators of gender in dinosaurs are usually lost during fossilization, along with other aspects of soft tissue anatomy. We report the presence of endosteally derived bone tissues lining the interior marrow cavities of portions of Tyrannosaurus rex (Museum of the Rockies specimen number 1125) hindlimb elements, and we hypothesize that these tissues are homologous to specialized avian tissues known as medullary bone. Because medullary bone is unique to female birds, its discovery in extinct dinosaurs solidifies the link between dinosaurs and birds, suggests similar reproductive strategies, and provides an objective means of gender differentiation in dinosaurs.	N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27695 USA; N Carolina State Museum Nat Sci, Raleigh, NC 27601 USA; Montana State Univ, Museum Rockies, Bozeman, MT 59717 USA	University of North Carolina; North Carolina State University; Montana State University System; Montana State University Bozeman	Schweitzer, MH (corresponding author), N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27695 USA.	schweitzer@ncsu.edu	schweitzer, mary h/A-6756-2010; Schweitzer, Mary/V-8143-2019	schweitzer, mary h/0000-0002-0427-3829; 				Arias JL, 2001, WORLD POULTRY SCI J, V57, P349, DOI 10.1079/WPS20010024; ASCENZI A, 1963, J ULTRA MOL STRUCT R, V8, P491, DOI 10.1016/S0022-5320(63)80051-9; BLOOM MA, 1958, AM J ANAT, V102, P411, DOI 10.1002/aja.1001020304; BONUCCI E, 1975, CELL TISSUE RES, V163, P81; BRYANT HN, 1992, PHILOS T ROY SOC B, V337, P405, DOI 10.1098/rstb.1992.0117; CARPENTER K, 1999, EGGS NESTS BAYB DINO; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; Chinsamy A, 1997, J VERTEBR PALEONTOL, V17, P450, DOI 10.1080/02724634.1997.10010993; Chinsamy A, 1995, PALEOBIOLOGY, V21, P561, DOI 10.1017/S0094837300013543; Cracraft J, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P143; DACKE CG, 1993, J EXP BIOL, V184, P63; ELSEY RM, 1986, COMP BIOCHEM PHYS A, V84, P107, DOI 10.1016/0300-9629(86)90050-2; Forster CA, 1998, SCIENCE, V279, P1915, DOI 10.1126/science.279.5358.1915; GAUTHIER JA, 1986, MEM CALIF ACAD SCI, V8, P1; Horner JR, 2004, P ROY SOC B-BIOL SCI, V271, P1875, DOI 10.1098/rspb.2004.2829; Knott L, 1999, BRIT POULTRY SCI, V40, P371, DOI 10.1080/00071669987476; Martill DM, 1996, NATURE, V379, P778, DOI 10.1038/379778a0; Mikhailov K.E., 1997, SPEC PAP PALAEONTOL, V56, P1; MILLER SC, 1981, DEV BIOL, V87, P52, DOI 10.1016/0012-1606(81)90060-9; OHASHI T, 1987, BRIT POULTRY SCI, V28, P727, DOI 10.1080/00071668708417008; Padian K, 1998, SCI AM, V278, P38, DOI 10.1038/scientificamerican0298-38; SATO T, SCIENCE, V308, P375; SCHRAER H, 1985, COMP BIOCHEM PHYS A, V82, P13, DOI 10.1016/0300-9629(85)90697-8; Schweitzer MH, 2005, SCIENCE, V307, P1952, DOI 10.1126/science.1108397; Schweitzer MH, 2001, J EXP ZOOL, V291, P317, DOI 10.1002/jez.1132; Sereno PC, 1997, ANNU REV EARTH PL SC, V25, P435, DOI 10.1146/annurev.earth.25.1.435; Sugiyama T, 2001, ASIAN AUSTRAL J ANIM, V14, P82; Whitehead CC, 2004, POULTRY SCI, V83, P193, DOI 10.1093/ps/83.2.193; Wilson S, 1998, CALCIFIED TISSUE INT, V62, P506, DOI 10.1007/s002239900470; WITMER LM, 1995, FUNCTIONAL MORPHOLOGY IN VERTEBRATE PALEONTOLOGY, P19; Yamamoto T, 2001, ANAT REC, V264, P25, DOI 10.1002/ar.1101; [No title captured]	32	107	134	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2005	308	5727					1456	1460		10.1126/science.1112158	http://dx.doi.org/10.1126/science.1112158			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933198	Green Submitted			2022-12-28	WOS:000229619300050
J	Stoykovich, MP; Muller, M; Kim, SO; Solak, HH; Edwards, EW; de Pablo, JJ; Nealey, PF				Stoykovich, MP; Muller, M; Kim, SO; Solak, HH; Edwards, EW; de Pablo, JJ; Nealey, PF			Directed assembly of block copolymer blends into nonregular device-oriented structures	SCIENCE			English	Article							GRAIN-BOUNDARIES; THIN-FILMS; POLYMERS; ARRAYS; NANOSTRUCTURES; SIMULATIONS; ORIENTATION	Self-assembly is an effective strategy for the creation of periodic structures at the nanoscale. However, because microelectronic devices use free-form design principles, the insertion point of self-assembling materials into existing nano-manufacturing processes is unclear. We directed ternary blends of diblock copolymers and homopolymers that naturally form periodic arrays to assemble into nonregular device-oriented structures on chemically nanopatterned substrates. Redistribution of homopolymer facilitates the defect-free assembly. in locations where the domain dimensions deviate substantially from those formed in the bulk. The ability to pattern nonregular structures using self-assembling materials creates new opportunities for nanoscale manufacturing.	Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA; Univ Wisconsin, Ctr Nanotechnol, Madison, WI 53706 USA; Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Korea Adv Inst Sci & Technol, Dept Mat Sci & Engn, Taejon 305701, South Korea; Paul Scherrer Inst, Lab Micro & Nanotechnol, CH-5232 Villigen, Switzerland	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Korea Advanced Institute of Science & Technology (KAIST); Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Nealey, PF (corresponding author), Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA.	nealey@engr.wisc.edu	Müller, Marcus/B-9898-2009; Kim, Sang Ouk/C-1632-2011; de Pablo, Juan/AAJ-9161-2021; Lee, Junyoung/D-5463-2012	Müller, Marcus/0000-0002-7472-973X; Kim, Sang Ouk/0000-0003-1513-6042; Lee, Junyoung/0000-0001-6689-2759				Angelescu DE, 2004, ADV MATER, V16, P1736, DOI 10.1002/adma.200400643; Bates FS, 1997, PHYS REV LETT, V79, P849, DOI 10.1103/PhysRevLett.79.849; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; Black CT, 2001, APPL PHYS LETT, V79, P409, DOI 10.1063/1.1383805; BROSETA D, 1990, J CHEM PHYS, V93, P2927, DOI 10.1063/1.458877; Burgaz E, 2000, MACROMOLECULES, V33, P8739, DOI 10.1021/ma000729s; Cheng JY, 2001, ADV MATER, V13, P1174, DOI 10.1002/1521-4095(200108)13:15<1174::AID-ADMA1174>3.0.CO;2-Q; Cheng JY, 2004, NAT MATER, V3, P823, DOI 10.1038/nmat1211; Duque D, 2002, J CHEM PHYS, V117, P10315, DOI 10.1063/1.1519537; Edwards EW, 2004, ADV MATER, V16, P1315, DOI 10.1002/adma.200400763; Fredrickson GH, 2002, MACROMOLECULES, V35, P16, DOI 10.1021/ma011515t; Fujita J, 1996, APPL PHYS LETT, V68, P1297, DOI 10.1063/1.115958; GIDO SP, 1994, MACROMOLECULES, V27, P6137, DOI 10.1021/ma00099a031; Gonsalves KE, 2001, ADV MATER, V13, P703, DOI 10.1002/1521-4095(200105)13:10<703::AID-ADMA703>3.0.CO;2-A; Guarini KW, 2003, 2003 IEEE INTERNATIONAL ELECTRON DEVICES MEETING, TECHNICAL DIGEST, P541; HERR DJC, 2005, FUTURE FAB INT, pCH5; Kim SO, 2003, NATURE, V424, P411, DOI 10.1038/nature01775; Knoll A, 2004, NAT MATER, V3, P886, DOI 10.1038/nmat1258; Li RR, 2000, APPL PHYS LETT, V76, P1689, DOI 10.1063/1.126137; Lopes WA, 2001, NATURE, V414, P735, DOI 10.1038/414735a; Mansky P, 1997, SCIENCE, V275, P1458, DOI 10.1126/science.275.5305.1458; Matsen MW, 1996, MACROMOLECULES, V29, P1091, DOI 10.1021/ma951138i; Morkved TL, 1996, SCIENCE, V273, P931, DOI 10.1126/science.273.5277.931; Muller M, 2005, J POLYM SCI POL PHYS, V43, P934, DOI 10.1002/polb.20385; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Rockford L, 1999, PHYS REV LETT, V82, P2602, DOI 10.1103/PhysRevLett.82.2602; Segalman RA, 2001, ADV MATER, V13, P1152, DOI 10.1002/1521-4095(200108)13:15<1152::AID-ADMA1152>3.0.CO;2-5; Solak HH, 2003, MICROELECTRON ENG, V67-8, P56, DOI 10.1016/S0167-9317(03)00059-5; Sundrani D, 2004, NANO LETT, V4, P273, DOI 10.1021/nl035005j; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Urbas A, 2000, ADV MATER, V12, P812, DOI 10.1002/(SICI)1521-4095(200006)12:11<812::AID-ADMA812>3.0.CO;2-8; Wang Q, 2000, J CHEM PHYS, V112, P9996, DOI 10.1063/1.481635; Yang XM, 2000, MACROMOLECULES, V33, P9575, DOI 10.1021/ma001326v	33	847	920	5	453	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1442	1446		10.1126/science.1111041	http://dx.doi.org/10.1126/science.1111041			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933196				2022-12-28	WOS:000229619300046
J	Wazni, OM; Marrouche, NF; Martin, DO; Verma, A; Bhargava, M; Saliba, W; Bash, D; Schweikert, R; Brachmann, J; Gunther, J; Gutleben, K; Pisano, E; Potenza, D; Fanelli, R; Raviele, A; Themistoclakis, S; Rossillo, A; Bonso, A; Natale, A				Wazni, OM; Marrouche, NF; Martin, DO; Verma, A; Bhargava, M; Saliba, W; Bash, D; Schweikert, R; Brachmann, J; Gunther, J; Gutleben, K; Pisano, E; Potenza, D; Fanelli, R; Raviele, A; Themistoclakis, S; Rossillo, A; Bonso, A; Natale, A			Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY VEIN STENOSIS; CATHETER ABLATION; SINUS RHYTHM; ESOPHAGEAL FISTULA; MANAGEMENT; COMPLICATION; IMPACT	Context Treatment with antiarrhythmic drugs and anticoagulation is considered first-line therapy in patients with symptomatic atrial fibrillation (AF). Pulmonary vein isolation (PVI) with radiofrequency ablation may cure AF, obviating the need for antiarrhythmic drugs and anticoagulation. Objective To determine whether PVI is feasible as first-line therapy for treating patients with symptomatic AF. Design, Setting, and Participants A multicenter prospective randomized study conducted from December 31, 2001, to July 1, 2002, of 70 patients aged 18 to 75 years who experienced monthly symptomatic AF episodes for at least 3 months and had not been treated with antiarrhythmic drugs. Intervention Patients were randomized to receive either PVI using radiofrequency ablation (n=33) or antiarrhythmic drug treatment (n=37), with a 1-year follow-up. Main Outcome Measures Recurrence of AF, hospitalization, and quality of life assessment. Results Two patients in the antiarrhythmic drug treatment group and 1 patient in the PVI group were lost to follow-up. At the end of 1-year follow-up, 22 (63%) of 35 patients who received antiarrhythmic drugs had at least 1 recurrence of symptomatic AF compared with 4 (13%) of 32 patients who received PVl (P<.001). Hospitalization during 1-year follow-up occurred in 19 (54%) of 35 patients in the antiarrhythmic drug group compared with 3 (9%) of 32 in the PVl group (P<.001). in the antiarrhythmic drug group, the mean (SD) number of AF episodes decreased from 12 (7) to 6 (4), after initiating therapy (P=.01). At 6-month follow-up, the improvement in quality of life of patients in the PVI group was significantly better than the improvement in the antiarrhythmic drug group in 5 subclasses of the Short-Form 36 health survey. There were no thromboembolic events in either group. Asymptomatic mild or moderate pulmonary vein stenosis was documented in 2 (6%) of 32 patients in the PVI group. Conclusion Pulmonary vein isolation appears to be a feasible first-line approach for treating patients with symptomatic AF. Larger studies are needed to confirm its safety and efficacy.	Cleveland Clin Fdn, Dept Cardiovasc Med, Ctr Atrial Fibrillat, Cleveland, OH 44195 USA; Klinikum Coburg, Coburg, Germany; Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy; Umberto I Hosp, Venice, Italy	Cleveland Clinic Foundation; Klinikum Coburg; IRCCS Casa Sollievo Della Sofferenza; ULSS 3 Serenissima	Natale, A (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Ctr Atrial Fibrillat, Desk F 15,9500 Euclid Ave, Cleveland, OH 44195 USA.	natalea@ccf.org	Natale, Andrea/ABE-7273-2020; Themistoclakis, Sakis/AAC-3385-2022; Brachmann, Johannes/AAD-1499-2021	Themistoclakis, Sakis/0000-0002-7998-7113				[Anonymous], 2001, CIRCULATION, V104, P2118; BERTAGLIA E, 2005, AM COLL CARD MARCH 1; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; Cappato R, 2005, CIRCULATION, V111, P1100, DOI 10.1161/01.CIR.0000157153.30978.67; Corley SD, 2004, CIRCULATION, V109, P1509, DOI 10.1161/01.CIR.0000121736.16643.11; CRIJNS HJ, 1991, AM J CARDIOL, V68, P335, DOI 10.1016/0002-9149(91)90828-9; Franz MR, 1997, J AM COLL CARDIOL, V30, P1785, DOI 10.1016/S0735-1097(97)00385-9; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Greene HL, 2003, J AM COLL CARDIOL, V42, P20, DOI 10.1016/S0735-1097(03)00559-X; Haissaguerre M, 2000, CIRCULATION, V101, P1409, DOI 10.1161/01.CIR.101.12.1409; Hohnloser SH, 2001, EUR HEART J, V22, P801, DOI 10.1053/euhj.2001.2596; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; Marrouche NF, 2002, J AM COLL CARDIOL, V40, P464, DOI 10.1016/S0735-1097(02)01972-1; Marrouche NF, 2003, CIRCULATION, V107, P2710, DOI 10.1161/01.CIR.0000070541.83326.15; Narasimhan C, 1998, J CARDIOVASC ELECTR, V9, pS146; Oral H, 2002, J AM COLL CARDIOL, V40, P100, DOI 10.1016/S0735-1097(02)01939-3; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; Packer DL, 2005, CIRCULATION, V111, P546, DOI 10.1161/01.CIR.0000154541.58478.36; Pappone C, 2004, CIRCULATION, V109, P2724, DOI 10.1161/01.CIR.0000131866.44650.46; Pappone C, 2003, J AM COLL CARDIOL, V42, P185, DOI 10.1016/S0735-1097(03)00577-1; Saad EB, 2003, ANN INTERN MED, V138, P634, DOI 10.7326/0003-4819-138-8-200304150-00010; Saad EB, 2003, CIRCULATION, V108, P3102, DOI 10.1161/01.CIR.0000104569.96907.7F; Scanavacca MI, 2004, J CARDIOVASC ELECTR, V15, P960, DOI 10.1046/j.1540-8167.2004.04083.x; Shah DC, 2002, HEART, V87, P6, DOI 10.1136/heart.87.1.6; Sonmez B, 2003, ANN THORAC SURG, V76, P281, DOI 10.1016/S0003-4975(03)00006-7; Stabile G, 2003, PACE, V26, P284, DOI 10.1046/j.1460-9592.2003.00033.x; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Verma A, 2004, J CARDIOVASC ELECTR, V15, P1335, DOI 10.1046/j.1540-8167.2004.04428.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328	31	759	799	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2634	2640		10.1001/jama.293.21.2634	http://dx.doi.org/10.1001/jama.293.21.2634			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930UU	15928285	Bronze			2022-12-28	WOS:000229443400022
J	Loke, YK				Loke, YK			The potassium-channel syndrome: does it exist?	LANCET			English	Editorial Material							HEMORRHAGIC-SHOCK; ACTIVATION		Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Loke, YK (corresponding author), Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.	Y.Loke@uea.ac.uk						Aronson JK, 2003, BRIT MED J, V326, P1346, DOI 10.1136/bmj.326.7403.1346; Maybauer DM, 2004, SHOCK, V22, P387, DOI 10.1097/01.shk.0000140661.78744.f6; Musser JB, 2004, ANESTHESIOLOGY, V101, P399, DOI 10.1097/00000542-200408000-00021; Pickkers P, 2004, SHOCK, V22, P320, DOI 10.1097/01.shk.0000142250.85264.10; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1834	1836		10.1016/S0140-6736(05)66599-3	http://dx.doi.org/10.1016/S0140-6736(05)66599-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924969				2022-12-28	WOS:000229481400008
J	Ahn, NG; Resing, KA				Ahn, NG; Resing, KA			Cell biology - Lessons in rational drug design for protein kinases	SCIENCE			English	Editorial Material							LUNG-CANCER; RESISTANCE; INHIBITORS; MUTATION; GEFITINIB; FAMILY		Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu						Bridges AJ, 1999, CURR MED CHEM, V6, P825; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799	8	15	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2005	308	5726					1266	1267		10.1126/science.1113707	http://dx.doi.org/10.1126/science.1113707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919981				2022-12-28	WOS:000229482300032
J	Fauser, BCJM; Devroey, P; Macklon, NS				Fauser, BCJM; Devroey, P; Macklon, NS			Mulltiple birth resulting from ovarian stimulation for subfertility treatment	LANCET			English	Review							IN-VITRO FERTILIZATION; SINGLE EMBRYO-TRANSFER; ASSISTED REPRODUCTIVE TECHNOLOGY; INTRAUTERINE INSEMINATION; MULTIPLE PREGNANCY; RANDOMIZED-TRIAL; NEUROLOGICAL SEQUELAE; OVULATION INDUCTION; BLASTOCYST TRANSFER; COST-EFFECTIVENESS	Assisted reproductive technologies (ARTs) aim to increase a woman's chances of becoming pregnant by bringing many female and male gametes into close proximity. Techniques to achieve this objective include ovarian hyperstimulation by maturation of several oocytes, intrauterine insemination (lUl) of concentrated sperm, or in-vitro fertilisation (IVF) by bringing gametes together outside the female body. The very nature of ovarian hyperstimulation-with or without IUI-enhances the risk of multiple pregnancy (eg, two or more babies). in most IVF cycles, more than one embryo is transferred, again resulting in an increased chance of multiple pregnancy. Developed societies have witnessed a large rise in prevalence of twin, triplet, and higher order multiple births, mainly resulting from ARTs. The primary aim of this Review is to increase awareness of the many implications of the present iatrogenic epidemic of multiple births. The background of ovarian hyperstimulation, trends supporting current practice, and strategies to reduce the chance of multiple pregnancy are highlighted.	Univ Med Ctr, Dept Reprod Med, NL-3584 CX Utrecht, Netherlands; Dutch Speaking Brussels Free Univ, Ctr Reprod Med, Brussels, Belgium; Erasmus MC, Ctr Reprod Med, Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Brussel; Erasmus University Rotterdam; Erasmus MC	Fauser, BCJM (corresponding author), Univ Med Ctr, Dept Reprod Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	b.c.fauser@azu.nl						Aboulghar MA, 2003, HUM REPROD UPDATE, V9, P275, DOI 10.1093/humupd/dmg018; Aboulghar Mohamed A., 2003, Archives of Gynecology and Obstetrics, V267, P177; Al-Inany H, 2002, HUM REPROD, V17, P874, DOI 10.1093/humrep/17.4.874; Amer Soc Reprod Med, 2002, FERTIL STERIL, V78, P918; Andereck WS, 1998, FERTIL STERIL, V70, P416; Andersen AN, 2004, HUM REPROD, V19, P490, DOI 10.1093/humrep/deh129; [Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; *ASRM, 2000, ASRM PRACT GUID, P1; Baird DT, 2000, HUM REPROD, V15, P723; Baird DT, 2004, HUM REPROD UPDATE, V10, P295, DOI 10.1093/humupd/dmh024; Bayram N, 2004, BMJ-BRIT MED J, V328, P192, DOI 10.1136/bmj.328.7433.192; Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Blickstein I, 2003, CURR OPIN OBSTET GYN, V15, P113, DOI 10.1097/00001703-200304000-00005; Blondel B, 2002, SEMIN PERINATOL, V26, P239, DOI 10.1053/sper.2002.34775; Bolton P, 2003, AUST NZ J OBSTET GYN, V43, P364, DOI 10.1046/j.0004-8666.2003.00107.x; Braude P, 2003, BMJ-BRIT MED J, V327, P852, DOI 10.1136/bmj.327.7419.852; Breart G, 2003, EUR J OBSTET GYN R B, V111, pS45, DOI 10.1016/j.ejogrb.2003.09.005; Cahill DJ, 2002, BMJ-BRIT MED J, V325, P28, DOI 10.1136/bmj.325.7354.28; CDC-Centers for Disease Control and Prevention, 2003, 2001 ASS REPR TECHN; *CDCP, 1996, 2000 ASS REPR TECHN; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P535; Coetsier T, 2001, HUM REPROD, V16, P790; Collins J, 2003, HUM REPROD, V18, P907, DOI 10.1093/humrep/deg170; Collins JA, 2004, HUM REPROD UPDATE, V10, P309, DOI 10.1093/humupd/dmh029; Collins JA, 2002, HUM REPROD UPDATE, V8, P265, DOI 10.1093/humupd/8.3.265; Crosignani PG, 2000, HUM REPROD, V15, P1856; De Neubourg Diane, 2003, Reprod Biomed Online, V7, P615; De Sutter P, 2002, HUM REPROD, V17, P2891, DOI 10.1093/humrep/17.11.2891; De Sutter P, 2003, Reprod Biomed Online, V6, P464; Devine PC, 2001, AM J PERINAT, V18, P225, DOI 10.1055/s-2001-15505; Devroey P, 2004, TRENDS ENDOCRIN MET, V15, P84, DOI 10.1016/j.tem.2004.01.009; Dodd JM, 2003, COCHRANE DB SYST REV, V2; Edwards RG, 1996, HUM REPROD, V11, P917; Eijkemans MJC, 2003, HUM REPROD, V18, P2357, DOI 10.1093/humrep/deg459; Evers JLH, 2002, LANCET, V360, P151, DOI 10.1016/S0140-6736(02)09417-5; FAUSER BC, 2004, YEN JAFFES REPROD EN, P965; Fauser BCJM, 2003, TRENDS ENDOCRIN MET, V14, P236, DOI 10.1016/S1043-2760(03)00075-4; Fauser BCJM, 2002, HUM REPROD UPDATE, V8, P1, DOI 10.1093/humupd/8.1.1; Fauser BCJM, 1997, ENDOCR REV, V18, P71, DOI 10.1210/edrv.18.1.0290; Fauser BCJM, 1999, HUM REPROD, V14, P2681, DOI 10.1093/humrep/14.11.2681; Filicori M, 2002, HUM REPROD UPDATE, V8, P543, DOI 10.1093/humupd/8.6.543; Francois K, 2001, J REPROD MED, V46, P1047; Frattarelli JL, 2003, FERTIL STERIL, V79, P228, DOI 10.1016/S0015-0282(02)04558-2; Garceau L, 2002, HUM REPROD, V17, P3090, DOI 10.1093/humrep/17.12.3090; Gardner DK, 2004, FERTIL STERIL, V81, P551, DOI 10.1016/j.fertnstert.2003.07.023; Gerris J, 2004, HUM REPROD, V19, P917, DOI 10.1093/humrep/deh188; Gerris J, 2002, HUM REPROD, V17, P2626, DOI 10.1093/humrep/17.10.2626; Glazebrook C, 2004, FERTIL STERIL, V81, P505, DOI 10.1016/j.fertnstert.2003.10.020; Gleicher N, 2000, NEW ENGL J MED, V343, P2, DOI 10.1056/NEJM200007063430101; Gosden R, 2003, LANCET, V361, P1975, DOI 10.1016/S0140-6736(03)13592-1; Goverde AJ, 2000, LANCET, V355, P13, DOI 10.1016/S0140-6736(99)04002-7; Guzick DS, 1999, NEW ENGL J MED, V340, P177, DOI 10.1056/NEJM199901213400302; Guzick DS, 1998, FERTIL STERIL, V70, P207, DOI 10.1016/S0015-0282(98)00177-0; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hargreave TB, 1998, BRIT MED J, V316, P1438, DOI 10.1136/bmj.316.7142.1438; Hazekamp J, 2000, HUM REPROD, V15, P1217, DOI 10.1093/humrep/15.6.1217; HEALY DL, 1994, LANCET, V343, P1539, DOI 10.1016/S0140-6736(94)92941-6; Heijnen EMEW, 2004, HUM REPROD, V19, P1936, DOI 10.1093/humrep/deh368; Helmerhorst FM, 2004, BRIT MED J, V328, P261, DOI 10.1136/bmj.37957.560278.EE; HELMERHORST FM, 1995, HUM REPROD, V10, P2027, DOI 10.1093/oxfordjournals.humrep.a136230; Hock DL, 2002, OBSTET GYNECOL, V99, P763, DOI 10.1016/S0029-7844(02)01950-6; HODGEN GD, 1982, FERTIL STERIL, V38, P281; Hogue CJR, 2002, OBSTET GYNECOL, V100, P1017, DOI 10.1016/S0029-7844(02)02327-X; Hohmann FP, 2003, J CLIN ENDOCR METAB, V88, P166, DOI 10.1210/jc.2002-020788; Hughes EG, 1997, HUM REPROD, V12, P1865, DOI 10.1093/humrep/12.9.1865; Hunault CC, 2002, FERTIL STERIL, V77, P725, DOI 10.1016/S0015-0282(01)03243-5; Jain T, 2004, NEW ENGL J MED, V350, P1639, DOI 10.1056/NEJMsa032073; Jain T, 2002, NEW ENGL J MED, V347, P661, DOI 10.1056/NEJMsa013491; Johnson NP, 2003, HUM REPROD, V18, P947, DOI 10.1093/humrep/deg260; Jones HW, 2003, FERTIL STERIL, V79, P17, DOI 10.1016/S0015-0282(02)04565-X; Karande VC, 1999, FERTIL STERIL, V71, P468, DOI 10.1016/S0015-0282(98)00490-7; Katz P, 2002, NAT CELL BIOL, V4, pS29, DOI 10.1038/ncb-nm-fertilityS29; Kuliev A, 2003, CURR OPIN OBSTET GYN, V15, P233, DOI 10.1097/00001703-200306000-00004; Land J. A., 2003, Human Reproduction (Oxford), V18, P455, DOI 10.1093/humrep/deg081; Lord JM, 2003, BRIT MED J, V327, P951, DOI 10.1136/bmj.327.7421.951; Lunenfeld B, 2004, HUM REPROD UPDATE, V10, P317, DOI 10.1093/humupd/dmh028; Martikainen H, 2001, HUM REPROD, V16, P1900, DOI 10.1093/humrep/16.9.1900; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; MENKEN J, 1986, SCIENCE, V233, P1389, DOI 10.1126/science.3755843; Min JK, 2004, HUM REPROD, V19, P3, DOI 10.1093/humrep/deh028; Mol BWJ, 2000, FERTIL STERIL, V73, P748, DOI 10.1016/S0015-0282(99)00610-X; Murray S, 2004, HUM REPROD, V19, P911, DOI 10.1093/humrep/deh176; *NICE, 2004, CLIN GUID, V11; Norman RJ, 2004, HUM REPROD UPDATE, V10, P267, DOI 10.1093/humupd/dmh018; Olivius C, 2004, FERTIL STERIL, V81, P258, DOI 10.1016/j.fertnstert.2003.06.029; Ombelet W, 2005, HUM REPROD UPDATE, V11, P3, DOI 10.1093/humupd/dmh048; PACHE TD, 1990, FERTIL STERIL, V54, P638; Pelinck MJ, 2002, HUM REPROD UPDATE, V8, P129, DOI 10.1093/humupd/8.2.129; PENDIAN Z, 2001, HUM REPROD, V18, P2001; Pinborg A, 2004, BMJ-BRIT MED J, V329, P311, DOI 10.1136/bmj.38156.715694.3A; Pinborg A, 2003, HUM REPROD, V18, P621, DOI 10.1093/humrep/deg145; Ryan GL, 2004, FERTIL STERIL, V81, P500, DOI 10.1016/j.fertnstert.2003.05.035; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; Schulman JD, 1996, HUM REPROD, V11, P697; Schultz RM, 2002, SCIENCE, V296, P2188, DOI 10.1126/science.1071741; Sharif K, 2003, HUM REPROD, V18, P483, DOI 10.1093/humrep/deg134; Soc As Reprod Tech Amer Reprod Med, 2004, FERTIL STERIL, V81, P1207, DOI 10.1016/j.fertnstert.2004.01.017; SOLIMAN S, 1993, FERTIL STERIL, V59, P1239; Stewart JA, 2003, HUM REPROD, V18, P903, DOI 10.1093/humrep/deg237; Strandell A, 2000, HUM REPROD, V15, P2520, DOI 10.1093/humrep/15.12.2520; Strauss A, 2002, FETAL DIAGN THER, V17, P209, DOI 10.1159/000059372; Stromberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Suri K, 2001, J Perinatol, V21, P293, DOI 10.1038/sj.jp.7200492; Taylor A, 2003, BRIT MED J, V327, P434, DOI 10.1136/bmj.327.7412.434; Templeton A, 1998, NEW ENGL J MED, V339, P573, DOI 10.1056/NEJM199808273390901; Tiitinen A, 2003, HUM REPROD, V18, P1449, DOI 10.1093/humrep/deg301; TUKER J, 2004, BMJ-BRIT MED J, V329, P675; Tur R, 2001, HUM REPROD, V16, P2124, DOI 10.1093/humrep/16.10.2124; Vail A, 2003, HUM REPROD, V18, P1000, DOI 10.1093/humrep/deg133; Van Royen E, 2001, HUM REPROD, V16, P326, DOI 10.1093/humrep/16.2.326; VANSANTBRINK EJP, 1995, FERTIL STERIL, V64, P37; Velde ERT, 2002, HUM REPROD UPDATE, V8, P141, DOI 10.1093/humupd/8.2.141; Wennerholm UB, 2004, ASSISTED REPODUCTIVE TECHNOLOGIES: QUALITY AND SAFETY, P23; Winston RML, 2002, NAT CELL BIOL, V4, pS14, DOI 10.1038/ncb-nm-fertilityS14; Wright Victoria C, 2003, MMWR Surveill Summ, V52, P1	115	255	266	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2005	365	9473					1807	1816		10.1016/S0140-6736(05)66478-1	http://dx.doi.org/10.1016/S0140-6736(05)66478-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910954				2022-12-28	WOS:000229291600026
J	Paterson, C; Dieppe, P				Paterson, C; Dieppe, P			Characteristic and incidental (placebo) effects in complex interventions such as acupuncture	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS		Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England	University of Bristol	Paterson, C (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England.	c.paterson@bristol.ac.uk						Barfod TS, 1999, CLIN DERMATOL, V17, P69, DOI 10.1016/S0738-081X(98)00061-3; Birch S, 2004, J ALTERN COMPLEM MED, V10, P481, DOI 10.1089/1075553041323911; Bootzin RR, 2002, SCI PLACEBO INTERDIS, P108; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; GRENCAVAGE LM, 1990, PROF PSYCHOL-RES PR, V21, P372, DOI 10.1037/0735-7028.21.5.372; GRUNBAUM A, 1985, PLACEBO THEORY RES M, P9; Hrobjartsson A, 2002, J CLIN EPIDEMIOL, V55, P430, DOI 10.1016/S0895-4356(01)00496-6; Johannessen Helle, 1996, COMPLEMENTARY ALTERN, P116; Kaptchuk TJ, 1996, COMPLEMENTARY MED OB, P31; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; Lewith G., 2002, CLIN RES COMPLEMENTA, P1; Mason S, 2002, BRIT MED J, V325, P832, DOI 10.1136/bmj.325.7368.832; Moerman Daniel E., 2002, CAMBRIDGE STUDIES ME; Paterson C, 2004, J ALTERN COMPLEM MED, V10, P791; Paterson C, 2003, J ALTERN COMPLEM MED, V9, P671, DOI 10.1089/107555303322524526; Paterson C, 2000, J Health Serv Res Policy, V5, P27; POWER R, 1994, HEALING BOND PATIENT, P193; Quilty B, 2003, J RHEUMATOL, V30, P1311; White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489	20	285	290	1	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2005	330	7501					1202	1205		10.1136/bmj.330.7501.1202	http://dx.doi.org/10.1136/bmj.330.7501.1202			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905259	Green Published			2022-12-28	WOS:000229320500025
J	Onda, K; Li, B; Zhao, J; Jordan, KD; Yang, JL; Petek, H				Onda, K; Li, B; Zhao, J; Jordan, KD; Yang, JL; Petek, H			Wet electrons at the H2O/TiO2(110) surface	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; INITIO MOLECULAR-DYNAMICS; HYDRATED ELECTRON; SEMICONDUCTOR; WATER; METALS; PHOTOCATALYSIS; TRANSITION; ADSORPTION; SIMULATION	At interfaces of metal oxide and water, partially hydrated or "wet-electron" states represent the lowest energy pathway for electron transfer. We studied the photoinduced electron transferatthe H2O/TiO2(110) interface by means of time-resolved two-photon photoemission spectroscopy and electronic structure theory. At &SIM; 1-monolayer coverage of water on partially hydroxylated TiO2 surfaces, we found an unoccupied electronic state 2.4 electron volts above the Fermi level. Density functional theory shows this to be a wet-electron state analogous to that reported in water clusters and which is distinct from hydrated electrons observed on water-covered metal surfaces. The decay of electrons from the wet-electron state to the conduction band of TiO2 occurs in &LE; 15 femtoseconds..	Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Onda, K (corresponding author), Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA.		Zhao, Jin/E-2735-2016; Yang, Jinlong/D-3465-2009; Onda, Ken/H-3389-2014; Petek, Hrvoje/A-3912-2009	Zhao, Jin/0000-0003-1346-5280; Onda, Ken/0000-0003-1724-2009; Petek, Hrvoje/0000-0001-9605-2590				Anderson NA, 2005, ANNU REV PHYS CHEM, V56, P491, DOI 10.1146/annurev.physchem.55.091602.094347; Bragg AE, 2004, SCIENCE, V306, P669, DOI 10.1126/science.1103527; Brookes IM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.266103; Brown GE, 1999, CHEM REV, V99, P77, DOI 10.1021/cr980011z; CHANDER M, 1993, PHYS REV B, V48, P2493, DOI 10.1103/PhysRevB.48.2493; Diebold U, 2003, SURF SCI REP, V48, P53, DOI 10.1016/S0167-5729(02)00100-0; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; Gahl C, 2003, SURF SCI, V532, P108, DOI 10.1016/S0039-6028(03)00186-9; Gahl C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.107402; Hagfeldt A, 2000, ACCOUNTS CHEM RES, V33, P269, DOI 10.1021/ar980112j; Hammer NI, 2004, SCIENCE, V306, P675, DOI 10.1126/science.1102792; Henderson MA, 2002, SURF SCI REP, V46, P1, DOI 10.1016/S0167-5729(01)00020-6; Henderson MA, 1996, SURF SCI, V355, P151, DOI 10.1016/0039-6028(95)01357-1; Henderson MA, 2003, J PHYS CHEM B, V107, P534, DOI 10.1021/jp0262113; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Huber R, 2000, J PHYS CHEM B, V104, P8995, DOI 10.1021/jp9944381; Jordan KD, 2004, SCIENCE, V306, P618, DOI 10.1126/science.1104678; KEVAN L, 1981, ACCOUNTS CHEM RES, V14, P138, DOI 10.1021/ar00065a002; Kim KS, 1996, PHYS REV LETT, V76, P956, DOI 10.1103/PhysRevLett.76.956; KRESSE G, 1994, PHYS REV B, V49, P14251, DOI 10.1103/PhysRevB.49.14251; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; KRESSE G, 1993, PHYS REV B, V48, P13115, DOI 10.1103/PhysRevB.48.13115; Leconte J, 2002, SURF SCI, V497, P194, DOI 10.1016/S0039-6028(01)01477-7; LINSEBIGLER AL, 1995, CHEM REV, V95, P735, DOI 10.1021/cr00035a013; Onda K, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.045415; Paik DH, 2004, SCIENCE, V306, P672, DOI 10.1126/science.1102827; PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244; Petek H, 1997, PROG SURF SCI, V56, P239, DOI 10.1016/S0079-6816(98)00002-1; Schaub R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.266104; Schnadt J, 2002, NATURE, V418, P620, DOI 10.1038/nature00952; SCHNITKER J, 1987, J CHEM PHYS, V86, P3471, DOI 10.1063/1.452003; Suzuki S, 2000, PHYS REV LETT, V84, P2156, DOI 10.1103/PhysRevLett.84.2156; Szczepankiewicz SH, 2000, J PHYS CHEM B, V104, P9842, DOI 10.1021/jp0007890; Verlet JRR, 2005, SCIENCE, V307, P93, DOI 10.1126/science.1106719; Wang R, 1997, NATURE, V388, P431, DOI 10.1038/41233; Zimmermann C, 2001, J PHYS CHEM B, V105, P9245, DOI 10.1021/jp011106z	37	220	226	5	286	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2005	308	5725					1154	1158		10.1126/science.1109366	http://dx.doi.org/10.1126/science.1109366			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905397				2022-12-28	WOS:000229293400039
J	Fialko, Y; Sandwell, D; Simons, M; Rosen, P				Fialko, Y; Sandwell, D; Simons, M; Rosen, P			Three-dimensional deformation caused by the Bam, Iran, earthquake and the origin of shallow slip deficit	NATURE			English	Article							HECTOR MINE EARTHQUAKE; SAN-ANDREAS FAULT; TRANSIENT STRAIN ACCUMULATION; RADAR INTERFEROMETRY; LANDERS-EARTHQUAKE; POSTSEISMIC DEFORMATION; SURFACE DISPLACEMENT; SUPERSTITION HILLS; IZMIT MAINSHOCK; HAYWARD FAULT	Our understanding of the earthquake process requires detailed insights into how the tectonic stresses are accumulated and released on seismogenic faults. We derive the full vector displacement field due to the Bam, Iran, earthquake of moment magnitude 6.5 using radar data from the Envisat satellite of the European Space Agency. Analysis of surface deformation indicates that most of the seismic moment release along the 20-km-long strike-slip rupture occurred at a shallow depth of 4 - 5 km, yet the rupture did not break the surface. The Bam event may therefore represent an end-member case of the 'shallow slip deficit' model, which postulates that coseismic slip in the uppermost crust is systematically less than that at seismogenic depths ( 4 - 10 km). The InSAR-derived surface displacement data from the Bam and other large shallow earthquakes suggest that the uppermost section of the seismogenic crust around young and developing faults may undergo a distributed failure in the interseismic period, thereby accumulating little elastic strain.	Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA; CALTECH, Div Geol & Planetary Sci, Seismol Lab, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Fialko, Y (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA.	fialko@radar.ucsd.edu	Fialko, Yuri/B-9567-2012; Simons, Mark/N-4397-2015	Fialko, Yuri/0000-0002-6161-8467; Simons, Mark/0000-0003-1412-6395; Sandwell, David/0000-0001-5657-8707				Ben-Zion Y, 2003, GEOPHYS J INT, V152, P699, DOI 10.1046/j.1365-246X.2003.01870.x; BILHAM R, 1989, B SEISMOL SOC AM, V79, P424; BOATWRIGHT J, 1980, B SEISMOL SOC AM, V70, P1; Burgmann R, 2000, SCIENCE, V289, P1178, DOI 10.1126/science.289.5482.1178; BYERLEE J, 1978, PURE APPL GEOPHYS, V116, P615, DOI 10.1007/BF00876528; Cakir Z, 2003, GEOPHYS J INT, V155, P93, DOI 10.1046/j.1365-246X.2003.02001.x; Chinnery M. A., 1961, B SEISMOL SOC AM, V51, P355, DOI DOI 10.1785/BSSA0510030355; Delouis B, 2002, B SEISMOL SOC AM, V92, P278, DOI 10.1785/0120000806; Dolan JF, 2003, SCIENCE, V300, P115, DOI 10.1126/science.1080593; Farr T. G., 2000, AM GEOPHYS UNION EOS, V81, P583, DOI DOI 10.1029/EO081I048P00583; Feigl KL, 2002, B SEISMOL SOC AM, V92, P138, DOI 10.1785/0120000830; Fialko Y, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002756; Fialko Y, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB002985; Fialko Y, 2002, SCIENCE, V297, P1858, DOI 10.1126/science.1074671; Fialko Y, 2001, GEOPHYS RES LETT, V28, P3063, DOI 10.1029/2001GL013174; HEATON TH, 1990, PHYS EARTH PLANET IN, V64, P1, DOI 10.1016/0031-9201(90)90002-F; Hickman S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020043; Jacobs A, 2002, B SEISMOL SOC AM, V92, P1433, DOI 10.1785/0120000908; Jonsson S, 2002, B SEISMOL SOC AM, V92, P1377, DOI 10.1785/0120000922; Lettis WR, 1997, B SEISMOL SOC AM, V87, P1171; Lyons S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001831; Manning CE, 1999, REV GEOPHYS, V37, P127, DOI 10.1029/1998RG900002; Marone C, 1998, ANNU REV EARTH PL SC, V26, P643, DOI 10.1146/annurev.earth.26.1.643; MARONE CJ, 1991, J GEOPHYS RES-SOLID, V96, P8441, DOI 10.1029/91JB00275; MASSONNET D, 1993, NATURE, V364, P138, DOI 10.1038/364138a0; Michel R, 1999, GEOPHYS RES LETT, V26, P875, DOI 10.1029/1999GL900138; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Oskin M, 2004, GEOLOGY, V32, P313, DOI 10.1130/G20223.1; Peltzer G, 1999, SCIENCE, V286, P272, DOI 10.1126/science.286.5438.272; Peltzer G, 1998, J GEOPHYS RES-SOL EA, V103, P30131, DOI 10.1029/98JB02302; Peltzer G, 2001, GEOLOGY, V29, P975, DOI 10.1130/0091-7613(2001)029<0975:TSAAFI>2.0.CO;2; ROSEN P, 2003, EOS, V85, P47; Rosen PA, 2000, P IEEE, V88, P333, DOI 10.1109/5.838084; Sandwell DT, 2000, GEOPHYS RES LETT, V27, P3101, DOI 10.1029/1999GL011209; SAVAGE JC, 1993, J GEOPHYS RES-SOL EA, V98, P787, DOI 10.1029/92JB01871; Savage JC, 1997, J GEOPHYS RES-SOL EA, V102, P7565, DOI 10.1029/97JB00210; Scharroo R, 1998, J GEOPHYS RES-OCEANS, V103, P8113, DOI 10.1029/97JC03179; SHARP RV, 1986, B SEISMOL SOC AM, V76, P949; SIEH KE, 1984, GEOL SOC AM BULL, V95, P883, DOI 10.1130/0016-7606(1984)95<883:HAOTSA>2.0.CO;2; SYLVESTER AG, 1988, GEOL SOC AM BULL, V100, P1666, DOI 10.1130/0016-7606(1988)100<1666:SSF>2.3.CO;2; Talebian M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020058; TATAR M, IN PRESS J SEISMOL E; THATCHER W, 1983, J GEOPHYS RES, V88, P5893, DOI 10.1029/JB088iB07p05893; TSE ST, 1986, J GEOPHYS RES-SOLID, V91, P9452, DOI 10.1029/JB091iB09p09452; Wang RJ, 2003, COMPUT GEOSCI-UK, V29, P195, DOI 10.1016/S0098-3004(02)00111-5; WILLIAMS PL, 1988, B SEISMOL SOC AM, V78, P1112	47	351	385	4	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					295	299		10.1038/nature03425	http://dx.doi.org/10.1038/nature03425			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902247	Green Submitted			2022-12-28	WOS:000229185000035
J	Hsieh, CH; Glaser, SM; Lucas, AJ; Sugihara, G				Hsieh, CH; Glaser, SM; Lucas, AJ; Sugihara, G			Distinguishing random environmental fluctuations from ecological catastrophes for the North Pacific Ocean	NATURE			English	Article							DETECTING REGIME SHIFTS; TIME-SERIES; STABLE POINTS; CHAOS; VARIABILITY; POPULATIONS; CALIFORNIA; MODELS; ERROR	The prospect of rapid dynamic changes in the environment is a pressing concern that has profound management and public policy implications(1,2). Worries over sudden climate change and irreversible changes in ecosystems are rooted in the potential that nonlinear systems have for complex and 'pathological' behaviours(1,2). Nonlinear behaviours have been shown in model systems(3) and in some natural systems(1,4-8), but their occurrence in large-scale marine environments remains controversial(9,10). Here we show that time series observations of key physical variables(11-14) for the North Pacific Ocean that seem to show these behaviours are not deterministically nonlinear, and are best described as linear stochastic. In contrast, we find that time series for biological variables(5,15-17) having similar properties exhibit a low-dimensional nonlinear signature. To our knowledge, this is the first direct test for nonlinearity in large-scale physical and biological data for the marine environment. These results address a continuing debate over the origin of rapid shifts in certain key marine observations as coming from essentially stochastic processes or from dominant nonlinear mechanisms(1,9,10,18-20). Our measurements suggest that large-scale marine ecosystems are dynamically nonlinear, and as such have the capacity for dramatic change in response to stochastic fluctuations in basin-scale physical states.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Sugihara, G (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	gsugihara@ucsd.edu	Hsieh, Chih-hao/B-3797-2008	Hsieh, Chih-hao/0000-0001-5935-7272; Lucas, Andrew/0000-0001-7722-7252				deYoung B, 2004, PROG OCEANOGR, V60, P143, DOI 10.1016/j.pocean.2004.02.017; Dixon PA, 1999, SCIENCE, V283, P1528, DOI 10.1126/science.283.5407.1528; Dixon PA, 2001, NONLINEAR DYNAMICS AND STATISTICS, P339; Hare SR, 2000, PROG OCEANOGR, V47, P103, DOI 10.1016/S0079-6611(00)00033-1; HASSELMANN K, 1976, TELLUS, V28, P473, DOI 10.1111/j.2153-3490.1976.tb00696.x; Hastings HM, 1993, FRACTALS USERS GUIDE; HSIEH CH, UNPUB PROG OCEANOGR; HURRELL J, 2003, N PACIFIC NP INDEX I; LUDWIG D, 1978, J ANIM ECOL, V47, P315, DOI 10.2307/3939; Mantua N, 2004, PROG OCEANOGR, V60, P165, DOI 10.1016/j.pocean.2004.02.016; MANTUA NJ, 2004, PACIFIC DECADAL OSCI; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; McGowan JA, 2003, DEEP-SEA RES PT II, V50, P2567, DOI 10.1016/S0967-0645(03)00135-8; *NAT CTR ATM RES, 2004, SO OSC IND; Patil DAS, 2001, MON WEATHER REV, V129, P2116, DOI 10.1175/1520-0493(2001)129<2116:ILDNBI>2.0.CO;2; Rebstock GA, 2002, GLOBAL CHANGE BIOL, V8, P71, DOI 10.1046/j.1365-2486.2002.00456.x; Rudnick DL, 2003, DEEP-SEA RES PT I, V50, P691, DOI 10.1016/S0967-0637(03)00053-0; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; STEELE JH, 1984, SCIENCE, V224, P985, DOI 10.1126/science.224.4652.985; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; Sugihara G, 1999, P NATL ACAD SCI USA, V96, P14210, DOI 10.1073/pnas.96.25.14210; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; SUGIHARA G, 1994, PHILOS T R SOC A, V348, P477, DOI 10.1098/rsta.1994.0106; SUTHERLAND JP, 1974, AM NAT, V108, P859, DOI 10.1086/282961; *WA DEP FISH WILDL, 2004, STAT REP COL RIV FIS; Wunsch C, 1999, B AM METEOROL SOC, V80, P245, DOI 10.1175/1520-0477(1999)080<0245:TIOSCR>2.0.CO;2; [No title captured]	29	245	250	2	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					336	340		10.1038/nature03553	http://dx.doi.org/10.1038/nature03553			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902256				2022-12-28	WOS:000229185000044
J	Shlipak, MG; Sarnak, MJ; Katz, R; Fried, LF; Seliger, SL; Newman, AB; Siscovick, DS; Stehman-Breen, C				Shlipak, MG; Sarnak, MJ; Katz, R; Fried, LF; Seliger, SL; Newman, AB; Siscovick, DS; Stehman-Breen, C			Cystatin C and the risk of death and cardiovascular events among elderly persons	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; RENAL-INSUFFICIENCY; MYOCARDIAL-INFARCTION; OLDER-ADULTS; MORTALITY; OUTCOMES; DYSFUNCTION; HOSPITALIZATION; PREDICTION	BACKGROUND: Cystatin C is a serum measure of renal function that appears to be independent of age, sex, and lean muscle mass. We compared creatinine and cystatin C levels as predictors of mortality from cardiovascular causes and from all causes in the Cardiovascular Health Study, a cohort study of elderly persons living in the community. METHODS: Creatinine and cystatin C were measured in serum samples collected from 4637 participants at the study visit in 1992 or 1993; follow-up continued until June 30, 2001. For each measure, the study population was divided into quintiles, with the fifth quintile subdivided into thirds (designated 5a, 5b, and 5c). RESULTS: Higher cystatin C levels were directly associated, in a dose-response manner, with a higher risk of death from all causes. As compared with the first quintile, the hazard ratios (and 95 percent confidence intervals) for death were as follows: second quintile, 1.08 (0.86 to 1.35); third quintile, 1.23 (1.00 to 1.53); fourth quintile, 1.34 (1.09 to 1.66); quintile 5a, 1.77 (1.34 to 2.26); 5b, 2.18 (1.72 to 2.78); and 5c, 2.58 (2.03 to 3.27). In contrast, the association of creatinine categories with mortality from all causes appeared to be J-shaped. As compared with the two lowest quintiles combined (cystatin C level, lessthan/equal 0.99 mg per liter), the highest quintile of cystatin C (greater/equal 1.29 mg per liter) was associated with a significantly elevated risk of death from cardiovascular causes (hazard ratio, 2.27 [1.73 to 2.97]), myocardial infarction (hazard ratio, 1.48 [1.08 to 2.02]), and stroke (hazard ratio, 1.47 [ 1.09 to 1.96]) after multivariate adjustment. The fifth quintile of creatinine, as compared with the first quintile, was not independently associated with any of these three outcomes. CONCLUSIONS: Cystatin C, a serum measure of renal function, is a stronger predictor of the risk of death and cardiovascular events in elderly persons than is creatinine.	Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Tufts New England Med Ctr, Dept Med, Div Nephrol, Boston, MA USA; Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA; Vet Affairs Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA USA; Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Amgen Inc, Thousand Oaks, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tufts Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Amgen	Shlipak, MG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu	Katz, Ronit/ABA-1880-2021; Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150; Seliger, Stephen/0000-0002-1693-0734	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085081, N01HC085086, N01HC085080, N01HC035129, N01HC015103, N01HC085082, N01HC085083, N01HC085084, N01HC085079, N01HC085085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073208] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85082, N01-HC-35129, N01-HC-85081, N01-HC-85079, N01-HC-85080, N01-HC-85086, N01-HC-85085, R01 HL073208-01, N01 HC-15103, N01-HC-85084, N01-HC-85083] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; Chertow GM, 1997, CIRCULATION, V95, P878; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; CUSHMAN M, 1995, CLIN CHEM, V41, P264; Erlandsen EJ, 1999, SCAND J CLIN LAB INV, V59, P1, DOI 10.1080/00365519950185940; Fliser D, 2001, AM J KIDNEY DIS, V37, P79, DOI 10.1053/ajkd.2001.20591; Fricker M, 2003, KIDNEY INT, V63, P1944, DOI 10.1046/j.1523-1755.2003.00925.x; Fried LF, 2003, J AM COLL CARDIOL, V41, P1364, DOI 10.1016/S0735-1097(03)00163-3; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Garg AX, 2004, KIDNEY INT, V65, P649, DOI 10.1111/j.1523-1755.2004.00412.x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Herget-Rosenthal S, 2000, AM J NEPHROL, V20, P97, DOI 10.1159/000013564; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Jayagopal V, 2003, CLIN CHEM, V49, P680, DOI 10.1373/49.4.680; Knight EL, 2004, KIDNEY INT, V65, P1416, DOI 10.1111/j.1523-1755.2004.00517.x; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; Shlipak MG, 2002, ANN INTERN MED, V137, P555, DOI 10.7326/0003-4819-137-7-200210010-00006; Shlipak MG, 2004, J AM SOC NEPHROL, V15, P2195, DOI 10.1097/01.ASN.0000135121.81744.75; Singer MA, 2001, AM J KIDNEY DIS, V37, P164, DOI 10.1016/S0272-6386(01)80073-1; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Wiesli P, 2003, CLIN CHIM ACTA, V338, P87, DOI 10.1016/j.cccn.2003.07.022	28	956	1014	2	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2049	2060		10.1056/NEJMoa043161	http://dx.doi.org/10.1056/NEJMoa043161			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901858				2022-12-28	WOS:000229180100003
J	Talbot, TR; Hartert, TV; Mitchel, E; Halasa, NB; Arbogast, PG; Poehling, KA; Schaffner, W; Craig, AS; Griffin, MR				Talbot, TR; Hartert, TV; Mitchel, E; Halasa, NB; Arbogast, PG; Poehling, KA; Schaffner, W; Craig, AS; Griffin, MR			Asthma as a risk factor for invasive pneumococcal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYSACCHARIDE VACCINE; OLDER-ADULTS; INFECTIONS; HEALTH	BACKGROUND: The risk of invasive pneumococcal disease among persons with asthma is unknown. METHODS: We conducted a nested case-control study to examine the association between asthma and invasive pneumococcal disease. The study population included persons 2 to 49 years of age who were enrolled in Tennessee's Medicaid program (TennCare) for more than one year during the study period (1995 through 2002) and who resided in counties participating in a prospective laboratory-based program of surveillance for invasive pneumococcal disease. For each subject with invasive pneumococcal disease, 10 age-matched controls without invasive pneumococcal disease were randomly selected from the same population. TennCare files were queried to identify the presence of coexisting conditions that confer a high risk of pneumococcal disease. For the purpose of our study, asthma was defined by documentation of one or more inpatient or emergency-department diagnoses of asthma, two outpatient diagnoses, or the use of asthma-related medications. High-risk asthma was defined as asthma requiring admission to a hospital or a visit to an emergency department, the use of rescue therapy or long-term use of oral corticosteroids, or the dispensing of three or more prescriptions for (beta)-agonists within the year before enrollment in the study. RESULTS: A total of 635 persons with invasive pneumococcal disease and 6350 controls were identified, of whom 114 (18.0 percent) and 516 (8.1 percent), respectively, had asthma. Persons with asthma had an increased risk of invasive pneumococcal disease (adjusted odds ratio, 2.4; 95 percent confidence interval, 1.9 to 3.1) as compared with controls. Among those without coexisting conditions, the annual incidence of invasive pneumococcal disease was 4.2 episodes per 10,000 persons with high-risk asthma and 2.3 episodes per 10,000 persons with low-risk asthma, as compared with 1.2 episodes per 10,000 persons without asthma. CONCLUSIONS: Asthma is an independent risk factor for invasive pneumococcal disease. The risk among persons with asthma was at least double that among controls.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Ctr Educ & Res Therapeut, Nashville, TN 37212 USA; Tennessee Dept Hlth, Nashville, TN USA; Vet Affairs Tennessee Valley Healthcare Syst, Ctr Geriatr Res Educ & Clin, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Tennessee Department Health; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Talbot, TR (corresponding author), A-4103C Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	tom.talbot@vanderbilt.edu		Talbot, Thomas/0000-0002-6139-212X	NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017697, M01RR000095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050884, K08AI001582] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00095, K12 RR-017697] Funding Source: Medline; NHLBI NIH HHS [UO1HL72471] Funding Source: Medline; NIAID NIH HHS [KO8 AI 001582, R01 AI 50884] Funding Source: Medline; ODCDC CDC HHS [U50/CCU416123] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ODCDC CDC HHS		[Anonymous], 2000, MMWR Recomm Rep, V49, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BARDIN PG, 1994, CLIN EXP ALLERGY, V24, P457, DOI 10.1111/j.1365-2222.1994.tb00934.x; BURMAN LA, 1985, REV INFECT DIS, V7, P133; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; *CDCP, 2002, ACT BACT COR SURV EM; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; HART AC, 2002, INT CLASSIFICATION D, V1; HART AC, 2002, INT CLASSIFICATION D, V3; HART AC, 2002, INT CLASSIFICATION D, V2; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; Hartert TV, 2000, J AM GERIATR SOC, V48, P651, DOI 10.1111/j.1532-5415.2000.tb04723.x; Hartert TV, 2002, ANN ALLERG ASTHMA IM, V89, P467, DOI 10.1016/S1081-1206(10)62083-2; Koehler DR, 2004, AM J RESP CELL MOL, V31, P377, DOI 10.1165/rcmb.2004-0124TR; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; *NAT ASTHM ED PREV, 1997, NIH PUBL; National Asthma Education and Prevention Program, 2003, J ALLERGY CLIN IMMUN, V111, P466, DOI DOI 10.1542/PEDS.2007-3825; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114; Talbot TR, 2004, PEDIATR INFECT DIS J, V23, P726, DOI 10.1097/01.inf.0000133046.60555.de; Talbot TR, 2004, CLIN INFECT DIS, V39, P641, DOI 10.1086/422653; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; US CENSUS 2000 STAT; 2004, MMWR MORB MORTAL WKL, V53, P145	32	299	313	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2082	2090		10.1056/NEJMoa044113	http://dx.doi.org/10.1056/NEJMoa044113			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901861	Bronze			2022-12-28	WOS:000229180100006
J	Bodenheimer, T				Bodenheimer, T			High and rising health care costs. Part 1: Seeking an explanation	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICARE BENEFICIARIES; INSURANCE; COMPETITION; BENEFITS; TRENDS; CONSOLIDATION; POPULATION; DISABILITY; HOSPITALS; EMPLOYERS	The United States has the most expensive health care system in the world, with per capita health expenditures far above those of any other nation. For many years, U.S. health care expenditures have been growing above the overall rate of inflation in the economy. A few experts have argued that high and rising costs are not such a serious problem. Most observers disagree with this view, pointing to the negative impact of employee health care costs on employers, the government budgetary problems caused by rising health care expenditures, and an association between high health care costs and reduced access for individuals needing health services. Several explanations have been offered for high and rising health care costs. These include the perspectives that high and rising costs are created by forces external to the health system, by the weakness of a competitive free market within the health system, by the rapid diffusion of new technologies, by excessive costs of administering the health system, by the absence of strong cost-containment measures, and by undue market power of health care providers. This article, the first in a 4-part series, discusses 3 perspectives on health care: 1) Are high and rising health care costs a serious problem? 2) Are rising costs explained by factors outside the health care system? 3) Does the absence of a free market in health care explain why costs are high and rising? The remaining 3 articles in this series address other perspectives on health care costs.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.	Tbodenheimer@medsch.ucsf.edu	Peters, Terry M/K-6853-2013	Peters, Terry M/0000-0003-1440-7488				Aaron H., 1991, SERIOUS UNSTABLE CON; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; BERENSON RA, 2001, HLTH AFF MILWOO 1128; Berk ML, 2001, HEALTH AFFAIR, V20, P9, DOI 10.1377/hlthaff.20.2.9; Blustein J, 2000, HEALTH AFFAIR, V19, P219, DOI 10.1377/hlthaff.19.2.219; Bodenheimer T, 1998, NEW ENGL J MED, V338, P1084, DOI 10.1056/NEJM199804093381525; BODENHEIMER T, 2005, UNDERSTANDING HLTH P, P167; Chernew ME, 2003, HEALTH AFFAIR, V22, P15, DOI 10.1377/hlthaff.22.4.15; Christianson JB, 2002, HEALTH AFFAIR, V21, P49, DOI 10.1377/hlthaff.21.1.49; *CTR MED MED SERV, 2000, CURR MED CURR BEN SU; Cuellar AE, 2003, HEALTH AFFAIR, V22, P77, DOI 10.1377/hlthaff.22.6.77; DAVIS K, 1990, HLTH CARE COST CONTA; Devers KJ, 2003, HEALTH SERV RES, V38, P447, DOI 10.1111/1475-6773.00124; Devers KJ, 2003, HEALTH SERV RES, V38, P419, DOI 10.1111/1475-6773.00123; ENTHOVEN AC, 2003, HLTH AFF MILWOO 0528; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Gabel J, 2003, HEALTH AFFAIR, V22, P117, DOI 10.1377/hlthaff.22.5.117; Gabel J, 2004, HEALTH AFFAIR, V23, P200, DOI 10.1377/hlthaff.23.5.200; Gabel J, 2002, HEALTH AFFAIR, V21, P143, DOI 10.1377/hlthaff.21.5.143; Gabel JR, 1999, HEALTH AFFAIR, V18, P62, DOI 10.1377/hlthaff.18.6.62; GINSBURG PB, 2003, HLTH AFF MILWOO 1008; Goetghebeur MM, 2003, AM J MANAG CARE, V9, pSP3; HALVORSON G, 2003, EPIDEMIC CARE; HEFFLER S, 2004, HLTH AFF        0211; HERZLINGER R, 1997, MARKET DRIVEN HLTH C; Institute of Medicine, 2000, AM HLTH CAR SAF NET; *KAIS COMM MED UN, 1998, UN AM CHART BOOK; *KAIS COMM MED UN, 2002, MED ENR 50 STAT; Keeler EB, 1999, J HEALTH ECON, V18, P69, DOI 10.1016/S0167-6296(98)00036-8; Krishnan R, 2001, J HEALTH ECON, V20, P213, DOI 10.1016/S0167-6296(00)00076-X; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; LIEBOWITZ S, 1994, WHY HLTH CARE COSTS; LOHR KN, 1986, MED CARE, V24, pUS1; Luft H S, 1986, Med Care Rev, V43, P217, DOI 10.1177/107755878604300202; LUFT HS, 1994, CRITICAL ISSUES US H, P303; MANNING WG, 1987, AM ECON REV, V77, P251; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; Meara E, 2004, HEALTH AFFAIR, V23, P176, DOI 10.1377/hlthaff.23.4.176; Melnick G, 1999, HEALTH AFFAIR, V18, P167, DOI 10.1377/hlthaff.18.3.167; MELNICK G, 1996, CHANGING US HLTH CAR, P302; MORRISON I, 2000, JOS-BAS HEA, P1; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; Newhouse JP, 2004, HEALTH AFFAIR, V23, P107, DOI 10.1377/hlthaff.23.6.107; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OECD, 2003, DIS BAS COMP HLTH SY; PAULY MV, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.3.152; Pauly MV, 2002, HEALTH AFFAIR, V21, P194, DOI 10.1377/hlthaff.21.1.194; PAULY MV, 2003, HLTH AFF        0108; Reinhardt UE, 2003, HEALTH AFFAIR, V22, P27, DOI 10.1377/hlthaff.22.6.27; Reinhardt UE, 2002, HEALTH AFFAIR, V21, P169, DOI 10.1377/hlthaff.21.3.169; RICE T, 1993, JAMA-J AM MED ASSOC, V270, P1357, DOI 10.1001/jama.270.11.1357; RICE T, 1994, CRITICAL ISSUES US H, P57; RICE TH, 1996, CHANGING US HLTH CAR, P62; Robinson JC, 2004, HEALTH AFFAIR, V23, P11, DOI 10.1377/hlthaff.23.6.11; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; ROBINSON JC, 2002, HLTH AFF MILLWOOD; ROBINSON JC, 2002, HLTH AFF MILWOO 0320; Sandy LG, 2002, NEW ENGL J MED, V347, P1971, DOI 10.1056/NEJMsb021260; Smith C, 2005, HEALTH AFFAIR, V24, P185, DOI 10.1377/hlthaff.24.1.185; STRUNK BC, 2002, HLTH AFF        0611; Sturm R, 2004, HEALTH AFFAIR, V23, P199, DOI 10.1377/hlthaff.23.2.199; Town R, 2001, J HEALTH ECON, V20, P733, DOI 10.1016/S0167-6296(01)00096-0; *US GEN ACC OFF, 1997, MED FEW LOW COST BEN; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Weil A, 2003, HEALTH AFFAIR, V22, P13, DOI 10.1377/hlthaff.22.1.13; ZWANZIGER J, 1994, HEALTH AFFAIR, V13, P118, DOI 10.1377/hlthaff.13.4.118; [No title captured]	68	189	190	2	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					847	854		10.7326/0003-4819-142-10-200505170-00010	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	926CE	15897535				2022-12-28	WOS:000229099600006
J	DuPont, HL; Jiang, ZD; Okhuysen, PC; Ericsson, CD; de la Cabada, FJ; Ke, S; DuPont, MW; Martinez-Sandoval, F				DuPont, HL; Jiang, ZD; Okhuysen, PC; Ericsson, CD; de la Cabada, FJ; Ke, S; DuPont, MW; Martinez-Sandoval, F			A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea	ANNALS OF INTERNAL MEDICINE			English	Article							IRRITABLE-BOWEL-SYNDROME; ESCHERICHIA-COLI; BACTERIAL GASTROENTERITIS; SUSCEPTIBILITY; THERAPY; ENTEROPATHOGENS; TRIMETHOPRIM; PROPHYLAXIS; EMERGENCE; RIFAMYCIN	Background: Travelers' diarrhea causes substantial morbidity and postinfectious irritable bowel syndrome. Objective: To evaluate nonabsorbable rifaximin for prevention of travelers' diarrhea. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Guadalajara, Mexico. Participants: U.S. students. Intervention: on arrival in Guadalajara, Mexico, 210 U.S. adults received rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 times daily) or placebo for 2 weeks. Measurements: Participants were followed daily for 3 weeks for enteric disease and symptoms and daily for 5 weeks for drug side effects. Changes in intestinal coliform flora were studied. Results: Travelers' diarrhea developed in 14.74% of participants taking rifaximin and 53.70% of those taking placebo (rate ratio, 0.27 [95% CI, 0.17 to 0.43]). Rifaximin provided 72% and 77% protection against travelers' diarrhea and anti biotic-treated travelers' diarrhea, respectively (P < 0.001 for both), and all rifaximin doses were superior to placebo. in the groups that did not report travelers' diarrhea, rifaximin significantly reduced the occurrence of mild diarrhea (P = 0.02) and moderate and severe intestinal problems (P = 0.009 for pain or cramps; P = 0.02 for excessive gas). Rates of adverse events were comparable in the rifaximin and placebo groups. Minimal changes in coliform flora were found during rifaximin therapy. Limitations: Rifaximin safely prevented travelers' diarrhea in Mexico, where most cases are caused by diarrhea-producing Escherichia coli. A study is needed in Asia to determine whether rifaximin can prevent diarrhea caused by invasive bacterial pathogens. Conclusions: Rifaximin prevents travelers' diarrhea with minimal changes in fecal flora, and more liberal chemoprophylaxis against this disease should be considered. Future studies should evaluate whether rifaximin is effective in preventing postinfectious irritable bowel syndrome.	Univ Texas, Baylor Coll Med, St Lukes Episcopal Hosp, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Hosp Gen Occidente Seguro Social, Guadalajara, Jalisco, Mexico; Univ Autonoma Guadalajara, Guadalajara, Jalisco, Mexico	Baylor College of Medicine; Saint Lukes Episcopal Hospital; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Universidad Autonoma de Guadalajara	DuPont, HL (corresponding author), 6720 Bertner Ave,MC 1-164, Houston, TX 77030 USA.	hdupont@sleh.com	DuPont, Herbert/AAH-6776-2021	Okhuysen, Pablo/0000-0002-1596-3411	NIAID NIH HHS [N01-AI-25465] Funding Source: Medline; NIDDK NIH HHS [DK 56338] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi JA, 2003, CLIN INFECT DIS, V37, P1165, DOI 10.1086/378746; Adachi JA, 2001, CLIN INFECT DIS, V32, P1706, DOI 10.1086/320756; ALEXANDER WJ, 1980, INFECT IMMUN, V28, P923; CORAZZA GR, 1988, J INT MED RES, V16, P312, DOI 10.1177/030006058801600410; DUPONT H, 1993, GASTROINTESTINAL DIS, V2, P1; DUPONT HL, 1982, REV INFECT DIS, V4, P533; DuPont HL, 2004, CLIN MICROBIOL INFEC, V10, P1009, DOI 10.1111/j.1469-0691.2004.00997.x; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; DuPont HL, 2001, CLIN INFECT DIS, V33, P1807, DOI 10.1086/323814; DuPont HL, 1998, DIGESTION, V59, P708, DOI 10.1159/000007580; DUPONT HL, 1987, JAMA-J AM MED ASSOC, V257, P1347, DOI 10.1001/jama.257.10.1347; GILLIS JC, 1995, DRUGS, V49, P467, DOI 10.2165/00003495-199549030-00009; Gomi H, 2001, ANTIMICROB AGENTS CH, V45, P212, DOI 10.1128/AAC.45.1.212-216.2001; Hilton, 1997, J Travel Med, V4, P41, DOI 10.1111/j.1708-8305.1997.tb00772.x; HOOVER WW, 1993, DIAGN MICR INFEC DIS, V16, P111, DOI 10.1016/0732-8893(93)90004-Q; Ilnyckyj A, 2003, AM J GASTROENTEROL, V98, P596, DOI [10.1016/S0002-9270(02)06019-7, 10.1111/j.1572-0241.2003.07297.x]; Jiang ZD, 2000, ANTIMICROB AGENTS CH, V44, P2205, DOI 10.1128/AAC.44.8.2205-2206.2000; Jiang ZD, 2000, J INFECT DIS, V181, P779, DOI 10.1086/315272; Jiang ZD, 2002, J INFECT DIS, V185, P497, DOI 10.1086/338834; JOHNSON PC, 1986, ANTIMICROB AGENTS CH, V30, P671, DOI 10.1128/AAC.30.5.671; MERSON MH, 1976, NEW ENGL J MED, V294, P1299, DOI 10.1056/NEJM197606102942401; Miglio F, 1997, CURR MED RES OPIN, V13, P593, DOI 10.1185/03007999709113333; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; MURRAY BE, 1982, NEW ENGL J MED, V306, P130, DOI 10.1056/NEJM198201213060302; Okhuysen PC, 2004, AM J GASTROENTEROL, V99, P1774, DOI 10.1111/j.1572-0241.2004.30435.x; Parry SD, 2003, AM J GASTROENTEROL, V98, P327, DOI [10.1016/S0002-9270(02)05910-5, 10.1111/j.1572-0241.2003.07242.x]; Parry SD, 2003, AM J GASTROENTEROL, V98, P1970, DOI 10.1016/S0002-9270(03)00627-0; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; REVES RR, 1988, ARCH INTERN MED, V148, P2421, DOI 10.1001/archinte.148.11.2421; RIVA S, 1973, ANTIMICROB AGENTS CH, V3, P456, DOI 10.1128/AAC.3.4.456; SACK DA, 1978, NEW ENGL J MED, V298, P758, DOI 10.1056/NEJM197804062981402; Som R., 1996, PRACTICAL SAMPLING T, V2nd; Soro Ornella, 1997, Clin Microbiol Infect, V3, P147; Spiller RC, 2000, GUT, V47, P804, DOI 10.1136/gut.47.6.804; Spiller RC, 2002, GUT, V51, P759, DOI 10.1136/gut.51.6.759; Steffen R, 2003, AM J GASTROENTEROL, V98, P1073, DOI [10.1016/S0002-9270(02)06005-7, 10.1111/j.1572-0241.2003.07283.x]; STEFFEN R, 1986, ANTIMICROB AGENTS CH, V29, P625, DOI 10.1128/AAC.29.4.625; STRACCIARI JM, 1987, CHEMIOTERAPIA, V6, P82; TAYLOR D, 2004, AM SOC TROP MED HYG; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; von Sonnenburg F, 2000, LANCET, V356, P133, DOI 10.1016/S0140-6736(00)02451-X; VOSBECK K, 1979, REV INFECT DIS, V1, P845; WOOD LV, 1983, APPL ENVIRON MICROB, V46, P328, DOI 10.1128/AEM.46.2.328-332.1983; 1985, TRAV DIARRH NAT I HL; 1986, REV INFECT DIS S2, V8, pS109	45	153	164	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					805	812		10.7326/0003-4819-142-10-200505170-00005	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897530				2022-12-28	WOS:000229099600001
J	Kanaya, AM; Herrington, D; Vittinghoff, E; Lin, F; Bittner, V; Cauley, JA; Hulley, S; Barrett-Connor, E				Kanaya, AM; Herrington, D; Vittinghoff, E; Lin, F; Bittner, V; Cauley, JA; Hulley, S; Barrett-Connor, E			Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-DISEASE; RISK-FACTOR; ESTROGEN/PROGESTIN REPLACEMENT; DIABETES-MELLITUS; HYPERGLYCEMIA; MORTALITY; ASSOCIATION; POPULATION; PREVENTION; INFARCTION	Background: Type 2 diabetes increases risk for cardiovascular disease. Persons with impaired fasting glucose levels may also have increased risk. Objective: To evaluate the association between glucose status and cardiovascular outcomes and the effect of lowering the fasting glucose level criterion for impaired fasting glucose from a lower limit of 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL). Design: Prospective cohort study. Setting: 20 U.S. clinical centers. Patients: 2763 postmenopausal women with established coronary heart disease (CHD) who were followed for 6.8 years. Measurements: Any CHD event (nonfatal myocardial infarction or CHD death), stroke or transient ischemic attack (TIA), congestive heart failure (CHF) hospitalization, and any cardiovascular event. Results: During follow-up, 583 women had a CHD event, 329 women had a stroke or TIA, and 348 women were hospitalized for CHF. Women with diabetes were at an approximately 75% increased risk for each outcome compared with normoglycemic women. The 218 women with impaired fasting glucose according to the 1997 definition (fasting glucose level, 6.1 to 6.9 mmol/L [110 to 125 mg/dL]) had increased risk for any CHID event (hazard ratio, 1.37 [95% CI, 1.08 to 1.74]), while the 698 women with impaired fasting glucose according to the 2003 definition (fasting glucose level, 5.6 to 6.9 mmol/L [100 to 125 mg/dL]) were not at increased risk (hazard ratio, 1.09 [CI, 0.90 to 1.34]). Most of the women (n = 480) with fasting glucose levels between 5.6 mmol/L (100 mg/dL) and 6.0 mmol/L (109 mg/dL) had no increased risk for CHD (hazard ratio, 0.90 [CI, 0.73 to 1.12]). Women with impaired fasting glucose according to either definition were not at increased risk for stroke or TIA or CHF. Limitations: These findings may not be generalizable to men or women without existing heart disease. Conclusions: Among postmenopausal women with coronary artery disease, the 2003 definition for impaired fasting glucose was not associated with increased risk for new CHID, stroke or TIA, or CHF.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Calif San Diego, La Jolla, CA 92093 USA	University of California System; University of California San Francisco; Wake Forest University; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Diego	Kanaya, AM (corresponding author), Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA.	alkak@itsa.ucsf.edu	Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Bittner, Vera/0000-0001-9456-850X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K12AR047659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG015272] Funding Source: NIH RePORTER; NIAMS NIH HHS [5 K12 AR47659] Funding Source: Medline; NIA NIH HHS [P30-AG15272] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2003, MMWR-MORBID MORTAL W, V52, P833; Arcavi L, 2004, AM HEART J, V147, P239, DOI 10.1016/j.ahj.2003.09.013; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371; Borch-Johnsen K, 1999, LANCET, V354, P617; Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397, DOI 10.1001/archinte.161.3.397; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Davidson MB, 2003, DIABETES CARE, V26, P3329, DOI 10.2337/diacare.26.12.3329; de Vegt F, 2001, JAMA-J AM MED ASSOC, V285, P2109, DOI 10.1001/jama.285.16.2109; Devereux RB, 2000, CIRCULATION, V101, P2271, DOI 10.1161/01.CIR.101.19.2271; Fisman EZ, 2001, AM HEART J, V141, P485, DOI 10.1067/mhj.2001.113219; Gavin JR, 1997, DIABETES CARE, V20, P1183; Genuth S, 2003, DIABETES CARE, V26, P3160; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kanaya AM, 2002, ARCH INTERN MED, V162, P1737, DOI 10.1001/archinte.162.15.1737; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Khaw KT, 2004, ANN INTERN MED, V141, P413, DOI 10.7326/0003-4819-141-6-200409210-00006; Levitan EB, 2004, ARCH INTERN MED, V164, P2147, DOI 10.1001/archinte.164.19.2147; Lindsberg PJ, 2004, STROKE, V35, P363, DOI 10.1161/01.STR.0000115297.92132.84; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Qureshi AI, 1998, STROKE, V29, P1329, DOI 10.1161/01.STR.29.7.1329; Scott JF, 1999, LANCET, V353, P376, DOI 10.1016/S0140-6736(05)74948-5; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Tuomilehto J, 1996, STROKE, V27, P210, DOI 10.1161/01.STR.27.2.210; Unwin N, 2002, DIABETIC MED, V19, P708, DOI 10.1046/j.1464-5491.2002.00835.x	28	60	67	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					813	820		10.7326/0003-4819-142-10-200505170-00006	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897531				2022-12-28	WOS:000229099600002
J	Wahlund, JE; Bostrom, R; Gustafsson, G; Gurnett, DA; Kurth, WS; Pedersen, A; Averkamp, TF; Hospodarsky, GB; Persoon, AM; Canu, P; Neubauer, FM; Dougherty, MK; Eriksson, AI; Morooka, MW; Gill, R; Andre, M; Eliasson, L; Muller-Wodarg, I				Wahlund, JE; Bostrom, R; Gustafsson, G; Gurnett, DA; Kurth, WS; Pedersen, A; Averkamp, TF; Hospodarsky, GB; Persoon, AM; Canu, P; Neubauer, FM; Dougherty, MK; Eriksson, AI; Morooka, MW; Gill, R; Andre, M; Eliasson, L; Muller-Wodarg, I			Cassini measurements of cold plasma in the ionosphere of Titan	SCIENCE			English	Article							WAVE OBSERVATIONS; MARS; MAGNETOSPHERE; SATURN; RADIO	The Cassini Radio and Plasma Wave Science (RPWS) Langmuir probe (LP) sensor observed the cold plasma environment around Titan during the first two flybys. The data show that conditions in Saturn's magnetosphere affect the structure and dynamics deep in the ionosphere of Titan. The maximum measured ionospheric electron number density reached 3800 per cubic centimeter near closest approach, and a complex chemistry was indicated. The electron temperature profiles are consistent with electron heat conduction from the hotter Titan wake. The ionospheric escape flux was estimated to be 10(25) ions per second.	Swedish Inst Space Phys, SE-75121 Uppsala, Sweden; Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA; Univ Oslo, Dept Phys, NO-0316 Oslo, Norway; Inst Pierre Simon Laplace, CNRS, Ctr Etud Environm Terr & Planetaires, F-78140 Velizy Villacoublay, France; Univ Cologne, Inst Geophys & Meteorol, D-50923 Cologne, Germany; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BW, England; Swedish Inst Space Phys, SE-98128 Kiruna, Sweden	University of Iowa; University of Oslo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Cologne; Imperial College London	Wahlund, JE (corresponding author), Swedish Inst Space Phys, Box 537, SE-75121 Uppsala, Sweden.	jwe@irfu.se	Kurth, William/AAA-7334-2019; Morooka, Michiko/AAO-8594-2020; Eriksson, Anders I/C-2887-2009; Wahlund, Jan-Erik/AAL-6439-2021; Hospodarsky, George B/A-7996-2015; Mueller-Wodarg, Ingo C. F./M-9945-2014	Kurth, William/0000-0002-5471-6202; Morooka, Michiko/0000-0001-9958-0241; Eriksson, Anders I/0000-0003-2926-6761; Hospodarsky, George B/0000-0001-9200-9878; Mueller-Wodarg, Ingo C. F./0000-0001-6308-7826				Backes H, 2005, SCIENCE, V308, P992, DOI 10.1126/science.1109763; BACKES H, 2004, AM GEOPH UN FALL M S; Blanc M, 2002, SPACE SCI REV, V104, P253, DOI 10.1023/A:1023605110711; COATES A, 2004, AM GEOPH UN FALL M S; CRAVENS TE, UNPUB; Gurnett DA, 2005, SCIENCE, V307, P1255, DOI 10.1126/science.1105356; Gurnett DA, 2004, SPACE SCI REV, V114, P395, DOI 10.1007/s11214-004-1434-0; GURNETT DA, 1982, J GEOPHYS RES-SPACE, V87, P1395, DOI 10.1029/JA087iA03p01395; Kallio E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020344; KELLER CN, 1994, J GEOPHYS RES-SPACE, V99, P6527, DOI 10.1029/93JA02681; Ledvina SA, 2004, ADV SPACE RES-SERIES, V33, P2092, DOI 10.1016/j.asr.2003.07.056; Lundin R, 2004, ADV SPACE RES-SERIES, V33, P1945, DOI 10.1016/j.asr.2003.07.054; Nagy AF, 2004, SPACE SCI REV, V111, P33, DOI 10.1023/B:SPAC.0000032718.47512.92; Nagy AF, 2001, J GEOPHYS RES-SPACE, V106, P6151, DOI 10.1029/2000JA000183; ROBOZ A, 1994, J GEOPHYS RES-SPACE, V99, P2087, DOI 10.1029/93JA02286; Vignes D, 2000, GEOPHYS RES LETT, V27, P49, DOI 10.1029/1999GL010703	16	163	163	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2005	308	5724					986	989		10.1126/science.1109807	http://dx.doi.org/10.1126/science.1109807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927JR	15894529				2022-12-28	WOS:000229190700035
J	Langer-Gould, A; Atlas, SW; Green, AJ; Bollen, AW; Pelletier, D				Langer-Gould, A; Atlas, SW; Green, AJ; Bollen, AW; Pelletier, D			Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JC VIRUS; ANTIRETROVIRAL THERAPY; AIDS; ANTIBODIES; CIDOFOVIR; INTEGRIN	We describe the clinical course of a patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the central nervous system, developed during treatment wit interferon beta-1a and a selective adhesion-molecule blocker, natalizumab. The first PML lesion apparent on magnetic resonance imaging was indistinguishable from a multiple sclerosis lesion. Despite treatment wit corticosteroids, cidofovir, and intravenous immune globulin, PML progressed rapidly, rendering the patient quadriparetic, globally aphasic, and minimally responsive. Three months after natalizumab therapy as discontinued, changes consistent with an immune-reconstitution inflammatory syndrome developed. The patient was treated with systemic cytarabine, and two months later, his condition has improved.	Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Hoover Inst, Dept Radiol, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Langer-Gould, A (corresponding author), HRP Redwood Bldg,Rm T202, Stanford, CA 94305 USA.	annettel@stanford.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS043207] Funding Source: NIH RePORTER; NINDS NIH HHS [NS43207-03] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROOKS BR, 1984, NEUROL CLIN, V2, P299, DOI 10.1016/S0733-8619(18)31105-8; CALABRESI P, 2005, AM AC NEUR 57 ANN M; Cinque P, 2003, J NEUROVIROL, V9, P73, DOI 10.1080/13550280390195351; De Luca A, 2001, J NEUROVIROL, V7, P364; Du Pasquier RA, 2003, J NEUROVIROL, V9, P25, DOI 10.1080/13550280390195315; Escudero E, 1998, J AM SOC NEPHROL, V9, P1881; Gasnault J, 2001, J NEUROVIROL, V7, P375; Hall CD, 1998, NEW ENGL J MED, V338, P1345, DOI 10.1056/NEJM199805073381903; Hou J, 1998, J NEUROVIROL, V4, P451, DOI 10.3109/13550289809114545; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; MARK AS, 1989, RADIOLOGY, V173, P517, DOI 10.1148/radiology.173.2.2798883; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; Post MJD, 1999, AM J NEURORADIOL, V20, P1896; Ryschkewitsch C, 2004, J VIROL METHODS, V121, P217, DOI 10.1016/j.jviromet.2004.06.021; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157	18	783	820	2	365	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					375	381		10.1056/NEJMoa051847	http://dx.doi.org/10.1056/NEJMoa051847			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	15947078	Bronze			2022-12-28	WOS:000230782800010
J	Walker, CL; Stewart, EA				Walker, CL; Stewart, EA			Uterine fibroids: The elephant in the room	SCIENCE			English	Review							RENAL-CELL CARCINOMA; GENE-EXPRESSION; EKER RAT; LEIOMYOMAS; GROWTH; IMMORTALIZATION; PATHOGENESIS; MICE	Uterine fibroids (leiomyomas) have historically been viewed as important chiefly as the major indication for hysterectomy. As new therapies are developed, the heterogeneity of this disease becomes therapeutically relevant. An awareness of the role of genetics, the extraceilular matrix, and hormones in tumor etiology is key to understanding this disease.	Univ Texas, Dept Carcinogenesis, Smithville, TX 78957 USA; MD Anderson Canc Ctr, Smithville, TX 78957 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Uterine Fibroids, Boston, MA 02115 USA	University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Walker, CL (corresponding author), Univ Texas, Dept Carcinogenesis, Pk Rd 1C, Smithville, TX 78957 USA.			Stewart, Elizabeth/0000-0003-1110-2400	NCI NIH HHS [CA 016672] Funding Source: Medline; NICHD NIH HHS [HD046226, HD046282] Funding Source: Medline; NIEHS NIH HHS [ES 07784, ES08263] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046226, R01HD046282] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008263, P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Hendy A, 2004, AM J OBSTET GYNECOL, V191, P1621, DOI 10.1016/j.ajog.2004.04.022; ANDERSEN J, 1995, J SOC GYNECOL INVEST, V2, P663, DOI 10.1016/1071-5576(95)00021-6; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; Catherino WH, 2004, GENE CHROMOSOME CANC, V40, P204, DOI 10.1002/gcc.20035; Cesen-Cummings K, 2000, ENVIRON HEALTH PERSP, V108, P817, DOI 10.2307/3454312; CHEGINI N, 2000, CYTOKINES HUMAN REPR, P133; CHRISTACOS N, 2003, 53 ANN M AM SOC GEN; Condon J, 2002, BIOL REPROD, V67, P506, DOI 10.1095/biolreprod67.2.506; Cook JD, 2004, SEMIN REPROD MED, V22, P105; Cook JD, 2004, CURR MOL MED, V4, P813, DOI 10.2174/1566524043359656; CRAMER SF, 1990, AM J CLIN PATHOL, V94, P435, DOI 10.1093/ajcp/94.4.435; Dal Cin P, 2003, GENE CHROMOSOME CANC, V36, P205, DOI 10.1002/gcc.10159; Flake GP, 2003, ENVIRON HEALTH PERSP, V111, P1037, DOI 10.1289/ehp.5787; Gross KL, 2004, GENE CHROMOSOME CANC, V41, P183, DOI 10.1002/gcc.20079; Henske EP, 2003, GENE CHROMOSOME CANC, V38, P376, DOI 10.1002/gcc.10252; KAWAGUCHI K, 1989, AM J OBSTET GYNECOL, V160, P637, DOI 10.1016/S0002-9378(89)80046-8; LINDER D, 1965, SCIENCE, V150, P67, DOI 10.1126/science.150.3692.67; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; Morton CC, 2000, ENVIRON HEALTH PERSP, V108, P775; Pavlovich CP, 2004, NAT REV CANCER, V4, P381, DOI 10.1038/nrc1364; Pron G, 2003, FERTIL STERIL, V79, P120, DOI 10.1016/S0015-0282(02)04538-7; REIN MS, 1991, OBSTET GYNECOL, V77, P923; REIN MS, 1995, AM J OBSTET GYNECOL, V172, P14, DOI 10.1016/0002-9378(95)90077-2; Romagnolo B, 1996, J CLIN INVEST, V98, P777, DOI 10.1172/JCI118850; Sandberg AA, 2005, CANCER GENET CYTOGEN, V158, P1, DOI 10.1016/j.cancergencyto.2004.08.025; Shozu M, 2004, SEMIN REPROD MED, V22, P51; Sozen I, 2002, FERTIL STERIL, V78, P1, DOI 10.1016/S0015-0282(02)03154-0; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Stewart EA, 1998, OBSTET GYNECOL, V92, P624, DOI 10.1016/S0029-7844(98)00243-9; Stewart EA, 1996, HUM REPROD UPDATE, V2, P295, DOI 10.1093/humupd/2.4.295; Tsibris JCM, 1999, CANCER RES, V59, P5737; Walker CL, 2003, GENE CHROMOSOME CANC, V38, P349, DOI 10.1002/gcc.10281; Wei JJ, 2005, MODERN PATHOL, V18, P179, DOI 10.1038/modpathol.3800283	33	399	408	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1589	1592		10.1126/science.1112063	http://dx.doi.org/10.1126/science.1112063			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947177				2022-12-28	WOS:000229827000044
J	Valet, JP; Meynadier, L; Guyodo, Y				Valet, JP; Meynadier, L; Guyodo, Y			Geomagnetic dipole strength and reversal rate over the past two million years	NATURE			English	Article							FIELD INTENSITY; RELATIVE PALEOINTENSITY; JARAMILLO SUBCHRON; SEDIMENTS; MATUYAMA; RECORD; CORE; SEA; PACIFIC; MAGNETIZATION	Independent records of relative magnetic palaeointensity from sediment cores in different areas of the world can be stacked together to extract the evolution of the geomagnetic dipole moment(1,2) and thus provide information regarding the processes governing the geodynamo. So far, this procedure has been limited to the past 800,000 years ( 800 kyr; ref. 3), which does not include any geomagnetic reversals. Here we present a composite curve that shows the evolution of the dipole moment during the past two million years. This reconstruction is in good agreement with the absolute dipole moments derived from volcanic lavas, which were used for calibration. We show that, at least during this period, the time-averaged field was higher during periods without reversals but the amplitude of the short-term oscillations remained the same. As a consequence, few intervals of very low intensity, and thus fewer instabilities, are expected during periods with a strong average dipole moment, whereas more excursions and reversals are expected during periods of weak field intensity. We also observe that the axial dipole begins to decay 60 - 80 kyr before reversals, but rebuilds itself in the opposite direction in only a few thousand years.	Inst Phys Globe, CNRS, UMR Geomagnetisme & Paleomagnetisme 7577, F-75252 Paris, France; Inst Phys Globe, CNRS, UMR Geochim & Cosmochim7579, F-75252 Paris, France; Lab Sci Climat & Environm, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Valet, JP (corresponding author), Inst Phys Globe, CNRS, UMR Geomagnetisme & Paleomagnetisme 7577, 4 Pl Jussieu, F-75252 Paris, France.	valet@ipgp.jussieu.fr	Meynadier, Laure/A-6349-2011; Valet, Jean-Pierre/A-6332-2011; guyodo, yohan/R-5079-2018; Guyodo, Yohan/G-8282-2011	Meynadier, Laure/0000-0003-3411-4551; guyodo, yohan/0000-0003-0485-5949; 				Baumgartner S, 1998, SCIENCE, V279, P1330, DOI 10.1126/science.279.5355.1330; Channell JET, 2000, PHILOS T ROY SOC A, V358, P1027, DOI 10.1098/rsta.2000.0572; Constable CG, 1998, J GEOPHYS RES-SOL EA, V103, P17735, DOI 10.1029/98JB01519; Dinares-Turell J, 2002, EARTH PLANET SC LETT, V194, P327, DOI 10.1016/S0012-821X(01)00563-5; Frank M, 2000, PHILOS T ROY SOC A, V358, P1089, DOI 10.1098/rsta.2000.0575; Gee JS, 2000, NATURE, V408, P827, DOI 10.1038/35048513; Guyodo Y, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000211; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; Guyodo Y, 2001, EARTH PLANET SC LETT, V191, P61, DOI 10.1016/S0012-821X(01)00402-2; Guyodo Y, 1999, J GEOPHYS RES-SOL EA, V104, P22953, DOI 10.1029/1999JB900163; Guyodo Y, 2000, EARTH PLANET SC LETT, V184, P109, DOI 10.1016/S0012-821X(00)00313-7; Guyodo Y, 1999, NATURE, V399, P249, DOI 10.1038/20420; GUYODO Y, IN PRESS PHYS EARTH; Hayashida A, 1999, GEOPHYS J INT, V139, P829, DOI 10.1046/j.1365-246x.1999.00979.x; Horng CS, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001698; KENT DV, 1977, NATURE, V266, P156, DOI 10.1038/266156a0; Kok YS, 1999, J GEOPHYS RES-SOL EA, V104, P25401, DOI 10.1029/1999JB900186; Laj C, 2000, PHILOS T ROY SOC A, V358, P1009, DOI 10.1098/rsta.2000.0571; Laj C, 1996, GEOPHYS RES LETT, V23, P3393, DOI 10.1029/96GL03261; Mazaud A, 1996, EARTH PLANET SC LETT, V139, P379, DOI 10.1016/0012-821X(96)00026-X; McMillan DG, 2004, PHYS EARTH PLANET IN, V145, P37, DOI 10.1016/j.pepi.2004.02.011; Meynadier L, 1996, EARTH PLANET SC LETT, V140, P123, DOI 10.1016/0012-821X(96)00018-0; MEYNADIER L, 1994, EARTH PLANET SC LETT, V126, P109, DOI 10.1016/0012-821X(94)90245-3; Perrin M, 2004, PHYS EARTH PLANET IN, V147, P255, DOI 10.1016/j.pepi.2004.06.005; Pouliquen G, 2001, J GEOPHYS RES-SOL EA, V106, P10941, DOI 10.1029/2000JB900442; Quidelleur X, 1999, EARTH PLANET SC LETT, V168, P233, DOI 10.1016/S0012-821X(99)00061-8; Sato T, 1998, GEOPHYS RES LETT, V25, P2221, DOI 10.1029/98GL01621; SCHNEIDER DA, 1992, EARTH PLANET SC LETT, V111, P395, DOI 10.1016/0012-821X(92)90192-X; VALET JP, 1994, GEOPHYS RES LETT, V21, P485, DOI 10.1029/93GL02815; Valet JP, 2003, REV GEOPHYS, V41, DOI 10.1029/2001RG000104; VALET JP, 1993, NATURE, V366, P234, DOI 10.1038/366234a0	31	305	316	8	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					802	805		10.1038/nature03674	http://dx.doi.org/10.1038/nature03674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944701				2022-12-28	WOS:000229638700047
J	Blumberg, HM; Leonard, MK; Jasmer, RM				Blumberg, HM; Leonard, MK; Jasmer, RM			Update on the treatment of tuberculosis and latent tuberculosis infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RIFAMPIN PREVENTIVE THERAPY; PULMONARY TUBERCULOSIS; ANTIRETROVIRAL THERAPY; TREATMENT COMPLETION; PYRAZINAMIDE; HEPATOTOXICITY; TWICE; ACCEPTABILITY; RIFAPENTINE; EXPERIENCE	Tuberculosis (TB) has emerged as a global public health epidemic. Despite decreasing numbers of cases in the United States since 1992, TB remains a serious public health problem among certain patient populations and is highly prevalent in many urban areas. The responsibility for prescribing an appropriate drug regimen and ensuring that treatment is completed is assigned to the public health program or the clinician not to the patient. The initial prescribed regimen for the treatment of TB usually consists of 4 drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. The minimum length for the treatment of drug-susceptible TB with a rifampin-based regimen is 6 to 9 months. Providing medications directly to the patient and watching him/ her swallow the anti-TB drugs, which is termed directly observed therapy, is recommended for all patients diagnosed with TB and can help ensure higher completion rates, prevent the emergence of drug resistant TB, and enhance TB control. There has been renewed interest in the treatment of those with latent TB infection as a TB-control strategy in the United States for eliminating the large reservoir of individuals at risk for progression to TB. The 2 broad categories of persons who should be tested for latent TB infection are those who are likely to have been recently infected (such as contacts to infectious TB cases) and persons who are at increased risk of progression to TB disease following infection with Mycobacterium tuberculosis (eg, human immunodeficiency virus infection and selected medical conditions; recent immigrants to the United States from high TB-burden countries). The preferred regimen for the treatment of latent TB infection is 9 months of isoniazid. There is now renewed interest in and great need for the development of new drugs to treat TB and latent TB infection.	Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30303 USA; Grady Mem Hosp, Dept Epidemiol, Atlanta, GA USA; Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA USA	Emory University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Blumberg, HM (corresponding author), Emory Univ, Sch Med, Div Infect Dis, Dept Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.	henry.m.blumberg@emory.edu	Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443	FIC NIH HHS [D43TW007124] Funding Source: Medline; NHLBI NIH HHS [K07 HL03078] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW007124] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603; Anonymous, 2005, Morbidity and Mortality Weekly Report, V54, P245; [Anonymous], 1948, BMJ-BRIT MED J, V2, P769; Barnes PF, 2004, AM J RESP CRIT CARE, V170, P5, DOI 10.1164/rccm.2404004; Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8; Blumberg HM, 2004, CLIN INFECT DIS, V39, P1772, DOI 10.1086/425620; Bock NN, 2001, CHEST, V119, P833, DOI 10.1378/chest.119.3.833; Brodie D, 2005, CLIN CHEST MED, V26, P247, DOI 10.1016/j.ccm.2005.02.012; Burman WJ, 2005, CLIN CHEST MED, V26, P283, DOI 10.1016/j.ccm.2005.02.002; BYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239, DOI 10.1001/jama.241.12.1239; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P37; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P735; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P214; Chaisson RE, 2002, JAMA-J AM MED ASSOC, V288, P165, DOI 10.1001/jama.288.2.165; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; Comstock GW, 1999, INT J TUBERC LUNG D, V3, P847; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Fox W, 1999, INT J TUBERC LUNG D, V3, pS231; FOX W, 1986, AM REV RESPIR DIS, V133, P779; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; Gordin F, 2000, JAMA-J AM MED ASSOC, V283, P1445, DOI 10.1001/jama.283.11.1445; Gordin FM, 2004, CLIN INFECT DIS, V39, P561, DOI 10.1086/422724; GROSS PA, 1994, CLIN INFECT DIS, V18, P428, DOI 10.1093/clinids/18.3.428; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; *I MED, 2000, END NEGL EL TUB US; Jasmer RM, 2002, ANN INTERN MED, V137, P640, DOI 10.7326/0003-4819-137-8-200210150-00007; Kwara A, 2005, INT J TUBERC LUNG D, V9, P248; Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1; Lee AM, 2002, INT J TUBERC LUNG D, V6, P995; Leung CC, 2003, CHEST, V124, P2112, DOI 10.1378/chest.124.6.2112; Lobato MN, 2005, CHEST, V127, P1296, DOI 10.1378/chest.127.4.1296; LoBue PA, 2003, AM J RESP CRIT CARE, V168, P443, DOI 10.1164/rccm.200303-390OC; Marks SM, 2000, AM J RESP CRIT CARE, V162, P2033, DOI 10.1164/ajrccm.162.6.2004022; Mazurek Gerald H, 2003, MMWR Recomm Rep, V52, P15; McNeill L, 2003, CHEST, V123, P102, DOI 10.1378/chest.123.1.102; MITCHELL JR, 1976, ANN INTERN MED, V84, P181, DOI 10.7326/0003-4819-84-2-181; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014; Nolan CM, 2003, AM J RESP CRIT CARE, V168, P412, DOI 10.1164/rccm.2306004; O'Brien RJ, 2005, CLIN CHEST MED, V26, P327, DOI 10.1016/j.ccm.2005.02.013; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Polesky A, 1996, AM J RESP CRIT CARE, V154, P1473, DOI 10.1164/ajrccm.154.5.8912767; Priest DH, 2004, CLIN INFECT DIS, V39, P1764, DOI 10.1086/425610; Saiman L, 2004, PEDIATRICS, V114, P1175, DOI 10.1542/peds.2004-0809; Sotir MJ, 1999, CLIN INFECT DIS, V29, P1138, DOI 10.1086/313453; *TB ALL, GLOB ALL TB DRUG DEV; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Tortajada C, 2005, INT J TUBERC LUNG D, V9, P276; Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8; Villarino ME, 1997, AM J RESP CRIT CARE, V155, P1735, DOI 10.1164/ajrccm.155.5.9154885; *WHO, 2004, GLOB TUB CONTR SURV	59	119	127	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2776	2784		10.1001/jama.293.22.2776	http://dx.doi.org/10.1001/jama.293.22.2776			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941808				2022-12-28	WOS:000229643700027
J	Kosfeld, M; Heinrichs, M; Zak, PJ; Fischbacher, U; Fehr, E				Kosfeld, M; Heinrichs, M; Zak, PJ; Fischbacher, U; Fehr, E			Oxytocin increases trust in humans	NATURE			English	Article							MATERNAL-BEHAVIOR; VASOPRESSIN; ATTACHMENT; FAIRNESS; AVERSION; BRAIN; RISK	Trust pervades human societies(1,2). Trust is indispensable in friendship, love, families and organizations, and plays a key role in economic exchange and politics(3). In the absence of trust among trading partners, market transactions break down. In the absence of trust in a country's institutions and leaders, political legitimacy breaks down. Much recent evidence indicates that trust contributes to economic, political and social success(4,5). Little is known, however, about the biological basis of trust among humans. Here we show that intranasal administration of oxytocin, a neuropeptide that plays a key role in social attachment and affiliation in non-human mammals(6-8), causes a substantial increase in trust among humans, thereby greatly increasing the benefits from social interactions. We also show that the effect of oxytocin on trust is not due to a general increase in the readiness to bear risks. On the contrary, oxytocin specifically affects an individual's willingness to accept social risks arising through interpersonal interactions. These results concur with animal research suggesting an essential role for oxytocin as a biological basis of prosocial approach behaviour.	Univ Zurich, Inst Empir Res Econ, CH-8006 Zurich, Switzerland; Univ Zurich, Dept Clin Psychol & Psychotherapy, CH-8044 Zurich, Switzerland; Claremont Grad Univ, Ctr Neuroecon Studies, Claremont, CA 91711 USA; Collegium Helveticum, CH-8092 Zurich, Switzerland	University of Zurich; University of Zurich; Claremont Colleges; Claremont Graduate School	Fehr, E (corresponding author), Univ Zurich, Inst Empir Res Econ, Blumlisalpstr 10, CH-8006 Zurich, Switzerland.	m.heinrichs@psychologie.unizh.ch; efehr@iew.unizh.ch	Fischbacher, Urs/H-2693-2014	Fischbacher, Urs/0000-0002-5115-8815				ARROW KJ, 1972, PHILOS PUBLIC AFF, V1, P343; BERG J, 1995, GAME ECON BEHAV, V10, P122, DOI 10.1006/game.1995.1027; Bohnet I, 2004, J ECON BEHAV ORGAN, V55, P467, DOI 10.1016/j.jebo.2003.11.004; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; CAMERER C, 1988, ECONOMETRICA, V56, P1, DOI 10.2307/1911840; Carter C S, 2001, Prog Brain Res, V133, P241; Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779; Coleman J, 1990, FDN SOCIAL THEORY, P91; Engelmann D, 2004, AM ECON REV, V94, P857, DOI 10.1257/0002828042002741; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; FEHR E, 1993, Q J ECON, V108, P437, DOI 10.2307/2118338; FISCHBACHER U, 1999, 21 U ZUR I EMP RES E; Gintis H, 2003, EVOL HUM BEHAV, V24, P153, DOI 10.1016/S1090-5138(02)00157-5; Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7; Heinrichs M, 2002, STRESS, V5, P195, DOI 10.1080/1025389021000010530; Holt CA, 2002, AM ECON REV, V92, P1644, DOI 10.1257/000282802762024700; HONG K, 2004, RW04041 HARV U KENN; Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636; INSEL TR, 1992, P NATL ACAD SCI USA, V89, P5981, DOI 10.1073/pnas.89.13.5981; Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579; Kendrick KM, 1997, BRAIN RES BULL, V44, P383, DOI 10.1016/S0361-9230(97)00218-9; Knack S, 1997, Q J ECON, V112, P1251, DOI 10.1162/003355300555475; Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001; LUHMANN Niklas, 1979, TRUST POWER; Pedersen CA, 1997, ANN NY ACAD SCI, V807, P126, DOI 10.1111/j.1749-6632.1997.tb51916.x; Steyer, 1997, MEHRDIMENSIONALE BEF; Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0; Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691; Zak PJ, 2001, ECON J, V111, P295, DOI 10.1111/1468-0297.00609	30	2236	2296	18	788	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					673	676		10.1038/nature03701	http://dx.doi.org/10.1038/nature03701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	931HK	15931222	Green Published, Green Accepted			2022-12-28	WOS:000229476200050
J	Martin, M; Pienkowski, T; Mackey, J; Pawlicki, M; Guastalla, JP; Weaver, C; Tomiak, E; Al-Tweigeri, T; Chap, L; Juhos, E; Guevin, R; Howell, A; Fornander, T; Hainsworth, J; Coleman, R; Vinholes, J; Modiano, M; Pinter, T; Tang, SC; Colwell, B; Prady, C; Provencher, L; Walde, D; Rodriguez-Lescure, A; Hugh, J; Loret, C; Rupin, M; Blitz, S; Jacobs, P; Murawsky, M; Riva, A; Vogel, C				Martin, M; Pienkowski, T; Mackey, J; Pawlicki, M; Guastalla, JP; Weaver, C; Tomiak, E; Al-Tweigeri, T; Chap, L; Juhos, E; Guevin, R; Howell, A; Fornander, T; Hainsworth, J; Coleman, R; Vinholes, J; Modiano, M; Pinter, T; Tang, SC; Colwell, B; Prady, C; Provencher, L; Walde, D; Rodriguez-Lescure, A; Hugh, J; Loret, C; Rupin, M; Blitz, S; Jacobs, P; Murawsky, M; Riva, A; Vogel, C		Breast Canc Int Res Grp 001 Inve	Adjuvant docetaxel for node-positive breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; RANDOMIZED-TRIAL; ANTHRACYCLINE-RESISTANT; GENE AMPLIFICATION; FOLLOW-UP; DOXORUBICIN; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; PACLITAXEL; FLUOROURACIL	BACKGROUND: We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS: We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS: At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P<0.001); rates of febrile neutropenia were 24.7 percent and 2.5 percent, respectively (P<0.001). Grade 3 or 4 infections occurred in 3.9 percent of the patients who received TAC and 2.2 percent of those who received FAC (P=0.05); no deaths occurred as a result of infection. Two patients in each group died during treatment. Congestive heart failure and acute myeloid leukemia occurred in less than 2 percent of the patients in each group. Quality-of-life scores decreased during chemotherapy but returned to baseline levels after treatment. CONCLUSIONS: Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.	Hosp Univ San Carlos, Med Oncol Serv, Madrid 28040, Spain; Maria Sklodowska Curie Canc Ctr, Warsaw, Poland; Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Maria Sklodowska Curie Mem Inst Oncol, Krakow, Poland; Ctr Leon Berard, F-69373 Lyon, France; Response Oncol, Memphis, TN USA; Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada; Saskatoon Canc Ctr, Saskatoon, SK, Canada; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Natl Inst Oncol, Budapest, Hungary; Hop St Luc, Montreal, PQ H2X 1P1, Canada; Christie Hosp, Manchester, Lancs, England; Onkol Kliniken Sodersjukhuset, Stockholm, Sweden; Cannon Canc Ctr, Nashville, TN USA; Weston Pk Hosp, Sheffield, S Yorkshire, England; Hosp Santa Casa Misericordia, Porto Alegre, RS, Brazil; Arizona Clin Res Ctr, Tucson, AZ USA; Petz Aladar Cty Teaching Hosp, Gyor, Hungary; Murphy Canc Ctr, St John, NB, Canada; Nova Scotia Canc Ctr, Halifax, NS, Canada; Dumont Hosp, Moncton, NB, Canada; Hop St Sacrement, Quebec City, PQ, Canada; Plummer Mem Hosp, Sault Ste Marie, ON, Canada; Gen Hosp, Elche, Spain; Breast Canc Int Res Grp, Paris, France; Inst Hlth Econ, Edmonton, AB, Canada; Aventis Pharma, Antony, France; Canc Res Network, Plantation, FL USA	Maria Sklodowska-Curie National Research Institute of Oncology; University of Alberta; Maria Sklodowska-Curie National Research Institute of Oncology; UNICANCER; Centre Leon Berard; University of Ottawa; Ottawa Hospital Research Institute; University of Saskatchewan; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institute of Oncology Hungary; Universite de Montreal; Christie NHS Foundation Trust; Christie Hospital; Weston Park Hospital; Laval University; Sanofi-Aventis; Sanofi France	Martin, M (corresponding author), Hosp Univ San Carlos, Med Oncol Serv, Madrid 28040, Spain.	mmartin@geicam.org	Martin, Miguel/AAJ-9242-2020; Rodríguez-Lescure, Álvaro/AAB-7039-2019	Martin, Miguel/0000-0001-9237-3231; Rodríguez-Lescure, Álvaro/0000-0002-6823-5290; Pienkowski, Tadeusz/0000-0002-0110-5950; Howell, Anthony/0000-0002-6233-719X				Abe O, 1998, LANCET, V352, P930; AISNER J, 1987, J CLIN ONCOL, V5, P1523, DOI 10.1200/JCO.1987.5.10.1523; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; BELLOT R, 1998, P AN M AM SOC CLIN, V17, pA221; Bontenbal M., 2003, EJC Supplements, V1, pS201, DOI 10.1016/S1359-6349(03)90702-6; Buzdar AU, 2002, CLIN CANCER RES, V8, P1073; Chan S, 1999, J CLIN ONCOL, V17, P2341, DOI 10.1200/JCO.1999.17.8.2341; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Elledge RM, 2000, INT J CANCER, V89, P111, DOI 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.3.CO;2-N; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; Fumoleau P, 2003, J CLIN ONCOL, V21, P298, DOI 10.1200/JCO.2003.04.148; Gehl J, 1996, ANN ONCOL, V7, P687; Gianni L, 1997, J CLIN ONCOL, V15, P1906, DOI 10.1200/JCO.1997.15.5.1906; GIANNI L, 1995, J CLIN ONCOL, V13, P2688, DOI 10.1200/JCO.1995.13.11.2688; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; HUTCHINS L, 1998, P AN M AM SOC CLIN, V17, pA1; Jacobs TW, 2000, AM J CLIN PATHOL, V113, P251, DOI 10.1309/980M-E24R-V19K-595D; Martin M, 2003, ANN ONCOL, V14, P833, DOI 10.1093/annonc/mdg260; MASS RD, 2000, P AN M AM SOC CLIN, V19, P75; Nabholtz JM, 2003, J CLIN ONCOL, V21, P968, DOI 10.1200/JCO.2003.04.040; Nabholtz JM, 2001, J CLIN ONCOL, V19, P314, DOI 10.1200/JCO.2001.19.2.314; NABHOLTZ JM, 2003, BREAST CANC MANAGEME, P147; Nabholtz JM PT, 2002, P AN M AM SOC CLIN, V21, p36a; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Parnes HL, 2003, J CLIN ONCOL, V21, P1819, DOI 10.1200/JCO.2003.05.119; Paterson A, 2002, P AN M AM SOC CLIN, V21, p35a; Pauletti G, 1996, ONCOGENE, V13, P63; Persons DL, 1997, MODERN PATHOL, V10, P720; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RAVDIN PM, 1995, J CLIN ONCOL, V13, P2879, DOI 10.1200/JCO.1995.13.12.2879; SCHULLER J, 1998, P AN M AM SOC CLIN, V17, pA205; SMALLEY RV, 1977, CANCER, V40, P625, DOI 10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M; VALERO V, 1995, J CLIN ONCOL, V13, P2886, DOI 10.1200/JCO.1995.13.12.2886	35	750	790	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2302	2313		10.1056/NEJMoa043681	http://dx.doi.org/10.1056/NEJMoa043681			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930421				2022-12-28	WOS:000229446400007
J	Rioux, JD; Abbas, AK				Rioux, JD; Abbas, AK			Paths to understanding the genetic basis of autoimmune disease	NATURE			English	Review							SINGLE-NUCLEOTIDE POLYMORPHISMS; MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOID TYROSINE PHOSPHATASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME SEQUENCE VARIATION; REGULATORY T-CELLS; CROHNS-DISEASE; LINKAGE-DISEQUILIBRIUM; RHEUMATOID-ARTHRITIS; WIDE ASSOCIATION	Some people inherit an unfortunate combination of genetic sequences, such that exposure to an external trigger causes their immune response to turn on their own tissues. Although mutations in a single gene can cause autoimmunity, most autoimmune diseases are associated with several sequence variants. Marked advances in genetic resources and tools are now making it possible to identify the sequence variants that contribute to autoimmune diseases - promising a better understanding of how we normally remain tolerant of our own tissue components, and how this goes wrong in autoimmune disease.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Broad Inst MIT & Harvard, Cambridge, MA 02139 USA; Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Broad Institute; Universite de Montreal; University of California System; University of California San Francisco	Rioux, JD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Broad Inst MIT & Harvard, 1 Kendall Sq,Bldg 300, Cambridge, MA 02139 USA.	rioux@broad.mit.edu	Rioux, John D/A-9599-2015	Rioux, John D/0000-0001-7560-8326				Ahmad T, 2003, HUM MOL GENET, V12, P647, DOI 10.1093/hmg/ddg066; Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488; ALPER CA, 1992, EXP CLIN IMMUNOGENET, V9, P58; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; ATKINSON JP, 1989, CLIN EXP RHEUMATOL, V7, pS95; Baroja ML, 2002, J IMMUNOL, V168, P5070, DOI 10.4049/jimmunol.168.10.5070; BAZERMAN M, 1983, LECT NOTES ECON MATH, V213, P186; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Blank C, 2003, J IMMUNOL, V171, P4574, DOI 10.4049/jimmunol.171.9.4574; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Daly MJ, 2004, INFLAMM BOWEL DIS, V10, P312, DOI 10.1097/00054725-200405000-00020; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Eisenbarth GS, 2003, ANN NY ACAD SCI, V1005, P109, DOI 10.1196/annals.1288.012; Fischer A, 2000, Rev Immunogenet, V2, P52; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Herr M, 2000, HUM MOL GENET, V9, P1291, DOI 10.1093/hmg/9.9.1291; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Hugot JP, 2004, INFLAMM BOWEL DIS, V10, pS11, DOI 10.1097/00054725-200402001-00003; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kyogoku C, 2004, AM J HUM GENET, V75, P504, DOI 10.1086/423790; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Lin SC, 2004, ARTHRITIS RHEUM-US, V50, P770, DOI 10.1002/art.20040; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Mathis D, 2004, IMMUNITY, V20, P509, DOI 10.1016/S1074-7613(04)00111-6; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Miretti MM, 2005, AM J HUM GENET, V76, P634, DOI 10.1086/429393; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nishimura H, 2001, TRENDS IMMUNOL, V22, P265, DOI 10.1016/S1471-4906(01)01888-9; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Onengut-Gumuscu S, 2004, GENES IMMUN, V5, P678, DOI 10.1038/sj.gene.6364138; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; Reich DE, 2002, NAT GENET, V32, P135, DOI 10.1038/ng947; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020; Stenzel A, 2004, HUM GENET, V114, P377, DOI 10.1007/s00439-003-1075-5; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vijayakrishnan L, 2004, IMMUNITY, V20, P563, DOI 10.1016/S1074-7613(04)00110-4; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Walsh EC, 2003, AM J HUM GENET, V73, P580, DOI 10.1086/378101; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	69	141	146	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2005	435	7042					584	589		10.1038/nature03723	http://dx.doi.org/10.1038/nature03723			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931210	Bronze			2022-12-28	WOS:000229476200035
J	Whelan, ET; Ray, TP; Bacciotti, F; Natta, A; Testi, L; Randich, S				Whelan, ET; Ray, TP; Bacciotti, F; Natta, A; Testi, L; Randich, S			A resolved outflow of matter from a brown dwarf	NATURE			English	Article							T-TAURI STARS; ACCRETION; EMISSION; BINARIES	The birth of stars involves not only accretion but also, counterintuitively, the expulsion of matter in the form of highly supersonic outflows(1,2). Although this phenomenon has been seen in young stars, a fundamental question is whether it also occurs among newborn brown dwarfs: these are the so-called 'failed stars', with masses between stars and planets, that never manage to reach temperatures high enough for normal hydrogen fusion to occur(3). Recently, evidence for accretion in young brown dwarfs has mounted(4-6), and their spectra show lines that are suggestive of outflows(7-9). Here we report spectro-astrometric data that spatially resolve an outflow from a brown dwarf. The outflow's characteristics appear similar to, but on a smaller scale than, outflows from normal young stars. This result suggests that the outflow mechanism is universal, and perhaps relevant even to the formation of planets.	Dublin Inst Adv Studies, Dublin 2, Ireland; Osserv Astrofis Arcetri, INAF, I-50125 Florence, Italy	Dublin Institute for Advanced Studies; Istituto Nazionale Astrofisica (INAF)	Whelan, ET (corresponding author), Dublin Inst Adv Studies, 5 Merrion Sq, Dublin 2, Ireland.	ewhelan@cp.dias.ie	Testi, Leonardo/L-7038-2013; BACCIOTTI, FRANCESCA/AAF-1359-2020	BACCIOTTI, FRANCESCA/0000-0001-5776-9476; Ray, Tom/0000-0002-2110-1068; Randich, Sofia/0000-0003-2438-0899				Bailey J, 1998, MON NOT R ASTRON SOC, V301, P161, DOI 10.1046/j.1365-8711.1998.02010.x; Basri G, 2000, ANNU REV ASTRON ASTR, V38, P485, DOI 10.1146/annurev.astro.38.1.485; Comeron F, 2003, ASTRON ASTROPHYS, V406, P1001, DOI 10.1051/0004-6361:20030848; DEGEUS EJ, 1989, ASTRON ASTROPHYS, V216, P44; Dougados C, 2000, ASTRON ASTROPHYS, V357, pL61; EISLOFFEL J, 2000, PROTOSTARS PLANETS, V44, P815; Fernandez M, 2001, ASTRON ASTROPHYS, V380, P264, DOI 10.1051/0004-6361:20011443; GREENE TP, 1992, ASTROPHYS J, V395, P516, DOI 10.1086/171672; Hirth GA, 1997, ASTRON ASTROPHYS SUP, V126, P437, DOI 10.1051/aas:1997275; Jayawardhana R, 2003, ASTROPHYS J, V592, P282, DOI 10.1086/375573; Konigl A., 2000, Protostars and planets 4, P759; Masciadri E, 2004, ASTROPHYS J, V615, P850, DOI 10.1086/424652; Muzerolle J, 2001, ASTROPHYS J, V550, P944, DOI 10.1086/319779; Natta A, 2004, ASTRON ASTROPHYS, V424, P603, DOI 10.1051/0004-6361:20040356; Natta A, 2002, ASTRON ASTROPHYS, V393, P597, DOI 10.1051/0004-6361:20021065; Pascucci I, 2003, ASTROPHYS J, V590, pL111, DOI 10.1086/376773; Takami M, 2003, ASTRON ASTROPHYS, V397, P675, DOI 10.1051/0004-6361:20021544; Takami M, 2001, MON NOT R ASTRON SOC, V323, P177, DOI 10.1046/j.1365-8711.2001.04172.x; Whelan ET, 2004, ASTRON ASTROPHYS, V417, P247, DOI 10.1051/0004-6361:20034381	19	97	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					652	654		10.1038/nature03598	http://dx.doi.org/10.1038/nature03598			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931217	Green Accepted			2022-12-28	WOS:000229476200044
J	Moldrup, C				Moldrup, C			No cure, no pay	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICINE		Danish Univ Pharmaceut Sci, Dept Social Pharm, DK-2100 Copenhagen, Denmark	University of Copenhagen	Moldrup, C (corresponding author), Danish Univ Pharmaceut Sci, Dept Social Pharm, Univ Pk 2, DK-2100 Copenhagen, Denmark.	cm@dfuni.dk						ANDERSON P, 1995, MED POST        0515; ANGELL M, 2004, NEW YORK REV, V51; [Anonymous], MED NEWS TODAY; Califano J A Jr, 1985, Health Matrix, V3, P32; DIMASI JA, 1995, CLIN PHARMACOL THER, V58, P1, DOI 10.1016/0009-9236(95)90066-7; Floyd EJ, 2003, J HEALTHC MANAG, V48, P233, DOI 10.1097/00115514-200307000-00007; GILBERT J, 2003, BUSINESS MED REP, V21; GRUND J, 2005, JYLLANDSPOSTEN  0303; *I RAT PHARM, WHAT IS RAT PHARM; Kalow Werner, 1963, PHARMACOGENETICS HER; Lee TH, 2004, NEW ENGL J MED, V350, P211, DOI 10.1056/NEJMp038215; Matthews M, 2004, MT SINAI J MED, V71, P225; *MERCK, PROD HIGHL; Moldrup Claus, 2001, Community Genet, V4, P204, DOI 10.1159/000064194; *NOV, 140 90 IN; *NOV, BP MON BACK GUAR; Silverstein K, 1999, NATION, V269, P13; Swick HM, 1998, ACAD MED, V73, P751, DOI 10.1097/00001888-199807000-00010; TONKS A, 1994, BRIT MED J, V309, P1252, DOI 10.1136/bmj.309.6964.1252a; 1998, DOCTORS GUIDE    NOV	20	16	16	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2005	330	7502					1262	1264		10.1136/bmj.330.7502.1262	http://dx.doi.org/10.1136/bmj.330.7502.1262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15920131	Green Published			2022-12-28	WOS:000229448900029
J	Mello, MM; Clarridge, BR; Studdert, DM				Mello, MM; Clarridge, BR; Studdert, DM			Academic medical centers' standards for clinical-trial agreements with industry	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Although industry sponsors provide approximately 70 percent of the funding for clinical drug trials in the United States, little is known about the legal agreements that exist between industry sponsors and academic investigators. We studied institutional standards regarding contractual provisions that restrict investigators' control over trials. Methods We used a structured, cross-sectional mail survey of medical-school research administrators responsible for negotiating clinical-trial agreements with industry sponsors. Results Of 122 institutions approached, 107 participated. There was a high degree of consensus among administrators about the acceptability of several contractual provisions relating to publications. For example, more than 85 percent reported that their office would not approve provisions giving industry sponsors the authority to revise manuscripts or decide whether results should be published. There was considerable disagreement about the acceptability of provisions allowing the sponsor to insert its own statistical analyses in manuscripts (24 percent allowed them, 47 percent disallowed them, and 29 percent were not sure whether they should allow them), draft the manuscript (50 percent allowed it, 40 percent disallowed it, and 11 percent were not sure whether they should allow it), and prohibit investigators from sharing data with third parties after the trial is over (41 percent allowed it, 34 percent disallowed it, and 24 percent were not sure whether they should allow it). Disputes were common after the agreements had been signed and most frequently centered on payment (75 percent of administrators reported at least one such dispute in the previous year), intellectual property (30 percent), and control of or access to data (17 percent). Conclusions Standards for certain restrictive provisions in clinical-trial agreements with industry sponsors vary considerably among academic medical centers. Greater sharing of information about legal relationships with industry sponsors is desirable in order to build consensus about appropriate standards.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Massachusetts System; University of Massachusetts Boston	Mello, MM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	mmello@hsph.harvard.edu	Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270	NINDS NIH HHS [1-R01-NS42438-01A1, 1-R01-NS46777-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042438, R01NS046777] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angell M., 2004, TRUTH DRUG CO THEY D; BAER I, 2004, CLIN TRIAL CONTRACTS; BLUMENTHAL D, 1992, JAMA-J AM MED ASSOC, V268, P3344, DOI 10.1001/jama.268.23.3344; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; COHEN W, 1994, U IND RES CTR US; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Drazen JM, 2002, NEW ENGL J MED, V347, P1362, DOI 10.1056/NEJMe020122; Gelijns AC, 2002, JAMA-J AM MED ASSOC, V287, P72, DOI 10.1001/jama.287.1.72; Hailey D, 2000, CAN MED ASSOC J, V162, P212; HILTS PJ, 2000, CHICAGO TRIBUNE 1101, pN4; Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193; KAHN JO, 2001, JAMA-J AM MED ASSOC, V285, P2197; Lee GS, 2001, J KOREAN PHYS SOC, V39, P14; Meier Barry, 2004, N Y Times Web, pA16; Moses HI, 2002, NEW ENGL J MED, V347, P1371, DOI 10.1056/NEJMsb021319; Nathan DG, 2002, NEW ENGL J MED, V347, P1368, DOI 10.1056/NEJMsb020394; Pharmaceutical Research and Manufacturers of America, PRINC COND CLIN TRIA; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; SALTUS R, 2000, BOSTON GLOBE    1101, pA3; Schulman KA, 2003, NEW ENGL J MED, V348, P477; Schulman KA, 2002, NEW ENGL J MED, V347, P1335, DOI 10.1056/NEJMsa020349; Shuchman M, 1998, CAN MED ASSOC J, V159, P983; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286	23	99	104	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2202	2210		10.1056/NEJMsa044115	http://dx.doi.org/10.1056/NEJMsa044115			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917385				2022-12-28	WOS:000229333300008
J	Morbidelli, A; Levison, HF; Tsiganis, K; Gomes, R				Morbidelli, A; Levison, HF; Tsiganis, K; Gomes, R			Chaotic capture of Jupiter's Trojan asteroids in the early Solar System	NATURE			English	Article							PLANETARY MIGRATION; KUIPER-BELT; PLANETESIMAL DISK; FAMILY COMETS; ORIGIN; ACCRETION; NEPTUNE; ORBIT; POPULATION; EVOLUTION	Jupiter's Trojans are asteroids that follow essentially the same orbit as Jupiter, but lead or trail the planet by an angular distance of similar to 60 degrees (co-orbital motion). They are hypothesized to be planetesimals that formed near Jupiter and were captured onto their current orbits while Jupiter was growing(1,2), possibly with the help of gas drag(3-6) and/or collisions(7). This idea, however, cannot explain some basic properties of the Trojan population, in particular its broad orbital inclination distribution, which ranges up to similar to 40 degrees ( ref. 8). Here we show that the Trojans could have formed in more distant regions and been subsequently captured into co-orbital motion with Jupiter during the time when the giant planets migrated by removing neighbouring planetesimals(9-12). The capture was possible during a short period of time, just after Jupiter and Saturn crossed their mutual 1: 2 resonance, when the dynamics of the Trojan region were completely chaotic. Our simulations of this process satisfactorily reproduce the orbital distribution of the Trojans and their total mass.	Observ Cote Azur, F-06304 Nice, France; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA; UFRJ, OV, GEA, BR-20080090 Rio De Janeiro, Brazil; MCT, ON, BR-20080090 Rio De Janeiro, Brazil	UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; Universidade Federal do Rio de Janeiro	Morbidelli, A (corresponding author), Observ Cote Azur, BP 4229, F-06304 Nice, France.	morby@obs-nice.fr	gomes, rodney/G-8091-2011; Tsiganis, Kleomenis/AAF-5316-2020	Tsiganis, Kleomenis/0000-0003-3334-6190				Barucci M. A., 2002, ASTEROIDS, P273; Britt D. T., 2002, ASTEROIDS 3, VIII, P485; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; Emery JP, 2004, ICARUS, V170, P131, DOI 10.1016/j.icarus.2004.02.004; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Fernandez YR, 2003, ASTRON J, V126, P1563, DOI 10.1086/377015; Fleming HJ, 2000, ICARUS, V148, P479, DOI 10.1006/icar.2000.6523; Gomes RS, 2004, ICARUS, V170, P492, DOI 10.1016/j.icarus.2004.03.011; Gomes RS, 2003, ICARUS, V161, P404, DOI 10.1016/S0019-1035(02)00056-8; Gomes RS, 1998, ASTRON J, V116, P2590, DOI 10.1086/300582; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; Jewitt DC, 2000, ASTRON J, V120, P1140, DOI 10.1086/301453; KARY DM, 1995, ICARUS, V117, P1, DOI 10.1006/icar.1995.1139; Kortenkamp S. J., 2001, BAAS, V33, P1086; Kortenkamp SJ, 2004, ICARUS, V167, P347, DOI 10.1016/j.icarus.2003.09.021; Levison HF, 1997, NATURE, V385, P42, DOI 10.1038/385042a0; Levison HF, 2003, NATURE, V426, P419, DOI 10.1038/nature02120; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; MALHOTRA R, 1993, NATURE, V365, P819, DOI 10.1038/365819a0; Marzari F, 1998, ICARUS, V131, P41, DOI 10.1006/icar.1997.5841; Marzari F., 2002, ASTEROIDS, V1, P725; Merline W.J., 2002, ASTEROIDS, VIII, P289; Michtchenko TA, 2001, ASTRON J, V122, P3485, DOI 10.1086/324464; Milani A, 1993, CELEST MECH DYN ASTR, V57, P59, DOI 10.1007/BF00692462; PEALE SJ, 1993, ICARUS, V106, P308, DOI 10.1006/icar.1993.1173; SHOEMAKER EM, 1989, ASTEROIDS, V2, P487; YODER CF, 1979, ICARUS, V40, P341, DOI 10.1016/0019-1035(79)90024-1	28	570	577	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					462	465		10.1038/nature03540	http://dx.doi.org/10.1038/nature03540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917801				2022-12-28	WOS:000229337800047
J	Juffer, F; van IJzendoorn, MH				Juffer, F; van IJzendoorn, MH			Behavior problems and mental health referrals of international adoptees - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PSYCHOLOGICAL ADJUSTMENT; PUBLICATION BIAS; INTERCOUNTRY ADOPTION; PSYCHIATRIC-DISORDERS; BIOLOGICAL CHILDREN; FAMILY; RISK; ADOLESCENTS; ETIOLOGY; PARENTS	Context International adoption involves more than 40000 children a year moving among more than 100 countries. Before adoption, international adoptees often experience insufficient medical care, malnutrition, maternal separation, and neglect and abuse in orphanages. Objective To estimate the effects of international adoption on behavioral problems and mental health referrals. Data Sources We searched MEDLINE, PsychLit, and ERIC from 1950 to January 2005 using the terms adopt* combined with (behavior) problem, disorder, (mal) adjustment, (behavioral) development, clinical or psychiatric (referral), or mental health; conducted a manual search of the references of articles, books, book chapters, and reports; and consulted experts for relevant studies. The search was not limited to English-language publications. Study Selection Studies that provided sufficient data to compute differences between adoptees (in all age ranges) and nonadopted controls were selected, resulting in 34 articles on mental health referrals and 64 articles on behavior problems. Data Extraction Data on international adoption, preadoption adversity, and other moderators were extracted from each study and inserted in the program Comprehensive Meta-analysis (CMA). Effect sizes (d) for the overall differences between adoptees and controls regarding internalizing, externalizing, total behavior problems, and use of mental health services were computed. Homogeneity across studies was tested with the Q statistic. Data Synthesis Among 25 281 cases and 80 260 controls, adoptees (both within and between countries) presented more behavior problems, but effect sizes were small (d, 0.16-0.24). Adoptees (5092 cases) were overrepresented in mental health services and this effect size was large (d, 0.72). Among 15 790 cases and 30 450 controls, international adoptees showed more behavior problems than nonadopted controls, but effect sizes were small (d, 0.07-0.11). International adoptees showed fewer total externalizing and internalizing behavior problems than domestic adoptees. Also, international adoptees were less often referred to mental health services (d, 0.37) than domestic adoptees (d, 0.81). International adoptees with preadoption adversity showed more total problems and externalizing problems than international adoptees without evidence of extreme deprivation. Conclusions Most international adoptees are well-adjusted although they are referred to mental health services more often than nonadopted controls. However, international adoptees present fewer behavior problems and are less often referred to mental health services than domestic adoptees.	Leiden Univ, Ctr Family & Child Studies, NL-2300 RB Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Juffer, F (corresponding author), Leiden Univ, Ctr Family & Child Studies, POB 9555, NL-2300 RB Leiden, Netherlands.	juffer@fsw.leidenuniv.nl	van IJzendoorn, Marinus/P-4907-2019	van IJzendoorn, Marinus/0000-0003-1144-454X				Achenbach T.M., 1991, MANUAL CHILD BEHAV C, DOI DOI 10.1023/A; ANDRESEN ILK, 1992, J CHILD PSYCHOL PSYC, V33, P427, DOI 10.1111/j.1469-7610.1992.tb00877.x; [Anonymous], 2011, ROBUST STAT APPROACH; BAGLEY C, 1991, INTERCOUNTRY ADOPTIO, P55; Barth R. P., 1988, ADOPTION DISRUPTION; Benson P. L., 1994, GROWING ADOPTED PORT; Berg-Kelly K, 1997, EUR CHILD ADOLES PSY, V6, P199; Bieman HJMV, 1995, J CHILD PSYCHOL PSYC, V36, P1411, DOI 10.1111/j.1469-7610.1995.tb01672.x; Bimmel N, 2003, HARVARD REV PSYCHIAT, V11, P64, DOI 10.1080/10673220303955; BOGAERTS S, 1998, ADOLESCENTIE INTERCU; Bohman Michael, 1970, ADOPTED CHILDREN THE; Borders LD, 1998, FAM RELAT, V47, P237, DOI 10.2307/584972; Borders LD, 2000, FAM RELAT, V49, P407, DOI 10.1111/j.1741-3729.2000.00407.x; BORENSTEIN M, 2000, COMPREHENSIVE META A; BORGATTA EF, 1965, BEHAV CHARACTERISTIC; BOTVAR PK, 1994, 2 CHANCE INT ADOPTEE; Brand AE, 1999, J CHILD PSYCHOL PSYC, V40, P1221, DOI 10.1111/1469-7610.00538; BRINICH PM, 1982, J NERV MENT DIS, V170, P489, DOI 10.1097/00005053-198208000-00008; BRODZINSKY D, 1993, AM J ORTHOPSYCHIAT, V63, P451, DOI 10.1037/h0079447; Brodzinsky D., 1990, PSYCHOL ADOPTION; BRODZINSKY DM, 1984, J CONSULT CLIN PSYCH, V52, P582, DOI 10.1037/0022-006X.52.4.582; CAREY WB, 1974, CHILD WELFARE, V53, P352; CASTLE J, 2000, ADOPTION FOSTERING, V24, P26; Cederblad M, 1999, J CHILD PSYCHOL PSYC, V40, P1239, DOI 10.1017/S0021963099004746; Cederblad M, 1991, Lakartidningen, V88, P1081; Cermak SA, 1997, AM J OCCUP THER, V51, P500, DOI 10.5014/ajot.51.7.500; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COHEN NJ, 1993, J CHILD PSYCHOL PSYC, V34, P545, DOI 10.1111/j.1469-7610.1993.tb01035.x; Cook R, 1997, J PSYCHOSOM OBST GYN, V18, P203, DOI 10.3109/01674829709080689; Dalen M., 2001, ADOPTION Q, V5, P39, DOI [https://doi.org/10.1300/J145v05n02_03, DOI 10.1300/J145V05N02_03]; DAMODARAN A, 2000, INTERCOUNTRY ADOPTIO; Deater-Deckard K, 1999, CHILD DEV, V70, P144, DOI 10.1111/1467-8624.00011; DEJONG DK, 2001, WELL BEING RUSSIAN R; DERYALFREDSSON I, 1986, UTLANDSKA ADOPTIVBAR; DEUTSCH CK, 1982, BEHAV GENET, V12, P231, DOI 10.1007/BF01065768; DICKSON LR, 1990, AM J ORTHOPSYCHIAT, V60, P594, DOI 10.1037/h0079211; DUMARET A, 1985, J CHILD PSYCHOL PSYC, V26, P553, DOI 10.1111/j.1469-7610.1985.tb01641.x; DUNCAN W, 2000, INTERCOUNTRY ADOPTIO; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; EIDUSON BT, 1953, AM J ORTHOPSYCHIAT, V23, P795, DOI 10.1111/j.1939-0025.1953.tb00107.x; FAN X, 2002, ADOPTION Q, V0006; Feigelman W, 1997, MARRIAGE FAM REV, V25, P199, DOI 10.1300/J002v25n03_05; FERGUSSON DM, 1995, J CHILD PSYCHOL PSYC, V36, P597, DOI 10.1111/j.1469-7610.1995.tb02316.x; FISCH RO, 1976, J PEDIATR-US, V89, P494, DOI 10.1016/S0022-3476(76)80562-8; Fisher L, 1997, INT J BEHAV DEV, V20, P67, DOI 10.1080/016502597385441; FORSTENLINDMAN N, 1993, FOREIGN BORN CHILDRE; GARDNER DB, 1961, CHILD DEV, V32, P225, DOI 10.1111/j.1467-8624.1961.tb05018.x; GEERARS H, 1995, GEADOPTEERDEN WEG NA; Gilbody SM, 2000, ACTA PSYCHIAT SCAND, V102, P241, DOI 10.1034/j.1600-0447.2000.102004241.x; GOLDBERG D, 1992, J CHILD PSYCHOL PSYC, V33, P935, DOI 10.1111/j.1469-7610.1992.tb01967.x; Goldney RD, 1996, AUST NZ J PSYCHIAT, V30, P534, DOI 10.3109/00048679609065029; GOLDSTEIN H, 1995, J ROY STAT SOC A STA, V158, P175, DOI 10.2307/2983411; Golombok S, 2001, CHILD DEV, V72, P599, DOI 10.1111/1467-8624.00299; Goodman J D, 1975, J Med Soc N J, V72, P922; GOODMAN JD, 1963, ARCH GEN PSYCHIAT, V9, P451; Groze V, 1996, CHILD YOUTH SERV REV, V18, P57, DOI 10.1016/0190-7409(95)00054-2; Gunnar MR, 2000, DEV PSYCHOPATHOL, V12, P677, DOI 10.1017/S0954579400004077; HARLOW HF, 1958, AM PSYCHOL, V13, P673, DOI 10.1037/h0047884; Hjern A, 2002, LANCET, V360, P443, DOI 10.1016/S0140-6736(02)09674-5; HODGES J, 1989, J CHILD PSYCHOL PSYC, V30, P53, DOI 10.1111/j.1469-7610.1989.tb00769.x; HOKSBERGEN RAC, 2002, PEDAGOGIEK, V22, P55; HOKSBERGEN RAC, 1988, BITTERE ERVARINGEN U; HOKSBERGEN RAC, 1983, ADOPTIE UIT KINDERSC, P223; HOLDEN NL, 1991, BRIT J PSYCHIAT, V158, P829, DOI 10.1192/bjp.158.6.829; HOLMAN P, 1953, J MENT SCI, V99, P654, DOI 10.1192/bjp.99.417.654; Hoopes JL, 1997, MARRIAGE FAM REV, V25, P131, DOI 10.1300/J002v25n03_01; HOOPES JL, 1970, FOLLOW UP STUDY ADOP, V2; HUMPHREY M, 1963, BRIT J PSYCHIAT, V109, P599, DOI 10.1192/bjp.109.462.599; Jameson G K, 1967, Tex Med, V63, P83; JEROME L, 1986, CAN J PSYCHIAT, V31, P526, DOI 10.1177/070674378603100609; Judge S, 2003, FAM RELAT, V52, P241, DOI 10.1111/j.1741-3729.2003.00241.x; JUNGMANN J, 1980, PRAX KINDERPSYCHOL K, V29, P225; KENNY T, 1967, CHILD WELFARE, V46, P24; KETCHUM BK, 1964, CHILD WELFARE, V43, P249; Kim WJ, 1999, CHILD PSYCHIAT HUM D, V29, P221, DOI 10.1023/A:1022665024514; KOTSOPOULOS S, 1988, AM J ORTHOPSYCHIAT, V58, P608, DOI 10.1111/j.1939-0025.1988.tb01625.x; Lansford JE, 2001, J MARRIAGE FAM, V63, P840, DOI 10.1111/j.1741-3737.2001.00840.x; Levy-Shiff R, 2001, INT J BEHAV DEV, V25, P97, DOI 10.1080/01650250042000131; LINDHOLM BW, 1980, PSYCHOL REP, V46, P307, DOI 10.2466/pr0.1980.46.1.307; LIPMAN EL, 1992, CAN J PSYCHIAT, V37, P627, DOI 10.1177/070674379203700906; Loebstein R, 1997, J PSYCHIATR NEUROSCI, V22, P192; LOGAN J, 1998, CHILD ABUSE REV, V7, P154; Marcovitch S, 1997, INT J BEHAV DEV, V20, P17, DOI 10.1080/016502597385414; Maughan B, 1998, J CHILD PSYCHOL PSYC, V39, P669, DOI 10.1017/S0021963098002625; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Mullen B., 1989, ADV BASIC METAANALYS; O'Connor TG, 2000, CHILD DEV, V71, P376, DOI 10.1111/1467-8624.00151; PALACIOS J, 1996, ANUARIO PSICOLOGIA, V71, P63; PIERSMA HL, 1987, PSYCHIATRIC HOSPITAL, V18, P153; Pinderhughes EE, 1998, CHILD YOUTH SERV REV, V20, P223, DOI 10.1016/S0190-7409(98)00005-X; Priel B, 2000, FAM RELAT, V49, P389, DOI 10.1111/j.1741-3729.2000.00389.x; PRINGLE MLK, 1961, BRIT J EDUC PSYCHOL, V31, P183, DOI 10.1111/j.2044-8279.1961.tb02930.x; REECE SA, 1968, SOC WORK, V13, P101; ROGENESS GA, 1988, J AM ACAD CHILD PSY, V27, P628, DOI 10.1097/00004583-198809000-00019; Rojewski JW, 2000, CHILD PSYCHIAT HUM D, V31, P79, DOI 10.1023/A:1001978122206; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; ROSENWALD T, 1994, INTERCOUNTRY ADOPTIV; Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236; SCHECHTER MD, 1960, ARCH GEN PSYCHIAT, V3, P21; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Selman P, 2002, POPUL RES POLICY REV, V21, P205, DOI 10.1023/A:1019583625626; SELMAN P, 2000, INTERCOUNTRY ADOPTIO; SENIOR N, 1985, CHILD PSYCHIAT HUM D, V15, P189, DOI 10.1007/BF00709612; Sharma AR, 1996, CHILD YOUTH SERV REV, V18, P83, DOI 10.1016/0190-7409(95)00055-0; Sharma AR, 1998, CHILD DEV, V69, P791, DOI 10.1111/j.1467-8624.1998.00791.x; SIMON NM, 1966, AM J PSYCHIAT, V122, P858, DOI 10.1176/ajp.122.8.858; SINGER LM, 1985, CHILD DEV, V56, P1543, DOI 10.1111/j.1467-8624.1985.tb00219.x; Smyer MA, 1998, PSYCHIATRY, V61, P191, DOI 10.1080/00332747.1998.11024831; Stams GJJM, 2000, J CHILD PSYCHOL PSYC, V41, P1025, DOI 10.1017/S0021963099006344; STORSBERGEN HE, 2004, PSYCHISCHE GEZONDHEI; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; SULLIVAN PF, 1995, ACTA PSYCHIAT SCAND, V92, P119, DOI 10.1111/j.1600-0447.1995.tb09554.x; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; SWEENY DM, 1963, CHILD WELFARE, V42, P345; TIZARD B, 1991, J CHILD PSYCHOL PSYC, V32, P743, DOI 10.1111/j.1469-7610.1991.tb01899.x; TOUSSIENG PW, 1962, CHILD WELFARE, V41, P59; TREFFERS PDA, 1998, MAANDBLAD GEESTELIJK, V11, P1103; TSITSIKAS H, 1988, CHILDREN FAMILIES ST, P399; *US STAT DEP, IMM VIS ISS ORPH COM; van Ijzendoorn MH, 2005, PSYCHOL BULL, V131, P301, DOI 10.1037/0033-2909.131.2.301; VERHULST FC, 1990, J AM ACAD CHILD PSY, V29, P94, DOI 10.1097/00004583-199001000-00015; VERHULST FC, 1993, J CHILD PSYCHOL PSYC, V34, P767, DOI 10.1111/j.1469-7610.1993.tb01070.x; VERHULST FC, 1989, BUITENLANDSE ADOPTIE; Vorria P, 2003, J CHILD PSYCHOL PSYC, V44, P1208, DOI 10.1111/1469-7610.00202; WARREN SB, 1992, J AM ACAD CHILD PSY, V31, P512, DOI 10.1097/00004583-199205000-00019; WIERZBICKI M, 1993, J CLIN CHILD PSYCHOL, V22, P447, DOI 10.1207/s15374424jccp2204_5; WITMER H, 1963, INDEPENDENT ADOPTION; Zosky DL, 2005, ADOPT Q, V8, P1, DOI 10.1300/J145v08n03_01; Zucker KJ, 1998, CAN J PSYCHIAT, V43, P1040, DOI 10.1177/070674379804301011	130	436	442	4	93	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2501	2515		10.1001/jama.293.20.2501	http://dx.doi.org/10.1001/jama.293.20.2501			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	929BX	15914751				2022-12-28	WOS:000229318200025
J	Choi, MH; Lee, IK; Kim, GW; Kim, BU; Han, YH; Yu, DY; Park, HS; Kim, KY; Lee, JS; Choi, CH; Bae, YS; Lee, BI; Rhee, SG; Kang, SW				Choi, MH; Lee, IK; Kim, GW; Kim, BU; Han, YH; Yu, DY; Park, HS; Kim, KY; Lee, JS; Choi, CH; Bae, YS; Lee, BI; Rhee, SG; Kang, SW			Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II	NATURE			English	Article							CYSTEINE-SULFINIC ACID; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; MAMMALIAN PEROXIREDOXIN; SITE CYSTEINE; ACTIVATION; MECHANISM; REQUIRES; RECEPTOR	Platelet-derived growth factor ( PDGF) is a potent mitogenic and migratory factor that regulates the tyrosine phosphorylation of a variety of signalling proteins via intracellular production of H2O2 (refs 1 - 3). Mammalian 2-Cys peroxiredoxin type II ( Prx II; gene symbol Prdx2) is a cellular peroxidase that eliminates endogenous H2O2 produced in response to growth factors such as PDGF and epidermal growth factor(4); however, its involvement in growth factor signalling is largely unknown. Here we show that Prx II is a negative regulator of PDGF signalling. Prx II deficiency results in increased production of H2O2, enhanced activation of PDGF receptor ( PDGFR) and phospholipase C gamma 1, and subsequently increased cell proliferation and migration in response to PDGF. These responses are suppressed by expression of wild-type Prx II, but not an inactive mutant. Notably, Prx II is recruited to PDGFR upon PDGF stimulation, and suppresses protein tyrosine phosphatase inactivation. Prx II also leads to the suppression of PDGFR activation in primary culture and a murine restenosis model, including PDGF-dependent neointimal thickening of vascular smooth muscle cells. These results demonstrate a localized role for endogenous H2O2 in PDGF signalling, and indicate a biological function of Prx II in cardiovascular disease.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Yonsei Univ, Coll Med, Dept Neurol, Seoul 120752, South Korea; Korea Res Inst Biosci & Biotechnol, Lab Human Genom, Taejon 305333, South Korea; Labfrontier Co Ltd, Inst Life Sci, Suwon 442766, Kyunggi Do, South Korea; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Korea Adv Inst Sci & Technol, Dept Biosyst, Taejon 305701, South Korea	Ewha Womans University; Ewha Womans University; Yonsei University; Yonsei University Health System; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Korea Advanced Institute of Science & Technology (KAIST)	Rhee, SG (corresponding author), Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.	sgrhee@nih.gov	Choi, Chulhee/C-1642-2011	Choi, Chulhee/0000-0001-5542-9136				Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Ohmi K, 1997, BIOCHEM BIOPH RES CO, V238, P154, DOI 10.1006/bbrc.1997.7218; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rosado JA, 2004, J BIOL CHEM, V279, P1665, DOI 10.1074/jbc.M307963200; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saito S, 2002, J BIOL CHEM, V277, P44695, DOI 10.1074/jbc.M208332200; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Sekiya F, 2004, J BIOL CHEM, V279, P32181, DOI 10.1074/jbc.M405116200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	23	310	326	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					347	353		10.1038/nature03587	http://dx.doi.org/10.1038/nature03587			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902258				2022-12-28	WOS:000229185000046
J	Wild, EM; Teschler-Nicola, M; Kutschera, W; Steier, P; Trinkaus, E; Wanek, W				Wild, EM; Teschler-Nicola, M; Kutschera, W; Steier, P; Trinkaus, E; Wanek, W			Direct dating of Early Upper Palaeolithic human remains from Mladec	NATURE			English	Article							HUMAN FOSSILS; BONE; COLLAGEN; DATES	The human fossil assemblage from the Mladec. Caves in Moravia ( Czech Republic)(1) has been considered to derive from a middle or later phase of the Central European Aurignacian period on the basis of archaeological remains ( a few stone artefacts and organic items such as bone points, awls, perforated teeth)(2), despite questions(3) of association between the human fossils and the archaeological materials and concerning the chronological implications of the limited archaeological remains(4). The morphological variability in the human assemblage, the presence of apparently archaic features in some specimens, and the assumed early date of the remains have made this fossil assemblage pivotal in assessments of modern human emergence within Europe(5-7). We present here the first successful direct accelerator mass spectrometry radiocarbon dating of five representative human fossils from the site. We selected sample materials from teeth and from one bone for C-14 dating. The four tooth samples yielded uncalibrated ages of similar to 31,000 C-14 years before present, and the bone sample ( an ulna) provided an uncertain more-recent age. These data are sufficient to confirm that the Mladec. human assemblage is the oldest cranial, dental and postcranial assemblage of early modern humans in Europe and is therefore central to discussions of modern human emergence in the northwestern Old World and the fate of the Neanderthals.	Univ Vienna, Inst Isotopenforsch & Kernphys, VERA Lab, A-1090 Vienna, Austria; Univ Vienna, Dept Chem Okol & Okosyst Wissensch, A-1090 Vienna, Austria; Nat Hist Museum Wien, Anthropol Abt, A-1010 Vienna, Austria; Washington Univ, Dept Anthropol, St Louis, MO 63130 USA	University of Vienna; University of Vienna; Washington University (WUSTL)	Teschler-Nicola, M (corresponding author), Univ Vienna, Inst Isotopenforsch & Kernphys, VERA Lab, Wahringerstr 17, A-1090 Vienna, Austria.	maria.teschler@univie.ac.at	Wanek, Wolfgang/E-7001-2012; Steier, Peter/AAZ-6043-2020	Wanek, Wolfgang/0000-0003-2178-8258; 				AMBROSE SH, 1990, J ARCHAEOL SCI, V17, P431, DOI 10.1016/0305-4403(90)90007-R; Bard E, 2004, SCIENCE, V303, P178, DOI 10.1126/science.1091964; Brauer G, 2004, ANAT REC PART A, V279A, P701, DOI 10.1002/ar.a.20064; Conard NJ, 2004, NATURE, V430, P198, DOI 10.1038/nature02690; DENIRO MJ, 1985, NATURE, V317, P806, DOI 10.1038/317806a0; FRAYER DW, 1986, ANTHROPOS, V23, P243; HEDGES REM, 1992, RADIOCARBON, V34, P279, DOI 10.1017/S0033822200063438; Henry-Gambier D., 2002, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V14, P89; Hublin JJ, 1996, NATURE, V381, P224, DOI 10.1038/381224a0; Kingston, 1989, APPLIED GEOCHEMISTRY, V4, P281, DOI DOI 10.1016/0883-2927(89)90030-9; Mellars P, 2004, NATURE, V432, P461, DOI 10.1038/nature03103; OLIVA M, 1993, UISPP 12 C BRAT I AR, V2, P207; ORSCHIEDT J, 2002, PALEO, V14, P239; PAUNESCU A, 2001, PALEOLITICUL MEZOLIT, P231; PETCHEY F, CHEM PRETREATMENT ME; Schmitz RW, 2002, P NATL ACAD SCI USA, V99, P13342, DOI 10.1073/pnas.192464099; Serre D, 2004, PLOS BIOL, V2, P313, DOI 10.1371/journal.pbio.0020057; Smith FH, 1999, P NATL ACAD SCI USA, V96, P12281, DOI 10.1073/pnas.96.22.12281; Steier P, 2004, RADIOCARBON, V46, P5, DOI 10.1017/S0033822200039291; STRINGER CB, 1990, HOMINID REMAINS UPDA, P1; Svoboda J, 2000, J HUM EVOL, V38, P523, DOI 10.1006/jhev.1999.0361; Svoboda JA, 2002, ANTIQUITY, V76, P957, DOI 10.1017/S0003598X00091754; SZOMBATHY J, 1925, EISZEIT, V2, P73; SZOMBATHY J, 1925, EISZEIT, V2, P1; TERBERGER T, 2001, ARCHAOL KORRESPONDEN, V31, P521; Trinkaus E, 2003, P NATL ACAD SCI USA, V100, P11231, DOI 10.1073/pnas.2035108100; van der Plicht J, 2004, RADIOCARBON, V46, P1225, DOI 10.1017/S0033822200033117; VANANDEL TH, 2004, NEANDERTHALS MODERN, P21; Wild E, 1998, RADIOCARBON, V40, P273; Wolpoff MH, 2001, SCIENCE, V291, P293, DOI 10.1126/science.291.5502.293	30	113	119	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					332	335		10.1038/nature03585	http://dx.doi.org/10.1038/nature03585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	927HM	15902255				2022-12-28	WOS:000229185000043
J	Dworkin, MS				Dworkin, MS			Adults are whooping, but are internists listening?	ANNALS OF INTERNAL MEDICINE			English	Article							BORDETELLA-PERTUSSIS INFECTION; UNITED-STATES; PERSISTENT COUGH; ADOLESCENTS; OUTBREAK; EPIDEMIOLOGY; AZITHROMYCIN; PROPHYLAXIS; PREVALENCE; ILLNESS	Although studies have shown that pertussis is responsible for approximately 20% to 30% of cases of cough lasting more than 2 weeks in adults and adolescents, physicians have generally considered pertussis a disease that affects only children. Epidemiologic trends demonstrate that the incidence of pertussis has been rising, especially in adolescents and adults. Consequently, pertussis is not a "zebra" diagnosis but deserves a place among the community-acquired list of adult pathogens. Increased awareness among physicians about pertussis is important because adults may transmit the infection to infants, in whom the disease often leads to hospitalization and may result in death. Reporting this disease to the local health department is critical to its control because both case-patients and their close contacts should receive antimicrobial prophylaxis. A booster vaccine for adolescents and adults is likely to become available in the near future, so this is an important time to ensure that all physicians, not just pediatricians, are knowledgeable about the diagnosis, treatment, and reporting requirements for pertussis.	Illinois Dept Publ Hlth, Chicago, IL 60601 USA		Dworkin, MS (corresponding author), Illinois Dept Publ Hlth, 160 N LaSalle,7th Floor, Chicago, IL 60601 USA.	mdworkin@idph.state.il.us						ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Baughman AL, 2004, CLIN DIAGN LAB IMMUN, V11, P1045, DOI 10.1128/CDLI.11.6.1045-1053.2004; Centers for Disease Control and Prevention (CDC) HIPAA Privacy Rule and Public Health, 2003, MMWR-MORBID MORTAL W, V52, P1; Cherry JD, 2004, CLIN INFECT DIS, V39, P1715, DOI 10.1086/425003; Cherry JD, 1998, ANN INTERN MED, V128, P64, DOI 10.7326/0003-4819-128-1-199801010-00010; Cloud JL, 2002, J CLIN MICROBIOL, V40, P3838, DOI 10.1128/JCM.40.10.3838-3840.2002; Dworkin MS, 1998, ANN INTERN MED, V128, P1047, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00025; DWORKIN MS, 2004, P 42 ANN M INF DIS S; DWORKIN MS, 1997, P 31 ANN NAT IMM C D; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; HERWALDT LA, 1991, ARCH INTERN MED, V151, P1510, DOI 10.1001/archinte.151.8.1510; HODDER SL, 1992, EPIDEMIOL REV, V14, P243, DOI 10.1093/oxfordjournals.epirev.a036089; Klass P, 2004, NEW ENGL J MED, V350, P2023, DOI 10.1056/NEJMp038243; LAMBERT HJ, 1965, PUBLIC HEALTH REP, V80, P365, DOI 10.2307/4592424; Langley JM, 2004, PEDIATRICS, V114, pE96, DOI 10.1542/peds.114.1.e96; Lee GM, 2004, CLIN INFECT DIS, V39, P1572, DOI 10.1086/425006; Mannerstedt G, 1934, J PEDIATR-US, V5, P596, DOI 10.1016/S0022-3476(34)80039-X; Marchant CD, 2004, CLIN INFECT DIS, V39, P1581, DOI 10.1086/425012; Martinez SM, 2001, INFECT CONT HOSP EP, V22, P781, DOI 10.1086/501863; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MORSE SI, 1968, ANN INTERN MED, V68, P953, DOI 10.7326/0003-4819-68-4-953; Nennig ME, 1996, JAMA-J AM MED ASSOC, V275, P1672, DOI 10.1001/jama.275.21.1672; *OKL STAT DEP HLTH, 2004, 2003 ANN SUMM INF DI; POSTELSMULTANI S, 1995, INFECTION, V23, P139, DOI 10.1007/BF01793853; Purdy KW, 2004, CLIN INFECT DIS, V39, P20, DOI 10.1086/421091; ROBERTSON PW, 1987, MED J AUSTRALIA, V146, P522, DOI 10.5694/j.1326-5377.1987.tb120392.x; ROSENTHAL S, 1995, J INFECT DIS, V171, P1650, DOI 10.1093/infdis/171.6.1650; SCHMITTGROHE S, 1995, CLIN INFECT DIS, V21, P860, DOI 10.1093/clinids/21.4.860; Senzilet LD, 2001, CLIN INFECT DIS, V32, P1691, DOI 10.1086/320754; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; 1995, MMWR MORB MORTAL WKL, V44, P74; 1997, MMWR MORB MORTAL WKL, V46, P822; 2004, MMWR MORB MORTAL WKL, V53, P131; 2002, MMWR MORB MORTAL WKL, V51, P616; 2002, MMWR MORB MORTAL WKL, V51, P73	38	22	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					832	835		10.7326/0003-4819-142-10-200505170-00008	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897533				2022-12-28	WOS:000229099600004
J	Marx, A; Pewsner, D; Egger, M; Nuesch, R; Bucher, HC; Genton, B; Hatz, C; Juni, P				Marx, A; Pewsner, D; Egger, M; Nuesch, R; Bucher, HC; Genton, B; Hatz, C; Juni, P			Meta-analysis: Accuracy of rapid tests for malaria in travelers returning from endemic areas	ANNALS OF INTERNAL MEDICINE			English	Review							PLASMODIUM-FALCIPARUM MALARIA; POLYMERASE-CHAIN-REACTION; DIAGNOSTIC-TEST; IMPORTED MALARIA; NONIMMUNE TRAVELERS; UNITED-KINGDOM; DIPSTICK TESTS; BIAS; PERFORMANCE; MICROSCOPY	Background: Microscopic diagnosis of malaria is unreliable outside specialized centers. Rapid tests have become available in recent years, but their accuracy has not been assessed systematically. Purpose: To determine the accuracy of rapid diagnostic tests for ruling out malaria in nonimmune travelers returning from malaria-endemic areas. Data Sources: The authors searched MEDLINE, EMBASE, CAB Health, and CINAHL (1988 to September 2004); hand-searched conference proceedings; checked reference lists; and contacted experts and manufacturers. Study Selection: Diagnostic accuracy studies in nonimmune individuals with suspected malaria were included if they compared rapid tests with expert microscopic examination or polymerase chain reaction tests. Data Extraction: Data on study and patient characteristics and results were extracted in duplicate. The main outcome was the likelihood ratio for a negative test result (negative likelihood ratio) for Plasmodium falciparum malaria. Likelihood ratios were combined by using random-effects meta-analysis, stratified by the antigen targeted (histidine-rich protein-2 [HRP-2] or parasite lactate dehydrogenase [LDH]) and by test generation. Nornograms of post-test probabilities were constructed. Data Synthesis: The authors included 21 studies and 5747 individuals. For P. falciparum, HRP-2-based tests were more accurate than parasite LDH-based tests: Negative likelihood ratios were 0.08 and 0.13, respectively (P = 0.019 for difference). Three-band HRP-2 tests had similar negative likelihood ratios but higher positive likelihood ratios compared with 2-band tests (34.7 vs. 98.5; P = 0.003). For P. vivax, negative likelihood ratios tended to be closer to 1.0 for HRP-2-based tests than for parasite LDH-based tests (0.24 vs. 0.13; P = 0.22), but analyses were based on a few heterogeneous studies. Negative likelihood ratios for the diagnosis of P. malariae or P. ovale were close to 1.0 for both types of tests. In febrile travelers returning from sub-Saharan Africa, the typical probability of P. falciparum malaria is estimated at 1.1 % (95% CI, 0.6% to 1.9%) after a negative 3-band HRP-2 test result and 97%(CI, 92% to 99%) after a positive test result. Limitations: Few studies evaluated 3-band HRP-2 tests. The evidence is also limited for species other than P. falciparum because of the few available studies and their more heterogeneous results. Further studies are needed to determine whether the use of rapid diagnostic tests improves outcomes in returning travelers with suspected malaria. Conclusions: Rapid malaria tests may be a useful diagnostic adjunct to microscopy in centers without major expertise in tropical medicine. Initial decisions on treatment initiation and choice of antimalarial drugs can be based on travel history and post-test probabilities after rapid testing. Expert microscopy is still required for species identification and confirmation.	Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; MediX Gen Practice Network, CH-3012 Bern, Switzerland; Univ Bristol, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Basel, Basel Inst Clin Epidemiol, Basel, Switzerland; Univ Basel, Swiss Trop Inst, Basel, Switzerland	University of Bern; University of Bristol; University of Basel; University of Basel; Swiss Tropical & Public Health Institute	Juni, P (corresponding author), Univ Bern, Dept Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	juni@ispm.unibe.ch	Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Egger, Matthias/0000-0001-7462-5132				Bellagra N, 1998, PATHOL BIOL, V46, P301; Bossuyt PMM, 2000, LANCET, V356, P1844, DOI 10.1016/S0140-6736(00)03246-3; Bouchaud O, 2000, AM J TROP MED HYG, V63, P76, DOI 10.4269/ajtmh.2000.63.76; Brenier-Pinchart MP, 2000, AM J TROP MED HYG, V63, P150, DOI 10.4269/ajtmh.2000.63.150; Cavallo J D, 1997, Med Trop (Mars), V57, P353; Chiodini PL, 1998, LANCET, V351, P80, DOI 10.1016/S0140-6736(05)78155-1; CHIODINI PL, 1996, MDA9633; Cropley IM, 2000, BMJ-BRIT MED J, V321, P484, DOI 10.1136/bmj.321.7259.484; De Monbrison F, 2004, EUR J CLIN MICROBIOL, V23, P784, DOI 10.1007/s10096-004-1202-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Deville Walter L, 2002, BMC Med Res Methodol, V2, P9, DOI 10.1186/1471-2288-2-9; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farcas GA, 2003, AM J TROP MED HYG, V69, P589, DOI 10.4269/ajtmh.2003.69.6.0690589; Filler Scott, 2003, MMWR Surveill Summ, V52, P1; Garavelli Pietro Luigi, 2002, Recenti Progressi in Medicina, V93, P682; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; Hernandez E, 2001, Med Trop (Mars), V61, P153; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Humar A, 1997, AM J TROP MED HYG, V56, P44, DOI 10.4269/ajtmh.1997.56.44; Irwig I, 1995, J CLIN EPIDEMIOL, V48, P131; IRWIG L, 1995, J CLIN EPIDEMIOL, V48, P119, DOI 10.1016/0895-4356(94)00099-C; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Jelinek T, 1999, J CLIN MICROBIOL, V37, P721, DOI 10.1128/JCM.37.3.721-723.1999; Jelinek T, 2000, J TRAVEL MED, V7, P175, DOI 10.2310/7060.2000.00055; Jelinek T, 2001, SCAND J INFECT DIS, V33, P752, DOI 10.1080/003655401317074563; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; Mills CD, 1999, B WORLD HEALTH ORGAN, V77, P553; MILNE LM, 1994, J CLIN PATHOL, V47, P740, DOI 10.1136/jcp.47.8.740; Moody A, 2000, BRIT J HAEMATOL, V109, P891, DOI 10.1046/j.1365-2141.2000.01974.x; Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002; Moody A H, 2002, Br J Biomed Sci, V59, P228; Mulherin SA, 2002, ANN INTERN MED, V137, P598, DOI 10.7326/0003-4819-137-7-200210010-00011; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Nuesch R, 2000, J TRAVEL MED, V7, P95; Pieroni P, 1998, T ROY SOC TROP MED H, V92, P166, DOI 10.1016/S0035-9203(98)90730-1; Playford EG, 2002, J CLIN MICROBIOL, V40, P4166, DOI 10.1128/JCM.40.11.4166-4171.2002; Richardson DC, 2002, J CLIN MICROBIOL, V40, P4528, DOI 10.1128/JCM.40.12.4528-4530.2002; Sox H, 1987, MED DECISION MAKING; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Uguen C, 1995, B WORLD HEALTH ORGAN, V73, P643; Van den Ende J, 1998, T ROY SOC TROP MED H, V92, P285, DOI 10.1016/S0035-9203(98)91013-6; *WHO, 2003, M REP 20 23 JAN 2003; WHO, JOINT WHO USAID INF	46	109	110	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					836	846		10.7326/0003-4819-142-10-200505170-00009	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897534				2022-12-28	WOS:000229099600005
J	Flasar, FM; Achterberg, RK; Conrath, BJ; Gierasch, PJ; Kunde, VG; Nixon, CA; Bjoraker, GL; Jennings, DE; Romani, PN; Simon-Miller, AA; Bezard, B; Coustenis, A; Irwin, PGJ; Teanby, NA; Brasunas, J; Pearl, JC; Segura, ME; Carlson, RC; Mamoutkine, A; Schinder, PJ; Barucci, A; Courtin, R; Fouchet, T; Gautier, D; Lellouch, E; Marten, A; Prange, R; Vinatier, S; Strobel, DF; Calcutt, SB; Read, PL; Taylor, FW; Bowles, N; Samuelson, RE; Orton, GS; Spilker, LJ; Owen, TC; Spencer, JR; Showalter, MR; Ferrari, C; Abbas, MM; Raulin, F; Edgington, S; Ade, P; Wishnow, EH				Flasar, FM; Achterberg, RK; Conrath, BJ; Gierasch, PJ; Kunde, VG; Nixon, CA; Bjoraker, GL; Jennings, DE; Romani, PN; Simon-Miller, AA; Bezard, B; Coustenis, A; Irwin, PGJ; Teanby, NA; Brasunas, J; Pearl, JC; Segura, ME; Carlson, RC; Mamoutkine, A; Schinder, PJ; Barucci, A; Courtin, R; Fouchet, T; Gautier, D; Lellouch, E; Marten, A; Prange, R; Vinatier, S; Strobel, DF; Calcutt, SB; Read, PL; Taylor, FW; Bowles, N; Samuelson, RE; Orton, GS; Spilker, LJ; Owen, TC; Spencer, JR; Showalter, MR; Ferrari, C; Abbas, MM; Raulin, F; Edgington, S; Ade, P; Wishnow, EH			Titan's atmospheric temperatures, winds, and composition	SCIENCE			English	Article							HETERODYNE OBSERVATIONS; VERTICAL PROFILE; POLAR VORTEX; PHOTOCHEMISTRY; OCCULTATION; STRATOSPHERE; MILLIMETER; CHEMISTRY; DYNAMICS; SYSTEM	Temperatures obtained from early Cassini infrared observations of Titan show a stratopause at an altitude of 310 kilometers (and 186 kelvin at 15 degrees S). Stratospheric temperatures are coldest in the winter northern hemisphere, with zonal winds reaching 160 meters per second. The concentrations of several stratospheric organic compounds are enhanced at mid- and high northern latitudes, and the strong zonal winds may, inhibit mixing between these latitudes and the rest of Titan. Above the south pole, temperatures in the stratosphere are 4 to 5 kelvin cooler than at the equator. The stratospheric mole fractions of methane and carbon monoxide are (1.6 +/- 0.5) x 10(-2) and (4.5 +/- 1.5) x 10(-5), respectively.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Sci Syst & Applicat, Lanham, MD 20706 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; Observ Paris, LESIA, CNRS, UMR 8109, F-91925 Meudon, France; Univ Oxford, Clarendon Lab, Oxford OX1 3PU, England; QSS Grp, Lanham, MD 20706 USA; Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA; Search Extraterr Intelligence Inst, Mountain View, CA 94043 USA; CEA, Serv Astrophys, F-91191 Gif Sur Yvette, France; NASA, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA; Univ Paris 07, Lab Interuniv Syst Atmospher, CNRS, UMR 7583, F-94010 Creteil, France; Univ Paris 12, Lab Interuniv Syst Atmospher, CNRS, UMR 7583, F-94010 Creteil, France; Univ Cardiff, Dept Phys & Astron, Cardiff CF24 3YB, S Glam, Wales; Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; Univ Calif Berkeley, Space Sci Lab, Livermore, CA 94551 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Cornell University; University System of Maryland; University of Maryland College Park; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Universite Paris Cite; University of Oxford; Johns Hopkins University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System; CEA; UDICE-French Research Universities; Universite Paris Saclay; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Cardiff University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Berkeley	Flasar, FM (corresponding author), NASA, Goddard Space Flight Ctr, Code 693, Greenbelt, MD 20771 USA.	f.m.flasar@nasa.gov	Ferrari, Cécile/P-9735-2016; Vinatier, Sandrine/AAB-8763-2019; Simon, Amy/C-8020-2012; Fouchet, Thierry/C-6374-2017; brasunas, john/I-2798-2013; Strobel, Darrell5/AAO-6643-2021; Jennings, Donald/D-7978-2012; Flasar, F Michael/C-8509-2012; Romani, Paul N/D-2729-2012; Bjoraker, Gordon L/D-5032-2012; Nixon, Conor A/A-8531-2009; Orton, Glenn/AAD-9862-2020	Ferrari, Cécile/0000-0001-5962-7439; Vinatier, Sandrine/0000-0001-5541-2502; Simon, Amy/0000-0003-4641-6186; Fouchet, Thierry/0000-0001-9040-8285; Strobel, Darrell5/0000-0002-0944-8675; Nixon, Conor A/0000-0001-9540-9121; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X; Calcutt, Simon/0000-0002-0102-3170; Achterberg, Richard/0000-0002-7643-7626; Bezard, Bruno/0000-0002-5433-5661; Taylor, Fred/0000-0002-0675-9769; Teanby, Nicholas/0000-0003-3108-5775; Ade, Peter/0000-0002-5127-0401				BACMEISTER JT, 1995, J GEOPHYS RES-ATMOS, V100, P11669, DOI 10.1029/94JD02958; BEZARD B, 1995, ICARUS, V113, P267, DOI 10.1006/icar.1995.1023; BOUCHEZ AH, 2004, THESIS CALTECH; COUSTENIS A, 1995, ICARUS, V115, P126, DOI 10.1006/icar.1995.1084; Coustenis A, 2003, ICARUS, V161, P383, DOI 10.1016/S0019-1035(02)00028-3; COUSTENIS A, 1993, ICARUS, V102, P240, DOI 10.1006/icar.1993.1047; Flasar FM, 2005, SCIENCE, V307, P1247, DOI 10.1126/science.1105806; Flasar FM, 2004, SPACE SCI REV, V115, P169, DOI 10.1007/s11214-004-1454-9; FLASAR FM, 1990, ICARUS, V85, P346, DOI 10.1016/0019-1035(90)90122-P; FLASAR FM, 1981, NATURE, V292, P693, DOI 10.1038/292693a0; Flasar FM, 1998, PLANET SPACE SCI, V46, P1125, DOI 10.1016/S0032-0633(97)00223-7; GURWELL MA, 1995, ICARUS, V117, P375, DOI 10.1006/icar.1995.1163; Hidayat T, 1998, ICARUS, V133, P109, DOI 10.1006/icar.1998.5908; Hourdin F, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002282; HOURDIN F, 1995, ICARUS, V117, P358, DOI 10.1006/icar.1995.1162; HUBBARD WB, 1993, ASTRON ASTROPHYS, V269, P541; Hunten D.M, 1984, SATURN, P671; KUNDE V, 1996, SPIE P, P162; Lebonnois S, 2001, ICARUS, V152, P384, DOI 10.1006/icar.2001.6632; Lellouch E, 2003, ICARUS, V162, P125, DOI 10.1016/S0019-1035(02)00079-9; LINDAL GF, 1983, ICARUS, V53, P348, DOI 10.1016/0019-1035(83)90155-0; Moses JI, 2000, ICARUS, V143, P244, DOI 10.1006/icar.1999.6270; Roe HG, 2004, ICARUS, V169, P440, DOI 10.1016/j.icarus.2004.01.002; Samuelson RE, 1997, PLANET SPACE SCI, V45, P959, DOI 10.1016/S0032-0633(97)00090-1; SCHOEBERL MR, 1991, SCIENCE, V251, P46, DOI 10.1126/science.251.4989.46; Sicardy B, 1999, ICARUS, V142, P357, DOI 10.1006/icar.1999.6219; STROBEL DF, 1982, PLANET SPACE SCI, V30, P839, DOI 10.1016/0032-0633(82)90116-7; TOUBLANC D, 1995, ICARUS, V113, P2, DOI 10.1006/icar.1995.1002; Wilson EH, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002181; YELLE RV, 1991, ASTROPHYS J, V383, P380, DOI 10.1086/170796; YUNG YL, 1987, ICARUS, V72, P468, DOI 10.1016/0019-1035(87)90186-2; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	33	277	278	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2005	308	5724					975	978		10.1126/science.1111150	http://dx.doi.org/10.1126/science.1111150			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927JR	15894528				2022-12-28	WOS:000229190700032
J	Barnett, TP; Pierce, DW; AchutaRao, KM; Gleckler, PJ; Santer, BD; Gregory, JM; Washington, WM				Barnett, TP; Pierce, DW; AchutaRao, KM; Gleckler, PJ; Santer, BD; Gregory, JM; Washington, WM			Penetration of human-induced warming into the world's oceans	SCIENCE			English	Article							CLIMATE-CHANGE; GREENHOUSE-GAS; OVERTURNING CIRCULATION; FINGERPRINT METHOD; INDIAN-OCEAN; HEAT UPTAKE; MODEL; SIMULATIONS; 20TH-CENTURY; ATTRIBUTION	A warming signal has penetrated into the world's oceans over the past 40 years. The signal is complex, with a vertical structure that varies widely by ocean; it cannot be explained by natural internal climate variability or solar and volcanic forcing, but is well simulated by two anthropogenicaliy forced climate models. We conclude that it is of human origin, a conclusion robust to,observational. sampling and model differences. Changes in advection combine with surface forcing to give the overall warming pattern. The implications of this study suggest that society needs to seriously consider model predictions of future climate change.	Univ Calif San Diego, Scripps Inst Oceanog, Div Climate Res, La Jolla, CA 92037 USA; Lawrence Livermore Natl Lab, Program Climate Model Diagnoses & Intercomparison, Livermore, CA 94550 USA; UK Med Off Hadley Ctr, Reading RG6 6BB, Berks, England; Univ Reading, Reading RG6 6BB, Berks, England; Natl Ctr Atmospher Res, Boulder, CO 80307 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Met Office - UK; Hadley Centre; University of Reading; National Center Atmospheric Research (NCAR) - USA	Barnett, TP (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Div Climate Res, 0224, La Jolla, CA 92037 USA.	tbarnett@ucsd.edu	Santer, Benjamin D/F-9781-2011; Santer, Ben/ABA-1099-2021; Gleckler, Peter/H-4762-2012; Gregory, Jonathan/J-2939-2016	Gleckler, Peter/0000-0003-2816-6224; Gregory, Jonathan/0000-0003-1296-8644				ACHUTARAO KM, UNPUB; Allen MR, 1999, CLIM DYNAM, V15, P419, DOI 10.1007/s003820050291; Barnett TP, 2001, SCIENCE, V292, P270, DOI 10.1126/science.1058304; Dai A, 2004, CLIMATIC CHANGE, V62, P29, DOI 10.1023/B:CLIM.0000013679.74883.e6; Gent PR, 2004, J CLIMATE, V17, P4058, DOI 10.1175/1520-0442(2004)017<4058:HUATTC>2.0.CO;2; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; Gregory JM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020258; Hansen J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001143; Hasselmann K, 1997, CLIM DYNAM, V13, P601, DOI 10.1007/s003820050185; Hegerl GC, 1996, J CLIMATE, V9, P2281, DOI 10.1175/1520-0442(1996)009<2281:DGGICC>2.0.CO;2; Hegerl GC, 1997, CLIM DYNAM, V13, P613, DOI 10.1007/s003820050186; Houghton J. T., 2001, 3 IPCC; Lee T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020884; Levitus S, 2001, SCIENCE, V292, P267, DOI 10.1126/science.1058154; Levitus S, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021592; McPhaden MJ, 2002, NATURE, V415, P603, DOI 10.1038/415603a; Meehl GA, 2003, J CLIMATE, V16, P426, DOI [10.1175/1520-0442(2003)016<0426:SAGGFA>2.0.CO;2, 10.1175/1520-0442(2003)016&lt;0426:SAGGFA&gt;2.0.CO;2]; NEUMANN G, 1966, PRINCIPLES PHYS OCEA; PIERCE DW, UNPUB; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; RAMANATHAN V, UNPUB; Reichert BK, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013954; Santer BD, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD005075; Santer BD, 2003, SCIENCE, V301, P479, DOI 10.1126/science.1084123; SANTER BD, TEMPERATURE TRENDS L; Sokolov AP, 2003, J CLIMATE, V16, P1573, DOI 10.1175/1520-0442-16.10.1573; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; Washington WM, 2000, CLIM DYNAM, V16, P755, DOI 10.1007/s003820000079	28	339	355	2	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2005	309	5732					284	287		10.1126/science.1112418	http://dx.doi.org/10.1126/science.1112418			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	944SP	15933161				2022-12-28	WOS:000230449800040
J	Wienholds, E; Kloosterman, WP; Miska, E; Alvarez-Saavedra, E; Berezikov, E; de Bruijn, E; Horvitz, HR; Kauppinen, S; Plasterk, RHA				Wienholds, E; Kloosterman, WP; Miska, E; Alvarez-Saavedra, E; Berezikov, E; de Bruijn, E; Horvitz, HR; Kauppinen, S; Plasterk, RHA			MicroRNA expression in zebrafish embryonic development	SCIENCE			English	Article								MicroRNAs (miRNAs) are small noncoding RNAs, about 21 nucleotides in length, that can regulate gene expression by base-pairing to partially complementary mRNAs. Regulation by miRNAs can play essential roles in embryonic development. We determined the temporal and spatial expression patterns of 115 conserved vertebrate miRNAs in zebrafish embryos by microarrays and by in situ hybridizations, using locked-nucleic acid-modified oligonucleotide probes. Most miRNAs were expressed in a highly tissue-specific manner during segmentation and later stages, but not early in development, which suggests that their role is not in tissue fate establishment but in differentiation or maintenance of tissue identity.	Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; Univ Cambridge, Canc Res UK, Gurdon Inst, Wellcome Trust, Cambridge CB2 1QN, England; Univ Copenhagen, Inst Med Biochem & Genet, Wilhelm Johannsen Ctr Funct Genome Res, DK-2200 Copenhagen, Denmark	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Wellcome Trust Sanger Institute; University of Copenhagen	Plasterk, RHA (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	plasterk@niob.knaw.nl	; Berezikov, Eugene/D-3363-2013	Miska, Eric/0000-0002-4450-576X; Berezikov, Eugene/0000-0002-1145-2884				Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Valoczi A, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh171; Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	8	1243	1367	3	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2005	309	5732					310	311		10.1126/science.1114519	http://dx.doi.org/10.1126/science.1114519			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	944SP	15919954				2022-12-28	WOS:000230449800048
J	Sun, T; Patoine, C; Abu-Khalil, A; Visvader, J; Sum, E; Cherry, TJ; Orkin, SH; Geschwind, DH; Walsh, CA				Sun, T; Patoine, C; Abu-Khalil, A; Visvader, J; Sum, E; Cherry, TJ; Orkin, SH; Geschwind, DH; Walsh, CA			Early asymmetry of gene transcription in embryonic human left and right cerebral cortex	SCIENCE			English	Article							HUMAN-BRAIN; HANDEDNESS; SPEECH; LATERALITY; EVOLUTION; MICE	The human left and right cerebral hemispheres are anatomically and functionally asymmetric. To test whether human cortical asymmetry has a molecular basis, we studied gene expression levels between the left and right embryonic hemispheres using serial analysis of gene expression (SAGE). We identified and verified 27 differentialty expressed genes, which suggests that human cortical asymmetry is accompanied by early, marked transcriptional asymmetries. LMO4 is consistently more highly expressed in the right perisylvian human cerebral cortex than in the left and is essential for cortical development in mice, suggesting that human left-right specialization reflects asymmetric cortical development at early stages.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Neurol, Program Neurogenet, Sch Med, Los Angeles, CA 90095 USA; Walter & Eliza Hall Inst Med Res, Victorian Breast Canc Res Consortium Lab, Melbourne, Vic 3050, Australia; Boston Childrens Hosp, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Walter & Eliza Hall Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, New Res Bldg Room 0266,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cwalsh@bidmc.harvard.edu		Walsh, Christopher/0000-0002-0156-2238	Howard Hughes Medical Institute Funding Source: Medline; NIMH NIH HHS [MH60233, R01 MH060233, R37 MH060233, R56 MH060233] Funding Source: Medline; NINDS NIH HHS [R37 NS035129, R01 R37 NS35129, R01 NS035129-03, R01 NS035129, R37 NS035129-05] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060233, R56MH060233, R37MH060233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035129, R37NS035129] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abu-Khalil A, 2004, J COMP NEUROL, V474, P276, DOI 10.1002/cne.20112; BARNEOUD P, 1993, P NATL ACAD SCI USA, V90, P3246, DOI 10.1073/pnas.90.8.3246; BIDDLE FG, 1993, GENOME, V36, P935, DOI 10.1139/g93-123; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; CHI JG, 1977, ANN NEUROL, V1, P86, DOI 10.1002/ana.410010109; CHI JG, 1977, ARCH NEUROL-CHICAGO, V34, P346, DOI 10.1001/archneur.1977.00500180040008; COLLINS RL, 1991, BRAIN RES, V564, P194, DOI 10.1016/0006-8993(91)91455-A; Corballis MC, 2003, BEHAV BRAIN SCI, V26, P199, DOI 10.1017/S0140525X03000062; FALKAI P, 1992, SCHIZOPHR RES, V7, P23, DOI 10.1016/0920-9964(92)90070-L; GALABURDA AM, 1978, SCIENCE, V199, P852, DOI 10.1126/science.341314; GALABURDA AM, 1994, P NATL ACAD SCI USA, V91, P8010, DOI 10.1073/pnas.91.17.8010; Geschwind DH, 2002, P NATL ACAD SCI USA, V99, P3176, DOI 10.1073/pnas.052494999; Geschwind DH, 2001, AM J MED GENET, V101, P370; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; Herbert MR, 2005, BRAIN, V128, P213, DOI 10.1093/brain/awh330; Hugdahl K, 1998, SCAND AUDIOL, V27, P26, DOI 10.1080/010503998420621; Kennedy DN, 1999, NEUROLOGY, V53, P1260, DOI 10.1212/WNL.53.6.1260; LEMAY M, 1972, NEW ENGL J MED, V287, P168, DOI 10.1056/NEJM197207272870404; Palmer AR, 2004, SCIENCE, V306, P828, DOI 10.1126/science.1103707; RIDDLE DR, 1995, J NEUROSCI, V15, P4184; Sidman RL, 1982, HISTOLOGY HISTOPATHO; SIGNORE P, 1991, PHYSIOL BEHAV, V49, P701, DOI 10.1016/0031-9384(91)90305-8; Toga AW, 2003, NAT REV NEUROSCI, V4, P37, DOI 10.1038/nrn1009	23	268	272	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1794	1798		10.1126/science.1110324	http://dx.doi.org/10.1126/science.1110324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15894532	Green Accepted			2022-12-28	WOS:000229926800057
J	Manasse, HR				Manasse, HR			Conscientious objection and the pharmacist	SCIENCE			English	Editorial Material									Amer Soc Hlth Syst Pharmacists, Bethesda, MD 20814 USA		Manasse, HR (corresponding author), Amer Soc Hlth Syst Pharmacists, Bethesda, MD 20814 USA.	evp@ashp.org						BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P389; Davey Monica, 2005, N Y Times Web, pA16	2	7	8	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1558	1559		10.1126/science.1114371	http://dx.doi.org/10.1126/science.1114371			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947160				2022-12-28	WOS:000229827000027
J	Ogata, J; Kanno, Y; Itoh, Y; Tsugawa, H; Suzuki, M				Ogata, J; Kanno, Y; Itoh, Y; Tsugawa, H; Suzuki, M			Anthocyanin biosynthesis in roses	NATURE			English	Editorial Material									Aomori Green BioCtr, Nogi Yamaguchi, Aomori 0300142, Japan; Tokyo Univ Agr & Technol, Fac Technol, Dept Biotechnol, Tokyo 1848588, Japan	Tokyo University of Agriculture & Technology	Ogata, J (corresponding author), Aomori Green BioCtr, Nogi Yamaguchi, Aomori 0300142, Japan.	masahiko_suzuki@ags.pref.aomori.jp						CAIRNS T, 2000, MODERN ROSES, V11; GUDIN S, 2003, ENCY ROSE SCI, V1, P25; Heller W., 1993, FLAVONOIDS ADV RES 1, P499; HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071; Jay M., 2003, ENCY ROSE SCI, V1, P248; Ogata J., 2004, PLANT BIOTECHNOL, V21, P367, DOI DOI 10.5511/PLANTBI0TECHN0L0GY.21.367; Springob K, 2003, NAT PROD REP, V20, P288, DOI 10.1039/b109542k; STRACK D, 1993, FLAVONOIDS ADV RES 1, P1; Tanaka Y, 2005, PLANT CELL TISS ORG, V80, P1, DOI 10.1007/s11240-004-0739-8; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405	10	90	120	9	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					757	758		10.1038/nature435757a	http://dx.doi.org/10.1038/nature435757a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944692				2022-12-28	WOS:000229638700038
J	Reichhardt, T				Reichhardt, T			Touched by an angel	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					734	735		10.1038/435734a	http://dx.doi.org/10.1038/435734a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944670				2022-12-28	WOS:000229638700018
J	Draper, G; Vincent, T; Kroll, ME; Swanson, J				Draper, G; Vincent, T; Kroll, ME; Swanson, J			Childhood cancer in relation to distance from high voltage power lines in England and Wales: a case-control study	BRITISH MEDICAL JOURNAL			English	Article							MAGNETIC-FIELDS; POOLED ANALYSIS; LEUKEMIA; CHILDREN; RISK	Objective To determine whether there is an association between distance of home address at birth from high voltage power lines and the incidence of leukaemia and other cancers in children in England and Wales. Design Case-control study. Setting Cancer registry and National Grid records. Subjects Records of 29 081 children with cancer, including 9700 with leukaemia. Children were aged 0-14 years and born in England and Wales, 1962-95. Controls were individually matched for sex, approximate date of birth, and birth registration district. No active participation was required. Main outcome measures Distance from home address at birth to the nearest high voltage overhead power line in existence at the time. Results Compared with those who lived > 600 m from a line at birth, children who lived within 200 m had a relative risk of leukaemia of 1.69 (95% confidence interval 1.13 to 2.53); those born between 200 and 600 m had a relative risk of 1.23 (1.02 to 1.49). There was a significant (P < 0.01) trend in risk in relation to the reciprocal of distance from the line. No excess risk in relation to proximity to lines was found for other childhood cancers. Conclusions There is an association between childhood leukaemia and proximity of home address at birth to high voltage power lines, and the apparent risk extends to a greater distance than would have been expected from previous studies. About 4% of children in England and Wales live within 600 in of high voltage lines at birth. If the association is causal, about 1% of childhood leukaemia in England and Wales would be attributable to these lines, though this estimate has considerable statistical uncertainty. There is no accepted biological mechanism to explain the epidemiological results; indeed, the relation may be due to chance or confounding.	Univ Oxford, Childhood Canc Res Grp, Oxford OX2 6HJ, England; Natl Grid Transco Plc, London WC2N 5EH, England	University of Oxford	Draper, G (corresponding author), Univ Oxford, Childhood Canc Res Grp, Oxford OX2 6HJ, England.	gerald.draper@ccrg.ox.ac.uk						Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; Cheng KK, 2000, BRIT J CANCER, V83, P1573, DOI 10.1054/bjoc.2000.1550; Dockerty JD, 2001, INT J EPIDEMIOL, V30, P1428, DOI 10.1093/ije/30.6.1428; DRAPER GJ, OPCS STUDIES MED POP, V53; Fews AP, 1999, INT J RADIAT BIOL, V75, P1523, DOI 10.1080/095530099139124; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; Greenland S, 2000, EPIDEMIOLOGY, V11, P624, DOI 10.1097/00001648-200011000-00003; Kinlen L, 2004, BRIT J CANCER, V91, P1, DOI 10.1038/sj.bjc.6601982; Kleinerman RA, 2000, AM J EPIDEMIOL, V151, P512, DOI 10.1093/oxfordjournals.aje.a010237; MADDOCK BJ, 1992, POWER ENG        SEP, P217; McBride ML, 1999, AM J EPIDEMIOL, V149, P831, DOI 10.1093/oxfordjournals.aje.a009899; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; Tynes T, 1997, AM J EPIDEMIOL, V145, P219, DOI 10.1093/oxfordjournals.aje.a009094; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681	15	206	218	0	45	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 4	2005	330	7503					1290	1292A		10.1136/bmj.330.7503.1290	http://dx.doi.org/10.1136/bmj.330.7503.1290			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933351	Green Published, Bronze			2022-12-28	WOS:000229655700014
J	Lakhani, M				Lakhani, M			GMC and the future of revalidation - A way forward	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Gen Practitioners, London SW7 1PU, England		Lakhani, M (corresponding author), Royal Coll Gen Practitioners, London SW7 1PU, England.	mlakhani@rcgp.org.uk						*GE PRACT COMM, 2002, GOOD PRACT GEN PRACT; General Medical Council, 2001, GOOD MED PRACT; *POSTGR MED ED TRA, PRINC ASS SYST POSTG; PRINGLE M, 1999, J CLIN GOVERN, V7, P102; *ROYAL COLL GEN PR, MEMB ASS PERF; *ROYAL COLL GEN PR, REV; *ROYAL COLL GEN PR, 2004, QUAL STAND APPR REP; *ROYAL COLL GEN PR, QUAL TEAM DEV; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; *SHIPM INQ, SAF PAT LESS PAST PR	10	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 4	2005	330	7503					1326	1328		10.1136/bmj.330.7503.1326	http://dx.doi.org/10.1136/bmj.330.7503.1326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933359	Green Published			2022-12-28	WOS:000229655700030
J	Peggs, KS; Hunter, A; Chopra, R; Parker, A; Mahendra, P; Milligan, D; Craddock, C; Pettengell, R; Dogan, A; Thomson, KJ; Morris, EC; Hale, G; Waldmann, H; Goldstone, AH; Linch, DC; Mackinnon, S				Peggs, KS; Hunter, A; Chopra, R; Parker, A; Mahendra, P; Milligan, D; Craddock, C; Pettengell, R; Dogan, A; Thomson, KJ; Morris, EC; Hale, G; Waldmann, H; Goldstone, AH; Linch, DC; Mackinnon, S			Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation	LANCET			English	Article							STEM-CELL TRANSPLANTATION; BONE-MARROW TRANSPLANTS; POSITRON-EMISSION-TOMOGRAPHY; DONOR LEUKOCYTE INFUSIONS; HIGH-DOSE CHEMOTHERAPY; ADOPTIVE IMMUNOTHERAPY; STATISTICAL-METHODS; DISEASE; THERAPY; BLOOD	Background In patients with multiply relapsed Hodgkin's lymphoma allogeneic stem-cell transplantation has been limited by prohibitive non-relapse-related mortality rates and by a lack of definitive evidence for a therapeutic graft-versus-tumour effect. Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation. Methods We undertook reduced-intensity transplantation in 49 patients with multiply relapsed Hodgkin's lymphoma, 44 (90%) of whom had progression of disease after previous autologous transplantation (median age 32 years [range 18-51], number of previous treatment courses was five [range 3-8], and time from diagnosis 4.8 years [range 0.6-4.8]). 31 patients had HLA-matched donors who were related and 18 had donors who were unrelated. Median follow-up was 967 days (range 102-2232). The primary endpoints were engraftment, toxic effects, non-relapse-related mortality, incidence of graft-versus-host disease (GVHD), and the toxic effects of adjuvant donor-lymphocyte infusion. Findings All patients engrafted. Eight of 49 (16%) had grade II-IV acute GVHD and seven (14%) had chronic GVHD before donor-lymphocyte infusion. 16 (33%) patients received donor-lymphocyte infusion from 3 months after transplantation for residual disease or progression. Six (38%) of the 16 developed grade II-IV acute GVHD and five developed chronic GVHD. Nine (56%) showed disease responses after infusion (eight complete, one partial). Non-relapse-related mortality was 16.3% at 730 days (7.2% for patients who had related donors vs 34.1% for those with unrelated donors, p=0.0206). Projected 4-year overall and progression-free survival were 55.7% and 39.0%, respectively (62.0% and 41.5% for related donors). Interpretation These data show the potential for durable responses in patients who have previously had substantial treatment for Hodgkin's lymphoma. The low non-relapse-related mortality suggests the procedure could be undertaken earlier in the course of the disease.	Royal Free & UCL, Dept Haematol, London WC1E 6HX, England; Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England; Christie Hosp, Dept Haematol, Manchester, Lancs, England; Glasgow Royal Infirm, Dept Haematol, Glasgow, Lanark, Scotland; Queen Elizabeth Hosp, Dept Haematol, Birmingham, W Midlands, England; Birmingham Heartlands Hosp, Dept Haematol, Birmingham B9 5ST, W Midlands, England; UCL Hosp, Dept Haematol, London, England; UCL Hosp, Dept Histopathol, London, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 2JD, England	University of London; University College London; University of Leicester; Christie NHS Foundation Trust; Christie Hospital; University of Glasgow; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; University College London Hospitals NHS Foundation Trust; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Oxford	Peggs, KS (corresponding author), Royal Free & UCL, Dept Haematol, London WC1E 6HX, England.	kpeggs@hotmail.com	PEGGS, Karl/B-3869-2009; waldmann, herman/F-7412-2011; waldmann, herman/W-8051-2019; Mackinnon, Stephen/C-5559-2008	Parker, Anne/0000-0002-4905-6860; Waldmann, Herman/0000-0001-7519-6720; Morris, Emma/0000-0003-4834-1130; Craddock, Charles/0000-0001-5041-6678; Hale, Geoff/0000-0001-9473-423X				Akpek G, 2001, J CLIN ONCOL, V19, P4314, DOI 10.1200/JCO.2001.19.23.4314; Anderlini P, 2000, BONE MARROW TRANSPL, V26, P615, DOI 10.1038/sj.bmt.1702580; Anderlini P, 2004, BONE MARROW TRANSPL, V34, P511, DOI 10.1038/sj.bmt.1704621; ANDERSON JE, 1993, J CLIN ONCOL, V11, P2342, DOI 10.1200/JCO.1993.11.12.2342; Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335; Branson K, 2002, J CLIN ONCOL, V20, P4022, DOI 10.1200/JCO.2002.11.088; Carella AM, 2001, HAEMATOLOGICA, V86, P1121; CHOPRA R, 1993, BLOOD, V81, P1137; Claviez A, 2004, ANN HEMATOL, V83, P237, DOI 10.1007/s00277-003-0814-y; Gajewski JL, 1996, J CLIN ONCOL, V14, P572, DOI 10.1200/JCO.1996.14.2.572; Hiddemann W, 1994, Drugs, V47 Suppl 6, P50; Johnston LJ, 2000, BIOL BLOOD MARROW TR, V6, P289, DOI 10.1016/S1083-8791(00)70054-1; JONES RJ, 1991, BLOOD, V77, P649; Josting A, 2000, BLOOD, V96, P1280, DOI 10.1182/blood.V96.4.1280.h8001280_1280_1286; Klein JP, 2001, BONE MARROW TRANSPL, V28, P909, DOI 10.1038/sj.bmt.1703260; Klein JP, 2001, BONE MARROW TRANSPL, V28, P1001, DOI 10.1038/sj.bmt.1703271; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940; Milpied N, 1996, J CLIN ONCOL, V14, P1291, DOI 10.1200/JCO.1996.14.4.1291; Morris EC, 2003, BLOOD, V102, P404, DOI 10.1182/blood-2002-09-2687; Porter DL, 1999, J CLIN ONCOL, V17, P1234, DOI 10.1200/JCO.1999.17.4.1234; Porter DL, 2003, BONE MARROW TRANSPL, V31, P739, DOI 10.1038/sj.bmt.1703895; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; SALISBURY JR, 1994, J CLIN PATHOL, V47, P313, DOI 10.1136/jcp.47.4.313; Schmitz N, 2002, LANCET, V359, P2065, DOI 10.1016/S0140-6736(02)08938-9; Spaepen K, 2003, BLOOD, V102, P53, DOI 10.1182/blood-2002-12-3842; Spaepen K, 2001, BRIT J HAEMATOL, V115, P272, DOI 10.1046/j.1365-2141.2001.03169.x; Sureda A, 2002, ANN ONCOL, V13, P128, DOI 10.1093/annonc/13.S1.128; Tarella C, 2003, CANCER-AM CANCER SOC, V97, P2748, DOI 10.1002/cncr.11414	29	210	220	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1934	1941		10.1016/S0140-6736(05)66659-7	http://dx.doi.org/10.1016/S0140-6736(05)66659-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936420				2022-12-28	WOS:000229587800027
J	Kronenberg, M; Rudensky, A				Kronenberg, M; Rudensky, A			Regulation of immunity by self-reactive T cells	NATURE			English	Review							NKT CELLS; CUTTING EDGE; ALPHA-GALACTOSYLCERAMIDE; DENDRITIC CELLS; T(H)2 BIAS; ACTIVATION; TOLERANCE; RECOGNITION; MICE; HOMEOSTASIS	A basic principle of immunology is that lymphocytes respond to foreign antigens but tolerate self tissues. For developing T cells, the ability to distinguish self from non-self is acquired in the thymus, where the majority of self-reactive cells are eliminated. Recently, however, it has become apparent that some self-reactive T cells avoid being destroyed and instead differentiate into specialized regulatory cells. This appears to be beneficial. Subpopulations of self-reactive T cells have a strong influence on self tolerance and may represent targets for therapeutic intervention to control a variety of autoimmune diseases, tumour growth and infection.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98102 USA; Univ Washington, Dept Immunol, Seattle, WA 98102 USA	La Jolla Institute for Immunology; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kronenberg, M (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	mitch@liai.org; aruden@u.washington.edu						Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Araki M, 2003, INT IMMUNOL, V15, P279, DOI 10.1093/intimm/dxg029; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Baldwin TA, 2004, J IMMUNOL, V173, P6515, DOI 10.4049/jimmunol.173.11.6515; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Barthlott T, 2005, INT IMMUNOL, V17, P279, DOI 10.1093/intimm/dxh207; Beaudoin L, 2002, IMMUNITY, V17, P725, DOI 10.1016/S1074-7613(02)00473-9; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bluestone JA, 2004, P NATL ACAD SCI USA, V101, P14622, DOI 10.1073/pnas.0405234101; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chung B, 2005, J IMMUNOL, V174, P3153, DOI 10.4049/jimmunol.174.6.3153; Coles MC, 2000, J IMMUNOL, V164, P2412, DOI 10.4049/jimmunol.164.5.2412; de Lafaille MAC, 2004, J IMMUNOL, V173, P7259, DOI 10.4049/jimmunol.173.12.7259; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827; Furlan R, 2003, EUR J IMMUNOL, V33, P1830, DOI 10.1002/eji.200323885; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Gapin L, 2001, NAT IMMUNOL, V2, P971, DOI 10.1038/ni710; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Hammond KJL, 2003, CURR OPIN IMMUNOL, V15, P683, DOI 10.1016/j.coi.2003.09.014; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Jahng AW, 2001, J EXP MED, V194, P1789, DOI 10.1084/jem.194.12.1789; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kawahara K, 1999, J IND MICROBIOL BIOT, V23, P408, DOI 10.1038/sj.jim.2900708; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim HY, 2005, J EXP MED, V201, P41, DOI 10.1084/jem.20041400; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lee PT, 2002, J CLIN INVEST, V110, P793, DOI 10.1172/JCI200215832; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; Modigliani Y, 1996, EUR J IMMUNOL, V26, P1807, DOI 10.1002/eji.1830260822; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Pasquier B, 2005, J EXP MED, V201, P695, DOI 10.1084/jem.20042432; Paust S, 2004, P NATL ACAD SCI USA, V101, P10398, DOI 10.1073/pnas.0403342101; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Rao PE, 2005, J IMMUNOL, V174, P1446, DOI 10.4049/jimmunol.174.3.1446; Rogers PR, 2004, J IMMUNOL METHODS, V285, P197, DOI 10.1016/j.jim.2003.12.003; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Seddon B, 1999, J EXP MED, V189, P877, DOI 10.1084/jem.189.5.877; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Sonoda KH, 2001, J IMMUNOL, V166, P42, DOI 10.4049/jimmunol.166.1.42; TAGUCHI O, 1994, IMMUNOLOGY, V82, P365; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433; van der Vliet HJJ, 2001, CLIN IMMUNOL, V100, P144, DOI 10.1006/clim.2001.5060; van Santen HM, 2004, J EXP MED, V200, P1221, DOI 10.1084/jem.20041022; Voyle RB, 2003, J EXP MED, V197, P919, DOI 10.1084/jem.20021615; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Zeng DF, 2003, J CLIN INVEST, V112, P1211, DOI 10.1172/JCI200317165; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	85	226	256	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					598	604		10.1038/nature03725	http://dx.doi.org/10.1038/nature03725			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931212				2022-12-28	WOS:000229476200037
J	Oltersdorf, T; Elmore, SW; Shoemaker, AR; Armstrong, RC; Augeri, DJ; Belli, BA; Bruncko, M; Deckwerth, TL; Dinges, J; Hajduk, PJ; Joseph, MK; Kitada, S; Korsmeyer, SJ; Kunzer, AR; Letai, A; Li, C; Mitten, MJ; Nettesheim, DG; Ng, S; Nimmer, PM; O'Connor, JM; Oleksijew, A; Petros, AM; Reed, JC; Shen, W; Tahir, SK; Thompson, CB; Tomaselli, KJ; Wang, BL; Wendt, MD; Zhang, HC; Fesik, SW; Rosenberg, SH				Oltersdorf, T; Elmore, SW; Shoemaker, AR; Armstrong, RC; Augeri, DJ; Belli, BA; Bruncko, M; Deckwerth, TL; Dinges, J; Hajduk, PJ; Joseph, MK; Kitada, S; Korsmeyer, SJ; Kunzer, AR; Letai, A; Li, C; Mitten, MJ; Nettesheim, DG; Ng, S; Nimmer, PM; O'Connor, JM; Oleksijew, A; Petros, AM; Reed, JC; Shen, W; Tahir, SK; Thompson, CB; Tomaselli, KJ; Wang, BL; Wendt, MD; Zhang, HC; Fesik, SW; Rosenberg, SH			An inhibitor of Bcl-2 family proteins induces regression of solid tumours	NATURE			English	Article							SMALL-MOLECULE INHIBITORS; CELL-DEATH; RATIONAL DESIGN; BH3 DOMAIN; APOPTOSIS; DISCOVERY; BCL-X(L); EXPRESSION; ANTISENSE; COMPOUND	Proteins in the Bcl-2 family are central regulators of programmed cell death(1), and members that inhibit apoptosis, such as Bcl-X-L and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy(2). Bcl-X-L expression correlates with chemo-resistance of tumour cell lines(3), and reductions in Bcl-2 increase sensitivity to anticancer drugs(4) and enhance in vivo survival(5). The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored(6-15), but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein - protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X-L and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds(7-15). Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.	Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA; Idun Pharmaceut, San Diego, CA 92121 USA; Burnham Inst, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Abbott Laboratories; Sanford Burnham Prebys Medical Discovery Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine	Rosenberg, SH (corresponding author), Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA.	stephen.fesik@abbott.com; saul.rosenberg@abbott.com						Amundson SA, 2000, CANCER RES, V60, P6101; Baell JB, 2002, BIOCHEM PHARMACOL, V64, P851, DOI 10.1016/S0006-2952(02)01148-6; Becattini B, 2004, CHEM BIOL, V11, P389, DOI 10.1016/j.chembiol.2004.02.020; BRUNGER AT, 1992, XPLOR VERSION 3 1; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; Kutzki O, 2002, J AM CHEM SOC, V124, P11838, DOI 10.1021/ja026861k; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Mao HY, 2000, PROTEIN EXPRES PURIF, V20, P492, DOI 10.1006/prep.2000.1330; Mao HY, 2001, J AM CHEM SOC, V123, P10429, DOI 10.1021/ja015955b; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Reed JC, 1997, J NATL CANCER I, V89, P988, DOI 10.1093/jnci/89.14.988; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zhang HC, 2002, ANAL BIOCHEM, V307, P70, DOI 10.1016/S0003-2697(02)00028-3	30	2760	2920	6	509	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					677	681		10.1038/nature03579	http://dx.doi.org/10.1038/nature03579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15902208				2022-12-28	WOS:000229476200051
J	Pappas, G; Akritidis, N; Bosilkovski, M; Tsianos, E				Pappas, G; Akritidis, N; Bosilkovski, M; Tsianos, E			Medical progress: Brucellosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LINKED IMMUNOSORBENT-ASSAY; OUTER-MEMBRANE PROTEINS; PCR ASSAY; INTERFERON-GAMMA; RISK-FACTORS; WHOLE-BLOOD; B-ABORTUS; DIAGNOSIS; MELITENSIS; SERUM		Univ Hosp Ioannina, Dept Internal Med, Brucellosis Unit, Ioannina 45110, Greece	University Hospital Ioannina	Pappas, G (corresponding author), Univ Hosp Ioannina, Dept Internal Med, Brucellosis Unit, Ioannina 45110, Greece.	gpele@otenet.gr	Pappas, Georgios/AAQ-1893-2021; Pappas, Georgios/A-1525-2008	Pappas, Georgios/0000-0002-8425-6091; 				Ahmed K, 1999, AM J TROP MED HYG, V61, P425, DOI 10.4269/ajtmh.1999.61.425; Akritidis N, 2001, SCAND J GASTROENTERO, V36, P110, DOI 10.1080/00365520150218147; Al Dahouk Sascha, 2003, Clin Lab, V49, P487; Al Dahouk Sascha, 2003, Clin Lab, V49, P577; Al Shaalan Mohammed, 2002, International Journal of Infectious Diseases, V6, P182, DOI 10.1016/S1201-9712(02)90108-6; Almuneef M, 2003, J CHEMOTHERAPY, V15, P148, DOI 10.1179/joc.2003.15.2.148; Almuneef MA, 2004, EPIDEMIOL INFECT, V132, P533, DOI 10.1017/S0950268803001857; Araj G F, 1999, Clin Lab Sci, V12, P207; ARAJ GF, 1988, APMIS, V96, P171, DOI 10.1111/j.1699-0463.1988.tb05286.x; Arenas GN, 2000, INFECT IMMUN, V68, P4255, DOI 10.1128/IAI.68.7.4255-4263.2000; ARIZA J, 1992, CLIN INFECT DIS, V14, P131, DOI 10.1093/clinids/14.1.131; ARIZA J, 1995, CLIN INFECT DIS, V20, P1241, DOI 10.1093/clinids/20.5.1241; Ariza J, 2001, CLIN INFECT DIS, V32, P1024, DOI 10.1086/319608; ARIZA J, 1993, CLIN INFECT DIS, V16, P761, DOI 10.1093/clind/16.6.761; BAILY GG, 1992, J TROP MED HYG, V95, P271; Bannatyne RM, 1997, J CLIN MICROBIOL, V35, P2673, DOI 10.1128/JCM.35.10.2673-2674.1997; BERTOTTO A, 1993, EUR J IMMUNOL, V23, P1177, DOI 10.1002/eji.1830230531; Bodur H, 2003, SCAND J INFECT DIS, V35, P337, DOI 10.1080/00365540310008348; Bosilkovski M, 2004, INT J CLIN PRACT, V58, P1023, DOI 10.1111/j.1742-1241.2004.00208.x; Bravo MJ, 2003, EUR J IMMUNOGENET, V30, P433, DOI 10.1111/j.1365-2370.2003.00419.x; Bravo MJ, 2003, J RHEUMATOL, V30, P1051; Capasso L, 2002, J INFECTION, V45, P122, DOI 10.1053/jinf.2002.0996; Casao MA, 2003, CLIN MICROBIOL INFEC, V9, P301, DOI 10.1046/j.1469-0691.2003.00519.x; Celli J, 2003, J EXP MED, V198, P545, DOI 10.1084/jem.20030088; CERVANTES F, 1982, POSTGRAD MED J, V58, P346, DOI 10.1136/pgmj.58.680.346; Chang MH, 2003, EMERG INFECT DIS, V9, P556, DOI 10.3201/eid0905.020477; Cloeckaert A, 2002, VET MICROBIOL, V90, P229, DOI 10.1016/S0378-1135(02)00211-0; Colmenero JD, 1997, MEDICINE, V76, P139; COLMENERO JD, 1994, ANTIMICROB AGENTS CH, V38, P2798, DOI 10.1128/AAC.38.12.2798; Corbel MJ, 1997, EMERG INFECT DIS, V3, P213, DOI 10.3201/eid0302.970219; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Demirdag K, 2003, FEMS IMMUNOL MED MIC, V39, P149, DOI 10.1016/S0928-8244(03)00207-4; DETILLEUX PG, 1991, AM J VET RES, V52, P1658; Dokuzoguz B, 2005, J INFECTION, V50, P41, DOI 10.1016/j.jinf.2004.02.005; Dornand J, 2002, VET MICROBIOL, V90, P383, DOI 10.1016/S0378-1135(02)00223-7; Ergonul O, 2004, J HOSP INFECT, V56, P223, DOI 10.1016/j.jhin.2003.12.020; EWALT DR, 1994, J VET DIAGN INVEST, V6, P448, DOI 10.1177/104063879400600408; FEKETE A, 1990, J APPL BACTERIOL, V69, P216, DOI 10.1111/j.1365-2672.1990.tb01512.x; Fosgate GT, 2002, EMERG INFECT DIS, V8, P877; Gorvel JP, 2002, VET MICROBIOL, V90, P281, DOI 10.1016/S0378-1135(02)00214-6; GOTUZZO E, 1986, J INFECT DIS, V153, P122, DOI 10.1093/infdis/153.1.122; Gross A, 2000, INFECT IMMUN, V68, P342, DOI 10.1128/IAI.68.1.342-351.2000; Guzman-Verri C, 2002, P NATL ACAD SCI USA, V99, P12375, DOI 10.1073/pnas.192439399; HADJICHRISTODOULOU C, 1994, EUR J CLIN MICROBIOL, V13, P129, DOI 10.1007/BF01982185; Jubier-Maurin V, 2001, INFECT IMMUN, V69, P4823, DOI 10.1128/IAI.69.8.4823-4830.2001; Karabay O, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-18; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; Khan MY, 2001, CLIN INFECT DIS, V32, P1172, DOI 10.1086/319758; Ko J, 2002, J IMMUNOL, V168, P2433, DOI 10.4049/jimmunol.168.5.2433; Ko JY, 2003, CLIN MICROBIOL REV, V16, P65, DOI 10.1128/CMR.16.1.65-78.2003; Lopez-Merino A, 2004, SCAND J INFECT DIS, V36, P636, DOI 10.1080/00365540410020767; LUBANI MM, 1989, PEDIATR INFECT DIS J, V8, P75; Matar GM, 1996, J CLIN MICROBIOL, V34, P477, DOI 10.1128/JCM.34.2.477-478.1996; McDonald R, 2001, MIL MED, V166, P237, DOI 10.1093/milmed/166.3.237; MCLEAN DR, 1992, CLIN INFECT DIS, V15, P582, DOI 10.1093/clind/15.4.582; Memish Z, 2000, J INFECTION, V40, P59, DOI 10.1053/jinf.1999.0586; Morata P, 2003, J CLIN MICROBIOL, V41, P144, DOI 10.1128/JCM.41.1.144-148.2003; Morata P, 1999, J CLIN MICROBIOL, V37, P4163, DOI 10.1128/JCM.37.12.4163-4166.1999; MORENO E, 1990, J BACTERIOL, V172, P3569, DOI 10.1128/jb.172.7.3569-3576.1990; Moreno E, 2002, VET MICROBIOL, V90, P209, DOI 10.1016/S0378-1135(02)00210-9; Moreno S, 1998, EUR J CLIN MICROBIOL, V17, P319, DOI 10.1007/BF01709454; Navarro E, 2004, EXPERT REV MOL DIAGN, V4, P115, DOI 10.1586/14737159.4.1.115; Navarro E, 2002, FEMS IMMUNOL MED MIC, V34, P147, DOI 10.1111/j.1574-695X.2002.tb00616.x; Navarro-Martinez A, 2001, CLIN INFECT DIS, V33, P2017, DOI 10.1086/324489; Nimri LF, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-5; Ottones F, 2000, J IMMUNOL, V165, P7133, DOI 10.4049/jimmunol.165.12.7133; Pappas G, 2005, EXPERT OPIN PHARMACO, V6, P201, DOI 10.1517/14656566.6.2.201; Pappas G, 2004, INT J ANTIMICROB AG, V24, P502, DOI 10.1016/j.ijantimicag.2004.05.003; Pappas G, 2004, AM J HEMATOL, V75, P139, DOI 10.1002/ajh.10473; Pappas G, 2003, CLIN INFECT DIS, V37, pE95, DOI 10.1086/378125; Paulsen IT, 2002, P NATL ACAD SCI USA, V99, P13148, DOI 10.1073/pnas.192319099; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Probert WS, 2004, J CLIN MICROBIOL, V42, P1290, DOI 10.1128/JCM.42.3.1290-1293.2004; Queipo-Ortuno MI, 2005, CLIN INFECT DIS, V40, P260, DOI 10.1086/426818; Redkar R, 2001, MOL CELL PROBE, V15, P43, DOI 10.1006/mcpr.2000.0338; Reguera JM, 2003, EUR J CLIN MICROBIOL, V22, P647, DOI 10.1007/s10096-003-1026-z; RodriguezZapata M, 1997, INFECTION, V25, P187, DOI 10.1007/BF02113611; ROMERO C, 1995, J CLIN MICROBIOL, V33, P615, DOI 10.1128/JCM.33.3.615-617.1995; Ross HM, 1996, VET REC, V138, P647, DOI 10.1136/vr.138.26.647; SALMERON I, 1992, CLIN INFECT DIS, V15, P764, DOI 10.1093/clind/15.5.764; Sanchez DO, 2001, INFECT IMMUN, V69, P865, DOI 10.1128/IAI.69.2.865-868.2001; Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9; SHAKIR RA, 1987, BRAIN, V110, P213, DOI 10.1093/brain/110.1.213; Smart J.K., 1997, MED ASPECTS CHEM BIO, P9; Sohn AH, 2003, EMERG INFECT DIS, V9, P485, DOI 10.3201/eid0904.020576; Solera J, 1997, DRUGS, V53, P245, DOI 10.2165/00003495-199753020-00005; Solera J, 1999, CLIN INFECT DIS, V29, P1440, DOI 10.1086/313524; SOLERA J, 1994, MED CLIN-BARCELONA, V102, P731; Solera J, 1998, J INFECTION, V36, P85, DOI 10.1016/S0163-4453(98)93342-4; Solera J, 2001, CLIN INFECT DIS, V32, P506, DOI 10.1086/318503; Solera J, 2004, CLIN INFECT DIS, V39, P1776, DOI 10.1086/426024; Vrioni G, 2004, EUR J CLIN MICROBIOL, V23, P194, DOI 10.1007/s10096-003-1082-4; Yagupsky P, 1999, J CLIN MICROBIOL, V37, P3437, DOI 10.1128/JCM.37.11.3437-3442.1999; Yingst S, 2003, CRIT REV MICROBIOL, V29, P313, DOI 10.1080/713608012; Young EJ, 2000, CLIN INFECT DIS, V31, P904, DOI 10.1086/318129; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283; YOUNG EJ, 1991, REV INFECT DIS, V13, P359; ZHAN YF, 1995, INFECT IMMUN, V63, P1387, DOI 10.1128/IAI.63.4.1387-1390.1995; ZHAN YF, 1993, INFECT IMMUN, V61, P4899, DOI 10.1128/IAI.61.11.4899-4901.1993	99	858	925	5	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2325	2336		10.1056/NEJMra050570	http://dx.doi.org/10.1056/NEJMra050570			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930423				2022-12-28	WOS:000229446400009
J	Rieder, MJ; Reiner, AP; Gage, BF; Nickerson, DA; Eby, CS; McLeod, HL; Blough, DK; Thummel, KE; Veenstra, DL; Rettie, AE				Rieder, MJ; Reiner, AP; Gage, BF; Nickerson, DA; Eby, CS; McLeod, HL; Blough, DK; Thummel, KE; Veenstra, DL; Rettie, AE			Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METABOLISM; PHARMACOGENETICS; ASSOCIATION; POPULATION; REDUCTASE; PREDICT; GENE	BACKGROUND: The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin. METHODS: We conducted a retrospective study of European-American patients receiving long-term warfarin maintenance therapy. Multiple linear-regression analysis was used to determine the effect of VKORC1 haplotypes on the warfarin dose. We determined VKORC1 haplotype frequencies in African-American, European-American, and Asian-American populations and VKORC1 messenger RNA (mRNA) expression in human liver samples. RESULTS: We identified 10 common noncoding VKORC1 single-nucleotide polymorphisms and inferred five major haplotypes. We identified a low-dose haplotype group (A) and a high-dose haplotype group (B). The mean (+/-SE) maintenance dose of warfarin differed significantly among the three haplotype group combinations, at 2.7+/-0.2 mg per day for A/A, 4.9+/-0.2 mg per day for A/B, and 6.2+/-0.3 mg per day for B/B (P<0.001). VKORC1 haplotype groups A and B explained approximately 25 percent of the variance in dose. Asian Americans had a higher proportion of group A haplotypes and African Americans a higher proportion of group B haplotypes. VKORC1 mRNA levels varied according to the haplotype combination. CONCLUSIONS: VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries. The molecular mechanism of this warfarin dose response appears to be regulated at the transcriptional level.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Washington Univ, Dept Med, St Louis, MO USA; Washington Univ, Dept Pathol & Immunol, St Louis, MO USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL)	Rieder, MJ (corresponding author), Univ Washington, Dept Genome Sci, Box 357730, Seattle, WA 98195 USA.	mrieder@u.washington.edu	Rieder, Michael J/L-2397-2013; McLeod, Howard/ABD-8364-2021	McLeod, Howard/0000-0002-9004-9232; Gage, Brian/0000-0002-4727-8742	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066682, R01HL074724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM063340, R01GM068797, P01GM032165] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL074724, U01 HL66682] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline; NIGMS NIH HHS [GM068797, GM32165, GM63340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Absher RK, 2002, ANN PHARMACOTHER, V36, P1512, DOI 10.1345/aph.1C025; Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; Ansell J, 2005, CHEST, V127, P415; Chenhsu RY, 2000, ANN PHARMACOTHER, V34, P1395; Crawford DC, 2004, AM J HUM GENET, V74, P610, DOI 10.1086/382227; D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; Gage BF, 2004, THROMB HAEMOSTASIS, V91, P87, DOI 10.1160/TH03-06-0379; Higashi MK, 2002, JAMA-J AM MED ASSOC, V287, P1690, DOI 10.1001/jama.287.13.1690; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Lesko LJ, 2004, NAT REV DRUG DISCOV, V3, P763, DOI 10.1038/nrd1499; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; Lin YS, 2002, MOL PHARMACOL, V62, P162, DOI 10.1124/mol.62.1.162; MARKETOS M, 2004, DRUG TOPICS, V148, P76; Paine MF, 1997, J PHARMACOL EXP THER, V283, P1552; Przeworski M, 2000, TRENDS GENET, V16, P296, DOI 10.1016/S0168-9525(00)02030-8; RETTIE AE, 1992, CHEM RES TOXICOL, V5, P54, DOI 10.1021/tx00025a009; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Voora D, 2005, THROMB HAEMOSTASIS, V93, P700, DOI 10.1160/TH04-08-0542; Yu HCM, 1996, QJM-MON J ASSOC PHYS, V89, P127	22	1067	1171	1	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2285	2293		10.1056/NEJMoa044503	http://dx.doi.org/10.1056/NEJMoa044503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930419				2022-12-28	WOS:000229446400005
J	Sykes, M; Nikolic, B				Sykes, M; Nikolic, B			Treatment of severe autoimmune disease by stem-cell transplantation	NATURE			English	Review							BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; REGULATORY T-CELLS; MIXED HEMATOPOIETIC CHIMERISM; TYPE-1 DIABETES-MELLITUS; STAGE RENAL-DISEASE; ALLOGRAFT TOLERANCE; LYMPHOHEMATOPOIETIC CHIMERISM; RHEUMATOID-ARTHRITIS; MULTIPLE-MYELOMA	Transplantation of haematopoietic stem cells - cells capable of self renewing and reconstituting all types of blood cell - can treat numerous lethal diseases, including leukaemias and lymphomas. It may now be applicable for the treatment of severe autoimmune diseases, such as therapy-resistant rheumatoid arthritis and multiple sclerosis. Studies in animal models show that the transfer of haematopoietic stem cells can reverse autoimmunity, and several mechanistic pathways may explain this phenomenon. The outcome of ongoing clinical trials, as well as of studies in patients and animal models, will help to determine the role that stem-cell transplantation can play in the treatment of autoimmune diseases.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Bone Marrow Transplantat Sect, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Renal Unit, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Sykes, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Bone Marrow Transplantat Sect, Transplantat Biol Res Ctr, MGH E,Bldg 149-5102,13th St, Boston, MA 02129 USA.	sykes@tbrc.mgh.harvard.edu; bnikolic@partners.org						Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brodsky RA, 2002, CURR OPIN ONCOL, V14, P143, DOI 10.1097/00001622-200203000-00001; Buhler LH, 2002, TRANSPLANTATION, V74, P1405, DOI 10.1097/01.TP.0000034627.37442.A4; Burt RK, 2004, J EXP MED, V199, P895, DOI 10.1084/jem.20031916; Burt RK, 2004, ARTHRITIS RHEUM, V50, P2466, DOI 10.1002/art.20451; Burt RK, 2003, BONE MARROW TRANSPL, V31, P521, DOI 10.1038/sj.bmt.1703868; Burt RK, 1998, BLOOD, V91, P2609, DOI 10.1182/blood.V91.7.2609.2609_2609_2616; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Guillaume T, 1998, BLOOD, V92, P1471, DOI 10.1182/blood.V92.5.1471; Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841; Hinterberger W, 2002, BONE MARROW TRANSPL, V30, P753, DOI 10.1038/sj.bmt.1703686; Hough RE, 2005, BRIT J HAEMATOL, V128, P432, DOI 10.1111/j.1365-2141.2004.05298.x; IKEHARA S, 1985, P NATL ACAD SCI USA, V82, P2483, DOI 10.1073/pnas.82.8.2483; Ikehara S, 2003, EXP HEMATOL, V31, P1142, DOI 10.1016/j.exphem.2003.08.020; Ikehara S, 1998, ACTA HAEMATOL-BASEL, V99, P116, DOI 10.1159/000040826; IKEHARA S, 1990, P NATL ACAD SCI USA, V87, P8341, DOI 10.1073/pnas.87.21.8341; IKEHARA S, 1989, P NATL ACAD SCI USA, V86, P3306, DOI 10.1073/pnas.86.9.3306; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KNAANSHANZER S, 1991, BONE MARROW TRANSPL, V8, P333; Kodama S, 2003, SCIENCE, V302, P1223, DOI 10.1126/science.1088949; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Kurtz J, 2004, TRENDS IMMUNOL, V25, P518, DOI 10.1016/j.it.2004.08.007; Lan P, 2004, BLOOD, V103, P3964, DOI 10.1182/blood-2003-10-3697; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lechner A, 2004, DIABETES, V53, P616, DOI 10.2337/diabetes.53.3.616; Luhder F, 1998, J EXP MED, V187, P379, DOI 10.1084/jem.187.3.379; Mapara MY, 2002, BLOOD, V100, P1903, DOI 10.1182/blood-2002-01-0023; Marmont AM, 2003, BONE MARROW TRANSPL, V31, P399, DOI 10.1038/sj.bmt.1703833; Mathews V, 2004, DIABETES, V53, P91, DOI 10.2337/diabetes.53.1.91; McKendry RJR, 1996, ARTHRITIS RHEUM, V39, P1246, DOI 10.1002/art.1780390727; Millan TLT, 2002, TRANSPLANTATION, V73, P1386, DOI 10.1097/00007890-200205150-00005; Morgan DJ, 2004, J IMMUNOL, V172, P1000, DOI 10.4049/jimmunol.172.2.1000; MORTON JI, 1974, P NATL ACAD SCI USA, V71, P2162, DOI 10.1073/pnas.71.6.2162; Nikolic B, 2004, DIABETES, V53, P376, DOI 10.2337/diabetes.53.2.376; Ohdan H, 1999, J CLIN INVEST, V104, P281, DOI 10.1172/JCI6656; Oyama Y, 2001, BONE MARROW TRANSPL, V28, P903, DOI 10.1038/sj.bmt.1703237; Passweg JR, 2004, BRIT J HAEMATOL, V125, P749, DOI 10.1111/j.1365-2141.2004.04978.x; PESTRONK A, 1983, ANN NEUROL, V14, P235, DOI 10.1002/ana.410140210; Popat U, 2004, BRIT J HAEMATOL, V126, P637, DOI 10.1111/j.1365-2141.2004.05076.x; Raetz E, 1997, BONE MARROW TRANSPL, V20, P427, DOI 10.1038/sj.bmt.1700907; Ridgway WM, 1999, SCIENCE, V284, P749, DOI 10.1126/science.284.5415.749; Roep BO, 2004, DIABETOLOGIA, V47, P1650, DOI 10.1007/s00125-004-1517-1; Rother KI, 2004, J CLIN INVEST, V114, P877, DOI 10.1172/JC1200423235; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Schmidt D, 1997, J EXP MED, V186, P1059, DOI 10.1084/jem.186.7.1059; Seung E, 2000, BLOOD, V95, P2175, DOI 10.1182/blood.V95.6.2175; Slavin S, 2000, EXP HEMATOL, V28, P853, DOI 10.1016/S0301-472X(00)00172-7; Snowden JA, 1998, ARTHRITIS RHEUM, V41, P453, DOI 10.1002/1529-0131(199803)41:3<453::AID-ART11>3.3.CO;2-R; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; Spitzer TR, 2003, TRANSPLANTATION, V75, P1748, DOI 10.1097/01.TP.0000064211.23536.AD; Su MA, 2004, CURR OPIN IMMUNOL, V16, P746, DOI 10.1016/j.coi.2004.09.009; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Takeuchi Y, 2004, AM J TRANSPLANT, V4, P31, DOI 10.1046/j.1600-6135.2003.00272.x; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tian CR, 2004, J CLIN INVEST, V114, P969, DOI 10.1172/JCI200422103; TYNDALL A, IN PRESS CLIN EXP IM; Van Bekkum DW, 2003, BONE MARROW TRANSPL, V32, pS37, DOI 10.1038/sj.bmt.1703941; vanGelder M, 1996, BONE MARROW TRANSPL, V18, P1029; Vogel A, 2002, J MOL MED, V80, P201, DOI 10.1007/s00109-001-0306-2; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037; Wraith DC, 2004, CURR OPIN IMMUNOL, V16, P695, DOI 10.1016/j.coi.2004.09.015; Wu T, 2002, TRANSPLANTATION, V74, P22, DOI 10.1097/00007890-200207150-00005; YASUMIZU R, 1987, P NATL ACAD SCI USA, V84, P6555, DOI 10.1073/pnas.84.18.6555; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zorina TD, 2003, STEM CELLS, V21, P377, DOI 10.1634/stemcells.21-4-377; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	68	165	207	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					620	627		10.1038/nature03728	http://dx.doi.org/10.1038/nature03728			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931215				2022-12-28	WOS:000229476200040
J	McElwain, JC; Wade-Murphy, J; Hesselbo, SP				McElwain, JC; Wade-Murphy, J; Hesselbo, SP			Changes in carbon dioxide during an oceanic anoxic event linked to intrusion into Gondwana coals	NATURE			English	Article							CENOMANIAN-TURONIAN BOUNDARY; ATMOSPHERIC CO2; MASS EXTINCTION; GAS-HYDRATE; TOARCIAN; DISSOCIATION; ANTARCTICA; METHANE	The marine sedimentary record exhibits evidence for episodes of enhanced organic carbon burial known as 'oceanic anoxic events' (OAEs)(1,2). They are characterized by carbon-isotope excursions in marine(3) and terrestrial(4) reservoirs and mass extinction of marine faunas(5). Causal mechanisms for the enhancement of organic carbon burial during OAEs are still debated(6,7), but it is thought that such events should draw down significant quantities of atmospheric carbon dioxide(7). In the case of the Toarcian OAE (similar to 183 million years ago), a short-lived negative carbon-isotope excursion in oceanic and terrestrial reservoirs has been interpreted to indicate raised atmospheric carbon dioxide(4) caused by oxidation of methane catastrophically released from either marine gas hydrates(4) or magma-intruded organic-rich rocks(8). Here we test these two leading hypotheses(4,8) for a negative carbon isotopic excursion marking the initiation of the Toarcian OAE using a high-resolution atmospheric carbon dioxide record obtained from fossil leaf stomatal frequency(9,10). We find that coincident with the negative carbon-isotope excursion carbon dioxide is first drawn down by 350 +/- 100 p. p. m. v. and then abruptly elevated by 1,200 6 400 p. p. m. v, and infer a global cooling and greenhouse warming of 2.5 +/- 0.1 degrees C and 6.5 +/- 1 degrees C, respectively. The pattern and magnitude of carbon dioxide change are difficult to reconcile with catastrophic input of isotopically light methane from hydrates(5) as the cause of the negative isotopic signal. Our carbon dioxide record better supports a magma-intrusion hypothesis(8), and suggests that injection of isotopically light carbon from the release of thermogenic methane occurred owing to the intrusion of Gondwana coals by Toarcian-aged Karoo-Ferrar dolerites.	Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	Field Museum of Natural History (Chicago); University of Chicago; University of Oxford	McElwain, JC (corresponding author), Field Museum Nat Hist, Dept Geol, 1400 S Lake Shore Dr, Chicago, IL 60605 USA.	jmcelwain@fieldmuseum.org	McElwain, Jennifer/B-1735-2009; McElwain, Jennifer/AAX-1605-2020	McElwain, Jennifer/0000-0002-1729-6755; 				ARTHUR MA, 1988, NATURE, V335, P714, DOI 10.1038/335714a0; Bailey TR, 2003, EARTH PLANET SC LETT, V212, P307, DOI 10.1016/S0012-821X(03)00278-4; Ballance PF, 2002, NEW ZEAL J GEOL GEOP, V45, P71, DOI 10.1080/00288306.2002.9514960; Beerling DJ, 2002, AM J SCI, V302, P28, DOI 10.2475/ajs.302.1.28; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Cohen AS, 2004, GEOLOGY, V32, P157, DOI 10.1130/G20158.1; Elliot DH, 2004, GONDWANA RES, V7, P223, DOI 10.1016/S1342-937X(05)70322-1; Harries PJ, 1999, PALAEOGEOGR PALAEOCL, V154, P39, DOI 10.1016/S0031-0182(99)00086-3; Hesselbo SP, 2000, NATURE, V406, P392, DOI 10.1038/35019044; JENKYNS HC, 1988, AM J SCI, V288, P101, DOI 10.2475/ajs.288.2.101; Jenkyns HC, 2002, J GEOL SOC LONDON, V159, P351, DOI 10.1144/0016-764901-130; Jenkyns HC, 2003, PHILOS T R SOC A, V361, P1885, DOI 10.1098/rsta.2003.1240; Kerr AC, 1998, J GEOL SOC LONDON, V155, P619, DOI 10.1144/gsjgs.155.4.0619; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; Koppelhus Eva Bundgaard, 1994, Palynology, V18, P139; Kothavala Z, 1999, GEOPHYS RES LETT, V26, P209, DOI 10.1029/1998GL900275; Kump LR, 1999, CHEM GEOL, V161, P181, DOI 10.1016/S0009-2541(99)00086-8; Kurschner WM, 1997, REV PALAEOBOT PALYNO, V96, P1, DOI 10.1016/S0034-6667(96)00051-6; Kurtz AC, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000908; McElwain JC, 1998, PHILOS T R SOC B, V353, P83, DOI 10.1098/rstb.1998.0193; McElwain JC, 2002, J QUATERNARY SCI, V17, P21, DOI 10.1002/jqs.664.abs; MICHELSON O, 2003, JURASSIC DENMARK GRE, P147; Milkov AV, 2004, EARTH-SCI REV, V66, P183, DOI 10.1016/j.earscirev.2003.11.002; Palfy J, 2000, GEOLOGY, V28, P747, DOI 10.1130/0091-7613(2000)28<747:SBEJEO>2.0.CO;2; Royer DL, 2001, SCIENCE, V292, P2310, DOI 10.1126/science.292.5525.2310; Royer DL, 2001, EARTH-SCI REV, V54, P349, DOI 10.1016/S0012-8252(00)00042-8; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; Svensen H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566; Vakhrameev V.A., 1991, JURASSIC CRETACEOUS; Veevers J. J., 1994, PERMIAN TRIASSIC PAN, P331	30	367	381	2	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					479	482		10.1038/nature03618	http://dx.doi.org/10.1038/nature03618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917805				2022-12-28	WOS:000229337800051
J	Ndayimirije, N; Kindhauser, MK				Ndayimirije, N; Kindhauser, MK			Marburg hemorrhagic fever in Angola - Fighting fear and a lethal pathogen.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									WHO, Brazzaville, Rep Congo; WHO, Geneva, Switzerland	World Health Organization; World Health Organization	Ndayimirije, N (corresponding author), WHO, Brazzaville, Rep Congo.								0	25	25	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2155	2157		10.1056/NEJMp058115	http://dx.doi.org/10.1056/NEJMp058115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917379	Bronze			2022-12-28	WOS:000229333300001
J	Smith, AD; Cowan, JO; Brassett, KP; Herbison, GP; Taylor, DR				Smith, AD; Cowan, JO; Brassett, KP; Herbison, GP; Taylor, DR			Use of exhaled nitric oxide measurements to guide treatment in chronic asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; SPUTUM; HYPERRESPONSIVENESS; CHILDREN; HEALTHY; ADULTS; NO	Background International guidelines for the treatment of asthma recommend adjusting the dose of inhaled corticosteroids on the basis of symptoms, bronchodilator requirements, and the results of pulmonary-function tests. Measurements of the fraction of exhaled nitric oxide (FENO) constitute a noninvasive marker that may be a useful alternative for the adjustment of inhaled-corticosteroid treatment. Methods In a single-blind, placebo-controlled trial, we randomly assigned 97 patients with asthma who had been regularly receiving treatment with inhaled corticosteroids to have their corticosteroid dose adjusted, in a stepwise fashion, on the basis of either FENO measurements or an algorithm based on conventional guidelines. After the optimal dose was determined (phase 1), patients were followed up for 12 months (phase 2). The primary outcome was the frequency of exacerbations of asthma; the secondary outcome was the mean daily dose of inhaled corticosteroid. Results Forty-six patients in the FENO group and 48 in the group whose asthma was treated according to conventional guidelines (the control group) completed the study. The final mean daily doses of fluticasone, the inhaled corticosteroid that was used, were 370 mu g per day for the FENO group (95 percent confidence interval, 263 to 477) and 641 mu g per day for the control group (95 percent confidence interval, 526 to 756; P=0.003), a difference of 270 mu g per day (95 percent confidence interval, 112 to 430). The rates of exacerbation were 0.49 episode per patient per year in the FENO group (95 percent confidence interval, 0.20 to 0.78) and 0.90 in the control group (95 percent confidence interval, 0.31 to 1.49), representing a nonsignificant reduction of 45.6 percent (95 percent confidence interval for mean difference, -78.6 percent to 54.5 percent) in the FENO group. There were no significant differences in other markers of asthma control, use of oral prednisone, pulmonary function, or levels of airway inflammation (sputum eosinophils). Conclusions With the use of FENO measurements, maintenance doses of inhaled corticosteroids may be significantly reduced without compromising asthma control.	Univ Otago, Dunedin Sch Med, Dept Med, Resp Res Unit, Dunedin, New Zealand; Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago; University of Otago	Taylor, DR (corresponding author), Univ Otago, Dunedin Sch Med, Dept Med, Resp Res Unit, POB 913, Dunedin, New Zealand.	robin.taylor@stonebow.otago.ac.nz		Herbison, Graham Peter/0000-0002-5684-024X				Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; *BRIT THOR SOC, 2003, THORAX S1, V58, pI1; *DHHS, DHHS PUBL; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hawkins G, 2003, BMJ-BRIT MED J, V326, P1115, DOI 10.1136/bmj.326.7399.1115; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Taylor DR, 1999, THORAX, V54, P188; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; van der Molen T, 1998, AM J RESP CRIT CARE, V158, P121, DOI 10.1164/ajrccm.158.1.9707035; Visser MJ, 2004, EUR RESPIR J, V24, P420, DOI 10.1183/09031936.04.00023904; Visser MJ, 2001, AM J RESP CRIT CARE, V164, P2073, DOI 10.1164/ajrccm.164.11.2103075; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	25	746	779	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2163	2173		10.1056/NEJMoa043596	http://dx.doi.org/10.1056/NEJMoa043596			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15914548				2022-12-28	WOS:000229333300004
J	Leach, MO; Boggis, CRM; Dixon, AK; Easton, DF; Eeles, RA; Evans, DGR; Gilbert, FF; Griebsch, I; Hoff, RJC; Kessar, P; Lakhani, SR; Moss, SM; Nerurkar, A; Padhani, AR; Pointon, LJ; Thompson, D; Warren, RML				Leach, MO; Boggis, CRM; Dixon, AK; Easton, DF; Eeles, RA; Evans, DGR; Gilbert, FF; Griebsch, I; Hoff, RJC; Kessar, P; Lakhani, SR; Moss, SM; Nerurkar, A; Padhani, AR; Pointon, LJ; Thompson, D; Warren, RML		MARIBS Study Grp	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)	LANCET			English	Article							GENETIC RISK; GADOPENTETATE DIMEGLUMINE; NATIONAL MULTICENTER; WOMEN; MRI; BRCA2; SURVEILLANCE; MUTATIONS; CARCINOMA; PROTOCOL	Background Women genetically predisposed to breast cancer often develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mammography. Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening. Methods We did a prospective multicentre cohort study in 649 women aged 35-49 years with a strong family history of breast cancer or a high probability of a BRCA1, BRCA2, or TP53 mutation. We recruited participants from 22 centres in the UK, and offered the women annual screening with CE MRI and mammography for 2-7 years. Findings We diagnosed 35 cancers in the 649 women screened with both mammography and CE MRI (1881 screens): 19 by CE MRI only, six by mammography only, and eight by both, with two interval cases. Sensitivity was significantly higher for CE MRI (77%, 95% CI 60-90) than for mammography (40%, 24-58; p=0.01), and was 94% (81-99) when both methods were used. Specificity was 93% (92-95) for mammography, 81% (80-83) for CE MRI (p<0.0001), and 77% (75-79) with both methods. The difference between CE MRI and mammography sensitivities was particularly pronounced in BRCA1 carriers (13 cancers; 92% vs 23%, p=0.004). Interpretation Our findings indicate that CE MRI is more sensitive than mammography for cancer detection. Specificity for both procedures was acceptable. Despite a high proportion of grade 3 cancers, tumours were small and few women were node positive. Annual screening, combining CE MRI and mammography, would detect most tumours in this risk group.	Inst Canc Res, Sect Magnet Resonance, MARIBS Study Off, Sutton SM2 5PT, Surrey, England	University of London; Institute of Cancer Research - UK	Leach, MO (corresponding author), Inst Canc Res, Sect Magnet Resonance, MARIBS Study Off, Sutton SM2 5PT, Surrey, England.	martin.leach@icr.ac.uk	Lakhani, Sunil R/I-1970-2018; leach, martin o/C-2248-2008; Coulthard, Alan/C-3649-2011; Evans, D Gareth/AAB-4308-2022	Lakhani, Sunil R/0000-0003-4067-2760; leach, martin o/0000-0002-0756-5368; Coulthard, Alan/0000-0003-1110-9207; Evans, D Gareth/0000-0002-8482-5784; Eeles, Rosalind/0000-0002-3698-6241; Eccles, Diana M/0000-0002-9935-3169				ACR, 2003, ACR BI RADS MAMM; [Anonymous], 2003, BREAST IM REP DAT SY; Barton MB, 2004, J NATL CANCER I, V96, P529, DOI 10.1093/jnci/djh083; Blanks RG, 1998, J MED SCREEN, V5, P195, DOI 10.1136/jms.5.4.195; Brown J, 2000, BREAST, V9, P78, DOI 10.1054/brst.2000.0136; Brown J, 2000, BREAST, V9, P72, DOI 10.1054/brst.2000.0135; Brown J, 2000, MAGN RESON IMAGING, V18, P765, DOI 10.1016/S0730-725X(00)00167-3; *CANC SCREEN PROGR, NAT BREAST SCREEN PR; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fischer U, 1999, RADIOLOGY, V213, P881, DOI 10.1148/radiology.213.3.r99dc01881; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; HEYWANGKOBRUNNER SH, 1994, RADIOLOGY, V191, P639, DOI 10.1148/radiology.191.3.8184040; Knopp MV, 2003, AM J ROENTGENOL, V181, P663, DOI 10.2214/ajr.181.3.1810663; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Kuhl CK, 2000, RADIOLOGY, V215, P267, DOI 10.1148/radiology.215.1.r00ap01267; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; Malur S, 2001, BREAST CANCER RES, V3, P55, DOI 10.1186/bcr271; Morris EA, 2003, AM J ROENTGENOL, V181, P619, DOI 10.2214/ajr.181.3.1810619; *NHSBSP, 1995, GUID NOT MAMM XRAY E; *NHSBSP, GUID NOT EV MAMM XRA; *NHSBSP, 1996, QUAL ASS GUID SURG W; Podo F, 2002, J EXP CLIN CANC RES, V21, P115; Sardanelli F, 2004, AM J ROENTGENOL, V183, P1149, DOI 10.2214/ajr.183.4.1831149; Stoutjesdijk MJ, 2001, JNCI-J NATL CANCER I, V93, P1095, DOI 10.1093/jnci/93.14.1095; Tilanus-Linthorst M, 2002, INT J CANCER, V102, P91, DOI 10.1002/ijc.10666; Tilanus-Linthorst MMA, 2000, BREAST CANCER RES TR, V63, P53, DOI 10.1023/A:1006480106487; Tilanus-Linthorst MMA, 2000, EUR J CANCER, V36, P514, DOI 10.1016/S0959-8049(99)00337-8; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; WARREN R, IN PRESS RADIOLOGY; Warren RML, 2002, MAGN RESON IMAGING, V20, P557, DOI 10.1016/S0730-725X(02)00535-0; WILSON R, 2001, CLIN GUIDELINES BREA; Ziv E, 2003, J NATL CANCER I, V95, P556, DOI 10.1093/jnci/95.7.556; [No title captured]	35	776	799	0	51	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1769	1778		10.1016/S0140-6736(05)66481-1	http://dx.doi.org/10.1016/S0140-6736(05)66481-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910949				2022-12-28	WOS:000229291600021
J	West, M; Sanchez, JJ; McNutt, SR				West, M; Sanchez, JJ; McNutt, SR			Periodically triggered seismicity at Mount Wrangell, Alaska, after the Sumatra earthquake	SCIENCE			English	Article							LANDERS	As surface waves from the 26 December 2004 earthquake in Sumatra swept across Alaska, they triggered an 11-minute swarm of 14 local earthquakes near Mount Wrangell, almost 11,000 kilometers away. Earthquakes occurred at intervals of 20 to 30 seconds, in phase with the largest positive vertical ground displacements during the Rayleigh surface waves. We were able to observe this correlation because of the combination of unusually long surface waves and seismic stations near the local earthquakes. This phase of Rayleigh wave motion was dominated by horizontal extensional stresses reaching 25 kilopascals. These observations imply that local events were triggered by simple shear failure on normal faults.	Univ Alaska, Inst Geophys, Alaska Volcano Observ, Fairbanks, AK 99775 USA	United States Department of the Interior; United States Geological Survey; University of Alaska System; University of Alaska Fairbanks	West, M (corresponding author), Univ Alaska, Inst Geophys, Alaska Volcano Observ, Fairbanks, AK 99775 USA.	west@gi.alaska.edu	Sánchez, John J. J./AAX-5395-2021	Sánchez, John J. J./0000-0002-9024-7554				Aki K., 2002, QUANTITATIVE SEISMOL, Vsecond; BENSON CS, 1995, EOS, V76, P198; Brodsky EE, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002321; CLARKE GKC, 1989, J GEOPHYS RES-SOLID, V94, P7237, DOI 10.1029/JB094iB06p07237; Cocco M, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000138; Gomberg J, 1996, J GEOPHYS RES-SOL EA, V101, P733, DOI 10.1029/95JB03250; Gomberg J, 2001, NATURE, V411, P462, DOI 10.1038/35078053; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; Husen S, 2004, B SEISMOL SOC AM, V94, pS317, DOI 10.1785/0120040617; Park J, 2005, SCIENCE, V308, P1139, DOI 10.1126/science.1112305; Prejean SG, 2004, B SEISMOL SOC AM, V94, pS348, DOI 10.1785/0120040610; Sanchez JJ, 2004, B SEISMOL SOC AM, V94, pS370, DOI 10.1785/0120040602; Scholz C.H., 2002, MECH EARTHQUAKES FAU, DOI 10.1017/CBO9780511818516; Streit JE, 2001, J GEOPHYS RES-SOL EA, V106, P2235, DOI 10.1029/2000JB900359; STURTEVANT B, 1996, J GEOPHYS RES, V101, P25	15	124	134	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1144	1146		10.1126/science.1112462	http://dx.doi.org/10.1126/science.1112462			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905395				2022-12-28	WOS:000229293400036
J	Buchanan, M				Buchanan, M			Capturing chaos	NATURE			English	Editorial Material																		Casetti L, 2000, PHYS REP, V337, P237, DOI 10.1016/S0370-1573(00)00069-7; FERMI E, 1955, LA1940 LOS AL SCI LA; LIEBERMAN MA, 1983, REGULAR STOCHASTIC M; Pettini M, 2005, CHAOS, V15, DOI 10.1063/1.1849131	4	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2005	435	7040					281	281		10.1038/435281a	http://dx.doi.org/10.1038/435281a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902238				2022-12-28	WOS:000229185000026
J	Kato, H; Goto, DB; Martienssen, RA; Urano, T; Furukawa, K; Murakami, Y				Kato, H; Goto, DB; Martienssen, RA; Urano, T; Furukawa, K; Murakami, Y			RNA polymerase II is required for RNAi-dependent heterochromatin assembly	SCIENCE			English	Article							FISSION YEAST; LYSINE-9 METHYLATION; EPIGENETIC CONTROL; NUCLEAR-RNA; TRANSCRIPTION; RITS; DNA	In Schizosaccharomyces pombe, the RNA interference (RNAi) machinery con. verts pericentromeric transcripts into small interfering RNAs (siRNAs) and is, required for the assembly of pericentromeric heterochromatin. Here we describe a. mutation in the second largest subunit of RNA polymerase II (RNAPII). Both wild-type and mutant RNAPII localized to the pericentromere. However, the mutation resulted in the loss of heterochromatic histone modifications and in the accumulation of pericentromeric transcripts, accompanied by the loss of siRNAs. This phenotype resembles mutants in RNAi and suggests that RNAPII couples pericentromeric transcription with siRNA processing and heterochromatin assembly.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Nagoya, Aichi 4668550, Japan	Kyoto University; Cold Spring Harbor Laboratory; Nagoya University	Murakami, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	yota@virus.kyoto-u.ac.jp	Murakami, Yota/F-8850-2012; Kato, Hiroaki/B-2799-2008; Goto, Derek B/B-7053-2009; Kato, Hiroaki/T-1674-2017	Kato, Hiroaki/0000-0001-9591-1875; Urano, Takeshi/0000-0003-3383-3554	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067014] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM067014] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; Hamada M, 2000, J BIOL CHEM, V275, P29076, DOI 10.1074/jbc.M003980200; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; KAWAGISHIKOBAYASHI, 1996, MOL GEN GENET, V250, P1; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651; Martienssen RA, 2003, NAT GENET, V35, P213, DOI 10.1038/ng1252; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Sadaie M, 2004, EMBO J, V23, P3825, DOI 10.1038/sj.emboj.7600401; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	19	230	240	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	2005	309	5733					467	469		10.1126/science.1114955	http://dx.doi.org/10.1126/science.1114955			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	946LY	15947136				2022-12-28	WOS:000230574900047
J	Zebrowitz, LA; Montepare, JM				Zebrowitz, LA; Montepare, JM			Appearance DOES matter	SCIENCE			English	Editorial Material									Brandeis Univ, Dept Psychol, Waltham, MA 02454 USA; Emerson Coll, Dept Mkt Commun, Boston, MA 02116 USA	Brandeis University	Zebrowitz, LA (corresponding author), Brandeis Univ, Dept Psychol, Waltham, MA 02454 USA.	zebrowit@brandeis.edu						Ambady N, 2000, ADV EXP SOC PSYCHOL, V32, P201, DOI 10.1016/S0065-2601(00)80006-4; BROWNLOW S, 1992, J NONVERBAL BEHAV, V16, P101, DOI 10.1007/BF00990325; FRIEDMAN H, 1992, PERS SOC PSYCHOL B, V18, P430, DOI 10.1177/0146167292184006; Keating CF, 1999, POLIT PSYCHOL, V20, P593, DOI 10.1111/0162-895X.00158; KINDER DR, 1986, POLITICAL COGNITION, P233; Montepare JM, 1998, ADV EXP SOC PSYCHOL, V30, P93, DOI 10.1016/S0065-2601(08)60383-4; Pettijohn II T. F., 1999, MEDIA PSYCHOL, V1, P229, DOI [10.1207/s1532785xmep0103_3, DOI 10.1207/S1532785XMEP0103_3]; Todorov A, 2005, SCIENCE, V308, P1623, DOI 10.1126/science.1110589; Zebrowitz L. A, 1997, READING FACES; Zebrowitz LA, 2003, PERS SOC PSYCHOL REV, V7, P194, DOI 10.1207/S15327957PSPR0703_01	10	78	80	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1565	1566		10.1126/science.1114170	http://dx.doi.org/10.1126/science.1114170			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	936BH	15947164				2022-12-28	WOS:000229827000031
J	Flewelling, LJ; Naar, JP; Abbott, JP; Baden, DG; Barros, NB; Bossart, GD; Bottein, MYD; Hammond, DG; Haubold, EM; Heil, CA; Henry, MS; Jacocks, HM; Leighfield, TA; Pierce, RH; Pitchford, TD; Rommel, SA; Scott, PS; Steidinger, KA; Truby, EW; Van Dolah, FM; Landsberg, JH				Flewelling, LJ; Naar, JP; Abbott, JP; Baden, DG; Barros, NB; Bossart, GD; Bottein, MYD; Hammond, DG; Haubold, EM; Heil, CA; Henry, MS; Jacocks, HM; Leighfield, TA; Pierce, RH; Pitchford, TD; Rommel, SA; Scott, PS; Steidinger, KA; Truby, EW; Van Dolah, FM; Landsberg, JH			Brevetoxicosis: Red tides and marine mammal mortalities	NATURE			English	Editorial Material							DINOFLAGELLATE		Florida Fish & Wildlife Conservat Commiss, Fish & Wildlife Res Inst, St Petersburg, FL 33701 USA; Univ N Carolina, Ctr Marine Sci, Wilmington, NC 28409 USA; Mote Marine Lab, Sarasota, FL 34236 USA; Harbor Branch Oceanog Inst Inc, Ft Pierce, FL 34946 USA; NOAA, NOS, Ctr Coastal Environm Hlth & Biomol Res, Charleston, SC 29412 USA	Florida Fish & Wildlife Conservation Commission; University of North Carolina; University of North Carolina Wilmington; Mote Marine Laboratory & Aquarium; Harbor Branch Oceanographic Institute Foundation; National Oceanic Atmospheric Admin (NOAA) - USA; National Ocean Service, NOAA	Flewelling, LJ (corresponding author), Florida Fish & Wildlife Conservat Commiss, Fish & Wildlife Res Inst, St Petersburg, FL 33701 USA.	naarj@uncw.edu	Bottein, Marie-Yasmine Dechraoui/J-8851-2018	Dechraoui Bottein, Marie-Yasmine/0000-0002-6468-7222	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES010594] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01 ES010594-05, P01 ES010594] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], HARMFUL ALGAL BLOOMS; BADEN DG, 1982, TOXICON, V20, P457, DOI 10.1016/0041-0101(82)90009-5; Bossart GD, 1998, TOXICOL PATHOL, V26, P276, DOI 10.1177/019262339802600214; GERACI J, 1989, CLIN INVESTIGATION 1; OSHEA TJ, 1991, MAR MAMMAL SCI, V7, P165, DOI 10.1111/j.1748-7692.1991.tb00563.x; Ross PS, 2000, HUM ECOL RISK ASSESS, V6, P29, DOI 10.1080/10807030091124437; Steidinger Karen A., 1993, P1; Van Dolah FM, 2003, N P TOX ENV, P247; *WORK GROUP MAR MA, 2004, BOTTL DOLPH TURS TRU	9	297	308	2	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					755	756		10.1038/nature435755a	http://dx.doi.org/10.1038/nature435755a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944690	Green Accepted			2022-12-28	WOS:000229638700036
J	Marty, FM; Whiteside, KR				Marty, FM; Whiteside, KR			Myiasis due to Dermatobia hominis (Human botfly).	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Marty, FM (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.			Marty, Francisco/0000-0002-3708-8734					0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					E21	E21		10.1056/NEJMicm041049	http://dx.doi.org/10.1056/NEJMicm041049			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944419				2022-12-28	WOS:000229638900010
J	Palla, G; Derenyi, I; Farkas, I; Vicsek, T				Palla, G; Derenyi, I; Farkas, I; Vicsek, T			Uncovering the overlapping community structure of complex networks in nature and society	NATURE			English	Article								Many complex systems in nature and society can be described in terms of networks capturing the intricate web of connections among the units they are made of(1-4). A key question is how to interpret the global organization of such networks as the coexistence of their structural subunits ( communities) associated with more highly interconnected parts. Identifying these a priori unknown building blocks ( such as functionally related proteins(5,6), industrial sectors(7) and groups of people(8,9)) is crucial to the understanding of the structural and functional properties of networks. The existing deterministic methods used for large networks find separated communities, whereas most of the actual networks are made of highly overlapping cohesive groups of nodes. Here we introduce an approach to analysing the main statistical features of the interwoven sets of overlapping communities that makes a step towards uncovering the modular structure of complex systems. After defining a set of new characteristic quantities for the statistics of communities, we apply an efficient technique for exploring overlapping communities on a large scale. We find that overlaps are significant, and the distributions we introduce reveal universal features of networks. Our studies of collaboration, word-association and protein interaction graphs show that the web of communities has non-trivial correlations and specific scaling properties.	Hungarian Acad Sci, Biol Phys Res Grp, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Dept Biol Phys, H-1117 Budapest, Hungary	Hungarian Academy of Sciences; Eotvos Lorand University	Vicsek, T (corresponding author), Hungarian Acad Sci, Biol Phys Res Grp, Pazmany Pstny 1A, H-1117 Budapest, Hungary.	vicsek@angel.elte.hu	Vicsek, Tamas/A-3305-2009; Derenyi, Imre/G-8087-2011; Palla, Gergely/H-1767-2016; Farkas, Illes/C-1504-2008	Derenyi, Imre/0000-0003-1171-1214; Palla, Gergely/0000-0002-3406-4200; Farkas, Illes/0000-0001-5341-5582				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BATAGELJ V, 2003, ARXIVCSDS0308011; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Derenyi I, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.160202; Everett M.G., 1998, CONNECTIONS, V21, P49; Everitt B. S., 1993, CLUSTER ANAL; Faust K., 2005, MODELS METHODS SOCIA, P117, DOI DOI 10.1017/CBO9780511811395.007; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799; Knudsen S., 2004, GUIDE ANAL DNA MICRO; Kosub S, 2005, LECT NOTES COMPUT SC, V3418, P112; Mendes J. F. F., 2003, EVOLUTION NETWORKS B; NELSON DL, U S FLORIDA WORLD AS; Newman MEJ, 2004, EUR PHYS J B, V38, P321, DOI 10.1140/epjb/e2004-00124-y; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.70.056131]; Onnela JP, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.056110; Radicchi F, 2004, P NATL ACAD SCI USA, V101, P2658, DOI 10.1073/pnas.0400054101; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Scott J., 2000, SOCIAL STRUCTURE, V2nd; Shiffrin RM, 2004, P NATL ACAD SCI USA, V101, P5183, DOI 10.1073/pnas.0307852100; Song CM, 2005, NATURE, V433, P392, DOI 10.1038/nature03248; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; Vicsek T, 2002, NATURE, V418, P131, DOI 10.1038/418131a; Warner S., 2003, Library Hi Tech, V21, P151, DOI 10.1108/07378830310479794; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Watts DJ, 2002, SCIENCE, V296, P1302, DOI 10.1126/science.1070120; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289	30	3108	3490	14	482	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					814	818		10.1038/nature03607	http://dx.doi.org/10.1038/nature03607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944704	Green Submitted			2022-12-28	WOS:000229638700050
J	Drobniewski, F; Balabanova, Y; Nikolayevsky, V; Ruddy, M; Kuznetzov, S; Zakharova, S; Melemyev, A; Fedorin, I				Drobniewski, F; Balabanova, Y; Nikolayevsky, V; Ruddy, M; Kuznetzov, S; Zakharova, S; Melemyev, A; Fedorin, I			Drug-resistant, tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; TREATMENT FAILURE; IMMUNE-RESPONSE; GENOTYPE; EPIDEMIOLOGY; VIETNAM; SPREAD; RISK	Context Tuberculosis and multidrug-resistant tuberculosis is a serious public health problem in Russia. Objective To address the extent of "Beijing strain" transmission in the prison/civil sectors and the association of drug resistance, clinical, and social factors with the Beijing genotype. Design and Setting Cross-sectional population-based molecular epidemiological study of all civilian and penitentiary tuberculosis facilities in the Samara region, Russia. Patients Consecutively recruited patients with bacteriologically proven tuberculosis (n = 880). Main Outcome Measure Proportion of Beijing strains and association with drug resistance, human immunodeficiency virus infection, imprisonment, radiological, clinical, and other social factors. Results Beijing-family strains (identified by spoligotyping and composed of 2 main types by mycobacterial interspersed repetitive unit analysis) were predominant: 586/880 (66.6%; 95% confidence interval ICU, 63.4%-69.7%) with a significantly higher prevalence in the prison population (rate ratio [RR], 1.3; 95% Cl, 1.2-1.5) and those aged younger than 35 years (RR, 1.2; 95% Cl, 1.0-1.3). Comparable proportions were coinfected with the human immunodeficiency virus ( 10%), concurrent hepatitis B and C (21.6%), drank alcohol (approximate to 90%), smoked (approximate to 90%), and had a similar sexual history. Drug resistance was nearly 2-fold higher in patients infected with Beijing strains compared with non-Beijing strains: multidrug resistance (RR, 2.4; 95% Cl, 1.9-3.0), for isoniazid (RR, 1.8; 95% Cl, 1.5-2.1), for rifampicin (RR, 2.2; 95% Cl, 1.7-2.7), for streptomycin (RR, 1.9; 95% Cl, 1.5-2.3), and for ethambutol (RR, 2.2; 95% Cl, 1.63.2). Univariate analysis demonstrated that male sex (odds ratio [OR], 1.5; 95% Cl, 1.1-1.9), advanced radiological abnormalities (OR, 3.3; 95% Cl, 1.3-8.4), homelessness (OR, 5.6; 95% Cl, 1.1-6.3), and previous imprisonment (OR, 2.0; 95% Cl, 1.52.7) were strongly associated with Beijing-strain family disease. Multivariate analysis supported previous imprisonment to be a risk factor (OR, 2.0; 95% Cl, 1.4-3.3) and night sweats to be less associated (OR 0.7; 95% Cl, 0.5-1.0) with Beijing-strain disease. Conclusions Drug resistance and previous imprisonment but not human immunodeficiency virus co-infection were significantly associated with Beijing-strain infection. There was evidence that Beijing isolates caused radiologically more advanced disease.	Guys & St Thomas Med Sch, Dept Microbiol & Infect, HPA Mycobacterium Reference Unit, London, England; Samara Reg TB Serv, Samara Oblast Dispensary, Samara, Russia; Samara City TB Serv, Samara, Russia; Samara Reg Minist Hlth, Samara, Russia; Samara Prison TB Serv, Samara, Russia	University of London; King's College London	Drobniewski, F (corresponding author), Queen Marys Sch Med, Inst Cell & Mol Sci, Ctr Clin Sci, Newark St, London E1, England.	francis.drobniewski@kcl.ac.uk	Nikolayevskyy, Vladyslav/HFZ-7738-2022	Nikolayevskyy, Vladyslav/0000-0002-9502-0332				ABRAMSON JH, 2001, COMPUTER PROGRAMS EP; Anh DD, 2000, EMERG INFECT DIS, V6, P302; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; Borydorff MW, 2004, TUBERCULOSIS, V84, P337, DOI 10.1016/j.tube.2003.10.002; Caminero JA, 2001, AM J RESP CRIT CARE, V164, P1165, DOI 10.1164/ajrccm.164.7.2101031; Coker RJ, 2003, INT J TUBERC LUNG D, V7, P920; Drobniewski F, 2004, CURR OPIN PULM MED, V10, P211, DOI 10.1097/00063198-200405000-00011; Glynn JR, 2002, EMERG INFECT DIS, V8, P843; Kimerling ME, 2003, INT J TUBERC LUNG D, V7, P866; Kruuner A, 2002, CLIN INFECT DIS, V35, P146, DOI 10.1086/340980; Kruuner A, 2001, J CLIN MICROBIOL, V39, P3339, DOI 10.1128/JCM.39.9.3339-3345.2001; Lan NTN, 2003, EMERG INFECT DIS, V9, P1633, DOI 10.3201/eid0912.030169; Lillebaek T, 2003, EMERG INFECT DIS, V9, P1553, DOI 10.3201/eid0912.030276; Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x; Mokrousov I, 2004, J CLIN MICROBIOL, V42, P2438, DOI 10.1128/JCM.42.6.2438-2444.2004; NARVSKAIA OV, 2002, PROBL TUBERK, V3, P50; Narvskaya O, 2002, EUR J CLIN MICROBIOL, V21, P596, DOI 10.1007/s10096-002-0775-4; Pfyffer GE, 2001, EMERG INFECT DIS, V7, P855, DOI 10.3201/eid0705.017514; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001; Toungoussova OS, 2002, INT J TUBERC LUNG D, V6, P406; Tracevska T, 2003, INT J TUBERC LUNG D, V7, P1097; Van Soolingen D, 2001, J MED MICROBIOL, V50, P749, DOI 10.1099/0022-1317-50-9-749; van Soolingen D, 2001, J INTERN MED, V249, P1, DOI 10.1046/j.1365-2796.2001.00772.x; VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234, DOI 10.1128/JCM.33.12.3234-3238.1995; VANSOOLINGEN D, 1995, EUR RESPIR J, V8, pS649	26	193	204	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2726	2731		10.1001/jama.293.22.2726	http://dx.doi.org/10.1001/jama.293.22.2726			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941801	Bronze			2022-12-28	WOS:000229643700020
J	Grant, AD; Charalambous, S; Fielding, KL; Day, JH; Corbett, EL; Chaisson, RE; De Cock, KM; Hayes, RJ; Churchyard, GJ				Grant, AD; Charalambous, S; Fielding, KL; Day, JH; Corbett, EL; Chaisson, RE; De Cock, KM; Hayes, RJ; Churchyard, GJ			Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa - A novel randomized incremental recruitment study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GOLD MINERS; ANTIRETROVIRAL THERAPY; IMPACT; PROPHYLAXIS; PREVALENCE; EFFICACY; RISK	Context Tuberculosis preventive therapy reduces tuberculosis incidence among human immunodeficiency virus (HIV)-infected individuals in clinical trials, but implementation has been limited and there are no data on effectiveness under routine conditions. Objective To determine the effect on tuberculosis incidence of a clinic providing isoniazid preventive therapy to HIV-infected adults under routine conditions., Design, Setting, and Participants Randomized intervention study with a novel incremental recruitment design. Between 1999 and 2001 (before antiretroviral therapy was available), 1655 HIV-infected male employees of a South African gold-mining company (median age, 37 years) were enrolled in the study. Median follow-up was 22.1 months. Intervention Employees were invited in random sequence to attend a workplace HIV clinic. Isoniazid, 300 mg/d, was self-administered for 6 months among attendees with no evidence of active tuberculosis. Main Outcome Measure Incidence of tuberculosis (including both first and recurrent episodes) during the periods before and after clinic enrollment. Results A total of 1016 of 1655 men included in the analysis attended the clinic at least once. Six hundred seventy-nine (97%) of 702 men eligible to start primary isoniazid preventive therapy did so. The tuberculosis incidence rate before vs after clinic enrollment was 11.9 vs 9.0 per 100 person-years, respectively (incidence rate ratio [IRR] after adjustment for calendar period, 0.68; 95% confidence interval [CI], 0.48-0.96). In a multivariable analysis adjusting for calendar period, age, and silicosis grade, the tuberculosis IRR for clinic enrollment was 0.62 (95% Cl, 0.43-0.89). In a further analysis excluding individuals with a history of tuberculosis (and, hence, ineligible for isoniazid preventive therapy), the adjusted IRR for clinic enrollment was 0.54 (95% Cl, 0.35-0.83). Conclusions Enrollment in a clinic offering primary isoniazid preventive therapy to HIV-infected adults reduced tuberculosis incidence by 38% overall and by 46% among individuals with no history of tuberculosis prior to the study. Tuberculosis incidence remained high despite isoniazid preventive therapy, and further work is needed to determine how to use additional interventions most effectively to reduce morbidity and mortality due to tuberculosis in HIV-infected persons.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Climat Res Unit, London WC1E 7HT, England; Aurum Hlth Res, Johannesburg, South Africa; Johns Hopkins Univ, Baltimore, MD USA	University of London; London School of Hygiene & Tropical Medicine; Johns Hopkins University	Grant, AD (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Climat Res Unit, Keppel St, London WC1E 7HT, England.	alison.grant@lshtm.ac.uk		Fielding, Katherine/0000-0002-6524-3754; Charalambous, Salome/0000-0001-7143-1009; Corbett, Elizabeth/0000-0002-3552-3181; Hayes, Richard/0000-0002-1729-9892	National Institute for Health Research [PHCS/03/01] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001637] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01637] Funding Source: Medline; Wellcome Trust Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; [Anonymous], 1987, CANCER RES, V47, P5782; ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; AYLES H, 2000, 13 INT C AIDS DURB S; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009; Cantwell MF, 1997, INT J TUBERC LUNG D, V1, P205; Charalambous S, 2004, AIDS CARE, V16, P47, DOI 10.1080/09540120310001633967; Churchyard CJ, 1999, INT J TUBERC LUNG D, V3, P791; Churchyard GJ, 2003, AIDS, V17, P2063, DOI 10.1097/00002030-200309260-00007; CHURCHYARD GJ, 2002, PROVISIONAL ASSESSME; CLAYTON D, RANDOM EFFECTS POISS; COMSTOCK GW, 1962, AM REV RESPIR DIS, V86, P810; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Corbett EL, 2004, AM J RESP CRIT CARE, V170, P673, DOI 10.1164/rccm.200405-590OC; Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540; CORBETT EL, 2002, 13 INT C AIDS BARC S; COWIE RL, 1994, AM J RESP CRIT CARE, V150, P1460, DOI 10.1164/ajrccm.150.5.7952577; Cowie RL, 1996, TUBERCLE LUNG DIS, V77, P239, DOI 10.1016/S0962-8479(96)90007-6; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015; Godfrey-Faussett P, 2003, TUBERCULOSIS, V83, P68, DOI 10.1016/S1472-9792(02)00083-5; *INT LAB OFF, 1981, SER OCC SAF HLTH, V22; Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009; Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4; Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011; Raviglione M C, 1997, AIDS, V11 Suppl B, pS115; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; *WHO GLOB TUB PROG, 1998, WHOTB98255 GLOB TUB; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625	31	108	112	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2719	2725		10.1001/jama.293.22.2719	http://dx.doi.org/10.1001/jama.293.22.2719			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941800	Bronze, Green Accepted			2022-12-28	WOS:000229643700019
J	Dewey, KG				Dewey, KG			Infant nutrition in developing countries: what works?	LANCET			English	Editorial Material							GROWTH; CHILDREN		Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Program Int & Community Nutr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Dewey, KG (corresponding author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.	kgdewey@ucdavis.edu						Bhandari N, 2004, J NUTR, V134, P2342; Bhandari N, 2001, J NUTR, V131, P1946, DOI 10.1093/jn/131.7.1946; Brown KH, 2002, AM J CLIN NUTR, V75, P1062, DOI 10.1093/ajcn/75.6.1062; Caulfield Laura E., 1999, Food and Nutrition Bulletin, V20, P183; Dewey K. G., 2002, NESTLE NUTR WORKSHOP, V48, P199; Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5; Dewey KG, 2001, J NUTR, V131, P1879, DOI 10.1093/jn/131.7.1879; Guldan GS, 2000, J NUTR, V130, P1204, DOI 10.1093/jn/130.5.1204; *PAN HLTH ORG WHO, 2003, GUID PRINC COMPL FEE; WHO, 1998, WHONUT981	10	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1832	1834		10.1016/S0140-6736(05)66427-6	http://dx.doi.org/10.1016/S0140-6736(05)66427-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	931JK	15924968				2022-12-28	WOS:000229481400007
J	Redmond, AD				Redmond, AD			ABC of conflict and disaster - Natural disasters	BRITISH MEDICAL JOURNAL			English	Review									Keele Univ, Keele, Staffs, England	Keele University	Redmond, AD (corresponding author), Keele Univ, Keele, Staffs, England.								0	21	25	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 28	2005	330	7502					1259	1261		10.1136/bmj.330.7502.1259	http://dx.doi.org/10.1136/bmj.330.7502.1259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15920130	Green Published			2022-12-28	WOS:000229448900028
J	Fujita, M; Takahashi, S; Tanaka, Y; Asano, T; Noda, S				Fujita, M; Takahashi, S; Tanaka, Y; Asano, T; Noda, S			Simultaneous inhibition and redistribution of spontaneous light emission in photonic crystals	SCIENCE			English	Article							QUANTUM DOTS; BANDGAP; EXTRACTION; ENHANCEMENT; TECHNOLOGY; SURFACES; SILICON; DEFECT; LASER; SLABS	Inhibiting spontaneous light emission and redistributing the energy into useful forms are desirable objectives for advances in various fields, including photonics, illuminations, displays, solar cells, and even quantum-information systems. We demonstrate both the "inhibition" and "redistribution" of spontaneous light emission by using two-dimensional (2D) photonic crystals, in which the refractive index is changed two-dimensionally. The overall spontaneous emission rate is found to be reduced by a factor of 5 as a result of the 2D photonic bandgap effect. Simultaneously, the light energy is redistributed from the 2D plane to the direction normal to the photonic crystal.	Kyoto Univ, Dept Elect Sci & Engn, Nishikyo Ku, Kyoto 6158510, Japan	Kyoto University	Noda, S (corresponding author), Kyoto Univ, Dept Elect Sci & Engn, Nishikyo Ku, Kyoto 6158510, Japan.	snoda@kuee.kyoto-u.ac.jp	Fujita, Masayuki/C-3243-2012	Fujita, Masayuki/0000-0003-1772-0891				Akahane Y, 2003, NATURE, V425, P944, DOI 10.1038/nature02063; Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; Boroditsky M, 1999, J LIGHTWAVE TECHNOL, V17, P2096, DOI 10.1109/50.803000; Coldren L. A., 1995, DIODE LASERS PHOTONI, P148; Fan SH, 1997, PHYS REV LETT, V78, P3294, DOI 10.1103/PhysRevLett.78.3294; Fujita M, 2004, JPN J APPL PHYS 2, V43, pL1400, DOI 10.1143/JJAP.43.L1400; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Hwang JK, 1999, PHYS REV B, V60, P4688, DOI 10.1103/PhysRevB.60.4688; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Lee RK, 2000, J OPT SOC AM B, V17, P1438, DOI 10.1364/JOSAB.17.001438; Lodahl P, 2004, NATURE, V430, P654, DOI 10.1038/nature02772; Loudon R., 2000, QUANTUM THEORY LIGHT; Mabuchi H, 2002, SCIENCE, V298, P1372, DOI 10.1126/science.1078446; Noda S, 2000, NATURE, V407, P608, DOI 10.1038/35036532; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Noda S, 2001, SCIENCE, V293, P1123, DOI 10.1126/science.1061738; O'Connor D.V., 1985, TIME CORRELATED SING; Ogawa SP, 2004, SCIENCE, V305, P227, DOI 10.1126/science.1097968; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Qi MH, 2004, NATURE, V429, P538, DOI 10.1038/nature02575; Ryu HY, 2001, APPL PHYS LETT, V79, P3573, DOI 10.1063/1.1420405; Saleh B.E.A., 2007, FUNDAMENTALS PHOTONI, V2nd; Steigerwald DA, 2002, IEEE J SEL TOP QUANT, V8, P310, DOI 10.1109/2944.999186; YABLONOVITCH E, 1987, APPL PHYS LETT, V51, P439, DOI 10.1063/1.98415; YABLONOVITCH E, 1986, PHYS REV LETT, V57, P249, DOI 10.1103/PhysRevLett.57.249; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; Ziemelis K, 1999, NATURE, V399, P408, DOI 10.1038/20798	27	407	414	4	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1296	1298		10.1126/science.1110417	http://dx.doi.org/10.1126/science.1110417			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919989				2022-12-28	WOS:000229482300043
J	Dharmasiri, N; Dharmasiri, S; Estelle, M				Dharmasiri, N; Dharmasiri, S; Estelle, M			The F-box protein TIR1 is an auxin receptor	NATURE			English	Article							SCF UBIQUITIN-LIGASE; AUX/IAA PROTEINS; DEGRADATION; COMPLEX; MECHANISMS; EXPRESSION; BINDING; GROWTH; DOMAIN; GENES	The plant hormone auxin regulates diverse aspects of plant growth and development. Recent studies indicate that auxin acts by promoting the degradation of the Aux/IAA transcriptional repressors through the action of the ubiquitin protein ligase SCFTIR1. The nature of the signalling cascade that leads to this effect is not known. However, recent studies indicate that the auxin receptor and other signalling components involved in this response are soluble factors. Using an in vitro pull-down assay, we demonstrate that the interaction between transport inhibitor response 1 (TIR1) and Aux/IAA proteins does not require stable modification of either protein. Instead auxin promotes the Aux/IAA-SCFTIR1 interaction by binding directly to SCFTIR1. We further show that the loss of TIR1 and three related F-box proteins eliminates saturable auxin binding in plant extracts. Finally, TIR1 synthesized in insect cells binds Aux/IAA proteins in an auxin-dependent manner. Together, these results indicate that TIR1 is an auxin receptor that mediates Aux/IAA degradation and auxin-regulated transcription.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Estelle, M (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	maestell@indiana.edu	Estelle, Mark/ABD-6742-2021					BLATT MR, 1994, PLANT J, V5, P55, DOI 10.1046/j.1365-313X.1994.5010055.x; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Davies Peter J., 1995, P1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dharmasiri N, 2003, CURR BIOL, V13, P1418, DOI 10.1016/S0960-9822(03)00536-0; Frias I, 1996, PLANT CELL, V8, P1533; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Hagen G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kepinski S, 2004, P NATL ACAD SCI USA, V101, P12381, DOI 10.1073/pnas.0402868101; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; Liscum E, 2002, PLANT MOL BIOL, V49, P387, DOI 10.1023/A:1015255030047; Luthen H, 1999, PROG BOT, V60, P315; Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955; Ouellet F, 2001, PLANT CELL, V13, P829, DOI 10.1105/tpc.13.4.829; Philippar K, 1999, P NATL ACAD SCI USA, V96, P12186, DOI 10.1073/pnas.96.21.12186; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ramos JA, 2001, PLANT CELL, V13, P2349, DOI 10.1105/tpc.13.10.2349; Reed JW, 2001, TRENDS PLANT SCI, V6, P420, DOI 10.1016/S1360-1385(01)02042-8; Tian Q, 2003, PLANT J, V36, P643, DOI 10.1046/j.1365-313X.2003.01909.x; Tiwari SB, 2001, PLANT CELL, V13, P2809, DOI 10.1105/tpc.13.12.2809; Weijers D, 2005, CURR OPIN PLANT BIOL, V8, P32, DOI 10.1016/j.pbi.2004.11.001; WENT F. W., 1928, REC TRAV BOT NEERL, V25, P1; Willemsen V, 2004, ANNU REV GENET, V38, P587, DOI 10.1146/annurev.genet.38.072902.092231; Xie DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/science.280.5366.1091; Yang XQ, 2004, PLANT J, V40, P772, DOI 10.1111/j.1365-313X.2004.02254.x; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zenser N, 2001, P NATL ACAD SCI USA, V98, P11795, DOI 10.1073/pnas.211312798	30	1432	1591	19	386	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					441	445		10.1038/nature03543	http://dx.doi.org/10.1038/nature03543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917797				2022-12-28	WOS:000229337800043
J	Gomes, R; Levison, HF; Tsiganis, K; Morbidelli, A				Gomes, R; Levison, HF; Tsiganis, K; Morbidelli, A			Origin of the cataclysmic Late Heavy Bombardment period of the terrestrial planets	NATURE			English	Article							MIGRATION; EVOLUTION; NEPTUNE; URANUS	The petrology record on the Moon suggests that a cataclysmic spike in the cratering rate occurred similar to 700 million years after the planets formed(1); this event is known as the Late Heavy Bombardment (LHB). Planetary formation theories cannot naturally account for an intense period of planetesimal bombardment so late in Solar System history(2). Several models have been proposed to explain a late impact spike(3-6), but none of them has been set within a self-consistent framework of Solar System evolution. Here we propose that the LHB was triggered by the rapid migration of the giant planets, which occurred after a long quiescent period. During this burst of migration, the planetesimal disk outside the orbits of the planets was destabilized, causing a sudden massive delivery of planetesimals to the inner Solar System. The asteroid belt was also strongly perturbed, with these objects supplying a significant fraction of the LHB impactors in accordance with recent geochemical evidence(7,8). Our model not only naturally explains the LHB, but also reproduces the observational constraints of the outer Solar System(9).	CNRS, Observ Cote Azur, F-06304 Nice, France; MCT, ON, BR-20080090 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, OV, GEA, BR-20080090 Rio de Janeiro, Brazil; SW Res Inst, Dept Space Studies, Boulder, CO USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; Universidade Federal do Rio de Janeiro	Morbidelli, A (corresponding author), CNRS, Observ Cote Azur, BP 4229, F-06304 Nice, France.	morby@obs-nice.fr	Levison, Harold F/C-6061-2013; Tsiganis, Kleomenis/AAF-5316-2020; gomes, rodney/G-8091-2011	Levison, Harold F/0000-0001-5847-8099; Tsiganis, Kleomenis/0000-0003-3334-6190; Gomes, Rodney/0000-0001-5712-3042				Bottke WF, 2005, ICARUS, V175, P111, DOI 10.1016/j.icarus.2004.10.026; CHAMBERS JE, 2002, LUNAR PLANET SCI C, V33; DAVIS DR, 1994, PLANET SPACE SCI, V42, P599, DOI 10.1016/0032-0633(94)90035-3; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Gomes RS, 2004, ICARUS, V170, P492, DOI 10.1016/j.icarus.2004.03.011; Gomes RS, 1997, ASTRON J, V114, P396, DOI 10.1086/118483; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; Haisch KE, 2001, ASTROPHYS J, V553, pL153, DOI 10.1086/320685; Hartmann W. K., 2000, ORIGIN EARTH MOON, P493; Kring DA, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001529; Levison HF, 2001, ICARUS, V151, P286, DOI 10.1006/icar.2001.6608; LEVISON HF, 2005, ASP C SER, V324, P152; Morbidelli A, 2001, METEORIT PLANET SCI, V36, P371, DOI 10.1111/j.1945-5100.2001.tb01880.x; TAGLE R, 2005, LUNAR PLANET SCI C, V36; WETHERILL GW, 1967, J GEOPHYS RES, V72, P2429, DOI 10.1029/JZ072i009p02429; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E; Zappala V, 1998, ICARUS, V134, P176, DOI 10.1006/icar.1998.5946	19	1129	1145	1	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					466	469		10.1038/nature03676	http://dx.doi.org/10.1038/nature03676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917802	Bronze			2022-12-28	WOS:000229337800048
J	Klie, RF; Buban, JP; Varela, M; Franceschetti, A; Jooss, C; Zhu, Y; Browning, ND; Pantelides, ST; Pennycook, SJ				Klie, RF; Buban, JP; Varela, M; Franceschetti, A; Jooss, C; Zhu, Y; Browning, ND; Pantelides, ST; Pennycook, SJ			Enhanced current transport at grain boundaries in high-T-c superconductors	NATURE			English	Article							YBA2CU3O7-DELTA; CALCIUM; DISLOCATIONS; CHARGE	Large-scale applications of high-transition-temperature (high-T-c) superconductors, such as their use in superconducting cables, are impeded by the fact that polycrystalline materials ( the only practical option) support significantly lower current densities than single crystals(1-6). The superconducting critical current density (J(c)) across a grain boundary drops exponentially if the misorientation angle exceeds 2 degrees- 7 degrees. Grain texturing reduces the average misorientation angle, but problems persist(7,8). Adding impurities ( such as Ca in YBa2Cu3O7-delta; YBCO) leads to increased J(c) (refs 9, 10), which is generally attributed to excess holes introduced by Ca2+ substituting for Y3+ (ref. 11). However, a comprehensive physical model for the role of grain boundaries and Ca doping has remained elusive. Here we report calculations, imaging and spectroscopy at the atomic scale that demonstrate that in poly-crystalline YBCO, highly strained grain-boundary regions contain excess O vacancies, which reduce the local hole concentration. The Ca impurities indeed substitute for Y, but in grain-boundary regions under compression and tension they also replace Ba and Cu, relieving strain and suppressing O-vacancy formation. Our results demonstrate that the ionic radii are more important than their electronic valences for enhancing J(c).	Brookhaven Natl Lab, Ctr Funct Nanomat, Upton, NY 11973 USA; Univ Tokyo, Inst Engn Innovat, Tokyo 1138656, Japan; Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA; Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37235 USA; Univ Gottingen, Inst Mat Phys, D-37073 Gottingen, Germany; Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; University of Tokyo; United States Department of Energy (DOE); Oak Ridge National Laboratory; Vanderbilt University; University of Gottingen; University of California System; University of California Davis	Klie, RF (corresponding author), Brookhaven Natl Lab, Ctr Funct Nanomat, Upton, NY 11973 USA.	klie@bnl.gov	Varela, Maria/H-2648-2012; Varela, Maria/E-2472-2014; Pennycook, Stephen/AAA-1112-2019	Varela, Maria/0000-0002-6582-7004; Pennycook, Stephen/0000-0002-3210-6323; Browning, Nigel/0000-0003-0491-251X; Klie, Robert/0000-0003-4773-6667				Allen LJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.105503; Browning ND, 1998, PHYSICA C, V294, P183, DOI 10.1016/S0921-4534(97)01689-4; BROWNING ND, 1993, NATURE, V366, P143, DOI 10.1038/366143a0; Cherns D, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.205504; Daniels GA, 2000, APPL PHYS LETT, V77, P3251, DOI 10.1063/1.1322053; DIMOS D, 1990, PHYS REV B, V41, P4038, DOI 10.1103/PhysRevB.41.4038; Egerton RF, 1986, ELECT ENERGY LOSS SP, DOI [10.1007/978-1-4419-9583-4, DOI 10.1007/978-1-4419-9583-4]; GROSS R, 1991, PHYSICA C, V180, P235, DOI 10.1016/0921-4534(91)90673-M; Gurevich A, 1998, PHYS REV B, V57, P13878, DOI 10.1103/PhysRevB.57.13878; Guth K, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.140508; Hammerl G, 2000, NATURE, V407, P162, DOI 10.1038/35025014; Heinig NF, 1996, APPL PHYS LETT, V69, P577, DOI 10.1063/1.117758; Hilgenkamp H, 2002, REV MOD PHYS, V74, P485, DOI 10.1103/RevModPhys.74.485; IIJIMA Y, 1993, J APPL PHYS, V74, P1905, DOI 10.1063/1.354801; Kim M, 2001, PHYS REV LETT, V86, P4056, DOI 10.1103/PhysRevLett.86.4056; Klie RF, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.214101; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; KUCERA JT, 1995, PHYS REV B, V51, P8582, DOI 10.1103/PhysRevB.51.8582; Kung H, 2001, PHIL MAG LETT, V81, P85, DOI 10.1080/09500830010012506; MANNHART J, 1988, PHYS REV LETT, V61, P2476, DOI 10.1103/PhysRevLett.61.2476; Nellist PD, 2004, SCIENCE, V305, P1741, DOI 10.1126/science.1100965; Norton DP, 1996, SCIENCE, V274, P755, DOI 10.1126/science.274.5288.755; Schmehl A, 1999, EUROPHYS LETT, V47, P110, DOI 10.1209/epl/i1999-00359-2; Schofield MA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.195502; SONG X, UNPUB NATURE MAT; Su HB, 2005, SUPERCOND SCI TECH, V18, P24, DOI 10.1088/0953-2048/18/1/005; Varela M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.095502; ZHU YM, 1994, PHILOS MAG A, V70, P969, DOI 10.1080/01418619408242943	28	155	156	4	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					475	478		10.1038/nature03644	http://dx.doi.org/10.1038/nature03644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917804				2022-12-28	WOS:000229337800050
J	Holmes, MD; Chen, WY; Feskanich, D; Kroenke, CH; Colditz, GA				Holmes, MD; Chen, WY; Feskanich, D; Kroenke, CH; Colditz, GA			Physical activity and survival after breast cancer diagnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; ADJUVANT CHEMOTHERAPY; WEIGHT-GAIN; RISK; EXERCISE; VALIDITY; DISEASE; OBESITY	Context Physical activity has been shown to decrease the incidence of breast cancer, but the effect on recurrence or survival after a breast cancer diagnosis is not known. Objective To determine whether physical activity among women with breast cancer decreases their risk of death from breast cancer compared with more sedentary women. Design, Setting, and Participants Prospective observational study based on responses from 2987 female registered nurses in the Nurses' Health Study who were diagnosed with stage I, II, or III breast cancer between 1984 and 1998 and who were followed up until death or June 2002, whichever came first. Main Outcome Measure Breast cancer mortality risk according to physical activity category (<3, 3-8.9, 9-14.9,15-23.9, or >= 24 metabolic equivalenttask [MET] hours per week). Results Compared with women who engaged in less than 3 MET-hours per week of physical activity, the adjusted relative risk (RR) of death from breast cancer was 0.80 (95% confidence interval [CI], 0.60-1.06) for 3 to 8.9 MET-hours per week; 0.50 (95% Cl, 0.31-0.82) for 9 to 14.9 MET-hours per week; 0.56 (95% Cl, 0.38-0.84) for 15 to 23.9 MET-hours per week; and 0.60 (95% Cl, 0.40-0.89) for 24 or more MET-hours per week (P for trend =.004). Three MET-hours is equivalent to walking at average pace of 2 to 2.9 mph for 1 hour. The benefit of physical activity was particularly apparent among women with hormone-responsive tumors. The RR of breast cancer death for women with hormone-responsive tumors who engaged in 9 or more MET-hours per week of activity compared with women with hormone-responsive tumors who engaged in less than 9 MET-hours per week was 0.50 (95% Cl, 0.34-0.74). Compared with women who engaged in less than 3 MET-hours per week of activity, the absolute unadjusted mortality risk reduction was 6% at 10 years for women who engaged in 9 or more MET-hours per week. Conclusions Physical activity after a breast cancer diagnosis may reduce the risk of death from this disease. The greatest benefit occurred in women who performed the equivalent of walking 3 to 5 hours per week at an average pace, with little evidence of a correlation between increased benefit and greater energy expenditure. Women with breast cancer who follow US physical activity recommendations may improve their survival.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Holmes, MD (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	michelle.holmes@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Holmes, Michelle/0000-0002-8664-2172	NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NCI NIH HHS [CA87969] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Bartelink H, 2001, NEW ENGL J MED, V345, P1378, DOI 10.1056/NEJMoa010874; BASTARRACHEA J, 1994, ANN INTERN MED, V120, P18, DOI 10.7326/0003-4819-120-1-199401010-00004; Bean JF, 2004, ARCH PHYS MED REHAB, V85, pS31, DOI 10.1016/j.apmr.2004.03.010; Bianchini Franca, 2002, Obes Rev, V3, P5, DOI 10.1046/j.1467-789X.2002.00046.x; Blair SN, 2004, AM J CLIN NUTR, V79, P913; BROOCKS A, 1990, J APPL PHYSIOL, V68, P2083, DOI 10.1152/jappl.1990.68.5.2083; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; *CDCP, ACT DO AD NEED BE GA; Chang VT, 1998, CANCER, V83, P173, DOI 10.1002/(SICI)1097-0142(19980701)83:1<173::AID-CNCR23>3.0.CO;2-T; Chlebowski RT, 2002, J CLIN ONCOL, V20, P1128, DOI 10.1200/JCO.20.4.1128; Daling JR, 2001, CANCER, V92, P720, DOI 10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T; Demark-Wahnefried W, 2001, J CLIN ONCOL, V19, P2381, DOI 10.1200/JCO.2001.19.9.2381; DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418; DemarkWahnefried W, 1997, AM J CLIN NUTR, V65, P1495, DOI 10.1093/ajcn/65.5.1495; Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300; Galanis DJ, 1998, CANCER CAUSE CONTROL, V9, P217, DOI 10.1023/A:1008842613331; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Goodwin PJ, 1999, J CLIN ONCOL, V17, P120, DOI 10.1200/JCO.1999.17.1.120; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Holmberg L, 2001, EUR J SURG ONCOL, V27, P152, DOI 10.1053/ejso.2000.1084; Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5&lt;826::AID-CNCR19&gt;3.0.CO;2-0; Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961; Hu FB, 2004, NEW ENGL J MED, V351, P2694, DOI 10.1056/NEJMoa042135; Hu FB, 2001, ANN INTERN MED, V134, P96, DOI 10.7326/0003-4819-134-2-200101160-00009; Irwin ML, 2004, MED SCI SPORT EXER, V36, P1484, DOI 10.1249/01.MSS.0000074670.03001.98; Irwin ML, 2003, CANCER-AM CANCER SOC, V97, P1746, DOI 10.1002/cncr.11227; Jebb SA, 1999, MED SCI SPORT EXER, V31, pS534, DOI 10.1097/00005768-199911001-00008; Kramer JA, 2000, EUR J CANCER, V36, P1498, DOI 10.1016/S0959-8049(00)00144-1; Kroenke CH, 2005, J CLIN ONCOL, V23, P1370, DOI 10.1200/JCO.2005.01.079; Leitzmann MF, 1999, NEW ENGL J MED, V341, P777, DOI 10.1056/NEJM199909093411101; Lonning PE, 1996, BREAST CANCER RES TR, V39, P335, DOI 10.1007/BF01806162; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; Martinez ME, 1997, J NATL CANCER I, V89, P948, DOI 10.1093/jnci/89.13.948; McTiernan A, 2003, J CLIN ONCOL, V21, P1961, DOI 10.1200/JCO.2003.07.057; McTiernan A, 2004, CANCER RES, V64, P2923, DOI 10.1158/0008-5472.CAN-03-3393; Michaud DS, 2001, JAMA-J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921; Newman SC, 1997, INT J EPIDEMIOL, V26, P484, DOI 10.1093/ije/26.3.484; NIEMAN DC, 1994, MED SCI SPORT EXER, V26, P128, DOI 10.1249/00005768-199402000-00002; Obermair A, 1995, ANTICANCER RES, V15, P2265; Pinto BM, 1999, PSYCHO-ONCOL, V8, P191, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<191::AID-PON355>3.3.CO;2-K; Reeves GK, 2000, INT J CANCER, V89, P293, DOI 10.1002/1097-0215(20000520)89:3<293::AID-IJC13>3.0.CO;2-R; Rich-Edwards JW, 2002, EPIDEMIOLOGY, V13, P184, DOI 10.1097/00001648-200203000-00013; Rockhill B, 1999, ARCH INTERN MED, V159, P2290, DOI 10.1001/archinte.159.19.2290; Rockhill B, 2001, AM J PUBLIC HEALTH, V91, P578, DOI 10.2105/AJPH.91.4.578; ROHAN TE, 1995, EUR J CANCER PREV, V4, P419, DOI 10.1097/00008469-199510000-00010; RUTQVIST LE, 1985, ACTA RADIOL ONCOL, V24, P385, DOI 10.3109/02841868509134405; Sathiakumar N, 1998, J OCCUP ENVIRON MED, V40, P808, DOI 10.1097/00043764-199809000-00010; Sesso HD, 1998, CANCER CAUSE CONTROL, V9, P433, DOI 10.1023/A:1008827903302; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Steindorf K, 2003, AM J EPIDEMIOL, V157, P121, DOI 10.1093/aje/kwf181; Taylor AH, 2004, J SPORT SCI, V22, P703, DOI 10.1080/02640410410001712421; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; ZHANG SM, 1995, CANCER, V76, P275, DOI 10.1002/1097-0142(19950715)76:2<275::AID-CNCR2820760218>3.0.CO;2-6	57	1174	1196	5	109	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2479	2486		10.1001/jama.293.20.2479	http://dx.doi.org/10.1001/jama.293.20.2479			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929BX	15914748	Bronze			2022-12-28	WOS:000229318200022
J	Kupfer, DJ				Kupfer, DJ			The increasing medical burden in bipolar disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MOOD DISORDERS; MAJOR DEPRESSION; I DISORDER; OBESITY; ILLNESS; EPIDEMIOLOGY; MORTALITY; RISK		Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	Kupfer, DJ (corresponding author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.	kupferdj@upmc.edu						Angst F, 2002, J AFFECT DISORDERS, V68, P167, DOI 10.1016/S0165-0327(01)00377-9; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Baldessarini RJ, 2003, JAMA-J AM MED ASSOC, V290, P1517, DOI 10.1001/jama.290.11.1517; Das AK, 2005, JAMA-J AM MED ASSOC, V293, P956, DOI 10.1001/jama.293.8.956; Evans DL, 2003, BIOL PSYCHIAT, V54, P177, DOI 10.1016/S0006-3223(03)00639-5; Fagiolini A, 2003, AM J PSYCHIAT, V160, P112, DOI 10.1176/appi.ajp.160.1.112; Fagiolini A, 2002, J CLIN PSYCHIAT, V63, P528, DOI 10.4088/JCP.v63n0611; FRANK E, IN PRESS ARCH GEN PS; Joynt KE, 2003, BIOL PSYCHIAT, V54, P248, DOI 10.1016/S0006-3223(03)00568-7; Katon WJ, 2003, BIOL PSYCHIAT, V54, P216, DOI 10.1016/S0006-3223(03)00273-7; Kilbourne AM, 2004, BIPOLAR DISORD, V6, P368, DOI 10.1111/j.1399-5618.2004.00138.x; Krishnan KRR, 2005, PSYCHOSOM MED, V67, P1, DOI 10.1097/01.psy.0000151489.36347.18; Malkoff-Schwartz S, 2000, PSYCHOL MED, V30, P1005, DOI 10.1017/S0033291799002706; Manson JE, 2003, JAMA-J AM MED ASSOC, V289, P229, DOI 10.1001/jama.289.2.229; McElroy SL, 2004, J CLIN PSYCHIAT, V65, P634; Musselman DL, 2003, BIOL PSYCHIAT, V54, P317, DOI 10.1016/S0006-3223(03)00569-9; Osby U, 2001, ARCH GEN PSYCHIAT, V58, P844, DOI 10.1001/archpsyc.58.9.844; Peele PB, 2003, AM J PSYCHIAT, V160, P1286, DOI 10.1176/appi.ajp.160.7.1286; Pi-Sunyer FX, 2002, OBES SURG, V12, p6S, DOI 10.3810/pgm.2009.11.2074; Simon GE, 1999, PSYCHIATR SERV, V50, P1303, DOI 10.1176/ps.50.10.1303; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Wilson PWF, 2002, ARCH INTERN MED, V162, P1867, DOI 10.1001/archinte.162.16.1867; WYATT RJ, 1995, SOC PSYCH PSYCH EPID, V30, P213	23	346	356	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2528	2530		10.1001/jama.293.20.2528	http://dx.doi.org/10.1001/jama.293.20.2528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	929BX	15914754				2022-12-28	WOS:000229318200028
J	Quesenberry, PJ; Dooner, G; Dooner, M; Abedi, M				Quesenberry, PJ; Dooner, G; Dooner, M; Abedi, M			Ignoratio elenchi: Red herrings stem cell research	SCIENCE			English	Editorial Material							BONE-MARROW-CELLS; PLASTICITY; TRANSDIFFERENTIATE		Ctr Stem Cell Biol, Dept Res, Providence, RI 02908 USA		Quesenberry, PJ (corresponding author), Ctr Stem Cell Biol, Dept Res, Providence, RI 02908 USA.	pquesenberry@rwmc.org	Abedi, Mehrdad/ABC-3565-2021	Dooner, Mark/0000-0003-0653-6562				Abedi M, 2004, EXP HEMATOL, V32, P426, DOI 10.1016/j.exphem.2004.02.007; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; COLVIN GA, 2004, BLOOD, V104; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Keating A, 2005, BIOL BLOOD MARROW TR, V11, P2, DOI 10.1016/j.bbmt.2004.11.002; Kogler G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lemischka I, 2002, EXP HEMATOL, V30, P848, DOI 10.1016/S0301-472X(02)00876-7; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wagers AJ, 2003, SCIENCE, V299, p1317B, DOI 10.1126/science.1079110	14	25	26	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1121	1122		10.1126/science.1104432	http://dx.doi.org/10.1126/science.1104432			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905387				2022-12-28	WOS:000229293400028
J	Nalbant, SS; Steacy, S; Sieh, K; Natawidjaja, D; McCloskey, J				Nalbant, SS; Steacy, S; Sieh, K; Natawidjaja, D; McCloskey, J			Earthquake risk on the Sunda trench	NATURE			English	Article									Univ Ulster, Sch Environm Sci, Coleraine BT52 1SA, Londonderry, North Ireland; CALTECH, Tecton Observ, Pasadena, CA 91125 USA	Ulster University; California Institute of Technology	Nalbant, SS (corresponding author), Univ Ulster, Sch Environm Sci, Coleraine BT52 1SA, Londonderry, North Ireland.	j.mccloskey@ulster.ac.uk	Steacy, Sandy/AAB-1173-2020	Steacy, Sandy/0000-0001-8606-3296; Nalbant, Suleyman Sami/0000-0002-7944-5912				McCloskey J, 2005, NATURE, V434, P291, DOI 10.1038/434291a; Natawidjaja DH, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002398; NEWCOMB KR, 1987, J GEOPHYS RES-SOLID, V92, P421, DOI 10.1029/JB092iB01p00421; Pollitz FF, 1997, B SEISMOL SOC AM, V87, P1; Pollitz FF, 1998, SCIENCE, V280, P1245, DOI 10.1126/science.280.5367.1245; Rivera L, 2002, B SEISMOL SOC AM, V92, P1721, DOI 10.1785/0120010106; SIEH K, 2005, EOS T AGU, V85; Stein RS, 1997, GEOPHYS J INT, V128, P594, DOI 10.1111/j.1365-246X.1997.tb05321.x	8	117	121	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					756	757		10.1038/nature435756a	http://dx.doi.org/10.1038/nature435756a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944691	Green Published			2022-12-28	WOS:000229638700037
J	Hopewell, PC; Pai, M				Hopewell, PC; Pai, M			Tuberculosis, vulnerability, and access to quality care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GENERAL-PRACTITIONERS; HIV/AIDS INFECTION; HEALTH; INDIA; DIAGNOSIS; MALARIA; DOCTORS; DISEASE; LEVEL; CHINA		Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, Francis J Curry Natl TB Ctr, San Francisco, CA 94110 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Hopewell, PC (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm & Crit Care Med, Francis J Curry Natl TB Ctr, 1001 Potrero Ave,Room 5K1, San Francisco, CA 94110 USA.	phopewell@medsfgh.ucsf.edu	PAL, MRINAL/ABG-9676-2020; Pai, Madhukar/AAX-9901-2021	PAL, MRINAL/0000-0002-1032-272X; Pai, Madhukar/0000-0003-3667-4536	FIC NIH HHS [1-D43-TW00003-16] Funding Source: Medline; NIAID NIH HHS [R01 AI 34238] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bates I, 2004, LANCET INFECT DIS, V4, P267, DOI 10.1016/S1473-3099(04)01002-3; Bates L, 2004, LANCET INFECT DIS, V4, P368, DOI 10.1016/S1473-3099(04)01047-3; Chen XY, 2004, LANCET, V364, P417; Cheng G, 2005, T ROY SOC TROP MED H, V99, P355, DOI 10.1016/j.trstmh.2004.07.005; Drobniewski F, 2005, JAMA-J AM MED ASSOC, V293, P2726, DOI 10.1001/jama.293.22.2726; Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767; Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719; Haddad MB, 2005, JAMA-J AM MED ASSOC, V293, P2762, DOI 10.1001/jama.293.22.2762; Hadley M, 2000, INT J TUBERC LUNG D, V4, P401; Lonnroth K, 1999, INT J TUBERC LUNG D, V3, P992; Olle-Goig JE, 1999, INT J TUBERC LUNG D, V3, P74; Prasad R, 2003, INT J TUBERC LUNG D, V7, P52; Shah S K, 2003, East Mediterr Health J, V9, P776; Singla N, 1998, INT J TUBERC LUNG D, V2, P384; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; Suleiman B A, 2003, East Mediterr Health J, V9, P789; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; UPLEKAR MW, 1991, TUBERCLE, V72, P284, DOI 10.1016/0041-3879(91)90055-W; *WHO, 2005, GLOB TUB CONTR SURV; World Health Organization, 2001, INV PRIV PRACT TUB C	20	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2790	2793		10.1001/jama.293.22.2790	http://dx.doi.org/10.1001/jama.293.22.2790			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941811				2022-12-28	WOS:000229643700030
J	Dulac, C				Dulac, C			Sex and the single splice	CELL			English	Editorial Material							MICE; DROSOPHILA; BEHAVIORS; TRP2	Drosophila male courtship offers a unique experimental system to uncover the molecular and neural basis of genetically preprogrammed behavior. In this issue of Cell, Demir and Dickson (2005) and Stockinger et al. (2005) demonstrate that this behavior relies on a single splicing of the fruitless transcript, and. on a specific olfactory-based neuronal circuit.	Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Dulac, C (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, Cambridge, MA 02138 USA.			Dulac, Catherine/0000-0001-5024-5418				Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Demirov E, 2002, J MARINE SYST, V33, P23, DOI 10.1016/S0924-7963(02)00051-9; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; Stockinger P, 2005, CELL, V121, P795, DOI 10.1016/j.cell.2005.04.026; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Usui-Aoki K, 2000, NAT CELL BIOL, V2, P500, DOI 10.1038/35019537	8	9	9	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 3	2005	121	5					664	666		10.1016/j.cell.2005.05.017	http://dx.doi.org/10.1016/j.cell.2005.05.017			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935752	Bronze			2022-12-28	WOS:000229658000004
J	Andraws, R; Berger, JS; Brown, DL				Andraws, R; Berger, JS; Brown, DL			Effects of antibiotic therapy on outcomes of patients with coronary artery disease - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CHLAMYDIA-PNEUMONIAE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; HELICOBACTER-PYLORI; HEART-DISEASE; ATHEROSCLEROSIS; AZITHROMYCIN; EVENTS; INFECTION; ASSOCIATION	Context Although Chlamydia pneumoniae infection has been associated with the initiation and progression of atherosclerosis, results of clinical trials investigating antichlamydial antibiotics as adjuncts to standard therapy in patients with coronary artery disease (CAD) have been inconsistent. Objective To conduct a meta-analysis of clinical trials of antichlamydial antibiotic therapy in patients with CAD. Data Sources The MEDLINE and Cochrane Central Register of Controlled Trials databases were searched from 1966 to April 2005 for English-language trials of antibiotic therapy in patients with CAD. Bibliographies of retrieved articles were searched for further studies. Presentations at major scientific meetings (2003-2004) were also reviewed. Search terms included antibacterial agents, myocardial infarction, unstable angina, and coronary arteriosclerosis. Study Selection Eligible studies were prospective, randomized, placebo-controlled trials of antichlamydial antibiotic therapy in patients with CAD that reported all-cause mortality, myocardial infarction, or unstable angina. Of the 110 potentially relevant articles identified, 11 reports enrolling 19 217 patients were included. Data Extraction Included studies were reviewed to determine the number of patients randomized, mean duration of follow-up, and end points. End points of interest included all-cause mortality, myocardial infarction (MI), and a combined end point of MI and unstable angina. Data Synthesis Event rates were combined using a random-effects model. Antibiotic therapy had no impact on all-cause mortality among treated vs untreated patients (4.7% vs 4.6%; odds ratio [OR], 1.02; 95% confidence interval [CI], 0.89-.16; P=.83), on the rates of MI (5.0% vs 5.4%; OR, 0.92; 95% CI, 0.81-1.04; P=.19), or on the combined end point of MI and unstable angina (9.2% vs 9.6%; OR, 0.91; 95% CI, 0.76-1.07; P=.25). Conclusion Evidence available to date does not demonstrate an overall benefit of antibiotic therapy in reducing mortality or cardiovascular events in patients with CAD.	SUNY Stony Brook, Sch Med, Hlth Sci Ctr T16 080, Div Cardiovasc Med, Stony Brook, NY 11794 USA; Beth Israel Deaconess Med Ctr, Dept Med, New York, NY 10003 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Beth Israel Deaconess Medical Center	Brown, DL (corresponding author), SUNY Stony Brook, Sch Med, Hlth Sci Ctr T16 080, Div Cardiovasc Med, Stony Brook, NY 11794 USA.	david.brown@stonybrook.edu		Berger, Jeffrey/0000-0001-8216-4647				Alber DG, 2000, CIRCULATION, V102, P779, DOI 10.1161/01.CIR.102.7.779; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Cannon CP, 2005, NEW ENGL J MED, V352, P1646, DOI 10.1056/NEJMoa043528; Cercek B, 2003, LANCET, V361, P809, DOI 10.1016/S0140-6736(03)12706-7; Espinola-Klein C, 2002, CIRCULATION, V105, P15, DOI 10.1161/hc0102.101362; Forrester JS, 2002, ANN INTERN MED, V137, P823, DOI 10.7326/0003-4819-137-10-200211190-00012; Grahame-Clarke C, 2003, CIRCULATION, V108, P678, DOI 10.1161/01.CIR.0000084505.54603.C7; Grayston JT, 2005, NEW ENGL J MED, V352, P1637, DOI 10.1056/NEJMoa043526; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; Higgins JP, 2003, MAYO CLIN PROC, V78, P321, DOI 10.4065/78.3.321; Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156; JACKSON LA, 2000, PRINCIPLES PRACTICE, P2007; Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724; Kalayoglu MV, 2000, J INFECT DIS, V181, pS483, DOI 10.1086/315619; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Leowattana Wattana, 2001, Journal of the Medical Association of Thailand, V84, pS669; Li L, 2002, CIRCULATION, V105, P861, DOI 10.1161/hc0702.104178; Libby P, 1997, CIRCULATION, V96, P4095; Maitra SR, 2003, SHOCK, V20, P280, DOI 10.1097/00024382-200309000-00014; Martin D, 1998, LANCET, V351, P1858, DOI 10.1016/S0140-6736(05)78804-8; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; Meier CR, 2000, J INFECT DIS, V181, pS558, DOI 10.1086/315632; MOAZED TC, 2000, J INFECT DIS S3, V181, pS1322; Muhlestein JB, 2000, CIRCULATION, V102, P1755; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; O'Connor CM, 2003, JAMA-J AM MED ASSOC, V290, P1459, DOI 10.1001/jama.290.11.1459; Parchure N, 2002, CIRCULATION, V105, P1298, DOI 10.1161/hc1102.105649; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saikku P, 2000, J INFECT DIS, V181, pS411, DOI 10.1086/315625; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Sander D, 2002, CIRCULATION, V106, P2428, DOI 10.1161/01.CIR.0000036748.26775.8D; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shimoyama T, 1998, GUT, V43, pS2; Sinisalo J, 2002, CIRCULATION, V105, P1555, DOI 10.1161/01.CIR.0000012544.07696.1F; Stone AFM, 2002, CIRCULATION, V106, P1219, DOI 10.1161/01.CIR.0000027820.66786.CF; Summersgill JT, 2000, J INFECT DIS, V181, pS479, DOI 10.1086/315620; Taylor-Robinson D, 2000, J INFECT DIS, V181, pS437, DOI 10.1086/315614; Torgano G, 1999, CIRCULATION, V99, P1555, DOI 10.1161/01.CIR.99.12.1555; Tousoulis D, 2003, HEART, V89, P993, DOI 10.1136/heart.89.9.993; Zahn R, 2003, CIRCULATION, V107, P1253, DOI 10.1161/01.CIR.0000054613.57105.06; Zhu JH, 2001, CIRCULATION, V103, P45	44	156	162	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2641	2647		10.1001/jama.293.21.2641	http://dx.doi.org/10.1001/jama.293.21.2641			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930UU	15928286				2022-12-28	WOS:000229443400023
J	De Angelis, C; Drazen, JM; Frizelle, FA; Haug, C; Hoey, J; Horton, R; Kotzin, S; Laine, C; Marusic, A; Overbeke, AJPM; Schroeder, TV; Sox, HC; Van der Weyden, MB				De Angelis, C; Drazen, JM; Frizelle, FA; Haug, C; Hoey, J; Horton, R; Kotzin, S; Laine, C; Marusic, A; Overbeke, AJPM; Schroeder, TV; Sox, HC; Van der Weyden, MB			Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors	LANCET			English	Editorial Material									Natl Lib Med, MEDLINE, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)			Drazen, Jeffrey M/E-5841-2012; Marusic, Ana/E-7683-2013	Marusic, Ana/0000-0001-6272-0917; Schroeder, Torben/0000-0002-9827-9438				*CTR DRUG EV RES, 2002, GUID IND INF PROGR C; De Angelis C, 2004, LANCET, V364, P911, DOI 10.1016/S0140-6736(04)17034-7	2	62	62	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1827	1829		10.1016/S0140-6736(05)66588-9	http://dx.doi.org/10.1016/S0140-6736(05)66588-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924965				2022-12-28	WOS:000229481400004
J	Nowotny, H				Nowotny, H			High- and low-cost realities for science and society	SCIENCE			English	Editorial Material												helga.novvotny@wzw.at						Appadurai A., 2004, CULTURE PUBLIC ACTIO, P59, DOI DOI 10.1596/0-8047-4787-3; Crichton M., 2004, STATE FEAR; Diamond J., 2004, COLLAPSE SOC CHOOSE; Ezrahi Y., 2004, STATES KNOWLEDGE COP, P254; FEYNMAN RP, 1986, QED STRANGE THEORY L, P10; HIGHFIELD R, 2003, H POTTER MAGIC REALL; Leshner AI, 2005, SCIENCE, V307, P815, DOI 10.1126/science.1110260; Nowotny H, 2005, PUBLIC NATURE OF SCIENCE UNDER ASSAULT: POLITICS, MARKETS, SCIENCE AND THE LAW, P1; WEINBERGER P, 2005, FALTER          0216, P14; 2005, NATURE, V433, P179	10	13	13	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1117	1118		10.1126/science.1113825	http://dx.doi.org/10.1126/science.1113825			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905384				2022-12-28	WOS:000229293400025
J	Tellinghuisen, TL; Marcotrigiano, J; Rice, CM				Tellinghuisen, TL; Marcotrigiano, J; Rice, CM			Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase	NATURE			English	Article							PROTEIN; NS5A; BOND	Hepatitis C virus (HCV) is a human pathogen affecting nearly 3% of the world's population(1). Chronic infections can lead to cirrhosis and liver cancer. The RNA replication machine of HCV is a multi-subunit membrane-associated complex. The nonstructural protein NS5A is an active component of HCV replicase(2,3), as well as a pivotal regulator of replication(2,4) and a modulator of cellular processes ranging from innate immunity to dysregulated cell growth(5,6). NS5A is a large phosphoprotein (56 - 58 kDa) with an amphipathic alpha-helix at its amino terminus that promotes membrane association(7-9). After this helix region, NS5A is organized into three domains(10). The N-terminal domain ( domain I) coordinates a single zinc atom per protein molecule(10). Mutations disrupting either the membrane anchor(7,8) or zinc binding(10) of NS5A are lethal for RNA replication. However, probing the role of NS5A in replication has been hampered by a lack of structural information about this multifunctional protein. Here we report the structure of NS5A domain I at 2.5-angstrom resolution, which contains a novel fold, a new zinc-coordination motif and a disulphide bond. We use molecular surface analysis to suggest the location of protein-, RNA- and membrane-interaction sites.	Rockefeller Univ, Ctr Study Hepatitis C, Lab Virol & Infect Dis, New York, NY 10021 USA	Rockefeller University	Marcotrigiano, J (corresponding author), Rockefeller Univ, Ctr Study Hepatitis C, Lab Virol & Infect Dis, 1230 York Ave Box 64, New York, NY 10021 USA.	marcotj@rockefeller.edu; ricec@rockefeller.edu	Marcotrigiano, Joseph/K-6697-2016	Marcotrigiano, Joseph/0000-0003-0346-3353	NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057973] Funding Source: Medline; NIAID NIH HHS [F32 AI051820] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Elazar M, 2003, J VIROL, V77, P6055, DOI 10.1128/JVI.77.10.6055-6061.2003; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huang LY, 2004, PROTEIN EXPRES PURIF, V37, P144, DOI 10.1016/j.pep.2004.05.005; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200; Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P341	28	372	405	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					374	379		10.1038/nature03580	http://dx.doi.org/10.1038/nature03580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902263	Green Accepted			2022-12-28	WOS:000229185000051
J	Hwang, WS; Roh, SI; Lee, BC; Kang, SK; Kwon, DK; Kim, S; Kim, SJ; Park, SW; Kwon, HS; Lee, CK; Lee, JB; Kim, JM; Ahn, C; Paek, SH; Chang, SS; Koo, JJ; Yoon, HS; Hwang, JH; Hwang, YY; Park, YS; Oh, SK; Kim, HS; Park, JH; Moon, SY; Schatten, G				Hwang, WS; Roh, SI; Lee, BC; Kang, SK; Kwon, DK; Kim, S; Kim, SJ; Park, SW; Kwon, HS; Lee, CK; Lee, JB; Kim, JM; Ahn, C; Paek, SH; Chang, SS; Koo, JJ; Yoon, HS; Hwang, JH; Hwang, YY; Park, YS; Oh, SK; Kim, HS; Park, JH; Moon, SY; Schatten, G			RETRACTED: Patient-specific embryonic stem cells derived from human SCNT blastocysts (Retracted Article. See vol 311, pg 335, 2006)	SCIENCE			English	Article; Retracted Publication							NUCLEAR TRANSFER; CENTROSOME; LINES; DERIVATION; DEFECTS; SCIENCE; PROTEIN; CLONING; FETAL; MICE	Patient-specific, immune-matched human embryonic stem cells (hESCs) are anticipated to be of great biomedical importance for studies of disease and development and to advance clinical deliberations regarding stem cell transplantation. Eleven hESC lines were established by somatic cell nuclear transfer (SCNT) of skin cells from patients with disease or injury into donated oocytes. These lines, nuclear transfer (NT)-hESCs, grown on human feeders from the same NT donor or from genetically unrelated individuals, were established at high rates, regardless of NT donor sex or age. NT-hESCs were pluripotent, chromosomally normal, and matched the NT patient's DNA. The major histocompatibility complex identity of each NT-hESC when compared to the patient's own showed immunological compatibility, which is important for eventual transplantation. With the generation of these NT-hESCs, evaluations of genetic and epigenetic stability can be made. Additional work remains to be done regarding the development of reliable directed differentiation and the elimination of remaining animal components. Before clinical use of these cells can occur, preclinical evidence is required to prove that transplantation of differentiated NT-hESCs can be safe, effective, and tolerated.	Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; MizMed Hosp, Med Res Ctr, Seoul 135280, South Korea; Seoul Natl Univ, Coll Med, Seoul 110744, South Korea; Hanna Womens Clin, Seoul 137872, South Korea; Hanyang Univ, Sch Med, Seoul 471701, South Korea; Univ Pittsburgh, Sch Med, Pittsburgh Dev Ctr, Magee Womens Res Inst,Dept Obstet Gynecol & Repro, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hwang, WS (corresponding author), Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea.	hwangws@snu.ac.kr; gschatten@pdc.magee.edu	Ahn, Curie/J-5527-2012; Schatten, Gerald/B-3253-2009	Schatten, Gerald/0000-0001-5206-7782				Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Drukker M, 2004, TRENDS BIOTECHNOL, V22, P136, DOI 10.1016/j.tibtech.2004.01.003; Gardner DK, 2004, FERTIL STERIL, V81, P551, DOI 10.1016/j.fertnstert.2003.07.023; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304; Kim SJ, 2005, MOL CELLS, V19, P46; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lanasa MC, 2000, SEMIN REPROD MED, V18, P97, DOI 10.1055/s-2000-13480; Lee GS, 2005, THERIOGENOLOGY, V63, P973, DOI 10.1016/j.theriogenology.2004.04.017; Lindvall O, 2003, P NATL ACAD SCI USA, V100, P7430, DOI 10.1073/pnas.1332673100; Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181; Navara CS, 1996, P NATL ACAD SCI USA, V93, P5384, DOI 10.1073/pnas.93.11.5384; Nolen LD, 2005, DEV BIOL, V279, P525, DOI 10.1016/j.ydbio.2005.01.016; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Rothstein JD, 2004, NAT BIOTECHNOL, V22, P283, DOI 10.1038/nbt0304-283; RUGGGUNN RJ, 2005, IN PRESS NAT GE 0501; Schatten G, 2003, SCIENCE, V299, P344; Semple JI, 2003, GENE, V314, P41, DOI 10.1016/S0378-1119(03)00735-2; Senda S, 2004, BIOCHEM BIOPH RES CO, V321, P38, DOI 10.1016/j.bbrc.2004.06.096; Simerly C, 2004, DEV BIOL, V276, P237, DOI 10.1016/j.ydbio.2004.10.006; SIMERLY C, 1995, NAT MED, V1, P47, DOI 10.1038/nm0195-47; St John JC, 2004, GENETICS, V167, P897, DOI 10.1534/genetics.103.025049; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	29	310	332	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1777	1783		10.1126/science.1112286	http://dx.doi.org/10.1126/science.1112286			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15905366				2022-12-28	WOS:000229926800052
J	Blankensteijn, JD; de Jong, SECA; Prinssen, M; van der Ham, AC; Buth, J; van Sterkenburg, SMM; Verhagen, HJM; Buskens, E; Grobbee, DE				Blankensteijn, JD; de Jong, SECA; Prinssen, M; van der Ham, AC; Buth, J; van Sterkenburg, SMM; Verhagen, HJM; Buskens, E; Grobbee, DE		DREAM Trial Grp	Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGERY; TERM; TRIAL; ASSOCIATION; MANAGEMENT; STANDARDS; MORTALITY; SURVIVAL	BACKGROUND: Two randomized trials have shown better outcomes with elective endovascular repair of abdominal aortic aneurysms than with conventional open repair in the first month after the procedure. We investigated whether this advantage is sustained beyond the perioperative period. METHODS: We conducted a multicenter, randomized trial comparing open repair with endovascular repair in 351 patients who had received a diagnosis of abdominal aortic aneurysm of at least 5 cm in diameter and who were considered suitable candidates for both techniques. Survival after randomization was calculated with the use of Kaplan-Meier analysis and compared with the use of the log-rank test on an intention-to-treat-basis. RESULTS: Two years after randomization, the cumulative survival rates were 89.6 percent for open repair and 89.7 percent for endovascular repair (difference, -0.1 percentage point; 95 percent confidence interval, -6.8 to 6.7 percentage points). The cumulative rates of aneurysm-related death were 5.7 percent for open repair and 2.1 percent for endovascular repair (difference, 3.7 percentage points; 95 percent confidence interval, -0.5 to 7.9 percentage points). This advantage of endovascular repair over open repair was entirely accounted for by events occurring in the perioperative period, with no significant difference in subsequent aneurysm-related mortality. The rate of survival free of moderate or severe complications was also similar in the two groups at two years (at 65.9 percent for open repair and 65.6 percent for endovascular repair; difference, 0.3 percentage point; 95 percent confidence interval, -10.0 to 10.6 percentage points). CONCLUSIONS: The perioperative survival advantage with endovascular repair as compared with open repair is not sustained after the first postoperative year.	Radboud Univ Nijmegen Med Ctr, Dept Vasc Surg, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr, Dept Surg, Div Vasc Surg, Utrecht, Netherlands; Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; St Franciscus Gasthuis, Dept Surg, Rotterdam, Netherlands; Catharina Hosp, Dept Surg, Eindhoven, Netherlands; Rijnstate Hosp, Dept Surg, Arnhem, Netherlands	Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Franciscus Gasthuis; Catharina Hospital; Rijnstate Hospital	Blankensteijn, JD (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Vasc Surg 410, POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.blankensteijn@chir.umcn.nl	Blankensteijn, Jan D/Q-9291-2016; Grobbee, Diederick/C-7651-2014	Blankensteijn, Jan D/0000-0002-2062-8749; Grobbee, Diederick/0000-0003-4472-4468				Brady AR, 2002, NEW ENGL J MED, V346, P1445; Cao P, 2004, J VASC SURG, V40, P841, DOI 10.1016/j.jvs.2004.08.040; Chaikof EL, 2002, J VASC SURG, V35, P1048, DOI 10.1067/mva.2002.123763; Eagle KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/hc1002.104956; Goueffic Y, 2005, J ENDOVASC THER, V12, P47, DOI 10.1583/04-1331R.1; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; Kertai MD, 2004, AM J MED, V116, P96, DOI 10.1016/j.amjmed.2003.08.029; Kertai MD, 2003, ARCH INTERN MED, V163, P2230, DOI 10.1001/archinte.163.18.2230; Lederle FA, 2004, NEW ENGL J MED, V351, P1677, DOI 10.1056/NEJMe048258; Maher MM, 2003, RADIOLOGY, V228, P647, DOI 10.1148/radiol.2283012185; Norman PE, 1998, BMJ-BRIT MED J, V317, P852, DOI 10.1136/bmj.317.7162.852; Prinssen M, 2002, J CARDIOVASC SURG, V43, P379; Prinssen M, 2004, NEW ENGL J MED, V351, P1607, DOI 10.1056/NEJMoa042002; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; Rutherford RB, 2001, J VASC SURG, V33, P805; Zarins CK, 2004, J CARDIOVASC SURG, V45, P321	17	709	763	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2398	2405		10.1056/NEJMoa051255	http://dx.doi.org/10.1056/NEJMoa051255			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944424	Green Published, Bronze			2022-12-28	WOS:000229638900006
J	Geng, E; Kreiswirth, B; Burzynski, J; Schluger, NW				Geng, E; Kreiswirth, B; Burzynski, J; Schluger, NW			Clinical and radiographic correlates of primary and reactivation tuberculosis - A molecular epidemiology study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; COMPLEX STRAINS; SAN-FRANCISCO; TRANSMISSION; INFECTION; MANIFESTATIONS; IS6110	Context The traditional teaching that pulmonary tuberculosis characterized by lymphadencipathy, effusions, and lower or mid lung zone infiltrates on chest radiography represents "primary" disease from recently acquired infection, whereas upper lobe infiltrates and cavities represent secondary or reactivation disease acquired in the more distant past, is not based on well-established clinical evidence. Furthermore, it is not known whether the atypical radiograph common in human immunodeficiency virus (HIV)-associated tuberculosis is due to a preponderance of primary progressive disease or altered immunity. Objective To analyze the relationship between recently acquired and remotely acquired pulmonary tuberculosis, clinical and demographic variables, and radiographic features by using molecular fingerprinting and conventional epidemiology. Design, Setting, and Population A retrospective, hospital-based series of 456 patients treated at a New York City medical center between 1990 and 1999. Eligible patients had to have had at least 1 positive respiratory culture for Mycobacterium tuberculosis and available radiographic data. Main Outcome Measures Radiographic appearance as measured by the presence or absence of 6 features: upper lobe infiltrate, cavitary lesion, adenopathy, effusions, lower or mid lung zone infiltrate, and miliary pattern. Radiographs were considered typical if they had an upper lobe infiltrate or cavity whether or not other features were present. Atypical radiographs were those that had adenopathy, effusion, or mid lower lung zone infiltrates or had none of the above features. Results Human immunodeficiency virus infection was most commonly associated with an atypical radiographic appearance on chest radiograph with an odds ratio of 0.20 (95% confidence interval, 0.13-0.31). Although a clustered fingerprint, representing recently acquired disease, was associated with typical radiograph in univariate analysis (odds ratio, 0.68; 95% confidence interval, 0.47-0.99), the association was lost when adjusted for HIV status. Conclusions Time from acquisition of infection to development of clinical disease does not reliably predict the, radiographic appearance of tuberculosis. Human immunodeficiency virus status, a probable surrogate for the integrity of the host immune response, is the only independent predictor of radiographic appearance. The altered radiographic appearance of pulmonary tuberculosis in HIV is due to altered immunity rather than recent acquisition of infection and progression to active disease.	Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA; Publ Hlth Res Inst, Newark, NJ USA; New York City Dept Hlth, TB Control Program, New York, NY 10013 USA	Columbia University; Columbia University; New York City Department of Health & Mental Hygiene	Schluger, NW (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg, 630 W 168th St PH-8 E, New York, NY 10032 USA.	ns311@columbia.edu			NHLBI NIH HHS [K24 HL004074] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004074] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; Bauer J, 1999, J CLIN MICROBIOL, V37, P2602, DOI 10.1128/JCM.37.8.2602-2606.1999; Burgos M, 2003, J INFECT DIS, V188, P1878, DOI 10.1086/379895; CHOYKE PL, 1983, RADIOLOGY, V148, P357, DOI 10.1148/radiology.148.2.6867325; Daley CL, 1995, TUBERCLE LUNG DIS, V76, P475, DOI 10.1016/0962-8479(95)90520-0; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FARMAN DP, 1986, CHEST, V89, P75, DOI 10.1378/chest.89.1.75; FRASER RS, 1999, FRASER PARES DIAGNOS, P798; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; Geng E, 2002, NEW ENGL J MED, V346, P1453, DOI 10.1056/NEJMoa012972; Glynn JR, 1999, INT J TUBERC LUNG D, V3, P1055; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Jones BE, 1997, AM J RESP CRIT CARE, V156, P1270, DOI 10.1164/ajrccm.156.4.9609143; Kremer K, 1999, J CLIN MICROBIOL, V37, P2607, DOI 10.1128/JCM.37.8.2607-2618.1999; Murray M, 2002, AM J EPIDEMIOL, V155, P565, DOI 10.1093/aje/155.6.565; Ong A, 2004, CLIN INFECT DIS, V38, P25, DOI 10.1086/380448; Perlman DC, 1997, CLIN INFECT DIS, V25, P242, DOI 10.1086/514546; Post FA, 1995, TUBERCLE LUNG DIS, V76, P518, DOI 10.1016/0962-8479(95)90527-8; Rizzi EB, 2004, EUR J RADIOL, V52, P170, DOI 10.1016/j.ejrad.2004.04.007; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Soini H, 2001, J CLIN MICROBIOL, V39, P217, DOI 10.1128/JCM.39.1.217-221.2001; van Soolingen D, 2001, J INTERN MED, V249, P1, DOI 10.1046/j.1365-2796.2001.00772.x; WOODRING JH, 1986, AM J ROENTGENOL, V146, P497, DOI 10.2214/ajr.146.3.497	26	125	130	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2740	2745		10.1001/jama.293.22.2740	http://dx.doi.org/10.1001/jama.293.22.2740			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941803	Bronze			2022-12-28	WOS:000229643700022
J	Bridgens, R				Bridgens, R			Commentary: Postpolio syndrome - "We aren't dead yet"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Cardiff UJniv, Sch Social Sci, Cardiff CF10 3WT, Wales	Cardiff University	Bridgens, R (corresponding author), Cardiff UJniv, Sch Social Sci, Cardiff CF10 3WT, Wales.	bridgensr@cardiff.ac.uk						Howard RS, 2005, BMJ-BRIT MED J, V330, P1314, DOI 10.1136/bmj.330.7503.1314	1	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1318	1319		10.1136/bmj.330.7503.1318	http://dx.doi.org/10.1136/bmj.330.7503.1318			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933356	Green Published			2022-12-28	WOS:000229655700027
J	Branas, CC; MacKenzie, EJ; Williams, JC; Schwab, CW; Teter, HM; Flanigan, MC; Blatt, AJ; ReVelle, CS				Branas, CC; MacKenzie, EJ; Williams, JC; Schwab, CW; Teter, HM; Flanigan, MC; Blatt, AJ; ReVelle, CS			Access to trauma centers in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJURED PATIENTS; TRAVEL DISTANCES; SYSTEM; MORTALITY; CARE; TRANSPORT; IMPACT; SURVIVAL; HELICOPTER; HOSPITALS	Context Previous studies have reported that the number and distribution of trauma centers are uneven across states, suggesting large differences in access to trauma center care. Objective To estimate the proportion of US residents having access to trauma centers within 45 and 60 minutes. Design and Setting Cross-sectional study using data from 2 national databases as part of the Trauma Resource Allocation Model for Ambulances and Hospitals (TRAMAH) project. Trauma centers, base helipads, and block group population were counted for all 50 states and the District of Columbia as of January 2005. Main Outcome Measures Percentages of national, regional, and state populations having access to all 703 level I, II, and III trauma centers in the United States by either ground ambulance or helicopter within 45 and 60 minutes. Results An estimated 69.2% and 84.1% of all US residents had access to a level I or 11 trauma center within 45 and 60 minutes, respectively. The 46.7 million Americans who had no access within an hour lived mostly in rural areas, whereas the 42.8 million Americans who had access to 20 or more level I or II trauma centers within an hour lived mostly in urban areas. Within 45 and 60 minutes, respectively, 26.7% and 27.7% of US residents had access to level I or II trauma centers by helicopter only and 1.9% and 3.1% of US residents had access to level I or II centers only from trauma centers or base helipads outside their home states. Conclusion Selecting trauma centers based on geographic need, appropriately locating medical helicopter bases, and establishing formal agreements for sharing trauma care resources across states should be considered to improve access to trauma care in the United States.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Johns Hopkins Whiting Sch Engn, Dept Geog & Environm Engn, Baltimore, MD USA; Amer Trauma Soc, Upper Marlboro, MD USA; Calspan Univ, Buffalo Res Ctr, Ctr Transportat Injury Res, Buffalo, NY USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Branas, CC (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Leonard Davis Inst Hlth Econ, Room 829 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	cbranas@cceb.med.upenn.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010914] Funding Source: NIH RePORTER; AHRQ HHS [R01HS010914] Funding Source: Medline; ODCDC CDC HHS [H28CCH319122] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); ODCDC CDC HHS		*ADAMS, COMP LIC CTR TRANSP; Aday L A, 1974, Health Serv Res, V9, P208; *AM COLL SURG, 1999, RES OPT CAR INJ PAT; American Trauma Society, TRAUM INF EXCH PROGR; [Anonymous], 2000, JAMA-J AM MED ASSOC, V284, P2048, DOI 10.1001/jama.284.16.2048; Askue V, 2001, Air Med J, V20, P10, DOI 10.1016/S1067-991X(01)70082-X; Baez AA, 2003, J TRAUMA, V54, P344, DOI 10.1097/01.TA.0000046258.81127.E1; Bass RR, 1999, J TRAUMA, V47, pS15, DOI 10.1097/00005373-199909001-00005; BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAZZOLI GJ, 1995, JAMA-J AM MED ASSOC, V273, P395; BONNIE RJ, 1999, REDUCING BURDEN INJU, pCH6; Branas C C, 2000, Prehosp Emerg Care, V4, P299, DOI 10.1080/10903120090940985; Branas C C, 2000, LDI Issue Brief, V6, P1; Branas CC, 2000, HEALTH SERV RES, V35, P489; BRANAS CC, 2005, IN PRESS LDI ISSUE B, V11, P1; Branas CC, 2001, SOCIOECON PLANN SCI, V35, P11, DOI DOI 10.1016/S0038-0121; Bravata DM, 2004, AHRQ PUBLICATION; *CLAR INC, 2004, CLAR DEM UPD METH; CLARK DE, 1994, J AM MED INFORM ASSN, P888; Cowley R A, 1975, Md State Med J, V24, P37; Diaz MA, 2005, J TRAUMA, V58, P148, DOI 10.1097/01.TA.0000124264.43941.41; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; FLANIGAN M, 2003, ATLAS DATABASE AIR M; FLANIGAN MC, 2004, INT TRANSP SYST SAF; Goldfarb MG, 1996, HEALTH SERV RES, V31, P71; KOLESAR P, 1975, OPER RES, V23, P614, DOI 10.1287/opre.23.4.614; KONVOLINKA CW, 1995, AM J SURG, V170, P333, DOI 10.1016/S0002-9610(99)80299-2; Lerner EB, 1999, ACAD EMERG MED, V6, P1127, DOI 10.1111/j.1553-2712.1999.tb00115.x; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; LOVE RF, 1979, MANAGE SCI, V25, P130, DOI 10.1287/mnsc.25.2.130; LOVE RF, 1988, FACILITIES LOCATION, P255; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Mann NC, 2005, J TRAUMA, V58, P136, DOI 10.1097/01.TA.0000151181.44658.0A; Mann NC, 2001, MED CARE, V39, P643, DOI 10.1097/00005650-200107000-00001; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; Melnick A L, 1999, J Public Health Manag Pract, V5, pviii; Mullins RJ, 2002, J TRAUMA, V52, P1019, DOI 10.1097/00005373-200206000-00002; *NAT RUR HLTH ASS, 1997, RUR FRONT EM MED SER; Nathens A B, 2001, Adv Surg, V35, P61; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Nathens AB, 2004, J TRAUMA, V56, P173, DOI 10.1097/01.TA.0000056159.65396.7C; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Nathens AB, 2003, J TRAUMA, V55, P444, DOI 10.1097/01.TA.0000047809.64699.59; National Emergency Management Association, EM MAN ASS COMP; PEPE PE, 1989, PREHOSP DISASTER MED, V4, P131; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SAMPALIS JS, 1993, J TRAUMA, V34, P252, DOI 10.1097/00005373-199302000-00014; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; Stanhope K, 1997, Air Med J, V16, P70, DOI 10.1016/S1067-991X(97)90017-1; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; *US CENS BUR, CTR POP COMP 1950 19; Whitney C L, 2000, Air Med J, V19, P22, DOI 10.1016/S1067-991X(00)90088-9	52	347	348	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2626	2633		10.1001/jama.293.21.2626	http://dx.doi.org/10.1001/jama.293.21.2626			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930UU	15928284	Bronze			2022-12-28	WOS:000229443400021
J	Topol, EJ; Blumenthal, D				Topol, EJ; Blumenthal, D			Physicians and the investment industry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Cleveland Clin Fdn, Cleveland, OH 44195 USA; Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Off Provost, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp Partners Hlth Care Syst, Inst Hlth Policy, Boston, MA USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Harvard University; Harvard Medical School; Massachusetts General Hospital; Partners Healthcare System	Topol, EJ (corresponding author), Cleveland Clin Fdn, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@ccf.org		Topol, Eric/0000-0002-1478-4729				ANAND G, 2002, WALL STREET J   0927, pA1; Anderson J.M., 2005, NEW STRATEGIES INTEG, P1; Blumenthal D, 2004, NEW ENGL J MED, V351, P1885, DOI 10.1056/NEJMhpr042734; Blumenthal D, 2003, NEW ENGL J MED, V349, P2452, DOI 10.1056/NEJMhpr035460; BODOW S, 2001, NY TIMES        1223, P8; DUBIN D, 2005, COMMUNICATION   0124; GERSON M, 2005, COMMUNICATION   0124; GOTTLEIB S, 2002, AM MED NEWS     0527; MALER K, 2005, NY TIMES        0103, pC14; *NAT FDN CANC RES, GEN GROUP TIES BIOT; PARTNOY F, 2004, NY TIMES        1215, pA33; *PRIC THOMS VENT E, VENT CAP INV HLTH IN; SINGER J, 2005, WALL ST J       0125, pA1; TOPOL E, 2004, FORTUNE         1227, P24; *US GEN ACC OFF, 2003, PHYS WORKF PHYS SUPP, P7; ZUCKERMAN G, 2004, WALL STREET J   0915, pC1; ZUCKERMAN G, 2005, WALL ST J       0422, pA1	17	23	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2654	2657		10.1001/jama.293.21.2654	http://dx.doi.org/10.1001/jama.293.21.2654			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930UU	15928288				2022-12-28	WOS:000229443400025
J	Singer, M; Coluzzi, F; O'Brien, A; Clapp, LH				Singer, M; Coluzzi, F; O'Brien, A; Clapp, LH			Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide	LANCET			English	Article							K-ATP CHANNELS; SMOOTH-MUSCLE	We describe three critically ill patients who received drugs with K(ATP) channel-opening properties and subsequently developed severe life-threatening complications, including hyperkalaemia and cardiovascular disturbances. Administration of the sulfonylurea-receptor inhibitor glibenclamide promptly reversed these abnormalities. Over the past 3 years, we have seen this syndrome and response in five patients taking nicorandil, ciclosporin, or isoflurane, which suggests that this disorder arises more frequently than is currently realised.	UCL, Middlesex Hosp, Dept Med, Bloomsbury Inst Intens Care Med, London W1T 3AA, England; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Univ Roma La Sapienza, Dept Anaesthesia, Rome, Italy; UCL, Dept Med, BHF Labs, London, England	University of London; University College London; University of London; University College London; Sapienza University Rome; University of London; University College London	Singer, M (corresponding author), UCL, Middlesex Hosp, Dept Med, Bloomsbury Inst Intens Care Med, London W1T 3AA, England.	m.singer@ucl.ac.uk	Clapp, Lucie/B-1088-2008; Clapp, Lucie/L-4199-2019; Singer, Mervyn/Q-6142-2019; Singer, Mervyn/J-4425-2012	Clapp, Lucie/0000-0001-7802-4481; Clapp, Lucie/0000-0001-7802-4481; Singer, Mervyn/0000-0002-1042-6350; Singer, Mervyn/0000-0002-1042-6350; O'Brien, Alastair/0000-0002-9168-7009	Medical Research Council [G117/440] Funding Source: Medline; MRC [G117/440] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Caliskan Y, 2003, TRANSPLANTATION, V75, P1069, DOI 10.1097/01.TP.0000057241.69355.59; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Montgomery H, 1997, CARDIOVASC DRUG THER, V11, P81, DOI 10.1023/A:1007764210280; O'Brien AJ, 2005, BRIT J PHARMACOL, V144, P367, DOI 10.1038/sj.bjp.0706065; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Wang WH, 2004, CURR OPIN NEPHROL HY, V13, P549, DOI 10.1097/00041552-200409000-00011; Wang XR, 2003, CIRC RES, V92, P1225, DOI 10.1161/01.RES.0000075601.95738.6D; Wilson AJ, 2000, CIRC RES, V87, P1019, DOI 10.1161/01.RES.87.11.1019	8	25	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1873	1875		10.1016/S0140-6736(05)66619-6	http://dx.doi.org/10.1016/S0140-6736(05)66619-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924984				2022-12-28	WOS:000229481400026
J	Schaefer, BF				Schaefer, BF			Geochemistry - When do rocks become oil?	SCIENCE			English	Editorial Material									Monash Univ, Sch Geosci, Clayton, Vic 3800, Australia	Monash University	Schaefer, BF (corresponding author), Monash Univ, Sch Geosci, Clayton, Vic 3800, Australia.	bruce.schaefer@sci.monash.edu.au	Schaefer, Bruce F/C-8718-2018	Schaefer, Bruce F/0000-0002-7366-0152				BROOKS PW, 1988, ORG GEOCHEM, V12, P519, DOI 10.1016/0146-6380(88)90144-1; ESSER BK, 1993, GEOCHIM COSMOCHIM AC, V57, P3093, DOI 10.1016/0016-7037(93)90296-9; Selby D, 2005, SCIENCE, V308, P1293, DOI 10.1126/science.1111081; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; [No title captured]	5	9	11	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2005	308	5726					1267	1268		10.1126/science.1113158	http://dx.doi.org/10.1126/science.1113158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919982				2022-12-28	WOS:000229482300033
J	Wright, SI; Bi, IV; Schroeder, SG; Yamasaki, M; Doebley, JF; McMullen, MD; Gaut, BS				Wright, SI; Bi, IV; Schroeder, SG; Yamasaki, M; Doebley, JF; McMullen, MD; Gaut, BS			The effects of artificial selection of the maize genome	SCIENCE			English	Article							MORPHOLOGICAL DIFFERENCES; DOMESTICATION; DIVERSITY; PATTERN; DEMOGRAPHY; GENETICS; TEOSINTE; MODELS	Domestication promotes rapid phenotypic evolution through artificial selection. We investigated the genetic history by which the wild grass teosinte (Zea mays ssp. parviglumis) was domesticated into modem maize (Z. mays ssp. mays). Analysis of single-nucleotide polymorphisms in 774 genes indicates that 2 to 4% of these genes experienced artificial selection. The remaining genes retain evidence of a population bottleneck associated with domestication. Candidate selected genes with putative function in plant growth are clustered near quantitative trait loci that contribute to phenotypic differences between maize and teosinte. If we assume that our sample of genes is representative, 1200 genes throughout the maize genome have been affected by artificial selection.	Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA; York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Missouri, Dept Agron, Plant Sci Unit, Columbia, MO 65211 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; ARS, Plant Genet Res Unit, USDA, Columbia, MO 65211 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; York University - Canada; University of Missouri System; University of Missouri Columbia; University of Wisconsin System; University of Wisconsin Madison; United States Department of Agriculture (USDA); University of Missouri System; University of Missouri Columbia	Gaut, BS (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA.	bgaut@uci.edu	Yamasaki, Masanori/C-5193-2018; Wright, Stephen I/C-3113-2008	Yamasaki, Masanori/0000-0001-7759-3965; Wright, Stephen I/0000-0001-9973-9697; Schroeder, Steven/0000-0001-9103-5150				Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; BRESSANI R, 1958, CEREAL CHEM, V35, P227; Buckler ES, 2001, GENET RES, V77, P213, DOI 10.1017/S0016672301005158; Clark RM, 2004, P NATL ACAD SCI USA, V101, P700, DOI 10.1073/pnas.2237049100; Doebley J, 2004, ANNU REV GENET, V38, P37, DOI 10.1146/annurev.genet.38.072902.092425; DOEBLEY J, 1993, GENETICS, V134, P559; DOEBLEY J, 1991, GENETICS, V129, P285; DOEBLEY J, 1995, GENETICS, V141, P333; Eyre-Walker A, 1998, P NATL ACAD SCI USA, V95, P4441, DOI 10.1073/pnas.95.8.4441; Galtier N, 2000, GENETICS, V155, P981; Hilton H, 1998, GENETICS, V150, P863; Hudson RR, 2001, GENETICS, V159, P1805; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; Matsuoka Y, 2002, P NATL ACAD SCI USA, V99, P6080, DOI 10.1073/pnas.052125199; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Messing J, 2004, P NATL ACAD SCI USA, V101, P14349, DOI 10.1073/pnas.0406163101; Palaisa K, 2004, P NATL ACAD SCI USA, V101, P9885, DOI 10.1073/pnas.0307839101; TAJIMA F, 1989, GENETICS, V123, P597; Tenaillon MI, 2004, MOL BIOL EVOL, V21, P1214, DOI 10.1093/molbev/msh102; Vigouroux Y, 2002, MOL BIOL EVOL, V19, P1251, DOI 10.1093/oxfordjournals.molbev.a004186; Wall JD, 2002, GENETICS, V162, P203; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Whitt SR, 2002, P NATL ACAD SCI USA, V99, P12959, DOI 10.1073/pnas.202476999; Zhang LQ, 2002, GENETICS, V162, P851	25	591	629	6	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1310	1314		10.1126/science.1107891	http://dx.doi.org/10.1126/science.1107891			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919994				2022-12-28	WOS:000229482300048
J	Tsiganis, K; Gomes, R; Morbidelli, A; Levison, HF				Tsiganis, K; Gomes, R; Morbidelli, A; Levison, HF			Origin of the orbital architecture of the giant planets of the Solar System	NATURE			English	Article							PLANETESIMAL DISK; CLOSE ENCOUNTERS; KUIPER-BELT; ACCRETION; EVOLUTION; NEPTUNE; BODIES; POPULATION; MIGRATION	Planetary formation theories(1,2) suggest that the giant planets formed on circular and coplanar orbits. The eccentricities of Jupiter, Saturn and Uranus, however, reach values of 6 per cent, 9 per cent and 8 per cent, respectively. In addition, the inclinations of the orbital planes of Saturn, Uranus and Neptune take maximum values of similar to 2 degrees with respect to the mean orbital plane of Jupiter. Existing models for the excitation of the eccentricity of extrasolar giant planets(3-5) have not been successfully applied to the Solar System. Here we show that a planetary system with initial quasi-circular, coplanar orbits would have evolved to the current orbital configuration, provided that Jupiter and Saturn crossed their 1: 2 orbital resonance. We show that this resonance crossing could have occurred as the giant planets migrated owing to their interaction with a disk of planetesimals(6,7). Our model reproduces all the important characteristics of the giant planets' orbits, namely their final semimajor axes, eccentricities and mutual inclinations.	CNRS, Observ Cote Azur, F-06304 Nice, France; UFRJ, OV, GEA, BR-20080090 Rio De Janeiro, Brazil; MCT, ON, BR-20080090 Rio De Janeiro, Brazil; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; Universidade Federal do Rio de Janeiro	Morbidelli, A (corresponding author), CNRS, Observ Cote Azur, BP 4229, F-06304 Nice, France.	morby@obs-nice.fr	gomes, rodney/G-8091-2011; Levison, Harold F/C-6061-2013; Tsiganis, Kleomenis/AAF-5316-2020	Levison, Harold F/0000-0001-5847-8099; Tsiganis, Kleomenis/0000-0003-3334-6190; Gomes, Rodney/0000-0001-5712-3042				Chambers JE, 1999, MON NOT R ASTRON SOC, V304, P793, DOI 10.1046/j.1365-8711.1999.02379.x; Duncan MJ, 1998, ASTRON J, V116, P2067, DOI 10.1086/300541; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Goldreich P, 2003, ASTROPHYS J, V585, P1024, DOI 10.1086/346202; Gomes RS, 2004, ICARUS, V170, P492, DOI 10.1016/j.icarus.2004.03.011; Gomes RS, 2003, ICARUS, V161, P404, DOI 10.1016/S0019-1035(02)00056-8; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; KOKUBO E, 1995, ICARUS, V114, P247, DOI 10.1006/icar.1995.1059; Levison HF, 2003, NATURE, V426, P419, DOI 10.1038/nature02120; Lubow SH, 1999, ASTROPHYS J, V526, P1001, DOI 10.1086/308045; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; MURRAY C, 1999, SOLAR SYSTEM DYNAMIC, P91802; Papaloizou JCB, 2001, ASTRON ASTROPHYS, V366, P263, DOI 10.1051/0004-6361:20000011; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; STERN SA, 1991, ICARUS, V90, P271, DOI 10.1016/0019-1035(91)90106-4; Zakamska NL, 2004, ASTRON J, V128, P869, DOI 10.1086/422023	16	927	936	2	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					459	461		10.1038/nature03539	http://dx.doi.org/10.1038/nature03539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917800				2022-12-28	WOS:000229337800046
J	Schweisguth, F				Schweisguth, F			Temporal regulation of planar cell polarity: Insights from the Drosophila eye	CELL			English	Editorial Material							LOCALIZATION; POLARIZATION; PROTEIN	In this issue of Cell, Djiane et al. (2005) identify a first regulatory link between planar cell polarity (PCP) signaling and apical-basal polarity. The authors propose that a component of the apical Crumbs complex regulates the phosphorylation of the Frizzled (Fz) PCP receptor, thus modulating PCP in the Drosophila eye.	Ecole Normale Super, CNRS, UMR8542, F-75230 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Schweisguth, F (corresponding author), Ecole Normale Super, CNRS, UMR8542, 46 Rue Ulm, F-75230 Paris, France.							Djiane A, 2005, CELL, V121, P621, DOI 10.1016/j.cell.2005.03.014; Eaton S, 1997, CURR OPIN CELL BIOL, V9, P860, DOI 10.1016/S0955-0674(97)80089-0; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Pielage J, 2003, DEV CELL, V5, P841, DOI 10.1016/S1534-5807(03)00358-7; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Strutt H, 2002, DEV CELL, V3, P851, DOI 10.1016/S1534-5807(02)00363-5; Wang Q, 2004, J BIOL CHEM, V279, P30715, DOI 10.1074/jbc.M401930200; Wu J, 2004, PLOS BIOL, V2, P1004, DOI 10.1371/journal.pbio.0020158	9	4	4	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					497	499		10.1016/j.cell.2005.05.006	http://dx.doi.org/10.1016/j.cell.2005.05.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907460	Bronze			2022-12-28	WOS:000229331200003
J	Berkley, KJ; Rapkin, AJ; Papka, RE				Berkley, KJ; Rapkin, AJ; Papka, RE			The pains of endometriosis	SCIENCE			English	Review							HYPERALGESIA; DISEASE; WOMEN; MODEL; RATS	Endometriosis is a disease defined by the presence of endometrial tissue outside of the uterus. Severe pelvic pain is often associated with endometriosis, and this pain can be diminished with therapies that suppress estrogen production. Many women with endometriosis also suffer from other chronic pain conditions. Recent studies suggest that mechanisms underlying these pains and sensitivity to estrogen involve the growth into the ectopic endometrial tissue of a nerve supply, which could have a varied and widespread influence on the activity of neurons throughout the central nervous system.	Florida State Univ, Dept Psychol, Program Neurosci, Tallahassee, FL 32306 USA; Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; NE Ohio Univ, Coll Med, Dept Neurobiol, Rootstown, OH 44272 USA	State University System of Florida; Florida State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Northeast Ohio Medical University (NEOMED)	Berkley, KJ (corresponding author), Florida State Univ, Dept Psychol, Program Neurosci, Tallahassee, FL 32306 USA.				NIDDK NIH HHS [R21 DK063937] Funding Source: Medline; NINDS NIH HHS [R01 NS11892, R01 NS22526] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK063937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022526, R01NS011892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott JA, 2003, HUM REPROD, V18, P1922, DOI 10.1093/humrep/deg275; Alagiri M, 1997, UROLOGY, V49, P52, DOI 10.1016/S0090-4295(99)80332-X; Anaf V, 2002, HUM REPROD, V17, P1895, DOI 10.1093/humrep/17.7.1895; Bajaj P, 2003, J PAIN, V4, P372, DOI 10.1016/S1526-5900(03)00720-X; Berkley KJ, 2004, P NATL ACAD SCI USA, V101, P11094, DOI 10.1073/pnas.0403663101; BERKLEY KJ, IN PRESS PHYSL BEHAV; Chapron C, 2003, HUM REPROD, V18, P760, DOI 10.1093/humrep/deg152; Giamberardino MA, 2002, PAIN, V95, P247, DOI 10.1016/S0304-3959(01)00405-5; Giamberardino MA, 2001, NEUROSCI LETT, V304, P61, DOI 10.1016/S0304-3940(01)01753-0; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Maggi A, 2004, ANNU REV PHYSIOL, V66, P291, DOI 10.1146/annurev.physiol.66.032802.154945; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; Olive David L, 2004, Treat Endocrinol, V3, P83, DOI 10.2165/00024677-200403020-00003; Papka RE, 2003, INT REV CYTOL, V231, P91, DOI 10.1016/S0074-7696(03)31003-4; Parazzini F, 2001, HUM REPROD, V16, P2668; RAPKIN RJ, 2002, PAIN MANAGEMENT PRAC, P251; Sharpe-Timms KL, 2002, ANN NY ACAD SCI, V955, P318, DOI 10.1111/j.1749-6632.2002.tb02792.x; Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715; Tulandi T, 2001, J AM ASSOC GYN LAP, V8, P95, DOI 10.1016/S1074-3804(05)60556-7; WRIGHT JA, 1995, FERTIL STERIL, V63, P1094, DOI 10.1016/S0015-0282(16)57554-2	20	319	343	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1587	1589		10.1126/science.1111445	http://dx.doi.org/10.1126/science.1111445			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947176				2022-12-28	WOS:000229827000043
J	Gerard, C				Gerard, C			Asthmatics breathe easier when it's SNO-ing	SCIENCE			English	Editorial Material							NITRIC-OXIDE; INFLAMMATION		Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Gerard, C (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA.	craig.ger-ard@childrens.harvard.edu						Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Xiong YL, 1999, J IMMUNOL, V162, P445	6	13	17	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1560	1561		10.1126/science.1114163	http://dx.doi.org/10.1126/science.1114163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947161				2022-12-28	WOS:000229827000028
J	Liu, PLF; Lynett, P; Fernando, H; Jaffe, BE; Fritz, H; Higman, B; Morton, R; Goff, J; Synolakis, C				Liu, PLF; Lynett, P; Fernando, H; Jaffe, BE; Fritz, H; Higman, B; Morton, R; Goff, J; Synolakis, C			Observations by the International Tsunami Survey Team in Sri Lanka	SCIENCE			English	Article							WAVES		Texas A&M Univ, Dept Civil Engn, College Stn, TX 77845 USA; Cornell Univ, Dept Civil & Environm Engn, Ithaca, NY 14853 USA; Arizona State Univ, Dept Mech & Aerosp Engn, Tempe, AZ 85287 USA; US Geol Survey, Pacific Sci Ctr, Santa Cruz, CA 95060 USA; Georgia Inst Technol, Sch Civil & Environm Engn, Savannah, GA 31407 USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Natl Inst Water & Atmospher Res Ltd, Lyttelton, New Zealand; Univ So Calif, Dept Civil Engn, Los Angeles, CA 90089 USA	Texas A&M University System; Texas A&M University College Station; Cornell University; Arizona State University; Arizona State University-Tempe; United States Department of the Interior; United States Geological Survey; University System of Georgia; Georgia Institute of Technology; University of Washington; University of Washington Seattle; National Institute of Water & Atmospheric Research (NIWA) - New Zealand; University of Southern California	Lynett, P (corresponding author), Texas A&M Univ, Dept Civil Engn, College Stn, TX 77845 USA.	plynett@tamu.edu	Lynett, Patrick/A-1458-2011; Fritz, Hermann M/H-5618-2013; Lynett, Patrick J/B-5932-2014; Liu, Philip/AAD-3262-2019; Fritz, Hermann M./AAH-5670-2020; Liu, Philip/E-3619-2013; Synolakis, Costas E/B-3197-2008; Jaffe, Bruce E/A-9979-2012	Fritz, Hermann M/0000-0002-6798-5401; Lynett, Patrick J/0000-0002-2856-9405; Fritz, Hermann M./0000-0002-6798-5401; Synolakis, Costas E/0000-0003-0140-5379; Jaffe, Bruce E/0000-0002-8816-5920; Liu, Philip/0000-0002-2170-5507				LIU PLF, 1995, J FLUID MECH, V302, P259, DOI 10.1017/S0022112095004095; Tadepalli S, 1996, PHYS REV LETT, V77, P2141, DOI 10.1103/PhysRevLett.77.2141	2	199	202	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1595	1595		10.1126/science.1110730	http://dx.doi.org/10.1126/science.1110730			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947179				2022-12-28	WOS:000229827000046
J	Redman, CW; Sargent, IL				Redman, CW; Sargent, IL			Latest advances in understanding preeclampsia	SCIENCE			English	Review							OXIDATIVE STRESS; RISK; PREGNANCY; PLACENTA; HYPOXIA	Preeclampsia is a relatively common pregnancy disorder that originates in the placenta and causes variable maternal and fetal problems. In the worst cases, it may threaten the survival of both mother and baby. We summarize recent work on the causes of preeclampsia, which reveals a new mode of maternal immune recognition of the fetus, relevant to the condition. The circulating factors derived from the placenta, which contributes to the clinical syndrome, are now better understood. This brief review on preeclampsia does not cover all aspects of this intriguing condition but focuses on some new and interesting findings.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford	Redman, CW (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.	christopher.redman@obs-gyn.ox.ac.uk						Burton GJ, 2004, J SOC GYNECOL INVEST, V11, P342, DOI 10.1016/j.jsgi.2004.03.003; Duckitt K, 2005, BRIT MED J, V330, P565, DOI 10.1136/bmj.38380.674340.E0; Haig D, 1999, EVOLUTION IN HEALTH AND DISEASE, P77; HALLER H, 1993, J REPROD IMMUNOL, V23, P41, DOI 10.1016/0165-0378(93)90025-D; Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214; Huppertz B, 2003, PLACENTA, V24, P181, DOI 10.1053/plac.2002.0903; Jauniaux E, 2003, PLACENTA, V24, pS86, DOI 10.1053/plac.2002.0932; Karumanchi SA, 2004, ENDOCRINOLOGY, V145, P4835, DOI 10.1210/en.2004-1028; Lain KY, 2002, JAMA-J AM MED ASSOC, V287, P3183, DOI 10.1001/jama.287.24.3183; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Ness RB, 1996, AM J OBSTET GYNECOL, V175, P1365, DOI 10.1016/S0002-9378(96)70056-X; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Raijmakers MTM, 2004, HYPERTENSION, V44, P374, DOI 10.1161/01.HYP.0000141085.98320.01; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; Redman CWG, 2003, PLACENTA, V24, pS21, DOI 10.1053/plac.2002.0930; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; Sattar N, 2002, BMJ-BRIT MED J, V325, P157, DOI 10.1136/bmj.325.7356.157; van Dijk M, 2005, NAT GENET, V37, P514, DOI 10.1038/ng1541	20	1907	2000	6	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1592	1594		10.1126/science.1111726	http://dx.doi.org/10.1126/science.1111726			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947178				2022-12-28	WOS:000229827000045
J	Benn, P; Lupton, M				Benn, P; Lupton, M			Ethics in practice - Sterilisation of young, competent, and childless adults	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci & Technol, Dept Primary Care & Social Med, Med Eth Unit, London W6 8RP, England; Chelsea & Westminster Hosp, Dept Maternal Fetal Med, London SW10 9NH, England	Imperial College London; Imperial College London	Benn, P (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Primary Care & Social Med, Med Eth Unit, London W6 8RP, England.	p.benn@imperial.ac.uk						*GEN MED COUNC, DUT DOCT REG GMC; Jamieson DJ, 2002, OBSTET GYNECOL, V99, P1073, DOI 10.1016/S0029-7844(02)01981-6; Lavin Michael, 1986, J Appl Philos, V3, P89; Marcil-gratton N, 1987, Sociol Soc, V19, P83; Pennings G, 2002, J MED ETHICS, V28, P297; Schmidt JE, 2000, FERTIL STERIL, V74, P892, DOI 10.1016/S0015-0282(00)01558-2	6	14	14	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1323	1325		10.1136/bmj.330.7503.1323	http://dx.doi.org/10.1136/bmj.330.7503.1323			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933358	Green Published			2022-12-28	WOS:000229655700029
J	Kerr, D				Kerr, D			As fit as a butcher's dog	LANCET			English	Editorial Material									Bournemouth Diabet & Endocrine Ctr, Bournemouth BH7 7DW, Dorset, England		Kerr, D (corresponding author), Bournemouth Diabet & Endocrine Ctr, Bournemouth BH7 7DW, Dorset, England.	david.kerr@rbch.nhs.uk							0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1981	1981		10.1016/S0140-6736(05)66668-8	http://dx.doi.org/10.1016/S0140-6736(05)66668-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936430				2022-12-28	WOS:000229587800036
J	Phillips-Silver, J; Trainor, LJ				Phillips-Silver, J; Trainor, LJ			Feeling the beat: Movement influences infant rhythm perception	SCIENCE			English	Article									McMaster Univ, Dept Psychol, Hamilton, ON L8S 4K1, Canada	McMaster University	Trainor, LJ (corresponding author), McMaster Univ, Dept Psychol, Hamilton, ON L8S 4K1, Canada.	LJT@mcmaster.ca		Trainor, Laurel/0000-0003-3397-2079				Brown S, 2000, ORIGINS OF MUSIC, P3; CLARK DL, 1977, SCIENCE, V196, P1228, DOI 10.1126/science.300899; Lackner J R, 1992, J Vestib Res, V2, P307; Lehrdal F., 1983, GENERATIVE THEORY TO; Trainor Laurel J., 2003, COGNITIVE NEUROSCIEN, P310; Trehub SE, 2003, NAT NEUROSCI, V6, P669, DOI 10.1038/nn1084	6	376	381	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1430	1430		10.1126/science.1110922	http://dx.doi.org/10.1126/science.1110922			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933193				2022-12-28	WOS:000229619300042
J	Yip, CK; Kimbrough, TG; Felise, HB; Vuckovic, M; Thomas, NA; Pfuetzner, RA; Frey, EA; Finlay, BB; Miller, SI; Strynadka, NCJ				Yip, CK; Kimbrough, TG; Felise, HB; Vuckovic, M; Thomas, NA; Pfuetzner, RA; Frey, EA; Finlay, BB; Miller, SI; Strynadka, NCJ			Structural characterization of the molecular platform for type III secretion system assembly	NATURE			English	Article							NEEDLE COMPLEX; ASSOCIATION; MULTIMER; INSIGHTS; PROGRAM	Type III secretion systems ( TTSSs) are multi-protein macromolecular 'machines' that have a central function in the virulence of many Gram-negative pathogens by directly mediating the secretion and translocation of bacterial proteins ( termed effectors) into the cytoplasm of eukaryotic cells(1). Most of the 20 unique structural components constituting this secretion apparatus are highly conserved among animal and plant pathogens and are also evolutionarily related to proteins in the flagellar-specific export system. Recent electron microscopy experiments have revealed the gross 'needle-shaped' morphology of the TTSS2-4, yet a detailed understanding of the structural characteristics and organization of these protein components within the bacterial membranes is lacking. Here we report the 1.8-angstrom crystal structure of EscJ from enteropathogenic Escherichia coli (EPEC), a member of the YscJ/ PrgK family whose oligomerization represents one of the earliest events in TTSS assembly(5). Crystal packing analysis and molecular modelling indicate that EscJ could form a large 24-subunit 'ring' superstructure with extensive grooves, ridges and electrostatic features. Electron microscopy, labelling and mass spectrometry studies on the orthologous Salmonella typhimurium PrgK within the context of the assembled TTSS support the stoichiometry, membrane association and surface accessibility of the modelled ring. We propose that the YscJ/ PrgK protein family functions as an essential molecular platform for TTSS assembly.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Washington, Dept Mol & Cellular Biol, Seattle, WA 98195 USA; Dept Microbiol & Med, Seattle, WA 98195 USA; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of Washington; University of Washington Seattle; University of British Columbia	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca		Thomas, Nikhil/0000-0003-3037-425X; Yip, Calvin/0000-0003-1779-9501				Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burghout P, 2004, J BACTERIOL, V186, P4645, DOI 10.1128/JB.186.14.4645-4654.2004; Crago AM, 1998, MOL MICROBIOL, V30, P47, DOI 10.1046/j.1365-2958.1998.01036.x; EVANS PR, 1993, P CCP4 STUD WEEK DAT, P1114; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; JONES CJ, 1990, J MOL BIOL, V212, P377, DOI 10.1016/0022-2836(90)90132-6; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; Kimbrough TG, 2002, MICROBES INFECT, V4, P75, DOI 10.1016/S1286-4579(01)01512-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; LESLIE AGW, 1992, CCP4 ESF EAMCB NEWSL; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Suzuki H, 2004, J MOL BIOL, V337, P105, DOI 10.1016/j.jmb.2004.01.034; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thomas J, 2004, P NATL ACAD SCI USA, V101, P3945, DOI 10.1073/pnas.0307223101	28	158	164	0	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					702	707		10.1038/nature03554	http://dx.doi.org/10.1038/nature03554			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931226				2022-12-28	WOS:000229476200056
J	Miller, N; Frieden, TR; Liu, SY; Matte, TD; Mostashari, F; Deitcher, DR; Cummings, KM; Chang, C; Bauer, U; Bassett, MT				Miller, N; Frieden, TR; Liu, SY; Matte, TD; Mostashari, F; Deitcher, DR; Cummings, KM; Chang, C; Bauer, U; Bassett, MT			Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation	LANCET			English	Article							SMOKING-CESSATION; ABSTINENCE; QUIT	Background After an increase in cigarette taxes and implementation of smoke-free workplace legislation, the New York City Department of Health and Mental Hygiene, the New York State Department of Health, and the Roswell Park Cancer Institute undertook large-scale distribution of free nicotine replacement therapy (NRT). We did a 6-month follow-up survey to assess the success of this programme in improving smoking cessation on a population basis. Methods 34 090 eligible smokers who phoned a toll-free quitline were sent a 6-week course of nicotine patches (2 weeks each of 21 mg, 14 mg, and 7 mg per day). Brief follow-up counselling calls were attempted. At 6 months after treatment, we assessed smoking status of 1305 randomly sampled NRT recipients and a non-randomly selected comparison group of eligible smokers who, because of mailing errors, did not receive the treatment. NRT recipients were compared with local survey-derived data for heavy smokers in New York City. Findings An estimated 5% of all adults in New York City who smoked ten cigarettes or more daily received NRT; most (64%) recipients were non-white, foreign-born, or resided in a low-income neighbourhood. Of individuals contacted at 6 months, more NRT recipients than comparison group members successfully quit smoking (33% vs 6%, p<0.0001), and this difference remained significant after adjustment for demographic factors and amount smoked (odds ratio 8.8, 95% CI 4.4-17.8). Highest quit rates were associated with those who were foreign born (87 [39%]), older than 65 years (40 [47%]), and smoked less than 20 cigarettes per day (116 [35%]). Those who received a counselling call were more likely to stop smoking than those who did not (246 [38%] vs 189 [27%], p=0.001). With the conservative assumption that every 6-month follow-up survey non-respondent continued to smoke, the stop rate among NRT recipients was 20%. At least 6038 successful quits were attributable to NRT receipt, and cost was US$464 per quit.	New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA; Roswell Pk Canc Inst, Dept Canc Prevent, Buffalo, NY 14263 USA; New York State Dept Hlth, Tobacco Control Program, Albany, NY USA	New York City Department of Health & Mental Hygiene; Roswell Park Cancer Institute; State University of New York (SUNY) System	Frieden, TR (corresponding author), New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA.	tfrieden@health.nyc.gov	Liu, Sze/ABB-4170-2021	Frieden, Thomas/0000-0002-4759-2256; Liu, Sze Yan/0000-0002-7148-356X				Alberg AJ, 2004, ADDICT BEHAV, V29, P1763, DOI 10.1016/j.addbeh.2004.04.007; [Anonymous], 2002, NEW YORK CIT COMM HL; Boyle RG, 2002, HEALTH AFFAIR, V21, P162, DOI 10.1377/hlthaff.21.6.162; Centers for Disease Control and Prevention, 2002, BEH RISK FACT SURV S; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1217; Evans CA, 2001, AM J PREV MED, V20, P10; Farkas AJ, 1999, TOB CONTROL, V8, P261, DOI 10.1136/tc.8.3.261; Farkas AJ, 1999, ANN BEHAV MED, V21, P71, DOI 10.1007/BF02895036; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; Fiore M C, 2000, WMJ, V99, P68; Fiore MC, 2004, AM J PUBLIC HEALTH, V94, P205, DOI 10.2105/AJPH.94.2.205; FIORE MC, 2000, TREATING TOBACCO USE; Grandes G, 2003, BRIT J GEN PRACT, V53, P101; Grigg M, 2003, TOB CONTROL, V12, P238, DOI 10.1136/tc.12.2.238-a; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P145; Hughes JR, 2003, NICOTINE TOB RES, V5, P13, DOI 10.1080/1462220031000070552; Hymowitz N, 1997, Tob Control, V6 Suppl 2, pS57, DOI 10.1136/tc.6.suppl_2.S57; Jolicoeur DG, 2000, PREV MED, V30, P504, DOI 10.1006/pmed.2000.0670; KOOPMAN P, 1987, INTRO CONT STAT METH; KOZLOWSKI LT, 1994, DRUG ALCOHOL DEPEN, V34, P211, DOI 10.1016/0376-8716(94)90158-9; Lawrence WF, 1998, TOB CONTROL, V7, P364, DOI 10.1136/tc.7.4.364; Mackay J, 2002, TOBACCO ATLAS; Macleod ZR, 2003, MED J AUSTRALIA, V179, P349, DOI 10.5694/j.1326-5377.2003.tb05590.x; Miller C, 2002, TOB CONTROL, V11, P380, DOI 10.1136/tc.11.4.380-a; Pierce JP, 2003, NICOTINE TOB RES, V5, P151, DOI 10.1080/0955300031000083427; RABIUS V, 2003, 2003 NAT C TOB HLTH; Schauffler HH, 2001, TOB CONTROL, V10, P175, DOI 10.1136/tc.10.2.175; Shiffman S, 2002, ADDICTION, V97, P505, DOI 10.1046/j.1360-0443.2002.00141.x; SORENSEN G, 1991, AM J PUBLIC HEALTH, V81, P202; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; U. S. Department of Health and Human Services, 1990, DHHS PUBL; *U WISC CTR TOB RE, 2003, UW CTRI REP, V3, P2; US Department of Health and Human Services, 2000, RED TOB US REP SURG; Zhu SH, 2000, AM J PREV MED, V18, P305, DOI 10.1016/S0749-3797(00)00124-0	34	146	147	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1849	1854		10.1016/S0140-6736(05)66615-9	http://dx.doi.org/10.1016/S0140-6736(05)66615-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	931JK	15924980				2022-12-28	WOS:000229481400022
J	Farkas, TA				Farkas, TA			Arrowwood contaminant in pap smear	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Farkas, TA (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					E20	E20		10.1056/NEJMicm040111	http://dx.doi.org/10.1056/NEJMicm040111			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917378				2022-12-28	WOS:000229333300011
J	Petersen, J; Hagan, IM				Petersen, J; Hagan, IM			Polo kinase links the stress pathway to cell cycle control and tip growth in fission yeast	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; GENETIC-CONTROL; DIVISION CYCLE; MAP KINASE; HISTONE H3; PHOSPHORYLATION; ADAPTATION; EXPRESSION; PROTEIN; LENGTH	Stress-activated mitogen-activated protein kinase cascades instigate a range of changes to enable eukaryotic cells to cope with particular insults. In Schizosaccharomyces pombe these responses include the transcription of specific gene sets and inhibition of entry into mitosis(1,2). The S. pombe stress response pathway (SRP) also promotes commitment to mitosis in unperturbed cell cycles to allow cells to match their rate of division with nutrient availability(1,3). The nature of this SRP function in cell cycle control is unknown. Entry into mitosis is controlled by mitosis-promoting factor (MPF; Cdc2/cyclin B) activity. Inhibitory phosphorylation of Cdc2 by Wee1 kinase inactivates MPF until Cdc25 removes this phosphate to promote mitosis(4). The balance between Wee1 and Cdc25 activities is influenced by the recruitment of polo kinase (Plo1) to the spindle pole body (SPB)(5). The SPB component Cut12 mediates this recruitment(5,6). Hyper-activating mutations in either cut12 or plo1 enable Cdc25-defective cells to enter mitosis(5,7). The hyperactive cut12.s11 mutation suppresses cdc25.22, as it promotes recruitment of active Plo1 to interphase SPBs(6,7). Here we show that the SRP promotes phosphorylation of Plo1 on Ser 402. In unperturbed cell cycles, SRP-mediated phosphorylation of Ser 402 promotes Plo1 recruitment to SPBs and thus commitment to mitosis. Ser 402 phosphorylation also ensures efficient reinitiation of cell tip growth and cell division during recovery from particular stresses. Thus, phosphorylation of Plo1 Ser 402 not only enables SRP signalling to modulate the timing of mitotic commitment in response to nutrient status in unperturbed cycles, but also promotes the return to normal cell cycle control after stress.	Paterson Inst Canc Res, Canc Res UK Cell Div Grp, Manchester M20 4BX, Lancs, England; Rockefeller Univ, New York, NY 10021 USA	Paterson Institute for Cancer Research; Rockefeller University	Hagan, IM (corresponding author), Paterson Inst Canc Res, Canc Res UK Cell Div Grp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	ihagan@picr.man.ac.uk		Petersen, Janni/0000-0003-0729-9335; Hagan, Iain/0000-0002-5858-9415				Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; HUDSON JD, 1990, GENETICS, V126, P309; MacIver FH, 2003, YEAST, V20, P587, DOI 10.1002/yea.983; MacIver FH, 2003, GENE DEV, V17, P1507, DOI 10.1101/gad.256003; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAY JW, 1986, NATURE, V322, P752, DOI 10.1038/322752a0; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OGDEN JE, 1986, CURR GENET, V10, P509, DOI 10.1007/BF00447384; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Shiozaki K, 1998, MOL BIOL CELL, V9, P1339, DOI 10.1091/mbc.9.6.1339; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toone WM, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P57; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	28	95	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					507	512		10.1038/nature03590	http://dx.doi.org/10.1038/nature03590			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917811				2022-12-28	WOS:000229337800057
J	Badolato, A; Hennessy, K; Atature, M; Dreiser, J; Hu, E; Petroff, PM; Imamoglu, A				Badolato, A; Hennessy, K; Atature, M; Dreiser, J; Hu, E; Petroff, PM; Imamoglu, A			Deterministic coupling of single quantum dots to single nanocavity modes	SCIENCE			English	Article							CAVITY; MICROCAVITIES; PHOTONS; DEVICE	We demonstrate a deterministic approach to the implementation of solid-state cavity quantum electrodynamics (QED) systems based on a precise spatial and spectral overlap between a single self-assembled quantum dot and a photonic crystal membrane nanocavity. By fine-tuning nanocavity modes with a high quality factor into resonance with any given quantum dot exciton, we observed clear signatures of cavity QED (such as the Purcell effect) in all fabricated structures. This approach removes the major hindrances that had limited the application of solid-state cavity QED and enables the realization of experiments previously proposed in the context of quantum information processing.	ETH Honggerberg, Inst Quantum Elect, CH-8093 Zurich, Switzerland; Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Imamoglu, A (corresponding author), ETH Honggerberg, Inst Quantum Elect, CH-8093 Zurich, Switzerland.	imamoglu@phys.ethz.ch	Dreiser, Jan/W-6261-2018; Hu, Evelyn/AAD-8459-2019; Petroff, Pierre/M-9840-2019; Atature, Mete/ABD-9297-2020; Badolato, Antonio/E-9778-2015	Dreiser, Jan/0000-0001-7480-1271; Badolato, Antonio/0000-0001-8266-2902; Atature, Mete/0000-0003-3852-0944				Bruls DM, 2003, APPL PHYS LETT, V82, P3758, DOI 10.1063/1.1578709; DeSalvo GC, 1996, J ELECTROCHEM SOC, V143, P3652, DOI 10.1149/1.1837266; Gerard JM, 2003, TOP APPL PHYS, V90, P269; Hennessy K, 2003, APPL PHYS LETT, V83, P3650, DOI 10.1063/1.1623319; Hennessy K., 2004, PHOTONIC NANOSTRUCT, V2, P65; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Kiraz A, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.032305; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; PETER E, UNPUB; Petroff PM, 2001, PHYS TODAY, V54, P46, DOI 10.1063/1.1381102; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Reithmaier JP, 2004, NATURE, V432, P197, DOI 10.1038/nature02969; Schulhauser C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.193303; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Wang CF, 2004, APPL PHYS LETT, V85, P3423, DOI 10.1063/1.1806251; XIE QH, 1995, PHYS REV LETT, V75, P2542, DOI 10.1103/PhysRevLett.75.2542; Yoshie T, 2004, NATURE, V432, P200, DOI 10.1038/nature03119	19	569	580	6	139	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1158	1161		10.1126/science.1109815	http://dx.doi.org/10.1126/science.1109815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905398				2022-12-28	WOS:000229293400040
J	Gould, DB; Phalan, FC; Breedveld, GJ; van Mil, SE; Smith, RS; Schimenti, JC; Aguglia, U; van der Knaap, MS; Heutink, P; John, SWM				Gould, DB; Phalan, FC; Breedveld, GJ; van Mil, SE; Smith, RS; Schimenti, JC; Aguglia, U; van der Knaap, MS; Heutink, P; John, SWM			Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly	SCIENCE			English	Article							IV COLLAGEN; CAENORHABDITIS-ELEGANS; MOUSE; HEMIPLEGIA; LETHALITY; MICE	Porencephaly is a rare neurological disease, typically manifest in infants, which is characterized by the existence of degenerative cavities in the brain. To investigate the molecular pathogenesis of porencephaly, we studied a mouse mutant that develops porencephaly secondary to focal disruptions of vascular basement membranes. Half of the mutant mice died with cerebral hemorrhage within a day of birth, and similar to 18% of survivors had porencephaly. We show that vascular defects are caused by a semidominant mutation ill the procollagen type IV alpha 1 gene (CoNa1) in mice, which inhibits the secretion of mutant and normal type IV collagen. We also show that COL4A1 mutations segregate with porencephaly in human families. Because not all mutant mice develop porencephaly, we propose that CoNa1 mutations conspire with environmental trauma in causing the disease.	Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Erasmus Med Ctr, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Human Genet, Sect Med Genom, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Ctr Neurogenom & Cognit Res, NL-1081 BT Amsterdam, Netherlands; Univ Catanzaro, Reg Epilepsy Ctr, I-89100 Reggio Di Calabria, Italy; Free Univ Amsterdam, Med Ctr, Dept Child Neurol, NL-1081 BT Amsterdam, Netherlands; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA	Howard Hughes Medical Institute; Jackson Laboratory; Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Magna Graecia University of Catanzaro; Vrije Universiteit Amsterdam; Tufts University	John, SWM (corresponding author), Howard Hughes Med Inst, Bar Harbor, ME 04609 USA.	swmj@jax.org	Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951; Heutink, Peter/0000-0001-5218-1737	NCI NIH HHS [CA34196] Funding Source: Medline; NEI NIH HHS [EY11721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011721, R29EY011721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aguglia U, 2004, NEUROLOGY, V62, P1613, DOI 10.1212/01.WNL.0000123113.46672.68; BERG RA, 1983, ARCH NEUROL-CHICAGO, V40, P567, DOI 10.1001/archneur.1983.04050080067013; BLUMBERG B, 1987, J BIOL CHEM, V262, P5947; CATTANACH BM, 1993, MOUSE GENOME, V91, P853; Debus OM, 2004, ANN NEUROL, V56, P287, DOI 10.1002/ana.20184; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GOULD DB, UNPUB; Gupta MC, 1997, J CELL BIOL, V137, P1185, DOI 10.1083/jcb.137.5.1185; HAAR F, 1977, NEUROLOGY, V27, P849, DOI 10.1212/WNL.27.9.849; KEFALIDES NA, 1971, BIOCHEM BIOPH RES CO, V45, P226, DOI 10.1016/0006-291X(71)90073-8; Mancini GMS, 2004, EUR J PAEDIATR NEURO, V8, P45, DOI 10.1016/j.ejpn.2003.10.002; MAYNE R, 1984, J CELL BIOL, V98, P1637, DOI 10.1083/jcb.98.5.1637; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; PASTERNAK JF, 1980, AM J DIS CHILD, V134, P673, DOI 10.1001/archpedi.1980.02130190041010; POSCHL E, 2004, DEVELOPMENT; Rautavuoma K, 2004, P NATL ACAD SCI USA, V101, P14120, DOI 10.1073/pnas.0404966101; RENIERI A, 1994, NEPHRON, V67, P444, DOI 10.1159/000188020; SCHUPPAN D, 1980, FEBS LETT, V115, P297, DOI 10.1016/0014-5793(80)81191-4; SENSI A, 1990, CLIN GENET, V38, P396; SIBLEY MH, 1994, EMBO J, V13, P3278, DOI 10.1002/j.1460-2075.1994.tb06629.x; SMIT LME, 1984, BRAIN DEV-JPN, V6, P54, DOI 10.1016/S0387-7604(84)80010-8; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRUEB B, 1982, J BIOL CHEM, V257, P5239; Urabe N, 2002, ARCH HISTOL CYTOL, V65, P133, DOI 10.1679/aohc.65.133; Vilain C, 2002, AM J MED GENET, V112, P198, DOI 10.1002/ajmg.10452; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; ZONANA J, 1986, J PEDIATR-US, V109, P671, DOI 10.1016/S0022-3476(86)80240-2	29	358	373	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1167	1171		10.1126/science.1109418	http://dx.doi.org/10.1126/science.1109418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905400				2022-12-28	WOS:000229293400043
J	Mohn, A; Capanna, R; Chiarelli, F				Mohn, A; Capanna, R; Chiarelli, F			A girl with persistent hyperferritinaemia	LANCET			English	Editorial Material							CATARACT SYNDROME; MUTATION		Univ Chieti, Dept Pediat, Chieti, Italy	G d'Annunzio University of Chieti-Pescara	Mohn, A (corresponding author), Univ Chieti, Dept Pediat, Chieti, Italy.	amohn@unich.it						Adams Paul C, 2004, Clin Liver Dis, V8, P735, DOI 10.1016/j.cld.2004.06.002; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; Brooks DG, 2002, INVEST OPHTH VIS SCI, V43, P1121; Craig JE, 2003, ARCH OPHTHALMOL-CHIC, V121, P1753, DOI 10.1001/archopht.121.12.1753; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468	5	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 14	2005	365	9472					1744	1744		10.1016/S0140-6736(05)66549-X	http://dx.doi.org/10.1016/S0140-6736(05)66549-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	925VV	15894102				2022-12-28	WOS:000229082300027
J	Cowell, SJ; Newby, DE; Prescott, RJ; Bloomfield, P; Reid, J; Northridge, DB; Boon, NA				Cowell, SJ; Newby, DE; Prescott, RJ; Bloomfield, P; Reid, J; Northridge, DB; Boon, NA		SALTIRE Investigators	A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; RISK-FACTORS; FAMILIAL HYPERCHOLESTEROLEMIA; REDUCTASE INHIBITORS; VALVE CALCIFICATION; COMPUTED-TOMOGRAPHY; CHOLESTEROL LEVELS; APOLIPOPROTEIN-B; EARLY LESION; PROGRESSION	BACKGROUND: Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression. METHODS: In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score. RESULTS: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet velocity were 0.199+/-0.210 m per second per year in the atorvastatin group and 0.203+/-0.208 m per second per year in the placebo group (P=0.95; adjusted mean difference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year). Progression in valvular calcification was 22.3+/-21.0 percent per year in the atorvastatin group, and 21.7+/-19.8 percent per year in the placebo group (P=0.93; ratio of post-treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to 1.050). CONCLUSIONS: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression. This study cannot exclude a small reduction in the rate of disease progression or a significant reduction in major clinical end points. Long-term, large-scale, randomized, controlled trials are needed to establish the role of statin therapy in patients with calcific aortic stenosis.	Royal Infirm, Dept Cardiol, Edinburgh EH16 4SU, Midlothian, Scotland; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Borders Gen Hosp, Dept Radiol, Melrose, Roxburghshire, Scotland; Western Gen Hosp, Dept Cardiol, Edinburgh EH4 2XU, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Newby, DE (corresponding author), Royal Infirm, Dept Cardiol, Old Dalkeith Rd, Edinburgh EH16 4SU, Midlothian, Scotland.	d.e.newby@ed.ac.uk	Newby, David Ernest/AAB-1364-2019					Achenbach S, 2002, CIRCULATION, V106, P1077, DOI 10.1161/01.CIR.0000027567.49283.FF; Aronow WS, 2001, AM J CARDIOL, V88, P693, DOI 10.1016/S0002-9149(01)01821-5; Bahler RC, 1999, AM J CARDIOL, V84, P1044, DOI 10.1016/S0002-9149(99)00496-8; Bellamy MF, 2002, J AM COLL CARDIOL, V40, P1723, DOI 10.1016/S0735-1097(02)02496-8; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BROWN H, 1999, APPL MIXED MODELS ME, P239; Budoff MJ, 2000, AM J CARDIOL, V86, P8, DOI 10.1016/S0002-9149(00)00820-1; Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cowell SJ, 2003, CLIN RADIOL, V58, P712, DOI 10.1016/S0009-9260(03)00184-3; DAVIES SW, 1991, EUR HEART J, V12, P10, DOI 10.1093/oxfordjournals.eurheartj.a059815; FAGGIANO P, 1992, AM J CARDIOL, V70, P229, DOI 10.1016/0002-9149(92)91280-H; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Jones P, 1998, AM J CARDIOL, V82, P128; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KELLER C, 1986, KLIN WOCHENSCHR, V64, P338, DOI 10.1007/BF01711956; MAUTNER GC, 1992, AM J CARDIOL, V70, P539, DOI 10.1016/0002-9149(92)91206-J; Nassimiha D, 2001, AM J CARDIOL, V87, P1313, DOI 10.1016/S0002-9149(01)01531-4; Novaro GM, 2001, CIRCULATION, V104, P2205, DOI 10.1161/hc4301.098249; OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; Olsson M, 1999, ARTERIOSCL THROM VAS, V19, P1218, DOI 10.1161/01.ATV.19.5.1218; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Otto CM, 1999, NEW ENGL J MED, V341, P142, DOI 10.1056/NEJM199907153410302; Otto CM, 1997, CIRCULATION, V95, P2262, DOI 10.1161/01.CIR.95.9.2262; Palta S, 2000, CIRCULATION, V101, P2497, DOI 10.1161/01.CIR.101.21.2497; Peltier M, 2003, AM J CARDIOL, V91, P97, DOI 10.1016/S0002-9149(02)03010-2; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Pohle K, 2001, CIRCULATION, V104, P1927, DOI 10.1161/hc4101.097527; Rallidis L, 1998, HEART, V80, P583, DOI 10.1136/hrt.80.6.583; Rosenhek R, 2004, CIRCULATION, V110, P1291, DOI 10.1161/01.CIR.0000140723.15274.53; Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903; Shavelle DM, 2002, LANCET, V359, P1125, DOI 10.1016/S0140-6736(02)08161-8; SHEMESH J, 1995, RADIOLOGY, V197, P779, DOI 10.1148/radiology.197.3.7480756; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3; Treasure T, 1998, BRIT MED J, V317, P362; ZHAO XQ, 1993, CIRCULATION, V88, P2744, DOI 10.1161/01.CIR.88.6.2744; Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3	39	739	781	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2389	2397		10.1056/NEJMoa043876	http://dx.doi.org/10.1056/NEJMoa043876			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944423				2022-12-28	WOS:000229638900005
J	Bodenheimer, T				Bodenheimer, T			High and rising health care costs. Part 2: Technologic innovation	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; REGIONAL-VARIATIONS; MANAGED CARE; MEDICARE; CANADA; CONTAINMENT; GROWTH; CALIFORNIA; POLICIES; VOLUME	Technologic innovation, in combination with weak cost-containment measures, is a major factor in high and rising health care costs. Evidence suggests that improved health care technologies generally increase rather than reduce health care expenditures. Greater availability of such technologies as magnetic resonance imaging, computed tomography, coronary artery bypass graft, angioplasty, cardiac and neonatal intensive care units, positron emission tomography, and radiation oncology facilities is associated with greater per capita use and higher spending on these services. Because the spread of new technologies is relatively unrestrained in the United States, many of these technologies are used to a greater extent than in other nations, and the United States thereby incurs higher health care costs. Nations with a greater degree of health system integration have relied on expenditure controls and global budgets to control costs. Although diffusion of technology takes place more slowly in more tightly budgeted systems, the use of innovative technologies in those systems tends to catch up over time.	Univ Calif San Francisco, San Francisco, CA 94110 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco Gen Hosp, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodenheimer@medsch.ucsf.edu						Aaron H., 1991, SERIOUS UNSTABLE CON; Aaron HJ, 2003, NEW ENGL J MED, V349, P801, DOI 10.1056/NEJMe030091; Baker L, 2003, HLTH AFF MILLWOOD; Banta D, 2003, HEALTH POLICY, V63, P121, DOI 10.1016/S0168-8510(02)00059-3; Barer ML, 1996, HEALTH AFFAIR, V15, P216, DOI 10.1377/hlthaff.15.2.216; BARER ML, 1988, MILBANK Q, V66, P1, DOI 10.2307/3349985; Boccuti C, 2003, HEALTH AFFAIR, V22, P230, DOI 10.1377/hlthaff.22.2.230; Bodenheimer T, 2005, ANN INTERN MED, V142, P847, DOI 10.7326/0003-4819-142-10-200505170-00010; Chernew ME, 1998, MED CARE RES REV, V55, P259, DOI 10.1177/107755879805500301; Chernew ME, 2004, HEALTH AFFAIR, V23, P122, DOI 10.1377/hlthaff.23.6.122; CHRISTENSEN S, 1992, HEALTH SERV RES, V27, P65; *CTR MED MED SERV, 1996, NAT HLTH EXP TABL 6, P81; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; ENTHOVEN AC, 2003, EMPLOYMENT BASED HLT; Etheredge L, 2000, HEALTH AFFAIR, V19, P60, DOI 10.1377/hlthaff.19.5.60; EVANS RG, 1991, ANNU REV PUBL HEALTH, V12, P481, DOI 10.1146/annurev.pu.12.050191.002405; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fuchs VR, 2001, HEALTH AFFAIR, V20, P30, DOI 10.1377/hlthaff.20.5.30; Garber AM, 2001, HEALTH AFFAIR, V20, P62, DOI 10.1377/hlthaff.20.5.62; GELIJNS A, 1994, HEALTH AFFAIR, V13, P28, DOI 10.1377/hlthaff.13.3.28; GINSBURG PB, 1994, CRITICAL ISSUES US H, P132; HALVORSON G, 2003, EPIDEMIC CARE; Institute of Medicine, 2001, CROSS QUAL CHASM; *INT NETW AG HLTH, INAHTA; Kim M, 2001, HEALTH AFFAIR, V20, P194, DOI 10.1377/hlthaff.20.5.194; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; LAWRENCE D, 2002, CHAOS CARE; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; LUFT HS, 1994, CRITICAL ISSUES US H, V303, P303; MULLAN F, WRESTLING VARIATION; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; *ORG EC COOP DEV, 2003, DIS BAS COMP HLTH SY; Rawlins MD, 2004, NEW ENGL J MED, V351, P1383, DOI 10.1056/NEJMp048221; Reinhardt UE, 2002, HEALTH AFFAIR, V21, P169, DOI 10.1377/hlthaff.21.3.169; RICE TH, 1996, CHANGING US HLTH CAR, P81; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Royle P, 2003, Health Technol Assess, V7, pix; ROYLE P, 2003, HEALTH TECHNOL ASSES, V7, pR1; WEISSMAN JS, 2003, CONSUMERS REPORTS HL; WENNBER JE, PERSPECTIVE PRACTICE; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033; Yip WC, 1998, J HEALTH ECON, V17, P675, DOI 10.1016/S0167-6296(98)00024-1; 1921, HLTH AFF MILLWOOD, V20, P25	45	195	196	2	35	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					932	937		10.7326/0003-4819-142-11-200506070-00012	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	932LX	15941701				2022-12-28	WOS:000229556300008
J	Rabinowitz, PM				Rabinowitz, PM			Is noise bad for your health?	LANCET			English	Editorial Material							AIRCRAFT NOISE; CHILDREN		Yale Univ, Sch Med, Yale Occupat & Environm Med Program, New Haven, CT 06880 USA	Yale University	Rabinowitz, PM (corresponding author), Yale Univ, Sch Med, Yale Occupat & Environm Med Program, New Haven, CT 06880 USA.	Peter.rabinowitz@yale.edu						American National Standards Institute, 2002, S1260 ANSI; [Anonymous], 2003, J OCCUP ENVIRON MED, V45, P579; Chepesiuk R, 2005, ENVIRON HEALTH PERSP, V113, pA34, DOI 10.1289/ehp.113-a34; Cmiel CA, 2004, AM J NURS, V104, P40, DOI 10.1097/00000446-200402000-00019; Evans GW, 2004, AM J PUBLIC HEALTH, V94, P1942, DOI 10.2105/AJPH.94.11.1942; Franssen EAM, 2004, OCCUP ENVIRON MED, V61, P405, DOI 10.1136/oem.2002.005488; Hygge S, 2002, PSYCHOL SCI, V13, P469, DOI 10.1111/1467-9280.00483; Niskar AS, 1998, JAMA-J AM MED ASSOC, V279, P1071, DOI 10.1001/jama.279.14.1071; Schmidt CW, 2005, ENVIRON HEALTH PERSP, V113, pA42, DOI 10.1289/ehp.113-a606; Shield B, 2004, J ACOUST SOC AM, V115, P730, DOI 10.1121/1.1635837; WETHERILL EA, 2002, QUIET ZONE NEWSL FAL	11	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1908	1909		10.1016/S0140-6736(05)66637-8	http://dx.doi.org/10.1016/S0140-6736(05)66637-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	932XJ	15936405				2022-12-28	WOS:000229587800006
J	Cowman, AF; Crabb, BS				Cowman, AF; Crabb, BS			Revealing the molecular determinants of gender in malaria parasites	CELL			English	Editorial Material							PLASMODIUM-FALCIPARUM; GENOME SEQUENCE; LIFE-CYCLE; TRANSMISSION	Malaria parasites have a complex life cycle with asexual multiplication in a vertebrate host and obligate sexual reproduction in the mosquito; however, commitment to sexual development begins in the vertebrate with differentiation of female and male gametocytes. In this issue of Cell, Khan et al. (2005) used elegant approaches to purify male and female gametocytes and elucidated their respective proteome, providing the basis for understanding sexual development in this pathogen.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Crabb, Brendan/F-5287-2013; Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004				Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Rangarajan R, 2005, EMBO REP, V6, P464, DOI 10.1038/sj.embor.7400404; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342	10	0	0	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 3	2005	121	5					659	660		10.1016/j.cell.2005.05.014	http://dx.doi.org/10.1016/j.cell.2005.05.014			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935749	Bronze			2022-12-28	WOS:000229658000001
J	Lifton, RJ				Lifton, RJ			Americans as survivors	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; Cambridge Hlth Alliance, Cambridge, MA USA	Harvard University; Harvard Medical School; Harvard University; Cambridge Health Alliance	Lifton, RJ (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.							Bush George., 1992, PUBLIC PAPERS PRESID, P197; Lifton R.J., 2005, HOME WAR LEARNING VI; LIFTON RJ, 1987, FUTURE IMMORTALITY O, P231; Lindemann E, 1944, AM J PSYCHIAT, V101, P141, DOI 10.1176/ajp.101.2.141; MANN J, 2004, RISE VULCANS HIST BU, P52	5	24	25	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2263	2265		10.1056/NEJMp058048	http://dx.doi.org/10.1056/NEJMp058048			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930415				2022-12-28	WOS:000229446400001
J	Liu, YF; Chen, WM; Lin, YF; Yang, RC; Lin, MW; Li, LH; Chang, YH; Jou, YS; Lin, PY; Su, JS; Huang, SF; Hsiao, KJ; Fann, CSJ; Hwang, HW; Chen, YT; Tsai, SF				Liu, YF; Chen, WM; Lin, YF; Yang, RC; Lin, MW; Li, LH; Chang, YH; Jou, YS; Lin, PY; Su, JS; Huang, SF; Hsiao, KJ; Fann, CSJ; Hwang, HW; Chen, YT; Tsai, SF			Type II collagen gene variants and inherited osteonecrosis of the femoral head	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPONDYLOEPIPHYSEAL DYSPLASIA; AVASCULAR NECROSIS; COL2A1 MUTATION; SERINE SUBSTITUTION; CARTILAGE; GLYCINE; HYPOCHONDROGENESIS; LINKAGE; FAMILY; BONE	BACKGROUND: Avascular necrosis of the femoral head (ANFH) causes disability that often requires surgical intervention. Most cases of ANFH are sporadic, but we identified three families in which there was autosomal dominant inheritance of the disease and mapped the chromosomal position of the gene to 12q13. METHODS: We carried out haplotype analysis in the families, selected candidate genes from the critical interval for ANFH on 12q13, and sequenced the promoter and exonic regions of the type II collagen gene (COL2A1) from persons with inherited and sporadic forms of ANFH. RESULTS: We identified a G(rightarrow)A transition in exon 50 of COL2A1 in affected members of a four-generation family with ANFH. This transition predicts the replacement of glycine with serine at codon 1170 in a GXY repeat of type II collagen. Another pedigree was shown to harbor the same transition, but the mutant allele occurred on a different haplotype background. In a third family, a G(rightarrow)A transition in exon 33 of the gene, causing a glycine-to-serine change at codon 717, was detected. No mutation was found in the COL2A1 coding region in sporadic cases of ANFH. CONCLUSIONS: All the patients with familial ANFH whom we studied carried COL2A1 mutations. In families with ANFH, haplotype and sequence analysis of the COL2A1 gene can be used to identify carriers of the mutant allele before the onset of clinical symptoms, allowing the initiation of measures that may delay progression of the disease.	Natl Yang Ming Univ, Sch Med, Inst Genet, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Genome Res Ctr, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Surg, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Orthoped & Traumatol, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan; Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei, Taiwan; Taipei Municipal Chung Hsing Hosp, Div Orthoped & Traumatol, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital; Academia Sinica - Taiwan	Tsai, SF (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan.	petsai@nhri.org.tw	Jou, Yuh-Shan/O-5921-2018; Tsai, Shih-Feng/E-3997-2010; Fann, Cathy SJ/F-9410-2010; Huang, Shiu-Feng Kathy/E-3977-2010	Jou, Yuh-Shan/0000-0001-5090-3732; Fann, Cathy SJ/0000-0001-9025-2276; Hwang, Hun-Way/0000-0003-0522-1577				Agarwala S, 2002, RHEUMATOLOGY, V41, P346, DOI 10.1093/rheumatology/41.3.346-a; Assouline-Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724; BONAVENTURE J, 1995, BIOCHEM J, V307, P823, DOI 10.1042/bj3070823; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHAN D, 1991, J BIOL CHEM, V266, P12487; Chen WM, 2004, AM J HUM GENET, V75, P310, DOI 10.1086/422702; Christgau S, 2001, BONE, V29, P209, DOI 10.1016/S8756-3282(01)00504-X; COLE WG, 1993, J MED GENET, V30, P27, DOI 10.1136/jmg.30.1.27; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301-620X.67B1.3155745; Gardeniers JW, 1993, ARCO NEWS LETT, V5, P79; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HORTON WA, 1992, P NATL ACAD SCI USA, V89, P4583, DOI 10.1073/pnas.89.10.4583; Korkko J, 2000, AM J MED GENET, V92, P95, DOI 10.1002/(SICI)1096-8628(20000515)92:2<95::AID-AJMG3>3.0.CO;2-9; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Lieberman Jay R, 2003, Instr Course Lect, V52, P337; Lieberman JR, 2004, CLIN ORTHOP RELAT R, P29; Mont M.A., 1998, CLIN ORTHOPAEDICS RE, V355, pS314, DOI [10.1097/00003086-199810001-00032, DOI 10.1097/00003086-199810001-00032]; MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623-199503000-00018; Mortier GR, 2000, J MED GENET, V37, P263, DOI 10.1136/jmg.37.4.263; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; RITVANIEMI P, 1994, HUM MUTAT, V3, P261, DOI 10.1002/humu.1380030314; Rozen S, 2000, Methods Mol Biol, V132, P365; URBANIAK JR, 1995, J BONE JOINT SURG AM, V77A, P681, DOI 10.2106/00004623-199505000-00004; VISSING H, 1989, J BIOL CHEM, V264, P18265; WILLIAMS CJ, 1995, HUM MOL GENET, V4, P309, DOI 10.1093/hmg/4.2.309; WINTERPACHT A, 1995, HUM GENET, V95, P437; WINTERPACHT A, 1994, HUM MUTAT, V4, P257, DOI 10.1002/humu.1380040405	30	116	134	3	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2294	2301		10.1056/NEJMoa042480	http://dx.doi.org/10.1056/NEJMoa042480			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930420				2022-12-28	WOS:000229446400006
J	de Saussure, P; Soravia, C				de Saussure, P; Soravia, C			Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hosp, CH-1211 Geneva, Switzerland	University of Geneva	de Saussure, P (corresponding author), Univ Hosp, CH-1211 Geneva, Switzerland.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2222	2222		10.1056/NEJMicm041035	http://dx.doi.org/10.1056/NEJMicm041035			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917387	Green Published			2022-12-28	WOS:000229333300010
J	Cochella, L; Green, R				Cochella, L; Green, R			An active role for tRNA in decoding beyond codon : anticodon pairing	SCIENCE			English	Article							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR TU; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; GTP HYDROLYSIS; RIBOSOME; SPECIFICITY; DISCRIMINATION; RECOGNITION; SELECTION	During transfer RNA (tRNA) selection, a cognate codon:anticodon interaction triggers a series of events that ultimately results in the acceptance of that tRNA into the ribosome for peptide-bond formation. High-fidelity discrimination between the cognate tRNA and near- and noncognate ones depends both on their differential dissociation rates from the ribosome and on specific acceleration of forward rate constants by cognate species. Here we show that a mutant tRNA(Trp) carrying a single substitution in its D-arm achieves elevated levels of miscoding by accelerating these forward rate constants independent of codon:anticodon pairing in the decoding center. These data provide evidence for a direct role for tRNA in signaling its own acceptance during decoding and support its fundamental role during the evolution of protein synthesis.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Green, R (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	ragreen@jhmi.edu	Cochella, Luisa/B-6536-2016; Cochella, Luisa/AHD-8261-2022	Cochella, Luisa/0000-0003-4018-7722; Cochella, Luisa/0000-0003-4018-7722	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059425] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059425, R01GM059425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKINGHAM RH, 1977, P NATL ACAD SCI USA, V74, P5496, DOI 10.1073/pnas.74.12.5496; COCHELLA L, UNPUB; Daviter T, 2003, J MOL BIOL, V332, P689, DOI 10.1016/S0022-2836(03)00947-1; FAVRE A, 1975, NUCLEIC ACIDS RES, V2, P1421, DOI 10.1093/nar/2.8.1421; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; HIRSH, 1971, J MOL BIOL, V58, P439, DOI 10.1016/0022-2836(71)90362-7; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Piepenburg O, 2000, BIOCHEMISTRY-US, V39, P1734, DOI 10.1021/bi992331y; SMITH D, 1989, J MOL BIOL, V206, P489, DOI 10.1016/0022-2836(89)90496-8; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; VACHER J, 1979, J MOL BIOL, V129, P287; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Weinger JS, 2004, NAT STRUCT MOL BIOL, V11, P1101, DOI 10.1038/nsmb841; Woese CR, 2001, RNA, V7, P1055, DOI 10.1017/S1355838201010615; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	23	182	188	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1178	1180		10.1126/science.1111408	http://dx.doi.org/10.1126/science.1111408			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905403	Green Accepted			2022-12-28	WOS:000229293400046
J	Hanson, B				Hanson, B			Learning from natural disasters	SCIENCE			English	Editorial Material																			0	5	7	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2005	308	5725					1125	1125		10.1126/science.308.5725.1125	http://dx.doi.org/10.1126/science.308.5725.1125			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	928TA	15905390				2022-12-28	WOS:000229293400031
J	Jones, T; Ehardt, CL; Butynski, TM; Davenport, TRB; Mpunga, NE; Machaga, SJ; De Luca, DW				Jones, T; Ehardt, CL; Butynski, TM; Davenport, TRB; Mpunga, NE; Machaga, SJ; De Luca, DW			The highland mangabey Lophocebus kipunji: A new species of African monkey	SCIENCE			English	Article							UDZUNGWA MOUNTAINS; CONSERVATION; HOTSPOTS; PRIMATES	A distinct species of mangabey was independently found at two sites 370 kilometers apart in southern Tanzania (Mount Rungwe and Livingstone in the Southern Highlands and Ndundulu in the Udzungwa Mountains). This new species is described here and given the name "highland mangabey" Lophocebus kipunji sp. nov. We place this monkey in Lophocebus, because it possesses noncontrasting black eyelids and is arboreal. L. kipunji is distinguished from other mangabeys by the color of its pelage; long, upright crest; off-white tail and ventrum; and loud call. This find has implications for primate evolution, African biogeography, and forest conservation.	Udzungwa Mt Natl Pk, Mangula, Tanzania; Univ Georgia, Dept Anthropol, Athens, GA 30602 USA; Conservat Int, Nairobi, Kenya; Wildlife Conservat Soc, So Highlands Conservat Programme, Mbeya, Tanzania	University System of Georgia; University of Georgia	Jones, T (corresponding author), Udzungwa Mt Natl Pk, Box 99, Mangula, Tanzania.	tembomkubwa@gmail.com						Brooks TM, 2002, CONSERV BIOL, V16, P909, DOI 10.1046/j.1523-1739.2002.00530.x; Burgess N.D., 2000, Journal of East African Natural History, V87, P37, DOI 10.2982/0012-8317(1998)87[37:FIOTEA]2.0.CO;2; Davenport TRB, 2002, ORYX, V36, P224; DAVENPORT TRB, 2004, SOC CONS BIOL ABST, V48, P20; Dinesen L, 2001, BIOL CONSERV, V99, P223, DOI 10.1016/S0006-3207(00)00218-4; Doody K., 2001, W KILOMBERO SCARP FO; DOWSETT RJ, 1990, SURVEY FAUNA FLORA N, P111; Ehardt C. L., 2001, AFRICAN PRIMATES, V4, P15; Ehardt CL, 2005, INT J PRIMATOL, V26, P557, DOI 10.1007/s10764-005-4366-y; EHARDT CL, 1999, CONSERVATION ENDANGE; Fleagle JG, 1999, P NATL ACAD SCI USA, V96, P1157, DOI 10.1073/pnas.96.3.1157; GROVES C P, 1978, Primates, V19, P1, DOI 10.1007/BF02373224; Groves C.P., 2001, PRIMATE TAXONOMY; Grubb P, 2003, INT J PRIMATOL, V24, P1301, DOI 10.1023/B:IJOP.0000005994.86792.b9; Harris EE, 1998, MOL BIOL EVOL, V15, P892, DOI 10.1093/oxfordjournals.molbev.a025993; HARRISON MJS, 1988, J ZOOL, V215, P561, DOI 10.1111/j.1469-7998.1988.tb02860.x; Homewood K.M., 1981, International Journal of Primatology, V2, P47, DOI 10.1007/BF02692299; [ IUCN] INTERNATIONAL UNION FOR CONSERVATION OF NATURE, 2012, IUCN RED LIST CATEGO; Kingdon J, 2011, KINGDON FIELD GUIDE, V4th; Marshall AR, 2005, INT J PRIMATOL, V26, P127, DOI 10.1007/s10764-005-0011-z; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; PERKIN A, COMMUNICATION; Range F, 2004, ETHOLOGY, V110, P301, DOI 10.1111/j.1439-0310.2004.00973.x; WAKEHAMDAWSON A, 2002, B ZOOL NOMENCLATURE, V59, P18; Waser P.M., 1982, P117	25	93	101	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1161	1164		10.1126/science.1109191	http://dx.doi.org/10.1126/science.1109191			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905399				2022-12-28	WOS:000229293400041
J	Monot, M; Honore, N; Garnier, T; Araoz, R; Coppee, JY; Lacroix, C; Sow, S; Spencer, JS; Truman, RW; Williams, DL; Gelber, R; Virmond, M; Flageul, B; Cho, SN; Ji, BH; Paniz-Mondolfi, A; Convit, J; Young, S; Fine, PE; Rasolofo, V; Brennan, PJ; Cole, ST				Monot, M; Honore, N; Garnier, T; Araoz, R; Coppee, JY; Lacroix, C; Sow, S; Spencer, JS; Truman, RW; Williams, DL; Gelber, R; Virmond, M; Flageul, B; Cho, SN; Ji, BH; Paniz-Mondolfi, A; Convit, J; Young, S; Fine, PE; Rasolofo, V; Brennan, PJ; Cole, ST			On the origin of leprosy	SCIENCE			English	Article							MYCOBACTERIUM-LEPRAE; GENOME; TUBERCULOSIS; SEQUENCES; STRAINS; REPEATS; DNA	Leprosy, a chronic human disease with potentially debilitating neurological consequences, results from infection with Mycobacterium leprae. This unculturable pathogen has undergone extensive reductive evolution, with half of its genome now occupied by pseudogenes. Using comparative genomics, we demonstrated that all extant cases of leprosy are attributable to a single clone whose dissemination worldwide can be retraced from analysis of very rare single-nucleotide polymorphisms. The disease seems to have originated in Eastern Africa or the Near East and spread with successive human migrations. Europeans or North Africans introduced leprosy into West Africa and the Americas within the past 500 years.	Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Inst Pasteur, Genopole, PF2, Paris, France; Ctr Natl Appui Lutte Malad, Bamako, Mali; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Louisiana State Univ, BPHC, HRSA, DHHS,Natl Hansens Dis Program, Baton Rouge, LA 70894 USA; Leonard Wood Mem Ctr Leprosy Res, Cebu, Philippines; Inst Lauro de Souza Lima, Sao Paulo, Brazil; Hop St Louis, Paris, France; Yonsei Univ, Coll Med, Seoul, South Korea; Univ Paris 06, Paris, France; Inst Biomed, Caracas, Venezuela; London Sch Hyg & Trop Med, London WC1, England; Inst Pasteur Madagascar, Antananarivo, Madagascar	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Colorado State University; Louisiana State University System; Louisiana State University; United States Health Resources & Service Administration (HRSA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Yonsei University; Yonsei University Health System; UDICE-French Research Universities; Sorbonne Universite; University of London; London School of Hygiene & Tropical Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar	Cole, ST (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France.	stcole@pasteur.fr	Visentainer, Jeane/AAJ-1618-2021; Visentainer, Jeane Eliete Laguila/B-3510-2009; Lacroix, Claudine/N-2715-2015; Truman, Richard/E-3025-2013; Monot, Marc/F-3058-2015; Spencer, John S/G-6968-2017	Visentainer, Jeane Eliete Laguila/0000-0002-5815-7903; Lacroix, Claudine/0000-0002-0731-725X; Monot, Marc/0000-0003-0738-7335; Spencer, John S/0000-0002-8051-3038; ARAOZ, Romulo/0000-0003-0435-0297	NIAID NIH HHS [R01-AI47197-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047197] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 2001, TRENDS MICROBIOL, V9, P452, DOI 10.1016/S0966-842X(01)02131-X; BROWNE SG, 1985, LEPROSY; Cavalli-Sforza LL, 2003, NAT GENET, V33, P266, DOI 10.1038/ng1113; Cole ST, 2001, LEPROSY REV, V72, P449; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Eiglmeier K, 2001, LEPROSY REV, V72, P462; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; Eiglmeier K, 2001, LEPROSY REV, V72, P387; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Groathouse NA, 2004, J CLIN MICROBIOL, V42, P1666, DOI 10.1128/JCM.42.4.1666-1672.2004; Hansen GHA., 1874, NORSK MAG LAEGEVIDEN, V4, P1; Kidgell C, 2002, INFECT GENET EVOL, V2, P39, DOI 10.1016/S1567-1348(02)00089-8; KIRCHHEIMER W F, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P693; Lovett ST, 2004, MOL MICROBIOL, V52, P1243, DOI 10.1111/j.1365-2958.2004.04076.x; Marsollier L, 2002, APPL ENVIRON MICROB, V68, P4623, DOI 10.1128/AEM.68.9.4623-4628.2002; Matsuoka M, 2000, INT J LEPROSY, V68, P121; Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901; SHEPARD CC, 1965, J BACTERIOL, V89, P365, DOI 10.1128/JB.89.2.365-372.1965; Shin YC, 2000, J CLIN MICROBIOL, V38, P4535, DOI 10.1128/JCM.38.12.4535-4538.2000; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x; Truman R, 2004, J CLIN MICROBIOL, V42, P2558, DOI 10.1128/JCM.42.6.2558-2565.2004; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; Wirth T, 2004, P NATL ACAD SCI USA, V101, P4746, DOI 10.1073/pnas.0306629101; Young SK, 2004, J CLIN MICROBIOL, V42, P4931, DOI 10.1128/JCM.42.11.4931-4936.2004	30	301	318	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2005	308	5724					1040	1042		10.1126/science/1109759	http://dx.doi.org/10.1126/science/1109759			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927JR	15894530	Green Submitted			2022-12-28	WOS:000229190700052
J	Iwamoto, N; Umeda, H; Tominaga, N; Nomoto, K; Maeda, K				Iwamoto, N; Umeda, H; Tominaga, N; Nomoto, K; Maeda, K			The first chemical enrichment in the universe and the formation of hyper metal-poor stars	SCIENCE			English	Article							POPULATION-III; ABUNDANCE ANALYSIS; MASSIVE STARS; AGB STARS; NUCLEOSYNTHESIS; SUPERNOVAE; EVOLUTION; HE-0107-5240; ELEMENTS; RICH	The recent discovery of a hyper-metal-poor (HMP) star, with a metalticity Fe/H smaller than 1/1000,000 of the solar ratio, together with one earlier HMP star, has raised a challenging question whether these HMP stars are the actual first-generation, tow-mass stars of the universe. We argue that these HMP stars are second-generation stars formed from gases that were chemically enriched by the first-generation supernovae. The key to this solution is the very unusual abundance patterns of these HMP stars and the similarities and differences between them. We can reproduce these abundance features with core-collapse "faint" supernova models that include extensive matter mixing and fallback during explosions.	Univ Tokyo, Sch Sci, Dept Astron, Tokyo 1130033, Japan; Japan Atom Energy Res Inst, Nucl Data Ctr, Ibaraki 3191195, Japan; Univ Tokyo, Coll Arts & Sci, Dept Earth Sci & Astron, Tokyo 1538902, Japan	University of Tokyo; Japan Atomic Energy Agency; University of Tokyo	Nomoto, K (corresponding author), Univ Tokyo, Sch Sci, Dept Astron, Tokyo 1130033, Japan.	nomoto@astron.s.u-tokyo.ac.jp	Iwamoto, Nobuyuki/F-4477-2019	Maeda, Keiichi/0000-0003-2611-7269; Tominaga, Nozomu/0000-0001-8537-3153				Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; Aoki W, 2001, ASTROPHYS J, V561, P346, DOI 10.1086/323230; ASPLUND M, 2004, IN PRESS COSMIC ABUN; Bessell MS, 2004, ASTROPHYS J, V612, pL61, DOI 10.1086/424443; Cayrel R, 2004, ASTRON ASTROPHYS, V416, P1117, DOI 10.1051/0004-6361:20034074; Chieffi A, 2002, ASTROPHYS J, V577, P281, DOI 10.1086/342170; Chieffi A, 2001, ASTROPHYS J, V554, P1159, DOI 10.1086/321387; Frebel A, 2005, NATURE, V434, P871, DOI 10.1038/nature03455; Goriely S, 2000, ASTRON ASTROPHYS, V362, P599; Heger A, 2002, ASTROPHYS J, V567, P532, DOI 10.1086/338487; Heger A, 2000, ASTROPHYS J, V528, P368, DOI 10.1086/308158; Hill V, 2002, ASTRON ASTROPHYS, V387, P560, DOI 10.1051/0004-6361:20020434; Lucatello S, 2003, ASTRON J, V125, P875, DOI 10.1086/345886; Siess L, 2002, ASTROPHYS J, V570, P329, DOI 10.1086/339733; Siess L, 2004, ASTRON ASTROPHYS, V415, P1089, DOI 10.1051/0004-6361:20034281; Sneden C, 2003, ASTROPHYS J, V591, P936, DOI 10.1086/375491; Suda T, 2004, ASTROPHYS J, V611, P476, DOI 10.1086/422135; Umeda H, 2005, ASTROPHYS J, V619, P427, DOI 10.1086/426097; Umeda H, 2003, NATURE, V422, P871, DOI 10.1038/nature01571; Umeda H, 2002, ASTROPHYS J, V565, P385, DOI 10.1086/323946; Umeda H, 2000, ESO ASTROPHY SYMP, P150, DOI 10.1007/10719504_27; WEISS A, 2000, 1 STARS; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; [No title captured]	27	212	212	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 15	2005	309	5733					451	453		10.1126/science.1112997	http://dx.doi.org/10.1126/science.1112997			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	946LY	15933160				2022-12-28	WOS:000230574900041
J	Ohinata, Y; Payer, B; O'Carroll, D; Ancelin, K; Ono, Y; Sano, M; Barton, SC; Obukhanych, T; Nussenzweig, M; Tarakhovsky, A; Saitou, M; Surani, MA				Ohinata, Y; Payer, B; O'Carroll, D; Ancelin, K; Ono, Y; Sano, M; Barton, SC; Obukhanych, T; Nussenzweig, M; Tarakhovsky, A; Saitou, M; Surani, MA			Blimp1 is a critical determinant of the germ cell lineage in mice	NATURE			English	Article							CLONAL ANALYSIS; MOUSE EMBRYO; GENE-EXPRESSION; SPECIFICATION; FATE; GASTRULATION; MATURATION; GENERATION; EXCISION; PROGRAM	Germ cell fate in mice is induced in pluripotent epiblast cells in response to signals from extraembryonic tissues. The specification of approximately 40 founder primordial germ cells and their segregation from somatic neighbours are important events in early development. We have proposed that a critical event during this specification includes repression of a somatic programme that is adopted by neighbouring cells. Here we show that Blimp1 ( also known as Prdm1), a known transcriptional repressor, has a critical role in the foundation of the mouse germ cell lineage, as its disruption causes a block early in the process of primordial germ cell formation. Blimp1-deficient mutant embryos form a tight cluster of about 20 primordial germ cell-like cells, which fail to show the characteristic migration, proliferation and consistent repression of homeobox genes that normally accompany specification of primordial germ cells. Furthermore, our genetic lineage-tracing experiments indicate that the Blimp1-positive cells originating from the proximal posterior epiblast cells are indeed the lineage-restricted primordial germ cell precursors.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst Canc & Dev, Cambridge CB2 1QN, England; RIKEN Kobe Inst, Ctr Dev Biol, Lab Mammalian Germ Cell Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan; Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Mol Cell Biol & Dev, Sakyo Ku, Kyoto 6068502, Japan	University of Cambridge; RIKEN; Howard Hughes Medical Institute; Rockefeller University; Japan Science & Technology Agency (JST); Kyoto University	Surani, MA (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst Canc & Dev, Tennis Court Rd, Cambridge CB2 1QN, England.	saitou@cdb.riken.jp; as10021@mole.bio.cam.ac.uk	Payer, Bernhard/F-7353-2010; Ancelin, Katia/R-1719-2019; Nussenzweig, Michel/AAE-7292-2019	Payer, Bernhard/0000-0002-4694-2082; Ancelin, Katia/0000-0002-2117-9754; Surani, Azim/0000-0002-8640-4318; O'Carroll, Donal/0000-0002-8626-2217	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blackwell TK, 2004, CURR BIOL, V14, pR229, DOI 10.1016/j.cub.2004.02.052; Chang DH, 2002, MECH DEVELOP, V117, P305, DOI 10.1016/S0925-4773(02)00189-2; Cox WG, 1999, J HISTOCHEM CYTOCHEM, V47, P1443, DOI 10.1177/002215549904701110; Forlani S, 2003, DEVELOPMENT, V130, P3807, DOI 10.1242/dev.00573; GARDNER RL, 1985, J EMBRYOL EXP MORPH, V88, P349; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; GINSBURG M, 1990, DEVELOPMENT, V110, P521; Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LAWSON KA, 1994, CIBA F SYMP, V182, P68; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Lopes SMCD, 2004, GENE DEV, V18, P1838, DOI 10.1101/gad.294004; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; McLaren A, 2003, DEV BIOL, V262, P1, DOI 10.1016/S0012-1606(03)00214-8; Mesnard D, 2004, CURR BIOL, V14, P184, DOI 10.1016/j.cub.2004.01.026; Nagy A., 2003, MANIPULATING MOUSE E; Payer B, 2003, CURR BIOL, V13, P2110, DOI 10.1016/j.cub.2003.11.026; Perea-Gomez A, 2004, CURR BIOL, V14, P197, DOI 10.1016/j.cub.2004.01.030; Rossant J, 2004, DEV CELL, V7, P155, DOI 10.1016/j.devcel.2004.07.012; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Santos AC, 2004, CURR BIOL, V14, pR578, DOI 10.1016/j.cub.2004.07.018; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Seki Y, 2005, DEV BIOL, V278, P440, DOI 10.1016/j.ydbio.2004.11.025; Seydoux G, 1999, DEVELOPMENT, V126, P3275; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Surani MA, 2004, COLD SPRING HARB SYM, V69, P1, DOI 10.1101/sqb.2004.69.40; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Vincent SD, 2005, DEVELOPMENT, V132, P1315, DOI 10.1242/dev.01711; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	34	741	786	1	55	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 14	2005	436	7048					207	213		10.1038/nature03813	http://dx.doi.org/10.1038/nature03813			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	944VR	15937476				2022-12-28	WOS:000230459500030
J	Kruger, F; Ohrnberger, M				Kruger, F; Ohrnberger, M			Tracking the rupture of the M-w=9.3 Sumatra earthquake over 1,150 km at teleseismic distance	NATURE			English	Article							PROPAGATION; ARRAY	On 26 December 2004, a moment magnitude M-w = 9.3 earthquake occurred along Northern Sumatra, the Nicobar and Andaman islands, resulting in a devastating tsunami in the Indian Ocean region(1). The rapid and accurate estimation of the rupture length and direction of such tsunami-generating earthquakes is crucial for constraining both tsunami wave-height models as well as the seismic moment of the events. Compressional seismic waves generated at the hypocentre of the Sumatra earthquake arrived after about 12 min at the broadband seismic stations of the German Regional Seismic Network (GRSN)(2,3), located approximately 9,000 km from the event. Here we present a modification of a standard array-seismological approach and show that it is possible to track the propagating rupture front of the Sumatra earthquake over a total rupture length of 1,150 km. We estimate the average rupture speed to be 2.3-2.7 km s(-1) and the total duration of rupture to be at least 430 s, and probably between 480 and 500 s.	Univ Potsdam, Inst Geosci, D-14476 Golm, Germany	University of Potsdam	Kruger, F (corresponding author), Univ Potsdam, Inst Geosci, Karl Liebknecht Str 24, D-14476 Golm, Germany.	kruegerf@geo.uni-potsdam.de		Ohrnberger, Matthias/0000-0003-1068-0401				[Anonymous], 2005, WIKIPEDIA; GOLDSTEIN P, 1991, J GEOPHYS RES-SOLID, V96, P6187, DOI 10.1029/90JB02472; *GRSN, 2002, 25 GRSN SEN COMM GEO; Huang BS, 2001, GEOPHYS RES LETT, V28, P3377, DOI 10.1029/2001GL012954; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; KRUGER F, 1996, CAHIERS CTR EUR GEOD, V12, P251; LOMAX A, 2004, GEOPHYS RES ABSTR, V7, DOI UNSP EGU05-A-02543; Ni S, 2005, NATURE, V434, P582, DOI 10.1038/434582a; SCHWEITZER J, 2002, IASPEI NEW MANUAL SE, V1, P1; SPUDICH P, 1984, B SEISMOL SOC AM, V74, P2083; Stein S, 2005, NATURE, V434, P581, DOI 10.1038/434581a; *US DEP INT, 2005, US GEOL SURV EARTHQ; YAMANAKA Y, 2005, 04 12 26 OFF W COAST	13	180	193	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					937	939		10.1038/nature03696	http://dx.doi.org/10.1038/nature03696			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15908983				2022-12-28	WOS:000229799700045
J	Greenberger, MD; Vogelstein, R				Greenberger, MD; Vogelstein, R			Pharmacist refusals: A threat to women's health	SCIENCE			English	Editorial Material									Natl Womens Law Ctr, Washington, DC 20036 USA		Greenberger, MD (corresponding author), Natl Womens Law Ctr, Washington, DC 20036 USA.	riaser@nwlc.org						*AMWA, 2005, STAT AMWA SUPP PHARM; *APHA, 2003, POL STAT 2003 15; WINCKLER SC, 2004, UNPUB COMMUNICA 0701; 2005, N CAROLINA BOARD PHA, V26, P1; 2005, SUNDAY MIRROR   0227; 2005, FINANCIAL TIMES 0331	6	6	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1557	1558		10.1126/science.1114466	http://dx.doi.org/10.1126/science.1114466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947159				2022-12-28	WOS:000229827000026
J	Girish, MP; Gupta, MD				Girish, MP; Gupta, MD			Xanthomatous pseudospectacles in familial hypercholesterolemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									GB Pant Hosp, New Delhi 110002, India	Govind Ballabh Pant Institute of Postgraduate Medical Education & Research	Girish, MP (corresponding author), GB Pant Hosp, New Delhi 110002, India.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2424	2424		10.1056/NEJMicm040859	http://dx.doi.org/10.1056/NEJMicm040859			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944427				2022-12-28	WOS:000229638900009
J	Pai, M; Gokhale, K; Joshi, R; Dogra, S; Kalantri, S; Mendiratta, DK; Narang, P; Daley, CL; Granich, RM; Mazurek, GH; Reingold, AL; Riley, LW; Colford, JM				Pai, M; Gokhale, K; Joshi, R; Dogra, S; Kalantri, S; Mendiratta, DK; Narang, P; Daley, CL; Granich, RM; Mazurek, GH; Reingold, AL; Riley, LW; Colford, JM			Mycobacterium tuberculosis infection in health care workers in rural India - Comparison of a whole-blood interferon gamma assay with tuberculin skin testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	101st International Conference of the American-Thoracic-Society	MAY 20-25, 2005	San Diego, CA	Amer Thorac Soc, Fogarty AIDS Int Training & Res Program			ANNUAL RISK; PREVALENCE; DIAGNOSIS; ESAT-6; REACTIVITY; RESPONSES	Context Mycobacterium tuberculosis infection in health care workers has not been adequately studied in developing countries using newer diagnostic tests. Objectives To estimate latent tuberculosis infection prevalence in healthcare workers using the tuberculin skin test (TST) and a whole-blood interferon gamma (IFN-gamma) assay; to determine agreement between the tests; and to compare their correlation with risk factors. Design, Setting, and Participants A cross-sectional comparison study of 726 health care workers aged 18 to 61 years (median age, 22 years) with no history of active tuberculosis conducted from January to May 2004, at a rural medical school in India. A total of 493 (68%) of the health care workers had direct contact with patients with tuberculosis and 514 (71%) had BCG vaccine scars. Interventions Tuberculin skin testing was performed using 1-TU dose of purified protein derivative RT23, and the IFN-gamma assay was performed by measuring IFN-gamma response to early secreted antigenic target 6, culture filtrate protein 10, and a portion of tuberculosis antigen TB7.7. Main Outcome Measures Agreement between TST and the IFN-gamma assay, and comparison of the tests with respect to their association with risk factors. Results A large proportion of the health care workers were latently infected; 360 (50%) were positive by either TST or IFN-gamma assay, and 226 (31%) were positive by both tests. The prevalence estimates of TST and IFN-gamma assay positivity were comparable (41%; 95% confidence interval[CI], 38%-45% and 40%; 95% Cl, 37%-43%, respectively). Agreement between the tests was high (81.4%; kappa=0.61; 95% Cl, 0.56-0.67). Increasing age and years in the health profession were significant risk factors for both IFN-gamma assay and TST positivity. BCG vaccination had little impact on TST and IFN-gamma assay results. Conclusions Our study showed high latent tuberculosis infection prevalence in Indian health care workers, high agreement between TST and IFN-gamma assay, and similar association between positive test results and risk factors. Although TST and IFN-gamma assay appear comparable in this population, they have different performance and operational characteristics; therefore, the decision to select one test over the other will depend on the population, purpose of testing, and resource availability.	Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; Mahatma Gandi Inst Med Sci, Dept Med, Sevagram, India; Mahatma Gandi Inst Med Sci, Dept Microbiol, Sevagram, India; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Off WHO Representat India, New Delhi, India	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Mahatma Gandhi Institute of Medical Sciences, Sevagram; Mahatma Gandhi Institute of Medical Sciences, Sevagram; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; World Health Organization	Pai, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, 140 Warren Hall, Berkeley, CA 94720 USA.	madhupai@berkeley.edu	PAL, MRINAL/ABG-9676-2020; Kalantri, Shriprakash/ABG-9318-2021; Pai, Madhukar/AAX-9901-2021; Daley, Charles L./AAC-3231-2021	PAL, MRINAL/0000-0002-1032-272X; Kalantri, Shriprakash/0000-0002-1633-1029; Pai, Madhukar/0000-0003-3667-4536; Narang, Pratibha/0000-0001-6135-1857; Colford, John/0000-0002-3288-6956; Joshi, Rajnish/0000-0002-4702-0522	FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [1-D43-TW00003-16] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alonso-Echanove J, 2001, CLIN INFECT DIS, V33, P589, DOI 10.1086/321892; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2; [Anonymous], GUID PREV TUB HLTH C; [Anonymous], 1999, EPIDEMIOLOGIC BASIS; Arend SM, 2002, J INFECT DIS, V186, P1797, DOI 10.1086/345760; Brock L, 2004, AM J RESP CRIT CARE, V170, P65, DOI 10.1164/rccm.200402-232OC; Chadha V. K., 2004, Indian Journal of Pediatrics, V71, P1063, DOI 10.1007/BF02829815; Chadha V K, 2003, J Indian Med Assoc, V101, P144; Chadha V. K., 2003, Indian Journal of Tuberculosis, V50, P125; Chadha V. K., 2000, Indian Journal of Tuberculosis, V47, P139; Chadha Vineet K., 2001, Indian Journal of Pediatrics, V68, P53, DOI 10.1007/BF02728860; Chadha VK, 2005, INT J TUBERC LUNG D, V9, P116; Chadha VK, 2004, INT J TUBERC LUNG D, V8, P1437; Chadha VK, 2003, INT J TUBERC LUNG D, V7, P172; CHAKRABORTY AK, 1976, INDIAN J MED RES, V64, P639; Do AN, 1999, INT J TUBERC LUNG D, V3, P377; Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Geluk A, 2002, INFECT IMMUN, V70, P2544, DOI 10.1128/IAI.70.5.2544-2548.2002; Gopi PG, 2003, INT J TUBERC LUNG D, V7, P1154; Gopinath KG, 2004, J HOSP INFECT, V57, P339, DOI 10.1016/j.jhin.2004.03.029; GRANICH R, 2003, J INDIAN MED ASSOC, V101, P156; Granich Reuben, 2003, J Indian Med Assoc, V101, P150; Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Kassim S, 2000, INT J TUBERC LUNG D, V4, P321; Khatri GR, 2002, NEW ENGL J MED, V347, P1420, DOI 10.1056/NEJMsa020098; Lalvani A, 2003, THORAX, V58, P916, DOI 10.1136/thorax.58.11.916; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; Mazurek Gerald H, 2003, MMWR Recomm Rep, V52, P15; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; Menzies D, 2003, AM J RESP CRIT CARE, V167, P599, DOI 10.1164/rccm.200208-873BC; MENZIES RI, 2000, LUNG BIOL HEALTH DIS, V144, P279; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Narang P, 1999, INT J TUBERC LUNG D, V3, P478; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Rao KG, 2004, INT J TUBERC LUNG D, V8, P1392; *REV NAT TUB CONTR, 1997, TECHN GUID TUB CONTR; Richeldi L, 2004, AM J RESP CRIT CARE, V170, P288, DOI 10.1164/rccm.200403-307OC; Sepkowitz KA, 1996, TUBERCLE LUNG DIS, V77, P81, DOI 10.1016/S0962-8479(96)90081-7; Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804; Watkins RE, 2000, INT J TUBERC LUNG D, V4, P895	45	275	281	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2746	2755		10.1001/jama.293.22.2746	http://dx.doi.org/10.1001/jama.293.22.2746			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	933OV	15941804	Bronze			2022-12-28	WOS:000229643700023
J	Dijkgraaf, MGW; van der Zanden, BP; de Borgie, CAJM; Blanken, P; van Ree, JM; van den Brink, W				Dijkgraaf, MGW; van der Zanden, BP; de Borgie, CAJM; Blanken, P; van Ree, JM; van den Brink, W			Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL PRESCRIPTION; EUROQOL	Objective To determine the cost utility of medical co-prescription of heroin compared with methadone maintenance treatment for chronic, treatment resistant heroin addicts. Design Cost utility analysis of two pooled open label randomised controlled trials. Setting Methadone maintenance programmes in six cities in the Netherlands. Participants 430 heroin addicts. Interventions Inhalable or injectable heroin prescribed over 12 months. Methadone (maximum 150 mg a day) plus heroin (maximum 1000 mg a day) compared with methadone alone (maximum 150 mg a day). Psychosocial treatment was offered throughout. Main outcome measures One year costs estimated from a societal perspective. Quality adjusted life years (QALYs) based on responses to the EuroQol EQ-5D at baseline and during the treatment period. Results Co-prescription of heroin was associated with 0.058 more QALYs per patient per year (95% confidence interval 0.016 to 0.099) and a mean saving of E12 793 (8793 pound, $16 122) (E1083 to E25 229) per patient per year. The higher programme costs (E16 222; lower 95% confidence limit E15 084) were compensated for by lower costs of law enforcement (- E4129; upper 95% confidence limit - E486) and damage to victims of crime (- E25 374; upper 95% confidence limit - E16 625). The results were robust for die use of national EQ-5D tariffs and for the exclusion of the initial implementation costs of heroin treatment. Completion of treatment is essential; having participated in any abstinence treatment in the past is not. Conclusions Co-prescription of heroin is cost effective compared with treatment with methadone alone for chronic, treatment resistant heroin addicts.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands; Cent Comm Treatment Heroin Addicts CCBH, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	Dijkgraaf, MGW (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, J1B-216,POB 22700, NL-1100 DE Amsterdam, Netherlands.	m.g.dijkgraaf@amc.uva.nl	Dijkgraaf, Marcel GW/G-6663-2011; Blanken, Peter/C-1054-2008; Blanken, Peter/J-4209-2012	Blanken, Peter/0000-0003-4847-4259				Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Barnett PG, 2000, MT SINAI J MED, V67, P365; Blanken P, 2005, ADDICTION, V100, P89, DOI 10.1111/j.1360-0443.2005.00937.x; Brehmer C, 2001, FORENSIC SCI INT, V121, P23, DOI 10.1016/S0379-0738(01)00448-0; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; *CENTR BUR STAT, 2003, US TERR DAT 1996; Coast J, 2004, BRIT MED J, V329, P1233, DOI 10.1136/bmj.329.7476.1233; *COLL TAR GEZ, 2001, BEL 3 686 BIJL 2 BIJ; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Doran CM, 2003, DRUG ALCOHOL DEPEN, V71, P295, DOI 10.1016/S0376-8716(03)00169-8; Gold MR, 1996, COST EFFECTIVENESS H; Gutzwiller F, 2000, COST BENEFIT ANAL HE, V2; KAPTEIN HJM, 2003, KERNGEGEVENS WINKELC; Kokkevi A., 1995, EUR ADDICT RES, V1, P208, DOI [10.1159/000259089, DOI 10.1159/000259089]; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; Masson CL, 2004, ADDICTION, V99, P718, DOI 10.1111/j.1360-0443.2004.00728.x; Oostenbrink JB, 2003, PHARMACOECONOMICS, V21, P263, DOI 10.2165/00019053-200321040-00004; Oostenbrink JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002; OOSTENBRINK JB, 2000, HANDLEIDING KASTEMON; Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13; Rehm J, 2001, LANCET, V358, P1417, DOI 10.1016/S0140-6736(01)06529-1; Richardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901; ROES T, 2001, SOCIALE STAAT NEDERL; SCHREUDERS MM, 1999, CRIMINALITEIT RECHTS; Sindelar JL, 2004, DRUG ALCOHOL DEPEN, V73, P41, DOI 10.1016/j.drugalcdep.2003.09.002; van den Brink W, 2003, BRIT MED J, V327, P310, DOI 10.1136/bmj.327.7410.310; VANDENBRINK W, 2002, MED COPRESCRIPTION H; VANDERKUY A, 2000, FARMACOTHERAPEUTSCH, P965; VANDERZANDEN BP, 2004, TYPE FREQUENCY COSTS	29	82	82	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1297	1300A		10.1136/bmj.330.7503.1297	http://dx.doi.org/10.1136/bmj.330.7503.1297			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	933TL	15933353	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000229655700020
J	Mattson, MP				Mattson, MP			The need for controlled studies of the effects of meal frequency on health	LANCET			English	Editorial Material							DIETARY RESTRICTION; GLUCOSE-METABOLISM; DISEASE; TERM		NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattson, MP (corresponding author), NIA, Neurosci Lab, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [ZIAAG000315, Z01AG000315] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adlouni A, 1997, ANN NUTR METAB, V41, P242, DOI 10.1159/000177999; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Aybak M, 1996, EUR J APPL PHYSIOL, V73, P552, DOI 10.1007/BF00357678; BEAUCHENE RE, 1986, J GERONTOL, V41, P13, DOI 10.1093/geronj/41.1.13; Bell HE, 1997, ACTA MATH HUNG, V77, P57, DOI 10.1023/A:1006531605931; Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Duan WZ, 2003, P NATL ACAD SCI USA, V100, P2911, DOI 10.1073/pnas.0536856100; FABRY P, 1964, LANCET, V2, P614; GEHRIG JJ, 1988, KIDNEY INT, V34, P620, DOI 10.1038/ki.1988.226; GOODRICK CL, 1983, J GERONTOL, V38, P36, DOI 10.1093/geronj/38.1.36; HOFMEKLER O, 2001, WARRIOR DIET; JENKINS DJA, 1989, NEW ENGL J MED, V321, P929, DOI 10.1056/NEJM198910053211403; Keski-Rahkonen A, 2003, EUR J CLIN NUTR, V57, P842, DOI 10.1038/sj.ejcn.1601618; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Martin A, 2000, BRIT J NUTR, V84, P337, DOI 10.1017/S0007114500001616; Mattson MP, 2003, ANN INTERN MED, V139, P441, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00012; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; Rocha NS, 2002, TERATOGEN CARCIN MUT, V22, P129, DOI 10.1002/tcm.10005; Rollo F, 2002, P NATL ACAD SCI USA, V99, P12594, DOI 10.1073/pnas.192184599; Speechly DP, 1999, APPETITE, V33, P285, DOI 10.1006/appe.1999.0265; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wan RQ, 2003, J NUTR, V133, P1921, DOI 10.1093/jn/133.6.1921; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2; Zhu HY, 1999, BRAIN RES, V842, P224, DOI 10.1016/S0006-8993(99)01827-2; Zimmet P, 2003, J INTERN MED, V254, P114, DOI 10.1046/j.1365-2796.2003.01170.x	26	47	47	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1978	1980		10.1016/S0140-6736(05)66667-6	http://dx.doi.org/10.1016/S0140-6736(05)66667-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936428				2022-12-28	WOS:000229587800035
J	Wyers, F; Rougemaille, M; Badis, G; Rousselle, JC; Dufour, ME; Boulay, J; Regnault, B; Devaux, F; Namane, A; Seraphin, B; Libri, D; Jacquier, A				Wyers, F; Rougemaille, M; Badis, G; Rousselle, JC; Dufour, ME; Boulay, J; Regnault, B; Devaux, F; Namane, A; Seraphin, B; Libri, D; Jacquier, A			Cryptic Pol II transcripts are degraded by a nuclear quality control pathway involving a new poly(A) polymerase	CELL			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; YEAST EXOSOME; PROTEIN; POLYADENYLATION; DEGRADATION; COMPLEXES; CYTOPLASM; INHIBIT; FAMILY	Since detection of an RNA molecule is the major criterion to define transcriptional activity, the fraction of the genome that is expressed is generally considered to parallel the complexity of the transcriptome. We show here that several supposedly silent intergenic regions in the genome of S. cerevisiae are actually transcribed by RNA polymerase 11, suggesting that the expressed fraction of the genome is higher than anticipated. Surprisingly, however, RNAs originating from these regions are rapidly degraded by the combined action of the exosome and a new poly(A) polymerase activity that is defined by the Trf4 protein and one of two RNA binding proteins, Air1p or Air2p. We show that such a polyadenylation-assisted degradation mechanism is also responsible for the degradation of several Pol I and Pol III transcripts. Our data strongly support the existence of a posttranscriptional quality control mechanism limiting inappropriate expression of genetic information.	Inst Pasteur, URA 2171, CNRS, Unite Genet Interact Macromol, F-75724 Paris, France; Inst Pasteur, URA 2185, CNRS, PT Proteom, F-75724 Paris, France; Inst Pasteur, PT Puces ADN, F-75724 Paris, France; CNRS, UPR 2167, Ctr Mol Genet, F-99190 Gif Sur Yvette, France; CNRS, UPR 2167, Equipe Labelisee Ligue, F-99190 Gif Sur Yvette, France; CNRS, Ecole Normale Super, Genet Mol Lab, UMR 8541, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Seraphin, B (corresponding author), Inst Pasteur, URA 2171, CNRS, Unite Genet Interact Macromol, F-75724 Paris, France.	bertrand.seraphin@cgm.cnrs-gif.fr; dominico.libri@cgm.cnrs-gif.fr; jacquier@pasteur.fr	DEVAUX, Frédéric/N-2288-2019; Namane, Abdelkader/O-1857-2013; Badis-Breard, Gwenael/AAE-3783-2019	DEVAUX, Frédéric/0000-0002-0039-9096; Namane, Abdelkader/0000-0001-7180-7619; REGNAULT, Beatrice/0000-0002-3914-1914; Rougemaille, Mathieu/0000-0002-9675-3888; Badis-Breard, Gwenael/0000-0003-2078-3076; Seraphin, Bertrand/0000-0002-5168-1921; JACQUIER, ALAIN/0000-0001-5707-9184				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Castano IB, 1996, NUCLEIC ACIDS RES, V24, P2404, DOI 10.1093/nar/24.12.2404; Das B, 2003, MOL CELL BIOL, V23, P5502, DOI 10.1128/MCB.23.16.5502-5515.2003; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; EGYHAZI E, 1976, CELL, V7, P507, DOI 10.1016/0092-8674(76)90201-4; Fleischmann J, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-17; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inoue K, 2000, J BIOL CHEM, V275, P32793, DOI 10.1074/jbc.M004560200; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Johnson AW, 1997, MOL CELL BIOL, V17, P6122, DOI 10.1128/MCB.17.10.6122; Johnson JM, 2005, TRENDS GENET, V21, P93, DOI 10.1016/j.tig.2004.12.009; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Kuai L, 2004, P NATL ACAD SCI USA, V101, P8581, DOI 10.1073/pnas.0402888101; Kwak JE, 2004, P NATL ACAD SCI USA, V101, P4407, DOI 10.1073/pnas.0400779101; LaCava J, 2005, CELL, V121, P713, DOI 10.1016/j.cell.2005.04.029; Liang S, 1996, MOL CELL BIOL, V16, P5139; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Proudfoot N, 2002, CURR BIOL, V12, pR855, DOI 10.1016/S0960-9822(02)01353-2; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; RUUSALA T, 1984, EMBO J, V3, P2575, DOI 10.1002/j.1460-2075.1984.tb02176.x; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Torchet C, 2002, MOL CELL, V9, P1285, DOI 10.1016/S1097-2765(02)00544-0; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Westendorp RGJ, 2004, EMBO REP, V5, P2, DOI 10.1038/sj.embor.7400059	40	666	681	1	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					725	737		10.1016/j.cell.2005.04.030	http://dx.doi.org/10.1016/j.cell.2005.04.030			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935759	Bronze			2022-12-28	WOS:000229658000011
J	Goodnow, CC; Sprent, J; Fazekas de St Groth, B; Vinuesa, CG				Goodnow, CC; Sprent, J; Fazekas de St Groth, B; Vinuesa, CG			Cellular and genetic mechanisms of self tolerance and autoimmunity	NATURE			English	Review							E3 UBIQUITIN LIGASE; REACTIVE T-CELLS; B-CELLS; NEGATIVE SELECTION; CLONAL DELETION; V(D)J RECOMBINATION; HUMORAL IMMUNITY; GERMINAL-CENTERS; CO-STIMULATION; HUMAN THYMUS	The mammalian immune system has an extraordinary potential for making receptors that sense and neutralize any chemical entity entering the body. Inevitably, some of these receptors recognize components of our own body, and so cellular mechanisms have evolved to control the activity of these 'forbidden' receptors and achieve immunological self tolerance. Many of the genes and proteins involved are conserved between humans and other mammals. This provides the bridge between clinical studies and mechanisms defined in experimental animals to understand how sets of gene products coordinate self-tolerance mechanisms and how defects in these controls lead to autoimmune disease.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Australian Natl Univ, Australian Phenon Facil, Canberra, ACT 2601, Australia; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Centenary Inst Canc Med & Cell Biol, Newtown, NSW 2042, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Scripps Research Institute; University of Sydney; Centenary Institute	Goodnow, CC (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.	Chris.Goodnow@anu.edu.au	Goodnow, Christopher C/V-8108-2018; Vinuesa, Carola G/B-1108-2010; de St Groth, Barbara Fazekas/O-3017-2017	Goodnow, Christopher C/0000-0001-5296-6155; Vinuesa, Carola G/0000-0001-9799-0298; de St Groth, Barbara Fazekas/0000-0001-6817-9690	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Akkaraju S, 1997, J EXP MED, V186, P2005, DOI 10.1084/jem.186.12.2005; Anandasabapathy N, 2003, IMMUNITY, V18, P535, DOI 10.1016/S1074-7613(03)00084-0; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Ang CW, 2004, TRENDS IMMUNOL, V25, P61, DOI 10.1016/j.it.2003.12.004; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; BELL SE, 1994, EMBO J, V13, P816, DOI 10.1002/j.1460-2075.1994.tb06324.x; Benschop RJ, 2001, IMMUNITY, V14, P33, DOI 10.1016/S1074-7613(01)00087-5; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Choisy-Rossi CM, 2004, J IMMUNOL, V173, P3791, DOI 10.4049/jimmunol.173.6.3791; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coles AJ, 1999, LANCET, V354, P1691, DOI 10.1016/S0140-6736(99)02429-0; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Fields ML, 2003, CURR OPIN IMMUNOL, V15, P709, DOI 10.1016/j.coi.2003.09.016; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Gao JX, 2002, J EXP MED, V195, P959, DOI 10.1084/jem.20011948; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Grossman Z, 2000, SEMIN IMMUNOL, V12, P197, DOI 10.1006/smim.2000.0232; HAN SH, 1995, J IMMUNOL, V155, P556; Hanahan D, 1998, CURR OPIN IMMUNOL, V10, P656, DOI 10.1016/S0952-7915(98)80085-X; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Hippen KL, 2000, J EXP MED, V191, P883, DOI 10.1084/jem.191.5.883; Hornum L, 2002, DIABETES, V51, P1972, DOI 10.2337/diabetes.51.6.1972; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; Inobe M, 2004, J IMMUNOL, V173, P7239, DOI 10.4049/jimmunol.173.12.7239; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jankovic M, 2004, ANNU REV IMMUNOL, V22, P485, DOI 10.1146/annurev.immunol.22.012703.104707; Jeon MS, 2004, IMMUNITY, V21, P167, DOI 10.1016/j.immuni.2004.07.013; Kanagawa O, 1998, P NATL ACAD SCI USA, V95, P1721, DOI 10.1073/pnas.95.4.1721; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; King C, 2004, CELL, V117, P265, DOI 10.1016/S0092-8674(04)00335-6; Kishimoto H, 2001, NAT IMMUNOL, V2, P1025, DOI 10.1038/ni726; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Kroczek RA, 2004, CURR OPIN IMMUNOL, V16, P321, DOI 10.1016/j.coi.2004.03.002; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; Le Deist F, 2004, IMMUNOL REV, V200, P142, DOI 10.1111/j.0105-2896.2004.00169.x; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lesage S, 2002, J EXP MED, V196, P1175, DOI 10.1084/jem.20020735; Lesley R, 2004, IMMUNITY, V20, P441, DOI 10.1016/S1074-7613(04)00079-2; Liston A, 2004, IMMUNITY, V21, P817, DOI 10.1016/S1074-7613(04)00313-9; Liston A, 2004, J EXP MED, V200, P1015, DOI 10.1084/jem.20040581; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; MacMurray AJ, 2002, GENOME RES, V12, P1029, DOI 10.1101/gr.412702; Mandik-Nayak L, 2002, P NATL ACAD SCI USA, V99, P14368, DOI 10.1073/pnas.182549099; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; McCarty N, 2005, NAT IMMUNOL, V6, P65, DOI 10.1038/ni1145; Monach PA, 2004, ADV IMMUNOL, V82, P217, DOI 10.1016/S0065-2776(04)82005-4; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nagata S, 1998, J HUM GENET, V43, P2, DOI 10.1007/s100380050029; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Nemazee D, 2003, CURR OPIN IMMUNOL, V15, P182, DOI 10.1016/S0952-7915(03)00008-6; Palmer E, 2003, NAT REV IMMUNOL, V3, P383, DOI 10.1038/nri1085; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Ray SK, 1996, P NATL ACAD SCI USA, V93, P2019, DOI 10.1073/pnas.93.5.2019; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; Richardson B, 2003, CLIN IMMUNOL, V109, P72, DOI 10.1016/S1521-6616(03)00206-7; Rosen A, 2001, NAT MED, V7, P664, DOI 10.1038/89034; Rui LX, 2003, NAT IMMUNOL, V4, P594, DOI 10.1038/ni924; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Scofield RH, 2004, LANCET, V363, P1544, DOI 10.1016/S0140-6736(04)16154-0; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Shiono H, 2003, ANN NY ACAD SCI, V998, P237, DOI 10.1196/annals.1254.026; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Smith K, 2001, J EXP MED, V194, P1253, DOI 10.1084/jem.194.9.1253; Sprent J, 2002, IMMUNOL REV, V185, P126, DOI 10.1034/j.1600-065X.2002.18512.x; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Strasser A, 2003, IMMUNOL REV, V193, P82, DOI 10.1034/j.1600-065X.2003.00036.x; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Thien M, 2004, IMMUNITY, V20, P785, DOI 10.1016/j.immuni.2004.05.010; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Villunger A, 2004, P NATL ACAD SCI USA, V101, P7052, DOI 10.1073/pnas.0305757101; Walker LSK, 2000, IMMUNOL TODAY, V21, P333, DOI 10.1016/S0167-5699(00)01636-4; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Weyand CM, 2001, AM J PATHOL, V159, P787, DOI 10.1016/S0002-9440(10)61751-8; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; Wipke BT, 2004, J IMMUNOL, V172, P7694, DOI 10.4049/jimmunol.172.12.7694; Wong P, 2001, J EXP MED, V193, P1179, DOI 10.1084/jem.193.10.1179; Xu LG, 2002, J LEUKOCYTE BIOL, V72, P410; Yokoi N, 2002, NAT GENET, V31, P391, DOI 10.1038/ng927; Zerrahn J, 1997, CELL, V88, P627, DOI 10.1016/S0092-8674(00)81905-4; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	99	485	504	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					590	597		10.1038/nature03724	http://dx.doi.org/10.1038/nature03724			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931211				2022-12-28	WOS:000229476200036
J	Dalziel, SR; Walker, NK; Parag, V; Martell, C; Rea, HH; Rodgers, A; Harding, JE				Dalziel, SR; Walker, NK; Parag, V; Martell, C; Rea, HH; Rodgers, A; Harding, JE			Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randornised controlled trial	LANCET			English	Article							BIRTH-WEIGHT; GLUCOCORTICOID TREATMENT; PRENATAL EXPOSURE; BLOOD-PRESSURE; INDEX; AGE	Background Antenatal betamethasone treatment is widely used for the prevention of neonatal respiratory distress syndrome in preterm infants and substantially reduces neonatal mortality and morbidity. Fetal exposure to excess glucocorticoids has been proposed as one of the core mechanisms of the fetal origins of adult disease hypothesis. We assessed whether antenatal exposure to betamethasone for the prevention of neonatal respiratory distress syndrome affects cardiovascular risk factors at 30 years of age. Methods We followed up at age 30 years 534 individuals whose mothers participated in a double-blind, placebo-controlled, randomised trial of antenatal betamethasone for the prevention of neonatal respiratory distress syndrome. Mothers received two doses of betamethasone or placebo given by intramuscular injection 24 h apart. Follow-up assessments included anthropometry; measurement of blood pressure, blood lipids (after overnight fasting), and early morning cortisol levels; and a 75 g oral glucose tolerance test. Findings There were no differences between those exposed to betamethasone and to placebo in body size, blood lipids, blood pressure, plasma cortisol, prevalence of diabetes, or history of cardiovascular disease. After a 75 g oral glucose tolerance test, participants exposed to betamethasone had higher plasma insulin concentrations at 30 min (60.5 vs 52.0 mIU/L; ratio of geometric means 1.16 [95% CI 1.03 to 1.31], p=0.02) and lower glucose concentrations at 120 min (4.8 vs 5.1 mmol/L; difference -0.26 mmol/L [-0.53 to 0.001, p=0.05) than did those exposed to placebo. Interpretation Antenatal exposure to betamethasone might result in insulin resistance in adult offspring, but has no clinical effect on cardiovascular risk factors at 30 years of age. Thus, obstetricians should continue to use a single course of antenatal betamethasone for the prevention of neonatal respiratory distress syndrome.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand; Univ Auckland, Div Maori & Pacific Hlth, Auckland 1, New Zealand; Univ Auckland, Dept Med, Auckland, New Zealand	University of Auckland; University of Auckland; University of Auckland; University of Auckland	Harding, JE (corresponding author), Univ Auckland, Liggins Inst, Private Bag 92019, Auckland 1, New Zealand.	j.harding@auckland.ac.nz	Harding, Jane E/J-5853-2015	Harding, Jane E/0000-0003-2697-1422; Rodgers, Anthony/0000-0003-1282-1896				Aghajafari F, 2002, AM J OBSTET GYNECOL, V186, P843, DOI 10.1067/mob.2002.121624; [Anonymous], 1994, NIH Consens Statement, V12, P1; [Anonymous], 1999, SAS SYST WIND; Barker DJP, 1998, MOTHERS BABIES HLTH; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Bland JM, 1996, BMJ-BRIT MED J, V312, P1153; Crowley P, 2007, COCHRANE DB SYST REV, V18, DOI [10.1002/14651858.CD000065, DOI 10.1002/14651858.CD000065, 10.1002/14651858.CD000065.pub2, DOI 10.1002/14651858.CD000065.PUB2]; Davis P, 1999, AUST NZ J PUBL HEAL, V23, P27, DOI 10.1111/j.1467-842X.1999.tb01201.x; Dessens AB, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.6.e77; Dodic M, 1998, CLIN SCI, V94, P149, DOI 10.1042/cs0940149; Doyle LW, 2000, CLIN SCI, V98, P137, DOI 10.1042/CS19990211; Erickson K, 2001, OBSTET GYNECOL, V97, P140, DOI 10.1016/S0029-7844(00)01122-4; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Howie RN, 1977, PRE TERM LAB P 5 STU, p:281; Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3; Kind KL, 2002, EXP PHYSIOL, V87, P469, DOI 10.1111/j.1469-445X.2002.tb00060.x; LIGGINS GC, 1972, PEDIATRICS, V50, P515; Liu L, 2001, AM J PHYSIOL-ENDOC M, V280, pE729, DOI 10.1152/ajpendo.2001.280.5.E729; MACARTHUR BA, 1982, PEDIATRICS, V70, P99; MACEWAN I, 1995, UPPER LIMITS RESPONS; Martin Joyce A, 2003, Natl Vital Stat Rep, V52, P1; Meadow WL, 2003, OBSTET GYNECOL, V102, P356, DOI 10.1016/S0029-7844(03)00510-6; NORTONK, 1996, ANTHROPOMETRICA; Nyirenda MJ, 2001, J ENDOCRINOL, V170, P653, DOI 10.1677/joe.0.1700653; Phillips DIW, 2000, HYPERTENSION, V35, P1301, DOI 10.1161/01.HYP.35.6.1301; THOMPSON JMD, 1994, NEW ZEAL MED J, V107, P1; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	31	322	331	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1856	1862		10.1016/S0140-6736(05)66617-2	http://dx.doi.org/10.1016/S0140-6736(05)66617-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924982				2022-12-28	WOS:000229481400024
J	Eastwood, JB; Conroy, RE; Naicker, S; West, PA; Tutt, RC; Plange-Rhule, J				Eastwood, JB; Conroy, RE; Naicker, S; West, PA; Tutt, RC; Plange-Rhule, J			Loss of health professionals from sub-Saharan Africa: the pivotal role of the UK	LANCET			English	Article							HUMAN-RESOURCES; MIGRATION; CRISIS; CARE	The already inadequate health systems of sub-Saharan Africa have been badly damaged by the emigration of their health professionals, a process in which the UK has played a prominent part. In 2005, there are special opportunities for the UK to take the lead in addressing that damage, and in focusing the attention of the G8 on the wider problems of health-professional migration from poor to rich countries. We suggest some practical measures to these ends. These include action the UK could take on its own, with the African countries most affected, and with other developed countries and WHO.	St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England; Univ Witwatersrand, Div Nephrol, Johannesburg, South Africa; Univ York, York Hlth Econ Consortium, York YO10 5DD, N Yorkshire, England; White House, Oxenhall, Newent, England; Komfo Anokye Teaching Hosp, Dept Med, Kumasi, Ghana	St Georges University London; University of Witwatersrand; University of York - UK; Kwame Nkrumah University Science & Technology	Eastwood, JB (corresponding author), St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England.	jbeastwood@sghms.ac.uk		Naicker, Saraladevi/0000-0002-7058-9725				ALKIRE S, MED EXCEPTIONALISM I; Buchan J., 2004, INT RECRUITMENT HLTH; Bundred PE, 2000, LANCET, V356, P245, DOI 10.1016/S0140-6736(00)02492-2; CARVEL J, 2004, GUARDIAN        0826; Chanda R, 2002, B WORLD HEALTH ORGAN, V80, P158; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; *COMM SECR, 2003, COMM COD PRACT INT R; *DEP INT DEV, UK PLEDG; Dovlo D, CAUSES HLTH WORKER M; Eastwood JB, 2001, QJM-MON J ASSOC PHYS, V94, P637, DOI 10.1093/qjmed/94.11.637; *GEN MED COUNC, 2003, ANN REP; GLOVER S, MIGRATION EC SOCIAL; Hagopian Amy, 2004, Hum Resour Health, V2, P17, DOI 10.1186/1478-4491-2-17; Hilary John, 2002, BMJ, V325, P219; Horton R, 2001, LANCET, V358, P2141, DOI 10.1016/S0140-6736(01)07221-X; *HOUS COMM HANS, 2004, WRITT ANSW 23 FEB; Loefler IJP, 2001, CROAT MED J, V42, P504; MARTINEAU T, 2002, BRIEFING NOTE INT MI; *MED SCH, DEL DOCT FUT; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; Ncayiyana D, 2004, BMJ-BRIT MED J, V329, P584, DOI 10.1136/bmj.329.7466.584; Ncayiyana DJ, 1999, S AFR MED J, V89, P1107; Oyowe A., 1996, COURIER ACP EU, V159, P59; Pang T, 2002, BMJ-BRIT MED J, V324, P499, DOI 10.1136/bmj.324.7336.499; Parry E, 1998, MED EDUC, V32, P630, DOI 10.1046/j.1365-2923.1998.00316.x; PHILP C, 2004, TIMES           0914; *UK DEP HLTH, 2001, COD PRACT NHS EMPL I; Walt G, 1998, LANCET, V351, P434, DOI 10.1016/S0140-6736(97)05546-3; Watkins PJ, 1999, T ROY SOC TROP MED H, V93, P355, DOI 10.1016/S0035-9203(99)90109-8; *WHO, 1998, WHO EST HLTH PERS PH; *WHO, ILO WHO DEV JOINT GU; 2000, LANCET, V356, P177	32	159	163	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1893	1900		10.1016/S0140-6736(05)66623-8	http://dx.doi.org/10.1016/S0140-6736(05)66623-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924988				2022-12-28	WOS:000229481400030
J	Penny, ME; Creed-Kanashiro, HM; Robert, RC; Narro, MR; Caulfield, LE; Black, RE				Penny, ME; Creed-Kanashiro, HM; Robert, RC; Narro, MR; Caulfield, LE; Black, RE			Effectiveness of an educational intervention delivered through the health services to improve nutrition in young children: a cluster-randomised controlled trial	LANCET			English	Article							GROWTH; INFANTS; PROMOTION	Background Malnutrition is the underlying cause of half of child mortality. Many programmes attempt to remedy this issue but there is a lack of evidence on effective ways to decrease child malnutrition. Methods We did a cluster-randomised trial of an educational intervention in a poor periurban area (ie, shanty town) of Peru. Guided by formative research, the intervention aimed to enhance the quality and coverage of existing nutrition education and to introduce an accreditation system in six government health facilities compared with six control facilities. The primary outcome measure was growth that was measured by weight, length, and Z scores for weight-for-age and length-for-age at age 18 months. Main secondary outcomes were the percentage of children receiving recommended feeding practices and the 24-h dietary intake of energy, iron, and zinc from complementary food at ages 6, 9, 12, and 18 months. Analysis was by intention to treat. Findings We enrolled a birth cohort of 187 infants from the catchment areas of intervention centres and 190 from control areas. Caregivers in intervention areas were more likely to report receiving nutrition advice from the health service than were caregivers in control health facilities (16 [52%] of 31 vs 9 [24%] of 37, p=0.02). At 6 months more babies in intervention areas were fed nutrient-dense thick foods at lunch (a recommended complementary feeding practice) than were controls (48 [31%] of 157 vs 29 [20%] of 147; difference between groups 19 [11%], p=0.03). Fewer children in intervention areas failed to meet dietary requirements for energy (8 months: 30 [18%] of 170 vs 45 [27%] of 167, p=0.04; 12 months: 64 [38%] of 168 vs 82 [49%] of 167, p=0.043), iron (8 months: 155 [91%] of 170 vs 161 [96%] of 167, 9 months: 152 [93%] of 163 vs 165 [99%] of 166, p=0.047), and zinc (9 months: 125 [77%] of 163 vs 145 [87%] of 166, p=0.012) than did controls. Children in control areas were more likely to have stunted growth (ie, length for age less than 2 SD below the reference population median) at 18 months than children in intervention groups (26 [16%] of 165 vs 8 [5%] of 171; adjusted odds ratio 3.04 [95% CI 1.21-7.64]). Adjusted mean changes in weight gain, length gain, and Z scores were all significantly better in the intervention area than in the control area. Interpretation Improvement of nutrition education delivered through health services can decrease the prevalence of stunted growth in childhood in areas where access to food is not a limiting factor.	Inst Invest Nutr, Lima, Peru; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Penny, ME (corresponding author), Inst Invest Nutr, Ave Molina 1885, Lima, Peru.	mpenny@iin.sld.pe	Penny, Mary/J-2286-2017; Hankey, Graeme J/H-4968-2014	Penny, Mary/0000-0001-5501-9399; Hankey, Graeme J/0000-0002-6044-7328; Creed-Kanashiro, Hilary/0000-0001-8282-0835; Black, Robert/0000-0001-9926-7984				ALLEN L, 2001, 19 ACCSCN, P27; Bhandari N, 2004, J NUTR, V134, P2342; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Caulfield Laura E., 1999, Food and Nutrition Bulletin, V20, P183; DEKANASHIRO HC, 1990, AM J CLIN NUTR, V52, P995, DOI 10.1093/ajcn/52.6.995; DEROMANA GL, 1987, ECOL FOOD NUTR, V19, P213, DOI 10.1080/03670244.1987.9990965; Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5; DEWEY KG, 1992, AM J CLIN NUTR, V56, P1012, DOI 10.1093/ajcn/56.6.1012; Fishman SM, 2004, COMP QUANTIFICATION, P39; Freire WB, 1997, NUTR REV, V55, P183, DOI 10.1111/j.1753-4887.1997.tb01605.x; Guldan GS, 2000, J NUTR, V130, P1204, DOI 10.1093/jn/130.5.1204; *I INV NUTR, 2001, FOOD COMP TABL IIN 2; *JOINT FAO WHO EXP, 2002, VIT MIN REQ HUM NUTR; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LUBROOK J, 1998, AM STAT, V52, P127; Lutter CK, 2003, J NUTR, V133, p2941S, DOI 10.1093/jn/133.9.2941S; McNelly B., 1998, 4 FREED HUNG; *NAT I STAT INF, 2003, DEM HLTH FAM SURV, P163; National Center for Health Statistics, 1977, GROWTH CURV CHILDR B; ROGERS BL, 2001, REDUCING CHRONIC MAL; Santos I, 2001, J NUTR, V131, P2866, DOI 10.1093/jn/131.11.2866; Schroeder D. G., 2002, FOOD NUTR BULL, V23, P50, DOI [10.1177/15648265020234s208, DOI 10.1177/15648265020234S108, 10.1177/15648265020234S208]; SCHROEDER DG, 1995, J NUTR, V125, pS1051; WEBB R, 1999, PERU NUMBERS 1999, P129; *WHO, 1983, MED CAMB EST NUTR; *WHO, 1997, WHOCHD973; World Health Organization, 1998, WHONOT981	27	225	231	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1863	1872		10.1016/S0140-6736(05)66426-4	http://dx.doi.org/10.1016/S0140-6736(05)66426-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	931JK	15924983				2022-12-28	WOS:000229481400025
J	Skotheim, JM; Mahadevan, L				Skotheim, JM; Mahadevan, L			Physical limits and design principles for plant and fungal movements	SCIENCE			English	Article								The typical scales for plant and fungal movements vary over many orders of magnitude in time and length, but they are ultimately based on hydraulics and mechanics. We show that quantification of the length and time scales involved in plant and fungal motions leads to a natural classification, whose physical basis can be understood through an analysis of the mechanics of water transport through an elastic tissue. Our study also suggests a design principle for nonmuscular hydraulically actuated structures: Rapid actuation requires either small size or the enhancement of motion on large scales via elastic instabilities.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Univ Cambridge, Ctr Math Sci, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England; Harvard Univ, Biol Labs, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University; University of Cambridge; Harvard University	Mahadevan, L (corresponding author), Harvard Univ, Div Engn & Appl Sci, Pierce Hall,29 Oxford St, Cambridge, MA 02138 USA.	lm@deas.harvard.edu	Skotheim, Jan/C-3238-2015	Skotheim, Jan/0000-0001-8420-6820				ASHIDA JOJI, 1934, MEM COLL SCI KYOTO IMP UNIV SER B, V9, P141; Attenborough D, 1995, PRIVATE LIFE PLANTS; Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886; Comandon J, 1938, CR SOC BIOL, V129, P620; Forterre Y, 2005, NATURE, V433, P421, DOI 10.1038/nature03185; FRENSCH J, 1989, PLANT PHYSIOL, V91, P719, DOI 10.1104/pp.91.2.719; HEATH O. V. S., 1938, NEW PHYTOL, V37, P385, DOI 10.1111/j.1469-8137.1938.tb06954.x; PAGE RM, 1964, SCIENCE, V146, P925, DOI 10.1126/science.146.3646.925; Skotheim JM, 2004, P ROY SOC A-MATH PHY, V460, P1995, DOI 10.1098/rspa.2003.1270; SWAINE MD, 1977, NEW PHYTOL, V78, P695, DOI 10.1111/j.1469-8137.1977.tb02174.x	10	219	224	8	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1308	1310		10.1126/science.1107976	http://dx.doi.org/10.1126/science.1107976			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919993				2022-12-28	WOS:000229482300047
J	Nee, S				Nee, S			The great chain of being	NATURE			English	Editorial Material									Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Nee, S (corresponding author), Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.							Dawkins R., 2004, THE ANCESTORS TALE; Gee H, 2002, NATURE, V420, P611, DOI 10.1038/420611a; Lovejoy A. O., 1965, GREAT CHAIN BEING; Nee S, 2004, NATURE, V429, P804, DOI 10.1038/429804a; Szathmary E, 1995, MAJOR TRANSITIONS EV	5	21	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					429	429		10.1038/435429a	http://dx.doi.org/10.1038/435429a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917787	Bronze			2022-12-28	WOS:000229337800032
J	Poynter, JN; Gruber, SB; Higgins, PDR; Almog, R; Bonner, JD; Rennert, HS; Low, M; Greenson, JK; Rennert, G				Poynter, JN; Gruber, SB; Higgins, PDR; Almog, R; Bonner, JD; Rennert, HS; Low, M; Greenson, JK; Rennert, G			Statins and the risk of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIINFLAMMATORY DRUG-USE; COENZYME-A REDUCTASE; INDUCED APOPTOSIS; RANDOMIZED-TRIAL; PRAVASTATIN; PREVENTION; INHIBITORS; ASPIRIN; TOLERABILITY; DISEASE	Background Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and effective lipid-lowering agents. Statins inhibit the growth of colon-cancer cell lines, and secondary analyses of some, but not all, clinical trials suggest that they reduce the risk of colorectal cancer. Methods The Molecular Epidemiology of Colorectal Cancer study is a population-based case-control study of patients who received a diagnosis of colorectal cancer in northern Israel between 1998 and 2004 and controls matched according to age, sex, clinic, and ethnic group. We used a structured interview to determine the use of statins in the two groups and verified self-reported statin use by examining prescription records in a subgroup of patients for whom prescription records were available. Results In analyses including 1953 patients with colorectal cancer and 2015 controls, the use of statins for at least five years (vs. the nonuse of statins) was associated with a significantly reduced relative risk of colorectal cancer (odds ratio, 0.50; 95 percent confidence interval, 0.40 to 0.63). This association remained significant after adjustment for the use or nonuse of aspirin or other nonsteroidal antiinflammatory drugs; the presence or absence of physical activity, hypercholesterolemia, and a family history of colorectal cancer; ethnic group; and level of vegetable consumption (odds ratio, 0.53; 95 percent confidence interval, 0.38 to 0.74). The use of fibric-acid derivatives was not associated with a significantly reduced risk of colorectal cancer (odds ratio, 1.08; 95 percent confidence interval, 0.59 to 2.01). Self-reported statin use was confirmed for 276 of the 286 participants (96.5 percent) who reported using statins and whose records were available. Conclusions The use of statins was associated with a 47 percent relative reduction in the risk of colorectal cancer after adjustment for other known risk factors. Because the absolute risk reduction is likely low, further investigation of the overall benefits of statins in preventing colorectal cancer is warranted.	Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Technion Israel Inst Technol, Carmel Med Ctr, Dept Community Med & Epidemiol, Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Natl Canc Control Ctr, Clalit Hlth Serv, Haifa, Israel	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services	Gruber, SB (corresponding author), Univ Michigan, Div Med & Mol Genet, 4301 MSRB 3, Ann Arbor, MI 48109 USA.	sgruber@umich.edu		Rennert, Gad/0000-0002-8512-068X; Poynter, Jenny/0000-0002-8460-3938	NCI NIH HHS [R01 CA081488, 1R01CA81488] Funding Source: Medline; NHGRI NIH HHS [T32 HG000040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081488] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000040] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Agarwal B, 1999, GASTROENTEROLOGY, V117, P838, DOI 10.1016/S0016-5085(99)70342-2; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; BAT L, 1986, CANCER-AM CANCER SOC, V58, P1167, DOI 10.1002/1097-0142(19860901)58:5<1167::AID-CNCR2820580532>3.0.CO;2-R; Bernini F, 2001, CARDIOVASC DRUG THER, V15, P211, DOI 10.1023/A:1011908004965; Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Downs JR, 2001, AM J CARDIOL, V87, P1074, DOI 10.1016/S0002-9149(01)01464-3; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Hentosh P, 2001, MOL CARCINOGEN, V32, P154, DOI 10.1002/mc.1074; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kaye JA, 2004, BRIT J CANCER, V90, P635, DOI 10.1038/sj.bjc.6601566; KELSEY JL, 1996, METHODS OBSERVATIONA, P239; Niell BL, 2003, AM J HUM GENET, V73, P1250, DOI 10.1086/379926; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Pfeffer MA, 2002, CIRCULATION, V105, P2341, DOI 10.1161/01.CIR.0000017634.00171.24; Rao CV, 2002, CANCER DETECT PREV, V26, P419, DOI 10.1016/S0361-090X(02)00119-8; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sandler RS, 2003, NEW ENGL J MED, V348, P1939; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; Strandberg TE, 2004, LANCET, V364, P771, DOI 10.1016/S0140-6736(04)16936-5; Swamy MV, 2002, INT J ONCOL, V20, P753; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; 2005, ISRAEL NATL CANC REG	34	607	630	1	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2184	2192		10.1056/NEJMoa043792	http://dx.doi.org/10.1056/NEJMoa043792			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917383				2022-12-28	WOS:000229333300006
J	Kessler, RC; Berglund, P; Borges, G; Nock, M; Wang, PS				Kessler, RC; Berglund, P; Borges, G; Nock, M; Wang, PS			Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-COMORBIDITY-SURVEY; INTERNATIONAL DIAGNOSTIC INTERVIEW; REPLICATION NCS-R; PRIMARY-CARE; MENTAL-HEALTH; DEPRESSIVE-DISORDERS; COMPETING DEMANDS; PREVALENCE; QUALITY; RECOMMENDATIONS	Context Little is known about trends in suicidal ideation, plans, gestures, or attempts or about their treatment. Such data are needed to guide and evaluate policies to reduce suicide-related behaviors. Objective To analyze nationally representative trend data on suicidal ideation, plans, gestures, attempts, and their treatment. Design, Setting, and Participants Data came from the 1990-1992 National Comorbidity Survey and the 2001-2003 National Comorbidity Survey Replication. These surveys asked identical questions to 9708 people aged 18 to 54 years about the past year's occurrence of suicidal ideation, plans, gestures, attempts, and treatment. Trends were evaluated by using pooled logistic regression analysis. Face-to-face interviews were administered in the homes of respondents, who were nationally representative samples of US English-speaking residents, Main Outcome Measure Self-reports about suicide-related behaviors and treatment in the year before interview. Results No significant changes occurred between 1990-1992 and 2001-2003 in suicidal ideation (2.8% vs 3.3%; P=.43), plans (0.7% vs 1.0%; P=.15), gestures (0.3% vs 0.2%; P=.24), or attempts (0.4%-0.6%; P=.45), whereas conditional prevalence of plans among ideators increased significantly (from 19.6% to 28.6%; P=.04), and conditional prevalence of gestures among planners decreased significantly (from 21.4% to 6.4%; P=.003). Treatment increased dramatically among ideators who made a gesture (40.3% vs 92.8%) and among ideators who made an attempt (49.6% vs 79.0%). Conclusions Despite a dramatic increase in treatment, no significant decrease occurred in suicidal thoughts, plans, gestures, or attempts in the United States during the 1990s. Continued efforts are needed to increase outreach to untreated individuals with suicidal ideation before the occurrence of attempts and to improve treatment effectiveness for such cases.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Univ Michigan, Inst Social Res, Ann Arbor, MI USA; Mexican Inst Psychiat, Mexico City, DF, Mexico; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Michigan System; University of Michigan; Harvard University	Kessler, RC (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	kessler@hcp.med.harvard.edu	Nock, Matthew/AAE-8330-2019; Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; Borges, Guilherme/0000-0002-3269-0507	NIMH NIH HHS [U01-MH60220] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH060220] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agency for Health Care Policy and Research, 1993, DEPR PRIM CAR, V2; *AM PSYCH ASS, 1998, PRACT GUID TREATM PA; American Psychiatric Association, 2003, PRACT GUID ASS TREAT; American Psychiatric Association, 2002, PRACT GUID TREATM PA; American Psychiatric Association, 2004, PRACT GUID TREATM PA; [Anonymous], SURG GEN CALL ACT PR; [Anonymous], PREV SUIC GUID FORM; BENDER E, 2002, PSYCHIAT NEWS, V2, P5; Burns J, 2005, AUST NZ J PSYCHIAT, V39, P121, DOI 10.1111/j.1440-1614.2005.01532.x; Centers for Disease Control and Prevention, YOUTH RISK BEH SURV; *FDA CTR DRUG EV R, 2004, US FOOD DRUG ADM SUM; FRANK RG, IN PRESS BETTER NOT; Gibbons RD, 2005, ARCH GEN PSYCHIAT, V62, P165, DOI 10.1001/archpsyc.62.2.165; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; HAZELL P, 2000, INT HDB SUICIDE ATTE, P539; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; Jackson JS, 2004, INT J METH PSYCH RES, V13, P196, DOI 10.1002/mpr.177; JACOBS DG, 1995, HARVARD REV PSYCHIAT, V3, P156, DOI 10.3109/10673229509017181; Karasu T.B., 2000, PRACTICE GUIDELINE T, V2nd; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kessler E., 2000, NEISS SAMPLE DESIGN; Kessler R.C., 1998, INT J METH PSYCH RES, V7, P33, DOI [DOI 10.1002/MPR.33, 10.1016/j.jad.2006.08.018]; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2004, INT J METH PSYCH RES, V13, P69, DOI 10.1002/mpr.167; KESSLER RC, 1995, EPIDEMIOL REV, V17, P192, DOI 10.1093/oxfordjournals.epirev.a036176; Kessler RC, 2001, HEALTH SERV RES, V36, P987; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; KESSLER RC, IN PRESS N ENGL J ME; Khan A, 2003, AM J PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; Klinkman MS, 1997, GEN HOSP PSYCHIAT, V19, P98, DOI 10.1016/S0163-8343(96)00145-4; Kuo WH, 2005, AM J PSYCHIAT, V162, P633, DOI 10.1176/appi.ajp.162.3.633; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; MANDERSCHEID RW, 2001, MENTAL HLTH US 2000, P135; Mechanic D, 2004, HEALTH AFFAIR, V23, P84, DOI 10.1377/hlthaff.23.4.84; Mechanic D, 1999, HEALTH AFFAIR, V18, P7, DOI 10.1377/hlthaff.18.5.7; Meltzer HY, 2003, ARCH GEN PSYCHIAT, V60, P82, DOI 10.1001/archpsyc.60.1.82; MOSCICKI EK, 1988, YALE J BIOL MED, V61, P259; *NAT COMM QUAL ASS, 1997, HEDIS 3 0 NARR WHATS; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; PAYKEL ES, 1974, BRIT J PSYCHIAT, V124, P460, DOI 10.1192/bjp.124.5.460; Pincus HA, 2003, INT J METH PSYCH RES, V12, P54, DOI 10.1002/mpr.142; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Rost K, 2002, MED CARE RES REV, V59, P231, DOI 10.1177/1077558702059003001; Sturm R, 1999, J BEHAV HEALTH SER R, V26, P360, DOI 10.1007/BF02287297; *SUBST AB MENT HLT, NAT SUIC PREV LIF; *SUBST AB MENT HLT, 1996, CONS OR MENT HLTH RE; SUDAAN, 2002, PROF SOFTW SURV DAT; US Department of Health and Human Services, MENT HLTH CULT RAC E; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; *US FDA, ANT US CHILDR AD AD; Wang PS, 2000, J GEN INTERN MED, V15, P284, DOI 10.1046/j.1525-1497.2000.9908044.x; Wang PS, 2003, INT J METH PSYCH RES, V12, P22, DOI 10.1002/mpr.139; WANG PS, IN PRESS ARCH GEN PS; Weissman E, 2000, PSYCHIATR SERV, V51, P664, DOI 10.1176/appi.ps.51.5.664; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Williams JW, 1998, J GEN INTERN MED, V13, P137, DOI 10.1046/j.1525-1497.1998.00032.x; Williams JW, 1999, ARCH FAM MED, V8, P58, DOI 10.1001/archfami.8.1.58; Wolter K. M., 1985, INTRO VARIANCE ESTIM; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	63	743	762	2	55	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2487	2495		10.1001/jama.293.20.2487	http://dx.doi.org/10.1001/jama.293.20.2487			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	929BX	15914749	Bronze, Green Published			2022-12-28	WOS:000229318200023
J	Birch, M; Miller, S				Birch, M; Miller, S			ABC of conflict and disaster - Humanitarian assistance: standards, skills, training, and experience	BRITISH MEDICAL JOURNAL			English	Review									Int Hlth Exchange RedR, London, England; FASC, Army Med Directorate, Camberley, England		Birch, M (corresponding author), Int Hlth Exchange RedR, London, England.							[Anonymous], 1997, REF HLTH APPR EM SIT; CHIN J, 2000, CONTROL COMMUNICABLE; *DEP HLTH, 1995, HLTH INF OV TRAV; HMSO, 1996, IMM INF DIS; RYAN J, 2002, CONFLICT CATASTROPHE; WEBBER R, 1996, COMMUNICABLE DIS EPI	6	25	25	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 21	2005	330	7501					1199	1201		10.1136/bmj.330.7501.1199	http://dx.doi.org/10.1136/bmj.330.7501.1199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905258	Green Published			2022-12-28	WOS:000229320500024
J	Bajjalieh, S				Bajjalieh, S			A new view of an old pore	CELL			English	Editorial Material							FUSION; COMPLEX	Despite reports suggesting a potential role in membrane fusion, the V-0 subunit of the H+/ATPase has remained an unlikely candidate for the fusion pore. In this issue of Cell, Hiesinger and coworkers (Hiesinger et al., 2005) present a forward genetic screen that reveals it to be necessary for synaptic vesicle fusion, independent of its role in vesicle acidification.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Bajjalieh, S (corresponding author), Univ Washington, Dept Pharmacol, D429 HSB,Box 357280, Seattle, WA 98195 USA.							Almers W, 2001, NATURE, V409, P567, DOI 10.1038/35054637; BROCHIER G, 1993, NEUROCHEM INT, V23, P525, DOI 10.1016/0197-0186(93)90100-J; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500	6	1	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					496	497		10.1016/j.cell.2005.05.002	http://dx.doi.org/10.1016/j.cell.2005.05.002			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907459	Bronze			2022-12-28	WOS:000229331200002
J	Djiane, A; Yogev, S; Mlodzik, M				Djiane, A; Yogev, S; Mlodzik, M			The apical determinants aPKC and dPatj regulate Frizzled-dependent planar cell polarity in the Drosophila eye	CELL			English	Article							PROTEIN-KINASE-C; EPITHELIAL POLARITY; DISCS LOST; ASYMMETRIC LOCALIZATION; SIGNALING SPECIFICITY; TISSUE POLARITY; PDZ DOMAIN; CRUMBS; NEUROBLASTS; COMPLEXES	Planar cell polarity (PCP) is a common feature of many vertebrate and invertebrate epithelia and is perpendicular to their apical/basal (A/B) polarity axis. While apical localization of PCP determinants such as Frizzled (Fz1) is critical for their function, the link between A/B polarity and PCP is poorly understood. Here, we describe a direct molecular link between A/B determinants and Fz1-mediated PCP establishment in the Drosophila eye. We demonstrate that dPatj binds the cytoplasmic tail of Fz1 and propose that it recruits aPKC, which in turn phosphorylates and inhibits Fz1. Accordingly, components of the aPKC complex and dPatj produce PCP defects in the eye. We also show that during PCP signaling, aPKC and dPatj are downregulated, while Bazooka is upregulated, suggesting an antagonistic effect of Bazooka on dPatj/aPKC. We propose a model whereby the dPatj/aPKC complex regulates PCP by inhibiting Fz1 in cells where it should not be active.	Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Mlodzik, M (corresponding author), Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA.	marek.mlodzik@mssm.edu		Djiane, Alexandre/0000-0001-6210-2713				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Axelrod JD, 2001, GENE DEV, V15, P1182; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Bellaiche Y, 2004, DEVELOPMENT, V131, P469, DOI 10.1242/dev.00928; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Benton R, 2003, CURR BIOL, V13, P1330, DOI 10.1016/S0960-9822(03)00508-6; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Das G, 2004, DEVELOPMENT, V131, P4467, DOI 10.1242/dev.01317; Hong Y, 2003, P NATL ACAD SCI USA, V100, P12712, DOI 10.1073/pnas.2135347100; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Jenny A, 2003, EMBO J, V22, P4409, DOI 10.1093/emboj/cdg424; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Mlodzik M, 1999, EMBO J, V18, P6873, DOI 10.1093/emboj/18.24.6873; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Nam SC, 2003, DEVELOPMENT, V130, P4363, DOI 10.1242/dev.00648; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Pielage J, 2003, DEV CELL, V5, P841, DOI 10.1016/S1534-5807(03)00358-7; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Strutt D, 2002, CURR BIOL, V12, P813, DOI 10.1016/S0960-9822(02)00841-2; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Wolff Tanya, 1993, P1277; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu J, 2004, PLOS BIOL, V2, P1004, DOI 10.1371/journal.pbio.0020158	45	144	147	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					621	631		10.1016/j.cell.2005.03.014	http://dx.doi.org/10.1016/j.cell.2005.03.014			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907474	Bronze			2022-12-28	WOS:000229331200017
J	Banerjee, P; Pollitz, FF; Burgmann, R				Banerjee, P; Pollitz, FF; Burgmann, R			The size and duration of the Sumatra-Andaman earthquake from far-field static offsets	SCIENCE			English	Article							DEFORMATION	The 26 December 2004 Sumatra earthquake produced static offsets at continuously operating GPS stations at distances of up to 4500 kilometers from the epicenter. We used these displacements to model the earthquake and include consideration of the Earth's shape and depth-varying rigidity. The results imply that the average slip was >5 meters along the full length of the rupture, including the similar to 650-kilometer-long Andaman segment. Comparison of the source derived from the far-field static offsets with seismically derived estimates suggests that 25 to 35% of the total moment release occurred at periods greater than 1 hour. Taking into consideration the strong dip dependence of moment estimates, the magnitude of the earthquake did not exceed M-w = 9.2.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA; Wadia Inst Himalayan Geol, Dehra Dun 248001, Uttar Pradesh, India; US Geol Survey, Menlo Pk, CA 94025 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Department of Science & Technology (India); Wadia Institute of Himalayan Geology (WIHG); United States Department of the Interior; United States Geological Survey	Burgmann, R (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	burgmann@seismo.berkeley.edu	Burgmann, Roland/AAE-5138-2022	Burgmann, Roland/0000-0002-3560-044X				Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GILBERT F, 1975, PHILOS T R SOC A, V278, P187, DOI 10.1098/rsta.1975.0025; Lay T, 2005, SCIENCE, V308, P1127, DOI 10.1126/science.1112250; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Pollitz FF, 1996, GEOPHYS J INT, V125, P1, DOI 10.1111/j.1365-246X.1996.tb06530.x; RAJENDRAN CP, UNPUB; Stein S, 2005, NATURE, V434, P581, DOI 10.1038/434581a	8	168	183	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1769	1772		10.1126/science.1113746	http://dx.doi.org/10.1126/science.1113746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15905364				2022-12-28	WOS:000229926800049
J	Johnson, AC; Petta, JR; Taylor, JM; Yacoby, A; Lukin, MD; Marcus, CM; Hanson, MP; Gossard, AC				Johnson, AC; Petta, JR; Taylor, JM; Yacoby, A; Lukin, MD; Marcus, CM; Hanson, MP; Gossard, AC			Triplet-singlet spin relaxation via nuclei in a double quantum dot	NATURE			English	Article							ELECTRON-SPIN; SEMICONDUCTOR; COMPUTATION; FIELD	The spin of a confined electron, when oriented originally in some direction, will lose memory of that orientation after some time. Physical mechanisms leading to this relaxation of spin memory typically involve either coupling of the electron spin to its orbital motion or to nuclear spins(1-7). Relaxation of confined electron spin has been previously measured only for Zeeman or exchange split spin states, where spin-orbit effects dominate relaxation(8-10); spin flips due to nuclei have been observed in optical spectroscopy studies(11). Using an isolated GaAs double quantum dot defined by electrostatic gates and direct time domain measurements, we investigate in detail spin relaxation for arbitrary splitting of spin states. Here we show that electron spin flips are dominated by nuclear interactions and are slowed by several orders of magnitude when a magnetic field of a few millitesla is applied. These results have significant implications for spin-based information processing(12).	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	Harvard University; Weizmann Institute of Science; University of California System; University of California Santa Barbara	Marcus, CM (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	marcus@harvard.edu	Marcus, Charles M./M-4526-2014; Taylor, Jacob M/B-7826-2011; Taylor, Jacob/O-1670-2019; Petta, Jason R/J-6663-2013	Marcus, Charles M./0000-0003-2420-4692; Taylor, Jacob M/0000-0003-0493-5594; Taylor, Jacob/0000-0003-0493-5594; Petta, Jason R/0000-0002-6416-0789; Johnson, Alex/0000-0003-4623-4147				ASHOORI RC, 1993, PHYS REV LETT, V71, P613, DOI 10.1103/PhysRevLett.71.613; Bracker AS, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.047402; Coish WA, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.195340; de Sousa R, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.115322; DiCarlo L, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.226801; DOBERS M, 1988, PHYS REV LETT, V61, P1650, DOI 10.1103/PhysRevLett.61.1650; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; Elzerman JM, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.161308; Erlingsson SI, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.195306; FIELD M, 1993, PHYS REV LETT, V70, P1311, DOI 10.1103/PhysRevLett.70.1311; Fujisawa T, 1998, SCIENCE, V282, P932, DOI 10.1126/science.282.5390.932; Fujisawa T, 2002, NATURE, V419, P278, DOI 10.1038/nature00976; JOHNSON AC, 2004, SINGLET TRIPLET SKIN; Khaetskii AV, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.186802; Khaetskii AV, 2000, PHYS REV B, V61, P12639, DOI 10.1103/PhysRevB.61.12639; Kroutvar M, 2004, NATURE, V432, P81, DOI 10.1038/nature03008; Kumada N, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.096802; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Merkulov IA, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.205309; Ono K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.256803; Ono K, 2002, SCIENCE, V297, P1313, DOI 10.1126/science.1070958; PAGET D, 1977, PHYS REV B, V15, P5780, DOI 10.1103/PhysRevB.15.5780; Petta JR, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.186802; PETTA JR, 2004, PULSED GATE MEASUREM; Salis G, 2001, PHYS REV LETT, V86, P2677, DOI 10.1103/PhysRevLett.86.2677; Smet JH, 2002, NATURE, V415, P281, DOI 10.1038/415281a; WALD KR, 1994, PHYS REV LETT, V73, P1011, DOI 10.1103/PhysRevLett.73.1011	29	445	450	2	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					925	928		10.1038/nature03815	http://dx.doi.org/10.1038/nature03815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15944715	Green Submitted			2022-12-28	WOS:000229799700042
J	Bix, M; Kim, S; Rao, A				Bix, M; Kim, S; Rao, A			Opposites attract in differentiating T cells	SCIENCE			English	Editorial Material							LOCUS-CONTROL REGION; RANGE INTRACHROMOSOMAL INTERACTIONS; TH2 CYTOKINE LOCUS; ENHANCER; BET		Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; CBR Inst Biomed Res, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Bix, M (corresponding author), Univ Washington, Sch Med, Dept Immunol, 1959 NE Pacific St,HSC I6071, Seattle, WA 98195 USA.	arao@cbr.med.harvard.edu		Bix, Mark/0000-0003-4617-0497	NHLBI NIH HHS [P01 HL67664] Funding Source: Medline; NIAID NIH HHS [R01 AI44432, R01 AI48636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044432, R01AI048636] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansel KM, 2004, NAT IMMUNOL, V5, P1251, DOI 10.1038/ni1135; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Lee DU, 2004, J BIOL CHEM, V279, P4802, DOI 10.1074/jbc.M307904200; Lee GR, 2005, NAT IMMUNOL, V6, P42, DOI 10.1038/ni1148; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Miller AT, 2004, IMMUNITY, V21, P67, DOI 10.1016/j.immuni.2004.06.009; Nardone J, 2004, NAT IMMUNOL, V5, P768, DOI 10.1038/ni0804-768; Shnyreva M, 2004, P NATL ACAD SCI USA, V101, P12622, DOI 10.1073/pnas.0400849101; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; SPILIANAKIS CG, 2005, NATURE          0508; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5	16	5	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1563	1565		10.1126/science.1114167	http://dx.doi.org/10.1126/science.1114167			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947163				2022-12-28	WOS:000229827000030
J	Krishnan, R; Lindquist, SL				Krishnan, R; Lindquist, SL			Structural insights into a yeast prion illuminate nucleation and strain diversity	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENETIC-VARIATION; NEURONAL ISOFORM; SPECIES BARRIER; PSI+ PRIONS; BETA-HELIX; SUP35 GENE; PROTEIN; INHERITANCE; FIBERS	Self-perpetuating changes in the conformations of amyloidogenic proteins play vital roles in normal biology and disease. Despite intense research, the architecture and conformational conversion of amyloids remain poorly understood. Amyloid conformers of Sup35 are the molecular embodiment of the yeast prion known as [ PSI], which produces heritable changes in phenotype through self-perpetuating changes in protein folding. Here we determine the nature of Sup35' s cooperatively folded amyloid core, and use this information to investigate central questions in prion biology. Specific segments of the amyloid core form intermolecular contacts in a 'Head-to-Head', 'Tail-to-Tail' fashion, but the 'Central Core' is sequestered through intramolecular contacts. The Head acquires productive interactions first, and these nucleate assembly. Variations in the length of the amyloid core and the nature of intermolecular interfaces form the structural basis of distinct prion 'strains', which produce variant phenotypes in vivo. These findings resolve several problems in yeast prion biology and have broad implications for other amyloids.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Lindquist, SL (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	Lindquist_admin@wi.mit.edu	Krishnan, Rajaraman/R-4874-2019	Krishnan, Rajaraman/0000-0002-5189-4097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM025874, R01 GM025874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Bradley ME, 2004, MOL MICROBIOL, V51, P1649, DOI 10.1111/j.1365-2958.2003.03955.x; Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Collins SR, 2004, PLOS BIOL, V2, P1582, DOI 10.1371/journal.pbio.0020321; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Eaglestone SS, 1999, EMBO J, V18, P1974, DOI 10.1093/emboj/18.7.1974; Eakin CM, 2004, BIOCHEMISTRY-US, V43, P7808, DOI 10.1021/bi049792q; Garzon-Rodriguez W, 2000, J BIOL CHEM, V275, P22645, DOI 10.1074/jbc.M000756200; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hwang W, 2004, P NATL ACAD SCI USA, V101, P12916, DOI 10.1073/pnas.0402634101; Jensen MA, 2001, GENETICS, V159, P527; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; Kamen DE, 2000, BIOCHEMISTRY-US, V39, P15932, DOI 10.1021/bi001900v; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Nakayashiki T, 2001, MOL CELL, V7, P1121, DOI 10.1016/S1097-2765(01)00259-3; Osherovich LZ, 2004, PLOS BIOL, V2, P442, DOI 10.1371/journal.pbio.0020086; Parham SN, 2001, EMBO J, V20, P2111, DOI 10.1093/emboj/20.9.2111; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Scheibel T, 2004, P NATL ACAD SCI USA, V101, P2287, DOI 10.1073/pnas.0308754101; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Shorter J, 2005, NAT REV GENET, V6, P435, DOI 10.1038/nrg1616; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; True HL, 2000, NATURE, V407, P477, DOI 10.1038/35035005; True HL, 2004, NATURE, V431, P184, DOI 10.1038/nature02885; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499	51	401	408	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					765	772		10.1038/nature03679	http://dx.doi.org/10.1038/nature03679			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944694	Green Accepted			2022-12-28	WOS:000229638700040
J	Martinson, BC; Anderson, MS; de Vries, R				Martinson, BC; Anderson, MS; de Vries, R			Scientists behaving badly	NATURE			English	Editorial Material									HealthPartners Res Fdn, Minneapolis, MN 55440 USA; Univ Minnesota, Educ Policy & Adm, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA	HealthPartners Institute for Education & Research; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Martinson, BC (corresponding author), HealthPartners Res Fdn, 8100 34th Ave S,POB 1524,Mailstop 21111R, Minneapolis, MN 55440 USA.		Martinson, Brian C/AAX-2860-2020	Martinson, Brian C/0000-0002-4255-5595; De Vries, Raymond/0000-0003-3087-3040				Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; *COMM SCI ENG PUBL, 1995, RESP COND RES; Freeman R, 2001, SCIENCE, V294, P2293, DOI 10.1126/science.1067477; Geggie D, 2001, J MED ETHICS, V27, P344; Institute of Medicine and US National Research Council, 2002, INT SCI RES CREAT EN; Korn D, 2002, NATURE, V420, P739, DOI 10.1038/420739b; OSTP, 2005, FED POL RES MISC; Ranstam J, 2000, CONTROL CLIN TRIALS, V21, P415, DOI 10.1016/S0197-2456(00)00069-6; Steneck N.H., 2004, ORI INTRO RESPONSIBL; SWAZEY JP, 1993, AM SCI, V81, P542; Teitelbaum SL, 2002, NATURE, V420, P739, DOI 10.1038/420739c	11	688	709	4	233	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					737	738		10.1038/435737a	http://dx.doi.org/10.1038/435737a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944677				2022-12-28	WOS:000229638700024
J	Utiger, RD				Utiger, RD			The multiplicity of thyroid nodules and carcinomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; CANCER		Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Utiger, RD (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Hollowell JG, 1998, J CLIN ENDOCR METAB, V83, P3401, DOI 10.1210/jc.83.10.3401; Hundahl SA, 2000, CANCER-AM CANCER SOC, V89, P202, DOI 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kaplan MM, 2005, WERNER INGBARS THYRO, P996; Mazzaferri EL, 2001, J CLIN ENDOCR METAB, V86, P1447, DOI 10.1210/jc.86.4.1447	5	30	35	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2376	2378		10.1056/NEJMp058061	http://dx.doi.org/10.1056/NEJMp058061			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944422				2022-12-28	WOS:000229638900003
J	Reynolds, E				Reynolds, E			There is more to treatment of epilepsy than control of seizures	LANCET			English	Editorial Material									Kings Coll London, Inst Epileptol, Weston Educ Ctr, London SE5 9PJ, England	University of London; King's College London	Reynolds, E (corresponding author), Kings Coll London, Inst Epileptol, Weston Educ Ctr, London SE5 9PJ, England.	Reynolds@buckles.u-net.com							0	1	1	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1981	1981		10.1016/S0140-6736(05)66669-X	http://dx.doi.org/10.1016/S0140-6736(05)66669-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936429				2022-12-28	WOS:000229587800037
J	von Plessen, C; Aslaksen, A				von Plessen, C; Aslaksen, A			Improving the quality of palliative care for ambulatory patients with lung cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Most patients with advanced lung cancer currently receive much of their health care, including chemotherapy, as outpatients. Patients have to deal with the complex and time consuming logistics of ambulatory cancer care. At the same time, members of staff often waste considerable time and energy in organisational aspects of care that could be better used in direct interaction with patients. Design Quality improvement study using direct observation and run and flow charts, and focus group meetings with patients and families regarding perceptions of the clinic and with staff regarding satisfaction with working conditions. Setting Thoracic oncology outpatient clinic at a Norwegian university hospital where patients receive chemotherapy and complementary palliative care. Key measures for improvement Waiting time and time wasted during consultations; calmer working situation at the clinic; satisfaction among patients. Strategies for change Rescheduled patients' appointments, automated retrieval of blood test results, systematic reporting in patients' files, design of an information leaflet, and refurnishing of the waiting area at the clinic. Effects of change Interventions resulted in increased satisfaction for patients and staff, reduced waiting time, and reduced variability of waiting time. Lessons learnt Direct observation, focus groups, questionnaires on patients' satisfaction, and measurement of process time were useful in systematically improving care in this outpatient clinic. The description of this experience can serve as an example for the improvement of a microsystem, particularly in other settings with similar problems.	Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway; Haukeland Univ Hosp, Dept Radiol, N-5021 Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	von Plessen, C (corresponding author), Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway.	christian.von.plessen@helse-bergen.no	von Plessen, Christian/AFZ-7617-2022	von Plessen, Christian/0000-0002-6134-6780				Batalden P B, 1997, Qual Manag Health Care, V5, P1; Benson RJ, 2001, CLIN ONCOL-UK, V13, P138; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; KLEINER A, 1994, 5 DISCIPLINE FIELDBO, P479; Lock Karen K, 2002, Can J Nurs Res, V34, P83; Mitchell Geoff, 2002, Aust Fam Physician, V31, P129; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Nelson EC, 1996, JOINT COMM J QUAL IM, V22, P243, DOI 10.1016/S1070-3241(16)30228-0; Nelson Eugene C, 2002, Jt Comm J Qual Improv, V28, P472; Newell S, 1999, EUR J CANCER CARE, V8, P73; Zimber J, 2001, MMW Fortschr Med, V143, P22	11	17	17	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1309	1313		10.1136/bmj.330.7503.1309	http://dx.doi.org/10.1136/bmj.330.7503.1309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933354	Green Published			2022-12-28	WOS:000229655700025
J	Young, AER; Chambers, TL				Young, AER; Chambers, TL			Standards for care of critically ill children with burns	LANCET			English	Editorial Material									N Bristol NHS Trust, S W Paediat Burn Serv, Bristol BS16 1LE, Avon, England; N Bristol NHS Trust, Dept Paediat, Bristol BS16 1LE, Avon, England	North Bristol NHS Trust; North Bristol NHS Trust	Young, AER (corresponding author), N Bristol NHS Trust, S W Paediat Burn Serv, Bristol BS16 1LE, Avon, England.	Amber.Young@north-bristol.swest.nhs.uk	Young, Amber/H-2988-2018	Young, Amber/0000-0001-7205-492X				*DEP HLTH NHS EX H, 1997, PAED INT CAR FRAM FU; Frame JD, 2003, LANCET, V361, P980, DOI 10.1016/S0140-6736(03)12840-1; Kennedy I., 2001, CM5207; National Service framework for Children, 2004, YOUNG PEOPL MAT SERV; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; Radcliffe J, 1998, BRIT MED J, V316, P1547	6	1	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1911	1913		10.1016/S0140-6736(05)66639-1	http://dx.doi.org/10.1016/S0140-6736(05)66639-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936407				2022-12-28	WOS:000229587800008
J	Huber, GW; Chheda, JN; Barrett, CJ; Dumesic, JA				Huber, GW; Chheda, JN; Barrett, CJ; Dumesic, JA			Production of liquid alkanes by aqueous-phase processing of biomass-derived carbohydrates	SCIENCE			English	Article							ALDOL CONDENSATION; CATALYSTS; GLUCOSE; WATER; FUEL	Liquid alkanes with the number of carbon atoms ranging from C-7 to C-15 were selectively produced from biomass-derived carbohydrates by acid-catalyzed dehydration, which was followed by aldol condensation over solid base catalysts to form large organic compounds. These molecules were then converted into alkanes by dehydration/hydrogenation over bifunctional catalysts that contained acid and metal sites in a four-phase reactor, in which the aqueous organic reactant becomes more hydrophobic and a hexadecane alkane stream removes hydrophobic species from the catalyst before they go on further to form coke. These liquid alkanes are of the appropriate molecular weight to be used as transportation fuel components, and they contain 90% of the energy of the carbohydrate and H-2 feeds.	Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dumesic, JA (corresponding author), Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA.	dumesic@engr.wisc.edu	Barrett, Christopher J/B-7474-2008; Huber, George/D-2569-2018; Huber, George/Y-2473-2019	Barrett, Christopher J/0000-0001-6194-9066; Huber, George/0000-0002-7838-6893				CHEN NY, 1986, CHEMTECH, V16, P506; Choudary BM, 1999, J MOL CATAL A-CHEM, V142, P361, DOI 10.1016/S1381-1169(98)00301-X; Climent MJ, 2004, J CATAL, V225, P316, DOI 10.1016/j.jcat.2004.04.027; COLLINS P, 1995, MONOSACCHARIDES; ELLIOTT DC, 1991, ENERG FUEL, V5, P399, DOI 10.1021/ef00027a008; GUTSCHE CD, 1967, J AM CHEM SOC, V89, P1235, DOI 10.1021/ja00981a033; Huber GW, 2004, ANGEW CHEM INT EDIT, V43, P1549, DOI 10.1002/anie.200353050; Huber GW, 2003, SCIENCE, V300, P2075, DOI 10.1126/science.1085597; Katzen R, 2000, ADV BIOCHEM ENG BIOT, V70, P77; KATZEN R, 1981, FUELS BIOMASS WASTES, P393; Klass DL., 1998, BIOMASS RENEWABLE EN; Lewkowski J, 2001, ARKIVOC, P17, DOI 10.3998/ark.5550190.0002.102; LOURVANIJ K, 1993, IND ENG CHEM RES, V32, P11, DOI 10.1021/ie00013a002; Ma FR, 1999, BIORESOURCE TECHNOL, V70, P1, DOI 10.1016/S0960-8524(99)00025-5; Moreau C, 1998, IND CROP PROD, V7, P95, DOI 10.1016/S0926-6690(97)00037-X; Moreau C, 1996, APPL CATAL A-GEN, V145, P211, DOI 10.1016/0926-860X(96)00136-6; OWEN K, 1990, AUTOMOTIVE FUELS HDB; Rao KK, 1998, J CATAL, V173, P115, DOI 10.1006/jcat.1997.1878; Sasaki M, 2002, GREEN CHEM, V4, P285, DOI 10.1039/b203968k; Serra-Holm V, 2000, APPL CATAL A-GEN, V198, P207, DOI 10.1016/S0926-860X(99)00510-4; Shabaker JW, 2003, J CATAL, V215, P344, DOI 10.1016/S0021-9517(03)00032-0; Shapouri H., 2002, 814 USDA OFF CHIEF E; WEISS MA, 2003, PUBLICATION MIT LAB; WEISZ PB, 1979, SCIENCE, V206, P57, DOI 10.1126/science.206.4414.57; Zhang WC, 1998, J CHEM SOC PERK T 1, P3131, DOI 10.1039/a806553e	25	1321	1444	23	797	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1446	1450		10.1126/science.1111166	http://dx.doi.org/10.1126/science.1111166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933197	Green Published			2022-12-28	WOS:000229619300047
J	Sutherland, WJ				Sutherland, WJ			The best solution	NATURE			English	Editorial Material									Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Sutherland, WJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England.		Sutherland, William/B-1291-2013	Sutherland, William/0000-0002-6498-0437				Alexander RM, 1996, OPTIMA ANIMALS; Lucas P., 2004, DENT FUNCTIONAL MORP; Sutherland W.J., 1996, INDIVIDUAL BEHAV POP	3	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2005	435	7042					569	569		10.1038/435569a	http://dx.doi.org/10.1038/435569a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931199				2022-12-28	WOS:000229476200025
J	Tarasov, L; Peltier, WR				Tarasov, L; Peltier, WR			Arctic freshwater forcing of the Younger Dryas cold reversal	NATURE			English	Article							GLACIAL LAKE AGASSIZ; ICE-SHEET; MELTWATER; HISTORY; DEEP; CIRCULATION; RECORD; EVENT; RATES	The last deglaciation was abruptly interrupted by a millennial-scale reversal to glacial conditions(1), the Younger Dryas cold event. This cold interval has been connected to a decrease in the rate of North Atlantic Deep Water formation and to a resulting weakening of the meridional overturning circulation(2-4) owing to surface water freshening. In contrast, an earlier input of fresh water ( meltwater pulse 1a), whose origin is disputed(5,6), apparently did not lead to a reduction of the meridional overturning circulation(4). Here we analyse an ensemble of simulations of the drainage chronology of the North American ice sheet in order to identify the geographical release points of freshwater forcing during deglaciation. According to the simulations with our calibrated glacial systems model, the North American ice sheet contributed about half the fresh water of meltwater pulse 1a. During the onset of the Younger Dryas, we find that the largest combined meltwater/ iceberg discharge was directed into the Arctic Ocean. Given that the only drainage outlet from the Arctic Ocean was via the Fram Strait into the Greenland - Iceland - Norwegian seas(7), where North Atlantic Deep Water is formed today, we hypothesize that it was this Arctic freshwater flux that triggered the Younger Dryas cold reversal.	Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada	University of Toronto	Tarasov, L (corresponding author), Univ Toronto, Dept Phys, 60 St George St, Toronto, ON M5S 1A7, Canada.	lev@atmosp.physics.utoronto.ca	Peltier, William R./A-1102-2008					AAGAARD K, 1989, J GEOPHYS RES-OCEANS, V94, P14485, DOI 10.1029/JC094iC10p14485; Bauch HA, 2001, QUATERNARY SCI REV, V20, P659, DOI 10.1016/S0277-3791(00)00098-6; BROECKER WS, 1989, NATURE, V341, P318, DOI 10.1038/341318a0; Clark PU, 1996, PALEOCEANOGRAPHY, V11, P563, DOI 10.1029/96PA01419; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; de Vernal A, 1996, NATURE, V381, P774, DOI 10.1038/381774a0; Dyke A., 2003, DEGLACIATION N AM; Dyke A.S., 1987, GEOGR PHYS QUATERNAI, V2, P237, DOI [10.7202/032681ar, DOI 10.7202/032681AR]; Dyke AS, 2004, DEV QUA SCI, V2, P373, DOI 10.1016/S1571-0866(04)80209-4; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Fisher TG, 2002, QUATERNARY SCI REV, V21, P873, DOI 10.1016/S0277-3791(01)00148-2; Hemming SR, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000128; KEIGWIN LD, 1991, J GEOPHYS RES-OCEANS, V96, P16811, DOI 10.1029/91JC01624; Licciardi JM, 1999, GEOPH MONOG SERIES, V112, P177; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; Marshall SJ, 1999, QUATERNARY RES, V52, P300, DOI 10.1006/qres.1999.2079; McManus JF, 2004, NATURE, V428, P834, DOI 10.1038/nature02494; Muscheler R, 2000, NATURE, V408, P567, DOI 10.1038/35046041; Norgaard-Pedersen N, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000781; Parsons JD, 2001, SEDIMENTOLOGY, V48, P465, DOI 10.1046/j.1365-3091.2001.00384.x; Peltier WR, 2002, J QUATERNARY SCI, V17, P491, DOI 10.1002/jqs.713; PELTIER WR, IN PRESS QUAT SCI RE; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; Svendsen JI, 2004, QUATERNARY SCI REV, V23, P1229, DOI 10.1016/j.quascirev.2003.12.008; Tarasov L, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001731; Tarasov L, 2004, QUATERNARY SCI REV, V23, P359, DOI 10.1016/j.quascirev.2003.08.004; Tarasov L, 1997, J GEOPHYS RES-ATMOS, V102, P21665, DOI 10.1029/97JD01766; Teller JT, 2004, GEOL SOC AM BULL, V116, P729, DOI 10.1130/B25316.1; TELLER JT, IN PRESS QUAT SCI RE; Vinje T, 1998, J GEOPHYS RES-OCEANS, V103, P10437, DOI 10.1029/97JC03360	30	228	237	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					662	665		10.1038/nature03617	http://dx.doi.org/10.1038/nature03617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931219				2022-12-28	WOS:000229476200047
J	Williams, HC				Williams, HC			Atopic dermatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND; FLUTICASONE PROPIONATE; MANAGEMENT; CHILDREN; PLACEBO; SEVERITY; CREAM; PIMECROLIMUS; TACROLIMUS		Univ Nottingham, Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England	University of Nottingham	Williams, HC (corresponding author), Univ Nottingham, Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England.	hywel.williams@nottingham.ac.uk		williams, hywel/0000-0002-5646-3093				AOKI T, 1992, ACTA DERM-VENEREOL, P19; Ashcroft DM, 2005, BMJ-BRIT MED J, V330, P516, DOI 10.1136/bmj.38376.439653.D3; Bannister M J, 2000, Australas J Dermatol, V41, P225; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beattie PE, 2003, CLIN EXP DERMATOL, V28, P549, DOI 10.1046/j.1365-2230.2003.01357.x; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Charman C, 2003, CLIN DERMATOL, V21, P193, DOI 10.1016/S0738-081X(02)00368-1; Charman C, 2003, J INVEST DERMATOL, V120, P932, DOI 10.1046/j.1523-1747.2003.12251.x; Cookson WOCM, 2002, CURR OPIN ALLERGY CL, V2, P383, DOI 10.1097/00130832-200210000-00003; *CTR DRUG EV RES, 2005, AL HEALTHC PROF PIM; *CTR DRUG EV RES, 2005, AL HEALTHC PROF TACR; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Ellison JA, 2000, PEDIATRICS, V105, P794, DOI 10.1542/peds.105.4.794; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Emerson RM, 1998, BRIT J DERMATOL, V139, P73; Ewing CI, 1998, BRIT J DERMATOL, V138, P1022; Fiocchi A, 2004, ALLERGY, V59, P78, DOI 10.1111/j.1398-9995.2004.00653.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Gradwell C, 2002, BRIT J DERMATOL, V147, P513, DOI 10.1046/j.1365-2133.2002.04901.x; Griffiths CEM, 2002, BRIT J DERMATOL, V147, P299, DOI 10.1046/j.1365-2133.2002.04894.x; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; Hanifin J, 2002, BRIT J DERMATOL, V147, P528, DOI 10.1046/j.1365-2133.2002.05006.x; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hoare C, 2000, Health Technol Assess, V4, P1; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jenner Nicole, 2004, Australas J Dermatol, V45, P16, DOI 10.1111/j.1440-0960.2004.00046.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kantor I, 1993, TODAY THER TRENDS, V11, P157; Kawashima M, 2003, BRIT J DERMATOL, V148, P1212, DOI 10.1046/j.1365-2133.2003.05293.x; Kemp AS, 2003, PHARMACOECONOMICS, V21, P105, DOI 10.2165/00019053-200321020-00003; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Kyllonen H, 2004, BRIT J DERMATOL, V150, P1174, DOI 10.1111/j.1365-2133.2004.06017.x; LAMMINTAUSTA K, 1991, INT J DERMATOL, V30, P563; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Levin Cheryl, 2002, Am J Clin Dermatol, V3, P141, DOI 10.2165/00128071-200203030-00001; Liu T, 2001, ARCH DERMATOL, V137, P630; Lucky AW, 1997, PEDIATR DERMATOL, V14, P321, DOI 10.1111/j.1525-1470.1997.tb00968.x; Luger T A, 2004, J Dermatolog Treat, V15, P169; LUOMA R, 1983, ALLERGY, V38, P339, DOI 10.1111/j.1398-9995.1983.tb04128.x; MAR A, 2000, ATOPIC DERMATITIS, P205; MCHENRY PM, 1995, BMJ-BRIT MED J, V310, P843, DOI 10.1136/bmj.310.6983.843; Munday J, 2002, DERMATOLOGY, V205, P40, DOI 10.1159/000063138; MUNKVAD M, 1989, BRIT J DERMATOL, V121, P763, DOI 10.1111/j.1365-2133.1989.tb08219.x; *NAT I CLIN EXC, FIN APPR DET FREQ AP; *NT I CLIN EXC, 2005, FIN APPR DET TACR PI; Olesen AB, 2003, ACTA DERM-VENEREOL, V83, P445, DOI 10.1080/00015550310014997; Patel L, 1998, ARCH DIS CHILD, V79, P169, DOI 10.1136/adc.79.2.169; RYSTEDT I, 1985, ACTA DERM-VENEREOL, P117; Sampson HA, 2003, CLIN DERMATOL, V21, P183, DOI 10.1016/S0738-081X(02)00363-2; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Shainhouse Tsippora, 2003, Expert Opin Drug Saf, V2, P457, DOI 10.1517/eods.2.5.457.21605; Staab D, 2002, PEDIAT ALLERG IMM-UK, V13, P84, DOI 10.1034/j.1399-3038.2002.01005.x; Thomas KS, 2002, BRIT MED J, V324, P768, DOI 10.1136/bmj.324.7340.768; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Vender R B, 2002, Skin Therapy Lett, V7, P4; Verboom P, 2002, BRIT J DERMATOL, V147, P716, DOI 10.1046/j.1365-2133.2002.04964.x; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; Williams H, 2003, ARCH DERMATOL, V139, P1490, DOI 10.1001/archderm.139.11.1490; Williams H, 2002, BRIT MED J, V324, P1533, DOI 10.1136/bmj.324.7353.1533; WILLIAMS HC, 1995, BRIT MED J, V311, P1241, DOI 10.1136/bmj.311.7015.1241; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams HC, 2003, BMJ-BRIT MED J, V327, P1358, DOI 10.1136/bmj.327.7428.1358; Williams HC, 2000, ATOPIC DERMATITIS EP, P41, DOI 10.1017/CBO9780511545771.005; Williams HC., 2000, ATOPIC DERMATITIS EP, P3; 2005, DRUG THER B, V43, P6	68	365	390	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2314	2324		10.1056/NEJMcp042803	http://dx.doi.org/10.1056/NEJMcp042803			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930422				2022-12-28	WOS:000229446400008
J	Aldaz, H; Rice, LM; Stearns, T; Agard, DA				Aldaz, H; Rice, LM; Stearns, T; Agard, DA			Insights into microtubule nucleation from the crystal structure of human gamma-tubulin	NATURE			English	Article							ALPHA-BETA-TUBULIN	Microtubules are hollow polymers of alpha beta-tubulin that show GTP-dependent assembly dynamics and comprise a critical part of the eukaryotic cytoskeleton. Initiation of new microtubules in vivo requires gamma-tubulin, organized as an oligomer within the 2.2-MDa gamma-tubulin ring complex (gamma-TuRC) of higher eukaryotes(1-3). Structural insight is lacking regarding gamma-tubulin, its oligomerization and how it promotes microtubule assembly. Here we report the 2.7-angstrom crystal structure of human gamma-tubulin bound to GTP-gamma S ( a non-hydrolysable GTP analogue). We observe a 'curved' conformation for gamma-tubulin -GTP gamma S, similar to that seen for GDP-bound, unpolymerized alpha beta-tubulin(4). Tubulins are thought to represent a distinct class of GTP-binding proteins, and conformational switching in gamma-tubulin might differ from the nucleotide-dependent switching of signalling GTPases. A crystal packing interaction replicates the lateral contacts between alpha- and beta-tubulins in the microtubule(5), and this association probably forms the basis for gamma-tubulin oligomerization within the gamma-TuRC. Laterally associated gamma-tubulins in the gamma-TuRC might promote microtubule nucleation by providing a template that enhances the intrinsically weak lateral interaction between alpha beta-tubulin heterodimers. Because they are dimeric, alpha beta-tubulins cannot form microtubule-like lateral associations in the curved conformation(5). The lateral array of gamma-tubulins we observe in the crystal reveals a unique functional property of a monomeric tubulin.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Agard, DA (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, 600 16th St, San Francisco, CA 94143 USA.	agard@msg.ucsf.edu		Stearns, Tim/0000-0002-0671-6582				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; DeLano W.L, PYMOL MOL GRAPHICS S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	15	139	140	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					523	527		10.1038/nature03586	http://dx.doi.org/10.1038/nature03586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917813				2022-12-28	WOS:000229337800060
J	Fauci, AS				Fauci, AS			Race against time	NATURE			English	Editorial Material							VACCINE; VIRUS		NIAID, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, US Dept HHS, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Choi YK, 2004, J VIROL, V78, P8609, DOI 10.1128/JVI.78.16.8609-8614.2004; CLEMENTS ML, 1984, LANCET, V1, P705; Gensheimer KF, 2003, EMERG INFECT DIS, V9, P1645, DOI 10.3201/eid0912.030289; Kilbourne ED, 1999, NAT MED, V5, P1119, DOI 10.1038/13436; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3	6	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					423	424		10.1038/435423a	http://dx.doi.org/10.1038/435423a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917781	Green Published			2022-12-28	WOS:000229337800027
J	Ho, D				Ho, D			Is China prepared for microbial threats?	NATURE			English	Editorial Material									Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Rockefeller University	Ho, D (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.								0	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					421	422		10.1038/435421a	http://dx.doi.org/10.1038/435421a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917780	Green Published, Bronze			2022-12-28	WOS:000229337800026
J	Wolfe, JM; Horowitz, TS; Kenner, NM				Wolfe, JM; Horowitz, TS; Kenner, NM			Rare items often missed in visual searches	NATURE			English	Editorial Material									Brigham & Womens Hosp, Visual Attent Lab, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wolfe, JM (corresponding author), Brigham & Womens Hosp, Visual Attent Lab, Cambridge, MA 02139 USA.	wolfe@search.bwh.harvard.edu	Horowitz, Todd S/J-3376-2013; Wolfe, Jeremy M/A-9248-2016; Wolfe, Jeremy M/C-1621-2012	Wolfe, Jeremy M/0000-0002-6475-1984; Wolfe, Jeremy M/0000-0002-6475-1984; Horowitz, Todd/0000-0001-5571-6266	NEI NIH HHS [R01 EY017001] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY017001] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Chun MM, 1996, COGNITIVE PSYCHOL, V30, P39, DOI 10.1006/cogp.1996.0002; Gur D, 2004, J NATL CANCER I, V96, P185, DOI 10.1093/jnci/djh067; Gur D, 2003, ACAD RADIOL, V10, P1324, DOI 10.1016/S1076-6332(03)00466-5; Kundel HL, 2000, PROC SPIE, V3981, P135, DOI 10.1117/12.383100; Mackworth J, 1970, VIGILANCE ATTENTION; Palmer J, 2000, VISION RES, V40, P1227, DOI 10.1016/S0042-6989(99)00244-8; Wickens C. D., 1993, WORKLOAD TRANSITION, P139; Wolfe Jeremy M, 2010, Curr Biol, V20, pR346, DOI 10.1016/j.cub.2010.02.016	8	328	332	4	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					439	440		10.1038/435439a	http://dx.doi.org/10.1038/435439a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917795	Green Accepted			2022-12-28	WOS:000229337800039
J	Daviter, T; Murphy, FV; Ramakrishnan, V				Daviter, T; Murphy, FV; Ramakrishnan, V			A renewed focus on transfer RNA	SCIENCE			English	Editorial Material							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR TU; RIBOSOME; SELECTION; RECOGNITION		MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Daviter, T (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ramak@mrc-lmb.cam.ac.uk		Ramakrishnan, V/0000-0002-4699-2194				Cochella L, 2005, SCIENCE, V308, P1178, DOI 10.1126/science.1111408; DAVIES J, 1964, P NATL ACAD SCI USA, V51, P883, DOI 10.1073/pnas.51.5.883; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; HIRSH, 1971, J MOL BIOL, V58, P439, DOI 10.1016/0022-2836(71)90362-7; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Piepenburg O, 2000, BIOCHEMISTRY-US, V39, P1734, DOI 10.1021/bi992331y; RAHLMAN RP, 2004, MOL CELL, V16, P799; Rodnina MV, 2001, ANNU REV BIOCHEM, V70, P415, DOI 10.1146/annurev.biochem.70.1.415; RUUSALA T, 1982, EMBO J, V1, P741, DOI 10.1002/j.1460-2075.1982.tb01240.x; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; SUGIMOTO N, 1986, BIOCHEMISTRY-US, V25, P5755, DOI 10.1021/bi00367a061; THOMPSON RC, 1977, P NATL ACAD SCI USA, V74, P198, DOI 10.1073/pnas.74.1.198; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Yarus Michael, 1995, P443	20	12	12	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1123	1124		10.1126/science.1113415	http://dx.doi.org/10.1126/science.1113415			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905389				2022-12-28	WOS:000229293400030
J	Fei, YW; Bertka, C				Fei, YW; Bertka, C			The interior of Mars	SCIENCE			English	Editorial Material							THERMAL EVOLUTION; CORE; PATHFINDER		Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Amer Assoc Advancement Sci, Washington, DC 20005 USA	Carnegie Institution for Science	Fei, YW (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.	fei@gl.ciw.edu; cbertka@aaas.org	Fei, Yingwei/F-3709-2011	Fei, Yingwei/0000-0001-9955-5353				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Bertka CM, 1998, SCIENCE, V281, P1838, DOI 10.1126/science.281.5384.1838; Bertka CM, 1998, EARTH PLANET SC LETT, V157, P79, DOI 10.1016/S0012-821X(98)00030-2; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; DREIBUS G, 1985, METEORITICS, V20, P367; ELKINSTANTON LT, 2003, LUNAR PLANET SCI, V34, P1479; FEI Y, 2003, LUNAR PLANET SCI, V34, P1829; Fei YW, 2000, AM MINERAL, V85, P1830; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; Lillis K.J., 2005, LUNAR PLANET SCI, VXXXVI, P1578; McSween HY, 2004, SCIENCE, V305, P842, DOI 10.1126/science.3050842; Stevenson DJ, 2001, NATURE, V412, P214, DOI 10.1038/35084155; Wieczorek MA, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002153; Williams JP, 2004, GEOLOGY, V32, P97, DOI 10.1130/G19975.1; Yoder CF, 2003, SCIENCE, V300, P299, DOI 10.1126/science.1079645; Zuber MT, 2000, SCIENCE, V287, P1788, DOI 10.1126/science.287.5459.1788	16	52	55	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2005	308	5725					1120	1121		10.1126/science.1110531	http://dx.doi.org/10.1126/science.1110531			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905386				2022-12-28	WOS:000229293400027
J	Liu, ET				Liu, ET			Systems biology, integrative biology, predictive biology	CELL			English	Editorial Material							TRANSCRIPTOME; NETWORK; IDENTIFICATION; GENES; STATE		Genome Inst Singapore, Singapore 138672, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Liu, ET (corresponding author), Genome Inst Singapore, 60 Biopolis St,02-01 Genome, Singapore 138672, Singapore.	liue@gis.a-star.edu.sg	Liu, Edison/C-4141-2008; CUNHA, JOEL/E-6916-2015	CUNHA, JOEL/0000-0001-9880-6974				Bolouri H, 2003, P NATL ACAD SCI USA, V100, P9371, DOI 10.1073/pnas.1533293100; Davidson EH, 2002, DEV BIOL, V246, P162, DOI 10.1006/dbio.2002.0635; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Hood L, 2004, SCIENCE, V306, P640, DOI 10.1126/science.1104635; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Liu ET, 2004, PHARMACOGENOMICS, V5, P1117, DOI 10.1517/14622416.5.8.1117; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Peng X, 2005, MOL BIOL CELL, V16, P1026, DOI 10.1091/mbc.E04-04-0299; Ruan YJ, 2004, TRENDS BIOTECHNOL, V22, P23, DOI 10.1016/j.tibtech.2003.11.002; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162	10	76	83	9	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					505	506		10.1016/j.cell.2005.04.021	http://dx.doi.org/10.1016/j.cell.2005.04.021			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907463	Bronze			2022-12-28	WOS:000229331200006
J	Okie, S				Okie, S			Traumatic brain injury in the war zone	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189	2	551	580	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2043	2047		10.1056/NEJMp058102	http://dx.doi.org/10.1056/NEJMp058102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	927GJ	15901856				2022-12-28	WOS:000229180100001
J	Stano, NM; Jeong, YJ; Donmez, I; Tummalapalli, P; Levin, MK; Patel, SS				Stano, NM; Jeong, YJ; Donmez, I; Tummalapalli, P; Levin, MK; Patel, SS			DNA synthesis provides the driving force to accelerate DNA unwinding by a helicase	NATURE			English	Article							SINGLE-STRANDED-DNA; REPLICATION FORK; BACTERIOPHAGE T7; BINDING PROTEIN; GENE-4 PROTEIN; POLYMERASE; PURIFICATION; MECHANISMS; DEFICIENT	Helicases are molecular motors that use the energy of nucleoside 5'-triphosphate (NTP) hydrolysis to translocate along a nucleic acid strand and catalyse reactions such as DNA unwinding. The ring-shaped helicase(1) of bacteriophage T7 translocates along single-stranded ( ss) DNA at a speed of 130 bases per second(2); however, T7 helicase slows down nearly tenfold when unwinding the strands of duplex DNA(3). Here, we report that T7 DNA polymerase, which is unable to catalyse strand displacement DNA synthesis by itself, can increase the unwinding rate to 114 base pairs per second, bringing the helicase up to similar speeds compared to its translocation along ssDNA. The helicase rate of stimulation depends upon the DNA synthesis rate and does not rely on specific interactions between T7 DNA polymerase and the carboxy-terminal residues of T7 helicase. Efficient duplex DNA synthesis is achieved only by the combined action of the helicase and polymerase. The strand displacement DNA synthesis by the DNA polymerase depends on the unwinding activity of the helicase, which provides ssDNA template. The rapid trapping of the ssDNA bases by the DNA synthesis activity of the polymerase in turn drives the helicase to move forward through duplex DNA at speeds similar to those observed along ssDNA.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Kookmin Univ, Dept Bio & Nanochem, Seoul 136702, South Korea; Univ Connecticut, Ctr Hlth, Ctr Cell Anal & Modeling, Farmington, CT 06030 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Kookmin University; University of Connecticut	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055310] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; CHA TA, 1989, J BIOL CHEM, V264, P12220; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KIM YT, 1992, J BIOL CHEM, V267, P15022; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Levin M.K., 2003, MOL MOTORS, P179; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MOK M, 1987, J BIOL CHEM, V262, P16644; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Wang H, 2002, APPL PHYS A-MATER, V75, P315, DOI 10.1007/s003390201340	25	128	130	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					370	373		10.1038/nature03615	http://dx.doi.org/10.1038/nature03615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902262	Green Accepted			2022-12-28	WOS:000229185000050
J	Thrasher, AD; Ford, CL; Nearing, KA				Thrasher, AD; Ford, CL; Nearing, KA			Cost-effectiveness of screening for HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Thrasher, AD (corresponding author), Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA.	adthrash@email.unc.edu						Aggleton P, 2002, CONCEPTUAL FRAMEWORK; Bozzette SA, 2005, NEW ENGL J MED, V352, P620, DOI 10.1056/NEJMe048347; Mechanic D, 2002, HEALTH AFFAIR, V21, P48, DOI 10.1377/hlthaff.21.2.48	3	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2137	2137						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15906435				2022-12-28	WOS:000229180100026
J	Christiansen, SC; Cannegieter, SC; Koster, T; Vandenbroucke, JP; Rosendaal, FR				Christiansen, SC; Cannegieter, SC; Koster, T; Vandenbroucke, JP; Rosendaal, FR			Thrombophilia, clinical factors, and recurrent venous thrombotic events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; FACTOR-V-LEIDEN; ACTIVATED PROTEIN-C; PROTHROMBIN GENE; RISK-FACTOR; HETEROZYGOUS CARRIERS; PLASMA-LEVELS; 1ST EPISODE; FACTOR-VIII; THROMBOEMBOLISM	Context Data on the recurrence rate of venous thrombotic events and the effect of several risk factors, including thrombophilia, remain controversial. The potential benefit of screening for thrombophilia with respect to prophylactic strategies and duration of anticoagulant treatment is not yet known. Objectives To estimate the recurrence rate of thrombotic events in patients after a first thrombotic event and its determinants, including thrombophilic abnormalities. Design, Setting, and Patients Prospective follow-up study of 474 consecutive patients aged 18 to 70 years without a known malignancy treated for a first objectively confirmed thrombotic event at anticoagulation clinics in the Netherlands. The Leiden Thrombophilia Study (LETS) was conducted from 1988 through 1992 and patients were followed up through 2000. Main Outcome Measures Recurrent thrombotic event based on thrombophilic risk factors, sex, type of initial thrombotic event (idiopathic or provoked), oral contraceptive use, elevated levels of factors VIII, IX, XI, fibrinogen, homocysteine, and anticoagulant deficiencies. Results A total of 474 patients were followed up for mean (SD) of 7.3 (2.7) years and complete follow-up was achieved in 447 (94%). Recurrence of thrombotic events occurred in 90 patients during a total of 3477 patient-years. The rate of thrombotic event recurrence was 25.9 per 1000 patient-years (95% confidence interval [CI], 20.8-31.8 per 1000 patient-years). The incidence rate of recurrence was highest during the first 2 years (31.9 per 1000 patient-years; 95% Cl, 20.3-43.5 per 1000 patient-years). The risk of thrombotic event recurrence was 2.7 times (95% Cl, 1.8-4.2 times) higher in men than in women. Patients whose initial thrombotic event was idiopathic had a higher risk of a thrombotic event recurrence than patients whose initial event was provoked (hazard ratio [HR], 1.9; 95% Cl, 1.2-2.9). Women who used oral contraceptives during follow-up had a higher thrombotic event recurrence rate (28.0 per,1000 patient-years; 95% Cl, 15.9-49.4 per 1000 patient-years) than those who did not (12.9 per 1000 patient-years; 95% Cl, 7.9-21.2 per 1000 patient-years). Recurrence risks of a thrombotic event by laboratory abnormality ranged from an HR of 0.6 (95% Cl, 0.3-1.1) in patients with elevated levels of factor XI to an HR of 1.8 (95% Cl, 0.9-3.7) for patients with anticoagulant deficiencies. Conclusions Prothrombotic abnormalities do not appear to play an important role in the risk of a recurrent thrombotic event. Testing for prothrombotic defects has little consequence with respect to prophylactic strategies. Clinical factors are probably more important than laboratory abnormalities in determining the duration of anticoagulation therapy.	Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Hematol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rosendaal, FR (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, POB 9600, NL-2300 RC Leiden, Netherlands.	F.R.Rosendaal@lumc.nl	Christiansen, Sverre/AAD-5214-2020; Vandenbroucke, Jan/AAM-3928-2020; Cannegieter, Suzanne/W-3696-2019; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Cannegieter, Suzanne/0000-0003-4707-2303; Rosendaal, Frits/0000-0003-2558-7496; Christiansen, Sverre Christian/0000-0002-0378-0474				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Baglin T, 2004, J THROMB HAEMOST, V2, P2152, DOI 10.1111/j.1538-7836.2004.01050.x; Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; De Stefano V, 1999, NEW ENGL J MED, V341, P801, DOI 10.1056/NEJM199909093411104; De Stefano V, 2001, BRIT J HAEMATOL, V113, P630, DOI 10.1046/j.1365-2141.2001.02827.x; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Eichinger S, 1999, THROMB HAEMOSTASIS, V81, P14; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Eichinger S, 2002, ARCH INTERN MED, V162, P2357, DOI 10.1001/archinte.162.20.2357; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702; Kyrle PA, 2004, NEW ENGL J MED, V350, P2558, DOI 10.1056/NEJMoa032959; Lensing AWA, 1999, THROMB HAEMOSTASIS, V82, P1564; Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684; Meijers JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004; Miles JS, 2001, J AM COLL CARDIOL, V37, P215, DOI 10.1016/S0735-1097(00)01080-9; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Prandoni P, 2002, ANN INTERN MED, V137, P955, DOI 10.7326/0003-4819-137-12-200212170-00008; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; Rosendaal FR, 1999, THROMB HAEMOSTASIS, V82, P610; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; Simioni P, 2003, J THROMB HAEMOST, V1, P16, DOI 10.1046/j.1538-7836.2003.00094.x; Simioni P, 2000, BLOOD, V96, P3329; vanderMeer FJM, 1997, THROMB HAEMOSTASIS, V78, P631; Vlieg AV, 2000, BLOOD, V95, P3678; Weltermann A, 2003, J THROMB HAEMOST, V1, P28, DOI 10.1046/j.1538-7836.2003.00038.x; DOCUMENT CLIN VALIDI	41	417	438	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2352	2361		10.1001/jama.293.19.2352	http://dx.doi.org/10.1001/jama.293.19.2352			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900005				2022-12-28	WOS:000229120600022
J	Moses-Kolko, EL; Bogen, D; Perel, J; Bregar, A; Uhl, K; Levin, B; Wisner, KL				Moses-Kolko, EL; Bogen, D; Perel, J; Bregar, A; Uhl, K; Levin, B; Wisner, KL			Neonatal signs after late in utero exposure to serotonin reuptake inhibitors - Literature review and implications for clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							WITHDRAWAL SYNDROME; MATERNAL USE; PROZAC TOXICITY; BIRTH OUTCOMES; PREGNANT-WOMEN; FLUOXETINE; SYMPTOMS; INFANTS; PHARMACOKINETICS; ANTIDEPRESSANTS	Context A neonatal behavioral syndrome linked to in utero serotonin reuptake inhibitor (SRI) exposure during the last trimester of pregnancy has been identified. The US Food and Drug Administration (FDA) and drug manufacturers have recently agreed to a class labeling change for SRIs, which include selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), to include information about potential adverse events in neonates exposed in utero. Integration of data about the neonatal behavioral syndrome into the management of pregnancy in women who take SRIs is a current challenge for physicians. Objectives To review evidence regarding the SRI-related neonatal syndrome and to help clinicians guide their patients in a risk-benefit decision-making process. Data Sources We searched MEDLINE (1966-February 2005) and PsycINFO (1974-February 2005). All articles related to neonatal signs after in utero SRI exposure were acquired, as well as unpublished data on this topic from the FDA advisory committee meeting of June 2004. References cited in case reports and studies were reviewed. Foreign - language literature was included and translated to English. Study Selection and Data Extraction Studies were included if they had clearly identified maternal SRI exposure for a minimum of the final trimester of pregnancy through delivery and assessed neonatal outcomes. We identified 13 case reports describing a total of 18 cases. Nine cohort studies met criteria. When not included in the published article, relative risks and 95% confidence intervals (CIS) were computed from raw data and summary risk ratios and 95% CIS were determined with Mantel-Haenszel estimates. Data Synthesis Compared with early gestational SRI exposure or no exposure, late SRI exposure carries an overall risk ratio of 3.0 (95% Cl, 2.0-4.4) for a neonatal behavioral syndrome. The most SRI-related neonatal case reports involved fluoxetine and paroxetine exposures. Neonates primarily display central nervous system, motor, respiratory, and gastrointestinal signs that are usually mild and disappear by 2 weeks of age. Medical management has consisted primarily of supportive care in special care nurseries. A severe syndrome that consists of seizures, dehydration, excessive weight loss, hyperpyrexia, or intubation is rare in term infants (1/313 quantifiable cases). There have been no reported neonatal deaths attributable to neonatal SRI exposure. Conclusions Available evidence indicates that in utero exposure to SRIs during the last trimester through delivery may result in a self-limited neonatal behavioral syndrome that can be managed with supportive care. The risks and benefits of discontinuing an SRI during pregnancy need to be carefully weighed for each individual patient. Development and validation of assessment methods and clinical management strategies are critical to advancing this research.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Clin Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Obstet & Gynecol, Pittsburgh, PA 15213 USA; Princeton Univ, Princeton, NJ 08544 USA; US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Princeton University; US Food & Drug Administration (FDA)	Moses-Kolko, EL (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.	mosesel@upmc.edu		Wisner, Katherine/0000-0003-3458-5986	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH030915, K23MH064561, P30MH030915, R01MH060335] Funding Source: NIH RePORTER; NICHD NIH HHS [K12 HD43441-01] Funding Source: Medline; NIMH NIH HHS [K23 MH064561, MH 30915, MH R01 60335, K23 MH 064561] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altshuler LL, 1996, AM J PSYCHIAT, V153, P592; *AM AC PED, 1998, PEDIATRICS, V107, P1079; [Anonymous], 2003, KANG MOTH CAR PRACT; Blier P, 2003, BIOL PSYCHIAT, V53, P193, DOI 10.1016/S0006-3223(02)01643-8; Burt VK, 2001, AM J PSYCHIAT, V158, P1001, DOI 10.1176/appi.ajp.158.7.1001; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Charpak Nathalie, 1996, Current Opinion in Pediatrics, V8, P108, DOI 10.1097/00008480-199604000-00004; Cohen LS, 2000, BIOL PSYCHIAT, V48, P996, DOI 10.1016/S0006-3223(00)00877-5; Costei AM, 2002, ARCH PEDIAT ADOL MED, V156, P1129, DOI 10.1001/archpedi.156.11.1129; Coupland NJ, 1996, J CLIN PSYCHOPHARM, V16, P356, DOI 10.1097/00004714-199610000-00003; Dahl ML, 1997, BRIT J PSYCHIAT, V171, P391, DOI 10.1192/bjp.171.4.391c; de Moor R A, 2003, Ned Tijdschr Geneeskd, V147, P1370; Diav-Citrin O, 2002, TERATOLOGY, V65, P38, DOI 10.1002/tera.1095.abs; Einarson A, 2001, AM J PSYCHIAT, V158, P1728, DOI 10.1176/appi.ajp.158.10.1728; Ericson A, 1999, EUR J CLIN PHARMACOL, V55, P503, DOI 10.1007/s002280050664; FIELD T, 1995, INFANT BEHAV DEV, V18, P1, DOI 10.1016/0163-6383(95)90003-9; Finnegan LP., 1975, BASIC THERAPEUTIC AS, P139; Fox E., 2001, PRINCIPLES CLIN PHAR, P293; GEROLA O, 1999, RIV ITALIANA PEDIAT, V25, P216; Gillman PK, 1999, J PSYCHOPHARMACOL, V13, P100, DOI 10.1177/026988119901300111; GOLDSTEIN DJ, 1995, J CLIN PSYCHOPHARM, V15, P417, DOI 10.1097/00004714-199512000-00005; Haddad PM, 2001, DRUG SAFETY, V24, P183, DOI 10.2165/00002018-200124030-00003; Hale TW, 2001, CLIN PEDIATR, V40, P681, DOI 10.1177/000992280104001207; Hegerl U, 1998, EUR ARCH PSY CLIN N, V248, P96, DOI 10.1007/s004060050024; Heikkinen T, 2003, CLIN PHARMACOL THER, V73, P330, DOI 10.1016/S0009-9236(02)17634-X; Hendrick V, 2003, AM J PSYCHIAT, V160, P993, DOI 10.1176/appi.ajp.160.5.993; Herbst F, 2003, Z Geburtshilfe Neonatol, V207, P232; Hines RN, 2004, BIRTH DEFECTS RES B, V71, P193, DOI 10.1002/bdrb.20014; Kallen B, 2004, ARCH PEDIAT ADOL MED, V158, P312, DOI 10.1001/archpedi.158.4.312; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; KENT LSW, 1995, BRIT J PSYCHIAT, V167, P412, DOI 10.1192/bjp.167.3.412b; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; Kulin NA, 1998, JAMA-J AM MED ASSOC, V279, P609, DOI 10.1001/jama.279.8.609; Laine K, 2003, ARCH GEN PSYCHIAT, V60, P720, DOI 10.1001/archpsyc.60.7.720; Lane R, 1997, J CLIN PSYCHOPHARM, V17, P208, DOI 10.1097/00004714-199706000-00012; MELTZER HY, 1979, J NEURAL TRANSM, V45, P165, DOI 10.1007/BF01250091; Mhanna MJ, 1997, PEDIATRICS, V100, P158, DOI 10.1542/peds.100.1.158; Misri S, 2004, CAN J PSYCHIAT, V49, P684, DOI 10.1177/070674370404901006; Mohan C G, 2000, J Perinatol, V20, P445, DOI 10.1038/sj.jp.7200388; Moore ER, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub2; MORSELLI PL, 1980, CLIN PHARMACOKINET, V5, P485, DOI 10.2165/00003088-198005060-00001; Nijhuis IJM, 2001, ARCH DIS CHILD-FETAL, V84, pF77; Nordeng H, 2001, ACTA PAEDIATR, V90, P288, DOI 10.1080/080352501300067596; Norton JD, 2004, PEDIATRICS, V114, P1739, DOI 10.1542/peds.2004-1626; Oberlander TF, 2004, J CLIN PSYCHIAT, V65, P230; Oberlander TF, 2002, PEDIATR RES, V51, P443, DOI 10.1203/00006450-200204000-00008; Oesterheld JR, 1998, J CHILD ADOL PSYCHOP, V8, P161, DOI 10.1089/cap.1998.8.161; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; Robins L.N., 1991, PSYCHIAT DISORDERS A; Sanz EJ, 2005, LANCET, V365, P482, DOI 10.1016/S0140-6736(05)17865-9; Schatzberg AF, 1997, J CLIN PSYCHIAT, V58, P23; Schmidt K, 2000, BIOL PSYCHIAT, V47, P164, DOI 10.1016/S0006-3223(99)00155-9; SPENCER MJ, 1993, PEDIATRICS, V92, P721; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; Stiskal JA, 2001, ARCH DIS CHILD-FETAL, V84, pF134, DOI 10.1136/fn.84.2.F134; Verghese C, 1996, BIOL PSYCHIAT, V39, P135, DOI 10.1016/0006-3223(95)00215-4; Wisner KL, 2000, AM J PSYCHIAT, V157, P1933, DOI 10.1176/appi.ajp.157.12.1933; Wisner KL, 1996, AM J PSYCHIAT, V153, P1132; Wisner KL, 1988, PSYCHIAT CONSULTATIO, P165; Zeskind PS, 2004, PEDIATRICS, V113, P368, DOI 10.1542/peds.113.2.368; EFFEXOR VENLAFAXINE; CDER 2004 M DOC	62	357	363	2	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2372	2383		10.1001/jama.293.19.2372	http://dx.doi.org/10.1001/jama.293.19.2372			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900008				2022-12-28	WOS:000229120600025
J	Kanwal, F; Gralnek, AM; Martin, P; Dulai, GS; Farid, M; Spiegel, BMR				Kanwal, F; Gralnek, AM; Martin, P; Dulai, GS; Farid, M; Spiegel, BMR			Treatment alternatives for chronic hepatitis B virus infection: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Review							TERM-FOLLOW-UP; E-ANTIGEN SEROCONVERSION; CHRONIC ACTIVE HEPATITIS; PRIMARY HEPATOCELLULAR-CARCINOMA; LAMIVUDINE/INTERFERON COMBINATION THERAPY; LYMPHOBLASTOID INTERFERON-ALPHA; CHRONIC PERSISTENT HEPATITIS; LONG-TERM; SURFACE-ANTIGEN; NATURAL-HISTORY	Background: Treatment options for chronic hepatitis B virus (HBV) infection have disparate risks and benefits. interferon has clinically significant side effects, and lamivudine is associated with viral resistance. In contrast, adefovir is safe and has lower viral resistance but is more expensive. The most cost-effective approach is uncertain. Objective: To determine whether and under what circumstances the improved efficacy of adefovir offsets its increased cost compared with lamivudine or interferon. Design: Cost-utility analysis stratified by hepatitis B e antigen (HBeAg) status. Data Sources: Systematic review of MEDLINE from 1970 to 2005. Target Population: Patients with chronic HBV infection, elevated aminotransferase levels, and no cirrhosis. Time Horizon: Lifetime. Perspective: Third-party payer. Interventions: 1) No HBV treatment ("do nothing" strategy), 2) interferon monotherapy, 3) lamivudine monotherapy, 4) adefovir monotherapy, or 5) lamivudine with crossover to adefovir upon resistance ("adefovir salvage" strategy). Outcome Measure: Incremental cost per quality-adjusted life-year (QALY) gained. Results of Base-Case Analysis: The "do nothing" strategy was least effective yet least expensive. Compared with the "do nothing" strategy, using interferon cost an incremental $6337 to gain 1 additional CIALY. Compared with interferon, the adefovir salvage strategy cost an incremental $8446 per QALY gained. Both the lamivudine and adefovir monotherapy strategies were more expensive yet less effective than the alternative strategies and were therefore dominated. Results of Sensitivity Analysis: In sensitivity analysis, interferon was most cost-effective in health care systems with tight budgetary constraints and a high prevalence of HBeAg-negative patients. Limitations: These results apply only to patients with chronic HBV infection, elevated aminotransferase levels, and no clinical or histologic evidence of cirrhosis. They do not apply to alternative populations. Conclusions: Neither lamivudine nor adefovir monotherapy is cost-effective in chronic HBV infection. However, a hybrid salvage strategy reserving adefovir only for lamivudine-associated viral resistance may be highly cost-effective across most health care settings. Interferon therapy may still be preferred in health care systems with limited resources, especially in those serving populations with a high prevalence of HBeAg-negative HBV.	Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Spiegel, BMR (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.	BSpiegel@mednet.ucla.edu			NCRR NIH HHS [RR-16188] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALDERSHVILE J, 1982, HEPATOLOGY, V2, P243; ALWARD WLM, 1985, J INFECT DIS, V151, P604, DOI 10.1093/infdis/151.4.604; *AM MED ASS, 2004, AMA CPT COD BOOK; *AMA, 2004, AMA CPT COD BOOK; ARTHURS Y, 1982, T J MED SCI, V151, P298; ARTHURS Y, 1982, J MED SCI, V151, P298; Atkins M, 1998, HEPATOLOGY, V28, p319A; BEASLEY RP, 1981, LANCET, V2, P1129; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Benvegnu L, 2004, GUT, V53, P744, DOI 10.1136/gut.2003.020263; Briggs AH, 2002, ANNU REV PUBL HEALTH, V23, P377, DOI 10.1146/annurev.publhealth.23.100901.140534; BROWN SD, 1995, BRIT J BIOMED SCI, V52, P106; Brunetto MR, 2002, J HEPATOL, V36, P263, DOI 10.1016/S0168-8278(01)00266-5; Buti M, 2004, HEPATOLOGY, V40, p671A; Buti M, 2001, J VIRAL HEPATITIS, V8, P270, DOI 10.1046/j.1365-2893.2001.00296.x; Chan HLY, 2005, ANN INTERN MED, V142, P240, DOI 10.7326/0003-4819-142-4-200502150-00006; Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324; Chapman RH, 2000, MED DECIS MAKING, V20, P451, DOI 10.1177/0272989X0002000409; Chien RN, 2003, HEPATOLOGY, V38, P1267, DOI 10.1053/jhep.2003.50458; Chien RN, 1999, HEPATOLOGY, V30, P770, DOI 10.1002/hep.510300313; Chong CAKY, 2003, AM J GASTROENTEROL, V98, P630, DOI 10.1111/j.1572-0241.2003.07332.x; Chu CJ, 2003, HEPATOLOGY, V38, P619, DOI 10.1053/jhep.2003.50352; Chu CM, 2004, AM J MED, V116, P829, DOI 10.1016/j.amjmed.2003.12.040; Craxi A, 1987, Ann Ist Super Sanita, V24, P257; Crook PD, 2003, INT J EPIDEMIOL, V32, P118, DOI 10.1093/ije/dyg039; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; Di Marco V, 2004, HEPATOLOGY, V40, P883, DOI 10.1002/hep.20381; Di Marco V, 1999, HEPATOLOGY, V30, P257, DOI 10.1002/hep.510300109; Dienstag JL, 2003, HEPATOLOGY, V37, P748, DOI 10.1053/jhep.2003.50117; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; Dienstag JL, 1999, HEPATOLOGY, V30, P1082, DOI 10.1002/hep.510300427; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; Fattovich G, 1997, HEPATOLOGY, V26, P1338; FATTOVICH G, 1988, HEPATOLOGY, V8, P1651, DOI 10.1002/hep.1840080630; FATTOVICH G, 1995, HEPATOLOGY, V21, P77; FATTOVICH G, 1991, GUT, V32, P294, DOI 10.1136/gut.32.3.294; FATTOVICH G, 1992, HEPATOLOGY, V15, P584, DOI 10.1002/hep.1840150405; FEINMAN SV, 1982, HEPATO-GASTROENTEROL, V29, P58; Fung SK, 2004, J VIRAL HEPATITIS, V11, P432, DOI 10.1111/j.1365-2893.2004.00556.x; Furusyo N, 1999, AM J TROP MED HYG, V60, P616, DOI 10.4269/ajtmh.1999.60.616; Ghany MG, 2000, HEPATOLOGY, V32, p376A, DOI 10.1053/jhep.2000.17912; Gold MR, 1996, COST EFFECTIVENESS H; HADZIYANNIS S, 1990, J HEPATOL, V11, pS133, DOI 10.1016/0168-8278(90)90180-Y; HADZIYANNIS S, 1990, BR J HEPATOL, V11, pS133; Hadziyannis SJ, 2000, HEPATOLOGY, V32, P847, DOI 10.1053/jhep.2000.17915; Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812; HADZIYANNIS SJ, 1995, VIRAL HEPATITIS REV, V1, P7; HEYWARD WL, 1985, JAMA-J AM MED ASSOC, V254, P3052, DOI 10.1001/jama.254.21.3052; HOOFNAGLE JH, 1981, ANN INTERN MED, V94, P744, DOI 10.7326/0003-4819-94-6-744; Hsu YS, 2002, HEPATOLOGY, V35, P1522, DOI 10.1053/jhep.2002.33638; Huo TI, 1998, HEPATOLOGY, V28, P231, DOI 10.1002/hep.510280130; IIJIMA T, 1984, GANN, V75, P571; Janssen HLA, 2005, LANCET, V365, P123, DOI 10.1016/S0140-6736(05)17701-0; Kao JH, 2004, J MED VIROL, V72, P363, DOI 10.1002/jmv.10534; Keeffe EB, 2004, CLIN GASTROENTEROL H, V2, P87, DOI 10.1016/S1542-3565(03)00312-4; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; KOSAKA Y, 1981, Gastroenterologia Japonica, V16, P592; Krogsgaard K, 1998, J VIRAL HEPATITIS, V5, P389, DOI 10.1046/j.1365-2893.1998.00118.x; KUBO Y, 1978, GASTROENTEROLOGY, V74, P578; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083; Lampertico P, 1997, HEPATOLOGY, V26, P1621, DOI 10.1002/hep.510260634; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Lee HC, 2003, GUT, V52, P1779, DOI 10.1136/gut.52.12.1779; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Leung NWY, 2001, HEPATOLOGY, V33, P1527, DOI 10.1053/jhep.2001.25084; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1983, GASTROENTEROLOGY, V84, P216; Liaw YF, 2000, GASTROENTEROLOGY, V119, P172, DOI 10.1053/gast.2000.8559; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Lin SM, 2004, J VIRAL HEPATITIS, V11, P349, DOI 10.1111/j.1365-2893.2004.00512.x; LINDH G, 1988, HEPATOLOGY, V8, P98, DOI 10.1002/hep.1840080120; Lindh M, 1996, HEPATOLOGY, V24, P494, DOI 10.1053/jhep.1996.v24.pm0008781313; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; LO KJ, 1982, J INFECT DIS, V146, P205, DOI 10.1093/infdis/146.2.205; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401; Lok ASF, 2003, GASTROENTEROLOGY, V125, P1714, DOI 10.1053/j.gastro.2003.09.033; Manesis EK, 2001, GASTROENTEROLOGY, V121, P101, DOI 10.1053/gast.2001.25524; Marcellin P, 2004, HEPATOLOGY, V40, p655A; Marcellin P, 2004, NEW ENGL J MED, V351, P1206, DOI 10.1056/NEJMoa040431; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; McMahon BJ, 2000, HEPATOLOGY, V32, P842, DOI 10.1053/jhep.2000.17914; MUENING P, 2002, DESIGNING CONDUCTING; MUENIP P, 2002, DESIGNING CONDUCTING; MUSCA A, 1983, HEPATO-GASTROENTEROL, V30, P3; NAIR PV, 1986, HEPATOLOGY, V6, P1319, DOI 10.1002/hep.1840060616; NAKAMURA S, 1982, TOHOKU J EXP MED, V136, P387, DOI 10.1620/tjem.136.387; *NAT I ALL INF DIS, 1999, NEW INS SPARK OPT NI; *NAT I ALL INF DIS, 2004, NEW INS SPARK OPT NI; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; NORKRANS G, 1982, SCAND J GASTROENTERO, V17, P383, DOI 10.3109/00365528209182072; OKA H, 1990, HEPATOLOGY, V12, P680, DOI 10.1002/hep.1840120411; Papatheodoridis GV, 2002, HEPATOLOGY, V36, P219, DOI 10.1053/jhep.2002.33894; Papatheodoridis GV, 2001, J HEPATOL, V34, P306, DOI 10.1016/S0168-8278(00)00094-5; Perrillo R, 2004, GASTROENTEROLOGY, V126, P81, DOI 10.1053/j.gastro.2003.10.050; Perrillo RP, 2002, HEPATOLOGY, V36, P186, DOI 10.1053/jhep.2002.34294; Peters MG, 2004, GASTROENTEROLOGY, V126, P91, DOI 10.1053/j.gastro.2003.10.051; QI X, 2004, J HEPATOL, V40, pA57; REALDI G, 1980, GASTROENTEROLOGY, V79, P195; SAKUGAWA H, 1991, J MED VIROL, V34, P122, DOI 10.1002/jmv.1890340210; SAKUMA K, 1988, HEPATOLOGY, V8, P1642, DOI 10.1002/hep.1840080628; Salomon JA, 2003, JAMA-J AM MED ASSOC, V290, P228, DOI 10.1001/jama.290.2.228; SANCHEZTAPIAS JM, 1985, J HEPATOL, V1, P15, DOI 10.1016/S0168-8278(85)80064-7; Santantonio T, 2000, J HEPATOL, V32, P300, DOI 10.1016/S0168-8278(00)80076-8; Santantonio T, 2002, J HEPATOL, V36, P799, DOI 10.1016/S0168-8278(02)00056-9; Schiff ER, 2003, J HEPATOL, V38, P818, DOI 10.1016/S0168-8278(03)00076-X; SHERMAN M, 1995, HEPATOLOGY, V22, P432, DOI 10.1016/0270-9139(95)90562-6; Song BC, 2000, HEPATOLOGY, V32, P803, DOI 10.1053/jhep.2000.16665; Spiegel BMR, 2003, ANN INTERN MED, V138, P795, DOI 10.7326/0003-4819-138-10-200305200-00007; Spigel BMR, 2002, GASTROENTEROLOGY, V122, P1270, DOI 10.1053/gast.2002.33019; SU IJ, 1986, J HEPATOL, V3, P182, DOI 10.1016/S0168-8278(86)80024-1; SULAIMAN H A, 1989, Gastroenterologia Japonica, V24, P567; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321; *THOMPS MED EC, 2004, 2004 RED BOOK; THYAGARAJAN SP, 1983, J MED MICROBIOL, V16, P227, DOI 10.1099/00222615-16-2-227; TSUCHIE H, 1984, BIKEN J, V27, P169; *US DEP LAB BUR LA, 2004, CONS PRIC IND CALC; van Nunen AB, 2003, GUT, V52, P420, DOI 10.1136/gut.52.3.420; Villa E, 2000, HEPATOLOGY, V32, P233, DOI 10.1053/jhep.2000.9603; VILLENEUVE JP, 1994, GASTROENTEROLOGY, V106, P1000, DOI 10.1016/0016-5085(94)90760-9; VIOLA LA, 1981, LANCET, V2, P1156; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; Xu B, 2003, J GASTROEN HEPATOL, V18, P1345, DOI 10.1046/j.1440-1746.2003.03187.x; YANG PM, 1987, HEPATO-GASTROENTEROL, V34, P251; Yu MW, 1997, AM J EPIDEMIOL, V145, P1039, DOI 10.1093/oxfordjournals.aje.a009060; Yuen MF, 2004, J CLIN MICROBIOL, V42, P5036, DOI 10.1128/JCM.42.11.5036-5040.2004; 2004, 2004 RED BOOK	132	109	114	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					821	831		10.7326/0003-4819-142-10-200505170-00007	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897532				2022-12-28	WOS:000229099600003
J	Reese, C; Heise, F; Mayer, A				Reese, C; Heise, F; Mayer, A			Trans-SNARE pairing can precede a hemifusion intermediate in intracellular membrane fusion	NATURE			English	Article							VACUOLE FUSION; INFLUENZA HEMAGGLUTININ; YEAST VACUOLES; VIRAL FUSION; LATE STEP; EXOCYTOSIS; DOCKING; PEPTIDES	The question concerning whether all membranes fuse according to the same mechanism has yet to be answered satisfactorily. During fusion of model membranes or viruses, membranes dock, the outer membrane leaflets mix ( termed hemifusion), and finally the fusion pore opens and the contents mix(1,2). Viral fusion proteins consist of a membrane-disturbing 'fusion peptide' and a helical bundle that pin the membranes together(2-4). Although SNARE ( soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complexes form helical bundles with similar topology, it is unknown whether SNARE-dependent fusion events on intracellular membranes proceed through a hemifusion state. Here we identify the first hemifusion state for SNARE-dependent fusion of native membranes, and place it into a sequence of molecular events: formation of helical bundles by SNAREs precedes hemifusion; further progression to pore opening requires additional peptides. Thus, SNARE-dependent fusion may proceed along the same pathway as viral fusion: both use a docking mechanism via helical bundles(5,6) and additional peptides to destabilize the membrane and efficiently induce lipid mixing(7-9). Our results suggest that a common lipidic intermediate(3) may underlie all fusion reactions of lipid bilayers.	Univ Lausanne, Dept Biochim, CH-1066 Epalinges, Switzerland; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	University of Lausanne; Ruprecht Karls University Heidelberg	Mayer, A (corresponding author), Univ Lausanne, Dept Biochim, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	Andreas.Mayer@unil.ch	Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Cohen FS, 2004, J MEMBRANE BIOL, V199, P1, DOI 10.1007/s00232-004-0669-8; Coorssen JR, 2003, J CELL SCI, V116, P2087, DOI 10.1242/jcs.00374; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759; REESE C, UNPUB J CELL BIOL; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Szule JA, 2003, J BIOL CHEM, V278, P24251, DOI 10.1074/jbc.C300197200; Tamm LK, 2002, BIOPOLYMERS, V66, P249, DOI 10.1002/bip.10261; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wang YX, 2001, J BIOL CHEM, V276, P35133, DOI 10.1074/jbc.M103937200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Zimmerberg J, 2001, TRENDS CELL BIOL, V11, P233, DOI 10.1016/S0962-8924(01)02003-7; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0	30	93	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	2005	436	7049					410	414		10.1038/nature03722	http://dx.doi.org/10.1038/nature03722			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	947DK	15924133				2022-12-28	WOS:000230623400046
J	Iversen, L; Hannaford, PC; Elliott, AM; Lee, AJ				Iversen, L; Hannaford, PC; Elliott, AM; Lee, AJ			Long term effects of hysterectomy on mortality: nested cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HORMONE REPLACEMENT THERAPY; EPITHELIAL OVARIAN-CANCER; MYOCARDIAL-INFARCTION; TUBAL-STERILIZATION; BREAST-CANCER; RISK; SUBSEQUENT; OOPHORECTOMY	Objectives To investigate the long term risk (mean >20 years) of death from all causes, cardiovascular disease, and cancer in women who had or had not had a hysterectomy. Design Nested cohort study. Setting Royal College of General Practitioners' oral contraception study. Participants 7410 women (3705 flagged at the NHS central registries for cancer and death who had a hysterectomy during the oral contraception study and 3705 who were flagged but did not have the operation). Main outcome measures Mortality from all causes, cardiovascular disease, and cancer. Results 623 (8.4%) women had died by the end of follow-up (308 in the hysterectomy group and 315 in the non-hysterectomy group). Older women who had had a hysterectomy had a 6% reduced risk of death compared with women of a similar age who did not have the operation (adjusted hazard ratio 0.94, 95% confidence interval 0.75 to 1.18). Compared with young women who did not have a hysterectomy those who were younger at hysterectomy had an adjusted hazard ratio for all cause mortality of 0.82 (95% confidence interval 0.65 to 1.03). Hysterectomy was not associated with a significantly altered risk of mortality from cardiovascular disease or cancer regardless of age. Conclusion Hysterectomy did not increase the risk of death in the medium to long term.	Univ Aberdeen, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland	University of Aberdeen	Iversen, L (corresponding author), Univ Aberdeen, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland.	l.iversen@abdn.ac.uk	Hannaford, Philip C/B-7867-2012	Iversen, Lisa/0000-0002-2524-5229				Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1996, EVIDENCE GUIDED PRES, P327; Bongers MY, 2004, MATURITAS, V47, P159, DOI 10.1016/j.maturitas.2003.08.002; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; Department of Health, HOSP EP STAT; Falkeborn M, 2000, J CLIN EPIDEMIOL, V53, P832, DOI 10.1016/S0895-4356(00)00187-6; Gago-Dominguez M, 1999, CANCER EPIDEM BIOMAR, V8, P999; *GEN REG OFF, 1969, CLASS SURG OP; General Register Office, 1966, CLASS OCC; Green A, 1997, INT J CANCER, V71, P948; Hsia J, 2003, AM J CARDIOL, V92, P264, DOI 10.1016/S0002-9149(03)00621-0; IRWIN KL, 1991, AM J EPIDEMIOL, V134, P362, DOI 10.1093/oxfordjournals.aje.a116098; *ISD SCOTL, HOSP OP PROC HYST; Keshavarz Homa, 2002, Morbidity and Mortality Weekly Report, V51, P1; Kreiger N, 1999, EUR J CANCER, V35, P97, DOI 10.1016/S0959-8049(98)00343-8; Lepine L A, 1997, MMWR CDC Surveill Summ, V46, P1; Luoto R, 1997, INT J EPIDEMIOL, V26, P476, DOI 10.1093/ije/26.3.476; Moorhead T, 1997, BRIT J OBSTET GYNAEC, V104, P290, DOI 10.1111/j.1471-0528.1997.tb11456.x; *OFF NAT STAT SMOK, LIV BRIT 2002 GEN HO; Owen-Smith V, 1998, J EPIDEMIOL COMMUN H, V52, P420, DOI 10.1136/jech.52.7.420; Parazzini F, 1997, OBSTET GYNECOL, V90, P453, DOI 10.1016/S0029-7844(97)00295-0; Riman T, 1998, CLIN ENDOCRINOL, V49, P695, DOI 10.1046/j.1365-2265.1998.00577.x; ROSENBERG L, 1981, AM J OBSTET GYNECOL, V139, P47, DOI 10.1016/0002-9378(81)90410-5; Royal College of General Practitioners, 1974, OR CONTR HLTH; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; World Health Organization, 1967, INT CLASS DIS INJ CA	26	18	18	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 25	2005	330	7506					1482	1485		10.1136/bmj.38483.669178.8F	http://dx.doi.org/10.1136/bmj.38483.669178.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942NR	15930026	Green Published, Bronze			2022-12-28	WOS:000230289600019
J	Ward, MD				Ward, MD			Snapshots of crystal growth	SCIENCE			English	Editorial Material							ATOMIC-FORCE MICROSCOPY; CRYSTALLIZATION; SURFACES; MECHANISMS; KINETICS		Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ward, MD (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	wardx004@umn.edu						BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; De Yoreo JJ, 2004, SCIENCE, V306, P1301, DOI 10.1126/science.1100889; DEYOREO JJ, 1994, PHYS REV LETT, V73, P838, DOI 10.1103/PhysRevLett.73.838; DURBIN SD, 1992, J CRYST GROWTH, V122, P71, DOI 10.1016/0022-0248(92)90228-B; Feeling-Taylor AR, 2004, BIOPHYS J, V87, P2621, DOI 10.1529/biophysj.104.039743; HILLIER AC, 1994, SCIENCE, V263, P1261, DOI 10.1126/science.263.5151.1261; Jung T, 2004, LANGMUIR, V20, P8587, DOI 10.1021/la0488755; LAND TA, 1995, PHYS REV LETT, V75, P2774, DOI 10.1103/PhysRevLett.75.2774; Last JA, 1998, CHEM MATER, V10, P422, DOI 10.1021/cm970582s; Liu XG, 2005, SCIENCE, V307, P1763, DOI 10.1126/science.1109487; MANNE S, 1993, J CRYST GROWTH, V130, P333, DOI 10.1016/0022-0248(93)90874-V; Orme CA, 2001, NATURE, V411, P775, DOI 10.1038/35081034; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Qiu SR, 2004, P NATL ACAD SCI USA, V101, P1811, DOI 10.1073/pnas.0307900100; Reviakine I, 2003, J AM CHEM SOC, V125, P11684, DOI 10.1021/ja030194t; Sheng XX, 2005, P NATL ACAD SCI USA, V102, P267, DOI 10.1073/pnas.0406835101; Sours RE, 2005, J PHYS CHEM B, V109, P9989, DOI 10.1021/jp0455733; Ward MD, 2001, CHEM REV, V101, P1697, DOI 10.1021/cr000020j; WEISENHORN AL, 1989, APPL PHYS LETT, V54, P2651, DOI 10.1063/1.101024; Yip CM, 1998, BIOPHYS J, V74, P2199, DOI 10.1016/S0006-3495(98)77929-9	20	21	23	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1566	1567		10.1126/science.1111099	http://dx.doi.org/10.1126/science.1111099			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947165				2022-12-28	WOS:000229827000032
J	Akiyama, K; Matsuzaki, K; Hayashi, H				Akiyama, K; Matsuzaki, K; Hayashi, H			Plant sesquiterpenes induce hyphal branching in arbuscular mycorrhizal fungi	NATURE			English	Article							SEED-GERMINATION STIMULANT; STRIGA-LUTEA LOUR; SYNTHETIC ANALOGS; RED-CLOVER; OROBANCHE; (+)-STRIGOL; RECOGNITION; SIGNALS; GROWTH	Arbuscular mycorrhizal (AM) fungi form mutualistic, symbiotic associations with the roots of more than 80% of land plants(1). The fungi are incapable of completing their life cycle in the absence of a host root. Their spores can germinate and grow in the absence of a host, but their hyphal growth is very limited. Little is known about the molecular mechanisms that govern signalling and recognition between AM fungi and their host plants. In one of the first stages of host recognition, the hyphae of AM fungi show extensive branching in the vicinity of host roots before formation of the appressorium(2-4), the structure used to penetrate the plant root. Host roots are known to release signalling molecules that trigger hyphal branching(5-7), but these branching factors have not been isolated. Here we have isolated a branching factor from the root exudates of Lotus japonicus and used spectroscopic analysis and chemical synthesis to identify it as a strigolactone, 5-deoxy-strigol. Strigolactones are a group of sesquiterpene lactones, previously isolated as seed-germination stimulants for the parasitic weeds Striga and Orobanche(8). The natural strigolactones 5-deoxy-strigol, sorgolactone and strigol, and a synthetic analogue, GR24, induced extensive hyphal branching in germinating spores of the AM fungus Gigaspora margarita at very low concentrations.	Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Div Appl Biol Chem, Osaka 5998531, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320112, Japan	Osaka Metropolitan University; Japan Science & Technology Agency (JST)	Akiyama, K (corresponding author), Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Div Appl Biol Chem, Osaka 5998531, Japan.	akiyama@biochem.osakafu-u.ac.jp	Akiyama, Kohki/B-4668-2012	Akiyama, Kohki/0000-0002-9171-9058				BECARD G, 1988, NEW PHYTOL, V108, P211, DOI 10.1111/j.1469-8137.1988.tb03698.x; BERGMANN C, 1993, J PLANT PHYSIOL, V142, P338, DOI 10.1016/S0176-1617(11)80432-3; Bouwmeester HJ, 2003, CURR OPIN PLANT BIOL, V6, P358, DOI 10.1016/S1369-5266(03)00065-7; BROOKS DW, 1985, J ORG CHEM, V50, P3779, DOI 10.1021/jo00220a020; Buee M, 2000, MOL PLANT MICROBE IN, V13, P693, DOI 10.1094/MPMI.2000.13.6.693; COOK CE, 1966, SCIENCE, V154, P1189, DOI 10.1126/science.154.3753.1189; COOK CE, 1972, J AM CHEM SOC, V94, P6198, DOI 10.1021/ja00772a048; FRISCHMUTH K, 1991, TETRAHEDRON, V47, P9793, DOI 10.1016/S0040-4020(01)80719-5; Giovannetti M, 1996, NEW PHYTOL, V133, P65, DOI 10.1111/j.1469-8137.1996.tb04342.x; GIOVANNETTI M, 1994, NEW PHYTOL, V127, P703, DOI 10.1111/j.1469-8137.1994.tb02973.x; GIOVANNETTI M, 1993, NEW PHYTOL, V125, P587, DOI 10.1111/j.1469-8137.1993.tb03907.x; HAUCK C, 1992, J PLANT PHYSIOL, V139, P474, DOI 10.1016/S0176-1617(11)80497-9; JOHNSON AW, 1981, J CHEM SOC PERK T 1, P1734, DOI 10.1039/p19810001734; MANGNUS EM, 1992, J AGR FOOD CHEM, V40, P1066, DOI 10.1021/jf00018a032; MOSSE B, 1975, PHYSIOL PLANT PATHOL, V5, P215, DOI 10.1016/0048-4059(75)90088-0; MULLER S, 1992, J PLANT GROWTH REGUL, V11, P77, DOI 10.1007/BF00198018; Nagahashi G, 1999, BIOTECHNOL TECH, V13, P893, DOI 10.1023/A:1008938527757; Nagahashi G, 2000, MYCOL RES, V104, P1453, DOI 10.1017/S0953756200002860; NAKANO S, 1995, BIOSCI BIOTECH BIOCH, V59, P1699, DOI 10.1271/bbb.59.1699; Parniske M, 2004, CURR OPIN PLANT BIOL, V7, P414, DOI 10.1016/j.pbi.2004.05.011; Sato D, 2003, J AGR FOOD CHEM, V51, P1162, DOI 10.1021/jf025997z; Schussler A, 2001, MYCOL RES, V105, P1413, DOI 10.1017/S0953756201005196; SIAME BA, 1993, J AGR FOOD CHEM, V41, P1486, DOI 10.1021/jf00033a025; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; Sugimoto Y, 1998, J ORG CHEM, V63, P1259, DOI 10.1021/jo9718408; Tamasloukht M, 2003, PLANT PHYSIOL, V131, P1468, DOI 10.1104/pp.012898; Westwood JH, 2000, WEED SCI, V48, P742, DOI 10.1614/0043-1745(2000)048[0742:COTOAS]2.0.CO;2; Yasuda N, 2003, PHYTOCHEMISTRY, V62, P1115, DOI 10.1016/S0031-9422(02)00679-9; Yokota T, 1998, PHYTOCHEMISTRY, V49, P1967, DOI 10.1016/S0031-9422(98)00419-1; Yoneyama K, 2001, PHYSIOL PLANTARUM, V112, P25, DOI 10.1034/j.1399-3054.2001.1120104.x	30	1429	1550	44	865	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					824	827		10.1038/nature03608	http://dx.doi.org/10.1038/nature03608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944706				2022-12-28	WOS:000229638700052
J	Stockinger, P; Kvitsiani, D; Rotkopf, S; Tirian, L; Dickson, BJ				Stockinger, P; Kvitsiani, D; Rotkopf, S; Tirian, L; Dickson, BJ			Neural circuitry that governs Drosophila male courtship behavior	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SEXUAL-DIMORPHISM; TARGETED EXPRESSION; FRUITLESS GENE; TASTE NEURONS; PHEROMONE; PATTERNS; MAP; TRANSMISSION; ORIENTATION	Male-specific fruitless (fru) products (Fru(M)) are both necessary and sufficient to "hardwire" the potential for male courtship behavior into the Drosophila nervous system. Fru(M) is expressed in similar to 2% of neurons in the male nervous system, but not in the female. We have targeted the insertion of GAL4 into the fru locus, allowing us to visualize and manipulate the Fru(M-)expressing neurons in the male as well as their counterparts in the female. We present evidence that these neurons are directly and specifically involved in male courtship behavior and that at least some of them are interconnected in a circuit. This circuit includes olfactory neurons required for the behavioral response to sex pheromones. Anatomical differences in this circuit that might account for the dramatic differences in male and female sexual behavior are not apparent.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Dickson, BJ (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3-5, A-1030 Vienna, Austria.	barry.dickson@imba.oeaw.ac.at	Stockinger, Petra/AAC-7359-2020; Dickson, Barry/AAE-7632-2019	Stockinger, Petra/0000-0002-9533-0437; Dickson, Barry/0000-0003-0715-892X; Kvitsiani, Duda/0000-0003-3175-1774				Anholt RRH, 1996, GENETICS, V143, P293; AVERHOFF WW, 1974, BEHAV GENET, V4, P207, DOI 10.1007/BF01074155; Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Billeter JC, 2004, J COMP NEUROL, V475, P270, DOI 10.1002/cne.20177; Boll W, 2002, DEVELOPMENT, V129, P5667, DOI 10.1242/dev.00157; COYNE JA, 1994, SCIENCE, V265, P1461, DOI 10.1126/science.8073292; Cropper EC, 2004, NEUROSIGNALS, V13, P70, DOI 10.1159/000076159; Dahanukar A, 2001, NAT NEUROSCI, V4, P1182, DOI 10.1038/nn765; Demir E, 2005, CELL, V121, P785, DOI 10.1016/j.cell.2005.04.027; Edwards DH, 1999, TRENDS NEUROSCI, V22, P153, DOI 10.1016/S0166-2236(98)01340-X; HALDER N, 1964, GENETICS, V50, P1269; HALL JC, 1979, GENETICS, V92, P437; HANSSON BS, 1992, SCIENCE, V256, P1313, DOI 10.1126/science.1598574; Heimbeck G, 2001, P NATL ACAD SCI USA, V98, P15336, DOI 10.1073/pnas.011314898; HOFBAUER A, 1991, THESIS U WURZBURG WU; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; Jefferis GSXE, 2001, NATURE, V414, P204, DOI 10.1038/35102574; Kaissling KE, 1996, CHEM SENSES, V21, P257, DOI 10.1093/chemse/21.2.257; Kido A, 2002, J NEUROBIOL, V52, P302, DOI 10.1002/neu.10100; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; Kondoh Y, 2003, P ROY SOC B-BIOL SCI, V270, P1005, DOI 10.1098/rspb.2003.2331; KULKARNI SJ, 1987, GENETICS, V115, P461; Lee G, 2001, J NEUROSCI, V21, P513, DOI 10.1523/JNEUROSCI.21-02-00513.2001; Lee G, 2000, J NEUROBIOL, V43, P404, DOI 10.1002/1097-4695(20000615)43:4<404::AID-NEU8>3.0.CO;2-D; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Luo MM, 2004, CURR OPIN NEUROBIOL, V14, P428, DOI 10.1016/j.conb.2004.07.001; Manoli DS, 2004, NATURE, V430, P564, DOI 10.1038/nature02713; MARKOW TA, 1987, P NATL ACAD SCI USA, V84, P6200, DOI 10.1073/pnas.84.17.6200; McBride SMJ, 1999, NEURON, V24, P967, DOI 10.1016/S0896-6273(00)81043-0; Morris JA, 2004, NAT NEUROSCI, V7, P1034, DOI 10.1038/nn1325; Newsome TP, 2000, DEVELOPMENT, V127, P851; Ng M, 2002, NEURON, V36, P463, DOI 10.1016/S0896-6273(02)00975-3; Nilsen SP, 2004, P NATL ACAD SCI USA, V101, P12342, DOI 10.1073/pnas.0404693101; NOTTEBOHM F, 1976, SCIENCE, V194, P211, DOI 10.1126/science.959852; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Schlote, 1984, DROS INFORM SERV, V60, P210; SCHNEIDERMAN AM, 1982, NATURE, V298, P844, DOI 10.1038/298844a0; Shah NM, 2004, NEURON, V43, P313, DOI 10.1016/j.neuron.2004.07.008; SHOREY HH, 1970, ANIM BEHAV, V18, P159, DOI 10.1016/0003-3472(70)90085-0; Song HJ, 2002, GENETICS, V162, P1703; Sorensen PW, 1998, CURR OPIN NEUROBIOL, V8, P458, DOI 10.1016/S0959-4388(98)80032-9; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; TOMPKINS L, 1984, BEHAV GENET, V14, P411, DOI 10.1007/BF01065443; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Wong AM, 2002, CELL, V109, P229, DOI 10.1016/S0092-8674(02)00707-9	49	411	422	1	79	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					795	807		10.1016/j.cell.2005.04.026	http://dx.doi.org/10.1016/j.cell.2005.04.026			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935765	Bronze			2022-12-28	WOS:000229658000017
J	Bartlett, S				Bartlett, S			Life, the universe, and everything	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Bartlett, S (corresponding author), Lancet, London NW1 7BY, England.							Adams Douglas, 1979, HITCHHIKERS GUIDE GA; *CHANDR XRAY OBS, 2005, PLAN PROT XRAY SUP F; *HUBBL, 1994, HUBBL CONF AB PROT D; WILGOREN J, 2005, NY TIMES        0506	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1836	1836		10.1016/S0140-6736(05)66600-7	http://dx.doi.org/10.1016/S0140-6736(05)66600-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924970				2022-12-28	WOS:000229481400009
J	Irvine, D				Irvine, D			GMC and the future of revalidation - Patients, professionalism, and revalidation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE					donald@donaldirvine.demon.co.uk						ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; [Anonymous], 1995, LEARN BRIST REP PUBL REPORT INSIDER DEALI; Bauman AE, 2003, MED J AUSTRALIA, V179, P253, DOI 10.5694/j.1326-5377.2003.tb05532.x; Bridgewater B, 2005, BMJ-BRIT MED J, V330, P506, DOI 10.1136/bmj.330.7490.506; Calnan MW, 2004, QUAL SAF HEALTH CARE, V13, P92, DOI 10.1136/qshc.2003.009001; Coulter A, 2003, EUROPEAN PATIENT FUT; Coulter A, 2002, AUTONOMOUS PATIENT; Department of Health, 1999, SUPP DOCT PROT PAT; *GEN MED COUNC, 2004, GOOD MED PRACT; General Medical Council, 2000, REV DOCT ENS STAND S; GRAY DP, 1995, FELLOWSHIP ASSESSMEN; *HEALTHC COMM, 2004, PAT SURV REP 2004 OV; Irvine D., 2003, DOCTORS TALE PROFESS; IRVINE DH, 2004, ANN ACAD MED SINGAP, V33, P2; Keogh B, 2003, 5 NATL ADULT CARDIAC; McKinley RK, 2001, BRIT MED J, V322, P712, DOI 10.1136/bmj.322.7288.712; *POL COMM PUBL SER, 2004, MAK PUBL SERV PERS N; Schattner A, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-26; *SHIPM INQ, SAF PAT LESS PAST PR; 2005, GUARDIAN        0316	20	32	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2005	330	7502					1265	1268		10.1136/bmj.330.7502.1265	http://dx.doi.org/10.1136/bmj.330.7502.1265			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15920132	Green Published			2022-12-28	WOS:000229448900030
J	Daley, DO; Rapp, M; Granseth, E; Melen, K; Drew, D; von Heijne, G				Daley, DO; Rapp, M; Granseth, E; Melen, K; Drew, D; von Heijne, G			Global topology analysis of the Escherichia coli inner membrane proteome	SCIENCE			English	Article							MULTIDRUG TRANSPORTER EMRE; GREEN FLUORESCENT PROTEIN; X-RAY-STRUCTURE; CONDUCTING CHANNEL; SELECTIVITY; PREDICTION; EVOLUTION; ANGSTROM; EFFLUX	The protein complement of cellular membranes is notoriously resistant to standard proteomic analysis and structural studies. As a result, membrane proteomes remain ill-defined. Here, we report a global topology analysis of the Escherichia coli inner membrane proteome. Using C-terminal tagging with the alkaline phosphatase and green fluorescent protein, we established the periplasmic or cytoplasmic locations of the C termini for 601 inner membrane proteins. By constraining a topology prediction algorithm with this data, we derived high-quality topology models for the 601 proteins, providing a firm foundation for future functional studies of this and other membrane proteomes. We also estimated the overexpression potential for 397 green fluorescent protein fusions; the results suggest that a large fraction of all inner membrane proteins can be produced in sufficient quantities for biochemical and structural work.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; AlbaNova, Stockholm Bioinformat Ctr, SE-10691 Stockholm, Sweden	Stockholm University	von Heijne, G (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	gunnar@dbb.su.se	von Heijne, Gunnar/F-5576-2011; Drew, David/AAY-3455-2020; Rapp, Mikaela/K-2298-2015; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Daley, Daniel/0000-0002-6425-5059; Drew, David/0000-0001-8866-6349				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; DREW D, IN PRESS PROTEIN SCI; Drew DE, 2001, FEBS LETT, V507, P220, DOI 10.1016/S0014-5793(01)02980-5; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Eshaghi S, 2005, PROTEIN SCI, V14, P676, DOI 10.1110/ps.041127005; Feilmeier BJ, 2000, J BACTERIOL, V182, P4068, DOI 10.1128/JB.182.14.4068-4076.2000; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Nishino K, 2001, J BACTERIOL, V183, P5803, DOI 10.1128/JB.183.20.5803-5812.2001; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Rapp M, 2004, PROTEIN SCI, V13, P937, DOI 10.1110/ps.03553804; Saaf A, 1999, P NATL ACAD SCI USA, V96, P8540, DOI 10.1073/pnas.96.15.8540; Shimizu T, 2004, J MOL BIOL, V339, P1, DOI 10.1016/j.jmb.2004.03.048; Ubarretxena-Belandia I, 2004, FEBS LETT, V564, P234, DOI 10.1016/S0014-5793(04)00228-5; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; White SH, 2004, PROTEIN SCI, V13, P1948, DOI 10.1110/ps.04712004; WU JH, 1992, J BIOL CHEM, V267, P12570	25	385	1023	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1321	1323		10.1126/science.1109730	http://dx.doi.org/10.1126/science.1109730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919996				2022-12-28	WOS:000229482300051
J	Vinuesa, CG; Cook, MC; Angelucci, C; Athanasopoulos, V; Rui, LX; Hill, KM; Yu, D; Domaschenz, H; Whittle, B; Lambe, T; Roberts, IS; Copley, RR; Bell, JI; Cornall, RJ; Goodnow, CC				Vinuesa, CG; Cook, MC; Angelucci, C; Athanasopoulos, V; Rui, LX; Hill, KM; Yu, D; Domaschenz, H; Whittle, B; Lambe, T; Roberts, IS; Copley, RR; Bell, JI; Cornall, RJ; Goodnow, CC			A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity	NATURE			English	Article							B-CELL; INDUCIBLE COSTIMULATOR; IN-VIVO; IMMUNE-RESPONSES; GERMINAL-CENTERS; DENDRITIC CELLS; CO-STIMULATION; CBL-B; ICOS; ACTIVATION	Despite the sequencing of the human and mouse genomes, few genetic mechanisms for protecting against autoimmune disease are currently known. Here we systematically screen the mouse genome for autoimmune regulators to isolate a mouse strain, sanroque, with severe autoimmune disease resulting from a single recessive defect in a previously unknown mechanism for repressing antibody responses to self. The sanroque mutation acts within mature T cells to cause formation of excessive numbers of follicular helper T cells and germinal centres. The mutation disrupts a repressor of ICOS, an essential co-stimulatory receptor for follicular T cells, and results in excessive production of the cytokine interleukin-21. sanroque mice fail to repress diabetes-causing T cells, and develop high titres of autoantibodies and a pattern of pathology consistent with lupus. The causative mutation is in a gene of previously unknown function, roquin (Rc3h1), which encodes a highly conserved member of the RING-type ubiquitin ligase protein family. The Roquin protein is distinguished by the presence of a CCCH zinc-finger found in RNA-binding proteins, and localization to cytosolic RNA granules implicated in regulating messenger RNA translation and stability.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia; Australian Natl Univ, Sch Med, Canberra, ACT 2601, Australia; Australian Phenom Facil, Canberra, ACT 2601, Australia; Univ Oxford, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Cellular Pathol, Oxford OX3 9DU, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	Australian National University; John Curtin School of Medical Research; Australian National University; University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Vinuesa, CG (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia.	carola.vinuesa@anu.edu.au; chris.goodnow@anu.edu.au	li, rui/GSD-4367-2022; rui, li/GYR-3791-2022; Yu, Di/C-2163-2009; Cook, matthew/F-4151-2019; Goodnow, Christopher C/V-8108-2018; Lambe, Teresa/E-5733-2016; Vinuesa, Carola G/B-1108-2010	Yu, Di/0000-0003-1721-8922; Cook, matthew/0000-0002-3331-9363; Goodnow, Christopher C/0000-0001-5296-6155; Lambe, Teresa/0000-0001-7711-897X; Vinuesa, Carola G/0000-0001-9799-0298; Athanasopoulos, Vicki/0000-0002-5764-5948; Angelucci, Constanza/0000-0002-7169-202X				Akkaraju S, 1997, IMMUNITY, V7, P255, DOI 10.1016/S1074-7613(00)80528-2; Anderson P, 2002, J CELL SCI, V115, P3227; Barabino SML, 2000, EMBO J, V19, P3778, DOI 10.1093/emboj/19.14.3778; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brocker T, 1999, EUR J IMMUNOL, V29, P1610, DOI 10.1002/(SICI)1521-4141(199905)29:05<1610::AID-IMMU1610>3.0.CO;2-8; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Fillatreau S, 2003, J EXP MED, V197, P195, DOI 10.1084/jem.20021750; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Greve B, 2004, J IMMUNOL, V173, P157, DOI 10.4049/jimmunol.173.1.157; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Hutloff A, 2004, ARTHRITIS RHEUM-US, V50, P3211, DOI 10.1002/art.20519; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Iwai H, 2003, J IMMUNOL, V171, P2848, DOI 10.4049/jimmunol.171.6.2848; Jeon MS, 2004, IMMUNITY, V21, P167, DOI 10.1016/j.immuni.2004.07.013; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim CH, 2004, BLOOD, V104, P1952, DOI 10.1182/blood-2004-03-1206; King C, 2004, CELL, V117, P265, DOI 10.1016/S0092-8674(04)00335-6; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lesage S, 2002, J EXP MED, V196, P1175, DOI 10.1084/jem.20020735; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Mak TW, 2003, NAT IMMUNOL, V4, P765, DOI 10.1038/ni947; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Mills DM, 2003, SEMIN IMMUNOL, V15, P325, DOI 10.1016/j.smim.2003.09.004; Morking PA, 2004, BIOCHEM BIOPH RES CO, V319, P169, DOI [10.1016/S0006-291X(04)00873-3, 10.1016/j.bbrc.2004.04.162]; Moser B, 2002, TRENDS IMMUNOL, V23, P250, DOI 10.1016/S1471-4906(02)02218-4; Okamoto S, 2004, EUR J IMMUNOL, V34, P3176, DOI 10.1002/eji.200324755; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; SCHERER MT, 1995, J EXP MED, V182, P1493, DOI 10.1084/jem.182.5.1493; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Toellner KM, 1998, J EXP MED, V187, P1193, DOI 10.1084/jem.187.8.1193; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1; Walker LSK, 2000, IMMUNOL TODAY, V21, P333, DOI 10.1016/S0167-5699(00)01636-4; Wickens M, 2003, SCIENCE, V300, P753, DOI 10.1126/science.1084512; Wong SC, 2003, BLOOD, V102, P1381, DOI 10.1182/blood-2002-08-2416; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	667	702	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					452	458		10.1038/nature03555	http://dx.doi.org/10.1038/nature03555			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917799				2022-12-28	WOS:000229337800045
J	Wildermuth, S; Hofferberth, S; Lesanovsky, I; Haller, E; Andersson, LM; Groth, S; Bar-Joseph, I; Kruger, P; Schmiedmayer, J				Wildermuth, S; Hofferberth, S; Lesanovsky, I; Haller, E; Andersson, LM; Groth, S; Bar-Joseph, I; Kruger, P; Schmiedmayer, J			Bose-Einstein condensates - Microscopic magnetic-field imaging	NATURE			English	Editorial Material									Heidelberg Univ, Inst Phys, D-69120 Heidelberg, Germany; Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel	Ruprecht Karls University Heidelberg; Weizmann Institute of Science	Wildermuth, S (corresponding author), Heidelberg Univ, Inst Phys, Philosophenweg 12, D-69120 Heidelberg, Germany.	schmiedmayer@atomchip.org	Schmiedmayer, Jörg/B-4717-2008; Lesanovsky, Igor/J-6012-2015; Hofferberth, Sebastian/G-7076-2019; Schmiedmayer, Jörg/M-9669-2019; Haller, Elmar/E-8916-2010; Krüger, Peter/B-3407-2009; Kruger, Peter/H-2832-2017	Schmiedmayer, Jörg/0000-0001-7799-5614; Lesanovsky, Igor/0000-0001-9660-9467; Hofferberth, Sebastian/0000-0003-0309-9715; Schmiedmayer, Jörg/0000-0001-7799-5614; Haller, Elmar/0000-0002-7951-1721; Kruger, Peter/0000-0001-9908-6454				Bending SJ, 1999, ADV PHYS, V48, P449, DOI 10.1080/000187399243437; Dunjko V, 2001, PHYS REV LETT, V86, P5413, DOI 10.1103/PhysRevLett.86.5413; Esteve J, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.043629; Faley MI, 2004, SUPERCOND SCI TECH, V17, pS324, DOI 10.1088/0953-2048/17/5/046; Folman R, 2002, ADV ATOM MOL OPT PHY, V48, P263; Fortagh J, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.041604; Freeman MR, 2001, SCIENCE, V294, P1484, DOI 10.1126/science.1065300; Jones MPA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.080401; Kominis IK, 2003, NATURE, V422, P596, DOI 10.1038/nature01484; Leanhardt AE, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.040401; Oral A, 2002, IEEE T MAGN, V38, P2438, DOI 10.1109/TMAG.2002.803607; Rous PJ, 2004, J APPL PHYS, V95, P2477, DOI 10.1063/1.1641149	12	118	118	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					440	440		10.1038/435440a	http://dx.doi.org/10.1038/435440a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917796	Bronze			2022-12-28	WOS:000229337800040
J	Vist, GE; Hagen, KB; Devereaux, PJ; Bryant, D; Kristofersen, DT; Oxman, AD				Vist, GE; Hagen, KB; Devereaux, PJ; Bryant, D; Kristofersen, DT; Oxman, AD			Systematic review to determine whether participation in a trial influences outcome	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CLINICAL-TRIALS; CELL LUNG-CANCER; PRIMARY-CARE; NONRANDOM ASSIGNMENT; MULTICENTER TRIAL; INFORMED CONSENT; NITROUS-OXIDE; CHILDREN; THERAPY; REVASCULARIZATION	Objective To systematically compare the outcomes of participants in randomised controlled trials (RCTs) with those in comparable non-participants who received the same or similar treatment. Data sources Bibliographic databases, reference lists from eligible articles, medical journals, and study authors. Review methods RCTs and cohort studies that evaluated the clinical outcomes of participants and comparable non-participants who received the salve or similar treatment. Results Five RCTs (six comparisons) and 50 cohort studies (85 comparisons) provided data on 31 140 patients treated in RCTs and 20 380 comparable patients treated outside RCTs. In the five RCTs, in which patients were given the option of participating or not, the comparisons provided limited information because of small sample sizes (a total of 412 patients) and the nature of the questions considered. 73 dichotomous outcomes were compared, of which 59 reported no statistically significant differences. For patients treated within RCTs, 10 comparisons reported significantly better outcomes and four reported significantly worse outcomes. Significantly heterogeneity was found (I-2 = 89%) among the comparisons of 73 dichotomous outcomes; none of our a priori explanatory factors helped explain this heterogeneity. The 18 comparisons of continuous outcomes showed no significant differences in heterogeneity (I-2 = 0%). The overall pooled estimate for continuous outcomes of the effect of participating in an RCT was not significant (standardised mean difference 0.01, 95% confidence interval -0.10 to 0.12). Conclusion Participating in RCTs neither harms nor benefits participants, compared with receiving the same or similar treatment outside such trials.	Norwegian Hlth Serv Res Ctr, N-0130 Oslo, Norway; Diakonhjemmet Hosp, Natl Res Ctr Rehabil Rheumatol, Oslo, Norway; McMaster Univ, Hlth Sci Ctr, Hamilton, ON, Canada	Diakonhjemmet Hospital; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Vist, GE (corresponding author), Norwegian Hlth Serv Res Ctr, POB 7004, N-0130 Oslo, Norway.	gee@nhsrc.no	Devereaux, PJ/AAY-1757-2021; Devereaux, PJ/AAF-2862-2019; Bryant, Dianne M/K-6766-2013; Oxman, Andrew/Y-3004-2019	Bryant, Dianne M/0000-0002-7535-8707; Oxman, Andrew/0000-0002-5608-5061; Devereaux, PJ/0000-0003-2935-637X				[Anonymous], 1984, J AM COLL CARDIOL, V3, P114; BALMUKHANOV SB, 1989, INT J RADIAT ONCOL, V16, P1061, DOI 10.1016/0360-3016(89)90916-4; BAUM E, 1979, MED PEDIATR ONCOL, V7, P25, DOI 10.1002/mpo.2950070106; Bedi N, 2000, BRIT J PSYCHIAT, V177, P312, DOI 10.1192/bjp.177.4.312; Berglund G, 1997, PSYCHO-ONCOL, V6, P35, DOI 10.1002/(SICI)1099-1611(199703)6:1<35::AID-PON241>3.3.CO;2-A; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; Bhattacharya S, 1998, EUR J OBSTET GYN R B, V76, P81, DOI 10.1016/S0301-2115(97)00140-1; BIJKER N, 2000, THESIS; BLICHERTTOFT M, 1988, ACTA ONCOL, V27, P671, DOI 10.3109/02841868809091767; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; CHAUHAN SP, 1992, J REPROD MED, V37, P817; Chilvers C, 2001, BMJ-BRIT MED J, V322, P772, DOI 10.1136/bmj.322.7289.772; CLAGETT GP, 1984, SURGERY, V96, P823; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1367, DOI 10.1111/j.1471-0528.1997.tb11005.x; CREUTZIG U, 1993, J CLIN ONCOL, V11, P279, DOI 10.1200/JCO.1993.11.2.279; DAHAN R, 1986, BRIT MED J, V293, P363, DOI 10.1136/bmj.293.6543.363; DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO;2-T; EDSMYR F, 1978, J UROLOGY, V120, P705, DOI 10.1016/S0022-5347(17)57336-X; *EM CAR RES I, 2002, PAT REAS PART CLIN T; Feit F, 2000, CIRCULATION, V101, P2795, DOI 10.1161/01.CIR.101.24.2795; Forbes GM, 2000, GASTROINTEST ENDOSC, V51, P271, DOI 10.1016/S0016-5107(00)70354-3; Forssell C, 1989, Eur J Vasc Surg, V3, P503, DOI 10.1016/S0950-821X(89)80124-0; Helsing M, 1998, EUR J CANCER, V34, P1036, DOI 10.1016/S0959-8049(97)10122-8; HENSHAW RC, 1993, BRIT MED J, V307, P714, DOI 10.1136/bmj.307.6906.714; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kieler H, 1998, ULTRASOUND OBST GYN, V11, P104, DOI 10.1046/j.1469-0705.1998.11020104.x; King SB, 1997, AM J CARDIOL, V79, P1453, DOI 10.1016/S0002-9149(97)00170-7; KUNZ R, 2002, COCHRANE METHODOLOGY; Kunz R, 2002, RANDOMISATION PROTEC; LIDBRINK E, 1995, BREAST CANCER RES TR, V35, P267, DOI 10.1007/BF00665978; LINK MP, 1991, CLIN ORTHOP RELAT R, V270, P8; Liu WF, 1998, AM J PERINAT, V15, P675, DOI 10.1055/s-2007-999301; Mahon J, 1996, BRIT MED J, V312, P1069; Mahon JL, 1999, CHEST, V115, P38, DOI 10.1378/chest.115.1.38; MARTINEZAMENOS A, 1990, J HUM HYPERTENS, V4, P362; McCaughey ES, 1998, LANCET, V351, P940; McKay JR, 1998, J CONSULT CLIN PSYCH, V66, P697, DOI 10.1037/0022-006X.66.4.697; MCKAY JR, 1995, J CONSULT CLIN PSYCH, V63, P70, DOI 10.1037/0022-006X.63.1.70; MOERTEL CG, 1984, J CLIN ONCOL, V2, P1249, DOI 10.1200/JCO.1984.2.11.1249; Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378-5122(00)00158-4; Nagel HTC, 1998, PRENATAL DIAG, V18, P465, DOI 10.1002/(SICI)1097-0223(199805)18:5<465::AID-PD325>3.3.CO;2-R; NICOLAIDES K, 1994, LANCET, V344, P435, DOI 10.1016/S0140-6736(94)91769-8; PARADISE JL, 1984, NEW ENGL J MED, V310, P674, DOI 10.1056/NEJM198403153101102; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; Peppercorn JM, 2004, LANCET, V363, P263, DOI 10.1016/S0140-6736(03)15383-4; PLAYFORTH MJ, 1988, DIS COLON RECTUM, V31, P90, DOI 10.1007/BF02562635; Rigg JRA, 2000, CONTROL CLIN TRIALS, V21, P244, DOI 10.1016/S0197-2456(00)00045-3; ROSEN MA, 1987, ANESTHESIOLOGY, V67, P42, DOI 10.1097/00000542-198707000-00007; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Rovers MM, 2001, J CLIN EPIDEMIOL, V54, P789, DOI 10.1016/S0895-4356(01)00340-7; Schmoor C, 1996, STAT MED, V15, P263, DOI 10.1002/(SICI)1097-0258(19960215)15:3<263::AID-SIM165>3.0.CO;2-K; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; STRANDBERG TE, 1995, BRIT HEART J, V74, P449; SULLIVAN MP, 1982, CANCER TREAT REP, V66, P937; Urban P, 1999, EUR HEART J, V20, P1030, DOI 10.1053/euhj.1998.1353; Villamaria FJ, 1997, J CARDIOTHOR VASC AN, V11, P708, DOI 10.1016/S1053-0770(97)90162-2; VIST GE, 2005, COCHRANE METHODOLOGY; WETZNER SM, 1979, RADIOLOGY, V131, P23, DOI 10.1148/131.1.23; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; WIKDAHL AM, 1992, ADV PERIT D, V8, P276; WILLIFORD WO, 1993, J CLIN EPIDEMIOL, V46, P1025, DOI 10.1016/0895-4356(93)90170-6; YAMAMOTO H, 1992, MAYO CLIN PROC, V67, P228, DOI 10.1016/S0025-6196(12)60097-4; Yersin B., 1996, EUR ADDICT RES, V2, P94; Young JDH, 1996, EYE, V10, P485, DOI 10.1038/eye.1996.107	64	79	79	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2005	330	7501					1175	1179		10.1136/bmj.330.7501.1175	http://dx.doi.org/10.1136/bmj.330.7501.1175			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905256	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000229320500015
J	Dierks, T; Dickmanns, A; Preusser-Kunze, A; Schmidt, B; Mariappan, M; von Figura, K; Ficner, R; Rudolph, MG				Dierks, T; Dickmanns, A; Preusser-Kunze, A; Schmidt, B; Mariappan, M; von Figura, K; Ficner, R; Rudolph, MG			Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme	CELL			English	Article							CYSTEINE-SULFENIC ACID; CRYSTAL-STRUCTURE; POSTTRANSLATIONAL FORMATION; BACTERIAL SULFATASES; PROTEIN MODIFICATION; ARYLSULFATASE; GENE; PEROXIDASE; CONVERSION; FAMILY	Sulfatases are enzymes essential for degradation and remodeling of sulfate esters. Formylglycine (FGly), the key catalytic residue in the active site, is unique to sulfatases. In higher eukaryotes, FGly is generated from a cysteine precursor by the FGly-generating enzyme (FGE). Inactivity of FGE results in multiple sulfatase deficiency (MSD), a fatal autosomal recessive syndrome. Based on the crystal structure, we report that FGE is a single-domain monomer with a surprising paucity of secondary structure and adopts a unique fold. The effect of all 18 missense mutations found in MSD patients is explained by the FGE structure, providing a molecular basis of MSD. The catalytic mechanism of FGly generation was elucidated by six high-resolution structures of FGE in different redox environments. The structures allow formulation of a novel oxygenase mechanism whereby FGE utilizes molecular oxygen to generate FGly via a cysteine sulfenic acid intermediate.	Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Univ Gottingen, Dept Mol Struct Biol, D-37073 Gottingen, Germany	University of Gottingen; University of Gottingen	von Figura, K (corresponding author), Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany.	kfigura@gwdg.de; markus.rudolph@bio.uni-goettingen.de	mariappan, malaiyalam/K-9024-2012; Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339; Rudolph, Markus/0000-0003-0447-1101				AHMED SA, 1989, J BIOL CHEM, V264, P19864; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Cosma MP, 2004, HUM MUTAT, V23, P576, DOI 10.1002/humu.20040; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dickmanns A, 2005, J BIOL CHEM, V280, P15180, DOI 10.1074/jbc.M414317200; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fang QH, 2004, J BIOL CHEM, V279, P14570, DOI 10.1074/jbc.M313855200; Ferrante P, 2002, EUR J HUM GENET, V10, P813, DOI 10.1038/sj.ejhg.5200887; Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Grossman SD, 2002, NEUROMOL MED, V2, P61, DOI 10.1385/NMM:2:1:61; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; Hernandez-Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; Luan P, 2000, TRAFFIC, V1, P270, DOI 10.1034/j.1600-0854.2000.010309.x; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Mariappan M, 2005, J BIOL CHEM, V280, P15173, DOI 10.1074/jbc.M413698200; Marquordt C, 2003, J BIOL CHEM, V278, P2212, DOI 10.1074/jbc.M209435200; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200; Xin XN, 2004, J BIOL CHEM, V279, P48159, DOI 10.1074/jbc.M407486200; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	54	146	162	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					541	552		10.1016/j.cell.2005.03.001	http://dx.doi.org/10.1016/j.cell.2005.03.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907468	Green Published, Bronze			2022-12-28	WOS:000229331200011
J	Lay, T; Kanamori, H; Ammon, CJ; Nettles, M; Ward, SN; Aster, RC; Beck, SL; Bilek, SL; Brudzinski, MR; Butler, R; DeShon, HR; Ekstrom, G; Satake, K; Sipkin, S				Lay, T; Kanamori, H; Ammon, CJ; Nettles, M; Ward, SN; Aster, RC; Beck, SL; Bilek, SL; Brudzinski, MR; Butler, R; DeShon, HR; Ekstrom, G; Satake, K; Sipkin, S			The great Sumatra-Andaman earthquake of 26 December 2004	SCIENCE			English	Article							RUPTURE PROCESS; RADIATION; MECHANISM	The two largest earthquakes of the past 40 years ruptured a 1600-kitometer-long portion of the fault boundary between the Indo-Australian and southeastern Eurasian plates on 26 December 2004 [seismic moment magnitude (M-W) = 9.1 to 9.3] and 28 March 2005 (M-W = 8.6). The first event generated a tsunami that caused more than 283,000 deaths. Fault slip of up to 15 meters occurred near Banda Aceh, Sumatra, but to the north, along the Nicobar and Andaman Islands, rapid slip was much smaller. Tsunami and geodetic observations indicate that additional slow slip occurred in the north over a time scale of 50 minutes or longer.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Inst Geophys & Planetary Phys, Santa Cruz, CA 95064 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; New Mexico Inst Min & Technol, Dept Earth & Environm Sci, Socorro, NM 87801 USA; New Mexico Inst Min & Technol, Geophys Res Ctr, Socorro, NM 87801 USA; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Miami Univ, Dept Geol, Oxford, OH 45056 USA; IRIS Consortium, Washington, DC 20005 USA; Geol Survey Japan, Tsukuba, Ibaraki 3058567, Japan; US Geol Survey, Natl Earthquake Informat Ctr, Golden, CO 80401 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Harvard University; New Mexico Institute of Mining Technology; New Mexico Institute of Mining Technology; University of Arizona; University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; Miami University; United States Department of the Interior; United States Geological Survey	Lay, T (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.	thorne@pmc.ucsc.edu	Ekstrom, Goran/C-9771-2012; Satake, Kenji/GMX-4217-2022; Brudzinski, Michael/A-8301-2011; Lay, Thorne/ABE-6272-2021	Ekstrom, Goran/0000-0001-6410-275X; Satake, Kenji/0000-0002-3368-3085; Bilek, Susan/0000-0001-6291-237X; Nettles, Meredith/0000-0003-4613-4162				ABE K, 1979, J GEOPHYS RES, V84, P1561, DOI 10.1029/JB084iB04p01561; ABE K, 2005, COMMUNICATION; Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; BANERJEE P, 2005, SCIENCE         0519, DOI DOI 10.1126/SCIENCE.1113746; BILHAM R, 2005, IN PRESS SEISM SEISM; Bock Y, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000324; Butler R., 2004, EOS T AM GEOPHYS UN, V85, P225; Ekstrom G, 2005, PHYS EARTH PLANET IN, V148, P327, DOI 10.1016/j.pepi.2004.09.006; Giovanni MK, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015774; Gower J, 2005, EOS T AGU, V86, P37, DOI DOI 10.1029/2005E0040002; HOUSTON H, 1986, B SEISMOL SOC AM, V76, P19; ISHII M, 2005, IN PRESS NATURE; Kanamori H, 2004, P JPN ACAD B-PHYS, V80, P297, DOI 10.2183/pjab.80.297; KANAMORI H, 1977, J GEOPHYS RES, V82, P2981, DOI 10.1029/JB082i020p02981; KANAMORI H, 1993, NATURE, V361, P714, DOI 10.1038/361714a0; KANAMORI H, 1970, J GEOPHYS RES, V75, P5029, DOI 10.1029/JB075i026p05029; Kanamori H., 1974, Physics of the Earth and Planetary Interiors, V9, P128, DOI 10.1016/0031-9201(74)90029-6; MCCAFFREY R, 1992, J GEOPHYS RES-SOL EA, V97, P8905, DOI 10.1029/92JB00483; MCCANN WR, 1979, PURE APPL GEOPHYS, V117, P1082, DOI 10.1007/BF00876211; Natawidjaja DH, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002398; NEWCOMB KR, 1987, J GEOPHYS RES-SOLID, V92, P421, DOI 10.1029/JB092iB01p00421; Ni S, 2005, NATURE, V434, P582, DOI 10.1038/434582a; Park J, 2005, SCIENCE, V308, P1139, DOI 10.1126/science.1112305; PARK J, 2005, EOS T AM GEOPHYS UN, V86, P57, DOI DOI 10.1029/2005EO060001; PARK J, 2005, IN PRESS SEISMOL RES; Paul J, 2001, GEOPHYS RES LETT, V28, P647, DOI 10.1029/2000GL011832; Romanowicz B, 2001, SCIENCE, V293, P2000, DOI 10.1126/science.1061771; RUFF L, 1983, TECTONOPHYSICS, V99, P99, DOI 10.1016/0040-1951(83)90097-5; SCHOLZ CH, 1995, J GEOPHYS RES-SOL EA, V100, P22103, DOI 10.1029/95JB01869; Sieh K, 2000, J GEOPHYS RES-SOL EA, V105, P28295, DOI 10.1029/2000JB900120; UYEDA S, 1979, J GEOPHYS RES, V84, P1049, DOI 10.1029/JB084iB03p01049; Venkataraman A, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002548; WU FT, 1973, J GEOPHYS RES, V78, P6082, DOI 10.1029/JB078i026p06082; Zachariasen J, 1999, J GEOPHYS RES-SOL EA, V104, P895, DOI 10.1029/1998JB900050	34	329	351	5	397	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1127	1133		10.1126/science.1112250	http://dx.doi.org/10.1126/science.1112250			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905392				2022-12-28	WOS:000229293400033
J	Lunyak, VV; Rosenfeld, MG				Lunyak, VV; Rosenfeld, MG			No rest for REST: REST/NRSF regulation of neurogenesis	CELL			English	Editorial Material							SILENCER FACTOR NRSF; NEURONAL GENES; PROTEIN; CELLS	Epigenetic strategies control the orderly acquisition and maintenance of neuronal traits. A complex network of transcriptional repressors and corepressors mediates gene specificity for these strategies. In this issue of Cell, a study by Ballas and coworkers (Ballas et al., 2005) provides insight into the early lineage commitment events during neurogenesis. This study demonstrates that regulation of the REST/NRSF transcriptional repressor plays a fundamental role in the progression of pluripotent cells to lineage-restricted neural progenitors.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Lunyak, VV (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA.		lunyak, victoria/R-3765-2017	lunyak, victoria/0000-0001-9093-2714				Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Nishimura E, 1996, NEUROSCI LETT, V211, P101, DOI 10.1016/0304-3940(96)12722-1; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shimojo M, 2003, MOL CELL BIOL, V23, P9025, DOI 10.1128/MCB.23.24.9025-9031.2003; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	10	93	95	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					499	501		10.1016/j.cell.2005.05.003	http://dx.doi.org/10.1016/j.cell.2005.05.003			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907461	Bronze			2022-12-28	WOS:000229331200004
J	Hill, RA; Barton, RA				Hill, RA; Barton, RA			Red enhances human performance in contests	NATURE			English	Editorial Material							MALE COLORATION; MATE CHOICE; DOMINANCE; ANGER		Univ Durham, Evolutionary Anthropol Res Grp, Durham DH1 3HN, England	Durham University	Hill, RA (corresponding author), Univ Durham, Evolutionary Anthropol Res Grp, Durham DH1 3HN, England.	r.a.hill@durham.ac.uk	Hill, Russell/D-9113-2013	Hill, Russell/0000-0002-7601-5802				Andersson S, 2002, AM NAT, V160, P683, DOI 10.1086/342817; Cuthill IC, 1997, P ROY SOC B-BIOL SCI, V264, P1093, DOI 10.1098/rspb.1997.0151; Darwin Charles, 1998, EXPRESS EMOT MAN, V3rd, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; Drummond PD, 1997, PERS INDIV DIFFER, V23, P575, DOI 10.1016/S0191-8869(97)00077-9; Drummond PD, 2001, PSYCHOPHYSIOLOGY, V38, P190, DOI 10.1111/1469-8986.3820190; MILINSKI M, 1990, NATURE, V344, P330, DOI 10.1038/344330a0; Pryke SR, 2002, BEHAV ECOL, V13, P622, DOI 10.1093/beheco/13.5.622; Ryan Michael J., 1997, P179; Setchell JM, 2005, ETHOLOGY, V111, P25, DOI 10.1111/j.1439-0310.2004.01054.x; Waitt C, 2003, P ROY SOC B-BIOL SCI, V270, pS144, DOI 10.1098/rsbl.2003.0065	10	270	279	5	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2005	435	7040					293	293		10.1038/435293a	http://dx.doi.org/10.1038/435293a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902246	Bronze			2022-12-28	WOS:000229185000034
J	Jokhio, AH; Winter, HR; Cheng, KK				Jokhio, AH; Winter, HR; Cheng, KK			An intervention involving traditional birth attendants and perinatal and maternal mortality in Pakistan	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SAFE MOTHERHOOD; OUTCOMES	BACKGROUND: There are approximately 4 million neonatal deaths and half a million maternal deaths worldwide each year. There is limited evidence from clinical trials to guide the development of effective maternity services in developing countries. METHODS: We performed a cluster-randomized, controlled trial involving seven subdistricts (talukas) of a rural district in Pakistan. In three talukas randomly assigned to the intervention group, traditional birth attendants were trained and issued disposable delivery kits; Lady Health Workers linked traditional birth attendants with established services and documented processes and outcomes; and obstetrical teams provided outreach clinics for antenatal care. Women in the four control talukas received usual care. The primary outcome measures were perinatal and maternal mortality. RESULTS: Of the estimated number of eligible women in the seven talukas, 10,114 (84.3 percent) were recruited in the three intervention talukas, and 9443 (78.7 percent) in the four control talukas. In the intervention group, 9184 women (90.8 percent) received antenatal care by trained traditional birth attendants, 1634 women (16.2 percent) were seen antenatally at least once by the obstetrical teams, and 8172 safe-delivery kits were used. As compared with the control talukas, the intervention talukas had a cluster-adjusted odds ratio for perinatal death of 0.70 (95 percent confidence interval, 0.59 to 0.82) and for maternal mortality of 0.74 (95 percent confidence interval, 0.45 to 1.23). CONCLUSIONS: Training traditional birth attendants and integrating them into an improved health care system were achievable and effective in reducing perinatal mortality. This model could result in large improvements in perinatal and maternal health in developing countries.	Liaquat Univ Med & Hlth Sci, Jamshoro, Sindh, Pakistan; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham, W Midlands, England	Liaquat University of Medical & Health Sciences; University of Birmingham	Jokhio, AH (corresponding author), Liaquat Univ Med & Hlth Sci, Jamshoro, Sindh, Pakistan.	jokhiohl@super.net.pk	Cheng, Kar/AAL-8899-2021	Cheng, Kar/0000-0002-1516-1857				Abou Zahr C., 2004, MATERNAL MORTALITY 2; *AG KHAN U, 1994, MAT INF MORT POL INT; Akalin MZ, 1997, STUD FAMILY PLANN, V28, P330, DOI 10.2307/2137863; CAMPBELL O, 1995, INT J GYNECOL OBSTET, V48, pS33, DOI 10.1016/0020-7292(95)02319-8; De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x; Dean AG, 1997, EPI INFO VERSION 6 0; Goodburn E, 2001, BRIT MED J, V322, P917, DOI 10.1136/bmj.322.7291.917; Graham WJ, 2002, LANCET, V359, P701, DOI 10.1016/S0140-6736(02)07817-0; Kamal IT, 1998, INT J GYNECOL OBSTET, V63, pS43, DOI 10.1016/S0020-7292(98)00183-0; Maine D, 1999, AM J PUBLIC HEALTH, V89, P480, DOI 10.2105/AJPH.89.4.480; Maine D, 1991, SAFE MOTHERHOOD PROG; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Miller S, 2003, J MIDWIFERY WOM HEAL, V48, P10, DOI 10.1016/S1526-9523(02)00369-0; Ministry of Health, 1994, PAK NAT PLAN PREV BL; Murray DM, 1998, DESIGN ANAL GROUP RA; *NAT I POP STUD, 1991, PAK DEM HLTH SURV 19; RASBASH J, 2000, USERS GUIDE MIW MULT; *SAV CHILDR, 2001, SAV NEWB LIV IN, P44; Sibley L, 2004, MIDWIFERY, V20, P51, DOI 10.1016/S0266-6138(03)00053-6; SIBLEY L, 2002, TRADITIONAL BIRTH AT; Ukoumunne OC, 1999, BRIT MED J, V319, P376, DOI 10.1136/bmj.319.7206.376; 2002, MAKING PREGNANCY S 1	22	243	247	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2091	2099		10.1056/NEJMsa042830	http://dx.doi.org/10.1056/NEJMsa042830			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901862				2022-12-28	WOS:000229180100007
J	Lindenbach, BD; Evans, MJ; Syder, AJ; Wolk, B; Tellinghuisen, TL; Liu, CC; Maruyama, T; Hynes, RO; Burton, DR; McKeating, JA; Rice, CM				Lindenbach, BD; Evans, MJ; Syder, AJ; Wolk, B; Tellinghuisen, TL; Liu, CC; Maruyama, T; Hynes, RO; Burton, DR; McKeating, JA; Rice, CM			Complete replication of hepatitis C virus in cell culture	SCIENCE			English	Article							EFFICIENT REPLICATION; PROTEASE INHIBITOR; RNA REPLICATION; CD81; MUTATIONS; REPLICON; ENTRY	Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen. Here, we describe a full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc). Replication of HCVcc was robust, producing nearly 10(5) infectious units per milliliter within 48 hours. Virus particles were filterable and neutralized with a monoclonal antibody against the viral glycoprotein E2. Viral entry was dependent on cellular expression of a putative HCV receptor, CD81. HCVcc replication was inhibited by interferon-alpha and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals.	Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Rockefeller University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Scripps Research Institute; Scripps Research Institute	Rice, CM (corresponding author), Rockefeller Univ, Ctr Study Hepatitis C, 1230 York Ave, New York, NY 10021 USA.	ricec@rockefeller.edu		McKeating, Jane/0000-0002-7229-5886; Evans, Matthew/0000-0002-4991-3877	NATIONAL CANCER INSTITUTE [R01CA085883, R01CA057973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050798, F32AI051820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK070497] Funding Source: NIH RePORTER; Medical Research Council [G0400802] Funding Source: Medline; NCI NIH HHS [CA57973, CA10702, CA85883] Funding Source: Medline; NIAID NIH HHS [AI40034, AI50798, AI51820] Funding Source: Medline; NIDDK NIH HHS [DK70497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agapov EV, 2004, J VIROL, V78, P2414, DOI 10.1128/JVI.78.5.2414-2425.2004; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P18; Bartenschlager R, 2004, ADV VIRUS RES, V63, P71, DOI 10.1016/S0065-3527(04)63002-8; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BRADLEY D, 1991, J MED VIROL, V34, P206, DOI 10.1002/jmv.1890340315; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Date T, 2004, J BIOL CHEM, V279, P22371, DOI 10.1074/jbc.M311120200; Fujita N, 2001, J MED VIROL, V63, P108, DOI 10.1002/1096-9071(20000201)63:2<108::AID-JMV1004>3.0.CO;2-6; Heller T, 2005, P NATL ACAD SCI USA, V102, P2579, DOI 10.1073/pnas.0409666102; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kummerer BM, 2002, J VIROL, V76, P4773, DOI 10.1128/JVI.76.10.4773-4784.2002; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Lin K, 2004, ANTIMICROB AGENTS CH, V48, P4784, DOI 10.1128/AAC.48.12.4784-4792.2004; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; PIETSCHMANN T, 2004, 11 INT S HCV REL VIR; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; SAKSENA AK, 2002, Patent No. 02008244; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; WAKITA T, 2004, 11 INT S HCV REL VIR; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	27	1838	2014	4	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	2005	309	5734					623	626		10.1126/science.1114016	http://dx.doi.org/10.1126/science.1114016			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SE	15947137	Green Submitted			2022-12-28	WOS:000230735200052
J	Silber, SJ; Lenahan, KM; Levine, DJ; Pineda, JA; Gorman, KS; Friez, MJ; Crawford, EC; Gosden, RG				Silber, SJ; Lenahan, KM; Levine, DJ; Pineda, JA; Gorman, KS; Friez, MJ; Crawford, EC; Gosden, RG			Ovarian transplantation between monozygotic twins discordant for premature ovarian failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRYOPRESERVED MOUSE OVARIES; CORTICAL STRIPS; LIVE BIRTHS; TISSUE; FERTILITY; FROZEN; AUTOGRAFTS; SHEEP; RESTORATION; LIVEBIRTH	Monozygotic 24-year-old twins presented with discordant ovarian function. One had premature ovarian failure at the age of 14 years, whereas her sister had normal ovaries and three naturally conceived children. After unsuccessful egg-donation therapy, the sterile twin received a transplant of ovarian cortical tissue from her sister by means of a minilaparotomy. Within three months after transplantation, the recipient's cycles resumed and serum gonadotropin levels fell to the normal range. During the second cycle, she conceived, and her pregnancy progressed uneventfully. At 38 weeks' gestation, she delivered a healthy-appearing female infant.	St Lukes Hosp, Infertil Ctr St Louis, St Louis, MO 63017 USA; Patern Testing, Columbia, MD USA; Greenwood Genet Ctr, Greenwood, SC 29646 USA; Sentara Hosp Cytogenet Lab, Norfolk, VA USA; Cornell Univ, Weill Med Coll, New York, NY USA	Saint Luke's Hospital - Missouri; Greenwood Genetic Center; Sentara Healthcare; Cornell University	Silber, SJ (corresponding author), St Lukes Hosp, Infertil Ctr St Louis, 224 S Woods Mill Rd,Suite 730, St Louis, MO 63017 USA.	drsherm@aol.com						ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Aubard Y, 1999, HUM REPROD, V14, P2149, DOI 10.1093/humrep/14.8.2149; Baird DT, 1999, ENDOCRINOLOGY, V140, P462, DOI 10.1210/en.140.1.462; Candy CJ, 2000, HUM REPROD, V15, P1300, DOI 10.1093/humrep/15.6.1300; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Donnez J, 2004, LANCET, V364, P2020; Gook DA, 1999, HUM REPROD, V14, P2061, DOI 10.1093/humrep/14.8.2061; Gosden R, 1996, TRANSPLANTATION OVAR; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; Gunasena KT, 1997, HUM REPROD, V12, P101, DOI 10.1093/humrep/12.1.101; Kim SS, 2004, FERTIL STERIL, V82, P679, DOI 10.1016/j.fertnstert.2004.05.022; Lee DM, 2004, NATURE, V428, P137, DOI 10.1038/428137a; Maddalena Anne, 2001, Genetics in Medicine, V3, P200, DOI 10.1097/00125817-200105000-00010; Newton H, 1996, HUM REPROD, V11, P1487; Nugent D, 1997, HUM REPROD UPDATE, V3, P267, DOI 10.1093/humupd/3.3.267; Oktay K, 2000, NEW ENGL J MED, V342, P1919, DOI 10.1056/NEJM200006223422516; Oktay K, 2004, LANCET, V363, P837, DOI 10.1016/S0140-6736(04)15728-0; Oktay K, 2001, JAMA-J AM MED ASSOC, V286, P1490, DOI 10.1001/jama.286.12.1490; Oktay K, 2004, LANCET, V364, P2091, DOI 10.1016/S0140-6736(04)17541-7; PARROTT DMV, 1960, J REPROD FERTIL, V1, P230, DOI 10.1530/jrf.0.0010230; Radford JA, 2001, LANCET, V357, P1172, DOI 10.1016/S0140-6736(00)04335-X; Salle B, 2002, FERTIL STERIL, V77, P403, DOI 10.1016/S0015-0282(01)02960-0; Sherman SL, 2000, AM J HUM GENET, V67, P11, DOI 10.1086/302985; SILBER SJ, 1978, FERTIL STERIL, V30, P181; Sonmezer M, 2004, HUM REPROD UPDATE, V10, P251, DOI 10.1093/humupd/dmh021; Wang X, 2002, NATURE, V415, P385, DOI 10.1038/415385a	26	171	180	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2005	353	1					58	63		10.1056/NEJMoa043157	http://dx.doi.org/10.1056/NEJMoa043157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942FC	15941849	Bronze			2022-12-28	WOS:000230267300008
J	Lourens, LJ; Sluijs, A; Kroon, D; Zachos, JC; Thomas, E; Rohl, U; Bowles, J; Raffi, I				Lourens, LJ; Sluijs, A; Kroon, D; Zachos, JC; Thomas, E; Rohl, U; Bowles, J; Raffi, I			Astronomical pacing of late Palaeocene to early Eocene global warming events	NATURE			English	Article							THERMAL MAXIMUM; COMET IMPACT; METHANE; RECORDS; DISSOCIATION; CHRONOLOGY; VOLCANISM; END	At the boundary between the Palaeocene and Eocene epochs, about 55 million years ago, the Earth experienced a strong global warming event, the Palaeocene-Eocene thermal maximum(1-4). The leading hypothesis to explain the extreme greenhouse conditions prevalent during this period is the dissociation of 1,400 to 2,800 gigatonnes of methane from ocean clathrates(5,6), resulting in a large negative carbon isotope excursion and severe carbonate dissolution in marine sediments. Possible triggering mechanisms for this event include crossing a threshold temperature as the Earth warmed gradually(7), comet impact(8), explosive volcanism(9,10) or ocean current reorganization and erosion at continental slopes(11), whereas orbital forcing has been excluded(12). Here we report a distinct carbonate-poor red clay layer in deep-sea cores from Walvis ridge(13), which we term the Elmo horizon. Using orbital tuning, we estimate deposition of the Elmo horizon at about 2 million years after the Palaeocene-Eocene thermal maximum. The Elmo horizon has similar geochemical and biotic characteristics as the Palaeocene-Eocene thermal maximum, but of smaller magnitude. It is coincident with carbon isotope depletion events in other ocean basins, suggesting that it represents a second global thermal maximum. We show that both events correspond to maxima in the similar to 405-kyr and similar to 100-kyr eccentricity cycles that post-date prolonged minima in the 2.25-Myr eccentricity cycle, implying that they are indeed astronomically paced.	Univ Utrecht, Fac Geosci, Dept Earth Sci, NL-3584 CD Utrecht, Netherlands; Univ Utrecht, Dept Palaeoecol, Palaeobot & Palynol Lab, NL-3584 CD Utrecht, Netherlands; Vrije Univ Amsterdam, Fac Earth & Life Sci, NL-1081 HV Amsterdam, Netherlands; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Wesleyan Univ, Dept Earth & Environm Sci, Middletown, CT 06459 USA; Yale Univ, Dept Geol & Geophys, Ctr Study Global Change, New Haven, CT 06520 USA; Univ Bremen, DFG Res Ctr Ocean Margins, D-28359 Bremen, Germany; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ G DAnnunzio, Dipartimento Sci Terra, Fac Sci, I-66013 Chieti, Italy	Utrecht University; Utrecht University; Vrije Universiteit Amsterdam; University of California System; University of California Santa Cruz; Wesleyan University; Yale University; German Research Foundation (DFG); University of Bremen; University of California System; University of California San Diego; Scripps Institution of Oceanography; G d'Annunzio University of Chieti-Pescara	Lourens, LJ (corresponding author), Univ Utrecht, Fac Geosci, Dept Earth Sci, Budapestlaan 4, NL-3584 CD Utrecht, Netherlands.	llourens@geo.uu.nl	Zachos, James C/A-7674-2008; Röhl, Ursula/G-5986-2011; Sluijs, Appy/B-3726-2009; Raffi, Isabella/AAY-5505-2020; Thomas, Ellen/E-5573-2011	Zachos, James C/0000-0001-8439-1886; Röhl, Ursula/0000-0001-9469-7053; Sluijs, Appy/0000-0003-2382-0215; Raffi, Isabella/0000-0002-5192-7477; Thomas, Ellen/0000-0002-7141-9904; Bowles, Julie/0000-0002-7484-8149				Bralower TJ, 1997, GEOLOGY, V25, P963, DOI 10.1130/0091-7613(1997)025<0963:HRROTL>2.3.CO;2; Bujak JP, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P277; Cramer BS, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000909; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Katz ME, 2001, PALEOCEANOGRAPHY, V16, P549, DOI 10.1029/2000PA000615; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Kent DV, 2003, EARTH PLANET SC LETT, V211, P13, DOI 10.1016/S0012-821X(03)00188-2; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; Koch PL., 2003, GEOLOGICAL SOC AM SP, V369, P49, DOI DOI 10.1130/0-8137-2369-8.49; Laskar J, 2004, ASTRON ASTROPHYS, V428, P261, DOI 10.1051/0004-6361:20041335; Machlus M, 2004, GEOLOGY, V32, P137, DOI 10.1130/G20091.1; Norris RD, 1999, NATURE, V401, P775, DOI 10.1038/44545; ONEIL JR, 1969, J CHEM PHYS, V51, P5547, DOI 10.1063/1.1671982; Rohl U, 2000, GEOLOGY, V28, P927, DOI 10.1130/0091-7613(2000)28<927:NCFTLP>2.0.CO;2; Rohl U., 2003, CAUSES CONSEQUENCES, P567; Schmitz B, 2004, EARTH PLANET SC LETT, V225, P1, DOI 10.1016/j.epsl.2004.06.017; SHACKLETON N, 1967, NATURE, V215, P15, DOI 10.1038/215015a0; Svensen H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566; Thomas E, 2000, GFF, V122, P169, DOI 10.1080/11035890001221169; Thomas E., 1996, Geological Society Special Publication, V101, P401, DOI 10.1144/GSL.SP.1996.101.01.20; Thomas Ellen, 2000, P132; Varadi F, 2003, ASTROPHYS J, V592, P620, DOI 10.1086/375560; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; Zachos J. C., 2004, EARLY CENOZOIC EXTRE; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110; ZACHOS JC, IN PRESS SCIENCE	27	422	441	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2005	435	7045					1083	1087		10.1038/nature03814	http://dx.doi.org/10.1038/nature03814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937ZT	15944716	Green Published			2022-12-28	WOS:000229970400045
J	Cook, RL; Hutchison, SL; Ostergaard, L; Braithwaite, RS; Ness, RB				Cook, RL; Hutchison, SL; Ostergaard, L; Braithwaite, RS; Ness, RB			Systematic review: Noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae	ANNALS OF INTERNAL MEDICINE			English	Review							SEXUALLY-TRANSMITTED-DISEASES; LIGASE CHAIN-REACTION; ACID AMPLIFICATION TESTS; TRANSCRIPTION-MEDIATED AMPLIFICATION; STRAND DISPLACEMENT AMPLIFICATION; AMPLICOR CT/NG TESTS; URINE SPECIMENS; MULTICENTER EVALUATION; DIAGNOSTIC-TEST; LOW-PREVALENCE	Background: Testing of urine samples is noninvasive and could overcome several barriers to screening for chlamydial and gonococcal infections, but most test samples are obtained directly from the cervix or urethra. Purpose: To systematically review studies that assessed the sensitivity and specificity of nucleic acid amplification tests for Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens and to compare test characteristics according to type of assay, site of sample collection, presence of symptoms, disease prevalence, and characteristics of the reference standard. Data Sources: Relevant studies in all languages were identified by searching the MEDLINE database (January 1991 to December 2004) and by hand-searching the references of identified articles and relevant journals. Study Selection: Studies were selected that evaluated 1 of 3 commercially available nucleic acid amplification tests, included data from tests of both a urine sample and a traditional sample (obtained from the cervix or urethra), and used an appropriate reference standard. Data Extraction: From 29 eligible studies, 2 investigators independently abstracted data on sample characteristics, reference standard, sensitivity, and specificity. Data Synthesis: Articles were assessed qualitatively and quantitatively. Summary estimates for men and women were calculated separately for chlamydial and gonococcal infections and were stratified by assay and presence of symptoms. The pooled study specificities of each of the 3 assays exceeded 97% when urine samples were tested, for both chlamydial infection and gonorrhea and in both men and women. The pooled study sensitivities for the polymerase chain reaction, transcription-mediated amplification, and strand displacement amplification assays, respectively, were 83.3%, 92.5%, and 79.9% for chlamydial infections in women; 84.0%, 87.7%, and 93.1% for chlamydial infections in men; and 55.6%, 91.3%, and 84.9% for gonococcal infections in women. The pooled specificity of polymerase chain reaction to gonococcal infections in men was 90.4%. In subgroup analyses, the sensitivity did not vary according to the prevalence of infection or the presence of symptoms but did vary according to the reference standard used. Limitations: Few published studies present data on the transcription-mediated amplification or strand displacement amplification assays, and few studies report data from asymptomatic patients or low-prevalence groups. Conclusions: Results of nucleic acid amplification tests for C trachomatis on urine samples are nearly identical to those obtained on samples collected directly from the cervix or urethra. Although all 3 assays can also be used to test for N. gonorrhoeae, the sensitivity of the polymerase chain reaction assay in women is too low to recommend its routine use to test for gonorrhea in urine specimens.	Univ Pittsburgh, Div Gen Internal Med, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA; Aarhus Univ Hosp, Skejby Hosp, DK-8000 Aarhus, Denmark	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Aarhus University	Cook, RL (corresponding author), Univ Pittsburgh, Div Gen Internal Med, Sch Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.	cookrl@upmc.edu	Cook, Robert Lewis/ABI-4866-2020; Ostergaard, Lars/AAA-3020-2020	Ostergaard, Lars/0000-0003-2459-0511; Ostergaard, Lars/0000-0002-7619-605X; Braithwaite, Ronald Scott/0000-0001-7067-3655	AHRQ HHS [R01HS10592-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010592] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; Black CM, 2002, J CLIN MICROBIOL, V40, P3757, DOI 10.1128/JCM.40.10.3757-3763.2002; Black CM, 1997, CLIN MICROBIOL REV, V10, P160, DOI 10.1128/CMR.10.1.160; Bloomfield PJ, 2002, SEX TRANSM DIS, V29, P294, DOI 10.1097/00007435-200205000-00008; *COCHR METH GROUP, 1996, REC METH; Cook RL, 2001, J ADOLESCENT HEALTH, V28, P204, DOI 10.1016/S1054-139X(00)00152-X; Cosentino LA, 2003, J CLIN MICROBIOL, V41, P3592, DOI 10.1128/JCM.41.8.3592-3596.2003; Crotchfelt KA, 1998, J CLIN MICROBIOL, V36, P391, DOI 10.1128/JCM.36.2.391-394.1998; Crotchfelt KA, 1997, J CLIN MICROBIOL, V35, P1536, DOI 10.1128/JCM.35.6.1536-1540.1997; Dicker LW, 2004, SEX TRANSM DIS, V31, P259, DOI 10.1097/01.OLQ.0000124609.84050.F3; Ferrero DV, 1998, J CLIN MICROBIOL, V36, P3230, DOI 10.1128/JCM.36.11.3230-3233.1998; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Gaydos CA, 2003, J CLIN MICROBIOL, V41, P304, DOI 10.1128/JCM.41.1.304-309.2003; Ginocchio RHS, 2003, SEX TRANSM DIS, V30, P99, DOI 10.1097/00007435-200302000-00001; Golden MR, 2004, CLIN INFECT DIS, V39, P1387, DOI 10.1086/424880; Green TA, 1998, J CLIN MICROBIOL, V36, P375, DOI 10.1128/JCM.36.2.375-381.1998; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HASSELBLAD VIC, 1995, MED DECIS MAKING, V15, P81, DOI 10.1177/0272989X9501500112; Higgins SP, 1998, INT J STD AIDS, V9, P21, DOI 10.1258/0956462981920982; Holland-Hall C M, 2002, J Pediatr Adolesc Gynecol, V15, P307, DOI 10.1016/S1083-3188(02)00197-3; Hollblad-Fadiman K, 2003, AM J PREV MED, V24, P287, DOI 10.1016/S0749-3797(02)00636-0; Honey E, 2002, SEX TRANSM INFECT, V78, P406, DOI 10.1136/sti.78.6.406; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Jensen IP, 2003, CLIN MICROBIOL INFEC, V9, P194, DOI 10.1046/j.1469-0691.2003.00483.x; Johnson RE, 2000, J CLIN MICROBIOL, V38, P4382, DOI 10.1128/JCM.38.12.4382-4386.2000; Johnson Robert E, 2002, MMWR Recomm Rep, V51, P1; Knox J, 2002, SEX TRANSM DIS, V29, P647, DOI 10.1097/00007435-200211000-00006; Kohl KS, 2004, INT J STD AIDS, V15, P822, DOI 10.1258/0956462042563738; Levine WC, 2004, AM J EPIDEMIOL, V160, P91, DOI 10.1093/aje/kwh162; Lijmer JG, 2002, STAT MED, V21, P1525, DOI 10.1002/sim.1185; Mahony J, 1998, J CLIN MICROBIOL, V36, P3122, DOI 10.1128/JCM.36.11.3122-3126.1998; Marrazzo JM, 1997, ANN INTERN MED, V127, P796, DOI 10.7326/0003-4819-127-9-199711010-00004; Martin DH, 2000, J CLIN MICROBIOL, V38, P3544, DOI 10.1128/JCM.38.10.3544-3549.2000; Martin DH, 2004, J CLIN MICROBIOL, V42, P4749, DOI 10.1128/JCM.42.10.4749-4758.2004; McCartney RA, 2001, BRIT J BIOMED SCI, V58, P235; Miller WC, 1998, J CLIN EPIDEMIOL, V51, P219, DOI 10.1016/S0895-4356(97)00264-3; Miller WC, 2004, JAMA-J AM MED ASSOC, V291, P2229, DOI 10.1001/jama.291.18.2229; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Mukenge-Tshibaka L, 2000, J CLIN MICROBIOL, V38, P4076, DOI 10.1128/JCM.38.11.4076-4079.2000; MULROW CD, 1989, J GEN INTERN MED, V4, P288, DOI 10.1007/BF02597398; Nelson HD, 2001, AM J PREV MED, V20, P95, DOI 10.1016/S0749-3797(01)00253-7; Oh MK, 1997, J ADOLESCENT HEALTH, V21, P80, DOI 10.1016/S1054-139X(96)00311-4; Olafsson JH, 1996, ACTA DERM-VENEREOL, V76, P226; Ossewaarde JM, 1997, GENITOURIN MED, V73, P207; Ostergaard L, 2000, CLIN INFECT DIS, V31, P951, DOI 10.1086/318139; Pasternack R, 1996, J CLIN MICROBIOL, V34, P995, DOI 10.1128/JCM.34.4.995-998.1996; Pimenta JM, 2003, SEX TRANSM INFECT, V79, P16, DOI 10.1136/sti.79.1.16; Puolakkainen M, 1998, J CLIN MICROBIOL, V36, P1489, DOI 10.1128/JCM.36.6.1489-1493.1998; Quinn TC, 1996, J CLIN MICROBIOL, V34, P1401, DOI 10.1128/JCM.34.6.1401-1406.1996; Schachter J, 1996, LANCET, V348, P1308, DOI 10.1016/S0140-6736(05)65783-2; Schachter J, 2003, J CLIN MICROBIOL, V41, P3784, DOI 10.1128/JCM.41.8.3784-3789.2003; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Shafer MAB, 2002, JAMA-J AM MED ASSOC, V288, P2846, DOI 10.1001/jama.288.22.2846; Shrier LA, 2004, AM J OBSTET GYNECOL, V190, P654, DOI 10.1016/j.ajog.2003.09.063; SKULNICK M, 1994, DIAGN MICR INFEC DIS, V20, P195, DOI 10.1016/0732-8893(94)90003-5; Stary A, 1996, SEX TRANSM DIS, V23, P97, DOI 10.1097/00007435-199603000-00002; Stary A, 1998, J CLIN MICROBIOL, V36, P2666, DOI 10.1128/JCM.36.9.2666-2670.1998; Stephenson J, 2000, SEX TRANSM INFECT, V76, P25, DOI 10.1136/sti.76.1.25; Sutton AJAK, 2000, METHODS METAANALYSIS; Toye B, 1996, J CLIN MICROBIOL, V34, P1396, DOI 10.1128/JCM.34.6.1396-1400.1996; Van der Pol B, 2000, J CLIN MICROBIOL, V38, P1105, DOI 10.1128/JCM.38.3.1105-1112.2000; van der Pol B, 2001, J CLIN MICROBIOL, V39, P1008, DOI 10.1128/JCM.39.3.1008-1016.2001; van Doornum GJJ, 2001, J CLIN MICROBIOL, V39, P829, DOI 10.1128/JCM.39.3.829-835.2001; Verkooyen RP, 2003, J CLIN MICROBIOL, V41, P3013, DOI 10.1128/JCM.41.7.3013-3016.2003; Vincelette J, 1999, J CLIN MICROBIOL, V37, P74, DOI 10.1128/JCM.37.1.74-80.1999; Watson EJ, 2002, J MED MICROBIOL, V51, P1021, DOI 10.1099/0022-1317-51-12-1021; Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1111/j.1931-2393.2004.tb00002.x; WHO World Health Organisation STD Statistics, 2001, GLOB PREV INC SEL CU; WIESENFELD HC, 1994, SEX TRANSM DIS, V21, P268, DOI 10.1097/00007435-199409000-00004; Wiesenfeld HC, 2001, SEX TRANSM DIS, V28, P321, DOI 10.1097/00007435-200106000-00003; Wiesenfeld HC, 1996, AM J OBSTET GYNECOL, V174, P1542, DOI 10.1016/S0002-9378(96)70603-8; Young H, 1998, INT J STD AIDS, V9, P661, DOI 10.1258/0956462981921314; Zenilman JM, 2003, SEX TRANSM INFECT, V79, P94, DOI 10.1136/sti.79.2.94; 2002, MMWR MORB MORTAL WKL, V51, P1	77	192	214	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					914	925		10.7326/0003-4819-142-11-200506070-00010	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941699				2022-12-28	WOS:000229556300006
J	Feng, L; Zhou, SP; Gu, LC; Gell, DA; Mackay, JP; Weiss, MJ; Gow, AJ; Shi, YG				Feng, L; Zhou, SP; Gu, LC; Gell, DA; Mackay, JP; Weiss, MJ; Gow, AJ; Shi, YG			Structure of oxidized alpha-haemoglobin bound to AHSP reveals a protective mechanism for haem	NATURE			English	Article							STABILIZING PROTEIN; SULFHEME PROTEINS; HYDROGEN-PEROXIDE; MYOGLOBIN; BINDING; SULFMYOGLOBIN; DEGRADATION; THALASSEMIA; INSIGHTS	The synthesis of haemoglobin A (HbA) is exquisitely coordinated during erythrocyte development to prevent damaging effects from individual alpha- and beta-subunits(1,2). The alpha-haemoglobin-stabilizing protein (AHSP) binds alpha-haemoglobin (alpha Hb), inhibits the ability of alpha Hb to generate reactive oxygen species and prevents its precipitation on exposure to oxidant stress(3-5). The structure of AHSP bound to ferrous alpha Hb is thought to represent a transitional complex through which alpha Hb is converted to a non-reactive, hexacoordinate ferric form(5). Here we report the crystal structure of this ferric alpha Hb - AHSP complex at 2.4 angstrom resolution. Our findings reveal a striking bis-histidyl configuration in which both the proximal and the distal histidines coordinate the haem iron atom. To attain this unusual conformation, segments of alpha Hb undergo drastic structural rearrangements, including the repositioning of several alpha-helices. Moreover, conversion to the ferric bis-histidine configuration strongly and specifically inhibits redox chemistry catalysis and haem loss from alpha Hb. The observed structural changes, which impair the chemical reactivity of haem iron, explain how AHSP stabilizes alpha Hb and prevents its damaging effects in cells.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Princeton University; University of Pennsylvania; University of Sydney	Gow, AJ (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	gow@email.chop.edu; yshi@molbio.princeton.edu	Weiss, Mitchell J/A-1245-2013; Gow, Andrew/AAR-2309-2020; Weiss, Mitchell J/W-9814-2018; Mackay, Joel P/D-6834-2011; Gow, Andrew/N-8566-2013	Gow, Andrew/0000-0003-0876-5158; Weiss, Mitchell J/0000-0003-2460-3036; Mackay, Joel P/0000-0001-7508-8033; Gow, Andrew/0000-0003-0876-5158; Gell, David/0000-0003-0382-1181; Shi, Yigong/0000-0003-2030-168X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061692] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alayash AI, 1999, J BIOL CHEM, V274, P2029, DOI 10.1074/jbc.274.4.2029; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BAGLIONI C, 1966, BIBL HAEMATOL, V29, P1056; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3783; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P3367; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNN HF, 1987, BLOOD, V69, P1; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Feng L, 2004, CELL, V119, P629, DOI 10.1016/j.cell.2004.11.025; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; Hankeln T, 2002, J BIOL CHEM, V277, P29012, DOI 10.1074/jbc.M204009200; Herold S, 2001, J BIOL INORG CHEM, V6, P543, DOI 10.1007/s007750100231; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kong Y, 2004, J CLIN INVEST, V114, P1457, DOI 10.1172/JCI200421982; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Nagababu E, 2000, BIOCHEMISTRY-US, V39, P12503, DOI 10.1021/bi992170y; Nagababu E, 2004, ANTIOXID REDOX SIGN, V6, P967, DOI 10.1089/1523086042259823; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Rachmilewitz EA, 2001, DISORDERS HEMOGLOBIN, P233; Reeder BJ, 2002, BIOCHEMISTRY-US, V41, P367, DOI 10.1021/bi011335b; Rifkind JM, 2004, ANTIOXID REDOX SIGN, V6, P657, DOI 10.1089/152308604773934422; Santiveri CM, 2004, J BIOL CHEM, V279, P34963, DOI 10.1074/jbc.M405016200; SCOTT MD, 1993, J CLIN INVEST, V91, P1706, DOI 10.1172/JCI116380; Sugimoto H, 2004, J MOL BIOL, V339, P873, DOI 10.1016/j.jmb.2004.04.024; Svistunenko DA, 2000, BIOCHEM J, V351, P595, DOI 10.1042/0264-6021:3510595; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832	30	92	100	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					697	701		10.1038/nature03609	http://dx.doi.org/10.1038/nature03609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931225				2022-12-28	WOS:000229476200055
J	Selsis, F; Lemmon, MT; Vaubaillon, J; Bell, JF				Selsis, F; Lemmon, MT; Vaubaillon, J; Bell, JF			A martian meteor and its parent comet	NATURE			English	Editorial Material									Ecole Normale Super Lyon, Ctr Rech Astron Lyon, F-69364 Lyon, France; Texas A&M Univ, Dept Atmospher Sci, College Stn, TX 77843 USA; Observ Paris, IMCCE, F-75014 Paris, France; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Texas A&M University System; Texas A&M University College Station; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Cornell University	Selsis, F (corresponding author), Ecole Normale Super Lyon, Ctr Rech Astron Lyon, F-69364 Lyon, France.	franck.selsis@ens-lyon.fr	Lemmon, Mark/X-2333-2019; Lemmon, Mark T/E-9983-2010	Lemmon, Mark/0000-0002-4504-5136; Lemmon, Mark T/0000-0002-4504-5136; Selsis, Franck/0000-0001-9619-5356				Adolfsson LG, 1996, ICARUS, V119, P144, DOI 10.1006/icar.1996.0007; Beech M, 2003, MON NOT R ASTRON SOC, V345, P696, DOI 10.1046/j.1365-8711.2003.06998.x; Bell JF, 2004, SCIENCE, V305, P800, DOI 10.1126/science.1100175; Campbell-Brown MD, 2004, ASTRON ASTROPHYS, V418, P751, DOI [10.1051/0004-6361:20041001-1, 10.1051/0004-6361:20041001]; Christou AA, 1999, PLANET SPACE SCI, V47, P1475, DOI 10.1016/S0032-0633(99)00064-1; Selsis F, 2004, ASTRON ASTROPHYS, V416, P783, DOI 10.1051/0004-6361:20031724; VAUBAILLON J, IN PRESS ASTRON ASTR; ZENDER JJ, 2002, ESA SP, V500, P121	8	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2005	435	7042					581	581		10.1038/435581a	http://dx.doi.org/10.1038/435581a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931208	Bronze			2022-12-28	WOS:000229476200033
J	Shear, K; Frank, E; Houck, PR; Reynolds, CF				Shear, K; Frank, E; Houck, PR; Reynolds, CF			Treatment of complicated grief - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEREAVEMENT-RELATED DEPRESSION; TRAUMATIC GRIEF; INTERPERSONAL PSYCHOTHERAPY; CONJUGAL BEREAVEMENT; DIAGNOSTIC-CRITERIA; RATING-SCALE; DISORDER; ANXIETY; HEALTH; NORTRIPTYLINE	Context Complicated grief is a debilitating disorder associated with important negative health consequences, but the results of existing treatments for it have been disappointing. Objective To compare the efficacy of a novel approach, complicated grief treatment, with a standard psychotherapy (interpersonal psychotherapy). Design Two-cell, prospective, randomized controlled clinical trial, stratified by manner of death of loved one and treatment site. Setting A university-based psychiatric research clinic as well as a satellite clinic in a low-income African American community between April 2001 and April 2004. Participants A total of 83 women and 12 men aged 18 to 85 years recruited through professional referral, self-referral, and media announcements who met criteria for complicated grief. Interventions Participants were randomly assigned to receive interpersonal psychotherapy (n=46) or complicated grief treatment (n=49); both were administered in 16 sessions during an average interval of 19 weeks per participant. Main Outcome Measure Treatment response, defined either as independent evaluator-rated Clinical Global Improvement score of 1 or 2 or as time to a 20-point or better improvement in the self-reported Inventory of Complicated Grief. Results Both treatments produced improvement in complicated grief symptoms. The response rate was greater for complicated grief treatment (51%) than for interpersonal psychotherapy (28%; P = .02) and time to response was faster for complicated grief treatment (P = .02). The number needed to treat was 4.3. Conclusion Complicated grief treatment is an improved treatment over interpersonal psychotherapy, showing higher response rates and faster time to response.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Shear, K (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St,Room E-1116, Pittsburgh, PA 15213 USA.	shearmk@upmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060783, P30MH052247, P30MH030915] Funding Source: NIH RePORTER; NIMH NIH HHS [P30 MH030915, R01 MH060783, P30MH52247, P30 MH052247, R01MH60783, P30MH30915] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ablon JS, 2002, AM J PSYCHIAT, V159, P775, DOI 10.1176/appi.ajp.159.5.775; Beck A., 1987, MANUAL REVISED BECK; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Breslow NE, 1980, IARC SCI PUBL, P5; Chatellier G, 1996, BRIT MED J, V312, P426; Chen JH, 1999, PSYCHOL MED, V29, P367, DOI 10.1017/S0033291798008137; CLAYTON PJ, 1972, BRIT J PSYCHIAT, V120, P71, DOI 10.1192/bjp.120.554.71; CYRANOWSKI J, IN PRESS DEPRESS ANX; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; First M.B., 2016, STRUCTURED CLIN INTE; Foa EB., 1998, TREATING TRAUMA RAPE, P286; Frank E, 2000, BIOL PSYCHIAT, V48, P593, DOI 10.1016/S0006-3223(00)00969-0; Frank E, 2000, J CLIN PSYCHIAT, V61, P51, DOI 10.4088/JCP.v61n0112; FRANK E, 1991, PSYCHOTHER, V28, P259, DOI 10.1037/0033-3204.28.2.259; Guy W, 1976, ECDEU ASSESSMENT MAN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hembree EA, 2003, J TRAUMA STRESS, V16, P555, DOI 10.1023/B:JOTS.0000004078.93012.7d; Horowitz MJ, 1997, AM J PSYCHIAT, V154, P904; JACOBS SC, 1987, BIOPSYCHOSOCIAL ASPE, P125; Jacobs SC, 1993, PATHOLOGIC GRIEF MAL; Jordan JR, 2003, DEATH STUD, V27, P765, DOI 10.1080/713842360; KEARNS NP, 1982, BRIT J PSYCHIAT, V141, P45, DOI 10.1192/bjp.141.1.45; Klerman GL, 1984, INTERPERSONAL PSYCHO; Kobak KA, 1993, PSYCHOL ASSESSMENT, V5, P487, DOI DOI 10.1037/1040-3590.5.4.487; MARMAR CR, 1988, AM J PSYCHIAT, V145, P203; MAWSON D, 1981, BRIT J PSYCHIAT, V138, P185, DOI 10.1192/bjp.138.3.185; Melhem NM, 2004, AM J PSYCHIAT, V161, P1411, DOI 10.1176/appi.ajp.161.8.1411; Middleton W, 1996, BRIT J PSYCHIAT, V169, P167, DOI 10.1192/bjp.169.2.167; Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461; *NAT CTR HLTH STAT, BIRTHS MARR DIV DEAT; Ott CH, 2003, DEATH STUD, V27, P249, DOI 10.1080/07481180302887; PRIGERSON HG, 1995, AM J PSYCHIAT, V152, P22; Prigerson HG, 1996, AM J PSYCHIAT, V153, P1484; Prigerson HG, 2001, JAMA-J AM MED ASSOC, V286, P1369, DOI 10.1001/jama.286.11.1369; Prigerson HG, 1997, AM J PSYCHIAT, V154, P616, DOI 10.1176/ajp.154.5.616; Prigerson HG, 1999, BRIT J PSYCHIAT, V174, P67, DOI 10.1192/bjp.174.1.67; Prigerson HG, 1995, PSYCHIAT RES, V59, P65, DOI 10.1016/0165-1781(95)02757-2; PRIGERSON HG, 2000, POSTTRAUMATIC STRESS, P163; RAMSAY RW, 1977, BEHAV RES THER, V15, P131, DOI 10.1016/0005-7967(77)90097-3; Reynolds CF, 1999, AM J PSYCHIAT, V156, P202; Shear MK, 2001, AM J PSYCHIAT, V158, P1506, DOI 10.1176/appi.ajp.158.9.1506; Shear MK, 2001, DEPRESS ANXIETY, V13, P166, DOI 10.1002/da.1033.abs; SHEAR MK, 2000, HDB PSYCHIAT MEASURE, P555; Silverman GK, 2000, PSYCHOL MED, V30, P857, DOI 10.1017/S0033291799002524; Stroebe M, 1999, DEATH STUD, V23, P197, DOI 10.1080/074811899201046; WEISSMAN MM, 2000, COMPREHENSIVE GUIDE; WINDHOLZ MJ, 1985, COMPR PSYCHIAT, V26, P433, DOI 10.1016/0010-440X(85)90080-X; YONKERS KA, 2000, HDB PSYCHIAT MEASURE, P527; Zisook S, 2001, J CLIN PSYCHIAT, V62, P227, DOI 10.4088/JCP.v62n0403; Zygmont M, 1998, J CLIN PSYCHIAT, V59, P241, DOI 10.4088/JCP.v59n0507	50	656	661	6	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2601	2608		10.1001/jama.293.21.2601	http://dx.doi.org/10.1001/jama.293.21.2601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	930UU	15928281	Green Accepted, Bronze			2022-12-28	WOS:000229443400018
J	Oremland, RS; Kulp, TR; Blum, JS; Hoeft, SE; Baesman, S; Miller, LG; Stolz, JF				Oremland, RS; Kulp, TR; Blum, JS; Hoeft, SE; Baesman, S; Miller, LG; Stolz, JF			A microbial arsenic cycle in a salt-saturated, extreme environment	SCIENCE			English	Article							MONO LAKE WATER; REDUCTION; CALIFORNIA; SEDIMENTS; SULFATE; ECOLOGY	Searles Lake is a salt-saturated, alkaline brine unusually rich in the toxic element arsenic. Arsenic speciation changed from arsenate [As(V)] to arsenite (As(III)) with sediment depth. Incubated anoxic sediment slurries displayed dissimilatory As(V)-reductase activity that was markedly stimulated by H-2 or sulfide, whereas aerobic slurries had rapid As(III)-oxidase activity. An anaerobic, extremely haloalkaliphilic bacterium was isolated from the sediment that grew via As(V) respiration, using either lactate or sulfide as its electron donor. Hence, a full biogeochemical cycle of arsenic occurs in Searles Lake, driven in part by inorganic electron donors.	US Geol Survey, Menlo Pk, CA 94025 USA; Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	United States Department of the Interior; United States Geological Survey; Duquesne University	Oremland, RS (corresponding author), US Geol Survey, MS 480,345 Middlefield Rd, Menlo Pk, CA 94025 USA.	roremlan@usgs.gov		Miller, Laurence/0000-0002-7807-3475; Baesman, Shaun/0000-0003-0741-8269				Bard A. J., 1985, STANDARD POTENTIALS; Blum JS, 1998, ARCH MICROBIOL, V171, P19, DOI 10.1007/s002030050673; Blum JS, 2001, ARCH MICROBIOL, V175, P208; Brandt KK, 2001, MICROBIAL ECOL, V41, P1; DiPasquale MM, 1998, MICR EXTREM UNUSUAL, P149; FELMY AR, 1986, GEOCHIM COSMOCHIM AC, V50, P2771, DOI 10.1016/0016-7037(86)90226-7; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Hoeft SE, 2004, APPL ENVIRON MICROB, V70, P2741, DOI 10.1128/AEM.70.5.2741-2747.2004; Hoeft SE, 2002, GEOMICROBIOL J, V19, P23, DOI 10.1080/014904502317246147; Hollibaugh JT, 2005, GEOCHIM COSMOCHIM AC, V69, P1925, DOI 10.1016/j.gca.2004.10.011; JAVOR B, 1989, HYPERSALINE ENV; KULP TR, UNPUB; Liu A, 2004, FEMS MICROBIOL ECOL, V48, P323, DOI 10.1016/j.femsec.2004.02.008; Newman DK, 1998, GEOMICROBIOL J, V15, P255, DOI 10.1080/01490459809378082; OREMLAND RS, 1987, GEOCHIM COSMOCHIM AC, V51, P2915, DOI 10.1016/0016-7037(87)90367-X; Oremland RS, 2003, SCIENCE, V300, P939, DOI 10.1126/science.1081903; Oremland RS, 2004, FEMS MICROBIOL ECOL, V48, P15, DOI 10.1016/j.femsec.2003.12.016; Oremland RS, 2002, APPL ENVIRON MICROB, V68, P4795, DOI 10.1128/AEM.68.10.4795-4802.2002; Oremland RS, 2005, TRENDS MICROBIOL, V13, P45, DOI 10.1016/j.tim.2004.12.002; Oremland RS, 2000, GEOCHIM COSMOCHIM AC, V64, P3073, DOI 10.1016/S0016-7037(00)00422-1; OREN A, 1988, ADV MICROB ECOL, V10, P193; Oren A, 1999, MICROBIOL MOL BIOL R, V63, P334, DOI 10.1128/MMBR.63.2.334-348.1999; Oren A, 1998, MICR EXTREM UNUSUAL, P1; SMITH GI, 1979, US GEOL SURV PROF PA, V1043, P143; Sorensen KB, 2004, APPL ENVIRON MICROB, V70, P1608, DOI 10.1128/AEM.70.3.1608-1616.2004; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; van der Wielen PWJJ, 2005, SCIENCE, V307, P121, DOI 10.1126/science.1103569	27	130	139	4	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1305	1308		10.1126/science.1110832	http://dx.doi.org/10.1126/science.1110832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919992				2022-12-28	WOS:000229482300046
J	Krauss, TF				Krauss, TF			Control at the quantum level	SCIENCE			English	Editorial Material							NANOCAVITY; DOT		Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland	University of St Andrews	Krauss, TF (corresponding author), Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland.	tfk@st-and.ac.uk	Krauss, Thomas/B-4550-2014	Krauss, Thomas/0000-0003-4367-6601				Badolato A, 2005, SCIENCE, V308, P1158, DOI 10.1126/science.1109815; McKeever J, 2004, SCIENCE, V303, P1992, DOI 10.1126/science.1095232; Reithmaier JP, 2004, NATURE, V432, P197, DOI 10.1038/nature02969; Song BS, 2005, NAT MATER, V4, P207, DOI 10.1038/nmat1320; Yoshie T, 2004, NATURE, V432, P200, DOI 10.1038/nature03119	5	7	7	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2005	308	5725					1122	1123		10.1126/science.1113753	http://dx.doi.org/10.1126/science.1113753			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905388				2022-12-28	WOS:000229293400029
J	Stein, AJ; Fuchs, G; Fu, CM; Wolin, SL; Reinisch, KM				Stein, AJ; Fuchs, G; Fu, CM; Wolin, SL; Reinisch, KM			Structural insights into RNA quality control: The Ro autoantigen binds misfolded RNAs via its central cavity	CELL			English	Article							SMALL CYTOPLASMIC RIBONUCLEOPROTEINS; 5S RIBOSOMAL-RNA; PROTEIN; RECOGNITION; EVOLUTION; DOMAIN	The Ro 60 kDa autoantigen is a major target of the immune response in patients with systemic lupus erythematosus. In vertebrate cells, Ro binds misfolded small RNAs and likely functions in RNA quality control. In eukaryotes and bacteria, Ro also associates with small RNAs called Y RNAs. We present structures of unliganded Ro and Ro complexed with two RNAs at 1.95 and 2.2 angstrom resolution, respectively. Ro consists of a von Willebrand factor A domain and a doughnut-shaped domain composed of HEAT repeats. In the complex, a fragment of Y RNA binds on the outer surface of the HEAT-repeat ring, and single-stranded RNA binds in the toroid hole. Mutagenesis supports a binding site for misfolded RNAs that encompasses both sites, with a single-stranded end inserted into the toroid cavity. Our experiments suggest that one role of Y RNAs may be to regulate access of other RNAs to Ro.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	Reinisch, KM (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.	karin.reinisch@yale.edu	Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399; Fuchs, Gabriele/0000-0002-6838-2100	NCRR NIH HHS [P41 RR012408] Funding Source: Medline; NIGMS NIH HHS [R01 GM073863-04, R01 GM048410, R01 GM073863-01, R01 GM 48410, R01 GM070521, R01 GM073863-02, R01 GM073863, R01 GM073863-03, R01 GM 70521] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070521, R01GM048410, R01GM073863] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Bateman A, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-49; Batey RT, 2001, J MOL BIOL, V307, P229, DOI 10.1006/jmbi.2000.4454; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buyon JP, 2004, LUPUS, V13, P705, DOI 10.1191/0961203304lu2008oa; CARTER DM, 1971, J BIOL CHEM, V246, P2502; Chen XG, 2000, GENE DEV, V14, P777; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; Chen XG, 2003, CURR BIOL, V13, P2206, DOI 10.1016/j.cub.2003.11.028; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; FARRIS AD, 1995, GENE, V154, P193, DOI 10.1016/0378-1119(94)00823-B; Green CD, 1998, RNA, V4, P750, DOI 10.1017/S1355838298971667; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; OBRIEN CA, 1994, GENE DEV, V8, P2891, DOI 10.1101/gad.8.23.2891; OBRIEN CA, 1993, P NATL ACAD SCI USA, V90, P7250, DOI 10.1073/pnas.90.15.7250; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Patel P, 2002, DERMATOL CLIN, V20, P373, DOI 10.1016/S0733-8635(02)00016-5; PRUIJN GJM, 1991, NUCLEIC ACIDS RES, V19, P5173, DOI 10.1093/nar/19.19.5173; Schroeder R, 2004, NAT REV MOL CELL BIO, V5, P908, DOI 10.1038/nrm1497; Shi H, 1996, RNA, V2, P769; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VANHORN DJ, 1995, RNA, V1, P293; Wang XQ, 2002, CELL, V110, P501, DOI 10.1016/S0092-8674(02)00873-5; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; WOLIN SL, 1984, P NATL ACAD SCI-BIOL, V81, P1996, DOI 10.1073/pnas.81.7.1996; Xue DH, 2003, P NATL ACAD SCI USA, V100, P7503, DOI 10.1073/pnas.0832411100	37	134	137	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					529	539		10.1016/j.cell.2005.03.009	http://dx.doi.org/10.1016/j.cell.2005.03.009			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907467	Green Accepted, Bronze			2022-12-28	WOS:000229331200010
J	Wilson, JF				Wilson, JF			Is sleep the new vital sign?	ANNALS OF INTERNAL MEDICINE			English	News Item							INSULIN-RESISTANCE; APNEA; RISK; DEPRIVATION; DURATION; INTERNS; MEN					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380; Barger LK, 2005, NEW ENGL J MED, V352, P125, DOI 10.1056/NEJMoa041401; Bryant PA, 2004, NAT REV IMMUNOL, V4, P457, DOI 10.1038/nri1369; Gami AS, 2004, CIRCULATION, V110, P364, DOI 10.1161/01.CIR.0000136587.68725.8E; Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Meier-Ewert HK, 2004, J AM COLL CARDIOL, V43, P678, DOI 10.1016/j.jacc.2003.07.050; Namen AM, 2001, SOUTHERN MED J, V94, P874; Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087; Quan SF, 2004, GERIATRICS-US, V59, P37; Roehrs T, 2004, SLEEP, V27, P887, DOI 10.1093/sleep/27.5.887; Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906; Spiegel K, 2004, ANN INTERN MED, V141, P846, DOI 10.7326/0003-4819-141-11-200412070-00008; Spiegel K, 2002, JAMA-J AM MED ASSOC, V288, P1471, DOI 10.1001/jama.288.12.1471-a; Tamakoshi A, 2004, SLEEP, V27, P51; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; Williamson AM, 2000, OCCUP ENVIRON MED, V57, P649, DOI 10.1136/oem.57.10.649	17	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					877	880		10.7326/0003-4819-142-10-200505170-00026	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897548				2022-12-28	WOS:000229099600022
J	Bloche, MG				Bloche, MG			Managing conflict at the end of life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Washington, DC 20057 USA.							Bercovitch Jacob, 1989, MEDIATION RES PROCES; Bloche MG, 2002, STANFORD LAW REV, V55, P919, DOI 10.2307/1229676; Dubler N. N., 2004, BIOETHICS MEDIATION; Frey B.S., 1999, EC VALUES ORG, P437; LYNCH RN, 2005, COMMUNICATION   0228	5	32	33	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2371	2373		10.1056/NEJMp058104	http://dx.doi.org/10.1056/NEJMp058104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944420				2022-12-28	WOS:000229638900001
J	Menetrey, J; Bahloul, A; Wells, AL; Yengo, CM; Morris, CA; Sweeney, HL; Houdusse, A				Menetrey, J; Bahloul, A; Wells, AL; Yengo, CM; Morris, CA; Sweeney, HL; Houdusse, A			The structure of the myosin VI motor reveals the mechanism of directionality reversal	NATURE			English	Article							KINETIC MECHANISM; LEVER ARM; CALMODULIN; PROTEIN; PROCESSIVITY; BINDING; DOMAIN; MODEL	Here we solve a 2.4-angstrom structure of a truncated version of the reverse-direction myosin motor, myosin VI, that contains the motor domain and binding sites for two calmodulin molecules. The structure reveals only minor differences in the motor domain from that in plus-end directed myosins, with the exception of two unique inserts. The first is near the nucleotide-binding pocket and alters the rates of nucleotide association and dissociation. The second unique insert forms an integral part of the myosin VI converter domain along with a calmodulin bound to a novel target motif within the insert. This serves to redirect the effective 'lever arm' of myosin VI, which includes a second calmodulin bound to an 'IQ motif', towards the pointed ( minus) end of the actin filament. This repositioning largely accounts for the reverse directionality of this class of myosin motors. We propose a model incorporating a kinesin-like uncoupling/docking mechanism to provide a full explanation of the movements of myosin VI.	CNRS, Inst Curie, F-75248 Paris, France; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Pennsylvania	Houdusse, A (corresponding author), CNRS, Inst Curie, 26 Rue Ulm, F-75248 Paris, France.	lsweeney@mail.med.upenn.edu; anne.houdusse@curie.fr	Sweeney, H Lee/F-1862-2010; Ménétrey, Julie/AAM-6408-2021	BAHLOUL, Amel/0000-0001-7042-4616	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048931] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR048931-03, R01 AR048931] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Bahloul A, 2004, P NATL ACAD SCI USA, V101, P4787, DOI 10.1073/pnas.0306892101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buss F, 2004, ANNU REV CELL DEV BI, V20, P649, DOI 10.1146/annurev.cellbio.20.012103.094243; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Fallon JL, 2003, STRUCTURE, V11, P1303, DOI 10.1016/j.str.2003.09.004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Hasson T, 2003, J CELL SCI, V116, P3453, DOI 10.1242/jcs.00669; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Millo H, 2004, MECH DEVELOP, V121, P1335, DOI 10.1016/j.mod.2004.06.007; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rock RS, 2005, MOL CELL, V17, P603, DOI 10.1016/j.molcel.2005.01.015; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Ruff C, 2001, NAT STRUCT BIOL, V8, P226, DOI 10.1038/84962; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Sasaki N, 2003, BIOCHEMISTRY-US, V42, P90, DOI 10.1021/bi026051l; Sweeney HL, 2004, PHILOS T R SOC B, V359, P1829, DOI 10.1098/rstb.2004.1576; Tsiavaliaris G, 2004, NATURE, V427, P558, DOI 10.1038/nature02303; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Yildiz A, 2004, J BIOL CHEM, V279, P37223, DOI 10.1074/jbc.C400252200	42	164	169	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					779	785		10.1038/nature03592	http://dx.doi.org/10.1038/nature03592			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944696	Green Accepted			2022-12-28	WOS:000229638700042
J	O'Donnell, KA; Wentzel, EA; Zeller, KI; Dang, CV; Mendell, JT				O'Donnell, KA; Wentzel, EA; Zeller, KI; Dang, CV; Mendell, JT			c-Myc-regulated microRNAs modulate E2F1 expression	NATURE			English	Article							TRANSCRIPTION FACTOR; GENOMIC TARGETS; IDENTIFICATION; GENES; LYMPHOMA; MECHANISM	MicroRNAs ( miRNAs) are 21 - 23 nucleotide RNA molecules that regulate the stability or translational efficiency of target messenger RNAs1. miRNAs have diverse functions, including the regulation of cellular differentiation, proliferation and apoptosis(2). Although strict tissue- and developmental-stage-specific expression is critical for appropriate miRNA function, mammalian transcription factors that regulate miRNAs have not yet been identified. The proto-oncogene c-MYC encodes a transcription factor that regulates cell proliferation, growth and apoptosis(3). Dysregulated expression or function of c-Myc is one of the most common abnormalities in human malignancy(4). Here we show that c-Myc activates expression of a cluster of six miRNAs on human chromosome 13. Chromatin immunoprecipation experiments show that c-Myc binds directly to this locus. The transcription factor E2F1 is an additional target of c-Myc that promotes cell cycle progression(5-7). We find that expression of E2F1 is negatively regulated by two miRNAs in this cluster, miR-17-5p and miR-20a. These findings expand the known classes of transcripts within the c-Myc target gene network, and reveal a mechanism through which c-Myc simultaneously activates E2F1 transcription and limits its translation, allowing a tightly controlled proliferative signal.	Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Mendell, JT (corresponding author), Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD 21205 USA.	jmendell@jhmi.edu	Jackson, Benjamin L/C-4297-2012; Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Guo QM, 2000, CANCER RES, V60, P5922; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Tanzer A, 2004, J MOL BIOL, V339, P327, DOI 10.1016/j.jmb.2004.03.065; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	30	2259	2464	2	204	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					839	843		10.1038/nature03677	http://dx.doi.org/10.1038/nature03677			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944709				2022-12-28	WOS:000229638700055
J	Zatz, M; Starling, A				Zatz, M; Starling, A			Mechanisms of disease: Calpains and disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GIRDLE MUSCULAR-DYSTROPHY; MUSCLE-SPECIFIC CALPAIN; ACTIVATED NEUTRAL PROTEINASE; KAPPA-B PATHWAY; ALZHEIMERS-DISEASE; IN-VIVO; MONOCLONAL-ANTIBODIES; MOTONEURON SURVIVAL; PROTEOLYTIC-ENZYME; CATALYTIC SUBUNIT		Univ Sao Paulo, Inst Biociencias, Dept Biol, Human Genome Res Ctr, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo	Zatz, M (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Biol, Human Genome Res Ctr, Rua Matao 277,Cidade Univ, BR-05508900 Sao Paulo, Brazil.	mayazatz@usp.br	Zatz, Mayana/M-5338-2015	Zatz, Mayana/0000-0003-3970-8025				Anderson LVB, 2000, NEUROMUSCULAR DISORD, V10, P553, DOI 10.1016/S0960-8966(00)00143-7; Anderson LVB, 1998, AM J PATHOL, V153, P1169, DOI 10.1016/S0002-9440(10)65661-1; Badalamente MA, 2000, MUSCLE NERVE, V23, P106, DOI 10.1002/(SICI)1097-4598(200001)23:1<106::AID-MUS14>3.0.CO;2-D; Baghdiguian S, 1999, NAT MED, V5, P849, DOI 10.1038/10579; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Banik NL, 1997, BRAIN RES, V748, P205, DOI 10.1016/S0006-8993(96)01302-9; Battaglia F, 2003, J MOL NEUROSCI, V20, P357, DOI 10.1385/JMN:20:3:357; Biswas S, 2004, TRENDS MOL MED, V10, P78, DOI 10.1016/j.molmed.2003.12.007; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; Bushby K M D, 2003, Neuromuscul Disord, V13, P80, DOI 10.1016/S0960-8966(02)00183-9; Bushby KMD, 1999, HUM MOL GENET, V8, P1875, DOI 10.1093/hmg/8.10.1875; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V249, P572, DOI 10.1006/bbrc.1998.9133; Chae J, 2001, NEUROMUSCULAR DISORD, V11, P547, DOI 10.1016/S0960-8966(01)00197-3; CONG JY, 1989, J BIOL CHEM, V264, P10096; CONG JY, 1993, J BIOL CHEM, V268, P25740; de Paula F, 2002, EUR J HUM GENET, V10, P825, DOI 10.1038/sj.ejhg.5200888; Fanin M, 2004, HUM MUTAT, V24, P52, DOI 10.1002/humu.20058; FANIN M, 1995, NEUROMUSCULAR DISORD, V5, P71; Fardeau M, 1996, NEUROMUSCULAR DISORD, V6, P447, DOI 10.1016/S0960-8966(96)00387-2; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; Garvey SM, 2002, GENOMICS, V79, P146, DOI 10.1006/geno.2002.6685; Gil-Parrado S, 2003, J BIOL CHEM, V278, P16336, DOI 10.1074/jbc.M208657200; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Guyon JR, 2003, MUSCLE NERVE, V28, P472, DOI 10.1002/mus.10465; Hackman P, 2002, J NEUROL SCI, V199, pS35; Hackman P, 2002, AM J HUM GENET, V71, P492, DOI 10.1086/342380; Haravuori H, 2001, NEUROLOGY, V56, P869, DOI 10.1212/WNL.56.7.869; Harding DI, 1996, NEUROSCIENCE, V70, P799, DOI 10.1016/S0306-4522(96)83016-8; Horikawa Y, 2000, NAT GENET, V26, P502; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; INOMATA M, 1988, J BIOL CHEM, V263, P19783; Itani SI, 2000, DIABETES, V49, P1353, DOI 10.2337/diabetes.49.8.1353; Johnson JD, 2004, J BIOL CHEM, V279, P24794, DOI 10.1074/jbc.M401216200; Kieran D, 2004, NEUROSCIENCE, V125, P427, DOI 10.1016/j.neuroscience.2004.01.046; Kramerova I, 2004, HUM MOL GENET, V13, P1373, DOI 10.1093/hmg/ddh153; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; Melloni E, 1996, BIOCHEM BIOPH RES CO, V229, P193, DOI 10.1006/bbrc.1996.1779; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; Mundo E, 1997, BIOL PSYCHIAT, V42, P228, DOI 10.1016/S0006-3223(97)00251-5; MURACHI T, 1989, BIOCHEM INT, V18, P263; Nakabayashi H, 2003, APPL IMMUNOHISTO M M, V11, P9, DOI 10.1097/00022744-200303000-00002; Nakagawa K, 2001, J BIOCHEM-TOKYO, V130, P605, DOI 10.1093/oxfordjournals.jbchem.a003025; Nakamura Y, 2000, INVEST OPHTH VIS SCI, V41, P1460; NIXON RA, 1999, CALPAIN PHARM TOXICO, P267; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; ORTHOMELANDER M, 2002, DIABETES, V51, P2658; ORTHOMELENDER M, 2003, DIABETES, V52, P1306; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; Papp Z, 2000, CARDIOVASC RES, V45, P981, DOI 10.1016/S0008-6363(99)00374-0; Passos-Bueno MR, 1999, AM J MED GENET, V82, P392, DOI 10.1002/(SICI)1096-8628(19990219)82:5<392::AID-AJMG7>3.0.CO;2-0; Paul DS, 2003, BIOCHEM J, V376, P625, DOI 10.1042/BJ20030681; Paula F, 2003, AM J HUM GENET, V73, P580; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Perrin C, 2003, Cell Mol Biol (Noisy-le-grand), V49 Online Pub, pOL497; PILUSO G, IN PRESS J MED GENET; Pollitt C, 2001, NEUROMUSCULAR DISORD, V11, P287, DOI 10.1016/S0960-8966(00)00197-8; PONTREMOLI S, 1988, BIOCHEM BIOPH RES CO, V157, P867, DOI 10.1016/S0006-291X(88)80955-0; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Reed NA, 2003, EXP EYE RES, V76, P433, DOI 10.1016/S0014-4835(02)00336-6; Richard I, 1999, AM J HUM GENET, V64, P1524, DOI 10.1086/302426; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SALAMINO F, 1994, BIOCHEM BIOPH RES CO, V199, P1326, DOI 10.1006/bbrc.1994.1376; SALAMINO F, 1992, ARCH BIOCHEM BIOPHYS, V298, P287, DOI 10.1016/0003-9861(92)90125-G; Sandmann S, 2001, BRIT J PHARMACOL, V132, P767, DOI 10.1038/sj.bjp.0703860; Sato Y, 2003, BIOL PHARM BULL, V26, P1765, DOI 10.1248/bpb.26.1765; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearer TR, 2000, METH MOL B, V144, P277; SHEARER TR, 1999, CALPAIN PHARM TOXICO, P331; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Sone H, 2001, TRENDS MOL MED, V7, P320, DOI 10.1016/S1471-4914(01)02041-X; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SORIMACHI H, 2002, STRUCTURAL MOL BASIS, P148; Spencer MJ, 2002, P NATL ACAD SCI USA, V99, P8874, DOI 10.1073/pnas.132269299; Starling A, 2004, EUR J HUM GENET, V12, P1033, DOI 10.1038/sj.ejhg.5201289; Starling A, 2003, J MOL NEUROSCI, V21, P233, DOI 10.1385/JMN:21:3:233; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Tagawa K, 2000, HUM MOL GENET, V9, P1393, DOI 10.1093/hmg/9.9.1393; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Tsuji T, 2001, AM J PHYSIOL-HEART C, V281, pH1286, DOI 10.1152/ajpheart.2001.281.3.H1286; Urtasun M, 1998, BRAIN, V121, P1735, DOI 10.1093/brain/121.9.1735; Vainzof M, 2000, NEUROLOGY, V54, pA436; Vainzof M, 2003, J CLIN PATHOL, V56, P624, DOI 10.1136/jcp.56.8.624; Vainzof M, 2002, BBA-MOL BASIS DIS, V1588, P33, DOI 10.1016/S0925-4439(02)00113-8; Vainzof M, 2001, J MOL NEUROSCI, V17, P71, DOI 10.1385/JMN:17:1:71; Wang K K, 1997, Adv Pharmacol, V37, P117; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054; Yamamoto LU, 2004, NEUROMUSCULAR DISORD, V14, P579; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; ZALEWSKA T, 2004, BIOCHIM BIOPHYS ACTA, V125, P1693; Zatz M, 2003, NEUROMUSCULAR DISORD, V13, P532, DOI 10.1016/S0960-8966(03)00100-7; Zatz M, 2000, CURR OPIN NEUROL, V13, P511, DOI 10.1097/00019052-200010000-00002; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1080, P275; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	121	184	191	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2413	2423		10.1056/NEJMra043361	http://dx.doi.org/10.1056/NEJMra043361			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944426				2022-12-28	WOS:000229638900008
J	Dye, C; Watt, CJ; Bleed, DM; Hosseini, SM; Raviglione, MC				Dye, C; Watt, CJ; Bleed, DM; Hosseini, SM; Raviglione, MC			Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISONIAZID PREVENTIVE THERAPY; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; COST-EFFECTIVENESS; HIV; CHEMOTHERAPY; TRANSMISSION; INFECTION; MORTALITY; EFFICACY	Context The United Nations Millennium Development Goals (MDGs) are stimulating more rigorous evaluations of the impact of DOTS (the WHO-recommended approach to tuberculosis control based on 5 essential elements) and other possible strategies for tuberculosis (TB) control. Objective To evaluate the prospects for detecting 70% of new sputum smear-positive cases and successfully treating 85% of these by the end of 2005, for reducing TB incidence, and for halving TB prevalence and deaths globally between 1990 and 2015, as specified by the MDGs. Data Sources TB case notifications (1980-2003) from DOTS and non-DOTS programs and cohort treatment outcomes (1994-2002) reported annually to the World Health Organization (WHO) by up to 200 countries, TB death registrations, and prevalence surveys of infection and disease. Study Selection Case notification series that reflect trends in incidence, treatment outcomes from DOTS cohorts, death statistics from countries with WHO-validated vital registration systems, and national prevalence surveys of infection and disease. Data Extraction Case reports, treatment outcomes, prevalence surveys - and death registrations from WHO's global TB database covering 1990-2003 to estimate TB incidence, prevalence, and death rates through 2015 for 9 epidemiologically different world regions. Data Synthesis TB incidence increased globally in 2003, but incidence, prevalence, and death rates were approximately stable or decreased in 7 of 9 regions. The exceptions were regions of Africa with low (<4% in adults 15-49 years) and high rates (>= 4%) of HIV infection. The global detection rate of new smear-positive cases by DOTS programs increased from 11% in 1995 to 45% in 2003 (with the lowest case-detection rates in Eastern Europe and the highest rates in the Western Pacific) and could reach 60% by 2005. More than 17 million patients were treated in DOTS programs between 1994 and 2003, with overall treatment success rates more than 80% since 1998. In 2003, overall reported treatment success was 82%, with much variation among regions. The highest rates were reported in the Western Pacific region (89%) and lowest rates in African countries with high and low HIV infection rates (71% and 74%, respectively), in established market economies (77%), and in Eastern Europe (75%). To halve the prevalence rate by 2015, TB control programs must reach global targets for detection (70%) and treatment success (85%) and also reduce the incidence rate by at least 2% annually. To halve the death rate, incidence must decrease more steeply, by at least 5% to 6% annually. Conclusion Reduction of TB incidence, prevalence, and deaths by 2015 could be achieved in most of the world, but the challenge will be greatest in Africa and Eastern Europe.	WHO, Stop TB Dept, CH-1211 Geneva, Switzerland	World Health Organization	Dye, C (corresponding author), WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.	dyec@who.int	Dye, Christopher/AIC-4659-2022	RAVIGLIONE, Mario/0000-0002-9331-2067; Dye, Christopher/0000-0002-2957-1793				AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; [Anonymous], 1999, EPIDEMIOLOGIC BASIS; BARNUM HN, 1986, SOC SCI MED, V23, P847, DOI 10.1016/0277-9536(86)90212-1; Barry C, 2001, TUBERCULOSIS, V81, P1, DOI 10.1054/tube.2001.0288; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Borgdorff MW, 2004, EMERG INFECT DIS, V10, P1523, DOI 10.3201/eid1009.040349; Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217; Chen XY, 2004, LANCET, V364, P417; Churchyard GJ, 2003, AIDS, V17, P2063, DOI 10.1097/00002030-200309260-00007; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Corbett EL, 2004, AM J RESP CRIT CARE, V170, P673, DOI 10.1164/rccm.200405-590OC; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; DYE C, IN PRESS DIS CONTROL; DYE C, 2003, CLIN TUBERCULOSIS; Elzinga G, 2004, LANCET, V363, P814, DOI 10.1016/S0140-6736(04)15698-5; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Frieden T, 2004, TOMANS TUBERCULOSIS; Harries AD, 2001, INT J TUBERC LUNG D, V5, P1109; IRAWATI SR, 2004, INT J TUBERC LUNG S1, V11, pS98; Jamison D.T., 1993, DIS CONTROL PRIORITI; Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009; Kim SJ, 1995, TUBERCLE LUNG DIS, V76, P534, DOI 10.1016/0962-8479(95)90530-8; Lietman T, 2000, CLIN INFECT DIS, V30, pS316, DOI 10.1086/313881; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011; Radhakrishna S, 2001, INT J TUBERC LUNG D, V5, P142; Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213; STOP TB, M 2 AD HOC COMM TB E; Styblo K, 1991, TUBERCULOSIS CAN BE, V2, P60; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; UN Millennium Project 2005, 2005, INV STRAT REV GLOB I; *UN STAT DIV, MILL IND DAT; Volmink J, 1997, BMJ-BRIT MED J, V315, P1403, DOI 10.1136/bmj.315.7120.1403; VOLMINK J, 2003, COCHRANE DATABASE SY; *WHO, 2004, INT POL COLL TB HIV; *WHO, 2005, WHOHTMTB2005349; *WHO, STOP TB DEP TUB; *WHO, 2000, 53 WORLD HLTH ASS ST; *WHO, 2004, 3 WHO; Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2002, WHOCDSTB2002297; World Health Organization, 1991, WHA441991REC1 WHO; World Hlth Org, 2002, INT J TUBERC LUNG D, V6, P378; Zachariah R, 2003, INT J TUBERC LUNG D, V7, P1033; FIND DIAGNOSTICS	51	362	378	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2767	2775		10.1001/jama.293.22.2767	http://dx.doi.org/10.1001/jama.293.22.2767			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941807				2022-12-28	WOS:000229643700026
J	Khan, SM; Franke-Fayard, B; Mair, GR; Lasonder, E; Janse, CJ; Mann, M; Waters, AP				Khan, SM; Franke-Fayard, B; Mair, GR; Lasonder, E; Janse, CJ; Mann, M; Waters, AP			Proteome analysis of separated male and female gametocytes reveals novel sex-specific Plasmodium biology	CELL			English	Article							HUMAN MALARIA PARASITE; GENE-EXPRESSION; FLOW-CYTOMETRY; DNA-SYNTHESIS; FALCIPARUM; KINASE; BERGHEI; IDENTIFICATION; TRANSMISSION; PURIFICATION	Gametocytes, the precursor cells of malaria-parasite gametes, circulate in the blood and are responsible for transmission from host to mosquito vector. The individual proteomes of male and female gametocytes were analyzed using mass spectrometry, following separation by flow sorting of transgenic parasites expressing green fluorescent protein, in a sex-specific manner. Promoter tagging in transgenic parasites confirmed the designation of stage and sex specificity of the proteins. The male proteome contained 36% (236 of 650) male-specific and the female proteome 19% (101 of 541) female-specific proteins, but they share only 69 proteins, emphasizing the diverged features of the sexes. Of all the malaria life-cycle stages analyzed, the male gametocyte has the most distinct proteome, containing many proteins involved in flagellar-based motility and rapid genome replication. By identification of gender-specific protein kinases and phosphatases and using targeted gene disruption of two kinases, new sex-specific regulatory pathways were defined.	Leiden Univ, Ctr Med, Dept Parasitol, Leiden, Netherlands; Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, Odense, Denmark; Univ Nijmegen, Dept Mol Biol, NCMLS 191, Nijmegen, Netherlands	Leiden University; Leiden University - Excl LUMC; University of Southern Denmark; Radboud University Nijmegen	Mann, M (corresponding author), Leiden Univ, Ctr Med, Dept Parasitol, Leiden, Netherlands.	mann@bmb.sdu.dk; waters@lumc.nl	Mann, Matthias/A-3454-2013; Waters, Andy P/C-9377-2009	Mann, Matthias/0000-0003-1292-4799; Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205; , Blandine/0000-0001-6041-4182; Mair, Gunnar/0000-0002-5187-3691; Lasonder, Edwin/0000-0003-2582-3444; Khan, Shahid/0000-0002-0533-4670	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anamika, 2005, PROTEINS, V58, P180, DOI 10.1002/prot.20278; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Beetsma AL, 1998, EXP PARASITOL, V88, P69, DOI 10.1006/expr.1998.4203; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Billker O, 1997, PARASITOLOGY, V115, P1, DOI 10.1017/S0031182097008895; Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; CREASEY A, 1994, MOL BIOCHEM PARASIT, V65, P95, DOI 10.1016/0166-6851(94)90118-X; Doerig CM, 1996, GENE, V177, P1, DOI 10.1016/0378-1119(96)00281-8; Dorin D, 2005, MOL MICROBIOL, V55, P184, DOI 10.1111/j.1365-2958.2004.04393.x; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; Dorin D, 2001, EUR J BIOCHEM, V268, P2600, DOI 10.1046/j.1432-1327.2001.02151.x; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Hayward RE, 2000, MOL MICROBIOL, V35, P6, DOI 10.1046/j.1365-2958.2000.01730.x; Hopkins J, 1999, PROTIST, V150, P283, DOI 10.1016/S1434-4610(99)70030-1; Horrocks P, 1998, MOL BIOCHEM PARASIT, V95, P171, DOI 10.1016/S0166-6851(98)00110-8; Inaba K, 2003, ZOOL SCI, V20, P1043, DOI 10.2108/zsj.20.1043; JANSE CJ, 1994, METHOD CELL BIOL, V42, P295; JANSE CJ, 1987, EXP PARASITOL, V64, P88, DOI 10.1016/0014-4894(87)90012-9; Janse CJ, 2004, MALARIA PARASITES: GENOMES AND MOLECULAR BIOLOGY, P445; JANSE CJ, 1986, T ROY SOC TROP MED H, V80, P154, DOI 10.1016/0035-9203(86)90219-1; JANSE CJ, 1985, PARASITOLOGY, V91, P19, DOI 10.1017/S0031182000056481; JANSE CJ, 1989, EXP PARASITOL, V68, P274, DOI 10.1016/0014-4894(89)90109-4; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2; Kaslow DC, 1997, INT J PARASITOL, V27, P183, DOI 10.1016/S0020-7519(96)00148-8; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; Mallik R, 2004, CURR BIOL, V14, pR971, DOI 10.1016/j.cub.2004.10.046; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; RAWLINGS DJ, 1992, MOL BIOCHEM PARASIT, V56, P239, DOI 10.1016/0166-6851(92)90173-H; Sinden RE, 2004, MALARIA PARASITES: GENOMES AND MOLECULAR BIOLOGY, P475; SINDEN RE, 1991, ACT LEIDENS, V60, P19; VAIDYA AB, 1993, MOL CELL BIOL, V13, P7349, DOI 10.1128/MCB.13.12.7349; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; van Spaendonk RML, 2001, J BIOL CHEM, V276, P22638, DOI 10.1074/jbc.M101234200; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Williamson KC, 1995, MOL BIOCHEM PARASIT, V75, P33, DOI 10.1016/0166-6851(95)02507-3	44	274	286	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					675	687		10.1016/j.cell.2005.03.027	http://dx.doi.org/10.1016/j.cell.2005.03.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935755	Bronze			2022-12-28	WOS:000229658000007
J	Lambert, S; Watson, A; Sheedy, DM; Martin, B; Carr, AM				Lambert, S; Watson, A; Sheedy, DM; Martin, B; Carr, AM			Gross chromosomal rearrangements and elevated recombination at an inducible site-specific replication fork barrier	CELL			English	Article							DNA-REPLICATION; RIBOSOMAL DNA; FISSION YEAST; S-PHASE; ESCHERICHIA-COLI; FRAGILE SITE; MATING-TYPE; SACCHAROMYCES-CEREVISIAE; CHECKPOINT RESPONSE; DELAYED REPLICATION	Genomic rearrangements linked to aberrant recombination are associated with cancer and human genetic diseases. Such recombination has indirectly been linked to replication fork stalling. Using fission yeast, we have developed a genetic system to block replication forks at nonhistone/DNA complexes located at a specific euchromatic site. We demonstrate that stalled replication forks lead to elevated intrachromosomal and ectopic recombination promoting site-specific gross chromosomal rearrangements. We show that recombination is required to promote cell viability when forks are stalled, that recombination proteins associate with sites of fork stalling, and that recombination participates in deleterious site-specific chromosomal rearrangements. Thus, recombination is a "double-edged sword," preventing cell death when the replisome disassembles at the expense of genetic stability.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Carr, AM (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	a.m.carr@sussex.ac.uk	; lambert, sarah/K-7750-2017	Watson, Adam/0000-0002-8140-8205; Carr, Antony Michael/0000-0002-2028-2389; lambert, sarah/0000-0002-1403-3204	MRC [G0001129] Funding Source: UKRI; Medical Research Council [G0001129] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Arcangioli B, 2000, EMBO REP, V1, P145, DOI 10.1093/embo-reports/kvd023; Arcangioli B, 2000, EMBO J, V19, P1389, DOI 10.1093/emboj/19.6.1389; ARIT MF, 2003, GENOME RES, V100, P92; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; Burkhalter MD, 2004, MOL CELL, V15, P409, DOI 10.1016/j.molcel.2004.06.024; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Codlin S, 2003, EMBO J, V22, P3431, DOI 10.1093/emboj/cdg330; Courcelle J, 2003, ANNU REV GENET, V37, P611, DOI 10.1146/annurev.genet.37.110801.142616; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; Dalgaard JZ, 2001, GENE DEV, V15, P2060, DOI 10.1101/gad.200801; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Doe CL, 2004, NUCLEIC ACIDS RES, V32, P5570, DOI 10.1093/nar/gkh853; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GAME JC, 1973, MUTAT RES, V20, P35, DOI 10.1016/0027-5107(73)90095-X; GLOVER TW, 1988, AM J HUM GENET, V43, P265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gruber M, 2000, MOL CELL BIOL, V20, P5777, DOI 10.1128/MCB.20.15.5777-5787.2000; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; Hartsuiker E, 2001, EMBO J, V20, P6660, DOI 10.1093/emboj/20.23.6660; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; Ivessa AS, 2003, MOL CELL, V12, P1525, DOI 10.1016/S1097-2765(03)00456-8; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kearsey SE, 2000, EMBO J, V19, P1681, DOI 10.1093/emboj/19.7.1681; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Krings G, 2004, P NATL ACAD SCI USA, V101, P14085, DOI 10.1073/pnas.0406037101; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; Lee BS, 2004, MOL CELL BIOL, V24, P9813, DOI 10.1128/MCB.24.22.9813-9822.2004; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Meister P, 2003, NUCLEIC ACIDS RES, V31, P5064, DOI 10.1093/nar/gkg719; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Muriana PM, 1996, J FOOD PROTECT, P54, DOI 10.4315/0362-028X-59.13.54; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Rothstein R, 2000, GENE DEV, V14, P1; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; Shaw CJ, 2004, HUM MOL GENET, V13, pR57, DOI 10.1093/hmg/ddh073; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Straube A, 2004, EUR J NEUROL, V11, P83, DOI 10.1046/j.1468-1331.2003.00754.x; STYRKARSDOTTIR U, 1993, CURR GENET, V23, P184, DOI 10.1007/BF00352020; Subramanian PS, 1996, AM J HUM GENET, V59, P407; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Verkade HM, 1999, MOL BIOL CELL, V10, P2905, DOI 10.1091/mbc.10.9.2905; Virgin JB, 2001, GENETICS, V157, P63; Ward TR, 2000, MOL CELL BIOL, V20, P4948, DOI 10.1128/MCB.20.13.4948-4957.2000; Warren ST, 1996, SCIENCE, V271, P1374, DOI 10.1126/science.271.5254.1374; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	66	209	211	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					689	702		10.1016/j.cell.2005.03.022	http://dx.doi.org/10.1016/j.cell.2005.03.022			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935756	Bronze			2022-12-28	WOS:000229658000008
J	Sullivan, CS; Grundhoff, AT; Tevethia, S; Pipas, JM; Ganem, D				Sullivan, CS; Grundhoff, AT; Tevethia, S; Pipas, JM; Ganem, D			SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells	NATURE			English	Article							INTERFERING RNAS; MESSENGER-RNA; VIRUS; ANTIGEN; SV40	MicroRNAs ( miRNAs) are small (similar to 22-nucleotide) RNAs that in lower organisms serve important regulatory roles in development and gene expression, typically by forming imperfect duplexes with target messenger RNAs1. miRNAs have also been described in mammalian cells and in infections with Epstein - Barr virus (EBV), but the function of most of them is unknown. Although one EBV miRNA probably altered the processing of a viral mRNA(2), the regulatory significance of this event is uncertain, because other transcripts exist that can supply the targeted function(3). Here we report the identification of miRNAs encoded by simian virus 40 (SV40) and define their functional significance for viral infection. SVmiRNAs accumulate at late times in infection, are perfectly complementary to early viral mRNAs, and target those mRNAs for cleavage. This reduces the expression of viral T antigens but does not reduce the yield of infectious virus relative to that generated by a mutant lacking SVmiRNAs. However, wild-type SV40-infected cells are less sensitive than the mutant to lysis by cytotoxic T cells, and trigger less cytokine production by such cells. Thus, viral evolution has taken advantage of the miRNA pathway to generate effectors that enhance the probability of successful infection.	Univ Calif San Francisco, George Williams Hooper Fdn, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, George Williams Hooper Fdn, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, George Williams Hooper Fdn, Dept Med, San Francisco, CA 94143 USA; Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ganem, D (corresponding author), Univ Calif San Francisco, George Williams Hooper Fdn, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	ganem@cgl.ucsf.edu		Grundhoff, Adam/0000-0003-0940-7045	NCI NIH HHS [R01 CA073506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALWINE JC, 1980, J VIROL, V36, P701, DOI 10.1128/JVI.36.3.701-708.1980; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; BATES MP, 1988, VIROLOGY, V162, P197, DOI 10.1016/0042-6822(88)90409-6; FURNARI FB, 1993, P NATL ACAD SCI USA, V90, P378, DOI 10.1073/pnas.90.2.378; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Mylin LM, 2000, J VIROL, V74, P6922, DOI 10.1128/JVI.74.15.6922-6934.2000; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Tremblay JD, 2001, METH MOL B, V165, P1; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	14	493	560	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					682	686		10.1038/nature03576	http://dx.doi.org/10.1038/nature03576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931223				2022-12-28	WOS:000229476200052
J	El Gabaly, F; Ling, WLW; McCarty, KF; de la Figuera, J				El Gabaly, F; Ling, WLW; McCarty, KF; de la Figuera, J			The importance of threading dislocations on the motion of domain boundaries in thin films	SCIENCE			English	Article							EMBEDDED-ATOM-METHOD; CU FILMS; METAL; SURFACES; RU(0001); MICROSCOPY; CRYSTAL; EPITAXY; GROWTH; COPPER	Thin films often present domain structures whose detailed evolution is a subject of debate. We analyze the evolution of copper films, which contain both rotational and stacking domains, on ruthenium. Real-time observation by low-energy electron microscopy shows that the stacking domains evolve in a seemingly complex way. Not only do the stacking boundaries move in preferred directions, but their motion is extremely uneven and they become stuck when they reach rotational boundaries. We show that this behavior occurs because the stacking-boundary motion is impeded by threading dislocations. This study underscores how the coarse-scale evolution of thin films can be controlled by defects.	Univ Autonoma Madrid, Dept Fis Mat Condensada, E-28049 Madrid, Spain; Sandia Natl Labs, Livermore, CA 94550 USA	Autonomous University of Madrid; United States Department of Energy (DOE); Sandia National Laboratories	de la Figuera, J (corresponding author), Univ Autonoma Madrid, Dept Fis Mat Condensada, E-28049 Madrid, Spain.	juan.delafiguera@uam.es	McCarty, Kevin/F-9368-2012; Ling, Wai Li W/F-9823-2012; de la Figuera, Juan/E-7046-2010	McCarty, Kevin/0000-0002-8601-079X; Ling, Wai Li W/0000-0002-4264-5750; de la Figuera, Juan/0000-0002-7014-4777				ALERHAND OL, 1988, PHYS REV LETT, V61, P1973, DOI 10.1103/PhysRevLett.61.1973; Ammer C, 1997, SURF SCI, V375, P302, DOI 10.1016/S0039-6028(97)01288-0; BAUER E, 1994, REP PROG PHYS, V57, P895, DOI 10.1088/0034-4885/57/9/002; BAUER E, 1982, APPL SURF SC, V11-2, P479, DOI 10.1016/0378-5963(82)90094-0; Busse C, 2004, SURF SCI, V552, P281, DOI 10.1016/j.susc.2004.01.031; CARTER CB, 1995, PHYS REV B, V51, P4730, DOI 10.1103/PhysRevB.51.4730; Cochrane W, 1936, P PHYS SOC, V48, P723, DOI 10.1088/0959-5309/48/5/305; DAW MS, 1993, MATER SCI REP, V9, P251, DOI 10.1016/0920-2307(93)90001-U; de la Figuera J, 2003, MATER SCI FORUM, V426-4, P3421, DOI 10.4028/www.scientific.net/MSF.426-432.3421; de la Figuera J, 2001, PHYS REV LETT, V86, P3819, DOI 10.1103/PhysRevLett.86.3819; de la Figuera J, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.165431; de la Figuera J, 1999, SURF SCI, V433, P93, DOI 10.1016/S0039-6028(99)00060-6; de la Fuente OR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevB.88.036101; El Gabaly F, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.012102; FOILES SM, 1986, PHYS REV B, V33, P7983, DOI 10.1103/PhysRevB.33.7983; GIESSEL T, 1999, 18 EUR C SURF SCI VI; GUNTHER C, 1995, PHYS REV LETT, V74, P754, DOI 10.1103/PhysRevLett.74.754; Hirth IP, 1992, THEORY DISLOCATIONS; Hrbek J, 1999, J PHYS CHEM B, V103, P10557, DOI 10.1021/jp992564z; Hwang RQ, 1997, CHEM REV, V97, P1063, DOI 10.1021/cr960070h; Phillips R., 2001, CRYSTALS DEFECTS MIC; Zajonz H, 2000, PHYS REV B, V62, P10436, DOI 10.1103/PhysRevB.62.10436; Zajonz H, 2000, SURF SCI, V447, pL141, DOI 10.1016/S0039-6028(99)01222-4; Zhou SJ, 1998, SCIENCE, V279, P1525, DOI 10.1126/science.279.5356.1525	24	12	12	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1303	1305		10.1126/science.1109889	http://dx.doi.org/10.1126/science.1109889			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919991				2022-12-28	WOS:000229482300045
J	Mazzali, PA; Kawabata, KS; Maeda, K; Nomoto, K; Filippenko, AV; Ramirez-Ruiz, E; Benetti, S; Pian, E; Deng, JS; Tominaga, N; Ohyama, Y; Iye, M; Foley, RJ; Matheson, T; Wang, LF; Gal-Yam, A				Mazzali, PA; Kawabata, KS; Maeda, K; Nomoto, K; Filippenko, AV; Ramirez-Ruiz, E; Benetti, S; Pian, E; Deng, JS; Tominaga, N; Ohyama, Y; Iye, M; Foley, RJ; Matheson, T; Wang, LF; Gal-Yam, A			An asymmetric energetic type Ic supernova viewed off-axis, and a link to gamma ray bursts	SCIENCE			English	Article							SN; SPECTROSCOPY; EXPLOSIONS; PHOTOMETRY; SPECTRA; 2003DH	Type Ic supernovae, the explosions after the core collapse of massive stars that have previously lost their hydrogen and helium envelopes, are particularly interesting because of their link with long-duration gamma ray bursts. Although indications exist that these explosions are aspherical, direct evidence has been missing. Late-time observations of supernova SN 2003jd, a luminous type Ic supernova, provide such evidence. Recent Subaru and Keck spectra reveal double-peaked profiles in the nebular lines of neutral oxygen and magnesium. These profiles are different from those of known type Ic supernovae, with or without a gamma ray burst, and they can be understood if SN 2003jd was an aspherical axisymmetric explosion viewed from near the equatorial plane. If SN 2003jd was associated with a gamma ray burst, we missed the burst because it was pointing away from us.	Univ Tokyo, Sch Sci, Dept Astron, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Sch Sci, Res Ctr Early Universe, Bunkyo Ku, Tokyo 1130033, Japan; Max Planck Inst Astrophys, D-85748 Garching, Germany; Osserv Astron Trieste, INAF, I-34131 Trieste, Italy; Hiroshima Univ, Hiroshima Astrophys Sci Ctr, Hiroshima 7398526, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Earth Sci & Astron, Meguro Ku, Tokyo 1538902, Japan; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Inst Adv Study, Princeton, NJ 08540 USA; Osserv Astron Padova, INAF, I-35122 Padua, Italy; Chinese Acad Sci, Natl Astron Observ, Beijing 100012, Peoples R China; Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Dept Infrared Astrophys, Kanagawa 2298510, Japan; Natl Astron Observ Japan, Subaru Telescope, Hilo, HI 96720 USA; Natl Astron Observ, Opt & Infrared Astron Div, Tokyo 1818588, Japan; Grad Univ Adv Studies, Sch Phys Sci, Dept Astron Sci, Tokyo 1818588, Japan; Natl Opt Astron Observ, Tucson, AZ 85719 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; CALTECH, Dept Astron, Pasadena, CA 91125 USA	University of Tokyo; University of Tokyo; Max Planck Society; Istituto Nazionale Astrofisica (INAF); Hiroshima University; University of Tokyo; University of California System; University of California Berkeley; Institute for Advanced Study - USA; Istituto Nazionale Astrofisica (INAF); University of Padua; Chinese Academy of Sciences; National Astronomical Observatory, CAS; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Graduate University for Advanced Studies - Japan; National Optical Astronomy Observatory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; California Institute of Technology	Mazzali, PA (corresponding author), Univ Tokyo, Sch Sci, Dept Astron, Bunkyo Ku, Tokyo 1130033, Japan.	mazzali@ts.astro.it; nomoto@astron.s.u-tokyo.ac.jp	Kawabata, Koji S/G-1957-2017; 大山陽一, Youichi Ohyama/ABA-5890-2020	Kawabata, Koji S/0000-0001-6099-9539; 大山陽一, Youichi Ohyama/0000-0001-9490-3582; Tominaga, Nozomu/0000-0001-8537-3153; Maeda, Keiichi/0000-0003-2611-7269; Mazzali, Paolo/0000-0001-6876-8284; Pian, Elena/0000-0001-8646-4858; Benetti, Stefano/0000-0002-3256-0016; Foley, Ryan/0000-0002-2445-5275; Matheson, Thomas/0000-0001-6685-0479				BENETTI S, UNPUB; BURKET J, 2003, 8232 INT ASTR UN; Deng J, 2005, ASTROPHYS J, V624, P898, DOI 10.1086/429284; FILIPPENKO AV, 1995, ASTROPHYS J, V450, pL11, DOI 10.1086/309659; Foley RJ, 2003, PUBL ASTRON SOC PAC, V115, P1220, DOI 10.1086/378242; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; Granot J, 2004, ASTROPHYS J, V609, pL9, DOI 10.1086/422516; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; HURLEY K, 2003, 2439 GRB COORD NETW; Iwamoto K, 1998, NATURE, V395, P672, DOI 10.1038/27155; Kashikawa N, 2002, PUBL ASTRON SOC JPN, V54, P819, DOI 10.1093/pasj/54.6.819; KAWABATA K, 2004, 8410 INT ASTR UN; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; Maeda K, 2002, ASTROPHYS J, V565, P405, DOI 10.1086/324487; Malesani D, 2004, ASTROPHYS J, V609, pL5, DOI 10.1086/422684; Matheson T, 2003, ASTROPHYS J, V599, P394, DOI 10.1086/379228; Matheson T, 2001, ASTRON J, V121, P1648, DOI 10.1086/319390; Mazzali P. A., 2002, APJ, V572, P61; Mazzali PA, 2003, ASTROPHYS J, V599, pL95, DOI 10.1086/381259; Mazzali PA, 2001, ASTROPHYS J, V559, P1047, DOI 10.1086/322420; Nomoto K, 2004, ASTROPHYS SPACE SC L, V302, P277; NOMOTO K, 1994, NATURE, V371, P227, DOI 10.1038/371227a0; OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562; Patat F, 2001, ASTROPHYS J, V555, P900, DOI 10.1086/321526; Ramirez-Ruiz E, 2004, ASTROPHYS J, V608, pL89, DOI 10.1086/422388; RAMIREZRUIZ E, IN PRESS; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; SODERBERG AM, 2003, 2435 GRB COORD NETW; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; WATSON D, 2003, 2445 GRB COORD NETW	30	168	168	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1284	1287		10.1126/science.1111384	http://dx.doi.org/10.1126/science.1111384			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919986	Green Accepted, Green Submitted			2022-12-28	WOS:000229482300039
J	Krasnoshchekov, DN; Kaazik, PB; Ovtchinnikov, VM				Krasnoshchekov, DN; Kaazik, PB; Ovtchinnikov, VM			Seismological evidence for mosaic structure of the surface of the Earth's inner core	NATURE			English	Article							TRAVEL-TIMES; CONSTRAINTS; DENSITY; PKIKP; BOUNDARY	The transition from the Earth's solid inner core to liquid outer core is the location where the inner core grows(1) and from which compositional convection in the outer core originates(2,3). Most seismological models of the Earth describe the inner-core boundary as sharp(4,5) and simple(6,7,8), although experimental data requiring the presence of a thin transition layer at the bottom of the outer core have been reported(9). The density jump at the inner-core boundary - an important parameter determining gravitational energy release(10) and constraining the compositional difference between the inner and outer core - is also not well known. Estimates of this density jump obtained using free-oscillation eigenfrequencies give low values(11-13) of 0.25-1.0 g cm(-3), whereas a method using the amplitude ratio of core-reflected phases yielded values of 0.6 - 1.8 g cm(-3) ( refs 14 - 17). Here we analyse properties of waves precritically reflected from the Earth's inner core (PKiKP phases) that show significant variability in amplitude, consistent high-frequency content and stable travel times with respect to a standard Earth model(4). We infer that the data are best explained by a mosaic structure of the inner core's surface. Such a mosaic may be composed of patches in which the transition from solid inner to liquid outer core includes a thin partially liquid layer interspersed with patches containing a sharp transition.	Russian Acad Sci, Inst Dynam Geospheres, Moscow 119334, Russia	Russian Academy of Sciences; Sadovsky Institute of Geosphere Dynamics of the Russian Academy of Sciences	Krasnoshchekov, DN (corresponding author), Russian Acad Sci, Inst Dynam Geospheres, Leninsky Pr 38,Korp 1, Moscow 119334, Russia.	krasnd@idg.chph.ras.ru	Ovtchinnikov, Vladimir/S-7263-2016; Krasnoshchekov, Dmitry/D-5049-2018; Ovtchinnikov, Vladimir/N-4614-2019	Ovtchinnikov, Vladimir/0000-0002-1886-2472				ADUSHKIN V, 1997, DOKL RUSS ACAD SCI E, V334, P595; Adushkin VV, 2004, DOKL EARTH SCI, V397A, P883; BOLT BA, 1970, NATURE, V228, P148, DOI 10.1038/228148a0; BUCHBINDER GG, 1973, B SEISMOL SOC AM, V63, P1699; Buffett BA, 1997, NATURE, V388, P571, DOI 10.1038/41534; Cao AM, 2004, GEOPHYS J INT, V157, P1146, DOI [10.1111/j.1365-246X.2004.02330.x, 10.1111/j.1365-246X.2004.02330.X]; CUMMINS P, 1988, GEOPHYS J INT, V94, P21; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; ENGDAHL ER, 1974, GEOPHYS J ROY ASTR S, V39, P457, DOI 10.1111/j.1365-246X.1974.tb05467.x; GILBERT F, 1975, PHILOS T R SOC A, V278, P187, DOI 10.1098/rsta.1975.0025; GUBBINS D, 1979, GEOPHYS J ROY ASTR S, V59, P57, DOI 10.1111/j.1365-246X.1979.tb02553.x; JACOBS JA, 1953, NATURE, V172, P297, DOI 10.1038/172297a0; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; Koper KD, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002750; Koper KD, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001995; MASTERS G, 1979, GEOPHYS J ROY ASTR S, V57, P507, DOI 10.1111/j.1365-246X.1979.tb04791.x; Masters G, 2003, PHYS EARTH PLANET IN, V140, P159, DOI 10.1016/j.pepi.2003.07.008; MCFADDEN PL, 1986, GEOPHYSICS, V51, P1879, DOI 10.1190/1.1442045; MCFADDEN PL, 1986, PHYS EARTH PLANET IN, V43, P22, DOI 10.1016/0031-9201(86)90118-4; MOFFATT HK, 1994, GEOPHYS J INT, V117, P394, DOI 10.1111/j.1365-246X.1994.tb03939.x; MULLER G, 1973, B SEISMOL SOC AM, V63, P847; Poupinet G, 2004, PHYS EARTH PLANET IN, V146, P497, DOI 10.1016/j.pepi.2004.05.003; RICHARDS PG, 1973, GEOPHYS J ROY ASTR S, V35, P243, DOI 10.1111/j.1365-246X.1973.tb02426.x; Schimmel M, 1997, GEOPHYS J INT, V130, P497, DOI 10.1111/j.1365-246X.1997.tb05664.x; SHEARER P, 1990, GEOPHYS J INT, V102, P491, DOI 10.1111/j.1365-246X.1990.tb04481.x; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9817, DOI 10.1029/94JB03135; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; SOURIAU A, 1989, GEOPHYS J INT, V98, P39, DOI 10.1111/j.1365-246X.1989.tb05512.x; Tibuleac IM, 2003, GEOPHYS J INT, V155, P1, DOI 10.1046/j.1365-246X.2003.01969.x	30	64	66	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					483	487		10.1038/nature03613	http://dx.doi.org/10.1038/nature03613			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917806				2022-12-28	WOS:000229337800052
J	Osterholm, MT				Osterholm, MT			A weapon the world needs	NATURE			English	Editorial Material									Univ Minnesota, Acad Hlth Ctr, Ctr Infect Dis Res & Policy, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Osterholm, MT (corresponding author), Univ Minnesota, Acad Hlth Ctr, Ctr Infect Dis Res & Policy, 420 Delaware St SE,MMC 263, Minneapolis, MN 55455 USA.							Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068	1	7	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					417	418		10.1038/435417a	http://dx.doi.org/10.1038/435417a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917778	Green Published			2022-12-28	WOS:000229337800024
J	Barlow, J; Stewart-Brown, S				Barlow, J; Stewart-Brown, S			Child abuse and neglect	LANCET			English	Editorial Material							RANDOMIZED TRIAL; HOME VISITATION		Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England	University of Warwick	Barlow, J (corresponding author), Univ Warwick, Warwick Med Sch, Med Sch Bldg, Coventry CV4 7AL, W Midlands, England.	Jane.Barlow@warwick.ac.uk	Barlow, Jane/O-7727-2016	Barlow, Jane/0000-0001-8418-4270				Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; CAWSON P, 2001, CHILD MALTREATMENT U; DAVIS H, 1997, CLIN CHILD PSYCHOL P, V2, P221; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Pianta R., 1989, CHILD MALTREATMENT T, P203; Roberts I, 1996, BRIT MED J, V312, P29, DOI 10.1136/bmj.312.7022.29	7	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1750	1752		10.1016/S0140-6736(05)66389-1	http://dx.doi.org/10.1016/S0140-6736(05)66389-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	928SI	15910937				2022-12-28	WOS:000229291600006
J	Liou, GG; Tanny, JC; Kruger, RG; Walz, T; Moazed, D				Liou, GG; Tanny, JC; Kruger, RG; Walz, T; Moazed, D			Assembly of the SIR complex and its regulation by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation	CELL			English	Article							SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; PROTEIN SIR2; SIR2/SIR4 COMPLEX; MOLECULAR-MODEL; N-TERMINUS; YEAST; CHROMATIN; GENE	Assembly of silent chromatin domains in budding yeast involves the deacetylation of histone tails by Sir2 and the association of the Sir3 and Sir4 proteins with hypoacetylated histone tails. Sir2 couples deacetylation to NAD hydrolysis and the synthesis of a metabolite, O-acetyl-ADP-ribose (AAR), but the functional significance of NAD hydrolysis or AAR, if any, is unknown. Here we examine the association of the Sir2, Sir3, and Sir4 proteins with each other and histone tails. Our analysis reveals that deacetylation of histone H4-lysine 16 (K16), which is critical for silencing in vivo, is also critical for the binding of Sir3 and Sir4 to histone H4 peptides in vitro. Moreover, AAR itself promotes the association of multiple copies of Sir3 with Sir2/Sir4 and induces a dramatic structural rearrangement in the SIR complex. These results suggest that Sir2 activity modulates the assembly of the SIR complex through both histone deacetylation and AAR synthesis.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Mol Pharmacol & Biochem, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Moazed, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	danesh@hms.harvard.edu	Tanny, Jason/AAD-3624-2022; Liou, Gan-Guang/E-3976-2010; Liou, Gunn‐Guang/AAI-9787-2020	Walz, Thomas/0000-0003-2606-2835				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Chang JF, 2003, STRUCTURE, V11, P637, DOI 10.1016/S0969-2126(03)00093-5; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Enomoto S, 2000, GENETICS, V155, P523; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Ghidelli S, 2001, EMBO J, V20, P4522, DOI 10.1093/emboj/20.16.4522; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Grienenberger A, 2002, CURR BIOL, V12, P762, DOI 10.1016/S0960-9822(02)00814-X; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 2000, GENE DEV, V14, P1021; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; KLAR AJS, 1979, GENETICS, V93, P37; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Neuwald AF, 1999, GENOME RES, V9, P27; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RINE J, 1987, GENETICS, V116, P9; RUDNER AD, 2005, IN PRESS MOL CELL BI; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rusche LN, 2002, MOL BIOL CELL, V13, P2207, DOI 10.1091/mbc.E02-03-0175; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Straube A, 2004, EUR J NEUROL, V11, P83, DOI 10.1046/j.1468-1331.2003.00754.x; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 2004, MOL CELL BIOL, V24, P6931, DOI 10.1128/MCB.24.16.6931-6946.2004; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016	57	208	213	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					515	527		10.1016/j.cell.2005.03.035	http://dx.doi.org/10.1016/j.cell.2005.03.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907466	Bronze			2022-12-28	WOS:000229331200009
J	Merrifield, CJ; Perrais, D; Zenisek, D				Merrifield, CJ; Perrais, D; Zenisek, D			Coupling between clathrin-coated-pit invagination, cortactin recruitment, and membrane scission observed in live cells	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; DYNAMIC ACTIN; IMAGING ACTIN; N-WASP; ACIDIFICATION; LAMELLIPODIA; PROTEIN; SITES; ASSOCIATION; POPULATION	During clathrin-mediated endocytosis, membrane scission marks the isolation of a cargo-laden clathrin-coated pit (CCP) from the cell exterior. Here we used live-cell imaging of a pH-sensitive cargo to visualize the formation of clathrin-coated vesicles (CCVs) at single CCPs with a time resolution of seconds. We show that CCPs are highly dynamic and can produce multiple vesicles in succession. Using alternating evanescent field and epifluorescence illumination, we show that CCP invagination and scission are tightly coupled, with scission coinciding with maximal displacement of CCPs from the plasma membrane and with peak recruitment of cortactin-DsRed, a dynamin and F-actin binding protein. Finally, perturbing actin polymerization with latrunculin-B drastically reduces the efficiency of membrane scission and affects many aspects of CCP dynamics. We propose that CCP invagination, actin polymerization, and CCV formation are highly coordinated for efficient endocytosis.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; CNRS, UMR 5091, Lab Physiol Cellulaire Synapse, F-33077 Bordeaux, France; Univ Bordeaux 2, Inst Francois Magendie, F-33077 Bordeaux, France; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	MRC Laboratory Molecular Biology; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Yale University	Merrifield, CJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	cjm@mrc-lmb.cam.ac.uk	Perrais, David/W-9360-2019; Zenisek, David/C-6555-2011	Perrais, David/0000-0002-5878-5408; 	MRC [MC_U105178789] Funding Source: UKRI; Medical Research Council [MC_U105178789] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; BRETSCHER MS, 1984, SCIENCE, V224, P681, DOI 10.1126/science.6719108; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Farsad K, 2003, CURR OPIN CELL BIOL, V15, P372, DOI 10.1016/S0955-0674(03)00073-5; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Giardini PA, 2003, P NATL ACAD SCI USA, V100, P6493, DOI 10.1073/pnas.1031670100; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; Iversen TG, 2003, P NATL ACAD SCI USA, V100, P5175, DOI 10.1073/pnas.0534231100; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kaksonen M, 2000, J CELL SCI, V113, P4421; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2004, TRENDS CELL BIOL, V14, P352, DOI 10.1016/j.tcb.2004.05.008; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Perrais D, 2004, J PHYSIOL-LONDON, V560, P413, DOI 10.1113/jphysiol.2004.064410; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rappoport J, 2004, TRAFFIC, V5, P327, DOI 10.1111/j.1600-0854.2004.00187.x; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Santini F, 2002, NAT CELL BIOL, V4, pE230, DOI 10.1038/ncb1002-e230; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; Upadhyaya A, 2003, P NATL ACAD SCI USA, V100, P4521, DOI 10.1073/pnas.0837027100; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617; WILLINGHAM MC, 1981, J HISTOCHEM CYTOCHEM, V29, P1003, DOI 10.1177/29.9.6169759; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774	47	359	363	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					593	606		10.1016/j.cell.2005.03.015	http://dx.doi.org/10.1016/j.cell.2005.03.015			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907472	Bronze			2022-12-28	WOS:000229331200015
J	Falcke, H; Apel, WD; Badea, AF; Bahren, L; Bekk, K; Bercuci, A; Bertaina, M; Biermann, PL; Blumer, J; Bozdog, H; Brancus, IM; Buitink, S; Bruggemann, M; Buchholz, P; Butcher, H; Chiavassa, A; Daumiller, K; de Bruyn, AG; de Vos, CM; Di Pierro, F; Doll, P; Engel, R; Gemmeke, H; Ghia, PL; Glasstetter, R; Grupen, C; Haungs, A; Heck, D; Horandel, JR; Horneffer, A; Huege, T; Kampert, KH; Kant, GW; Klein, U; Kolotaev, Y; Koopman, Y; Kromer, O; Kuijpers, J; Lafebre, S; Maier, G; Mathes, HJ; Mayer, HJ; Milke, J; Mitrica, B; Morello, C; Navarra, G; Nehls, S; Nigl, A; Obenland, R; Oehlschlager, J; Ostapchenko, S; Over, S; Pepping, HJ; Petcu, M; Petrovic, J; Plewnia, S; Rebel, H; Risse, A; Roth, M; Schieler, H; Schoonderbeek, G; Sima, O; Stumpert, M; Toma, G; Trinchero, GC; Ulrich, H; Valchierotti, S; van Buren, J; van Cappellen, W; Walkowiak, W; Weindl, A; Wijnholds, S; Wochele, J; Zabierowski, J; Zensus, JA; Zimmermann, D				Falcke, H; Apel, WD; Badea, AF; Bahren, L; Bekk, K; Bercuci, A; Bertaina, M; Biermann, PL; Blumer, J; Bozdog, H; Brancus, IM; Buitink, S; Bruggemann, M; Buchholz, P; Butcher, H; Chiavassa, A; Daumiller, K; de Bruyn, AG; de Vos, CM; Di Pierro, F; Doll, P; Engel, R; Gemmeke, H; Ghia, PL; Glasstetter, R; Grupen, C; Haungs, A; Heck, D; Horandel, JR; Horneffer, A; Huege, T; Kampert, KH; Kant, GW; Klein, U; Kolotaev, Y; Koopman, Y; Kromer, O; Kuijpers, J; Lafebre, S; Maier, G; Mathes, HJ; Mayer, HJ; Milke, J; Mitrica, B; Morello, C; Navarra, G; Nehls, S; Nigl, A; Obenland, R; Oehlschlager, J; Ostapchenko, S; Over, S; Pepping, HJ; Petcu, M; Petrovic, J; Plewnia, S; Rebel, H; Risse, A; Roth, M; Schieler, H; Schoonderbeek, G; Sima, O; Stumpert, M; Toma, G; Trinchero, GC; Ulrich, H; Valchierotti, S; van Buren, J; van Cappellen, W; Walkowiak, W; Weindl, A; Wijnholds, S; Wochele, J; Zabierowski, J; Zensus, JA; Zimmermann, D			Detection and imaging of atmospheric radio flashes from cosmic ray air showers	NATURE			English	Article							MASS COMPOSITION; ENERGY-SPECTRUM; EMISSION; NEUTRINOS; RADIATION; PULSES; CHARGE	The nature of ultrahigh-energy cosmic rays (UHECRs) at energies > 10(20) eV remains a mystery(1). They are likely to be of extragalactic origin, but should be absorbed within &SIM; 50 Mpc through interactions with the cosmic microwave background. As there are no sufficiently powerful accelerators within this distance from the Galaxy, explanations for UHECRs range from unusual astrophysical sources to exotic string physics(2). Also unclear is whether UHECRs consist of protons, heavy nuclei, neutrinos or &gamma;-rays. To resolve these questions, larger detectors with higher duty cycles and which combine multiple detection techniques(3) are needed. Radio emission from UHECRs, on the other hand, is unaffected by attenuation, has a high duty cycle, gives calorimetric measurements and provides high directional accuracy. Here we report the detection of radio flashes from cosmic-ray air showers using low-cost digital radio receivers. We show that the radiation can be understood in terms of the geosynchrotron effect(4-8). Our results show that it should be possible to determine the nature and composition of UHECRs with combined radio and particle detectors, and to detect the ultrahigh-energy neutrinos expected from flavour mixing(9,10).	Max Planck Inst Radioastron, D-53121 Bonn, Germany; Univ Bonn, Inst Radioastron, D-53121 Bonn, Germany; Natl Inst Phys & Nucl Engn, Bucharest 7690, Romania; ASTRON, NL-7990 AA Dwingeloo, Netherlands; Univ Karlsruhe, Inst Expt Kernphys, D-76021 Karlsruhe, Germany; Forschungszentrum Karlsruhe, Inst Kernphys, D-76021 Karlsruhe, Germany; FZK, Inst Prozessdatenverarbeitung & Elektron, D-76021 Karlsruhe, Germany; Soltan Inst Nucl Studies, PL-90950 Lodz, Poland; Radboud Univ, Dept Astrophys, NL-6525 ED Nijmegen, Netherlands; Univ Siegen, Fachbereich Phys, D-57072 Siegen, Germany; Univ Turin, Dipartimento Fis Gen, I-10125 Turin, Italy; INAF, Ist Fis Spazio Interplanetario, I-10133 Turin, Italy; Univ Wuppertal, Fachbereich Phys C, D-42097 Wuppertal, Germany	Max Planck Society; University of Bonn; Horia Hulubei National Institute of Physics & Nuclear Engineering; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology; Soltan Institute for Nuclear Studies; Radboud University Nijmegen; Universitat Siegen; University of Turin; Istituto Nazionale Astrofisica (INAF); University of Wuppertal	Falcke, H (corresponding author), Max Planck Inst Radioastron, D-53121 Bonn, Germany.	falcke@astron.nl	Sima, Octavian/C-3565-2011; Chiavassa, Andrea/A-7597-2012; Sima, Octavian/HHZ-5390-2022; Sima, Octavian/HII-5549-2022; Brancus, Iliana/C-2829-2011; Ostapchenko, Sergey/L-5242-2017; Buitink, Stijn/F-2113-2016; Lafebre, S.J./L-4469-2015; Toma, Gabriel/C-2704-2011; Zabierowski, Janusz/G-8487-2013; Mitrica, Bogdan/D-5201-2009; Falcke, Heino D. E./H-5262-2012	Buitink, Stijn/0000-0002-6177-497X; Falcke, Heino D. E./0000-0002-2526-6724; Trinchero, Gian Carlo/0000-0003-0866-6379; Kampert, Karl-Heinz/0000-0002-2805-0195; Maier, Gernot/0000-0001-9868-4700; Zensus, J. Anton/0000-0001-7470-3321; Zabierowski, Janusz/0000-0001-6742-7146; Daumiller, Kai/0000-0002-0527-4823; Bertaina, Mario Edoardo/0000-0003-1069-1397; Biermann, Peter/0000-0003-3948-6143; Walkowiak, Wolfgang/0000-0002-0385-3784; Di Pierro, Federico/0000-0003-4861-432X; Horandel, Jorg/0000-0001-6604-547X; Huege, Tim/0000-0002-2783-4772; Roth, Markus/0000-0003-1281-4477				Allan H.R., 1971, PROGR ELEMENTARY PAR, V10, P169; Antoni T, 2003, NUCL INSTRUM METH A, V513, P490, DOI 10.1016/S0168-9002(03)02076-X; Antoni T, 2002, ASTROPART PHYS, V16, P245, DOI 10.1016/S0927-6505(01)00111-6; ASKARYAN GA, 1962, SOV PHYS JETP-USSR, V14, P441; Bertou X, 2002, ASTROPART PHYS, V17, P183, DOI 10.1016/S0927-6505(01)00147-5; Capelle KS, 1998, ASTROPART PHYS, V8, P321, DOI 10.1016/S0927-6505(97)00059-5; Falcke H, 2003, ASTROPART PHYS, V19, P477, DOI 10.1016/S0927-6505(02)00245-1; Gousset T, 2004, ASTROPART PHYS, V22, P103, DOI 10.1016/j.astropartphys.2004.05.004; Haungs A, 2003, REP PROG PHYS, V66, P1145, DOI 10.1088/0034-4885/66/7/202; Horneffer A, 2004, P SOC PHOTO-OPT INS, V5500, P129, DOI 10.1117/12.551466; Huege T, 2005, ASTRON ASTROPHYS, V430, P779, DOI 10.1051/0004-6361:20041873; Huege T, 2003, ASTRON ASTROPHYS, V412, P19, DOI 10.1051/0004-6361:20031422; HUEGE T, 2005, UNPUB ASTROPART PHYS; JELLEY JV, 1965, NATURE, V205, P327, DOI 10.1038/205327a0; Nagano M, 2000, REV MOD PHYS, V72, P689, DOI 10.1103/RevModPhys.72.689; Ravel O, 2004, NUCL INSTRUM METH A, V518, P213, DOI 10.1016/j.nima.2003.10.063; Saltzberg D, 2001, PHYS REV LETT, V86, P2802, DOI 10.1103/PhysRevLett.86.2802; Sigl G, 2003, ANN PHYS-NEW YORK, V303, P117, DOI 10.1016/S0003-4916(02)00021-0; Suprun DA, 2003, ASTROPART PHYS, V20, P157, DOI 10.1016/S0927-6505(03)00177-4; ZAS E, 1992, PHYS REV D, V45, P362, DOI 10.1103/PhysRevD.45.362	20	302	304	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2005	435	7040					313	316		10.1038/nature03614	http://dx.doi.org/10.1038/nature03614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902250	Green Submitted			2022-12-28	WOS:000229185000038
J	Lyons, JR; Young, ED				Lyons, JR; Young, ED			CO self-shielding as the origin of oxygen isotope anomalies in the early solar nebula	NATURE			English	Article							INTERSTELLAR CLOUDS; CARBON-MONOXIDE; GRAIN CHEMISTRY; DISKS; METEORITES; SYSTEM; PHOTODISSOCIATION; FRACTIONATION; DISTRIBUTIONS; CHONDRITES	The abundances of oxygen isotopes in the most refractory mineral phases (calcium-aluminium-rich inclusions, CAIs) in meteorites(1) have hitherto defied explanation. Most processes fractionate isotopes by nuclear mass; that is, O-18 is twice as fractionated as O-17, relative to O-16. In CAIs O-17 and O-18 are nearly equally fractionated, implying a fundamentally different mechanism. The CAI data were originally interpreted as evidence for supernova input of pure O-16 into the solar nebula(1), but the lack of a similar isotope trend in other elements argues against this explanation(2). A symmetry-dependent fractionation mechanism(3,4) may have occurred in the inner solar nebula(5), but experimental evidence is lacking. Isotope-selective photodissociation of CO in the innermost solar nebula(6) might explain the CAI data, but the high temperatures in this region would have rapidly erased the signature(7). Here we report time-dependent calculations of CO photodissociation in the cooler surface region of a turbulent nebula. If the surface were irradiated by a far-ultraviolet flux similar to 10(3) times that of the local interstellar medium ( for example, owing to an O or B star within,1 pc of the protosun), then substantial fractionation of the oxygen isotopes was possible on a timescale of similar to 10(5) years. We predict that similarly irradiated protoplanetary disks will have H2O enriched in O-17 and O-18 by several tens of per cent relative to CO.	Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lyons, JR (corresponding author), Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA.	jrl@ess.ucla.edu		Young, Edward/0000-0002-1299-0801				Adams FC, 2004, ASTROPHYS J, V611, P360, DOI 10.1086/421989; Aikawa Y, 2001, ASTRON ASTROPHYS, V371, P1107, DOI 10.1051/0004-6361:20010416; BALLY J, 1982, ASTROPHYS J, V255, P143, DOI 10.1086/159812; Choi BG, 1998, NATURE, V392, P577, DOI 10.1038/33356; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Clayton RN, 2002, NATURE, V415, P860, DOI 10.1038/415860b; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; CLAYTON RN, 1984, EARTH PLANET SC LETT, V67, P151, DOI 10.1016/0012-821X(84)90110-9; Cuzzi JN, 2004, ASTROPHYS J, V614, P490, DOI 10.1086/423611; CUZZI JN, 1996, CHONDRULES PROTOPLAN, P35; Federman SR, 2003, ASTROPHYS J, V591, P986, DOI 10.1086/375483; Gammie CF, 1996, ASTROPHYS J, V457, P355, DOI 10.1086/176735; Gao YQ, 2001, SCIENCE, V293, P259, DOI 10.1126/science.1058528; HASEGAWA TI, 1992, ASTROPHYS J SUPPL S, V82, P167, DOI 10.1086/191713; Le Teuff YH, 2000, ASTRON ASTROPHYS SUP, V146, P157, DOI 10.1051/aas:2000265; Lee HH, 1996, ASTRON ASTROPHYS, V311, P690; LYONS JR, 2003, LUNAR PLANET SCI C, V34; LYONS JR, 2004, LUNAR PLANET SCI C, V35; Marcus RA, 2004, J CHEM PHYS, V121, P8201, DOI 10.1063/1.1803507; Markwick AJ, 2002, ASTRON ASTROPHYS, V385, P632, DOI 10.1051/0004-6361:20020050; NAVON O, 1985, EARTH PLANET SC LETT, V73, P1, DOI 10.1016/0012-821X(85)90030-5; Prieto CA, 2002, ASTROPHYS J, V573, pL137, DOI 10.1086/342095; Stone J. M., 2000, Protostars and planets 4, P589; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; van Zadelhoff GJ, 2003, ASTRON ASTROPHYS, V397, P789, DOI 10.1051/0004-6361:20021592; VANDISHOECK EF, 1988, ASTROPHYS J, V334, P771, DOI 10.1086/166877; Willacy K, 1998, ASTRON ASTROPHYS, V338, P995; Young ED, 1998, SCIENCE, V282, P452, DOI 10.1126/science.282.5388.452; Young ED, 2001, PHILOS T ROY SOC A, V359, P2095, DOI 10.1098/rsta. 2001.0900; Yurimoto H, 2004, SCIENCE, V305, P1763, DOI 10.1126/science.1100989	30	311	311	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					317	320		10.1038/nature03557	http://dx.doi.org/10.1038/nature03557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902251				2022-12-28	WOS:000229185000039
J	Xu, QF; Schmidt, B; Pradhan, S; Lipson, M				Xu, QF; Schmidt, B; Pradhan, S; Lipson, M			Micrometre-scale silicon electro-optic modulator	NATURE			English	Article							WAVE-GUIDES; LIGHT; FABRICATION; TECHNOLOGY; GAIN; SI	Metal interconnections are expected to become the limiting factor for the performance of electronic systems as transistors continue to shrink in size. Replacing them by optical interconnections, at different levels ranging from rack-to-rack down to chip-to-chip and intra-chip interconnections, could provide the low power dissipation, low latencies and high bandwidths that are needed(1-4). The implementation of optical interconnections relies on the development of micro-optical devices that are integrated with the microelectronics on chips. Recent demonstrations of silicon low-loss waveguides(5-7), light emitters(8), amplifiers(9-11) and lasers(12,13) approach this goal, but a small silicon electro-optic modulator with a size small enough for chip-scale integration has not yet been demonstrated. Here we experimentally demonstrate a high-speed electro-optical modulator in compact silicon structures. The modulator is based on a resonant light-confining structure that enhances the sensitivity of light to small changes in refractive index of the silicon and also enables high-speed operation. The modulator is 12 micrometres in diameter, three orders of magnitude smaller than previously demonstrated. Electro-optic modulators are one of the most critical components in optoelectronic integration, and decreasing their size may enable novel chip architectures.	Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14853 USA	Cornell University	Lipson, M (corresponding author), Cornell Univ, Sch Elect & Comp Engn, 411 Phillips Hall, Ithaca, NY 14853 USA.	lipson@ece.cornell.edu						Almeida VR, 2004, NATURE, V431, P1081, DOI 10.1038/nature02921; Almeida VR, 2003, OPT LETT, V28, P1302, DOI 10.1364/OL.28.001302; Barrios CA, 2003, J LIGHTWAVE TECHNOL, V21, P2332, DOI 10.1109/JLT.2003.818167; Boyraz O, 2004, OPT EXPRESS, V12, P5269, DOI 10.1364/OPEX.12.005269; Chan S, 2001, OPT MATER, V17, P31, DOI 10.1016/S0925-3467(01)00016-7; Dainesi P, 2000, IEEE PHOTONIC TECH L, V12, P660, DOI 10.1109/68.849076; Dumon P, 2004, IEEE PHOTONIC TECH L, V16, P1328, DOI 10.1109/LPT.2004.826025; Espinola RL, 2004, OPT EXPRESS, V12, P3713, DOI 10.1364/OPEX.12.003713; FAITH TJ, 1983, J VAC SCI TECHNOL A, V1, P443, DOI 10.1116/1.571943; GAN F, IN PRESS IEEE PHOTON; Heebner JE, 2004, OPT LETT, V29, P769, DOI 10.1364/OL.29.000769; Jones R, 2005, OPT EXPRESS, V13, P519, DOI 10.1364/OPEX.13.000519; Kibar O, 1999, J LIGHTWAVE TECHNOL, V17, P546, DOI 10.1109/50.754783; Lee KK, 2001, OPT LETT, V26, P1888, DOI 10.1364/OL.26.001888; Little BE, 1998, IEEE PHOTONIC TECH L, V10, P549, DOI 10.1109/68.662590; Liu AS, 2004, NATURE, V427, P615, DOI 10.1038/nature02310; Maune B, 2003, APPL PHYS LETT, V83, P4689, DOI 10.1063/1.1630370; Meindl JD, 2002, IBM J RES DEV, V46, P245, DOI 10.1147/rd.462.0245; Miller DAB, 2000, IEEE J SEL TOP QUANT, V6, P1312, DOI 10.1109/2944.902184; Mohammed EM, 2004, PROC SPIE, V5358, P60, DOI 10.1117/12.530160; MULLER J, 1978, IEEE J SOLID-ST CIRC, V13, P173, DOI 10.1109/JSSC.1978.1051011; PRADHAN S, 2004, OPTICAL AMPLIFIERS T; Rong HS, 2005, NATURE, V433, P292, DOI 10.1038/nature03273; SADAGOPAN T, 2004, LEOS SUMM TOP M, pMC2; Sciuto A, 2003, J LIGHTWAVE TECHNOL, V21, P228, DOI 10.1109/JLT.2003.808608; SOREF RA, 1987, IEEE J QUANTUM ELECT, V23, P123, DOI 10.1109/JQE.1987.1073206; TANG CK, 1995, ELECTRON LETT, V31, P451, DOI 10.1049/el:19950328; Vlasov YA, 2004, OPT EXPRESS, V12, P1622, DOI 10.1364/OPEX.12.001622; Xu QF, 2004, OPT EXPRESS, V12, P4437, DOI 10.1364/OPEX.12.004437	29	1766	1865	25	573	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					325	327		10.1038/nature03569	http://dx.doi.org/10.1038/nature03569			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902253				2022-12-28	WOS:000229185000041
J	Ramanan, S				Ramanan, S			An act of unkindness	LANCET			English	Editorial Material									St Francis Hosp & Med Ctr, Hartford, CT 06105 USA	Saint Francis Hospital & Medical Center	Ramanan, S (corresponding author), St Francis Hosp & Med Ctr, 114 Woodland St, Hartford, CT 06105 USA.	sramanan@stfranciscare.org							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 14	2005	365	9472					1743	1743		10.1016/S0140-6736(05)66548-8	http://dx.doi.org/10.1016/S0140-6736(05)66548-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	925VV	15894101				2022-12-28	WOS:000229082300026
J	Depaepe, V; Suarez-Gonzalez, N; Dufour, A; Passante, L; Gorski, JA; Jones, KR; Ledent, C; Vanderhaeghen, P				Depaepe, V; Suarez-Gonzalez, N; Dufour, A; Passante, L; Gorski, JA; Jones, KR; Ledent, C; Vanderhaeghen, P			Ephrin signalling controls brain size by regulating apoptosis of neural progenitors	NATURE			English	Article							CELL-DEATH; MOUSE NEOCORTEX; RECEPTORS; MIGRATION; SURVIVAL; PROLIFERATION; NEUROGENESIS; INHIBITION; NEURONS; CORTEX	Mechanisms controlling brain size include the regulation of neural progenitor cell proliferation, differentiation, survival and migration(1,2). Here we show that ephrin-A/EphA receptor signalling plays a key role in controlling the size of the mouse cerebral cortex by regulating cortical progenitor cell apoptosis. In vivo gain of EphA receptor function, achieved through ectopic expression of ephrin-A5 in early cortical progenitors expressing EphA7, caused a transient wave of neural progenitor cell apoptosis, resulting in premature depletion of progenitors and a subsequent dramatic decrease in cortical size. In vitro treatment with soluble ephrin-A ligands similarly induced the rapid death of cultured dissociated cortical progenitors in a caspase-3-dependent manner, thereby confirming a direct effect of ephrin/Eph signalling on apoptotic cascades. Conversely, in vivo loss of EphA function, achieved through EphA7 gene disruption, caused a reduction in apoptosis occurring normally in forebrain neural progenitors, resulting in an increase in cortical size and, in extreme cases, exencephalic forebrain overgrowth. Together, these results identify ephrin/Eph signalling as a physiological trigger for apoptosis that can alter brain size and shape by regulating the number of neural progenitors.	Univ Brussels, IRIBHM, B-1070 Brussels, Belgium; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Universite Libre de Bruxelles; University of Colorado System; University of Colorado Boulder	Vanderhaeghen, P (corresponding author), Univ Brussels, IRIBHM, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.	pvdhaegh@ulb.ac.be		JONES, KEVIN/0000-0002-3802-7562; Vanderhaeghen, Pierre/0000-0001-7899-5720				Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bello BC, 2003, NEURON, V37, P209, DOI 10.1016/S0896-6273(02)01181-9; Campbell DS, 2003, NEURON, V37, P939, DOI 10.1016/S0896-6273(03)00158-2; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dorus S, 2004, CELL, V119, P1027, DOI 10.1016/j.cell.2004.11.040; Dufour A, 2003, NEURON, V39, P453, DOI 10.1016/S0896-6273(03)00440-9; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Gorski JA, 2002, J NEUROSCI, V22, P6309; Holmberg J, 2005, GENE DEV, V19, P462, DOI 10.1101/gad.326905; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; Mochida GH, 2001, CURR OPIN NEUROL, V14, P151, DOI 10.1097/00019052-200104000-00003; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Vanderhaeghen P, 2000, NAT NEUROSCI, V3, P358, DOI 10.1038/73929; Wilkie AL, 2004, DEV BIOL, V267, P109, DOI 10.1016/j.ydbio.2003.11.006; Williams ME, 2003, J BIOL CHEM, V278, P17483, DOI 10.1074/jbc.M300415200; Yue Y, 1999, J NEUROSCI, V19, P10026; Yun ME, 2003, J COMP NEUROL, V456, P203, DOI 10.1002/cne.10498; Zhang YM, 2000, NAT BIOTECHNOL, V18, P1314, DOI 10.1038/82449	30	222	230	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2005	435	7046					1244	1250		10.1038/nature03651	http://dx.doi.org/10.1038/nature03651			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940JJ	15902206				2022-12-28	WOS:000230140500046
J	Hatfield, SD; Shcherbata, HR; Fischer, KA; Nakahara, K; Carthew, RW; Ruohola-Baker, H				Hatfield, SD; Shcherbata, HR; Fischer, KA; Nakahara, K; Carthew, RW; Ruohola-Baker, H			Stem cell division is regulated by the microRNA pathway	NATURE			English	Article							DEPENDENT KINASE INHIBITOR; DROSOPHILA OVARY; CYCLE; PROLIFERATION; EMBRYOGENESIS; RENEWAL; DACAPO; ROLES; NICHE	One of the key characteristics of stem cells is their capacity to divide for long periods of time in an environment where most of the cells are quiescent. Therefore, a critical question in stem cell biology is how stem cells escape cell division stop signals. Here, we report the necessity of the microRNA (miRNA) pathway(1-4) for proper control of germline stem cell (GSC) division in Drosophila melanogaster. Analysis of GSCs mutant for dicer-1 (dcr-1), the double-stranded RNaseIII essential for miRNA biogenesis, revealed a marked reduction in the rate of germline cyst production. These dcr-1 mutant GSCs exhibit normal identity but are defective in cell cycle control. On the basis of cell cycle markers and genetic interactions, we conclude that dcr-1 mutant GSCs are delayed in the G1 to S transition, which is dependent on the cyclin-dependent kinase inhibitor Dacapo, suggesting that miRNAs are required for stem cells to bypass the normal G1/S checkpoint. Hence, the miRNA pathway might be part of a mechanism that makes stem cells insensitive to environmental signals that normally stop the cell cycle at the G1/S transition.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Washington; University of Washington Seattle; Northwestern University	Ruohola-Baker, H (corresponding author), Univ Washington, Dept Biochem, J591,HSB, Seattle, WA 98195 USA.	r-carthew@northwestern.edu; hannele@u.washington.edu	Shcherbata, Halyna/J-5712-2017; Nakahara, Kenji/F-5780-2012	Shcherbata, Halyna/0000-0002-3855-0345; Nakahara, Kenji/0000-0002-9541-3208	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077581] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM077581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Calvi BR, 2004, METH MOL B, V247, P203; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Enright AJ, 2004, GENOME BIOL, V5; Gilboa L, 2004, DEVELOPMENT, V131, P4895, DOI 10.1242/dev.01373; Gonczy P, 1996, DEVELOPMENT, V122, P2437; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Meyer CA, 2002, DEVELOPMENT, V129, P319; Nakahara K, 2004, CURR OPIN CELL BIOL, V16, P127, DOI 10.1016/j.ceb.2004.02.006; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Schauer SE, 2002, TRENDS PLANT SCI, V7, P487, DOI 10.1016/S1360-1385(02)02355-5; Shcherbata HR, 2004, DEVELOPMENT, V131, P3169, DOI 10.1242/dev.01172; Song XQ, 2004, DEVELOPMENT, V131, P1353, DOI 10.1242/dev.01026; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019	30	546	607	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					974	978		10.1038/nature03816	http://dx.doi.org/10.1038/nature03816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15944714	Green Published			2022-12-28	WOS:000229799700053
J	Corradini, P; Farina, L				Corradini, P; Farina, L			Immune-mediated attack in relapsed Hodgkin's lymphoma	LANCET			English	Editorial Material							STEM-CELL TRANSPLANTATION; DONOR LEUKOCYTE INFUSIONS; MARROW TRANSPLANTATION; DISEASE		Univ Milan, Ist Nazl Studio & Cura Tumori, Dept Haematol, Milan, Italy; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Corradini, P (corresponding author), Univ Milan, Ist Nazl Studio & Cura Tumori, Dept Haematol, Milan, Italy.	paolo.corradini@istitutotumori.mi.it	Farina, Lucia/F-3673-2017; Corradini, Paolo/N-7584-2017	Farina, Lucia/0000-0002-5219-0673; Corradini, Paolo/0000-0002-9186-1353				Akpek G, 2001, J CLIN ONCOL, V19, P4314, DOI 10.1200/JCO.2001.19.23.4314; Anderlini P, 2004, BONE MARROW TRANSPL, V34, P511, DOI 10.1038/sj.bmt.1704621; ANDERSON JE, 1993, J CLIN ONCOL, V11, P2342, DOI 10.1200/JCO.1993.11.12.2342; Corradini P, 2004, BLOOD, V104, p230A, DOI 10.1182/blood.V104.11.808.808; DELABIE J, 1995, LEUKEMIA LYMPHOMA, V18, P35, DOI 10.3109/10428199509064920; DREGER P, 2000, BONE MARROW TRANS S1, V25, pS173; Gajewski JL, 1996, J CLIN ONCOL, V14, P572, DOI 10.1200/JCO.1996.14.2.572; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; Milpied N, 1996, J CLIN ONCOL, V14, P1291, DOI 10.1200/JCO.1996.14.4.1291; Porter DL, 1999, J CLIN ONCOL, V17, P1234, DOI 10.1200/JCO.1999.17.4.1234; Robinson SP, 2004, BLOOD, V104, p639A, DOI 10.1182/blood.V104.11.2322.2322	11	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1906	1908		10.1016/S0140-6736(05)66636-6	http://dx.doi.org/10.1016/S0140-6736(05)66636-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936404				2022-12-28	WOS:000229587800005
J	Duenas-Laita, A; Perez-Miranda, M; Gonzalez-Lopez, MA; Martin-Escudero, JC; Ruiz-Mambrilla, M; Blanco-Varela, J				Duenas-Laita, A; Perez-Miranda, M; Gonzalez-Lopez, MA; Martin-Escudero, JC; Ruiz-Mambrilla, M; Blanco-Varela, J			Acute arsenic poisoning	LANCET			English	Editorial Material									Univ Valladolid, Rio Hortega Hosp, Unit Clin Toxicol, Valladolid 47010, Spain; Univ Valladolid, Rio Hortega Hosp, Dept Gastroenterol, Valladolid 47010, Spain; Univ Valladolid, Rio Hortega Hosp, Dept Internal Med, Valladolid 47010, Spain; Univ Valladolid, Rio Hortega Hosp, Crit Care Unit, Valladolid 47010, Spain; Univ Valladolid, Dept Med, E-47005 Valladolid, Spain	Hospital del Rio Hortega; Universidad de Valladolid; Hospital del Rio Hortega; Universidad de Valladolid; Hospital del Rio Hortega; Universidad de Valladolid; Hospital del Rio Hortega; Universidad de Valladolid; Universidad de Valladolid	Duenas-Laita, A (corresponding author), Univ Valladolid, Rio Hortega Hosp, Unit Clin Toxicol, Rondilla de Santa Teresa 9, Valladolid 47010, Spain.	aduenas.laita@eresmas.net		Martin-Escudero, Juan Carlos/0000-0002-6209-6509				FORD MD, 1998, GOLDFRANKS TOXICOLOG, P1261; FOXFORD R, 1985, ANN EMERG MED, V14, P1223, DOI 10.1016/S0196-0644(85)81034-9; LEE DC, 1995, AM J EMERG MED, V13, P244, DOI 10.1016/0735-6757(95)90111-6; MARSTELLER HJ, 1977, NEW ENGL J MED, V296, P1003; Tennebein M, 1991, Pediatr Emerg Care, V7, P286	5	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1982	1982		10.1016/S0140-6736(05)66670-6	http://dx.doi.org/10.1016/S0140-6736(05)66670-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936431				2022-12-28	WOS:000229587800038
J	McClellan, AJ; Scott, MD; Frydman, J				McClellan, AJ; Scott, MD; Frydman, J			Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways	CELL			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; INTERACTING PROTEINS; ABNORMAL PROTEINS; ELONGIN C; YEAST	The mechanisms by which molecular chaperones assist quality control of cytosolic proteins are poorly understood. Analysis of the chaperone requirements for degradation of misfolded variants of a cytosolic protein, the VHL tumor suppressor, reveals that distinct chaperone pathways mediate its folding and quality control. While both folding and degradation of VHL require Hsp70, the chaperonin TRiC is essential for folding but is dispensable for degradation. Conversely, the chaperone Hsp90 neither participates in VHL folding nor is required to maintain misfolded VHL solubility but is essential for its degradation. The cochaperone HOP/Sti1 p also participates in VHL quality control and may direct the triage decision by bridging the Hsp70-Hsp90 interaction. Our finding that a distinct chaperone complex is uniquely required for quality control provides evidence for active and specific chaperone participation in triage decisions and suggests that a hierarchy of chaperone interactions can control the alternate fates of a cytosolic protein.	Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA; Stanford Univ, BioX Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Frydman, J (corresponding author), Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA.	jfrydman@stanford.edu	McClellan, Amie/V-8950-2019	McClellan, Amie/0000-0002-8033-6748; , judith/0000-0003-2302-6943	NIGMS NIH HHS [GM64992, GM56433] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM056433, R01GM056433, F32GM064992] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Becker J, 1996, MOL CELL BIOL, V16, P4378; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Botuyan MV, 1999, P NATL ACAD SCI USA, V96, P9033, DOI 10.1073/pnas.96.16.9033; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Camasses A, 2003, MOL CELL, V12, P87, DOI 10.1016/S1097-2765(03)00244-2; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Dougan DA, 2002, CELL MOL LIFE SCI, V59, P1607, DOI 10.1007/PL00012487; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Goasduff T, 2000, ARCH BIOCHEM BIOPHYS, V379, P321, DOI 10.1006/abbi.2000.1870; Goeckeler JL, 2002, MOL BIOL CELL, V13, P2760, DOI 10.1091/mbc.02-04-0051; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Jackson T, 2000, BBA-GENE STRUCT EXPR, V1491, P161, DOI 10.1016/S0167-4781(00)00052-X; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; KANDROR O, 1994, J BIOL CHEM, V269, P23575; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; Mitsui K, 2002, J NEUROSCI, V22, P9267; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yamano T, 2002, J EXP MED, V196, P185, DOI 10.1084/jem.20011922; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	58	201	205	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					739	748		10.1016/j.cell.2005.03.024	http://dx.doi.org/10.1016/j.cell.2005.03.024			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935760	Bronze			2022-12-28	WOS:000229658000012
J	Clark, S				Clark, S			Personal account - On giving up smoking	LANCET			English	Article																			0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1855	1855		10.1016/S0140-6736(05)66616-0	http://dx.doi.org/10.1016/S0140-6736(05)66616-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924981				2022-12-28	WOS:000229481400023
J	Anderson, JD; Johnson, TV; Schubert, G; Asmar, S; Jacobson, RA; Johnston, D; Lau, EL; Lewis, G; Moore, WB; Taylor, A; Thomas, PC; Weinwurm, G				Anderson, JD; Johnson, TV; Schubert, G; Asmar, S; Jacobson, RA; Johnston, D; Lau, EL; Lewis, G; Moore, WB; Taylor, A; Thomas, PC; Weinwurm, G			Amalthea's density is less than that of water	SCIENCE			English	Article							SMALL INNER SATELLITES; JUPITER; DISCOVERY; ORBITS	Radio Doppler data from the Galileo spacecraft's encounter with Amalthea, one of Jupiter's small inner moons, on 5 November 2002 yield a mass of (2.08 +/- 0.15) x 10(18) kilograms. Images of Amalthea from two Voyager spacecraft in 1979 and Galileo imaging between November 1996 and June 1997 yield a volume of (2.43 +/- 0.22) x 10(6) cubic kilometers. The satellite thus has a density of 857 +/- 99 kilograms per cubic meter. We suggest that Amalthea is porous and composed of water ice, as well as rocky material, and thus formed in a cold region of the solar system, possibly not at its present location near Jupiter.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Cornell Univ, Ctr Radio Phys & Space Res, Ithaca, NY 14853 USA; Vienna Univ Technol, Inst Geodesy & Geophys, A-1040 Vienna, Austria	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles; Cornell University; Technische Universitat Wien	Anderson, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	john.d.anderson@jpl.nasa.gov						Anderson JD, 1999, ICARUS, V138, P309, DOI 10.1006/icar.1998.6075; Barnard E. E., 1892, AJ, V12, P81; Canup RM, 2002, ASTRON J, V124, P3404, DOI 10.1086/344684; DEIMAND D, 2001, TR0112 ERDCCRREL US; Drummond J.D., 1989, ASTEROIDS, VII, P171; Gundlach JH, 2000, PHYS REV LETT, V85, P2869, DOI 10.1103/PhysRevLett.85.2869; JEWITT DC, 1979, SCIENCE, V206, P951, DOI 10.1126/science.206.4421.951; JOHNSON TV, 1973, ICARUS, V18, P612, DOI 10.1016/0019-1035(73)90064-X; Lagerkvist C.-I., 1989, ASTEROIDS, P1162; LOCKNER DA, 1995, HDB PHYSICAL CONSTAN, V3, P127; Millis R. L., 1989, ASTEROIDS, V148; Simonelli DP, 2000, ICARUS, V147, P353, DOI 10.1006/icar.2000.6474; SYNNOTT SP, 1980, SCIENCE, V210, P786, DOI 10.1126/science.210.4471.786; SYNNOTT SP, 1984, ICARUS, V58, P178, DOI 10.1016/0019-1035(84)90036-8; SYNNOTT SP, 1981, SCIENCE, V212, P191, DOI 10.1126/science.212.4491.191; SYNNOTT SP, 1980, SCIENCE, V210, P1392; THOLEN DJ, 2000, ALLENS ASTROPHYSICAL, P302; Thomas P., 1986, IAU C 77 SOME BACKGR, P802; Thomas PC, 1998, ICARUS, V135, P360, DOI 10.1006/icar.1998.5976; *USA CORPS ENG, 1951, 4 SIPRE US ARM CORPS; Veverka J, 2000, SCIENCE, V289, P2088, DOI 10.1126/science.289.5487.2088; [No title captured]	22	53	53	2	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2005	308	5726					1291	1293		10.1126/science.1110422	http://dx.doi.org/10.1126/science.1110422			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919987				2022-12-28	WOS:000229482300041
J	Mihaylova, B; Briggs, A; Armitage, J; Parish, S; Gray, A; Collins, R				Mihaylova, B; Briggs, A; Armitage, J; Parish, S; Gray, A; Collins, R		Heart Protection Study Collaborati	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals	LANCET			English	Article								Background Statin therapy reduces the rates of heart attack, stroke, and revascularisation among a wide range of individuals. Reliable assessment of its cost-effectiveness in different circumstances is needed. Methods 20 536 adults (aged 40-80 years) with vascular disease or diabetes were randomly allocated 40 mg sinnivastatin daily (10 269) or placebo (10 267) for an average of 5 years. Comparisons were made of hospitalisation and statin costs (2001 UK prices) during the scheduled treatment period between all simvastatin-allocated versus all placebo-allocated participants. Cost-effectiveness was estimated among different categories of participant. Findings Allocation to simvastatin was associated with a highly significant 22% (95% Cl 16-27; p<0.0001) proportional reduction in hospitalisation costs for all vascular events, with similar proportional reductions in every subcategory of participant studied. During an average of 5 years, estimated absolute reductions in vascular event costs per person allocated 40 mg simvastatin daily ranged from UK 847 pound (SE 137) in the highest risk quintile studied to,[264 (48) in the lowest. Mean excess cost of statin therapy among participants allocated simvastatin was 1497 pound (8), with similar absolute increases in every subcategory. Costs of preventing a major vascular event with 40 mg simvastatin daily ranged from,C4500 (95% CI 2300-7400) among participants with a 42% 5-year major vascular event rate to 31 pound 100 (22 900-42 500) among those with a 12% rate (corresponding to 5-year major coronary event rates of 22% and 4%, respectively). Interpretation Statin therapy is cost effective for a wider range of individuals with vascular disease or diabetes than previously recognised (particularly with lower-priced generics). It would be appropriate to consider reducing the estimated level of vascular event risk at which statin therapy is recommended.	Radcliffe Infirm, Clin Trial Serv Unit, Heart Protect Study, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Mihaylova, B (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Heart Protect Study, Harkness Bldg, Oxford OX2 6HE, England.	hps@ctsu.ox.ac.uk		Mihaylova, Borislava/0000-0002-0951-1304; Briggs, Andrew/0000-0002-0777-1997				Caro J, 1997, BRIT MED J, V315, P1577, DOI 10.1136/bmj.315.7122.1577; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2004, LANCET, V363, P757; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; *DEP HLTH, 2003, GOV EXP PLANS DEP RE; Department of Health, 2004, PRESCR COST AN ENGL; Efron B., 1994, MONOGRAPHS STAT APPL; FIELLER EC, 1954, J ROY STAT SOC B, V16, P175; Glasziou PP, 2002, MED J AUSTRALIA, V177, P428; *JOINT FORM COMM, 2001, BRIT NAT FORM, V41; Jonsson B, 1999, DIABETOLOGIA, V42, P1293, DOI 10.1007/s001250051441; Jonsson B, 1996, EUR HEART J, V17, P1001; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Meade T, 1999, EUR HEART J, V20, P725; *NHS EX, 2001, TRUST FIN RET; *NHS EX, 2002, TRUST FIN RET; *PRESCR PRIC AUTH, NHS EL DRUG TAR; Sniderman AD, 2004, AM J CARDIOL, V94, p30F, DOI 10.1016/j.amjcard.2004.07.052; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; *TAMR, 2003, INT REP JAN JUN; Wood D, 2000, BRIT MED J, V320, P705, DOI 10.1136/bmj.320.7236.705; ZOCOR DATASHEET	23	88	90	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2005	365	9473					1779	1785		10.1016/S0140-6736(05)63014-0	http://dx.doi.org/10.1016/S0140-6736(05)63014-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910950				2022-12-28	WOS:000229291600022
J	Hiesinger, PR; Fayyazuddin, A; Mehta, SQ; Rosenmund, T; Schulze, KL; Zhai, RG; Verstreken, P; Cao, Y; Zhou, Y; Kunz, J; Bellen, HJ				Hiesinger, PR; Fayyazuddin, A; Mehta, SQ; Rosenmund, T; Schulze, KL; Zhai, RG; Verstreken, P; Cao, Y; Zhou, Y; Kunz, J; Bellen, HJ			The v-ATPase V-0 subunit a1 is required for a late step in synaptic vesicle exocytosis in Drosophila	CELL			English	Article							READILY RELEASABLE POOL; VACUOLAR H+-ATPASE; MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; SYNAPTOBREVIN; CELLS; YEAST; TRANSMISSION; MUTATIONS; SECRETION	The V-0 complex forms the proteolipid pore of an ATPase that acidifies vesicles. In addition, an independent function in membrane fusion has been proposed largely based on yeast vacuolar fusion experiments. We have isolated mutations in the largest V-0 component vha100-1 in flies in an unbiased genetic screen for synaptic malfunction. The protein is only required in neurons, colocalizes with markers for synaptic vesicles as well as active zones, and interacts with t-SNAREs. Loss of vha100-1 leads to vesicle accumulation in synaptic terminals, suggesting a deficit in release. The amplitude of spontaneous release events and release with hypertonic stimulation indicate normal levels of neurotransmitter loading, yet mutant embryos display severe defects in evoked synaptic transmission and FM1-43 uptake. Our data suggest that Vha100-1 functions downstream of SNAREs in synaptic vesicle fusion.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bellen, HJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.	hbellen@bcm.tmc.edu	Zhai, R. Grace/AGZ-3936-2022; Verstreken, Patrik/AAC-7591-2022	Verstreken, Patrik/0000-0002-5073-5393; Zhai, Rong/0000-0002-7599-1430; Bellen, Hugo/0000-0001-5992-5989; Mehta, Sunil/0000-0003-3020-4939	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068098] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 068098, R01 GM068098, R01 GM068098-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Aravamudan B, 1999, NAT NEUROSCI, V2, P965, DOI 10.1038/14764; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHOU TB, 1992, GENETICS, V131, P643; Cousin MA, 1997, J NEUROCHEM, V69, P1927; Deitcher DL, 1998, J NEUROSCI, V18, P2028; Drose S, 1997, J EXP BIOL, V200, P1; FalkVairant J, 1996, P NATL ACAD SCI USA, V93, P5203, DOI 10.1073/pnas.93.11.5203; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; Hiesinger PR, 1999, J NEUROSCI, V19, P7548, DOI 10.1523/JNEUROSCI.19-17-07548.1999; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; ISRAEL M, 1986, P NATL ACAD SCI USA, V83, P9226, DOI 10.1073/pnas.83.23.9226; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 2004, ANN NY ACAD SCI, V1014, P170, DOI 10.1196/annals.1294.018; Jena BP, 2004, J CELL MOL MED, V8, P1, DOI 10.1111/j.1582-4934.2004.tb00255.x; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Kuromi H, 2000, NEURON, V27, P133, DOI 10.1016/S0896-6273(00)00015-5; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; Mehta SQ, 2005, NEURON, V46, P219, DOI 10.1016/j.neuron.2005.02.029; Meinertzhagen Ian A., 1993, P1363; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Morel N, 2003, J CELL SCI, V116, P4751, DOI 10.1242/jcs.00791; Morel N, 2003, BIOL CELL, V95, P453, DOI 10.1016/S0248-4900(03)00075-3; Nelson N, 2003, J BIOENERG BIOMEMBR, V35, P281, DOI 10.1023/A:1025768529677; Newsome TP, 2000, DEVELOPMENT, V127, P851; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; PAK WL, 1969, NATURE, V222, P351, DOI 10.1038/222351a0; Perzov N, 2002, J EXP BIOL, V205, P1209; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Pujol N, 2001, J BIOL CHEM, V276, P11913, DOI 10.1074/jbc.M009451200; Richmond JE, 2002, CURR OPIN NEUROBIOL, V12, P499, DOI 10.1016/S0959-4388(02)00360-4; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Sorensen JB, 2004, PFLUG ARCH EUR J PHY, V448, P347, DOI 10.1007/s00424-004-1247-8; Stowers RS, 1999, GENETICS, V152, P1631; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimer RM, 2003, J CELL SCI, V116, P3661, DOI 10.1242/jcs.00687; Wucherpfennig T, 2003, J CELL BIOL, V161, P609, DOI 10.1083/jcb.200211087; Zhai RG, 2003, P NATL ACAD SCI USA, V100, P10860, DOI 10.1073/pnas.1832753100; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	50	239	249	3	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					607	620		10.1016/j.cell.2005.03.012	http://dx.doi.org/10.1016/j.cell.2005.03.012			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907473	Bronze, Green Accepted			2022-12-28	WOS:000229331200016
J	Oransky, I				Oransky, I			Maurice R Hilleman - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 14	2005	365	9472					1682	1682		10.1016/S0140-6736(05)66536-1	http://dx.doi.org/10.1016/S0140-6736(05)66536-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	925VV	15912596				2022-12-28	WOS:000229082300014
J	Eder, M; Scherr, M				Eder, M; Scherr, M			MicroRNA and lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hannover Med Sch, Dept Hematol & Oncol, D-3000 Hannover, Germany	Hannover Medical School	Eder, M (corresponding author), Hannover Med Sch, Dept Hematol & Oncol, D-3000 Hannover, Germany.							Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637	3	89	98	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2446	2448		10.1056/NEJMcibr051201	http://dx.doi.org/10.1056/NEJMcibr051201			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944431				2022-12-28	WOS:000229638900016
J	Ritter, C; Maddelein, ML; Siemer, AB; Luhrs, T; Ernst, M; Meier, BH; Saupe, SJ; Riek, R				Ritter, C; Maddelein, ML; Siemer, AB; Luhrs, T; Ernst, M; Meier, BH; Saupe, SJ; Riek, R			Correlation of structural elements and infectivity of the HET-s prion	NATURE			English	Article							FUNGUS PODOSPORA-ANSERINA; SOLID-STATE NMR; HETEROKARYON INCOMPATIBILITY; SECONDARY STRUCTURE; AMYLOID FIBRILS; BACKBONE ASSIGNMENTS; H/D-EXCHANGE; IN-VIVO; PROTEIN; SCRAPIE	Prions are believed to be infectious, self-propagating polymers of otherwise soluble, host-encoded proteins(1,2). This concept is now strongly supported by the recent findings that amyloid fibrils of recombinant prion proteins from yeast(3-5), Podospora anserina(6) and mammals(7) can induce prion phenotypes in the corresponding hosts. However, the structural basis of prion infectivity remains largely elusive because acquisition of atomic resolution structural properties of amyloid fibrils represents a largely unsolved technical challenge. HET-s, the prion protein of P. anserina, contains a carboxy-terminal prion domain comprising residues 218 - 289. Amyloid fibrils of HET-s( 218 - 289) are necessary and sufficient for the induction and propagation of prion infectivity(6). Here, we have used fluorescence studies, quenched hydrogen exchange NMR and solid-state NMR to determine the sequence-specific positions of amyloid fibril secondary structure elements of HET-s( 218 - 289). This approach revealed four beta-strands constituted by two pseudo-repeat sequences, each forming a beta-strand-turn-beta- strand motif. By using a structure-based mutagenesis approach, we show that this conformation is the functional and infectious entity of the HET-s prion. These results correlate distinct structural elements with prion infectivity.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Bordeaux 2, CNRS,Unite Mixte Rech 5095, Inst Biochim & Genet Cellulaires, Lab Genet Mol Champignons, F-33077 Bordeaux, France; ETH Honggerberg, ETH Zurich, Phys Chem, CH-8093 Zurich, Switzerland	Salk Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Swiss Federal Institutes of Technology Domain; ETH Zurich	Riek, R (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	riek@salk.edu	MADDELEIN, Marie-Lise/G-5395-2010; Ernst, Matthias/A-6732-2010; Meier, Beat H/K-4066-2016	Ernst, Matthias/0000-0002-9538-6086; Meier, Beat H/0000-0002-9107-4464; saupe, sven/0000-0002-5589-721X; Riek, Roland/0000-0002-6333-066X	NINDS NIH HHS [R01 NS045774-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045774] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Balguerie A, 2004, J CELL SCI, V117, P2599, DOI 10.1242/jcs.01116; Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213; Bracken C, 1997, J BIOMOL NMR, V9, P94, DOI 10.1023/A:1018679819693; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; Coustou-Linares V, 2001, MOL MICROBIOL, V42, P1325, DOI 10.1046/j.1365-2958.2001.02707.x; Dos Reis S, 2002, J BIOL CHEM, V277, P5703, DOI 10.1074/jbc.M110183200; Glass NL, 2003, EUKARYOT CELL, V2, P1, DOI 10.1128/EC.2.1.1-8.2003; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Javitch JA, 2002, METHOD ENZYMOL, V343, P137; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Laws DD, 2001, P NATL ACAD SCI USA, V98, P11686, DOI 10.1073/pnas.201404298; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; LUHRS T, UNPUB NATURE; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Samoson A, 2002, CHEM PHYS LETT, V365, P292, DOI 10.1016/S0009-2614(02)01486-0; Saupe SJ, 2000, MICROBIOL MOL BIOL R, V64, P489, DOI 10.1128/MMBR.64.3.489-502.2000; Siemer AB, 2005, ANGEW CHEM INT EDIT, V44, P2441, DOI 10.1002/anie.200462952; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TURCQ B, 1991, MOL GEN GENET, V228, P265, DOI 10.1007/BF00282475; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Verel R, 2001, J MAGN RESON, V150, P81, DOI 10.1006/jmre.2001.2310; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yamaguchi KI, 2004, J MOL BIOL, V338, P559, DOI 10.1016/j.jmb.2004.02.067	30	374	378	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					844	848		10.1038/nature03793	http://dx.doi.org/10.1038/nature03793			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944710	Green Accepted			2022-12-28	WOS:000229638700056
J	Kang, YA; Lee, HW; Yoon, HI; Cho, BL; Han, SK; Shim, YS; Yim, JJ				Kang, YA; Lee, HW; Yoon, HI; Cho, BL; Han, SK; Shim, YS; Yim, JJ			Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALMETTE-GUERIN VACCINATION; T-CELLS; PREVALENCE; ENUMERATION; PROTEIN; ESAT-6; SCALE	Context A recently developed whole-blood interferon gamma (IFN-gamma) assay based on stimulation with the Mycobacterium tuberculosis-specific antigens early secreted antigenic target 6 and culture filtrate protein 10 shows promise for the diagnosis of latent tuberculosis (TB) infection. Objective To compare the tuberculin skin test (TST) and the whole-blood IFN-gamma assay in the diagnosis of latent TB infection according to the intensity of exposure. Design and Setting A prospective comparison between the whole-blood IFN-gamma assay and the TST using a 2-TU dose of purified protein derivative RT23 in a population with intermediate TB burden was conducted sequentially between February 1, 2004, and February 28, 2005, in a Korean tertiary referral hospital. Participants Of 273 participants, 220 (95.7%) had received BCG vaccine. Participants were grouped according to their risk of infection: group 1, no identifiable risk of M tuberculosis infection (n = 99); group 2, recent casual contacts (n = 72); group 3, recent close contacts (n = 48); group 4, bacteriologically or pathologically confirmed TB patients (n = 54). Main Outcome Measures Levels of agreement between the TST and the IFN-gamma assay and the likelihood of infection in the various groups. Results For the TST with a 10-mm induration cutoff, the positive response rate in group 1 was 51%; group 2, 60%; group 3, 71%, and group 4, 78%. For the IFN-gamma assay, the positive response rate in group 1 was 4%; group 2, 10%; group 3, 44%; and group 4, 81%. The overall agreement between the TST and the IFN-gamma assay in healthy volunteers was kappa = 0.16. The odds of a positive test result per unit increase in exposure across the 4 groups increased by a factor of 5.31 (95% confidence interval [01, 3.62-7.79) for the IFN-gamma assay and by a factor of 1.52 (95% Cl, 1.20-1.91) for the TST (P<.001). Using a 15-mm induration cutoff for the TST did not make a substantial difference to the test results. Conclusion The IFN-gamma assay is abetter indicator of the risk of M tuberculosis infection than TST in a BCG-vaccinated population.	Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Lung Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Family Med, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Yim, JJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, 28 Yongon Dong, Seoul 110744, South Korea.	yimjj@snu.ac.kr	Han, Sung Koo/J-5706-2012; Yoon, Ho Il/J-5567-2012; Yim, Jae Joon/J-2783-2012; Cho, Belong/GLU-3443-2022	Cho, Belong/0000-0001-9558-689X; Yim, Jae-Joon/0000-0002-9605-0074; Kang, Young Ae/0000-0002-7783-5271				*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2; Bahrmand AR, 1996, SCAND J INFECT DIS, V28, P275, DOI 10.3109/00365549609027172; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Brock L, 2004, AM J RESP CRIT CARE, V170, P65, DOI 10.1164/rccm.200402-232OC; Broekmans JF, 2002, EUR RESPIR J, V19, P765, DOI 10.1183/09031936.02.00261402; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Demangel C, 2004, INFECT IMMUN, V72, P2170, DOI 10.1128/IAI.72.4.2170-2176.2004; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362; Hoft DF, 1999, ANN INTERN MED, V131, P32, DOI 10.7326/0003-4819-131-1-199907060-00007; Hong YP, 1998, INT J TUBERC LUNG D, V2, P27; Jasmer RM, 2002, NEW ENGL J MED, V347, P1860, DOI 10.1056/NEJMcp021045; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; *KOR NAT TUB ASS, TUB; Lalvani A, 2004, CLIN INFECT DIS, V38, P757, DOI 10.1086/381763; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; Liu XQ, 2004, INFECT IMMUN, V72, P2574, DOI 10.1128/IAI.72.5.2574-2581.2004; Mazurek Gerald H, 2003, MMWR Recomm Rep, V52, P15; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Nam JM, 2002, BIOMETRICAL J, V44, P558, DOI 10.1002/1521-4036(200207)44:5<558::AID-BIMJ558>3.0.CO;2-5; Pathan AA, 2001, J IMMUNOL, V167, P5217, DOI 10.4049/jimmunol.167.9.5217; Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000; von Reyn CF, 2001, INT J TUBERC LUNG D, V5, P1122; Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804; World Health Organization, TUB	34	359	374	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2756	2761		10.1001/jama.293.22.2756	http://dx.doi.org/10.1001/jama.293.22.2756			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941805	Bronze			2022-12-28	WOS:000229643700024
J	Beaglehole, R; Horton, R				Beaglehole, R; Horton, R			Chronic diseases of adults - a call for papers	LANCET			English	Editorial Material									WHO, CH-1211 Geneva, Switzerland; The Lancet, London NW1 7BY, England	World Health Organization	Beaglehole, R (corresponding author), WHO, CH-1211 Geneva, Switzerland.	beaglehole@WHO.int						LEEDER S, 2004, RACE TIME; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743	2	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1913	1914		10.1016/S0140-6736(05)66640-8	http://dx.doi.org/10.1016/S0140-6736(05)66640-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936408				2022-12-28	WOS:000229587800009
J	Piva, PG; DiLabio, GA; Pitters, JL; Zikovsky, J; Rezeq, M; Dogel, S; Hofer, WA; Wolkow, RA				Piva, PG; DiLabio, GA; Pitters, JL; Zikovsky, J; Rezeq, M; Dogel, S; Hofer, WA; Wolkow, RA			Field regulation of single-molecule conductivity by a charged surface atom	NATURE			English	Article							GENERALIZED GRADIENT APPROXIMATION; SELF-DIRECTED GROWTH; NANOSTRUCTURES; SILICON	Electrical transport through molecules has been much studied since it was proposed(1) that individual molecules might behave like basic electronic devices, and intriguing single-molecule electronic effects have been demonstrated(2,3). But because transport properties are sensitive to structural variations on the atomic scale(4-7), further progress calls for detailed knowledge of how the functional properties of molecules depend on structural features. The characterization of two-terminal structures has become increasingly robust and reproducible(8-12), and for some systems detailed structural characterization of molecules on electrodes or insulators is available(13-17). Here we present scanning tunnelling microscopy observations and classical electrostatic and quantum mechanical modelling results that show that the electrostatic field emanating from a fixed point charge regulates the conductivity of nearby substrate-bound molecules. We find that the onset of molecular conduction is shifted by changing the charge state of a silicon surface atom, or by varying the spatial relationship between the molecule and that charged centre. Because the shifting results in conductivity changes of substantial magnitude, these effects are easily observed at room temperature.	Univ Alberta, Dept Phys, Avadh Bhatia Phys Lab 534, Edmonton, AB T6G 2J1, Canada; Natl Res Council Canada, Natl Inst Nanotechnol, Edmonton, AB T6G 2V4, Canada; Univ Liverpool, Surface Sci Res Ctr, Liverpool L69 3BX, Merseyside, England	University of Alberta; National Research Council Canada; University of Liverpool	Wolkow, RA (corresponding author), Univ Alberta, Dept Phys, Avadh Bhatia Phys Lab 534, Edmonton, AB T6G 2J1, Canada.	rwolkow@ualberta.ca	Rezeq, Moh'd/S-6387-2019; Rezeq, Moh'd/O-9548-2016	Rezeq, Moh'd/0000-0001-9616-2511; Rezeq, Moh'd/0000-0001-9616-2511; DiLabio, Gino/0000-0002-3778-3892; Hofer, Werner/0000-0002-1305-4716				AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; BARDEEN J, 1947, PHYS REV, V71, P717, DOI 10.1103/PhysRev.71.717; Boese AD, 2001, J CHEM PHYS, V114, P5497, DOI 10.1063/1.1347371; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Damle P, 2002, IEEE T NANOTECHNOL, V1, P145, DOI 10.1109/TNANO.2002.806825; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; DiLabio GA, 2004, J AM CHEM SOC, V126, P16048, DOI 10.1021/ja0460007; Emberly EG, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.188301; Feenstra RM, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.081309; Frisch M.J., 2016, GAUSSIAN16 REV B01; Grill L, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.035416; HERZBERG G, 1944, ATOMIC SPECTRA ATOMI, P114; Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6; Kaun CC, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.195309; Kubatkin S, 2003, NATURE, V425, P698, DOI 10.1038/nature02010; Lopinski GP, 2000, NATURE, V406, P48, DOI 10.1038/35017519; Mayne AJ, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.045409; Moresco F, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.036601; Nazin GV, 2003, SCIENCE, V302, P77, DOI 10.1126/science.1088971; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Pitters JL, 2005, J AM CHEM SOC, V127, P48, DOI 10.1021/ja045012p; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Repp J, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.026803; Selzer Y, 2005, NANO LETT, V5, P61, DOI 10.1021/nl048372j; STEVENS WJ, 1984, J CHEM PHYS, V81, P6026, DOI 10.1063/1.447604; Sze S. M, 1981, PHYSICS SEMICONDUCTO; TERSOFF J, 1983, PHYS REV LETT, V50, P1998, DOI 10.1103/PhysRevLett.50.1998; Wold DJ, 2002, J PHYS CHEM B, V106, P2813, DOI 10.1021/jp013476t; Yang Z, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.041402	30	263	267	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2005	435	7042					658	661		10.1038/nature03563	http://dx.doi.org/10.1038/nature03563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931218				2022-12-28	WOS:000229476200046
J	Cohen, MS; Zhang, C; Shokat, KM; Taunton, J				Cohen, MS; Zhang, C; Shokat, KM; Taunton, J			Structural bioinformatics-based design of selective, irreversible kinase inhibitors	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; IDENTIFICATION; COMPLEX; SITE; LCK	The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge. We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK). A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells. Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter. Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.	Univ Calif San Francisco, Program Chem & Chem Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Taunton, J (corresponding author), Univ Calif San Francisco, Program Chem & Chem Biol, San Francisco, CA 94143 USA.	taunton@cmp.ucsf.edu			NIGMS NIH HHS [R01 GM071434-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker AJ, 2001, BIOORG MED CHEM LETT, V11, P1911, DOI 10.1016/S0960-894X(01)00344-4; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Burchat AF, 2000, BIOORG MED CHEM LETT, V10, P2171, DOI 10.1016/S0960-894X(00)00442-X; Buzko O, 2002, BIOINFORMATICS, V18, P1274, DOI 10.1093/bioinformatics/18.9.1274; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chrestensen CA, 2002, J BIOL CHEM, V277, P27733, DOI 10.1074/jbc.M202663200; COHEN M, UNPUB; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Hanauer A, 2002, J MED GENET, V39, P705, DOI 10.1136/jmg.39.10.705; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tsigelny I, 1999, BIOPOLYMERS, V50, P513, DOI 10.1002/(SICI)1097-0282(19991015)50:5<513::AID-BIP5>3.0.CO;2-I; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	21	401	494	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1318	1321		10.1126/science1108367	http://dx.doi.org/10.1126/science1108367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919995	Green Accepted			2022-12-28	WOS:000229482300050
J	Bernal-Mizrachi, C; Gates, AC; Weng, S; Imamura, T; Knutsen, RH; DeSantis, P; Coleman, T; Townsend, RR; Muglia, LJ; Semenkovich, CF				Bernal-Mizrachi, C; Gates, AC; Weng, S; Imamura, T; Knutsen, RH; DeSantis, P; Coleman, T; Townsend, RR; Muglia, LJ; Semenkovich, CF			Vascular respiratory uncoupling increases blood pressure and atherosclerosis	NATURE			English	Article							BROWN ADIPOSE-TISSUE; IDENTIFICATION; METABOLISM; DEFICIENT; PROTEINS; RADICALS; LIPIDS; CELLS; MICE	The observations that atherosclerosis often occurs in nonsmokers without elevated levels of low-density lipoprotein cholesterol, and that most atherosclerosis loci so far identified in mice do not affect systemic risk factors associated with atherosclerosis(1), suggest that as-yet-unidentified mechanisms must contribute to vascular disease. Arterial walls undergo regional disturbances of metabolism(2) that include the uncoupling of respiration and oxidative phosphorylation, a process that occurs to some extent in all cells and may be characteristic of blood vessels being predisposed to the development of atherosclerosis(3). To test the hypothesis that inefficient metabolism in blood vessels promotes vascular disease, we generated mice with doxycycline-inducible expression of uncoupling protein-1 (UCP1) in the artery wall. Here we show that UCP1 expression in aortic smooth muscle cells causes hypertension and increases dietary atherosclerosis without affecting cholesterol levels. UCP1 expression also increases superoxide production and decreases the availability of nitric oxide, evidence of oxidative stress. These results provide proof of principle that inefficient metabolism in blood vessels can cause vascular disease.	Washington Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA.	csemenko@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Bernal-Mizrachi, Carlos/0000-0002-8991-7522	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088083] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK088083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allayee H, 2003, ARTERIOSCL THROM VAS, V23, P1501, DOI 10.1161/01.ATV.0000090886.40027.DC; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Chen JQ, 2001, CIRCULATION, V104, P2391, DOI 10.1161/hc4501.099729; CORNWELL D G, 1981, Progress in Lipid Research, V20, P365, DOI 10.1016/0163-7827(81)90069-2; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; HAYASHIDA T, 1960, P SOC EXP BIOL MED, V103, P656, DOI 10.3181/00379727-103-25625; HEATON JM, 1972, J ANAT, V112, P35; HEUPER WC, 1944, ARCH PATHOL, V38, P162; JENNINGS RB, 1967, ARCH PATHOL, V84, P15; Kanski J, 2005, AM J PHYSIOL-HEART C, V288, pH371, DOI 10.1152/ajpheart.01030.2003; KLEIN PD, 1954, J BIOL CHEM, V211, P103; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Levin M, 2003, ARTERIOSCL THROM VAS, V23, P1801, DOI 10.1161/01.ATV.0000092872.54026.8D; Manning MW, 2003, ARTERIOSCL THROM VAS, V23, P483, DOI 10.1161/01.ATV.0000058404.92759.32; Moessler H, 1996, DEVELOPMENT, V122, P2415; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NOHL H, 1994, ANN BIOL CLIN-PARIS, V52, P199; PETTERSSON G, 1985, ACTA PHARMACOL TOX, V57, P184, DOI 10.1111/bcpt.1985.57.3.184; SANTERRE RF, 1974, EXP MOL PATHOL, V20, P397, DOI 10.1016/0014-4800(74)90069-0; SJODIN B, 1990, SPORTS MED, V10, P236; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SMITH EB, 1962, BIOCHEM J, V84, pP49; SMITH EB, 1962, LANCET, V2, P530; Su B, 2001, CIRC RES, V89, P39, DOI 10.1161/hh1301.093615; SZEKELY M, 1970, EXPERIENTIA, V26, P1314, DOI 10.1007/BF02112999; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; WATTS HF, 1963, EVOLUTION ATHEROSCLE, P117; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890	30	141	150	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					502	506		10.1038/nature03527	http://dx.doi.org/10.1038/nature03527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917810				2022-12-28	WOS:000229337800056
J	Haynes, RB; McKibbon, KA; Wilczynski, NL; Walter, SD; Werre, SR				Haynes, RB; McKibbon, KA; Wilczynski, NL; Walter, SD; Werre, SR		Hedges Team	Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS	Objective To develop and test optimal Medline search strategies for retrieving sound clinical studies on prevention or treatment of health disorders. Design Analytical survey. Data sources 161 clinical journals indexed in Medline for the year 2000. Main outcome measures Sensitivity, specificity, precision, and accuracy of 4862 unique terms in 18 404 combinations. Results Only 1587 (24.2%) of 6568 articles on treatment met criteria for testing clinical interventions. Combinations of search terms reached peak sensitivities of 99.3% (95% confidence interval 98.7% to 99.8%) at a specificity of 70.4% (69.8% to 70.9%). Compared with best single terms, best multiple terms increased sensitivity for sound studies by 4.1% (absolute increase), but with substantial loss of specificity (absolute difference 23.7%) when sensitivity was maximised. When terms were combined to maximise specificity, 97.4% (97.3% to 97.6%) was achieved, about the same as that achieved by the best single term (97.6%, 97.4% to 97.7%). The strategies newly reported in this paper outperformed other validated search strategies except for two strategies that had slightly higher specificity (98.1% and 97.6% v 97.4%) but lower sensitivity (42.0% and 92.8% v 93.1%). Conclusion New empirical search strategies have been validated to optimise retrieval of articles from Medline reporting high quality clinical studies on prevention or treatment of health disorders.	McMaster Univ, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Sch Grad Studies, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; Univ Pittsburgh, Ctr Biomed Informat, Pittsburgh, PA USA	McMaster University; McMaster University; McMaster University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Haynes, RB (corresponding author), McMaster Univ, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada.	bhaynes@mcmaster.ca	Walter, Stephen/AAB-5548-2022	Walter, Stephen/0000-0003-4157-8928; Haynes, Robert Brian/0000-0002-1453-3196	NATIONAL LIBRARY OF MEDICINE [R01LM006866] Funding Source: NIH RePORTER; NLM NIH HHS [R01 LM06866-01] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ADAMS CE, 1994, PSYCHOL MED, V24, P741, DOI 10.1017/S0033291700027896; Dumbrigue H B, 2000, J Prosthodont, V9, P8, DOI 10.1111/j.1532-849X.2000.00008.x; Haynes RB, 2004, BMJ-BRIT MED J, V328, P1040, DOI 10.1136/bmj.38068.557998.EE; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Jadad AR., 1993, ONLINE J CURR CLIN T; Julien JP, 2000, LANCET, V355, P528, DOI 10.1016/S0140-6736(99)06341-2; Marson AG, 1996, EPILEPSIA, V37, P377, DOI 10.1111/j.1528-1157.1996.tb00575.x; Montori VM, 2005, BMJ-BRIT MED J, V330, P68, DOI 10.1136/bmj.38336.804167.47; *NAT LIB MED, NUMB MEDL RES; Nwosu CR, 1998, OBSTET GYNECOL, V91, P618, DOI 10.1016/S0029-7844(97)00703-5; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; *U ROCH MED CTR, 2003, EV BAS FILT OV MED; *U ROCH MED CTR EG, EV BAS FILT OV MEDL; Wilczynski NL, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P904; Wilczynski NL, 2001, STUD HEALTH TECHNOL, V84, P390	15	333	338	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2005	330	7501					1179	1182A		10.1136/bmj.38446.498542.8F	http://dx.doi.org/10.1136/bmj.38446.498542.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15894554	Green Published, Bronze			2022-12-28	WOS:000229320500016
J	Ballas, N; Grunseich, C; Lu, DD; Speh, JC; Mandel, G				Ballas, N; Grunseich, C; Lu, DD; Speh, JC; Mandel, G			REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis	CELL			English	Article							RESTRICTIVE SILENCER FACTOR; EMBRYONIC STEM-CELLS; RETT-SYNDROME; TARGET GENES; METHYLATION PATTERNS; HISTONE METHYLATION; REPRESSOR COMPLEX; ACTIVE REPRESSION; NEURAL INDUCTION; IN-VIVO	Regulation of neuronal gene expression is critical to central nervous system development. Here, we show that REST regulates the transitions from pluripotent to neural stem/progenitor cell and from progenitor to mature neuron. In the transition to progenitor cell, REST is degraded to levels just sufficient to maintain neuronal gene chromatin in an inactive state that is nonetheless poised for expression. As progenitors differentiate into neurons, REST and its corepressors dissociate from the RE1 site, triggering activation of neuronal genes. In some genes, the level of expression is adjusted further in neurons by CoREST/MeCP2 repressor complexes that remain bound to a site of methylated DNA distinct from the RE1 site. Expression profiling based on this mechanism indicates that REST defines a gene set subject to plasticity in mature neurons. Thus, a multistage repressor mechanism controls the orderly expression of genes during development while still permitting fine tuning in response to specific stimuli.	SUNY Stony Brook, Howard Hughes Med Inst, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ballas, N (corresponding author), SUNY Stony Brook, Howard Hughes Med Inst, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.	nballas@notes.cc.sunysb.edu						Anderson D, 1997, MOL CELLULAR APPROAC, P26; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Arnold DB, 1997, P NATL ACAD SCI USA, V94, P8842, DOI 10.1073/pnas.94.16.8842; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Casarosa S, 1999, DEVELOPMENT, V126, P525; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Koide T, 2001, GENE DEV, V15, P2111, DOI 10.1101/gad.908801; Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Nan XH, 2001, BRAIN DEV-JPN, V23, pS32, DOI 10.1016/S0387-7604(01)00333-3; Paquette AJ, 2000, P NATL ACAD SCI USA, V97, P12318, DOI 10.1073/pnas.97.22.12318; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Sasai Y, 1998, NEURON, V21, P455, DOI 10.1016/S0896-6273(00)80554-1; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; Van den Veyver IB, 2001, BRAIN DEV-JPN, V23, pS147, DOI 10.1016/S0387-7604(01)00376-X; Weston AD, 2003, J CELL BIOL, V161, P223, DOI 10.1083/jcb.200211117; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8	48	683	707	0	38	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					645	657		10.1016/j.cell.2005.03.013	http://dx.doi.org/10.1016/j.cell.2005.03.013			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907476	Bronze			2022-12-28	WOS:000229331200019
J	Bilham, R				Bilham, R			A flying start, then a slow slip	SCIENCE			English	Editorial Material								The human tragedy caused by the Sumatra-Andaman earthquake (moment magnitude 9.3) on 26 December 2004 and its companion Nias earthquake (moment magnitude 8.7) on 28 March 2005 is difficult to comprehend. These earthquakes, the largest in 40 years, have also left seismologists searching for the words and tools to describe the enormity of the geological processes involved. Four papers in this issue discuss aspects of a rupture process of surprising complexity, the first such event to test the sensitivity and range of many new technologies. A surprising feature of the earthquake is that after the initial rapid rupture, subsequent slip of the plate interface occurred with decreasing speed toward the north.	Univ Colorado, Cooperat Inst Res Environm Sci & Geol Sci, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Bilham, R (corresponding author), Univ Colorado, Cooperat Inst Res Environm Sci & Geol Sci, Boulder, CO 80309 USA.	roger.bilham@colorado.edu		Bilham, Roger/0000-0002-5547-4102				Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; BANERJEE P, 2005, SCIENCE         0519, DOI DOI 10.1126/SCIENCE.1113746; BILHAM R, IN PRESS SEISM RES L; Bilham R., 2005, GEOL SURV INDIA SPEC, V85, P1; CUMMINS P, 2005, AUSGEO NEWS      MAR; Curray JR, 2005, J ASIAN EARTH SCI, V25, P187, DOI 10.1016/j.jseaes.2004.09.001; ISHII M, IN PRESS NATURE; JADE S, IN PRESS CURRENT SCI; MCCLOSKEY J, IN PRESS NATURE; Ortiz M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001941; Park J, 2005, SCIENCE, V308, P1139, DOI 10.1126/science.1112305; RAJENDRAN CP, UNPUB; West M, 2005, SCIENCE, V308, P1144, DOI 10.1126/science.1112462	13	128	143	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1126	1127		10.1126/science.1113363	http://dx.doi.org/10.1126/science.1113363			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905391				2022-12-28	WOS:000229293400032
J	Bowerman, B				Bowerman, B			Oxidative stress and cancer: A beta-catenin convergence	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTORS; CELL-CYCLE; GENE		Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Bowerman, B (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	bbowerman@molbio.uoregon.edu						Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; KOPS GJ, 2002, MOL CELL BIOL, V22, P316; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319	12	40	46	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2005	308	5725					1119	1120		10.1126/science.1113356	http://dx.doi.org/10.1126/science.1113356			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905385				2022-12-28	WOS:000229293400026
J	Zupan, J				Zupan, J			Prenatal mortality in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									WHO, Dept Making Pregnancy Safer, Geneva, Switzerland	World Health Organization	Zupan, J (corresponding author), WHO, Dept Making Pregnancy Safer, Geneva, Switzerland.							VAYENA E, 2002, MED ETH SOC ASP ASS; World Health Organization, 2005, WORLD HLTH REP 2005	2	108	110	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2047	2048		10.1056/NEJMp058032	http://dx.doi.org/10.1056/NEJMp058032			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	927GJ	15901857				2022-12-28	WOS:000229180100002
J	Lassen, K; Hannemann, P; Ljungqvist, O; Fearon, K; Dejong, CHC; von Meyenfeldt, MF; Hausel, J; Nygren, J; Andersen, J; Revhaug, A				Lassen, K; Hannemann, P; Ljungqvist, O; Fearon, K; Dejong, CHC; von Meyenfeldt, MF; Hausel, J; Nygren, J; Andersen, J; Revhaug, A		ERAS Grp	Patterns in current perioperative practice: survey of colorectal surgeons in five northern European countries	BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS		Univ Hosp No Norway, Dept Gastrointestinal Surg, N-9038 Tromso, Norway; Univ Hosp Maastricht, Dept Surg, NL-6202 AZ Maastricht, Netherlands; Karolinska Univ Hosp, Div Surg, Surg Sci Ctr, Stockholm, Sweden; Univ Edinburgh, Sch Clin Sci & Community Hlth, Edinburgh EH16 4SA, Midlothian, Scotland; Hvidovre Univ Hosp 435, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark	UiT The Arctic University of Tromso; University Hospital of North Norway; Maastricht University; Maastricht University Medical Centre (MUMC); Karolinska Institutet; Karolinska University Hospital; University of Edinburgh	Lassen, K (corresponding author), Univ Hosp No Norway, Dept Gastrointestinal Surg, N-9038 Tromso, Norway.	lassen@unn.no	Nygren, Jonas/AAQ-2775-2021	Hannemann, Pascal/0000-0003-1861-4329; Revhaug, Arthur/0000-0002-7949-3770				Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23; CHEATHAM ML, 1995, ANN SURG, V221, P469, DOI 10.1097/00000658-199505000-00004; KEHLET H, 1998, NEURAL BLOCKADE CLIN, P129; Lewis SJ, 2001, BRIT MED J, V323, P773, DOI 10.1136/bmj.323.7316.773; Willcox B, 2003, COMMUN ACM, V46, P13	5	182	190	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 18	2005	330	7505					1420	1421		10.1136/bmj.38478.568067.AE	http://dx.doi.org/10.1136/bmj.38478.568067.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15911535	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000230010400017
J	de Beaufort, I				de Beaufort, I			Patients in a persistent vegetative state - A dutch perspective	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Erasmus Univ, Erasmus Med Ctr, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	de Beaufort, I (corresponding author), Erasmus Univ, Erasmus Med Ctr, Rotterdam, Netherlands.							*HLTH COUNC, 1994, PAT VEG TOEST; Lavrijsen J, 2005, BRAIN INJURY, V19, P67, DOI 10.1080/02699050410001720013; LAVRIJSEN JCM, IN PRESS J NEUROL NE; *ROYAL DUTCH MED A, 1997, MED HAND ROND LEV BI	4	13	13	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2373	2375		10.1056/NEJMp058094	http://dx.doi.org/10.1056/NEJMp058094			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944421				2022-12-28	WOS:000229638900002
J	Edwards, P; Arango, M; Balica, L; Cottingham, R; El-Sayed, H; Farrell, B; Fernandes, J; Gogichaisvili, T; Golden, N; Hartzenberg, B; Husain, M; Ulloa, MI; Jerbi, Z; Khamis, H; Komolafe, E; Laloe, V; Lomas, G; Ludwig, S; Mazairac, G; Sanchz, MDAM; Nasi, L; Olldashi, F; Plunkett, P; Roberts, I; Sandercock, P; Shakur, H; Soler, C; Stocker, R; Svoboda, P; Trenkler, S; Venkataramana, NK; Wasserberg, J; Yates, D; Yutthakasemsunt, S				Edwards, P; Arango, M; Balica, L; Cottingham, R; El-Sayed, H; Farrell, B; Fernandes, J; Gogichaisvili, T; Golden, N; Hartzenberg, B; Husain, M; Ulloa, MI; Jerbi, Z; Khamis, H; Komolafe, E; Laloe, V; Lomas, G; Ludwig, S; Mazairac, G; Sanchz, MDAM; Nasi, L; Olldashi, F; Plunkett, P; Roberts, I; Sandercock, P; Shakur, H; Soler, C; Stocker, R; Svoboda, P; Trenkler, S; Venkataramana, NK; Wasserberg, J; Yates, D; Yutthakasemsunt, S		CRASH Trial Collaborators	Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury - outcomes at 6 months	LANCET			English	Article								MRC CRASH is a randomised controlled trial (ISRCTN74459797) of the effect of corticosteroids on death and disability after head injury. We randomly allocated 10 008 adults with head injury and a Glasgow Coma Scale score of 14 or less, within 8 h of injury, to a 48-h infusion of corticosteroid (methylprednisolone) or placebo. Data at 6 months were obtained for 9673 (96.7%) patients. The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25.7%] vs 1075 [22.3%] deaths; relative risk 1.15, 95% Cl 1.07-1.24; p=0.0001), as was the risk of death or severe disability (1828 [38.1%] vs 1728 [36.3%] dead or severely disabled; 1.05, 0.99-1.10; p=0.079). There was no evidence that the effect of corticosteroids differed by injury severity or time since injury. These results lend support to our earlier conclusion that corticosteroids should not be used routinely in the treatment of head injury.	Univ London London Sch Hyg & Trop Med, CRASH Trials Coordinating Ctr, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Edwards, P (corresponding author), Univ London London Sch Hyg & Trop Med, CRASH Trials Coordinating Ctr, Keppel St, London WC1E 7HT, England.	crash@lshtm.ac.uk	Wasserberg, Jonathan/AAB-7099-2020; Khalil, Nabil/A-9528-2015; Abdullah, Jafri Malin/C-2828-2011	Wasserberg, Jonathan/0000-0002-3782-0390; Khalil, Nabil/0000-0001-6293-7972; Edwards, Phil/0000-0003-4431-8822; Shakur-Still, Haleema/0000-0002-6511-109X; MacMahon, Stephen/0000-0003-2064-7699; komolafe, edward/0000-0003-1261-3501; Plunkett, Patrick/0000-0003-0714-2717; Abdullah, Jafri Malin/0000-0002-0258-7410				Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Peto R, 2005, LANCET, V365, P213; Pocock S, 1999, LANCET, V353, P943, DOI 10.1016/S0140-6736(98)00379-1; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	5	463	485	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1957	1959						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936423				2022-12-28	WOS:000229587800030
J	Demir, E; Dickson, BJ				Demir, E; Dickson, BJ			fruitless splicing specifies male courtship behavior in Drosophila	CELL			English	Article							DETERMINATION GENE FRUITLESS; MALE-SPECIFIC MUSCLE; AXON GUIDANCE; EXPRESSION PATTERNS; SEXUAL ORIENTATION; FEMALE DROSOPHILA; MUTANT DROSOPHILA; MELANOGASTER; DOUBLESEX; PROTEIN	All animals exhibit innate behaviors that are specified during their development. Drosophila melanogaster males (but not females) perform an elaborate and innate courtship ritual directed toward females (but not males). Male courtship requires products of the fruitless (fru) gene, which is spliced differently in males and females. We have generated alleles of fru that are constitutively spliced in either the male or the female mode. We show that male splicing is essential for male courtship behavior and sexual orientation. More importantly, male splicing is also sufficient to generate male behavior in otherwise normal females. These females direct their courtship toward other females (or males engineered to produce female pheromones). The splicing of a single neuronal gene thus specifies essentially all aspects of a complex innate behavior.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Dickson, BJ (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3-5, A-1030 Vienna, Austria.	barry.dickson@imba.oeaw.ac.at	Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X				AIGAKI T, 1991, NEURON, V7, P557, DOI 10.1016/0896-6273(91)90368-A; Anand A, 2001, GENETICS, V158, P1569; Arthur BI, 1998, CURR BIOL, V8, P1187, DOI 10.1016/S0960-9822(07)00491-5; Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Billeter JC, 2004, J COMP NEUROL, V475, P270, DOI 10.1002/cne.20177; Billeter JC, 2002, ADV GENET, V47, P87, DOI 10.1016/S0065-2660(02)47003-4; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Chen S, 2002, P NATL ACAD SCI USA, V99, P5664, DOI 10.1073/pnas.082102599; CURRIE DA, 1995, DEVELOPMENT, V121, P2549; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; Ferveur JF, 1997, SCIENCE, V276, P1555, DOI 10.1126/science.276.5318.1555; GAILEY DA, 1991, DEVELOPMENT, V113, P879; GARCIABELLIDO A, 1975, CIBA F SYMP, P161, DOI DOI 10.1002/9780470720110.CH8; GILL KULBIR S., 1963, AMER ZOOL, V3, P507; Goeke S, 2003, NAT NEUROSCI, V6, P917, DOI 10.1038/nn1105; Goodwin SF, 2000, GENETICS, V154, P725; GREENSPAN RJ, 1995, SCI AM, V272, P72, DOI 10.1038/scientificamerican0495-72; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HALL JC, 1978, BEHAV GENET, V8, P125, DOI 10.1007/BF01066870; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; Horiuchi T, 2003, GENE DEV, V17, P2496, DOI 10.1101/gad.1137303; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; Kido A, 2002, J NEUROBIOL, V52, P302, DOI 10.1002/neu.10100; LAWRENCE PA, 1984, CELL, V36, P775, DOI 10.1016/0092-8674(84)90357-X; Lee G, 2001, J NEUROBIOL, V47, P121, DOI 10.1002/neu.1021; Lee G, 2001, J NEUROSCI, V21, P513, DOI 10.1523/JNEUROSCI.21-02-00513.2001; Lee G, 2000, J NEUROBIOL, V43, P404, DOI 10.1002/1097-4695(20000615)43:4<404::AID-NEU8>3.0.CO;2-D; Lim MM, 2004, NATURE, V429, P754, DOI 10.1038/nature02539; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Newsome TP, 2000, DEVELOPMENT, V127, P851; Nilsen SP, 2004, P NATL ACAD SCI USA, V101, P12342, DOI 10.1073/pnas.0404693101; Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Santel A, 1997, MECH DEVELOP, V64, P19, DOI 10.1016/S0925-4773(97)00031-2; Schlote, 1984, DROS INFORM SERV, V60, P210; SIEGEL RW, 1979, P NATL ACAD SCI USA, V76, P3430, DOI 10.1073/pnas.76.7.3430; Stockinger P, 2005, CELL, V121, P795, DOI 10.1016/j.cell.2005.04.026; TAYLOR BJ, 1992, DEVELOPMENT, V114, P625; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; TAYLOR BJ, 1992, GENETICS, V132, P179; Tinbergen N, 1951, STUDY INSTINCT; Usui-Aoki K, 2000, NAT CELL BIOL, V2, P500, DOI 10.1038/35019537; Vargha-Khadem F, 2005, NAT REV NEUROSCI, V6, P131, DOI 10.1038/nrn1605; Villella A, 1996, GENETICS, V143, P331; Villella A, 1997, GENETICS, V147, P1107; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475	52	328	336	3	77	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					785	794		10.1016/j.cell.2005.04.027	http://dx.doi.org/10.1016/j.cell.2005.04.027			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935764	Bronze			2022-12-28	WOS:000229658000016
J	Rostrup-Nielsen, JR				Rostrup-Nielsen, JR			Making fuels from biomass	SCIENCE			English	Editorial Material							ENERGY		Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark	Haldor Topsoe	Rostrup-Nielsen, JR (corresponding author), Haldor Topsoe Res Labs, Nymollevej 55, DK-2800 Lyngby, Denmark.	jrn@topsoe.dk						Deluga GA, 2004, SCIENCE, V303, P993, DOI 10.1126/science.1093045; Huber GW, 2005, SCIENCE, V308, P1446, DOI 10.1126/science.1111166; Huber GW, 2003, SCIENCE, V300, P2075, DOI 10.1126/science.1085597; Rostrup-Nielsen JR, 2004, CATAL REV, V46, P247, DOI 10.1081/CR-200036716; Weisz PB, 2004, PHYS TODAY, V57, P47, DOI 10.1063/1.1784302	5	166	175	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1421	1422		10.1126/science.1113354	http://dx.doi.org/10.1126/science.1113354			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933189				2022-12-28	WOS:000229619300038
J	Kimel, AV; Kirilyuk, A; Usachev, PA; Pisarev, RV; Balbashov, AM; Rasing, T				Kimel, AV; Kirilyuk, A; Usachev, PA; Pisarev, RV; Balbashov, AM; Rasing, T			Ultrafast non-thermal control of magnetization by instantaneous photomagnetic pulses	NATURE			English	Article							RAMAN-SCATTERING; ELECTRIC-FIELD; NICKEL; FERROMAGNETISM; SEMICONDUCTOR; EXCITATIONS; DYNAMICS	The demand for ever-increasing density of information storage and speed of manipulation has triggered an intense search for ways to control the magnetization of a medium by means other than magnetic fields(1-5). Recent experiments on laser-induced demagnetization(6-8) and spin reorientation(9) use ultrafast lasers as a means to manipulate magnetization, accessing timescales of a picosecond or less. However, in all these cases the observed magnetic excitation is the result of optical absorption followed by a rapid temperature increase. This thermal origin of spin excitation considerably limits potential applications because the repetition frequency is limited by the cooling time(10). Here we demonstrate that circularly polarized femtosecond laser pulses can be used to non-thermally excite and coherently control the spin dynamics in magnets by way of the inverse Faraday effect. Such a photomagnetic interaction is instantaneous and is limited in time by the pulse width (similar to 200 fs in our experiment). Our finding thus reveals an alternative mechanism of ultrafast coherent spin control, and offers prospects for applications of ultrafast lasers in magnetic devices.	Radboud Univ Nijmegen, IMM, NL-6525 ED Nijmegen, Netherlands; AF Ioffe Phys Tech Inst, St Petersburg 194021, Russia; Moscow Power Engn Inst, Moscow 111250, Russia	Radboud University Nijmegen; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Ioffe Physical Technical Institute; Moscow Power Engineering Institute	Rasing, T (corresponding author), Radboud Univ Nijmegen, IMM, NL-6525 ED Nijmegen, Netherlands.	th.rasing@science.ru.nl	Rasing, Theo/D-5207-2012; Usachev, Pavel A/G-3310-2013; Kirilyuk, Andrei/D-7798-2012; Kimel, Alexey/D-5112-2012	Rasing, Theo/0000-0002-6656-5528; Usachev, Pavel A/0000-0002-1386-6466; Kirilyuk, Andrei/0000-0003-1479-9872; Kimel, Alexey/0000-0002-0709-042X				Asamitsu A, 1997, NATURE, V388, P50, DOI 10.1038/40363; AWSCHALOM DD, 1987, PHYS REV LETT, V58, P812, DOI 10.1103/PhysRevLett.58.812; Balbashov A. M., 1985, Soviet Physics - JETP, V61, P573; Beaurepaire E, 1996, PHYS REV LETT, V76, P4250, DOI 10.1103/PhysRevLett.76.4250; Dzyaloshinsky I. E., 1957, SOV PHYS JETP, V32, P1547; Faraday M., 1846, PHIL T R SOC, V136, P104; Gomez-Abal R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.227402; Hohlfeld J, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.012413; Hohlfeld J, 1997, PHYS REV LETT, V78, P4861, DOI 10.1103/PhysRevLett.78.4861; Kato Y, 2004, NATURE, V427, P50, DOI 10.1038/nature02202; Keller U, 2003, NATURE, V424, P831, DOI 10.1038/nature01938; Kimel AV, 2004, NATURE, V429, P850, DOI 10.1038/nature02659; Koopmans B, 2000, PHYS REV LETT, V85, P844, DOI 10.1103/PhysRevLett.85.844; KOSHIZUKA N, 1988, J PHYS SOC JPN, V57, P4418, DOI 10.1143/JPSJ.57.4418; Landau LD., 1984, ELECTRODYNAMICS CONT; Lottermoser T, 2004, NATURE, V430, P541, DOI 10.1038/nature02728; MORIYA T, 1960, PHYS REV, V120, P91, DOI 10.1103/PhysRev.120.91; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; PERSHAN PS, 1966, PHYS REV, V143, P574, DOI 10.1103/PhysRev.143.574; PITAEVSKII LP, 1961, SOV PHYS JETP-USSR, V12, P1008; SHEN YR, 1960, PHYS REV, V143, P372; VANDERZIEL JP, 1965, PHYS REV LETT, V15, P190, DOI 10.1103/PhysRevLett.15.190; WHITE RM, 1982, PHYS REV B, V25, P1822, DOI 10.1103/PhysRevB.25.1822; Wijn H. P. J., 1981, LANDOLTBORNSTEIN, VIII, P125; Yamanouchi M, 2004, NATURE, V428, P539, DOI 10.1038/nature02441; Zvezdin A.K., 1997, MODERN MAGNETOOPTICS	26	842	859	5	340	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					655	657		10.1038/nature03564	http://dx.doi.org/10.1038/nature03564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15917826				2022-12-28	WOS:000229476200045
J	Kaner, RB; Gilman, JJ; Tolbert, SH				Kaner, RB; Gilman, JJ; Tolbert, SH			Materials science - Designing superhard materials	SCIENCE			English	Editorial Material							COMPRESSIBILITY; CARBON; NITRIDE; DIAMOND		Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kaner, RB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	kaner@chem.ucla.edu; gilman@seas.ucla.edu; tolbert@chem.ucla.edu	Kaner, Richard B./K-1594-2019; Tolbert, Sarah H./L-2321-2016	Kaner, Richard B./0000-0003-0345-4924; 				Barnett S, 1998, PHYS WORLD, V11, P45; Brazhkin VV, 2002, PHILOS MAG A, V82, P231, DOI 10.1080/0141861011006774-3; Cumberland RW, 2005, J AM CHEM SOC, V127, P7264, DOI 10.1021/ja043806y; Dubrovinskaia NA, 1999, J ALLOY COMPD, V285, P242, DOI 10.1016/S0925-8388(98)00932-3; HAINES J, 1993, PHYS REV B, V48, P13344, DOI 10.1103/PhysRevB.48.13344; Haines J, 2001, ANN REV MATER RES, V31, P1, DOI 10.1146/annurev.matsci.31.1.1; LI D, 1995, APPL PHYS LETT, V67, P203, DOI 10.1063/1.114667; LIU AY, 1989, SCIENCE, V245, P841, DOI 10.1126/science.245.4920.841; Orlov Y.L., 1977, MINERALOGY DIAMOND; SASAKI T, 1993, CHEM MATER, V5, P695, DOI 10.1021/cm00029a020; Teter DM, 1998, MRS BULL, V23, P22, DOI 10.1557/S0883769400031420; Teter DM, 1996, SCIENCE, V271, P53, DOI 10.1126/science.271.5245.53; Weiler M, 1996, PHYS REV B, V53, P1594, DOI 10.1103/PhysRevB.53.1594; Yip S, 1998, NATURE, V391, P532, DOI 10.1038/35254	14	618	637	16	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2005	308	5726					1268	1269		10.1126/science.1109830	http://dx.doi.org/10.1126/science.1109830			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919983				2022-12-28	WOS:000229482300034
J	Selby, D; Creaser, RA				Selby, D; Creaser, RA			Direct radiometric dating of hydrocarbon deposits using rhenium-osmium isotopes	SCIENCE			English	Article							CRETACEOUS MANNVILLE GROUP; BLACK SHALE; ALBERTA; CONSTRAINTS; ORIGIN; SYSTEM; BASIN; OILS	Rhenium-osmium (Re-Os) data from migrated hydrocarbons establish the timing of petroleum emplacement for the giant oil sand deposits of Alberta, Canada, at 112 +/- 5.3 million years ago. This date does not support models that invoke oil generation and migration for these deposits in the Late Cretaceous. Most Re-Os data from a variety of deposits within the giant hydrocarbon system show similar characteristics, supporting the notion of a single source for these hydrocarbons. The Re-Os data disqualify Cretaceous rocks as the primary hydrocarbon source but suggest an origin from older source rocks. This approach should be applicable to dating oil deposits worldwide.	Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada; Univ Durham, Dept Earth Sci, Durham DH1 3LE, England	University of Alberta; Durham University	Selby, D (corresponding author), Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada.	dselby@ualberta.ca		Creaser, Robert/0000-0002-7672-035X				Adams JJ, 2004, CAN J EARTH SCI, V41, P1077, DOI 10.1139/E04-052; ALLAN J, 1991, B CAN PETROL GEOL, V39, P107; ALLEGRE CJ, 1980, EARTH PLANET SC LETT, V48, P148, DOI 10.1016/0012-821X(80)90177-6; [Anonymous], 1993, ORG GEOCHEM; BARSON D, 2000, 3946 GEOL SURV CAN; BROOKS PW, 1988, ORG GEOCHEM, V12, P519, DOI 10.1016/0146-6380(88)90144-1; BROOKS PW, 1989, P E OIL SHAL S NOV 1, P104; Burden E. T., 1984, CANADIAN SOC PETROLE, V9, P249; CAO S, 1992, USE QUANTITATIVE BAS; Cioppa MT, 2003, AAPG BULL, V87, P71; Cohen AS, 1999, EARTH PLANET SC LETT, V167, P159, DOI 10.1016/S0012-821X(99)00026-6; CREANEY S, 1994, GEOLOGICAL ATLAS W C, P455; Creaney S., 1990, GEOLOGICAL SOC LONDO, DOI [10.1144/GSL.SP.1990.050.01.9, DOI 10.1144/GSL.SP.1990.050.01.9]; Creaser RA, 2002, GEOCHIM COSMOCHIM AC, V66, P3441, DOI 10.1016/S0016-7037(02)00939-0; Deroo G., 1977, GEOLOGICAL SURVEY CA, V262, P136; Dickin A.P., 1995, RADIOGENIC ISOTOPE G; ESSER BK, 1993, GEOCHIM COSMOCHIM AC, V57, P3093, DOI 10.1016/0016-7037(93)90296-9; Issler DR, 1999, B CAN PETROL GEOL, V47, P475; John B. St, 1980, SEDIMENTARY BASINS W; Kendall BS, 2004, EARTH PLANET SC LETT, V222, P729, DOI 10.1016/j.epsl.2004.04.004; KRAMERS JW, 1987, GEOL ASS CAN MIN ASS, P48; Masters J.A., 1984, ELMWORTH CASE STUDY, V38, P1, DOI [10.1306/M38441C1, DOI 10.1306/M38441C1]; MOSHIER SO, 1985, AAPG BULL, V69, P161; Peucker-Ehrenbrink B, 2000, TERRA NOVA, V12, P205, DOI 10.1046/j.1365-3121.2000.00295.x; RAVIZZA G, 1989, GEOCHIM COSMOCHIM AC, V53, P3257, DOI 10.1016/0016-7037(89)90105-1; RIEDIGER C, 2000, GEOCANADA 2000; Riediger CL, 1999, B CAN PETROL GEOL, V47, P43; Selby D, 2003, CHEM GEOL, V200, P225, DOI 10.1016/S0009-2541(03)00199-2; SELBY D, IN PRESS GEOLOGY; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; Sun WD, 2003, NATURE, V422, P294, DOI 10.1038/nature01482; SYMONS DTA, 1993, CAN J EARTH SCI, V30, P1028, DOI 10.1139/e93-086; [No title captured]	33	131	155	8	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1293	1295		10.1126/science.1111081	http://dx.doi.org/10.1126/science.1111081			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919988				2022-12-28	WOS:000229482300042
J	Gigant, B; Wang, CG; Ravelli, RBG; Roussi, F; Steinmetz, MO; Curmi, PA; Sobel, A; Knossow, M				Gigant, B; Wang, CG; Ravelli, RBG; Roussi, F; Steinmetz, MO; Curmi, PA; Sobel, A; Knossow, M			Structural basis for the regulation of tubulin by vinblastine	NATURE			English	Article							STATHMIN-LIKE DOMAIN; VINCA ALKALOIDS; BETA-TUBULIN; BINDING-SITE; MICROTUBULE; COLCHICINE; MECHANISM; CRYSTALLOGRAPHY; LOCALIZATION; INHIBITION	Vinblastine is one of several tubulin-targeting Vinca alkaloids that have been responsible for many chemotherapeutic successes since their introduction in the clinic as antitumour drugs(1). In contrast with the two other classes of small tubulin-binding molecules (Taxol(2) and colchicine(3)), the binding site of vinblastine is largely unknown and the molecular mechanism of this drug has remained elusive. Here we report the X-ray structure of vinblastine bound to tubulin in a complex with the RB3 protein stathmin-like domain (RB3-SLD). Vinblastine introduces a wedge at the interface of two tubulin molecules and thus interferes with tubulin assembly. Together with electron microscopical and biochemical data, the structure explains vinblastine-induced tubulin self-association into spiral aggregates at the expense of microtubule growth(4). It also shows that vinblastine and the amino-terminal part of RB3-SLD binding sites share a hydrophobic groove on the alpha-tubulin surface that is located at an intermolecular contact in microtubules. This is an attractive target for drugs designed to perturb microtubule dynamics by interfacial interference, for which tubulin seems ideally suited because of its propensity to self-associate.	Lab Enzymol & Biochim Struct, CNRS, UPR 9063, F-91198 Gif Sur Yvette, France; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France; CNRS, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France; Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Inst Fer Moulin, UPMC, INSERM, U706, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Knossow, M (corresponding author), Lab Enzymol & Biochim Struct, CNRS, UPR 9063, Batiment 34,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	knossow@lebs.cnrs-gif.fr	Steinmetz, Michel O/AAA-3349-2022; CURMI, Patrick/G-4036-2013	Steinmetz, Michel O/0000-0001-6157-3687; CURMI, Patrick A./0000-0001-5045-8501; Ravelli, Raimond/0000-0001-6056-5888; Gigant, Benoit/0000-0002-5946-6759				Bau R, 2000, J CHEM SOC PERK T 1, P2079, DOI 10.1039/b001855o; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Ennifar E, 2002, ACTA CRYSTALLOGR D, V58, P1262, DOI 10.1107/S0907444902009526; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; HASKINS KM, 1981, J CELL SCI, V47, P237; HIMES RH, 1991, PHARMACOL THERAPEUT, V51, P257, DOI 10.1016/0163-7258(91)90081-V; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; JORDAN MA, 1991, CANCER RES, V51, P2212; Lobert S, 2000, BIOCHEMISTRY-US, V39, P12053, DOI 10.1021/bi001038r; Mitra A, 2004, BIOCHEMISTRY-US, V43, P13955, DOI 10.1021/bi0487387; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; NA GC, 1986, BIOCHEMISTRY-US, V25, P6214, DOI 10.1021/bi00368a057; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 2003, CURR OPIN STRUC BIOL, V13, P256, DOI 10.1016/S0959-440X(03)00029-0; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Ogawa T, 2004, CELL, V116, P591, DOI 10.1016/S0092-8674(04)00129-1; Rai SS, 1996, J BIOL CHEM, V271, P14707, DOI 10.1074/jbc.271.25.14707; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Ravelli RBG, 2003, STRUCTURE, V11, P217, DOI 10.1016/S0969-2126(03)00006-6; Redeker V, 2000, J BIOL CHEM, V275, P6841, DOI 10.1074/jbc.275.10.6841; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; SACKETT DL, 1995, BIOCHEMISTRY-US, V34, P7010, DOI 10.1021/bi00021a012; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; TROUET ABL, 1987, Patent No. 4639456; Usui T, 2004, CHEM BIOL, V11, P799, DOI 10.1016/j.chembiol.2004.03.028; WEISENBE.RC, 1970, BIOCHEMISTRY-US, V9, P4110, DOI 10.1021/bi00823a012; WILSON L, 1982, J MOL BIOL, V159, P125, DOI 10.1016/0022-2836(82)90035-3	30	533	556	2	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					519	522		10.1038/nature03566	http://dx.doi.org/10.1038/nature03566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917812				2022-12-28	WOS:000229337800059
J	Korzenik, JR; Dieckgraefe, BK; Valentine, JF; Hausman, DF; Gilbert, MJ				Korzenik, JR; Dieckgraefe, BK; Valentine, JF; Hausman, DF; Gilbert, MJ		Sargramostim Crohns Dis Study Grp	Sargramostim for active Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY-BOWEL-DISEASE; COLONY-STIMULATING FACTOR; PANETH CELLS; EPITHELIAL-CELLS; NOD2; ASSOCIATION; SUSCEPTIBILITY; IDENTIFICATION; PATHOGENESIS; LETHALITY	Background Sargramostim, granulocyte-macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the intestinal innate immune system. Preliminary studies suggest sargramostim may have activity in Crohn's disease. To evaluate this novel therapeutic approach, we conducted a randomized, placebo-controlled trial. Methods Using a 2:1 ratio, we randomly assigned 124 patients with moderate-to-severe active Crohn's disease to receive 6 mug of sargramostim per kilogram per day or placebo subcutaneously for 56 days. Antibiotics and aminosalicylates were allowed; immunosuppressants and glucocorticoids were prohibited. The primary end point was a clinical response, defined by a decrease from baseline of at least 70 points in the Crohn's Disease Activity Index (CDAI) at the end of treatment (day 57). Other end points included changes in disease severity and the health-related quality of life and adverse events. Results There was no significant difference in the rate of the primary end point of a clinical response defined by a decrease of at least 70 points in the CDAI score on day 57 between the sargramostim and placebo groups (54 percent vs. 44 percent, P=0.28). However, significantly more patients in the sargramostim group than in the placebo group reached the secondary end points of a clinical response defined by a decrease from baseline of at least 100 points in the CDAI score on day 57 (48 percent vs. 26 percent, P=0.01) and of remission, defined by a CDAI score of 150 points or less on day 57 (40 percent vs. 19 percent, P=0.01). The rates of either type of clinical response and of remission were significantly higher in the sargramostim group than in the placebo group on day 29 of treatment and 30 days after treatment. The sargramostim group also had significant improvements in the quality of life. Mild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group, and three patients in this group had serious adverse events possibly or probably related to treatment. Conclusions This study was negative for the primary end point, but findings for the secondary end points suggest that sargramostim therapy decreased disease severity and improved the quality of life in patients with active Crohn's disease.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Inflammatory Bowel Dis Ctr, Boston, MA USA; Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA; Univ Florida, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USA; Vet Affairs Med Ctr, Gainesville, FL 32608 USA; Berlex Labs Inc, Seattle, WA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Washington University (WUSTL); State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Korzenik, JR (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Crohns & Colitis Ctr, 100 Charles River Plaza,9th Fl,Cambridge St, Boston, MA 02114 USA.	jkorzenik@partners.org	Valentine, John/L-6631-2019	Valentine, John/0000-0002-1894-9930				Armitage JO, 1998, BLOOD, V92, P4491, DOI 10.1182/blood.V92.12.4491; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; COUPER R, 1991, GASTROENTEROLOGY, V100, P549, DOI 10.1016/0016-5085(91)90229-E; Dieckgraefe BK, 2002, EUR J PEDIATR, V161, pS88, DOI 10.1007/s00431-002-1011-z; Dieckgraefe BK, 2002, LANCET, V360, P1478, DOI 10.1016/S0140-6736(02)11437-1; Fukuzawa H, 2003, BIOCHEM BIOPH RES CO, V312, P897, DOI 10.1016/j.bbrc.2003.11.009; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Kimura K, 2000, MAYO CLIN PROC, V75, P802, DOI 10.4065/75.8.802; KITAMURA T, 1989, BLOOD, V73, P375; Korzenik JR, 2000, DIGEST DIS SCI, V45, P1121, DOI 10.1023/A:1005541700805; Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9; MARY JY, 1989, GUT, V30, P983, DOI 10.1136/gut.30.7.983; Miehsler W, 2004, GUT, V53, P542, DOI 10.1136/gut.2003.025411; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Peeters M, 2001, AM J GASTROENTEROL, V96, P730, DOI 10.1111/j.1572-0241.2001.03613.x; Pelaez A, 2004, AM J PHYSIOL-LUNG C, V286, pL106, DOI 10.1152/ajplung.00148.2003; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Ramsay RG, 2004, J INTERF CYTOK RES, V24, P416, DOI 10.1089/1079990041535638; TALBOT RW, 1986, MAYO CLIN PROC, V61, P140, DOI 10.1016/S0025-6196(12)65200-8; Unal AE, 2001, EUR J SURG, V167, P366; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Wilk Jacque N, 2002, Curr Opin Investig Drugs, V3, P1291; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187	29	244	261	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2193	2201		10.1056/NEJMoa041109	http://dx.doi.org/10.1056/NEJMoa041109			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917384				2022-12-28	WOS:000229333300007
J	Wilkinson, GR				Wilkinson, GR			Drug therapy - Drug metabolism and variability among patients in drug response	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CYTOCHROME P4502C9 POLYMORPHISMS; ST-JOHNS-WORT; HELICOBACTER-PYLORI; CLINICAL-PRACTICE; CURE RATES; IN-VITRO; CYP2D6; PHARMACOGENETICS; DISPOSITION; OMEPRAZOLE		Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Wilkinson, GR (corresponding author), Vanderbilt Univ, Dept Pharmacol, 542 Robinson Res Bldg, Nashville, TN 37232 USA.	grant.wilkinson@vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31304] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; BAILEY DG, 1991, LANCET, V337, P268, DOI 10.1016/0140-6736(91)90872-M; Bailey DG, 1998, BRIT J CLIN PHARMACO, V46, P101, DOI 10.1046/j.1365-2125.1998.00764.x; Bertilsson L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/j.0306-5251.2001.01548.x; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Brandolese R, 2001, CLIN PHARMACOL THER, V70, P391, DOI 10.1067/mcp.2001.118868; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CAPEWELL S, 1988, LANCET, V2, P480; Chou WH, 2000, J CLIN PSYCHOPHARM, V20, P246, DOI 10.1097/00004714-200004000-00019; Cropp JS, 1997, PHARMACOTHERAPY, V17, P917; D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111; Dalen P, 1997, THER DRUG MONIT, V19, P543, DOI 10.1097/00007691-199710000-00011; Daly AK, 2003, PHARMACOGENETICS, V13, P247, DOI 10.1097/00008571-200305000-00002; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; *FDA, 2005, FED REGISTER, V70, P11865; Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649; Furuta T, 2000, CLIN PHARMACOL THER, V67, P684, DOI 10.1067/mcp.2000.106826; Furuta T, 1998, ANN INTERN MED, V129, P1027, DOI 10.7326/0003-4819-129-12-199812150-00006; Furuta T, 1999, CLIN PHARMACOL THER, V65, P552, DOI 10.1016/S0009-9236(99)70075-5; Furuta T, 2001, CLIN PHARMACOL THER, V69, P158, DOI 10.1067/mcp.2001.113959; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Gasche Y, 2005, NEW ENGL J MED, V352, P638; Henderson L, 2002, BRIT J CLIN PHARMACO, V54, P349, DOI 10.1046/j.1365-2125.2002.01683.x; Higashi MK, 2003, AM J MANAG CARE, V9, P493; Kane GC, 2000, MAYO CLIN PROC, V75, P933, DOI 10.4065/75.9.933; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; KIMURA S, 1989, AM J HUM GENET, V45, P889; Kirchheiner J, 2005, CLIN PHARMACOL THER, V77, P1, DOI 10.1016/j.clpt.2004.08.009; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee CR, 2002, PHARMACOGENETICS, V12, P251, DOI 10.1097/00008571-200204000-00010; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Lessard E, 1999, PHARMACOGENETICS, V9, P435; Levy R.H., 2000, METABOLIC DRUG INTER; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Piscitelli SC, 2000, LANCET, V355, P547; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; Richelson E, 1997, MAYO CLIN PROC, V72, P835, DOI 10.4065/72.9.835; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Sindrup SH, 1995, PHARMACOGENETICS, V5, P335, DOI 10.1097/00008571-199512000-00001; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Steimer W, 2002, CLIN CHIM ACTA, V315, P137, DOI 10.1016/S0009-8981(01)00713-6; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Thummel KE, 1997, ADV DRUG DELIVER REV, V27, P99, DOI 10.1016/S0169-409X(97)00039-2; Wedlund PJ, 2000, PHARMACOLOGY, V61, P174, DOI 10.1159/000028398; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Wuttke H, 2002, CLIN PHARMACOL THER, V72, P429, DOI 10.1067/mcp.2002.127111; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815	49	771	805	3	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2211	2221		10.1056/NEJMra032424	http://dx.doi.org/10.1056/NEJMra032424			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917386				2022-12-28	WOS:000229333300009
J	Ammon, CJ; Ji, C; Thio, HK; Robinson, D; Ni, SD; Hjorleifsdottir, V; Kanamori, H; Lay, T; Das, S; Helmberger, D; Ichinose, G; Polet, J; Wald, D				Ammon, CJ; Ji, C; Thio, HK; Robinson, D; Ni, SD; Hjorleifsdottir, V; Kanamori, H; Lay, T; Das, S; Helmberger, D; Ichinose, G; Polet, J; Wald, D			Rupture process of the 2004 Sumatra-Andaman earthquake	SCIENCE			English	Article							1999 HECTOR MINE; CALIFORNIA; INVERSION; WAVES; DECONVOLUTION; DIVERSITY; LANDERS; SLIP	The 26 December 2004 Sumatra-Andaman earthquake initiated slowly, with small slip and a slow rupture speed for the first 40 to 60 seconds. Then the rupture expanded at a speed of about 2.5 kilometers per second toward the north northwest, extending 1200 to 1300 kilometers along the Andaman trough. Peak displacements reached similar to 15 meters along a 600-kilometer segment of the plate boundary offshore of northwestern Sumatra and the southern Nicobar islands. Slip was less in the northern 400 to 500 kilometers of the aftershock zone, and at least some slip in that region may have occurred on a time scale beyond the seismic band.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA; URS Corp, Pasadena, CA 91101 USA; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Univ Sci & Technol China, Chinese Acad Sci, Key Lab Crust Mantle Mat & Environm, Hefei 230026, Anhui, Peoples R China; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Inst Geophys & Planetary Phys, Santa Cruz, CA 95064 USA; Univ Calif Santa Barbara, Inst Crustal Studies, Santa Barbara, CA 93106 USA; US Geol Survey, Natl EArthquake Informat Ctr, Golden, CO 80401 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; California Institute of Technology; University of Oxford; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Santa Barbara; United States Department of the Interior; United States Geological Survey	Ammon, CJ (corresponding author), Penn State Univ, Dept Geosci, 440 Deike Bldg, University Pk, PA 16802 USA.	cammon@geosc.psu.edu	Thio, Hong Kie/R-6410-2019; Ichinose, Gene/I-4420-2016; Wald, David/AAD-2535-2020; Lay, Thorne/ABE-6272-2021	Thio, Hong Kie/0000-0002-9051-9601; Ichinose, Gene/0000-0003-2081-9825; Wald, David/0000-0002-1454-4514; Ni, Sidao/0000-0003-2988-4850; Hjorleifsdottir, Vala/0000-0003-3275-108X				AMMON CJ, 1993, GEOPHYS RES LETT, V20, P97, DOI 10.1029/92GL03032; Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; Bassin C., 2000, EOS T AM GEOPHYS UN, V81, pF897; CLAYTON RW, 1976, GEOPHYS J ROY ASTR S, V47, P151, DOI 10.1111/j.1365-246X.1976.tb01267.x; DAS S, 1994, PHYS EARTH PLANET IN, V85, P293, DOI 10.1016/0031-9201(94)90119-8; DEGROOTHEDLIN C, UNPUB; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Ekstrom G, 1997, J GEOPHYS RES-SOL EA, V102, P8137, DOI 10.1029/96JB03729; Gudmundsson O, 1998, J GEOPHYS RES-SOL EA, V103, P7121, DOI 10.1029/97JB02488; HOUSTON H, 1986, B SEISMOL SOC AM, V76, P19; ISHII MA, UNPUB; Ji C, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001764; Ji C, 2002, B SEISMOL SOC AM, V92, P1192, DOI 10.1785/0120000916; Ji C, 2002, B SEISMOL SOC AM, V92, P1208, DOI 10.1785/0120000917; Kanamori H, 2004, P JPN ACAD B-PHYS, V80, P297, DOI 10.2183/pjab.80.297; Kerr RA, 2005, SCIENCE, V308, P341; KIKUCHI M, 1982, B SEISMOL SOC AM, V72, P491; Komatitsch D, 2002, SCIENCE, V298, P1737, DOI 10.1126/science.1076024; KOYAMA J, 1985, PHYS EARTH PLANET IN, V37, P108, DOI 10.1016/0031-9201(85)90045-7; LOMAX A, IN PRESS GEOPHYS RES; Ni S, 2005, NATURE, V434, P582, DOI 10.1038/434582a; Park J, 2005, SCIENCE, V308, P1139, DOI 10.1126/science.1112305; PARK J, 2005, EOS T AM GEOPHYS UN, V86, P57, DOI DOI 10.1029/2005EO060001; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Ruff L.J., 1987, SEISMIC TOMOGRAPHY P, P339, DOI [10.1007/978-94-009-3899-1_15, DOI 10.1007/978-94-009-3899-1_15]; RUFF LJ, 1984, GEOPHYS RES LETT, V11, P629, DOI 10.1029/GL011i007p00629; Sieh K, 2005, NATURE, V434, P573, DOI 10.1038/434573a; Thio HK, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2002JB002381; VELASCO AA, 1994, B SEISMOL SOC AM, V84, P735; WALD DJ, 1994, B SEISMOL SOC AM, V84, P668	30	848	894	2	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1133	1139		10.1126/science.1112260	http://dx.doi.org/10.1126/science.1112260			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905393				2022-12-28	WOS:000229293400034
J	Morimoto, M; Takahashi, Y; Endo, M; Saga, Y				Morimoto, M; Takahashi, Y; Endo, M; Saga, Y			The Mesp2 transcription factor establishes segmental borders by suppressing Notch activity	NATURE			English	Article							LUNATIC-FRINGE EXPRESSION; SOMITE BOUNDARY FORMATION; VERTEBRATE SEGMENTATION; RETINOIC ACID; CLOCK; GENE; SOMITOGENESIS; MESODERM; GLYCOSYLTRANSFERASE; PATHWAY	The serially segmented ( metameric) structures of vertebrates are based on somites that are periodically formed during embryogenesis. A 'clock and wavefront' model has been proposed to explain the underlying mechanism of somite formation(1), in which the periodicity is generated by oscillation of Notch components ( the clock) in the posterior pre-somitic mesoderm (PSM)(2-6). This temporal periodicity is then translated into the segmental units in the 'wavefront'(7,8). The wavefront is thought to exist in the anterior PSM and progress backwards at a constant rate; however, there has been no direct evidence as to whether the levels of Notch activity really oscillate and how such oscillation is translated into a segmental pattern in the anterior PSM. Here, we have visualized endogenous levels of Notch1 activity in mice, showing that it oscillates in the posterior PSM but is arrested in the anterior PSM. Somite boundaries formed at the interface between Notch1-activated and - repressed domains. Genetic and biochemical studies indicate that this interface is generated by suppression of Notch activity by mesoderm posterior 2 (Mesp2) through induction of the lunatic fringe gene (Lfng). We propose that the oscillation of Notch activity is arrested and translated in the wavefront by Mesp2.	Natl Inst Genet, Div Mammalian Dev, Mishima, Shizuoka 4118540, Japan; Natl Inst Hlth Sci, Cellular & Mol Toxicol Div, Setagaya Ku, Tokyo 1588501, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; National Institute of Health Sciences - Japan	Saga, Y (corresponding author), Natl Inst Genet, Div Mammalian Dev, Mishima, Shizuoka 4118540, Japan.	ysaga@lab.nig.ac.jp						Bessho Y, 2003, GENE DEV, V17, P1451, DOI 10.1101/gad.1092303; Bessho Y, 2001, GENE DEV, V15, P2642, DOI 10.1101/gad.930601; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Buchberger A, 1998, DEV BIOL, V199, P201, DOI 10.1006/dbio.1998.8919; Cole SE, 2002, DEV CELL, V3, P75, DOI 10.1016/S1534-5807(02)00212-5; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morales AV, 2002, DEV CELL, V3, P63, DOI 10.1016/S1534-5807(02)00211-3; Moreno TA, 2004, DEV CELL, V6, P205, DOI 10.1016/S1534-5807(04)00026-7; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pourquie O, 2003, SCIENCE, V301, P328, DOI 10.1126/science.1085887; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Sawada A, 2000, DEVELOPMENT, V127, P1691; Sawada A, 2001, DEVELOPMENT, V128, P4873; Sparrow DB, 1998, DEVELOPMENT, V125, P2041; Takahashi Y, 2000, NAT GENET, V25, P390, DOI 10.1038/78062	29	195	206	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					354	359		10.1038/nature03591	http://dx.doi.org/10.1038/nature03591			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902259				2022-12-28	WOS:000229185000047
J	Gostin, LO				Gostin, LO			Ethics, the constitution, and the dying process - The case of Theresa Marie Schiavo	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRUZAN; DEATH; LIFE		Georgetown Univ, Ctr Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						*AM MED ASS, 1986, WITHH WITHDR LIF PRO; *AM NURS ASS, 1988, GUID WITHDR WITHH FO; BABINGTON C, 2005, WASH POST       0908, pA6; CERMINARA KL, KEY EVENTS CASE TM S; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; HULSE C, 2005, NY TIMES        0519, pA1; JOHNSON HM, 2005, WASHINGTON POST 0325, pA19; MEISEL A, 2004, RIGHT DIE LAW END LI; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; SANGER D, 2003, NY TIMES, pA23; Wolfson Jay, 2003, REPORT GOVERNOR J BU	12	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2403	2407		10.1001/jama.293.19.2403	http://dx.doi.org/10.1001/jama.293.19.2403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	926JX	15900011				2022-12-28	WOS:000229120600028
J	Woolacott, NF; Puhan, MA; Steurer, J; Kleijnen, J				Woolacott, NF; Puhan, MA; Steurer, J; Kleijnen, J			Ultrasonography in screening for developmental dysplasia of the hip in newborns: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEONATAL HIP; INFANT HIP; ULTRASOUND; DISLOCATION; SONOGRAPHY; MANAGEMENT; DIAGNOSIS; CHILDREN; GERMANY; TRIAL	Objective To assess the accuracy and effectiveness of the screening of all newborn infants for developmental dysplasia of the hip (DDH) using ultrasound imaging, as is standard practice in some European countries but not in the United Kingdom, the United States, or Scandinavia. Design Systematic review Data sources Twenty three medical, economic, and grey literature databases (to March 2004), with no limitations of design or language; some references were provided by experts. Selection of studies Only diagnostic accuracy studies and comparative studies conducted in an unselected newborn population were eligible for the review. Two reviewers independently selected the studies and performed the quality assessment. Results The review identified one diagnostic accuracy study, and this was of limited quality. In this study the reference standard was treatment up to age of 8 months or an abnormal ultrasound finding at age 8 months. Ultrasound screening had a sensitivity of 88.5% (95% confidence interval 84.1% to 92.1%), specificity of 96.7% (96.4% to 97.4%), a positive predictive value of 61.6% and a negative predictive value of 99.4%. Ten studies evaluated the impact of ultrasound in screening, but these too had various methodological weaknesses, limiting the reliability of their findings. Compared with clinical screening, general ultrasound screening in newborns may increase overall treatment rates, but ultrasound screening seems to be associated with shorter and less intrusive treatment. Conclusions Clear evidence is lacking either for or against general ultrasound screening of newborn infants for DDH. Studies that investigate the natural course of the disorder, the optimal treatment for DDH, and the best strategy for ultrasound screening are needed.	Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England; Univ Zurich, Horten Ctr, Zurich, Switzerland	University of York - UK; University of Zurich	Woolacott, NF (corresponding author), Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England.	nw11@york.ac.uk	Puhan, Milo/ABE-6298-2020	Puhan, Milo/0000-0003-4721-1879				[Anonymous], 2000, Pediatrics, V105, P896; Clegg J, 1999, J BONE JOINT SURG BR, V81B, P852, DOI 10.1302/0301-620X.81B5.9746; Cox S L, 1998, Pediatr Rehabil, V2, P129; Dezateux C, 2003, ARCH DIS CHILD, V88, P753, DOI 10.1136/adc.88.9.753; EGGL H, 1993, ORTHOPADE, V22, P277; Elbourne D, 2002, LANCET, V360, P2009, DOI 10.1016/S0140-6736(02)12024-1; Gardner F, 2005, ARCH DIS CHILD-FETAL, V90, pF17, DOI 10.1136/adc.2002.025684; GRAF R, 1984, ARCH ORTHOP TRAUM SU, V102, P248, DOI 10.1007/BF00436138; GRAF R, 1993, J PEDIATR ORTHOP B, V2, P115, DOI 10.1097/01202412-199302020-00005; Grill F, 1997, ORTHOPADE, V26, P25; Gunther KP, 1998, Z ORTHOP GRENZGEB, V136, P508, DOI 10.1055/s-2008-1045178; HARCKE HT, 1990, AM J ROENTGENOL, V155, P837, DOI 10.2214/ajr.155.4.2119119; HARCKE HT, 1984, J ULTRAS MED, V3, P131; Holen KJ, 2002, J BONE JOINT SURG BR, V84B, P886, DOI 10.1302/0301-620X.84B6.12093; Kobler G, 2003, SWISS MED WKLY, V133, P484; Kocher M S, 2000, Am J Orthop (Belle Mead NJ), V29, P929; Krolo I, 2003, COLLEGIUM ANTROPOL, V27, P627; Maj S, 1989, Pol Tyg Lek, V44, P916; Malkawi H, 1997, SAUDI MED J, V18, P507; MARKS DS, 1994, J BONE JOINT SURG BR, V76B, P534, DOI 10.1302/0301-620X.76B4.8027134; NHS Centre for Reviews and Dissemination, 2001, 4 NHS CRD; Patel H, 2001, CAN MED ASSOC J, V164, P1669; Puhan MA, 2003, ULTRASCHALL MED, V24, P377, DOI 10.1055/s-2003-45213; Roovers EA, 2005, ARCH DIS CHILD-FETAL, V90, pF25, DOI 10.1136/adc.2003.029496; ROOVERS EA, 2004, THESIS U TWENTE ENSC, P55; ROSENDAHL K, 1994, PEDIATRICS, V94, P47; SUZUKI S, 1993, J BONE JOINT SURG BR, V75, P483, DOI 10.1302/0301-620X.75B3.8496228; TEGNANDER A, 1994, J PEDIATR ORTHOP B, V3, P86, DOI 10.1097/01202412-199403010-00015; Tegnander A, 1999, ACTA ORTHOP SCAND, V70, P335, DOI 10.3109/17453679908997820; Terjesen T, 1996, J PEDIATR ORTHOP B, V5, P123, DOI 10.1097/01202412-199605020-00013; TERJESEN T, 1989, ACTA ORTHOP SCAND, V60, P651, DOI 10.3109/17453678909149596; TERJESEN T, 1989, J BONE JOINT SURG BR, V71, P767, DOI 10.1302/0301-620X.71B5.2684989; von Kries R, 2003, LANCET, V362, P1883, DOI 10.1016/S0140-6736(03)14957-4; Whiting P, 2004, ANN INTERN MED, V140, P189, DOI 10.7326/0003-4819-140-3-200402030-00010; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Wientroub S, 2000, J BONE JOINT SURG AM, V82A, P1004, DOI 10.2106/00004623-200007000-00012	36	83	90	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	2005	330	7505					1413	1415		10.1136/bmj.38450.646088.E0	http://dx.doi.org/10.1136/bmj.38450.646088.E0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938NP	15930025	Green Published, Bronze			2022-12-28	WOS:000230010400014
J	Ellis, GFR				Ellis, GFR			Physics, complexity and causality	NATURE			English	Editorial Material									Univ Cape Town, Dept Math, ZA-7701 Cape Town, South Africa	University of Cape Town	Ellis, GFR (corresponding author), Univ Cape Town, Dept Math, ZA-7701 Cape Town, South Africa.							BISHOP RC, IN PRESS PHIL SCI; ELLIS GFR, IN PRESS PHYS TODAY	2	50	52	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					743	743		10.1038/435743a	http://dx.doi.org/10.1038/435743a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944681	Bronze			2022-12-28	WOS:000229638700028
J	Kratchmarova, I; Blagoev, B; Haack-Sorensen, M; Kassem, M; Mann, M				Kratchmarova, I; Blagoev, B; Haack-Sorensen, M; Kassem, M; Mann, M			Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; OSTEOBLAST DIFFERENTIATION; QUANTITATIVE PROTEOMICS; PROGENITOR CELLS; EXPRESSION; IDENTIFICATION; ENDOCYTOSIS; INHIBITION	Closely related signals often lead to very different cellular outcomes. We found that the differentiation of human mesenchymal stem cells into bone-forming cells is stimulated by epidermal growth factor (EGF) but not platelet-derived growth factor (PDGF). We used mass spectrometry-based proteomics to comprehensively compare proteins that were tyrosine phosphorylated in response to EGF and PDGF and their associated partners. More than 90% of these signaling proteins were used by both ligands, whereas the phosphatidylinositol 3-kinase (PI3K) pathway was exclusively activated by PDGF, implicating it as a possible control point. Indeed, chemical inhibition of PI3K in PDGF-stimulated cells removed the differential effect of the two growth factors, bestowing full differentiation effect onto PDGF. Thus, quantitative proteomics can directly compare entire signaling networks and discover critical differences capable of changing cell fate.	Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Odense Univ Hosp, Dept Endocrinol, DK-5000 Odense, Denmark	University of Southern Denmark; University of Southern Denmark; Odense University Hospital	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.	mann@bmb.sdu.dk	Kassem, Moustapha/J-7688-2013; Kassem, Moustapha/O-3819-2019; Mann, Matthias/A-3454-2013	Kassem, Moustapha/0000-0003-1557-0869; Kassem, Moustapha/0000-0003-1557-0869; Mann, Matthias/0000-0003-1292-4799; Kratchmarova, Irina/0000-0001-6613-7315; Blagoev, Blagoy/0000-0002-3596-0066				Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181; Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukuyama R, 2004, BIOCHEM BIOPH RES CO, V315, P636, DOI 10.1016/j.bbrc.2004.01.104; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645; Katoh Y, 2004, J BIOL CHEM, V279, P24435, DOI 10.1074/jbc.M400059200; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Szymkiewicz I, 2004, BIOCHEM J, V383, P1, DOI 10.1042/BJ20040913; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7	31	462	499	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1472	1477		10.1126/science.1107627	http://dx.doi.org/10.1126/science.1107627			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933201				2022-12-28	WOS:000229619300055
J	Li, Y; Moon, KS; Wong, CP				Li, Y; Moon, KS; Wong, CP			Electronics without lead	SCIENCE			English	Editorial Material									Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Li, Y (corresponding author), Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA.	cp.wong@mse.gatech.edu	Wong, CP/M-6587-2017; Moon, Kyoung-Sik/AAP-5877-2020	Wong, CP/0000-0003-3556-8053; 				Abtew M, 2000, MAT SCI ENG R, V27, P95, DOI 10.1016/S0927-796X(00)00010-3; Efremov MY, 2000, PHYS REV LETT, V85, P3560, DOI 10.1103/PhysRevLett.85.3560; Hwang J. S., 2001, ENV FRIENDLY ELECT L; LAU JH, 2002, ELECT MANUFACTURING; Li Y, 2005, J ELECTRON MATER, V34, P266, DOI 10.1007/s11664-005-0212-4; Li Y, 2004, 9TH INTERNATIONAL SYMPOSIUM ON ADVANCED PACKAGING MATERIALS: PROCESSES, PROPERTIES AND INTERFACES, 2004 PROCEEDINGS, P1; LIU J, 1996, P 2 INT S EL PACK TE, P313; Liu J, 1999, CONDUCTIVE ADHESIVES; LU D, 2002, ENCY SMART MAT, V1, P331; MATSUBA Y, 2003, EREKUTORONIKUSU JISS, V6, P130; Miric AZ, 1998, SOLDER SURF MT TECH, V10, P19, DOI 10.1108/09540919810203793; Moon KS, 2005, J ELECTRON MATER, V34, P168, DOI 10.1007/s11664-005-0229-8; PUTTLITZ KJ, 2004, HDB LEAD FREE SOLD T, pCH1; Tong QK, 1998, 3RD INTERNATIONAL CONFERENCE ON ADHESIVE JOINING AND COATING TECHNOLOGY IN ELECTRONICS MANUFACTURING 1998, PROCEEDINGS, P272, DOI 10.1109/ADHES.1998.742039; ZARROW P, 1999, CIRCUITS ASSEMBLY, V10, P18	15	411	437	3	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1419	1420		10.1126/science.1110168	http://dx.doi.org/10.1126/science.1110168			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933187				2022-12-28	WOS:000229619300036
J	Reverter, D; Lima, CD				Reverter, D; Lima, CD			Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex	NATURE			English	Article							SUMO CONJUGATION; ENZYME UBC9; PROTEIN; NUCLEOPORIN; RANBP2; RANGAP1; DOMAIN	SUMO-1 ( for small ubiquitin-related modifier) belongs to the ubiquitin (Ub) and ubiquitin-like (Ubl) protein family. SUMO conjugation occurs on specific lysine residues within protein targets, regulating pathways involved in differentiation, apoptosis, the cell cycle and responses to stress by altering protein function through changes in activity or cellular localization or by protecting substrates from ubiquitination(1,2). Ub/Ubl conjugation occurs in sequential steps and requires the concerted action of E2 conjugating proteins and E3 ligases(1,2). In addition to being a SUMO E3, the nucleoporin Nup358/RanBP2 localizes SUMO-conjugated RanGAP1 to the cytoplasmic face of the nuclear pore complex by means of interactions in a complex that also includes Ubc9, the SUMO E2 conjugating protein(3-6). Here we describe the 3.0-angstrom crystal structure of a four-protein complex of Ubc9, a Nup358/RanBP2 E3 ligase domain ( IR1-M) and SUMO-1 conjugated to the carboxy-terminal domain of RanGAP1. Structural insights, combined with biochemical and kinetic data obtained with additional substrates, support a model in which Nup358/ RanBP2 acts as an E3 by binding both SUMO and Ubc9 to position the SUMO - E2- thioester in an optimal orientation to enhance conjugation.	Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Lima, CD (corresponding author), Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA.	limac@mskcc.org	Reverter, David/H-5360-2015	Reverter, David/0000-0002-5347-0992; Lima, Christopher/0000-0002-9163-6092	NIGMS NIH HHS [R01 GM065872] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065872] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Tatham MH, 2005, NAT STRUCT MOL BIOL, V12, P67, DOI 10.1038/nsmb878; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Wu PY, 2003, EMBO J, V22, P5241, DOI 10.1093/emboj/cdg501; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	29	369	387	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					687	692		10.1038/nature03588	http://dx.doi.org/10.1038/nature03588			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931224	Green Accepted			2022-12-28	WOS:000229476200053
J	Gulmezoglu, AM; Pang, T; Horton, R; Dickersin, K				Gulmezoglu, AM; Pang, T; Horton, R; Dickersin, K			WHO facilitates international collaboration in setting standards for clinical trial registration	LANCET			English	Editorial Material							STATEMENT		WHO, UNDP INFPA WHO World Bank Special Programme Res D, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland; WHO, Dept Res Policy & Cooperat, CH-1211 Geneva, Switzerland; Lancet, London, England; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA	The World Bank; World Health Organization; World Health Organization; Brown University	Gulmezoglu, AM (corresponding author), WHO, UNDP INFPA WHO World Bank Special Programme Res D, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland.	gulmezoglum@who.int	Dickersin, Kay/A-4576-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*CAN I HLTH RES, 2005, INT EXP REN CALLS RE; De Angelis C, 2004, LANCET, V364, P911, DOI 10.1016/S0140-6736(04)17034-7; DEANGELIS CD, 2005, LANCET; Evans T, 2004, LANCET, V363, P1413, DOI 10.1016/S0140-6736(04)16136-9; *INT FED PHARM MAN, 2005, GLOB IND POS DISCL I; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1995, E3 ICH; Krleza-Jeric K, 2005, BMJ-BRIT MED J, V330, P956, DOI 10.1136/bmj.330.7497.956; WHO, INT CLIN TRIALS REG; *WHO, 2005, MEX STAT HLTH RES	9	60	61	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1829	1831		10.1016/S0140-6736(05)66589-0	http://dx.doi.org/10.1016/S0140-6736(05)66589-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924966				2022-12-28	WOS:000229481400005
J	Fouchier, R; Kuiken, T; Rimmelzwaan, G; Osterhaus, A				Fouchier, R; Kuiken, T; Rimmelzwaan, G; Osterhaus, A			Global task force for influenza	NATURE			English	Editorial Material									Erasmus MC, Natl Influenza Ctr, NL-3015 GE Rotterdam, Netherlands; Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Fouchier, R (corresponding author), Erasmus MC, Natl Influenza Ctr, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.		Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; Kuiken, Thijs/0000-0001-5501-9049				de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Fouchier Ron Am, 2005, Curr Opin Infect Dis, V18, P141; Kuiken T, 2003, CURR OPIN BIOTECH, V14, P641, DOI 10.1016/j.copbio.2003.10.010; Stohr K, 2004, SCIENCE, V306, P2195, DOI 10.1126/science.1108165; Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992	7	38	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					419	420		10.1038/435419a	http://dx.doi.org/10.1038/435419a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917779	Green Published, Bronze			2022-12-28	WOS:000229337800025
J	Ooms, G; Schrecker, T				Ooms, G; Schrecker, T			Expenditure ceilings, multilateral financial institutions, and the health of poor populations	LANCET			English	Editorial Material							AGREEMENT; UGANDA		Univ Ottawa, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada; Med Sans Frontieres, Brussels, Belgium	University of Ottawa; Doctors Without Borders	Schrecker, T (corresponding author), Univ Ottawa, Inst Populat Hlth, 1 Stewart St, Ottawa, ON K1N 6N5, Canada.	tschrecker@sympatico.ca	Ooms, Gorik/A-2537-2015	Ooms, Gorik/0000-0002-9804-0128; Schrecker, Ted/0000-0002-4447-5281				[Anonymous], 2001, MACR HLTH INV HLTH E; BACHRACH P, 1963, AM POLIT SCI REV, V57, P632, DOI 10.2307/1952568; CHERU F, PRSPECN4200156 UN EC; DAWSON T, 2004, RESPONSE ACTION AID; EBRAHIMZADEH C, DUTCH DIS TOO MUCH W; FOSTER M, 2004, MDG ORIENTATED SECTO; *GLOB FUND FIGHT A, PLEDG CONTR; *INT MON FUND, 2002, REV POV RED GROWTH F; *INT MON FUND WORL, 2004, US GRANTS LOW INC CO; Labonte R, 2004, SOC SCI MED, V59, P1661, DOI 10.1016/j.socscimed.2004.02.010; MICHAUD C, 2003, DEV ASS HLTH DAH REC; Pettifor A. R. G., 2002, DEBT RELIEF MILLENNI; Piot Peter, 2003, AIDS NEED EXCEPTIONA; UNAIDS, 2004 REP GLOB HIV AI; United Nations Development Program, HUM DEV REP 2003 MIL; Wendo C, 2004, LANCET, V363, P222; Wendo C, 2003, LANCET, V361, P942, DOI 10.1016/S0140-6736(03)12794-8; Wendo C, 2002, LANCET, V360, P1847, DOI 10.1016/S0140-6736(02)11854-X; *WHO, 2003, HARM MDGS PERSP TANZ; *WORLD BANK, 2003, AIDS NEED EXC RESP U; *WORLD BANK, 2003, MILL DEV GOALS HLTH	21	39	39	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2005	365	9473					1821	1823		10.1016/S0140-6736(05)66586-5	http://dx.doi.org/10.1016/S0140-6736(05)66586-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910956				2022-12-28	WOS:000229291600028
J	Patsopoulos, NA; Analatos, AA; Ioannidis, JPA				Patsopoulos, NA; Analatos, AA; Ioannidis, JPA			Relative citation impact of various study designs in the health sciences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED-TRIALS; RECOMMENDATIONS; METAANALYSIS; JOURNALS; ARTICLE	Context The relative merits of various study designs and their placement in hierarchies of evidence are often discussed. However, there is limited knowledge about the relative citation impact of articles using various study designs. Objective To determine whether the type of study design affects the rate of citation in subsequent articles. Design and Setting We measured the citation impact of articles using various study designs-including meta-analyses, randomized controlled trials, cohort studies, case-control studies, case reports, nonsystematic reviews, and decision analysis or cost-effectiveness analysis-published in 1991 and in 2001 for a sample of 2646 articles. Main Outcome Measure The citation count through the end of the second year after the year of publication and the total received citations. Results Meta-analyses received more citations than any other study design both in 1991 (P<.05 for all comparisons) and in 2001 (P<.001 for all comparisons) and both in the first 2 years and in the longer term. More than 10 citations in the first 2 years were received by 32.4% of meta-analyses published in 1991 and 43.6% of meta-analyses published in 2001. Randomized controlled trials did not differ significantly from epidemiological studies and nonsystematic review articles in 1991 but clearly became the second-cited study design in 2001. Epidemiological studies, nonsystematic review articles, and decision and cost-effectiveness analyses had relatively similar impact; case reports received negligible citations. Meta-analyses were cited significantly more often than all other designs after adjusting for year of publication, high journal impact factor, and country of origin. When limited to studies addressing treatment effects, meta-analyses received more citations than randomized trials. Conclusion Overall, the citation impact of various study designs is commensurate with most proposed hierarchies of evidence.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece; Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece; Univ Thessaly, Fac Med, Dept Immunol & Histocompatibil, Larisa, Greece; Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Med,Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	University of Ioannina; University of Ioannina; University of Thessaly; Tufts Medical Center; Tufts University	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Analatos, Apostolos/AAF-1257-2020; Ioannidis, John P. A./G-9836-2011	Patsopoulos, Nikolaos/0000-0003-3757-8941				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bhandari M, 2004, J BONE JOINT SURG AM, V86A, P1012, DOI 10.2106/00004623-200405000-00019; Clarke M, 2002, JAMA-J AM MED ASSOC, V287, P2799, DOI 10.1001/jama.287.21.2799; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; FEINSTEIN AR, 1995, J CLIN EPIDEMIOL, V48, P71, DOI 10.1016/0895-4356(94)00110-C; Garfield E, 1996, BRIT MED J, V313, P411, DOI 10.1136/bmj.313.7054.411; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Ioannidis JPA, 2001, BRIT MED J, V322, P879, DOI 10.1136/bmj.322.7291.879; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P319, DOI 10.1001/jama.279.4.319; Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0; Loke Yoon K, 2003, BMC Med Res Methodol, V3, P14, DOI 10.1186/1471-2288-3-14; McAlister FA, 1999, ANN INTERN MED, V131, P947, DOI 10.7326/0003-4819-131-12-199912210-00007; Montori VM, 2003, BMC MED, V1, DOI 10.1186/1741-7015-1-2; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; Phillips B, LEVELS EVIDENCE GRAD; SHAPIRO S, 1994, AM J EPIDEMIOL, V140, P771, DOI 10.1093/oxfordjournals.aje.a117324; Stampfer M, 1997, CONTROL CLIN TRIALS, V18, P494, DOI 10.1016/S0197-2456(97)00050-0; *THOMPS CORP, 2004, ESS SCI IND ISI; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2; Weale Andy R, 2004, BMC Med Res Methodol, V4, P14, DOI 10.1186/1471-2288-4-14; West S, 2002, AHRQ PUBLICATION, P64	24	341	355	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2362	2366		10.1001/jama.293.19.2362	http://dx.doi.org/10.1001/jama.293.19.2362			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900006				2022-12-28	WOS:000229120600023
J	Takano, A; Endo, T; Yoshihisa, T				Takano, A; Endo, T; Yoshihisa, T			tRNA actively shuttles between the nucleus and cytosol in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; EXPORT; TRANSPORT; AMINOACYLATION; TRANSCRIPTION; TRANSLATION; CYTOPLASM; PATHWAY	Previous evidence suggested that transfer RNAs (tRNAs) cross the nuclear envelope to the cytosol only once after maturing in the nucleus. We now present evidence for nuclear import of tRNAs in yeast. Several export mutants accumulate mature tRNAs in the nucleus even in the absence of transcription. Import requires energy but not the Ran cycle. These results indicate that tRNAs shuttle between the nucleus and cytosol.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Res Ctr Mat Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Core Res Evolut Sci & Technol, Japan Sci & Technol Corp, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Yoshihisa, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	tyoshihi@biochem.chem.nagoya-u.ac.jp						Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; AZPIROZ R, 1993, MOL BIOL CELL, V4, P21, DOI 10.1091/mbc.4.1.21; Feng WQ, 2002, P NATL ACAD SCI USA, V99, P5412, DOI 10.1073/pnas.082682699; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grosshans H, 2000, GENE DEV, V14, P830; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hopper AK, 2003, GENE DEV, V17, P162, DOI 10.1101/gad.1049103; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; WILLIS I, 1984, EMBO J, V3, P1573, DOI 10.1002/j.1460-2075.1984.tb02013.x; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; Yoshihisa T, 2003, MOL BIOL CELL, V14, P3266, DOI 10.1091/mbc.E02-11-0757	19	130	136	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2005	309	5731					140	142		10.1126/science.1113346	http://dx.doi.org/10.1126/science.1113346			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15905365				2022-12-28	WOS:000230212800078
J	Reilly, JJ; Armstrong, J; Dorosty, AR; Emmett, PM; Ness, A; Rogers, I; Steer, C; Sherriff, A				Reilly, JJ; Armstrong, J; Dorosty, AR; Emmett, PM; Ness, A; Rogers, I; Steer, C; Sherriff, A		Avon Longitudinal Study Parents Ch	Early life risk factors for obesity in childhood: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; ADULT OBESITY; CHILDREN; WEIGHT; PREVENTION; OVERWEIGHT; ADIPOSITY; BEHAVIORS; EXPOSURE; UK	Objective To identify risk factors in early life (up to 3 years of age) for obesity in children in the United Kingdom. Design Prospective cohort study. Setting Avon longitudinal study of parents and children, United Kingdom. Participants 8234 children in cohort aged 7 years and a subsample of 909 children (children in focus) with data on additional early growth related risk factors for obesity. Main outcome measures Obesity at age 7 years, defined as a body mass index >= 95th centile relative to reference data for the UK population in 1990. Results Eight of 25 putative risk factors were associated with a risk of obesity in the final models: parental obesity (both parents: adjusted odds ratio, 10.44, 95% confidence interval 5.11 to 21.32), very early (by 43 months) body mass index or adiposity rebound (15.00, 5.32 to 42.30), more than eight hours spent watching television per week at age 3 years (1.55, 1.13 to 2.12), catch-up growth (2.60, 1.09 to 6.16), standard deviation score for weight at age 8 months (3.13, 1.43 to 6.85) and 18 months (2.65, 1, 25 to 5.59); weight gain in first year (1.06, 1.02 to 1.10 per 100 g increase); birth weight, per 100 g (1.05, 1.03 to 1.07); and short (< 10.5 hours) sleep duration at age 3 years (1.45, 1.10 to 1.89). Conclusion Eight factors in early life are associated with an increased risk of obesity in childhood.	Univ Glasgow, Div Dev Med, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland; Univ Bristol, Unit Paediat & Perinatal Epidemiol, Inst Child Hlth, Bristol BS8 1TH, Avon, England; Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran	University of Glasgow; University of Bristol; Tehran University of Medical Sciences	Reilly, JJ (corresponding author), Univ Glasgow, Div Dev Med, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland.	jjr2y@clinmed.gla.ac.uk	Dorosty-Motlagh, Ahmad-Reza/E-1003-2018; Ness, Andy R/M-7612-2013; Emmett, Pauline/AAL-6815-2021	Dorosty-Motlagh, Ahmad-Reza/0000-0002-6937-7776; Ness, Andy R/0000-0003-3548-9523; Rogers, Imogen/0000-0001-7275-2437; sherriff, andrea/0000-0002-1016-037X; Emmett, Pauline/0000-0003-1076-4779	Intramural NIH HHS Funding Source: Medline; Wellcome Trust Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission)		Armstrong J, 2002, LANCET, V359, P2003, DOI 10.1016/S0140-6736(02)08837-2; Birch LL, 1998, PEDIATRICS, V101, P539; Bogen DL, 2004, OBES RES, V12, P1527, DOI 10.1038/oby.2004.190; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208; Dietz WH, 2000, AM J CLIN NUTR, V72, P335; Dietz WH, 1997, J NUTR, V127, pS1884, DOI 10.1093/jn/127.9.1884S; Dietz WH, 2001, JAMA-J AM MED ASSOC, V285, P2506, DOI 10.1001/jama.285.19.2506; Dorosty AR, 2000, PEDIATRICS, V105, P1115, DOI 10.1542/peds.105.5.1115; Francis LA, 2003, OBES RES, V11, P143, DOI 10.1038/oby.2003.23; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003; Grove KL, 2001, J CLIN ENDOCR METAB, V86, P5420, DOI 10.1210/jc.86.11.5420; North K, 2000, EUR J CLIN NUTR, V54, P73, DOI 10.1038/sj.ejcn.1600896; Ong KKL, 2000, BRIT MED J, V320, P967, DOI 10.1136/bmj.320.7240.967; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Reilly JJ, 2002, ARCH DIS CHILD, V86, P392, DOI 10.1136/adc.86.6.392; Reilly JJ, 2003, ARCH DIS CHILD, V88, P748, DOI 10.1136/adc.88.9.748; Reilly JJ, 1999, LANCET, V354, P1874, DOI 10.1016/S0140-6736(99)04555-9; Reilly JJ, 2000, INT J OBESITY, V24, P1623, DOI 10.1038/sj.ijo.0801436; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Stettler N, 2002, PEDIATRICS, V109, P194, DOI 10.1542/peds.109.2.194; STEULER N, 2002, PEDIATRICS, V109, P194; von Kries R, 2002, AM J EPIDEMIOL, V156, P954, DOI 10.1093/aje/kwf128; Whitaker RC, 2003, ARCH PEDIAT ADOL MED, V157, P725, DOI 10.1001/archpedi.157.8.725	25	1090	1128	1	196	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2005	330	7504					1357	1359		10.1136/bmj.38470.670903.E0	http://dx.doi.org/10.1136/bmj.38470.670903.E0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15908441	Green Published			2022-12-28	WOS:000229840100017
J	Sanderson, WC; Scherbov, S				Sanderson, WC; Scherbov, S			Average remaining lifetimes can increase as human populations age	NATURE			English	Article							SOCIAL-SECURITY; DEATH; LIFE; DEMOGRAPHY; LONGEVITY; SAVINGS; TIME	Increases in median ages, the most commonly used measure of population ageing(1,2), are rapid in today's wealthier countries(2,3), and population ageing is widely considered to be a significant challenge to the well-being of citizens there(4). Conventional measures of age count years since birth; however, as lives lengthen, we need to think of age also in terms of years left until death or in proportion to the expanding lifespan. Here we propose a new measure of ageing: the median age of the population standardized for expected remaining years of life. We show, using historical data and forecasts for Germany, Japan and the United States, that although these populations will be growing older, as measured by their median ages, they will probably experience periods in which they grow younger, as measured by their standardized median ages. Furthermore, we provide forecasts for these countries of the old-age dependency ratio rescaled for increases in life expectancy at birth(5). These ratios are forecasted to change much less than their unscaled counterparts, and also exhibit periods when the population is effectively growing younger.	SUNY Stony Brook, Dept Econ & Hist, Stony Brook, NY 11794 USA; Int Inst Appl Syst Anal, World Populat Project, A-2361 Laxenburg, Austria; Vienna Inst Demog, A-1040 Vienna, Austria	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; International Institute for Applied Systems Analysis (IIASA)	Sanderson, WC (corresponding author), SUNY Stony Brook, Dept Econ & Hist, Stony Brook, NY 11794 USA.	wsanderson@notes.cc.sunysb.edu	Sanderson, Warren/R-3398-2019; Scherbov, Sergey/F-3158-2019	Scherbov, Sergey/0000-0001-5902-3790; Scherbov, Sergei/0000-0002-0881-1073; Sanderson, Warren/0000-0002-2205-948X				[Anonymous], 2005, WORLD POP PROSP 2004; Bloom DE, 2003, SCAND J ECON, V105, P319, DOI 10.1111/1467-9442.t01-1-00001; CREIGHTON S, 2002, PARTICIPATION PATTER; Disney R, 2010, ECON J, V110, P1, DOI [10.1111/1468-0297.00505, DOI 10.1111/1468-0297.00505]; Gan L.., 2004, 10789 NBER; Gavrilov LA, 2003, ENCY POPULATION, V1, P32; Higgins M, 1998, INT ECON REV, V39, P343, DOI 10.2307/2527297; Hurd MD, 2004, J APPL ECONOM, V19, P761, DOI 10.1002/jae.752; Lee R, 1997, DEMOGRAPHY, V34, P67, DOI 10.2307/2061660; Lee R, 2003, POPUL DEV REV, V29, P183; Lutz W, 2001, NATURE, V412, P543, DOI 10.1038/35087589; Lutz W, 2004, END WORLD POPULATION, P17; LUTZ W, 2004, END WORLD POPULATION, P85; Miller T, 2001, DEMOGRAPHY, V38, P215, DOI 10.1353/dem.2001.0018; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Peterson Peter G., 1999, GRAY DAWN; SANDERSON W, 2004, IR04049 INT I APPL S; Seshamani M, 2004, J HEALTH ECON, V23, P217, DOI 10.1016/j.jhealeco.2003.08.004; Stearns SC, 2004, HEALTH ECON, V13, P315, DOI 10.1002/hec.831	19	102	107	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					811	813		10.1038/nature03593	http://dx.doi.org/10.1038/nature03593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	933NK	15944703	Green Accepted			2022-12-28	WOS:000229638700049
J	Cooke, CA; Best, RM				Cooke, CA; Best, RM			Intraocular glasses	LANCET			English	Editorial Material									Royal Victoria Hosp, Dept Ophthalmol, Belfast B12 6BA, Antrim, North Ireland		Cooke, CA (corresponding author), Royal Victoria Hosp, Dept Ophthalmol, Belfast B12 6BA, Antrim, North Ireland.	carolecooke322@ntlworld.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1960	1960		10.1016/S0140-6736(05)66663-9	http://dx.doi.org/10.1016/S0140-6736(05)66663-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936425				2022-12-28	WOS:000229587800031
J	Sullivan, AK; Curtis, H; Sabin, CA; Johnson, MA				Sullivan, AK; Curtis, H; Sabin, CA; Johnson, MA			Newly diagnosed FHV infections: review in UK and Ireland	BRITISH MEDICAL JOURNAL			English	Review									Chelsea & Westminster Healthcare NHS Trust, London SW10 9NH, England; British HIV Assoc, London, England; UCL Royal Free & Univ Coll Med Sch, London, England; UCL Royal Free Hampstead NHS Trust, London, England	University of London; University College London; UCL Medical School; University of London; University College London	Sullivan, AK (corresponding author), Chelsea & Westminster Healthcare NHS Trust, London SW10 9NH, England.	Ann.Sullivan@Chelwest.nhs.uk	Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760; Curtis, Hilary/0000-0002-1440-1812				Curtis H, 2003, HIV Med, V4, P11, DOI 10.1046/j.1468-1293.2003.00137.x; Miners A H, 2001, HIV Med, V2, P52, DOI 10.1046/j.1468-1293.2001.00048.x; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; POZNIAK A, 2003, HIV MED S, V4, pS1	4	119	127	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 4	2005	330	7503					1301	1302		10.1136/bmj.38398.590602.E0	http://dx.doi.org/10.1136/bmj.38398.590602.E0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15894552	Green Published, Bronze			2022-12-28	WOS:000229655700021
J	Greaves, GN; Meneau, F; Majerus, O; Jones, DG; Taylor, J				Greaves, GN; Meneau, F; Majerus, O; Jones, DG; Taylor, J			Identifying vibrations that destabilize crystals and characterize the glassy state	SCIENCE			English	Article							LOW-FREQUENCY MODES; VITREOUS SILICA; AMORPHOUS SOLIDS; RAMAN-SCATTERING; FLOPPY MODES; TEMPERATURE; DYNAMICS; LIQUIDS; LOCALIZATION; RELAXATION	High-resolution inelastic neutron scattering was used to identify major sources of low-frequency vibrations in zeolite crystals. Dispersed and nondispersed modes were found, both of which are prominent in the early stages of compressive amorphization but decline dramatically in strength once a glass of conventional density is created. By identifying the dispersed modes with the characteristic vibrations of the various secondary building units of zeolitic structures, the Boson peak, a characteristic of the glassy state, can be attributed to vibrations within connected rings of many different sizes. The nondispersed phonon features in zeolites, retained in the amorphized glass, were also replicated in silica. These modes are librational in origin and are responsible for destabilizing the microporous crystalline structure, for converting the resulting glass from a low- to a high-density phase, and for the associated changes in network topology that affect the Boson peak.	Univ Wales, Inst Math & Phys Sci, Aberystwyth SY23 3BZ, Dyfed, Wales; European Synchrotron Radiat Facil, DUBBLE CRG, Netherlands Org Sci Res NWO, F-38043 Grenoble, France; Ecole Natl Super Chim Paris, F-75231 Paris, France; Rutherford Appleton Lab, ISIS Facil, Didcot OX11 0QX, Oxon, England	Aberystwyth University; European Synchrotron Radiation Facility (ESRF); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Greaves, GN (corresponding author), Univ Wales, Inst Math & Phys Sci, Aberystwyth SY23 3BZ, Dyfed, Wales.		MAJERUS, Odile/AAQ-6866-2020; Instrument, MARI/AAB-2270-2020	MAJERUS, Odile/0000-0003-2811-8804; 				ANDERSON PW, 1972, PHILOS MAG, V25, P1, DOI 10.1080/14786437208229210; Angell CA, 2000, J PHYS-CONDENS MAT, V12, P6463, DOI 10.1088/0953-8984/12/29/318; Angell CA, 2000, J APPL PHYS, V88, P3113, DOI 10.1063/1.1286035; Boerio-Goates J, 2002, J THERM ANAL CALORIM, V69, P773, DOI 10.1023/A:1020639502445; BOHMER R, 1994, DISORDER EFFECTS ON RELAXATIONAL PROCESSES, P11; Born M., 1954, DYNAMICAL THEORY CRY; BUCHENAU U, 1986, PHYS REV B, V34, P5665, DOI 10.1103/PhysRevB.34.5665; BUCHENAU U, 1988, PHYS REV LETT, V60, P1318, DOI 10.1103/PhysRevLett.60.1318; Courtens E, 2001, SOLID STATE COMMUN, V117, P187, DOI 10.1016/S0038-1098(00)00434-8; DOORYHEE E, 1991, J PHYS CHEM-US, V95, P1229; Dove MT, 1997, PHYS REV LETT, V78, P1070, DOI 10.1103/PhysRevLett.78.1070; DUVAL E, 1986, PHYS REV LETT, V56, P2052, DOI 10.1103/PhysRevLett.56.2052; Dyer A., 1988, INTRO ZEOLITE MOL SI; Elliott S.R., 1990, PHYS AMORPHOUS MAT; ELLIOTT SR, 1992, EUROPHYS LETT, V19, P201, DOI 10.1209/0295-5075/19/3/009; Greaves GN, 2003, NAT MATER, V2, P622, DOI 10.1038/nmat963; GREAVES GN, 2004, J PHYS CONDENS MATT, V16, P1; Hammonds KD, 1997, PHYS REV LETT, V78, P3701, DOI 10.1103/PhysRevLett.78.3701; Hehlen B, 2000, PHYS REV LETT, V84, P5355, DOI 10.1103/PhysRevLett.84.5355; Inamura Y, 2001, J NON-CRYST SOLIDS, V293, P389, DOI 10.1016/S0022-3093(01)00824-9; Ioffe A. F., 1960, PROG SEMICOND, V4, P237; LAUGHLIN WT, 1972, J PHYS CHEM-US, V76, P2317, DOI 10.1021/j100660a023; MENEAU F, IN PRESS NUCL INST B; Mukhopadhyay AB, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.012202; Mukhopadhyay AB, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.024205; Nakamura M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.024203; Phillips W.A., 1981, AMORPHOUS SOLIDS LOW; PONYATOVSKY EG, 1992, MATER SCI REP, V8, P147, DOI 10.1016/0920-2307(92)90007-N; Sette F, 1998, SCIENCE, V280, P1550, DOI 10.1126/science.280.5369.1550; SMITH JV, 1971, ACS SYM SER, V101, P170; Sokolov AP, 1997, PHYS REV LETT, V78, P2405, DOI 10.1103/PhysRevLett.78.2405; STEBBINS JF, 1995, REV MINERALOGY, V32; Taraskin SN, 1997, EUROPHYS LETT, V39, P37, DOI 10.1209/epl/i1997-00310-1; Taraskin SN, 1999, PHYS REV B, V59, P8572, DOI 10.1103/PhysRevB.59.8572; VASHISHTA P, 1990, PHYS REV B, V41, P12197, DOI 10.1103/PhysRevB.41.12197; Wales D. J., 2003, ENERGY LANDSCAPES	36	86	88	8	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2005	308	5726					1299	1302		10.1126/science.1109411	http://dx.doi.org/10.1126/science.1109411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919990				2022-12-28	WOS:000229482300044
J	Kanai, T; Minemoto, S; Sakai, H				Kanai, T; Minemoto, S; Sakai, H			Quantum interference during high-order harmonic generation from aligned molecules	NATURE			English	Article							LASER-PULSES; MULTIPHOTON IONIZATION; GASES; ALIGNMENT; FIELDS	High-order harmonic generation (HHG) from atoms and molecules offers potential application as a coherent ultrashort radiation source in the extreme ultraviolet and soft X-ray regions(1-3). In the three-step model(4-6) of HHG, an electron tunnels out from the atom and may recombine with the parent ion ( emitting a high-energy photon) after undergoing laser-driven motion in the continuum. Aligned molecules(7-11) can be used to study quantum phenomena in HHG associated with molecular symmetries; in particular, simultaneous observations of both ion yields and harmonic signals under the same conditions serve to disentangle the contributions from the ionization and recombination processes. Here we report evidence for quantum interference of electron de Broglie waves(12-14) in the recombination process of HHG from aligned CO2 molecules. The interference takes place within a single molecule and within one optical cycle. Characteristic modulation patterns of the harmonic signals measured as a function of the pump - probe delay are explained with simple formulae determined by the valence orbital of the molecules. We propose that simultaneous observations of both ion yields and harmonic signals can serve as a new route to probe the instantaneous structure of molecular systems.	Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Sakai, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hsakai@phys.s.u-tokyo.ac.jp	Kanai, Tsuneto/I-3838-2016; SAKAI, HIROFUMI/G-5096-2014	Kanai, Tsuneto/0000-0003-1248-8122; 				Chang ZH, 1997, PHYS REV LETT, V79, P2967, DOI 10.1103/PhysRevLett.79.2967; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; de Nalda R, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.031804; Dooley PW, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.023406; Drescher M, 2002, NATURE, V419, P803, DOI 10.1038/nature01143; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Itatani J, 2004, NATURE, V432, P867, DOI 10.1038/nature03183; Kaku M, 2004, JPN J APPL PHYS 2, V43, pL591, DOI 10.1143/JJAP.43.L591; KRAUSE JL, 1992, PHYS REV LETT, V68, P3535, DOI 10.1103/PhysRevLett.68.3535; Lein M, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.023819; Lein M, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.051404; Lein M, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023805; Lein M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.183903; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; LIANG Y, 1994, J PHYS B-AT MOL OPT, V27, P5119, DOI 10.1088/0953-4075/27/20/024; Litvinyuk IV, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.233003; Lynga C, 1996, J PHYS B-AT MOL OPT, V29, P3293, DOI 10.1088/0953-4075/29/14/032; Muth-Bohm J, 2000, PHYS REV LETT, V85, P2280, DOI 10.1103/PhysRevLett.85.2280; Rosca-Pruna F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.153902; SAKAI H, 1994, PHYS REV A, V50, P4204, DOI 10.1103/PhysRevA.50.4204; Sakai H, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.063404; Sakai H, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.083001; Sakai H, 1999, J CHEM PHYS, V110, P10235, DOI 10.1063/1.478039; SAKAI H, 1995, APPL PHYS B-LASERS O, V61, P493, DOI 10.1007/BF01081279; Shan B, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.021404; Tong XM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.033402; Velotta R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.183901; Young T I, 1804, PHILOS T ROYAL SOC L, V94, P1, DOI DOI 10.1098/RSTL.1804.0001	28	639	644	5	163	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					470	474		10.1038/nature03577	http://dx.doi.org/10.1038/nature03577			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917803				2022-12-28	WOS:000229337800049
J	Warner, E; Causer, PA				Warner, E; Causer, PA			MRI surveillance for hereditary breast-cancer risk	LANCET			English	Editorial Material							MUTATION CARRIERS; BRCA1; WOMEN; MAMMOGRAPHY; PREDISPOSITION; EFFICACY; SURGERY		Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Imaging, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Warner, E (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada.	ellen.warner@sw.ca						Botkin JR, 2003, AM J MED GENET A, V118A, P201, DOI 10.1002/ajmg.a.10102; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Komenaka IK, 2004, CANCER, V100, P2079, DOI 10.1002/cncr.20221; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; *NAT COMPR CANC NE, 2005, GEN FAM HIGH RISK AS; Scheuer L, 2002, J CLIN ONCOL, V20, P1260, DOI 10.1200/JCO.2002.20.5.1260; Schwartz MD, 2004, J CLIN ONCOL, V22, P1823, DOI 10.1200/JCO.2004.04.086; Tilanus-Linthorst M, 2002, INT J CANCER, V102, P91, DOI 10.1002/ijc.10666; Warner E, 2005, JAMA-J AM MED ASSOC, V293, P931, DOI 10.1001/jama.293.8.931-b; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; WEINREB JC, 1995, RADIOLOGY, V196, P593, DOI 10.1148/radiology.196.3.7644617	14	29	30	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1747	1749		10.1016/S0140-6736(05)66520-8	http://dx.doi.org/10.1016/S0140-6736(05)66520-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910935				2022-12-28	WOS:000229291600004
J	Schoenfeld, P; Cash, B; Flood, A; Dobhan, R; Eastone, J; Coyle, W; Kikendall, JW; Kim, HM; Weiss, DG; Emory, T; Schatzkin, A; Lieberman, D				Schoenfeld, P; Cash, B; Flood, A; Dobhan, R; Eastone, J; Coyle, W; Kikendall, JW; Kim, HM; Weiss, DG; Emory, T; Schatzkin, A; Lieberman, D		CONCeRN Study Investigators	Colonoscopic screening of average-risk women for colorectal neoplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FLEXIBLE SIGMOIDOSCOPY; COST-EFFECTIVENESS; CANCER; POLYPS; SIZE	BACKGROUND: Veterans Affairs (VA) Cooperative Study 380 showed that some advanced colorectal neoplasias (i.e., adenomas at least 1 cm in diameter, villous adenomas, adenomas with high-grade dysplasia, or cancer) in men would be missed with the use of flexible sigmoidoscopy but detected by colonoscopy. In a tandem study, we examined the yield of screening colonoscopy in women. METHODS: To determine the prevalence and location of advanced neoplasia, we offered colonoscopy to consecutive asymptomatic women referred for colon-cancer screening. The diagnostic yield of flexible sigmoidoscopy was calculated by estimating the proportion of patients with advanced neoplasia whose lesions would have been identified if they had undergone flexible sigmoidoscopy alone. Lesions were considered detectable by flexible sigmoidoscopy if they were in the distal colon or if they were in the proximal colon in patients who had concurrent small adenomas in the distal colon, a finding that would have led to colonoscopy. The results were compared with the results from VA Cooperative Study 380 for age-matched men and women with negative fecal occult-blood tests and no family history of colon cancer. RESULTS: Colonoscopy was complete in 1463 women, 230 of whom (15.7 percent) had a family history of colon cancer. Colonoscopy revealed advanced neoplasia in 72 women (4.9 percent). If flexible sigmoidoscopy alone had been performed, advanced neoplasia would have been detected in 1.7 percent of these women (25 of 1463) and missed in 3.2 percent (47 of 1463). Only 35.2 percent of women with advanced neoplasia would have had their lesions identified if they had undergone flexible sigmoidoscopy alone, as compared with 66.3 percent of matched men from VA Cooperative Study 380 (P<0.001). CONCLUSIONS: Colonoscopy may be the preferred method of screening for colorectal cancer in women.	VAMC, Vet Affairs Ctr Excellence Hlth Serv Res, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI USA; Uniformed Serv Univ Hlth Sci, Div Gastroenterol, Bethesda, MD 20814 USA; Natl Naval Med Ctr, Div Gastroenterol, Bethesda, MD 20889 USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA; Natl Naval Med Ctr, Div Gastroenterol, San Diego, CA USA; Natl Naval Med Ctr, Div Gastroenterol, Portsmouth, VA USA; Walter Reed Army Med Ctr, Div Gastroenterol, Washington, DC 20307 USA; Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Biostat, Perry Point, MD USA; Armed Forces Inst Pathol, Washington, DC 20306 USA; NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR USA	University of Michigan System; University of Michigan; Uniformed Services University of the Health Sciences - USA; Walter Reed National Military Medical Center; University of Minnesota System; University of Minnesota Twin Cities; United States Department of Defense; United States Navy; Naval Medical Center San Diego; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); United States Department of Defense; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Schoenfeld, P (corresponding author), VAMC, Vet Affairs Ctr Excellence Hlth Serv Res, 111-D,2215 Fuller Rd, Ann Arbor, MI 48105 USA.	pschoenf@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK060040] Funding Source: NIH RePORTER; NIDDK NIH HHS [K23-DK-60040] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM CANC SOC, 1996, PUBL AM CANC SOC; Atkin WS, 2001, J MED SCREEN, V8, P137, DOI 10.1136/jms.8.3.137; Byrne MF, 2003, AM J GASTROENTEROL, V98, P2587; CORDICE JWV, 1991, J NATL MED ASSOC, V83, P730; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Gopalswamy N, 1997, GASTROINTEST ENDOSC, V46, P497, DOI 10.1016/S0016-5107(97)70003-8; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; GUILLEM JG, 1988, AM J GASTROENTEROL, V83, P271; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; Imperiale TF, 2003, ANN INTERN MED, V139, P959, DOI 10.7326/0003-4819-139-12-200312160-00005; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; MARTINEZ ME, 1995, JNCI-J NATL CANCER I, V87, P274, DOI 10.1093/jnci/87.4.274; Ness RM, 2000, AM J GASTROENTEROL, V95, P1800; NEUGUT AI, 1993, ANN INTERN MED, V118, P91, DOI 10.7326/0003-4819-118-2-199301150-00002; OTT DJ, 1982, J CLIN GASTROENTEROL, V4, P337, DOI 10.1097/00004836-198208000-00009; Painter J, 1999, ENDOSCOPY, V31, P227, DOI 10.1055/s-1999-13673; Rex DK, 1999, GASTROINTEST ENDOSC, V50, P468, DOI 10.1016/S0016-5107(99)70067-2; Schoen RE, 1997, GASTROINTEST ENDOSC, V46, P492, DOI 10.1016/S0016-5107(97)70002-6; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Winawer SJ, 2003, ANN INTERN MED, V139, P1034, DOI 10.7326/0003-4819-139-12-200312160-00013; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	25	384	401	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2061	2068		10.1056/NEJMoa042990	http://dx.doi.org/10.1056/NEJMoa042990			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901859				2022-12-28	WOS:000229180100004
J	Merchant, RC; Mayer, KH				Merchant, RC; Mayer, KH			Perspectives on new recommendations for nonoccupational HIV postexposure prophylaxis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EXPOSURE		Brown Med Sch, Dept Emergency Med, Providence, RI USA; Brown Med Sch, Dept Med, Providence, RI USA; Brown Med Sch, Dept Community Hlth, Providence, RI USA	Brown University; Brown University; Brown University	Merchant, RC (corresponding author), Rhode Isl Hosp, Dept Emergency Med, 593 Eddy St,Potter 228, Providence, RI 02903 USA.	rmerchant@lifespan.org						*AIDS I NEW YORK D, 1998, HIV PROPH FOLL SEX A; *AIDS I NEW YORK S, 2004, HIV PROPH FOLL NON E; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Bassett IV, 2004, CLIN INFECT DIS, V39, P395, DOI 10.1086/422459; *CAL TASK FORC NON, 2005, OFF HIV POST EXP PRO; *DEP HLTH COMM MAS, 2000, CLIN ADV HIV PROPH N; Merchant RC, 2003, ACAD EMERG MED, V10, P1345, DOI 10.1197/S1069-6563(03)00537-2; MERCHANT RC, 2002, NONOCCUPATIONAL HIV; MYLES JE, 2001, OFFERING HIV PROPHYL; National Association of State Public Health Veterinarians Inc. (NASPHV), 2005, MMWR Recomm Rep, V54, P1; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV 1; Rey D, 2000, AIDS CARE, V12, P695, DOI 10.1080/09540120020014228; 1996, MMWR MORB MORTAL WKL, V45, P468	14	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2407	2409		10.1001/jama.293.19.2407	http://dx.doi.org/10.1001/jama.293.19.2407			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900012				2022-12-28	WOS:000229120600029
J	Kleinschmidt-DeMasters, BK; Tyler, KL				Kleinschmidt-DeMasters, BK; Tyler, KL			Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN POLYOMAVIRUSES; DISEASE; ENCEPHALOMYELITIS; INTEGRIN; ANTIBODY	A 46-year-old woman with relapsing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PM) after having received 37 doses of natalizumab (300 mg every four weeks) as part of a clinical trial of natalizumab and interferon beta-1a. PML was diagnosed on the basis of the finding of JC viral DNA in cerebrospinal fluid on polymerase-chain-reaction assay and was confirmed at autopsy. Nearly every tissue section from bilateral cerebral hemispheres contained either macroscopic or microscopic PML lesions. There was extensive tissue destruction and cavitation in the left frontoparietal area, large numbers of bizarre astrocytes, and inclusion-bearing oligodendrocytes, which were positive for JC virus DNA on in situ hybridization.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurosurg, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Kleinschmidt-DeMasters, BK (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, B-216,4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888				Gasnault J, 2003, AIDS, V17, P1443, DOI 10.1097/00002030-200307040-00004; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Goldberg SL, 2002, BLOOD, V99, P1486, DOI 10.1182/blood.V99.4.1486; Imperato AK, 2004, CLIN EXP RHEUMATOL, V22, pS108; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; Knowles WA, 2003, J MED VIROL, V71, P115, DOI 10.1002/jmv.10450; Koralnik IJ, 2004, CURR OPIN NEUROL, V17, P365, DOI 10.1097/00019052-200406000-00019; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Rice GPA, 2005, NEUROLOGY, V64, P1336, DOI 10.1212/01.WNL.0000158329.30470.D0; Stolt A, 2003, J GEN VIROL, V84, P1499, DOI 10.1099/vir.0.18842-0; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	13	789	825	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					369	374		10.1056/NEJMoa051782	http://dx.doi.org/10.1056/NEJMoa051782			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	15947079	Bronze			2022-12-28	WOS:000230782800009
J	Van Assche, G; Van Ranst, M; Sciot, R; Dubois, B; Vermeire, S; Noman, M; Verbeeck, J; Geboes, K; Robberecht, W; Rutgeerts, P				Van Assche, G; Van Ranst, M; Sciot, R; Dubois, B; Vermeire, S; Noman, M; Verbeeck, J; Geboes, K; Robberecht, W; Rutgeerts, P			Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JC VIRUS; TRANSPLANT RECIPIENTS; CONTROLLED TRIAL; T-LYMPHOCYTES; AIDS PATIENTS; EPIDEMIOLOGY; INTEGRIN	The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab, a monoclonal antibody against (alpha)(sub 4) integrins, was reclassified as JC virus-related progressive multifocal leukoencephalopathy (PML). Analysis of frozen serum samples showed that JC virus DNA had appeared in the serum three months after the initiation of open-label natalizumab monotherapy and two months before the appearance of symptomatic PML. There was staining of the brain lesion for polyomavirus. This case report, along with two others, suggests that anti-(alpha)(sub 4)-integrin therapy can result in JC virus-induced PML.	Katholieke Univ Leuven Hosp, Div Gastroenterol, B-3000 Louvain, Belgium; Katholieke Univ Leuven Hosp, Lab Clin & Epidemiol Virol, B-3000 Louvain, Belgium; Katholieke Univ Leuven Hosp, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium; Katholieke Univ Leuven Hosp, Dept Neurol, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven	Rutgeerts, P (corresponding author), Katholieke Univ Leuven Hosp, Div Gastroenterol, Herestr 49, B-3000 Louvain, Belgium.	rutgeerts@uz.kuleuven.ac.be	Verbeeck, Jannick/P-6027-2017; Van Ranst, Marc/P-7522-2017; Dubois, Benedicte/A-4338-2019	Verbeeck, Jannick/0000-0001-7226-1398; Van Ranst, Marc/0000-0002-1674-4157; sciot, raf/0000-0003-2244-5839; Vermeire, Severine/0000-0001-9942-3019; Dubois, Benedicte/0000-0003-0604-8702				Agostini H T, 1998, J Hum Virol, V1, P200; ASTROM KE, 1958, BRAIN, V81, P93, DOI 10.1093/brain/81.1.93; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; Dubois V, 2001, J INFECT DIS, V183, P213, DOI 10.1086/317927; Ferrante P, 1997, J MED VIROL, V52, P235, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;235::AID-JMV1&gt;3.0.CO;2-3; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gordon FH, 2001, GASTROENTEROLOGY, V121, P268, DOI 10.1053/gast.2001.26260; Herman J, 2004, PEDIATR TRANSPLANT, V8, P485, DOI 10.1111/j.1399-3046.2004.00211.x; HOLMAN RC, 1991, NEUROLOGY, V41, P1733, DOI 10.1212/WNL.41.11.1733; Jobes DV, 1998, J GEN VIROL, V79, P2491, DOI 10.1099/0022-1317-79-10-2491; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Koralnik IJ, 2004, CURR OPIN NEUROL, V17, P365, DOI 10.1097/00019052-200406000-00019; Koralnik IJ, 1999, NEUROLOGY, V52, P253, DOI 10.1212/WNL.52.2.253; Koralnik IJ, 2001, J VIROL, V75, P3483, DOI 10.1128/JVI.75.7.3483-3487.2001; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Milner R, 2002, MOL CELL NEUROSCI, V20, P616, DOI 10.1006/mcne.2002.1151; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; RICHARDSON E, 1961, NEW ENGL J MED, V265, P815, DOI 10.1056/NEJM196110262651701; Richardson E P Jr, 1983, Prog Clin Biol Res, V105, P191; Shitrit D, 2004, TRANSPL INT, V17, P658, DOI 10.1007/s00147-004-0779-3; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wei G, 2000, J NEUROVIROL, V6, P127, DOI 10.3109/13550280009013156	23	778	809	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2005	353	4					362	368		10.1056/NEJMoa051586	http://dx.doi.org/10.1056/NEJMoa051586			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949JW	15947080	Bronze			2022-12-28	WOS:000230782800008
J	Davis, CH; Li, YH; McConnell, JR; Frey, MM; Hanna, E				Davis, CH; Li, YH; McConnell, JR; Frey, MM; Hanna, E			Snowfall-driven growth in East Antarctic ice sheet mitigates recent sea-level rise	SCIENCE			English	Article							ELEVATION CHANGE; MASS-BALANCE	Satellite radar altimetry measurements indicate that the East Antarctic ice-sheet interior north of 81.6 degrees S increased in mass by 45 +/- 7 billion metric tons per year from 1992 to 2003. Comparisons with contemporaneous meteorological model snowfall estimates suggest that the gain in mass was associated with increased precipitation. A gain of this magnitude is enough to slow sea-level rise by 0.12 +/- 0.02 millimeters per year.	Univ Missouri, Dept Elect & Comp Engn, Columbia, MO 65211 USA; Univ & Community Coll Syst Nevada, Desert Res Inst, Reno, NV 89512 USA; Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA; Univ Sheffield, Dept Geog, Sheffield S10 2TN, S Yorkshire, England	University of Missouri System; University of Missouri Columbia; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; University of Arizona; University of Sheffield	Davis, CH (corresponding author), Univ Missouri, Dept Elect & Comp Engn, Columbia, MO 65211 USA.	davisch@missouri.edu	Hanna, Edward/W-5927-2019; Hanna, Edward/H-2219-2016; Frey, Markus/G-1756-2012; Frey, Markus/AAT-5882-2020	Hanna, Edward/0000-0002-8683-182X; Hanna, Edward/0000-0002-8683-182X; Frey, Markus/0000-0003-0535-0416; Frey, Markus/0000-0003-0535-0416				Arthern RJ, 1998, CLIMATIC CHANGE, V40, P605, DOI 10.1023/A:1005320713306; Chen QS, 1997, J CLIMATE, V10, P839, DOI 10.1175/1520-0442(1997)010<0839:POGRBA>2.0.CO;2; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; Davis CH, 2004, IEEE T GEOSCI REMOTE, V42, P2437, DOI 10.1109/TGRS.2004.836789; Ferguson AC, 2004, IEEE T GEOSCI REMOTE, V42, P2426, DOI 10.1109/TGRS.2004.836788; Goodwin I, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002995; HANNA E, IN PRESS J CLIM; Huybrechts P., 1990, CLIM DYNAM, V5, P93, DOI DOI 10.1007/BF00207424; Intergovernmental Panel on Climate Change, 2001, IPCC 3 ASS REP CLIM; Ivins ER, 2002, IAG SYMP, V123, P361; JACOBS SS, 1992, NATURE, V360, P29, DOI 10.1038/360029a0; Krabill W, 2000, SCIENCE, V289, P428, DOI 10.1126/science.289.5478.428; Krabill W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021533; LI Y, IN PRESS P 2005 INT; McConnell JR, 2000, NATURE, V406, P877, DOI 10.1038/35022555; MCCONNELL JR, 1998, J GEOPHYS RES, V40, P605; MORGAN VI, 1991, NATURE, V354, P58, DOI 10.1038/354058a0; Mosley-Thompson E, 1999, J GEOPHYS RES-ATMOS, V104, P3877, DOI 10.1029/1998JD200092; MOSLEYTHOMPSON E, 1995, ANN GLACIOL, V21, P131, DOI DOI 10.3189/S0260305500015718; OERLEMANS J, 1982, J CLIMATOL, V2, P1, DOI 10.1002/joc.3370020102; Rignot E, 2002, SCIENCE, V296, P2020, DOI 10.1126/science.1070942; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Shepherd A, 2001, SCIENCE, V291, P862, DOI 10.1126/science.291.5505.862; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Vaughan DG, 1999, J CLIMATE, V12, P933, DOI 10.1175/1520-0442(1999)012<0933:RONSMB>2.0.CO;2; WEN J, 2001, POLAR METEOROL GLACI, V15, P43; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456	27	194	201	1	206	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2005	308	5730					1898	1901		10.1126/science.1110662	http://dx.doi.org/10.1126/science.1110662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940BZ	15905362				2022-12-28	WOS:000230120000037
J	McClenahan, J				McClenahan, J			A good man	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											McClenahan, J (corresponding author), 413 Stuart Circle,Apartment B2, Richmond, VA 23220 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					944	945		10.7326/0003-4819-142-11-200506070-00016	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941705				2022-12-28	WOS:000229556300012
J	Redmond, AD				Redmond, AD			ABC of conflict and disaster - Needs assessment of humanitarian crises	BRITISH MEDICAL JOURNAL			English	Review									Univ Keele, Keele ST5 5BG, Staffs, England	Keele University	Redmond, AD (corresponding author), Univ Keele, Keele ST5 5BG, Staffs, England.								0	24	24	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 4	2005	330	7503					1320	1322		10.1136/bmj.330.7503.1320	http://dx.doi.org/10.1136/bmj.330.7503.1320			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933357	Green Published			2022-12-28	WOS:000229655700028
J	Cliffe, LJ; Humphreys, NE; Lane, TE; Potten, CS; Booth, C; Grencis, RK				Cliffe, LJ; Humphreys, NE; Lane, TE; Potten, CS; Booth, C; Grencis, RK			Accelerated intestinal epithelial cell turnover: A new mechanism of parasite expulsion	SCIENCE			English	Article							TRICHURIS-MURIS; INFECTION; RESISTANCE; IL-13; MICE	The functional integrity of the intestinal epithelial barrier forms a major defense against invading pathogens, including gastrointestinal-dwelting nematodes, which are ubiquitous in their distribution worldwide. Here, we show that an increase in the rate of epithelial. cell turnover in the large intestine acts like an "epithelia[ escalator" to expel Trichuris and that the rate of epithelial cell movement is under immune control by the cytokine interieukin-13 and the chemokine CXCL10. This host protective mechanism against intestinal pathogens has implications for our wider understanding of the multifunctional role played by intestinal epithelium in mucosal defense.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Epistem Ltd, Manchester M13 9XX, Lancs, England	University of Manchester; University of California System; University of California Irvine	Grencis, RK (corresponding author), Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.	Richard.K.Grencis@manchester.ac.uk	Eckhardt, Erik/G-1567-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Artis D, 2004, P NATL ACAD SCI USA, V101, P13596, DOI 10.1073/pnas.0404034101; Artis D, 1999, EXP PARASITOL, V92, P144, DOI 10.1006/expr.1999.4407; Bancroft AJ, 2000, EUR J IMMUNOL, V30, P2083, DOI 10.1002/1521-4141(200007)30:7&lt;2083::AID-IMMU2083&gt;3.0.CO;2-3; Bancroft AJ, 1998, J IMMUNOL, V160, P3453; Betts CJ, 1999, PARASITE IMMUNOL, V21, P45, DOI 10.1046/j.1365-3024.1999.00200.x; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; Koyama K, 2002, PARASITE IMMUNOL, V24, P527, DOI 10.1046/j.1365-3024.2002.00497.x; LEE TDG, 1983, INT J PARASITOL, V13, P349, DOI 10.1016/S0020-7519(83)80039-3; MacDonald TT, 2003, INT J MED MICROBIOL, V293, P87, DOI 10.1078/1438-4221-00247; Montresor A., 2002, HELMINTH CONTROL SCH; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; Sasaki S, 2002, EUR J IMMUNOL, V32, P3197, DOI 10.1002/1521-4141(200211)32:11<3197::AID-IMMU3197>3.0.CO;2-1	12	307	315	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1463	1465		10.1126/science.1108661	http://dx.doi.org/10.1126/science.1108661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933199				2022-12-28	WOS:000229619300052
J	Prockop, DJ				Prockop, DJ			Type II collagen and avascular necrosis of the femoral head	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA	Tulane University	Prockop, DJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA.								0	8	12	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2268	2270		10.1056/NEJMp058072	http://dx.doi.org/10.1056/NEJMp058072			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930417				2022-12-28	WOS:000229446400003
J	Studdert, DM; Mello, MM; Sage, WM; DesRoches, CM; Peugh, J; Zapert, K; Brennan, TA				Studdert, DM; Mello, MM; Sage, WM; DesRoches, CM; Peugh, J; Zapert, K; Brennan, TA			Defensive medicine among high-risk specialist physicians in a volatile malpractice environment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-PRACTITIONERS; LITIGATION; QUESTIONNAIRE; EXPERIENCE; ATTITUDES; LIABILITY; DECISION; CLAIMS; COST; FEAR	Context How often physicians alter their clinical behavior because of the threat of malpractice liability, termed defensive medicine, and the consequences of those changes, are central questions in the ongoing medical malpractice reform debate. Objective To study the prevalence and characteristics of defensive medicine among physicians practicing in high-liability specialties during a period of substantial instability in the malpractice environment. Design, Setting, and Participants Mail survey of physicians in 6 specialties at high risk of litigation (emergency medicine, general surgery, orthopedic surgery, neurosurgery, obstetrics/gynecology, and radiology) in Pennsylvania in May 2003. Main Outcome Measures Number of physicians in each specialty reporting defensive medicine or changes in scope of practice and characteristics of defensive medicine (assurance and avoidance behavior). Results A total of 824 physicians (65%) completed the survey. Nearly all (93%) reported practicing defensive medicine. "Assurance behavior" such as ordering tests, performing diagnostic procedures, and referring patients for consultation, was very common (92%). Among practitioners of defensive medicine who detailed their most recent defensive act, 43% reported using imaging technology in clinically unnecessary circumstances. Avoidance of procedures and patients that were perceived to elevate the probability of litigation was also widespread. Forty-two percent of respondents reported that they had taken steps to restrict their practice in the previous 3 years, including eliminating procedures prone to complications, such as trauma surgery, and avoiding patients who had complex medical problems or were perceived as litigious. Defensive practice correlated strongly with respondents' lack of confidence in their liability insurance and perceived burden of insurance premiums. Conclusion Defensive medicine is highly prevalent among physicians in Pennsylvania who pay the most for liability insurance, with potentially serious implications for cost, access, and both technical and interpersonal quality of care.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Columbia Law Sch, New York, NY USA; Harris Interact Inc, Rochester, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Columbia University	Studdert, DM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	studdert@hsph.harvard.edu	DesRoches, Catherine/ABC-9869-2020; Studdert, David/AAF-3116-2021	DesRoches, Catherine/0000-0001-5373-855X; Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270				BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; Ballard DW, 2002, J PEDIATR-US, V140, P713, DOI 10.1067/mpd.2002.124184; Blumenthal D, 2004, NEW ENGL J MED, V350, P1780, DOI 10.1056/NEJMhpr033066; BOVBJERG RR, UNDERSTANDING PENNSY; BRADLEY CP, 1992, BRIT J GEN PRACT, V42, P454; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; COOK WR, 1994, CAN FAM PHYSICIAN, V40, P689; COYTE PC, 1991, NEW ENGL J MED, V324, P89, DOI 10.1056/NEJM199101103240204; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; ENNIS M, 1991, LANCET, V338, P616, DOI 10.1016/0140-6736(91)90616-W; Glassman PA, 1996, J HEALTH POLIT POLIC, V21, P219, DOI 10.1215/03616878-21-2-219; GOOLD SD, 1994, J GEN INTERN MED, V9, P544, DOI 10.1007/BF02599278; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; Griffin L P, 1999, Obstet Gynecol Surv, V54, P77, DOI 10.1097/00006254-199902000-00001; GRUMBACH K, 1993, CHARGES OBSTET LIABI; HERSHEY N, 1972, MILBANK MEML FUND Q, V50, P69, DOI 10.2307/3349487; Joint Commission on Accreditation of Healthcare Organisations, SPEAK HELP PREV ERR; Kessler D, 1996, Q J ECON, V111, P353, DOI 10.2307/2946682; Klingman D, 1996, J HEALTH POLIT POLIC, V21, P185, DOI 10.1215/03616878-21-2-185; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; Mello MM, 2004, HEALTH AFFAIR, V23, P42, DOI 10.1377/hlthaff.23.4.42; Mello MM, 2002, TEX LAW REV, V80, P1595; Passmore K, 2002, POSTGRAD MED J, V78, P671, DOI 10.1136/pmj.78.925.671; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; Rosenblatt R A, 1988, Fam Med, V20, P101; SAGE WM, 2003, HLTH LAW HDB; SLOAN FA, 1995, MED CARE, V33, P700, DOI 10.1097/00005650-199507000-00006; SUMMERTON N, 1995, BRIT MED J, V310, P27, DOI 10.1136/bmj.310.6971.27; Swanson JW, 1996, SOC SCI MED, V42, P125, DOI 10.1016/0277-9536(95)00082-8; TANCREDI LR, 1978, SCIENCE, V200, P879, DOI 10.1126/science.644329; TUSSING AD, 1992, MED CARE, V30, P529, DOI 10.1097/00005650-199206000-00006; *US C, 1994, PUBL US C; Veldhuis M, 1994, Fam Med, V26, P27; Vimercati A, 2000, J PERINAT MED, V28, P111, DOI 10.1515/JPM.2000.014; WEISMAN CS, 1988, MED CARE, V26, P298, DOI 10.1097/00005650-198803000-00006; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; WOODWARD CA, 1989, CAN MED ASSOC J, V141, P291; 2003, PUBLICATION; 2003, MED LIABILITY MONITO, V28, P1	40	774	785	3	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2609	2617		10.1001/jama.293.21.2609	http://dx.doi.org/10.1001/jama.293.21.2609			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	930UU	15928282				2022-12-28	WOS:000229443400019
J	Mahawar, KK				Mahawar, KK			Misguided enthusiasm	LANCET			English	Editorial Material									Arrowe Pk Hosp, Wirral CH49 5PE, Merseyside, England		Mahawar, KK (corresponding author), Arrowe Pk Hosp, Wirral CH49 5PE, Merseyside, England.	kamal_mahawat@hotmail.com	Mahawar, Kamal/L-1884-2019	Mahawar, Kamal/0000-0003-2551-3462					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1901	1901		10.1016/S0140-6736(05)66624-X	http://dx.doi.org/10.1016/S0140-6736(05)66624-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924989				2022-12-28	WOS:000229481400031
J	Steinbrook, R				Steinbrook, R			Gag clauses in clinical-trial agreements.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Berenson Alex, 2005, N Y Times Web, pC13; Davidoff F, 2001, NEW ENGL J MED, V345, P825, DOI 10.1056/NEJMed20010093; Drazen JM, 2002, NEW ENGL J MED, V347, P1362, DOI 10.1056/NEJMe020122; MEIER B, NY TIMES        1129, pA104; Schulman KA, 2002, NEW ENGL J MED, V347, P1335, DOI 10.1056/NEJMsa020349	5	49	49	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2160	2162		10.1056/NEJMp048353	http://dx.doi.org/10.1056/NEJMp048353			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917381				2022-12-28	WOS:000229333300003
J	Hoffmann, MHK; Shi, HS; Schmitz, BL; Schmid, FT; Lieberknecht, ML; Schulze, R; Ludwig, B; Kroschel, U; Jahnke, N; Haerer, W; Brambs, HJ; Aschoff, AJ				Hoffmann, MHK; Shi, HS; Schmitz, BL; Schmid, FT; Lieberknecht, ML; Schulze, R; Ludwig, B; Kroschel, U; Jahnke, N; Haerer, W; Brambs, HJ; Aschoff, AJ			Noninvasive coronary angiography with multislice computed tomography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; MULTIDETECTOR ROW CT; CONE-BEAM CT; HEART-RATE; TEMPORAL RESOLUTION; AMERICAN-COLLEGE; DIAGNOSTIC-ACCURACY; RECONSTRUCTION; ARTERIES	Context Multislice computed tomography(MSCT) has recently evolved as a modality for noninvasive coronary imaging. Objective To assess the accuracy and robustness of MSCT vs the criterion standard of invasive coronary angiography for detection of obstructive coronary artery disease. Design, Setting, and Patients Prospective, single-center study conducted in a referral center setting in Germany and enrolling 103 consecutive patients (mean age, 61.5 [SD, 9.7] years) from November 2003-August 2004 who were undergoing both invasive coronary angiography and MSCT using a scanner with 16 detector rows. Main Outcome Measures Blinded results for both modalities compared using the patient as the primary unit of analysis, with supplementary segment- and vessel-based analyses. Results One thousand three hundred eighty-four segments ( &GE; 1.5 mm diameter) were identified by invasive coronary angiography; nondiagnostic image quality of MSCT was identified for only 88 (6.4%) of these segments, mainly due to faster heart rates. Compared with invasive coronary angiography for detection of significant lesions (>50% stenosis), segment-based sensitivity, specificity, and positive and negative predictive values of MSCT were 95%, 98%, 87%, and 99%, respectively. Quantitative comparison of MSCT and invasive coronary angiography showed good correlation (r=0.87, P<.001), with MSCT systematically measuring greater-percentage stenoses (bias, + 12%). In the patient-based analysis, the area under the receiver operating characteristic curve was 0.97 (95% confidence interval, 0.90-1.00), indicating high discriminative power to identify patients who might be candidates for revascularization (>50% left main artery stenosis and/or >70% stenosis in any other epicardial vessel). Threshold optimization allowed either detection of these patients with 100% sensitivity at a reasonable false-positive rate (specificity, 76.5%; MSCT stenosis, >66%) or optimization of both the sensitivity and specificity (>90%; MSCT stenosis, >76%). Conclusions Multislice computed tomography provides high accuracy for noninvasive detection of suspected obstructive coronary artery disease. This promising technology has potential to complement diagnostic invasive coronary angiography in routine clinical care.	Univ Hosp, Dept Diagnost Radiol, D-89070 Ulm, Germany; Ctr Heart, Dept Cardiol, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Hoffmann, MHK (corresponding author), Univ Hosp, Dept Diagnost Radiol, Steinhoevelstr 9, D-89070 Ulm, Germany.	martin.hoffmann@medizin.uni-ulm.de	Schmitz, Bernd L/G-2615-2014	Schmitz, Bernd L/0000-0003-1770-295X; , Heshui/0000-0002-5587-2696				Achenbach S, 2004, J AM COLL CARDIOL, V43, P840, DOI 10.1016/j.jacc.2003.12.014; Austen W G, 1975, Circulation, V51, P5; Bashore TM, 2001, J AM COLL CARDIOL, V37, P2170, DOI 10.1016/S0735-1097(01)01346-8; de Feyter PJ, 2004, J AM COLL CARDIOL, V44, P1238, DOI 10.1016/j.jacc.2004.06.044; Flohr T, 2001, J COMPUT ASSIST TOMO, V25, P907, DOI 10.1097/00004728-200111000-00014; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; Giesler T, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.4.1790911; Gonen M, 2001, RADIOLOGY, V221, P763, DOI 10.1148/radiol.2212010280; Grass M, 2003, PHYS MED BIOL, V48, P3069, DOI 10.1088/0031-9155/48/18/308; Hoffmann MHK, 2005, RADIOLOGY, V234, P86, DOI 10.1148/radiol.2341031408; Hoffmann MHK, 2004, AM J ROENTGENOL, V182, P601, DOI 10.2214/ajr.182.3.1820601; Kuettner A, 2005, J AM COLL CARDIOL, V45, P123, DOI 10.1016/j.jacc.2004.10.050; Lenth RV, 2001, AM STAT, V55, P187, DOI 10.1198/000313001317098149; LEWIS RP, 1977, CIRCULATION, V56, P146, DOI 10.1161/01.CIR.56.2.146; Manzke R, 2004, MED PHYS, V31, P3345, DOI 10.1118/1.1791351; Manzke R, 2004, IEEE T MED IMAGING, V23, P1150, DOI 10.1109/TMI.2004.830804; Manzke R, 2003, MED PHYS, V30, P3072, DOI 10.1118/1.1624756; Mollet NR, 2004, J AM COLL CARDIOL, V43, P2265, DOI 10.1016/j.jacc.2004.03.032; Mollet NR, 2005, J AM COLL CARDIOL, V45, P128, DOI 10.1016/j.jacc.2004.09.074; Nieman K, 2002, CIRCULATION, V106, P2051, DOI 10.1161/01.CIR.0000037222.58317.3D; Obuchowski NA, 2005, AM J ROENTGENOL, V184, P364, DOI 10.2214/ajr.184.2.01840364; OHNESORGE BM, 2002, MULTISLICE CT CARDIA; Pannu HK, 2003, RADIOGRAPHICS, V23, pS111, DOI 10.1148/rg.23si035514; Prokop M, 2003, EUR RADIOL, V13, pM3, DOI 10.1007/s00330-003-2178-z; Ropers D, 2003, CIRCULATION, V107, P664, DOI 10.1161/01.CIR.0000055738.31551.A9; Scanlon PJ, 1999, J AM COLL CARDIOL, V33, P1756, DOI 10.1016/S0735-1097(99)00126-6; Schoenhagen P, 2004, RADIOLOGY, V232, P7, DOI 10.1148/radiol.2321021803; Schoepf UJ, 2004, RADIOLOGY, V232, P18, DOI 10.1148/radiol.2321030636; Schroeder S, 2002, CLIN IMAG, V26, P106, DOI 10.1016/S0899-7071(01)00371-0; Shechter G, 2003, P SOC PHOTO-OPT INS, V5032, P1820, DOI 10.1117/12.480117; UEHATA A, 1993, CIRCULATION, V88, P1724, DOI 10.1161/01.CIR.88.4.1724	32	383	415	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2471	2478		10.1001/jama.293.20.2471	http://dx.doi.org/10.1001/jama.293.20.2471			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929BX	15914747	Bronze			2022-12-28	WOS:000229318200021
J	Ward, H; Cassell, J; Williams, S; Aylin, P				Ward, H; Cassell, J; Williams, S; Aylin, P			Dr Foster's case notes - Hospital indicators of poor sexual health	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Ward, H (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Ward, Helen/A-1836-2009; Aylin, Paul/A-1073-2014	Ward, Helen/0000-0001-8238-5036; Aylin, Paul/0000-0003-4589-1743; Cassell, Jackie/0000-0003-0777-0385				Department of Health, 2004, CHOOS HLTH MAK HLTH; Simms I, 2005, SEX TRANSM DIS, V32, P220, DOI 10.1097/01.olq.0000149848.03733.c1; Sowter MC, 2001, BRIT J OBSTET GYNAEC, V108, P204, DOI 10.1111/j.1471-0528.2001.00037.x; 2004, FOCUS PREVENTION HIV	4	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 21	2005	330	7501					1173	+		10.1136/bmj.330.7501.1173	http://dx.doi.org/10.1136/bmj.330.7501.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905255	Green Published			2022-12-28	WOS:000229320500014
J	Charras, GT; Yarrow, JC; Horton, MA; Mahadevan, L; Mitchison, TJ				Charras, GT; Yarrow, JC; Horton, MA; Mahadevan, L; Mitchison, TJ			Non-equilibration of hydrostatic pressure in blebbing cells	NATURE			English	Article							MEMBRANE; EXTENSION; MIGRATION; MOTILITY; KINASE; FLOW	Current models for protrusive motility in animal cells focus on cytoskeleton-based mechanisms, where localized protrusion is driven by local regulation of actin biochemistry(1-3). In plants and fungi, protrusion is driven primarily by hydrostatic pressure(4-6). For hydrostatic pressure to drive localized protrusion in animal cells(7,8), it would have to be locally regulated, but current models treating cytoplasm as an incompressible viscoelastic continuum(9) or viscous liquid(10) require that hydrostatic pressure equilibrates essentially instantaneously over the whole cell. Here, we use cell blebs as reporters of local pressure in the cytoplasm. When we locally perfuse blebbing cells with cortex-relaxing drugs to dissipate pressure on one side, blebbing continues on the untreated side, implying non-equilibration of pressure on scales of approximately 10 mu m and 10 s. We can account for localization of pressure by considering the cytoplasm as a contractile, elastic network infiltrated by cytosol. Motion of the fluid relative to the network generates spatially heterogeneous transients in the pressure field, and can be described in the framework of poroelasticity(11,12).	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; UCL, London Ctr Nanotechnol, London WC1E 6JF, England; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; University of London; University College London; Harvard University; Harvard University	Charras, GT (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	gcharras@hms.harvard.edu	Charras, Guillaume/F-8571-2014	Charras, Guillaume/0000-0002-7902-0279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048027] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM048027] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRECHTBUEHLER G, 1981, COLD SPRING HARB SYM, V46, P45; Baumgartner M, 2004, AM J PHYSIOL-CELL PH, V287, pC844, DOI 10.1152/ajpcell.00094.2004; Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886; Boal D. H., 2002, MECH CELL; Cheung A, 2002, NAT CELL BIOL, V4, P83, DOI 10.1038/ncb734; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dai JW, 1999, BIOPHYS J, V77, P3363, DOI 10.1016/S0006-3495(99)77168-7; Drury JL, 1999, BIOPHYS J, V76, P110, DOI 10.1016/S0006-3495(99)77183-3; EVANS E, 1984, J CELL BIOL, V98, P1201, DOI 10.1083/jcb.98.4.1201; FISHKIND DJ, 1991, J CELL BIOL, V114, P967, DOI 10.1083/jcb.114.5.967; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Harold FM, 2002, FUNGAL GENET BIOL, V37, P271, DOI 10.1016/S1087-1845(02)00528-5; Mahadevan L, 2000, SCIENCE, V288, P95, DOI 10.1126/science.288.5463.95; Messerli MA, 2003, PLANTA, V217, P147, DOI 10.1007/s00425-003-0972-0; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Mogilner A, 2003, CURR BIOL, V13, pR721, DOI 10.1016/j.cub.2003.08.050; MONEY NP, 1992, P NATL ACAD SCI USA, V89, P4245, DOI 10.1073/pnas.89.10.4245; O'Connell CB, 2001, CURR BIOL, V11, P702, DOI 10.1016/S0960-9822(01)00181-6; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; Rafelski SM, 2004, ANNU REV BIOCHEM, V73, P209, DOI 10.1146/annurev.biochem.73.011303.073844; Takayama S, 2003, CHEM BIOL, V10, P123, DOI 10.1016/S1074-5521(03)00019-X; TILNEY LG, 1985, J CELL BIOL, V100, P1273, DOI 10.1083/jcb.100.4.1273; TRINKAUS JP, 1973, DEV BIOL, V30, P68, DOI 10.1016/0012-1606(73)90049-3; Wang H.F., 2000, PRI SER GEO; Yarrow JC, 2005, CHEM BIOL, V12, P385, DOI 10.1016/j.chembiol.2005.01.015; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	29	459	471	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					365	369		10.1038/nature03550	http://dx.doi.org/10.1038/nature03550			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902261	Green Accepted			2022-12-28	WOS:000229185000049
J	Brain, EGC; Bachelot, T; Serin, D; Kirscher, S; Graic, Y; Eymard, JC; Extra, JM; Combe, M; Fourme, E; Nogues, C; Rouesse, J				Brain, EGC; Bachelot, T; Serin, D; Kirscher, S; Graic, Y; Eymard, JC; Extra, JM; Combe, M; Fourme, E; Nogues, C; Rouesse, J		RAPP-01 Trial Investigators	Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	40th Annual Meeting of the American-Society-of-Clinical-Oncology	JUN 05-08, 2004	New Orleans, LA	Amer Soc Clin Oncol			CHEMOTHERAPY; CYCLOPHOSPHAMIDE; TRIAL; RECOMMENDATIONS; MULTICENTER; PACLITAXEL; THERAPY; COLITIS; REGIMEN	Context Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity. Objective To describe adverse events associated with adjuvant chemotherapy for breast cancer, which led to premature termination of a clinical trial. Design, Setting, and Patients We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et Predictifs [RAPP]-01) to compare the effectiveness of 2 chemotherapy regimens. Patients (women aged 18-70 years) had primary unilateral breast cancer and either a moderate number of positive axillary lymph nodes (:53) or no positive axillary lymph nodes (NO), but were at a high risk of relapse. Patients were treated at 11 French cancer referral centers from June 1999 through January 2003. Primary prophylaxis for febrile neutropenia was not recommended in the study protocol. Interventions Doxorubicin, 50 mg/m(2), plus docetaxel, 75 mg/m(2), or doxorubicin, 60 mg/m(2), plus cyclophosphamide, 600 mg/m(2), given postoperatively for 4 courses. Main Outcome Measures The main end point was the disease-free survival rate at 5 years, as estimated using the Kaplan-Meier product limit method. Secondary end points included safety, which is the focus of this article, and overall survival. Results A total of 627 women were enrolled. Median follow-up is currently too short (24 months) to analyze the primary end point. The trial was terminated prematurely when 2 deaths related to drug toxicity and 1 case of perforative peritonitis occurred among patients with febrile neutropenia, all in the doxorubicin-docetaxel group. The incidence of febrile neutropenia was significantly higher with the doxorubicin-docetaxel regimen (40.8%) than with the doxorubicin-cyclophosphamide regimen (7.1 %) (P<.001). Conclusions A high risk of life-threatening complications associated with the doxorubicin-docetaxel regimen was found in this open-label controlled trial. The doxorubicin-docetaxel combination should not be considered as an alternative to the doxorubicin-cyclophosphamide regimen outside carefully designed studies that include primary prophylaxis for febrile neutropenia.	Rene Huguenin Canc Ctr, Dept Med Oncol, F-92210 St Cloud, France; Rene Huguenin Canc Ctr, Dept Biostat, F-92210 St Cloud, France; Leon Berard Canc Ctr, Dept Med Oncol, Lyon, France; St Catherine Inst Breast Clin, Avignon, France; Henri Becquerel Canc Ctr, Dept Radiotherapy, Rouen, France; Jean Godinot Canc Ctr, Dept Med Oncol, Reims, France; Inst Curie, Dept Med Oncol, Paris, France; Ctr Hosp Mans, Dept Med, Le Mans, France	Rene Huguenin Hospital; Rene Huguenin Hospital; UNICANCER; Centre Leon Berard; UNICANCER; Centre Henri Becquerel; UNICANCER; Institut Jean Godinot; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre Hospitalier Le Mans	Brain, EGC (corresponding author), Rene Huguenin Canc Ctr, Dept Med Oncol, 35 Rue Dailly, F-92210 St Cloud, France.	e.brain@stcloud-huguenin.org						Adenis A, 2001, J CLIN ONCOL, V19, P602, DOI 10.1200/JCO.2001.19.3.602; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; Blay JY, 2000, PRESSE MED, V29, P2004; Cardoso F, 2002, CANCER TREAT REV, V28, P275, DOI 10.1016/S0305-7372(02)00091-9; Fisher B, 2001, J CLIN ONCOL, V19, P931, DOI 10.1200/JCO.2001.19.4.931; Fumoleau P, 2003, J CLIN ONCOL, V21, P1190, DOI 10.1200/JCO.2003.99.223; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Ibrahim NK, 2000, LANCET, V355, P281, DOI 10.1016/S0140-6736(99)06195-4; Jassem J, 2001, J CLIN ONCOL, V19, P1707, DOI 10.1200/JCO.2001.19.6.1707; Li ZY, 2004, CANCER-AM CANCER SOC, V101, P1508, DOI 10.1002/cncr.20546; MACKEY JR, 2001, P AN M AM SOC CLIN, V20, pA10; MAMOUNAS EP, 2003, P AN M AM SOC CLIN, V22, P4; MARTIN M, 2004, P AN M AM SOC CLIN, V23, P32; Misset JL, 1999, ANN ONCOL, V10, P553, DOI 10.1023/A:1026418831238; Nabholtz JM, 2003, J CLIN ONCOL, V21, P968, DOI 10.1200/JCO.2003.04.040; Nabholtz JM PT, 2002, P AN M AM SOC CLIN, V21, p36a; *NAT CANC I, COMM TOX CRIT VERS 2; Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Stollman N, 2004, LANCET, V363, P631, DOI 10.1016/S0140-6736(04)15597-9; TALCOTT JA, 1992, J CLIN ONCOL, V10, P316, DOI 10.1200/JCO.1992.10.2.316	22	40	42	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2367	2371		10.1001/jama.293.19.2367	http://dx.doi.org/10.1001/jama.293.19.2367			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900007				2022-12-28	WOS:000229120600024
J	Vidal, L; Shavit, M; Fraser, A; Paul, M; Leibovici, L				Vidal, L; Shavit, M; Fraser, A; Paul, M; Leibovici, L			Systematic comparison of four sources of drug information regarding adjustment of dose for renal function	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To compare advice on dosage adjustment for renal impairment provided by four commonly used secondary pharmacotherapeutic sources. Design Systematic comparison of the definitions of renal impairment, recommendations for dosage adjustment, and the evidence in support of these recommendations in four information sources. Data sources British National Formulary, Martindale: the Complete Drug Reference, American Hospital Formulary System Drug Information, and Drug Prescribing in Renal Failure. Review methods Two reviewers independently extracted data on recommendations for dosage adjustment for impaired renal function of 100 drugs often used in our hospital. Results The four sources differed in their recommendations for adjustments of dosage and dosing interval. They vary in their definitions of renal impairment; some are qualitative and remain unclear, All sources provide only a general description; the methods on which the advice is based and references for original data are rarely presented. Conclusions The remarkable variation in definitions and recommendations, along with scarce details of the methods used to reach this advice, makes the available sources of drug information ill suited for clinical use. The methods used to retrieve information and use data should be described and made available to the reader. Advice on drug prescription, dose and dosing interval, contraindications, and adverse effects should be evidence based.	Rabin Med Ctr, Dept Med E, Res Unit, Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Med E, Res Unit, Beilinson Campus, Petah Tiqwa, Israel.	leibovic@post.tau.ac.il		Fraser, Abigail/0000-0002-7741-9470				Aronoff GR, 1999, DRUG PRESCRIBING REN; *JOINT FORM COMM, 2004, BRIT NAT FORM; Jones CA, 1998, AM J KIDNEY DIS, V32, P992, DOI 10.1016/S0272-6386(98)70074-5; MCEVOY GK, 2004, AM HOSP FORMULARY SY; Sweetman SC., 2004, MARTINDALE COMPLETE	5	67	68	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 30	2005	331	7511					263	266		10.1136/bmj.38476.471088.3A	http://dx.doi.org/10.1136/bmj.38476.471088.3A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953FJ	15905228	Green Published, Bronze			2022-12-28	WOS:000231061700017
J	Brandes, M; Willimann, K; Moser, B				Brandes, M; Willimann, K; Moser, B			Professional antigen-presentation function by human gamma delta T cells	SCIENCE			English	Article							ADAPTIVE IMMUNE-RESPONSE; DENDRITIC CELLS; IN-VIVO; ACTIVATION; RECEPTOR; IMMUNOTHERAPY; RECOGNITION; COMPLEX; SYSTEM; CANCER	Human gamma delta T cells are considered to play a vital role in protective immunity through cytokine secretion and cytotoxic activity. We report that cells expressing the V delta 2V delta 2(+)-T cell receptor (V delta 2(+) T cells) also display principal characteristics of professional antigen-presenting cells such as dendritic cells. Thus, when activated, these cells efficiently processed and displayed antigens and provided co-stimulatory signals sufficient for strong induction of naive alpha beta T cell proliferation and differentiation. We suggest that, upon microbial activation, V delta 2(+) T cells participate in the induction of adaptive immune responses and that these cells may be a useful tool in vaccine development and immunotherapy.	Japan Sci & Technol Agcy, Int Cooperat Res Project, Quantum Spin Informat Project, Atsugi, Kanagawa 2430198, Japan; Harvard Univ, Ctr Nanoscale Syst, Cambridge, MA 02138 USA; Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1130033, Japan	Japan Science & Technology Agency (JST); Harvard University; University of Tokyo	Moser, B (corresponding author), Japan Sci & Technol Agcy, Int Cooperat Res Project, Quantum Spin Informat Project, Morinosato Wakamiya 3-1, Atsugi, Kanagawa 2430198, Japan.	bernhard.moser@izb.unibe.ch		Moser, Bernhard/0000-0002-4354-4572				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Brandes M, 2003, BLOOD, V102, P3693, DOI 10.1182/blood-2003-04-1016; Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797; Chen ZW, 2003, TRENDS IMMUNOL, V24, P213, DOI 10.1016/S1471-4906(03)00032-2; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Eberl M, 2003, FEBS LETT, V544, P4, DOI 10.1016/S0014-5793(03)00483-6; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Germain RN, 2004, CURR OPIN IMMUNOL, V16, P120, DOI 10.1016/j.coi.2003.11.001; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Hayes SM, 2002, IMMUNITY, V16, P827, DOI 10.1016/S1074-7613(02)00320-5; INABA K, 1989, J EXP MED, V170, P527, DOI 10.1084/jem.170.2.527; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Langenkamp A, 2002, EUR J IMMUNOL, V32, P2046, DOI 10.1002/1521-4141(200207)32:7<2046::AID-IMMU2046>3.0.CO;2-M; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Leslie DS, 2002, J EXP MED, V196, P1575, DOI 10.1084/jem.20021515; Morita CT, 2000, SPRINGER SEMIN IMMUN, V22, P191, DOI 10.1007/s002810000042; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Moser M, 2003, IMMUNITY, V19, P5, DOI 10.1016/S1074-7613(03)00182-1; Petersen TR, 2004, INT IMMUNOL, V16, P889, DOI 10.1093/intimm/dxh098; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3; Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819; Shin S, 2005, SCIENCE, V308, P252, DOI 10.1126/science.1106480; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Vincent MS, 2002, NAT IMMUNOL, V3, P1163, DOI 10.1038/ni851; WYMANN MP, 1990, J BIOL CHEM, V265, P619	35	483	525	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2005	309	5732					264	268		10.1126/science.1110267	http://dx.doi.org/10.1126/science.1110267			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	944SP	15933162				2022-12-28	WOS:000230449800034
J	Wardle, DA; Zackrisson, O				Wardle, DA; Zackrisson, O			Effects of species and functional group loss on island ecosystem properties	NATURE			English	Article							MICROBIAL BIOMASS; CURRENT KNOWLEDGE; PLANT DIVERSITY; MODEL SYSTEMS; PRODUCTIVITY; BIODIVERSITY; COMMUNITIES; RICHNESS; AREA	Considerable recent attention has focused on predicting how the losses of species and functional groups influence ecosystem properties(1,2), but the extent to which these effects vary among ecosystems remains poorly understood(3,4). Island systems have considerable scope for studying how biotic and abiotic factors influence processes in different ecosystems, because they enable the simultaneous study of large numbers of independent replicate systems at ecologically meaningful spatial scales(5-7). We studied a group of 30 islands in northern Sweden, for which island size determined disturbance history, and therefore vegetation successional stage and biotic and abiotic ecosystem properties. On each island we conducted a seven-year study that involved experimental removals of combinations of both plant functional groups and plant species. We show that although losses of functional groups and species often impaired key ecosystem processes, these effects were highly context-dependent and strongly influenced by island size. Our study provides evidence that the consequences of biotic loss for ecosystem functioning vary greatly among ecosystems and depend on the specific abiotic and biotic attributes of the system.	Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, S-90183 Umea, Sweden; Landcare Res, Lincoln 8152, New Zealand	Swedish University of Agricultural Sciences; Landcare Research - New Zealand	Wardle, DA (corresponding author), Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, S-90183 Umea, Sweden.	david.wardle@svek.slu.se	Wardle, David A./F-6031-2011	Wardle, David A./0000-0002-0476-7335				ANDERSON JPE, 1978, SOIL BIOL BIOCHEM, V10, P215, DOI 10.1016/0038-0717(78)90099-8; Anderson WB, 1999, OECOLOGIA, V118, P324, DOI 10.1007/s004420050733; Coomes DA, 2000, ECOL MONOGR, V70, P171, DOI 10.1890/0012-9615(2000)070[0171:IORCIF]2.0.CO;2; Diaz S, 2003, TRENDS ECOL EVOL, V18, P140, DOI 10.1016/S0169-5347(03)00007-7; Enquist BJ, 2001, NATURE, V410, P655, DOI 10.1038/35070500; Fridley JD, 2002, OECOLOGIA, V132, P271, DOI 10.1007/s00442-002-0965-x; Gonzalez A, 2002, J ANIM ECOL, V71, P594, DOI 10.1046/j.1365-2656.2002.00625.x; Grime JP, 1998, J ECOL, V86, P902, DOI 10.1046/j.1365-2745.1998.00306.x; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hooper DU, 2004, ECOL LETT, V7, P95, DOI 10.1046/j.1461-0248.2003.00555.x; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Mulder CPH, 1999, ECOL LETT, V2, P237; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; Schmid B, 2002, TRENDS ECOL EVOL, V17, P113, DOI 10.1016/S0169-5347(01)02422-3; Spiller DA, 1997, OIKOS, V78, P15, DOI 10.2307/3545795; *TECHN IND SYST, 1997, IND SIM DET NITR PHO; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; Tscharntke T, 2002, ECOL APPL, V12, P354, DOI 10.1890/1051-0761(2002)012[0354:COSHFT]2.0.CO;2; Vitousek PM, 2002, J BIOGEOGR, V29, P573, DOI 10.1046/j.1365-2699.2002.00707.x; Wardle DA, 1998, BIOL REV, V73, P305, DOI 10.1017/S0006323198005192; WARDLE DA, 1993, FUNCT ECOL, V7, P346, DOI 10.2307/2390215; Wardle DA, 2003, SCIENCE, V300, P972, DOI 10.1126/science.1082709; Wardle DA, 2002, J BIOGEOGR, V29, P583, DOI 10.1046/j.1365-2699.2002.00708.x; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; WARDLE DA, 2002, COMMUNICATIES ECOSYS	27	198	218	9	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					806	810		10.1038/nature03611	http://dx.doi.org/10.1038/nature03611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944702	Green Published			2022-12-28	WOS:000229638700048
J	Ciancio, A; Manzini, P; Castagno, F; D'Antico, S; Reynaudo, P; Coucourde, L; Ciccone, G; Del Piano, M; Ballare, M; Peyre, S; Rizzi, R; Barletti, C; Bruno, M; Caronna, S; Carucci, P; Venon, WD; De Angelis, C; Morgando, A; Musso, A; Repici, A; Rizzetto, M; Saracco, G				Ciancio, A; Manzini, P; Castagno, F; D'Antico, S; Reynaudo, P; Coucourde, L; Ciccone, G; Del Piano, M; Ballare, M; Peyre, S; Rizzi, R; Barletti, C; Bruno, M; Caronna, S; Carucci, P; Venon, WD; De Angelis, C; Morgando, A; Musso, A; Repici, A; Rizzetto, M; Saracco, G			Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus	ANNALS OF INTERNAL MEDICINE			English	Article							TO-PATIENT TRANSMISSION; DISINFECTION PROCEDURES; BIOPSY FORCEPS; INFECTION; PERSPECTIVE; COLONOSCOPY; POPULATION; SYSTEM	Background: The potential role of digestive endoscopy as a mode for transmission of hepatitis C virus (HCV) is controversial. Objective: To evaluate the role of digestive endoscopy in transmitting HCV by comparing the incidence of HCV infection in a cohort of patients undergoing endoscopy and in a cohort of blood donors. Design: Prospective cohort study. Setting: 3 endoscopic units and 2 blood banks in northwestern Italy. Patients: The potentially exposed cohort consisted of 9188 outpatients consecutively recruited from 3 endoscopic units. Of 9008 patients negative for antibody to HCV (anti-HCV), 8260 (92%) were retested for anti-HCV 6 months after endoscopy. The unexposed cohort consisted of 51 230 healthy, anti-HCV-negative persons who donated blood at 2 blood banks in the same area and during the same time period; 38 280 of them (75%) were tested again for anti-HCV 6 to 48 months after the first blood donation (95 317 person-years of observation). Measurements: Differences in the anti-HCV seroconversion rate between the exposed cohort (patients undergoing endoscopy) and the unexposed cohort (blood donors). Seroconversion was evaluated by a third-generation enzyme immunoassay for anti-HCV; persons positive for anti-HCV were tested for HCV RNA by polymerase chain reaction. Results: All 8260 persons undergoing endoscopy remained negative for anti-HCV 6 months after the procedure (risk per 1000 persons, 0 [95% Cl, 0 to 0.465]); in particular, none of the 912 patients who underwent endoscopy with the same instrument previously used on HCV carriers showed anti-HCV seroconversion (risk per 1000 persons, 0 [Cl, 0 to 4.195]). Four blood donors became positive for anti-HCV and HCV RNA (mean follow-up, 2.49 years; 0.042 case per 1000 person-years [Cl, 0.011 to 0.107 case per 1000 person-years]); each had undergone minor surgery before the second test. Limitations: In the endoscopy cohort, 8.3% of patients were lost to follow-up. Conclusions: These findings support the hypothesis that properly performed digestive endoscopy is not a major risk factor for the transmission of HCV.	Osped Molinette, Dipartimento Gastroenterol, Banca Sangue & Plasma Citta Turin, I-10126 Turin, Italy; Serv Immunotrasfus, Pinerolo, Italy; Osped Maggiore La Carita, Novara, Italy; ASL 9, Ivrea, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Saracco, G (corresponding author), Osped Molinette, Dipartimento Gastroenterol, Banca Sangue & Plasma Citta Turin, Corso Bramante 88, I-10126 Turin, Italy.	g.saracco@tin.it	Ciccone, Giovannino/K-3136-2016; repici, alessandro/HFH-8162-2022	Ciccone, Giovannino/0000-0001-7644-9574; repici, alessandro/0000-0002-1621-6450; Saracco, Giorgio Maria/0000-0001-5310-4143				Alfa MJ, 2002, INFECT CONT HOSP EP, V23, P198, DOI 10.1086/502035; ALLEN JI, 1987, GASTROENTEROLOGY, V92, P759, DOI 10.1016/0016-5085(87)90029-1; Altman D.G., 2000, STAT CONFIDENCE, Vsecond; *AM SOC GASTR END, 1988, GASTROINTEST ENDOS S, V34, P37; ANDRIEU J, 1995, GASTROEN CLIN BIOL, V19, P340; [Anonymous], 1996, GASTROINTEST ENDOSC, V43, P540; Axon A, 1996, ENDOSCOPY, V28, P722, DOI 10.1055/s-2007-1005584; AXON ATR, 1991, J GASTROEN HEPATOL, V6, P23, DOI 10.1111/j.1440-1746.1991.tb01138.x; Bronowicki JP, 1997, NEW ENGL J MED, V337, P237, DOI 10.1056/NEJM199707243370404; Chanzy B, 1999, GASTROINTEST ENDOSC, V50, P147, DOI 10.1016/S0016-5107(99)70216-6; COUROUCE AM, 1997, P 9 TRIENN INT S VIR, P250; Cronmiller JR, 1999, GASTROINTEST ENDOSC, V50, P152, DOI 10.1016/S0016-5107(99)70217-8; Gaudin JL, 1996, ENDOSCOPY, V28, pS42; Jung M, 2003, ENDOSCOPY, V35, P197, DOI 10.1055/s-2003-37270; Kondili LA, 2002, GUT, V50, P693, DOI 10.1136/gut.50.5.693; Kozarek RA, 2001, GASTROINTEST ENDOSC, V53, P747, DOI 10.1067/mge.2001.114055; LANGENBERG W, 1990, J INFECT DIS, V161, P507, DOI 10.1093/infdis/161.3.507; Mele A, 2001, J HEPATOL, V35, P284, DOI 10.1016/S0168-8278(01)00111-8; Orsi GB, 1997, ENDOSCOPY, V29, P732, DOI 10.1055/s-2007-1004298; Petersen BT, 1999, GASTROINTEST ENDOSC, V50, P287, DOI 10.1016/S0016-5107(99)70246-4; Ponchon T, 1997, ENDOSCOPY, V29, P199, DOI 10.1055/s-2007-1004164; Rey JF, 1997, ENDOSCOPY, V29, P203; Rey JF, 2003, ENDOSCOPY, V35, P869; Rutala WA, 2004, J HOSP INFECT, V56, pS27, DOI 10.1016/j.jhin.2003.12.035; SPACH DH, 1993, ANN INTERN MED, V118, P117, DOI 10.7326/0003-4819-118-2-199301150-00008; Tallis GF, 2003, J VIRAL HEPATITIS, V10, P234, DOI 10.1046/j.1365-2893.2003.00424.x; TENNENBAUM R, 1993, GASTROEN CLIN BIOL, V17, P763; Walter V A, 2000, Gastrointest Endosc Clin N Am, V10, P265; WELLER IVD, 1988, GUT, V29, P1134, DOI 10.1136/gut.29.8.1134	29	40	42	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					903	909		10.7326/0003-4819-142-11-200506070-00008	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941697				2022-12-28	WOS:000229556300004
J	Harding, R; Higginson, IJ				Harding, R; Higginson, IJ			Palliative care in sub-Saharan Africa	LANCET			English	Article							OF-LIFE CARE; ANTIRETROVIRAL THERAPY; DEVELOPING-COUNTRIES; SOUTH-AFRICA; GOOD DEATH; UGANDA; CANCER; AIDS; END; SERVICES	Control of pain and symptoms and terminal care are necessary for quality HIV and cancer care in sub-Saharan Africa. However, what constitutes feasible, accessible, and effective palliative care, and how to develop such services, remains to be resolved. Africa-specific palliative care includes components that carry resource implications. Home and community-based care has been largely successful, but community capacity and the resources and clinical supervision necessary to sustain quality care are lacking. Coverage and referrals must be primary concerns. Simple lay and professional protocols have been developed, but opioid availability remains a major constraint. Areas of good practice, and areas where further success may be achieved include: attention to community needs and capacity; explicit frameworks for service development and palliative-care integration throughout the disease course (including antiretroviral provision); further education and protocols; strengthening and dissemination of diverse referral and care systems; increasing advocacy; and funding and technical skills to build audit and quality assessment.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Palliat Care & Policy, Weston Educ Ctr, London SE5 9PJ, England	University of London; King's College London	Harding, R (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Palliat Care & Policy, Weston Educ Ctr, Cutcombe Rd, London SE5 9PJ, England.	Richard.harding@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				ADAMOLEKUN K, 1998, OMEGA, V36, P23; ARCHETTI J, 2003, REACT OUT MBUYA PARI; ARCHETTI J, REACT OUT MBUYA PARI; Bateman C, 2001, S AFR MED J, V91, P364; Bateman Chris, 2002, S Afr Med J, V92, P936; Beck SL, 1999, J PAIN SYMPTOM MANAG, V17, P16, DOI 10.1016/S0885-3924(98)00120-1; Bicego G, 2003, SOC SCI MED, V56, P1235, DOI 10.1016/S0277-9536(02)00125-9; Browde S, 2001, SAMJ S AFR MED J, V91, P732; CAMPBELL L, 2001, S AFR J HIV MED, V6, P9; Crowe S, 2001, Nurs Times, V97, P26; *CTR AIDS DEV RES, 2002, INT COMM BAS HOM CAR; Defilippi K, 2000, Int J Palliat Nurs, V6, P108; *DEP STAT HLTH, 2001, GAMB HANDS CAR HIV T; DREW R, 2001, OPTIONS EXTENDING RE; Drew RS, 1997, TROP DOCT, V27, P210, DOI 10.1177/004947559702700408; Easterbrook P, 2001, J ROY SOC MED, V94, P442, DOI 10.1177/014107680109400907; FOSTER S, 1991, SOC SCI MED, V32, P1201, DOI 10.1016/0277-9536(91)90035-B; GELFAND M, 1983, CENT AFR J MED, V29, P111; *GRAH HOSP, 2002, QUAL LIF PROJ; Gwyther E, 2002, J PAIN SYMPTOM MANAG, V24, P236, DOI 10.1016/S0885-3924(02)00455-4; Harding R, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-33; Harding R, 2004, PALLIATIVE CARE SUBS; Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000; Hartwig K, 2001, J PALLIATIVE CARE, V17, P121, DOI 10.1177/082585970101700209; Higginson IJ, 2002, PALLIATIVE MED, V16, P546, DOI 10.1191/0269216302pm576xx; HIGGINSON IJ, 2003, WHIT HOUS C HIV PALL; *HOSP AFR UG, 2003, 10 ANN REP APR 2002; *HOSP AFR UG, 2002, PALL MED PAIN SYMPT; *ISL HOSP BER SERV, 2003, ISL HOSP; JACKSON H, 1995, AIDS CARE, V7, P663, DOI 10.1080/09540129550126317; Jagwe Jack G M, 2002, J Palliat Med, V5, P160; JORDAN IB, 1995, TROP DOCT, V25, P21, DOI 10.1177/004947559502500107; Kaleeba N, 1997, AIDS CARE, V9, P13, DOI 10.1080/09540129750125307; KEBIRUNGI H, 2003, J PALLIAT CARE, V5, P2; KIHARA M, 2003, HLTH EXCHANGE   0821, P21; Kikule E, 2003, BRIT MED J, V327, P192, DOI 10.1136/bmj.327.7408.192; KRAUS P, 2002, PROG PALLIAT CARE, V10, P168; MACLACHLAN M, 1993, J ROY SOC HEALTH, V113, P136, DOI 10.1177/146642409311300309; Merriman A, 1999, J PALLIATIVE CARE, V15, P50, DOI 10.1177/082585979901500108; Merriman A, 2002, J PAIN SYMPTOM MANAG, V24, P252, DOI 10.1016/S0885-3924(02)00447-5; MERRIMAN A, 2002, INNOVATIONS END  MAY; MERRIMAN A, 2001, HOSPICE UGANDA J PAL, V4, P9; Minja B M, 1989, J Palliat Care, V5, P31; Moore J, 2003, PALLIATIVE CARE 21 C; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; MOSS V, 2003, P 6 INT C HEALTHC RE; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; MUSOKE RK, 2000, P PAPOS 2000 C SCI P; MUSOKE SF, AVAILABILITY MORPHIN; MWANGIPOWELL F, 2003, KEN PALL CAR WORKSH; Ngalula J, 2002, TROP MED INT HEALTH, V7, P873, DOI 10.1046/j.1365-3156.2002.00922.x; Nyambedha EO, 2003, SOC SCI MED, V57, P301, DOI 10.1016/S0277-9536(02)00359-3; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Ramsay S, 2003, LANCET, V362, P1812, DOI 10.1016/S0140-6736(03)14945-8; Ramsay S, 2001, LANCET, V358, P734, DOI 10.1016/S0140-6736(01)05942-6; Sabin CA, 2002, AIDS, V16, pS61, DOI 10.1097/00002030-200216004-00009; Selwyn Peter A, 2003, J Palliat Med, V6, P475, DOI 10.1089/109662103322144853; Sepulveda C, 2003, BRIT MED J, V327, P209, DOI 10.1136/bmj.327.7408.209; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; *SO AFR AIDS TRAIN, 2001, COUNS GUID PALL CAR; Soares LGL, 2003, J PAIN SYMPTOM MANAG, V26, P693, DOI 10.1016/S0885-3924(03)00251-3; Solanke TF, 1997, ANN NY ACAD SCI, V809, P109, DOI 10.1111/j.1749-6632.1997.tb48074.x; Somse P, 1998, AIDS EDUC PREV, V10, P558; Soyannwo A, 2001, Niger Postgrad Med J, V8, P175; Stjernsward J, 2002, J PAIN SYMPTOM MANAG, V24, P257, DOI 10.1016/S0885-3924(02)00451-7; Swartz L, 2002, BMJ-BRIT MED J, V325, P914, DOI 10.1136/bmj.325.7370.914; *U WISC PAIN POL S, 2003, DISS HOSP UG APPR OB; UNAIDS, 2003, AIDS EP UPD; Walter T, 2003, BMJ-BRIT MED J, V327, P218, DOI 10.1136/bmj.327.7408.218; *WHO, 2003, EXT ESS CAR INT MAN; *WHO, 2002, PROGR REP COMM HLTH; *WHO IMAI, 2003, PALL CAR SYMPT MAN E; Williams S, 2000, PALLIATIVE MED, V14, P225, DOI 10.1191/026921600673636094; World Health Organization, 2002, NAT CANC CONTR PROGR; World Health Organization, 1996, CANC PAIN REL; World Health Organization, 1996, CANC PAIN REL GUID O; 1984, LANCET, V323, P1136; 2003, HANDS CAR HOM BAS CA; 2000, AIDS PALL CAR UNAIDS	79	149	149	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1971	1977		10.1016/S0140-6736(05)66666-4	http://dx.doi.org/10.1016/S0140-6736(05)66666-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936427				2022-12-28	WOS:000229587800034
J	Stansfeld, SA; Berglund, B; Clark, C; Lopez-Barrio, I; Fischer, P; Ohrstrom, E; Haines, MM; Head, J; Hygge, S; van Kamp, I; Berry, BF				Stansfeld, SA; Berglund, B; Clark, C; Lopez-Barrio, I; Fischer, P; Ohrstrom, E; Haines, MM; Head, J; Hygge, S; van Kamp, I; Berry, BF		RANCH Sudy Team	Aircraft and road traffic noise and children"s cognition and health: a cross-national study	LANCET			English	Article							ENVIRONMENTAL-STRESS; READING-ABILITY; EXPOSURE; PERFORMANCE; SCHOOLS; LONDON; SOUND	Background Exposure to environmental stressors can impair children's health and their cognitive development. The effects of air pollution, lead, and chemicals have been studied, but there has been less emphasis on the effects Of noise. Our aim, therefore, was to assess the effect of exposure to aircraft and road traffic noise on cognitive performance and health in children. of Methods We did a cross-national, cross-sectional study in which we assessed 2844 of 3207 children aged 9-10 years who were attending 89 schools of 77 approached in the Netherlands, 27 in Spain, and 30 in the UK located in local authority areas around three major airports. We selected children by extent of exposure to external aircraft and road traffic noise at school as predicted from noise contour maps, modelling, and on-site measurements, and matched schools within countries for socioeconomic status. We measured cognitive and health outcomes with standardised tests and questionnaires administered in the classroom. We also used a questionnaire to obtain information from parents about socioeconomic status, their education, and ethnic origin. Findings We identified linear exposure-effect associations between exposure to chronic aircraft noise and impairment of reading comprehension (p=0.0097) and recognition memory (p=0.0141), and a non-linear association with annoyance (p<0.0001) maintained after adjustment for mother's education, socioeconomic status, longstanding illness, and extent of classroom insulation against noise. Exposure to road traffic noise was linearly associated with increases in episodic memory (conceptual recall: p=0.0066; information recall: p=0.0489), but also with annoyance (p=0.0047). Neither aircraft noise nor traffic noise affected sustained attention, self-reported health, or overall mental health. Interpretation Our findings indicate that a chronic environmental stressor-aircraft noise-could impair cognitive development in children, specifically reading comprehension. Schools exposed to high levels of aircraft noise are not healthy educational environments.	Univ London, Marys Sch Med & Dent, London E1 4NS, England; Karolinska Inst, Stockholm, Sweden; CSIC, Madrid, Spain; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Univ Gothenburg, Gothenburg, Sweden; Univ Gavle, Gavle, Sweden; Berry Environm, London, England	University of London; Karolinska Institutet; Consejo Superior de Investigaciones Cientificas (CSIC); Netherlands National Institute for Public Health & the Environment; University of Gothenburg; University of Gavle	Stansfeld, SA (corresponding author), Univ London, Marys Sch Med & Dent, London E1 4NS, England.	S.A.Stansfeld@qmul.ac.uk	Head, Jenny/GYA-2625-2022	Hygge, Staffan/0000-0003-4298-7459; Head, Jennifer/0000-0002-6054-0872; Clark, Charlotte/0000-0003-3031-4986				Banbury SP, 2001, HUM FACTORS, V43, P12, DOI 10.1518/001872001775992462; Bellinger DC, 2004, PEDIATRICS, V113, P1016; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; BRYANT P, 1985, CHILDRENS READING PR; Cohen MJ., 1997, CHILDRENS MEMORY SCA; COHEN S, 1980, AM PSYCHOL, V35, P231, DOI 10.1037/0003-066X.35.3.231; COHEN S, 1973, J EXP SOC PSYCHOL, V9, P407, DOI 10.1016/S0022-1031(73)80005-8; Cohen S., 1986, BEHAV HLTH ENV STRES; DELACRUZ V, 1999, ECL 2; Evans G. W., 1993, CHILDRENS ENV, P31, DOI DOI 10.2307/41515250; Evans GW, 1998, PSYCHOL SCI, V9, P75, DOI 10.1111/1467-9280.00014; Evans GW, 1997, ENVIRON BEHAV, V29, P638, DOI 10.1177/0013916597295003; Evans GW, 2004, J ENVIRON PSYCHOL, V24, P143, DOI 10.1016/S0272-4944(03)00076-8; Evans GW, 1995, PSYCHOL SCI, V6, P333, DOI 10.1111/j.1467-9280.1995.tb00522.x; Fields JM, 1997, J SOUND VIB, V206, P685, DOI 10.1006/jsvi.1997.1144; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; GREEN KB, 1982, ARCH ENVIRON HEALTH, V37, P24; Hagley F, 2002, SUFFOLK READING SCAL; Haines MM, 2002, J EPIDEMIOL COMMUN H, V56, P139, DOI 10.1136/jech.56.2.139; Haines MM, 2001, PSYCHOL MED, V31, P1385, DOI 10.1017/S003329170100469X; Haines MM, 2001, PSYCHOL MED, V31, P265, DOI 10.1017/S0033291701003282; Hygge S, 2003, SCAND J PSYCHOL, V44, P13, DOI 10.1111/1467-9450.00316; Hygge S, 2002, PSYCHOL SCI, V13, P469, DOI 10.1111/1467-9280.00483; Hygge S, 2003, APPL COGNITIVE PSYCH, V17, P895, DOI 10.1002/acp.926; Kryter KD, 1985, EFFECTS NOISE MAN, V2nd; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Schwartz J, 2004, PEDIATRICS, V113, P1037; SMITH AP, 1987, INT ARCH OCC ENV HEA, V59, P83, DOI 10.1007/BF00377682; Smith P, 2003, UNDERSTANDING CHILDR; STAPHORSIUS G, 1994, THESIS ARNHEM CITO; Toulouse E., 1986, PRUEBA PERCEPTIVA AT; Tremblay S, 1999, J EXP PSYCHOL HUMAN, V25, P1005, DOI 10.1037/0096-1523.25.4.1005; 1998, CALC ROAD TRAFF NOIS; 2004, LANCET, V363, P1409	34	363	376	6	153	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1942	1949		10.1016/S0140-6736(05)66660-3	http://dx.doi.org/10.1016/S0140-6736(05)66660-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	932XJ	15936421				2022-12-28	WOS:000229587800028
J	Summerskill, W				Summerskill, W			Our children, our future	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Summerskill, W (corresponding author), The Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1914	1914		10.1016/S0140-6736(05)66641-X	http://dx.doi.org/10.1016/S0140-6736(05)66641-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936409				2022-12-28	WOS:000229587800010
J	Fathman, CG; Soares, L; Chan, SM; Utz, PJ				Fathman, CG; Soares, L; Chan, SM; Utz, PJ			An array of possibilities for the study of autoimmunity	NATURE			English	Review							PROTEIN MICROARRAYS; RHEUMATOID-ARTHRITIS; BLOOD-CELLS; EXPRESSION; DISEASE; SERUM; TECHNOLOGIES; PREDICTION; CYTOKINE; CANCER	Since the completion of the sequencing of the human genome, scientific focus has shifted from studying genes to analysing the much larger number of proteins encoded by them. Several proteins can be generated from a single gene depending on how the genetic information is read ( transcribed) and how the resultant protein is modified following translation (post-translational modification). Genomic and proteomic technologies are already providing useful information about autoimmune disease, and they are likely to lead to important discoveries within the next decade.	Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; IBMP, Curitiba, Parana, Brazil	Stanford University	Fathman, CG (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA.	cfathman@stanford.edu						Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Aune TM, 2004, GENET EPIDEMIOL, V27, P162, DOI 10.1002/gepi.20013; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Buckner JH, 2002, CURR OPIN RHEUMATOL, V14, P254, DOI 10.1097/00002281-200205000-00011; Castle J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r66; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chan SM, 2004, NAT MED, V10, P1390, DOI 10.1038/nm1139; COOMBES KR, NATURE BIOTECHNOL, V23, P291; Crow MK, 2003, ARTHRITIS RES THER, V5, P279, DOI 10.1186/ar1015; de Vegvar HEN, 2003, J VIROL, V77, P11125, DOI 10.1128/JVI.77.20.11125-11138.2003; Drynda S, 2004, PATHOL RES PRACT, V200, P165, DOI 10.1016/j.prp.2004.02.011; Dumont D, 2004, PROTEOMICS, V4, P2117, DOI 10.1002/pmic.200300715; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ermann J, 2001, NAT IMMUNOL, V2, P759, DOI 10.1038/ni0901-759; Espina V, 2003, PROTEOMICS, V3, P2091, DOI 10.1002/pmic.200300592; Gilburd Boris, 2004, Clin Dev Immunol, V11, P53, DOI 10.1080/10446670410001670490; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X; Kader HA, 2005, AM J GASTROENTEROL, V100, P414, DOI 10.1111/j.1572-0241.2005.40819.x; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Liao H, 2004, ARTHRITIS RHEUM-US, V50, P3792, DOI 10.1002/art.20720; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lorenz P, 2003, PROTEOMICS, V3, P991, DOI 10.1002/pmic.200300412; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Michaud GA, 2003, NAT BIOTECHNOL, V21, P1509, DOI 10.1038/nbt910; Moses T, 2004, POWER ENGINEER, V18, P22, DOI 10.1049/pe:20040402; Ng B, 2004, J ALLERGY CLIN IMMUN, V114, P1463, DOI 10.1016/j.jaci.2004.09.006; Perez OD, 2002, NAT BIOTECHNOL, V20, P155, DOI 10.1038/nbt0202-155; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Quackenbush J, 2003, SCIENCE, V302, P240, DOI 10.1126/science.1090887; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Quintana FJ, 2004, P NATL ACAD SCI USA, V101, P14615, DOI 10.1073/pnas.0404848101; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Robinson WH, 2002, ARTHRITIS RHEUM-US, V46, P885, DOI 10.1002/art.10129; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Rus V, 2002, CLIN IMMUNOL, V102, P283, DOI 10.1006/clim.2001.5182; Schweitzer B, 2002, NAT BIOTECHNOL, V20, P359, DOI 10.1038/nbt0402-359; Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017; Soen Y, 2003, PLOS BIOL, V1, P429, DOI 10.1371/journal.pbio.0000065; Stone JH, 2005, ARTHRITIS RHEUM, V52, P902, DOI 10.1002/art.20938; Su L, 2004, J IMMUNOL, V173, P4994, DOI 10.4049/jimmunol.173.8.4994; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Utz PJ, 2005, IMMUNOL REV, V204, P264, DOI 10.1111/j.0105-2896.2005.00251.x; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wang DN, 2002, NAT BIOTECHNOL, V20, P275, DOI 10.1038/nbt0302-275; Wilson DS, 2003, ANGEW CHEM INT EDIT, V42, P494, DOI 10.1002/anie.200390150; Wiltshire S, 2000, CLIN CHEM, V46, P1990; Ye SQ, 2002, J BIOMED SCI, V9, P384, DOI 10.1159/000064547; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	58	74	81	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					605	611		10.1038/nature03726	http://dx.doi.org/10.1038/nature03726			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931213				2022-12-28	WOS:000229476200038
J	Fairbank, J; Frost, H; Wilson-MacDonald, J; Yu, LM; Barker, K; Collins, R				Fairbank, J; Frost, H; Wilson-MacDonald, J; Yu, LM; Barker, K; Collins, R		Spine Stabilisation Trial Grp	Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilisation trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FUSION; SURGERY; QUESTIONNAIRE	Objectives To assess the clinical effectiveness of surgical stabilisation (spinal fusion) compared with intensive rehabilitation for patients with chronic low back pain. Design Multicentre randomised controlled trial. Setting 15 secondary care orthopaedic and rehabilitation centres across the United Kingdom. Participants 349 participants aged 18-55 with chronic low back pain of at least one year's duration who were considered candidates for spinal fusion. Intervention Lumbar spine fusion or an intensive rehabilitation programme based on principles of cognitive behaviour therapy. Main outcome measure The primary outcomes were the Oswestry disability index and the shuttle walking test measured at baseline and two years after randomisation. The SF-36 instrument was used as a secondary outcome measure. Results 176 participants were assigned to surgery and 173 to rehabilitation. 284 (81%) provided follow-up data at 24 months. The mean Oswestry disability index changed favourably from 46.5 (SD 14.6) to 34.0 (SD 21.1) in the surgery group and from 44.8 (SD 14.8) to 36.1 (SD 20.6) in the rehabilitation group. The estimated mean difference between the groups was - 4.1(95% confidence interval - 8.1 to - 0. 1, P = 0.045) in favour of surgery. No significant differences between the treatment groups were observed in the shuttle walking test or any of the other outcome measures. Conclusions Both groups reported reductions in disability during two years of follow-up, possibly unrelated to the interventions. The statistical difference between treatment groups in one of the two primary outcome measures was marginal and only just reached the predefined minimal clinical difference, and the potential risk and additional cost of surgery also need to be considered. No clear evidence emerged that primary spinal fusion surgery was any more beneficial than intensive rehabilitation.	Nuffield Orthopaed Ctr, Oxford OX3 7LD, England; Univ Warwick, Div Hlth Community, Coventry CV4 7AL, W Midlands, England; Ctr Stat Med, Oxford OX3 7LF, England; Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Nuffield Orthopaedic Centre; University of Warwick; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Fairbank, J (corresponding author), Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.	jeremy.fairbank@ndos.ox.ac.uk	Fairbank, Jeremy/AAA-3411-2019; Yu, LM/J-4284-2012	Yu, Ly-Mee/0000-0003-0331-7364; Frost, Helen/0000-0001-9241-8970				Brox JI, 2003, SPINE, V28, P1913; CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; *DEP HLTH, 1998, HOSP EP STAT 1998 20; DEYO RA, 2005, IN PRESS SPINE; *EUR COMM RES DIR, 2005, B13 COST EUR COMM RE; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Fritzell P, 2002, SPINE, V27, P1131, DOI 10.1097/00007632-200206010-00002; Frost H, 2000, PHYSIOTHERAPY, V86, P285, DOI DOI 10.1016/S0031-9406(05)61002-4; Gibson JNA, 1999, SPINE, V24, P1820, DOI 10.1097/00007632-199909010-00012; Guzman J, 2001, BMJ-BRIT MED J, V322, P1511, DOI 10.1136/bmj.322.7301.1511; Hagg O, 2003, EUR SPINE J, V12, P22, DOI 10.1007/s00586-002-0465-z; Katz JN, 1995, SPINE, V20, pS78, DOI 10.1097/00007632-199512151-00002; Liddle SD, 2004, PAIN, V107, P176, DOI 10.1016/j.pain.2003.10.017; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; MAIN CJ, 1992, SPINE, V17, P42, DOI 10.1097/00007632-199201000-00007; MAYER TG, 1985, SPINE, V10, P482, DOI 10.1097/00007632-198507000-00002; Moller H, 2000, SPINE, V25, P1711, DOI 10.1097/00007632-200007010-00016; *NHS STAND GROUP, 1994, HLTH TECHN SGHT REP; Pratt RK, 2002, SPINE, V27, P84, DOI 10.1097/00007632-200201010-00020; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Schonstein E, 2003, SPINE, V28, pE391, DOI 10.1097/01.BRS.0000092482.76386.97; Taylor S, 2001, Physiother Res Int, V6, P170, DOI 10.1002/pri.225; Taylor SJ, 1999, SPINE, V24, P1805, DOI 10.1097/00007632-199909010-00010; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756	26	318	322	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2005	330	7502					1233	1239		10.1136/bmj.38441.620417.8F	http://dx.doi.org/10.1136/bmj.38441.620417.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15911537	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000229448900016
J	McMurray, JJV; Pfeffer, MA				McMurray, JJV; Pfeffer, MA			Heart failure	LANCET			English	Review							VENTRICULAR SYSTOLIC DYSFUNCTION; CARDIAC-RESYNCHRONIZATION THERAPY; CONVERTING-ENZYME INHIBITORS; RECEPTOR BLOCKER VALSARTAN; POSITIVE AIRWAY PRESSURE; NORMAL EJECTION FRACTION; ACUTE PULMONARY-EDEMA; QUALITY-OF-LIFE; DIASTOLIC DYSFUNCTION; NATRIURETIC PEPTIDE	Although heart failure is common, disabling, and deadly, there are now many effective treatments, at least for patients with low left-ventricular ejection fraction. For all, angiotensin-converting-enzyme inhibitors and beta blockers are the essential disease-modifying treatments, improving symptoms, reducing hospital admissions, and increasing survival. Implantable cardioverter defibrillators also improve survival. For patients with persistent symptoms, angiotensin-receptor blockers and aldosterone antagonists have additional benefits. These treatments are now preferred to digoxin, although this drug can still be useful at an earlier stage in patients with atrial fibrillation. In some patients with persistently severe symptoms and a wide QRS on the electrocardiogram, cardiac resynchronisation therapy also reduces mortality and morbidity. The role of other markers of ventricular dyssynchrony is under investigation. There is growing evidence that left-ventricular assist devices are indicated in some patients with end-stage heart failure. Organised delivery of care also improves outcome. However, there is still no firmly evidence-based treatment for heart failure with preserved ejection fraction. Many new pharmacological, device, and surgical treatments for heart failure are currently under evaluation in clinical trials, and other approaches, including stem-cell treatment, are at an earlier stage of investigation.	Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA	University of Glasgow; Harvard University; Brigham & Women's Hospital	McMurray, JJV (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Level 4, Glasgow G11 6NT, Lanark, Scotland.	j.mcmurray@bio.gla.ac.uk	mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				Agarwal AK, 2001, EUR J HEART FAIL, V3, P301, DOI 10.1016/S1388-9842(00)00149-5; Agner E, 2002, AM HEART J, V144, P597, DOI 10.1067/mhj.2002.125326; Amabile CM, 2004, ARCH INTERN MED, V164, P709, DOI 10.1001/archinte.164.7.709; Anand I, 2004, CIRCULATION, V110, P149, DOI 10.1161/01.CIR.0000134279.79571.73; Anker SD, 2004, HEART, V90, P464, DOI 10.1136/hrt.2002.007005; Anker SD, 2003, LANCET, V361, P1077, DOI 10.1016/S0140-6736(03)12892-9; Aronow Wilbert S, 2003, Congest Heart Fail, V9, P142, DOI 10.1111/j.1527-5299.2003.01388.x; Aurigemma GP, 2004, NEW ENGL J MED, V351, P1097, DOI 10.1056/NEJMcp022709; Badano LP, 2004, J AM SOC ECHOCARDIOG, V17, P253, DOI 10.1016/j.echo.2003.11.002; Baker DW, 2003, AM HEART J, V146, P258, DOI 10.1016/S0002-8703(02)94784-8; Banerjee P, 2002, J AM COLL CARDIOL, V39, P138, DOI 10.1016/S0735-1097(01)01704-1; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Blackledge HM, 2003, HEART, V89, P615, DOI 10.1136/heart.89.6.615; Bleasdale RA, 2004, HEART, V90, P2, DOI 10.1136/hrt.2004.048546; Bleumink GS, 2004, EUR HEART J, V25, P1614, DOI 10.1016/j.ehj.2004.06.038; Braunstein JB, 2003, J AM COLL CARDIOL, V42, P1226, DOI 10.1016/S0735-1097(03)00947-1; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Burkhoff D, 2003, CIRCULATION, V107, P656, DOI 10.1161/01.CIR.0000053947.82595.03; Camici PG, 2004, HEART, V90, P141, DOI 10.1136/hrt.2003.023119; Carson P, 2003, J CARD FAIL, V9, P164, DOI 10.1054/jcaf.2003.22; Ceia F, 2002, EUR J HEART FAIL, V4, P531, DOI 10.1016/S1388-9842(02)00034-X; Chagan L, 2002, AM J MANAG CARE, V8, P270; Chaudhry PA, 2001, J CARDIAC SURG, V16, P118, DOI 10.1111/j.1540-8191.2001.tb00496.x; Cleland JGF, 1999, EUR J HEART FAIL, V1, P211, DOI 10.1016/S1388-9842(99)00039-2; Cleland JGF, 2004, AM HEART J, V148, P157, DOI 10.1016/j.ahj.2004.03.010; Cleland JGF, 2003, EUR J HEART FAIL, V5, P295, DOI 10.1016/S1388-9842(03)00056-4; Cleland JGF, 2001, BRIT MED BULL, V59, P135, DOI 10.1093/bmb/59.1.135; CLELAND JGF, 2005, N ENGL J MED    0307; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cohn JN, 2003, CIRCULATION, V108, P1306, DOI 10.1161/01.CIR.0000091234.45664.62; Cooper HA, 2000, J AM COLL CARDIOL, V35, P1753, DOI 10.1016/S0735-1097(00)00625-2; Copeland JG, 2004, NEW ENGL J MED, V351, P859, DOI 10.1056/NEJMoa040186; Cortina A, 2001, AM J CARDIOL, V87, P1417, DOI 10.1016/S0002-9149(01)01568-5; Cowie MR, 2000, HEART, V83, P505, DOI 10.1136/heart.83.5.505; Cowie MR, 2002, EUR HEART J, V23, P877, DOI 10.1053/euhj.2001.2973; Cubillos-Garzon LA, 2004, AM HEART J, V147, P412, DOI 10.1016/j.ahj.2003.07.026; Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541; Daubert JC, 2004, EUROPACE, V5, pS1, DOI 10.1016/j.eupc.2004.07.002; Davie AP, 1997, QJM-MON J ASSOC PHYS, V90, P335, DOI 10.1093/qjmed/90.5.335; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; Dunselman P, 2003, LANCET, V362, P1854, DOI 10.1016/S0140-6736(03)14908-2; Faris R, 2002, INT J CARDIOL, V82, P149, DOI 10.1016/S0167-5273(01)00600-3; Feldman AM, 2001, LANCET, V357, P654, DOI 10.1016/S0140-6736(00)04151-9; Fischer M, 2003, EUR HEART J, V24, P320, DOI 10.1016/S0195-668X(02)00428-1; Flather MD, 2005, EUR HEART J, V26, P215, DOI 10.1093/eurheartj/ehi118; Follath F, 2002, LANCET, V360, P196, DOI 10.1016/S0140-6736(02)09455-2; Francis Gary S., 2001, American Journal of Medicine, V110, p37S; Freudenberger RS, 2004, EXPERT OPIN INV DRUG, V13, P1509, DOI 10.1517/13543784.13.11.1509; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; GARDIN JM, 1995, CIRCULATION, V91, P1739, DOI 10.1161/01.CIR.91.6.1739; Giannuzzi P, 2003, CIRCULATION, V108, P554, DOI 10.1161/01.CIR.0000081780.38477.FA; Goodlin SJ, 2004, J CARD FAIL, V10, P200, DOI 10.1016/j.cardfail.2003.09.006; Gottdiener JS, 2002, ANN INTERN MED, V137, P631, DOI 10.7326/0003-4819-137-8-200210150-00006; Gottlieb SS, 2000, J AM COLL CARDIOL, V35, P56, DOI 10.1016/S0735-1097(99)00532-X; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Guccione JM, 2003, ANN THORAC SURG, V76, P1171, DOI 10.1016/S0003-4975(03)00731-8; Heart Failure Society of America, 2000, Congest Heart Fail, V6, P11; Hedberg P, 2001, EUR HEART J, V22, P676, DOI 10.1053/euhj.2000.2284; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hjalmarson A, 1999, LANCET, V353, P2001; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Hobbs FDR, 2002, EUR HEART J, V23, P1867, DOI 10.1053/euhj.2002.3255; Hogg K, 2004, J AM COLL CARDIOL, V43, P317, DOI 10.1016/j.jacc.2003.07.046; Hood WB, 2004, J CARD FAIL, V10, P155, DOI 10.1016/j.cardfail.2003.12.005; Hsu LF, 2004, NEW ENGL J MED, V351, P2373, DOI 10.1056/NEJMoa041018; Hung MJ, 2002, INT J CLIN PRACT, V56, P57; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Hwang J J, 2001, Curr Cardiol Rep, V3, P198, DOI 10.1007/s11886-001-0023-z; Jaarsma T, 2004, EUR J HEART FAIL, V6, P227, DOI 10.1016/j.ejheart.2003.09.010; Jones RH, 2001, J AM COLL CARDIOL, V37, P1210, DOI 10.1016/S0735-1097(01)01123-8; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Katz Stuart D, 2004, Congest Heart Fail, V10, P243, DOI 10.1111/j.1527-5299.2004.03298.x; Kelly CA, 2002, EUR HEART J, V23, P1379, DOI 10.1053/euhj.2001.3156; Khunti K, 2000, BRIT J GEN PRACT, V50, P50; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Konstam MA, 2003, J CARD FAIL, V9, P350, DOI 10.1054/j.cardfail.2003.09.001; Krum H, 2004, EUR J HEART FAIL, V6, P937, DOI 10.1016/j.ejheart.2004.09.005; Krum H, 2001, MED J AUSTRALIA, V174, P459; Kupari M, 1997, J INTERN MED, V241, P387, DOI 10.1046/j.1365-2796.1997.129150000.x; Lechat P, 1999, LANCET, V353, P9; Leclercq C, 2002, J AM COLL CARDIOL, V39, P194, DOI 10.1016/S0735-1097(01)01747-8; Lee DS, 2004, AM J MED, V116, P581, DOI 10.1016/j.amjmed.2003.11.025; Lenzen MJ, 2004, EUR HEART J, V25, P1214, DOI 10.1016/j.ehj.2004.06.006; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; LOEB HS, 1993, CIRCULATION, V87, P78; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; MacMahon KMA, 2002, ARCH INTERN MED, V162, P509, DOI 10.1001/archinte.162.5.509; Maggioni AP, 2002, J AM COLL CARDIOL, V40, P1414, DOI 10.1016/S0735-1097(02)02304-5; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; Marshall D, 2000, HEART, V84, P355, DOI 10.1136/heart.84.4.355; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; McAlister FA, 2004, CIRCULATION, V109, P1004, DOI 10.1161/01.CIR.0000116764.53225.A9; McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C; McDonagh TA, 2004, EUR J HEART FAIL, V6, P269, DOI 10.1016/j.ejheart.2004.01.010; McKelvie RS, 2003, EUR HEART J, V24, P1727, DOI 10.1016/S0195-668X(03)00477-9; McKelvie RS, 2002, AM HEART J, V144, P23, DOI 10.1067/mhj.2002.123310; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; McMurray J, 2001, EUR J HEART FAIL, V3, P495, DOI 10.1016/S1388-9842(01)00173-8; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; McMurray JJV, 2004, CIRCULATION, V110, P3281, DOI 10.1161/01.CIR.0000147274.83071.68; Mehra MR, 2004, J AM COLL CARDIOL, V43, P1145, DOI 10.1016/j.jacc.2003.10.050; Melo LG, 2004, FASEB J, V18, P648, DOI 10.1096/fj.03-1171rev; Menasche P, 2004, SURG CLIN N AM, V84, P125, DOI 10.1016/S0039-6109(03)00210-X; Mendez GF, 2001, INT J CARDIOL, V80, P213, DOI 10.1016/S0167-5273(01)00497-1; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; Mosterd A, 2002, HEART, V87, P75, DOI 10.1136/heart.87.1.75; Murphy NF, 2004, HEART, V90, P1129, DOI 10.1136/hrt.2003.029553; *NAT HEART FDN NZ, 1997, NZ MED J, V1110, P99; Nesser HJ, 2004, HEART, V90, P5, DOI 10.1136/hrt.2004.047167; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Nielsen OW, 2001, HEART, V86, P172, DOI 10.1136/heart.86.2.172; Nieminen MS, 2005, EUR HEART J, V26, P384; O'Connor CM, 2004, J AM COLL CARDIOL, V43, P1550, DOI 10.1016/j.jacc.2004.02.003; O'Meara E, 2004, EUR HEART J, V25, P1920, DOI 10.1016/j.ehj.2004.07.025; Ogata K, 2004, J HEART LUNG TRANSPL, V23, P515, DOI 10.1016/j.healun.2003.07.007; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 2003, CIRCULATION, V108, P2950, DOI 10.1161/01.CIR.0000109205.35813.8E; Pantilat SZ, 2004, JAMA-J AM MED ASSOC, V291, P2476, DOI 10.1001/jama.291.20.2476; Park SJ, 2005, J THORAC CARDIOV SUR, V129, P9, DOI 10.1016/j.jtcvs.2004.04.044; Pedersen F, 2005, AM J MED, V118, P25, DOI 10.1016/j.amjmed.2004.07.048; Pedersen F, 2004, EUR J HEART FAIL, V6, P439, DOI 10.1016/j.ejheart.2003.12.003; Perry G, 1997, NEW ENGL J MED, V336, P525; Petrie MC, 2004, HEART, V90, P511, DOI 10.1136/hrt.2003.011403; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Piepoli MF, 2004, BMJ-BRIT MED J, V328, P189, DOI 10.1136/bmj.37938.645220.EE; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0; Raman JS, 2003, ANN THORAC SURG, V76, P141, DOI 10.1016/S0003-4975(03)00185-1; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Roger VL, 2004, JAMA-J AM MED ASSOC, V292, P344, DOI 10.1001/jama.292.3.344; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Schaufelberger M, 2004, EUR HEART J, V25, P300, DOI 10.1016/j.ehj.2003.12.012; Senni M, 2001, J AM COLL CARDIOL, V38, P1277, DOI 10.1016/S0735-1097(01)01567-4; Sesti C, 2004, CIRCULATION, V110, P242, DOI 10.1161/01.CIR.0000137593.62669.67; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Shlipak MG, 2003, ANN INTERN MED, V138, P917, DOI 10.7326/0003-4819-138-11-200306030-00013; Silverberg DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7; Sim MFV, 2004, EUR J HEART FAIL, V6, P433, DOI 10.1016/j.ejheart.2003.08.002; Sin DD, 2000, CIRCULATION, V102, P61, DOI 10.1161/01.CIR.102.1.61; Sirak TE, 2004, J AM COLL CARDIOL, V44, P497, DOI 10.1016/j.jacc.2004.03.063; Smart N, 2004, AM J MED, V116, P693, DOI 10.1016/j.amjmed.2003.11.033; Smart N, 2003, J CARD FAIL, V9, P49, DOI 10.1054/jcaf.2003.2; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; Stewart S, 2002, EUR J HEART FAIL, V4, P345, DOI 10.1016/S1388-9842(02)00019-3; Stewart S, 2002, EUR J HEART FAIL, V4, P361, DOI 10.1016/S1388-9842(01)00198-2; Stewart S, 2001, EUR HEART J, V22, P209, DOI 10.1053/euhj.2000.2291; Strickberger SA, 2005, CIRCULATION, V111, P2146, DOI 10.1161/01.CIR.0000161276.09685.4A; Struthers AD, 2004, HEART, V90, P1229, DOI 10.1136/hrt.2003.025312; Suskin N, 2001, J AM COLL CARDIOL, V37, P1677, DOI 10.1016/S0735-1097(01)01195-0; Sutton MGS, 2003, CIRCULATION, V107, P1985, DOI 10.1161/01.CIR.0000065226.24159.E9; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Swedberg K, 2000, EUR J HEART FAIL, V2, P229, DOI 10.1016/S1388-9842(00)00102-1; SWEDBERG K, 2005, EUR HEART J, DOI DOI 10.1093/EURHEARTJ.EHI204; Tang WHW, 2005, CURR CARDIOL REV, V1, P1, DOI 10.2174/1573403052952392; Tang WHW, 2003, J AM COLL CARDIOL, V41, P1394, DOI 10.1016/S0735-1097(03)00159-1; Tang WHW, 2001, ENDOCRIN METAB CLIN, V30, P1031, DOI 10.1016/S0889-8529(05)70226-7; Tavazzi L, 2004, EUR J HEART FAIL, V6, P635, DOI 10.1016/j.ejheart.2004.03.001; Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934; Thomas JT, 2002, AM J MED, V112, P437, DOI 10.1016/S0002-9343(02)01048-3; Thomas MD, 2004, EUR J HEART FAIL, V6, P125, DOI 10.1016/j.ejheart.2003.11.002; Trohman RG, 2004, LANCET, V364, P1701, DOI 10.1016/S0140-6736(04)17358-3; Troughton RW, 2000, LANCET, V355, P1126, DOI 10.1016/S0140-6736(00)02060-2; Trulock EP, 2004, J HEART LUNG TRANSPL, V23, P804, DOI 10.1016/j.healun.2004.05.013; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; Ventura HO, 2004, AM HEART J, V147, P386, DOI 10.1016/j.ahj.2003.10.009; Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E; Wang TJ, 2003, ANN INTERN MED, V138, P907, DOI 10.7326/0003-4819-138-11-200306030-00012; Witte KKA, 2004, HEART, V90, P1144, DOI 10.1136/hrt.2003.025684; Wolfe F, 2004, AM J MED, V116, P305, DOI 10.1016/j.amjmed.2003.09.039; Young JB, 2004, CIRCULATION, V110, P2618, DOI 10.1161/01.CIR.0000146819.43235.A9; Young JB, 2002, JAMA-J AM MED ASSOC, V287, P1531, DOI 10.1001/jama.287.12.1531; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566; Zile MR, 2001, CIRCULATION, V104, P779, DOI 10.1161/hc3201.094226; Zile MR, 2002, CIRCULATION, V105, P1503, DOI 10.1161/hc1202.105290; Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289	191	592	626	0	73	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1877	1889		10.1016/S0140-6736(05)66621-4	http://dx.doi.org/10.1016/S0140-6736(05)66621-4			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924986				2022-12-28	WOS:000229481400028
J	Gilbert, M; Mitchell, A; Bourn, D; Mawdsley, J; Cliton-Hadley, R; Wint, W				Gilbert, M; Mitchell, A; Bourn, D; Mawdsley, J; Cliton-Hadley, R; Wint, W			Cattle movements and bovine tuberculosis in Great Britain	NATURE			English	Article							DISEASE; PREDICTION; EPIDEMIC; DYNAMICS	For 20 years, bovine tuberculosis (BTB) has been spreading in Great Britain ( England, Wales and Scotland) and is now endemic in the southwest and parts of central England and in southwest Wales, and occurs sporadically elsewhere. Although its transmission pathways remain poorly understood, the disease's distribution was previously modelled statistically by using environmental variables and measures of their seasonality(1). Movements of infected animals have long been considered a critical factor in the spread of livestock diseases, as reflected in strict import/export regulations, the extensive movement restrictions imposed during the 2001 foot-and-mouth disease outbreak(2,3), the tracing procedures after a new case of BTB has been confirmed and the Government's recently published strategic framework for the sustainable control on BTB4. Since January 2001 it has been mandatory for stock-keepers in Great Britain to notify the British Cattle Movement Service of all cattle births, movements and deaths(5). Here we show that movements as recorded in the Cattle Tracing System data archive, and particularly those from areas where BTB is reported, consistently outperform environmental, topographic and other anthropogenic variables as the main predictor of disease occurrence. Simulation distribution models for 2002 and 2003, incorporating all predictor categories, are presented and used to project distributions for 2004 and 2005.	Environm Res Grp Oxford Ltd, Oxford OX1 3QE, England; Univ Libre Bruxelles, B-1050 Brussels, Belgium; Vet Labs Agcy, Addlestone KT15 3NB, Surrey, England	Universite Libre de Bruxelles; Veterinary Laboratories Agency	Wint, W (corresponding author), Environm Res Grp Oxford Ltd, POB 346, Oxford OX1 3QE, England.	william.wint@zoo.ox.ac.uk	Mitchell, Andrew P/L-6141-2014; Gilbert, Marius/C-6969-2009; Clifton-Hadley, Richard S/C-2503-2011	Wint, William/0000-0003-0916-0847; Gilbert, Marius/0000-0003-3708-3359				BOURNE FJ, 2001, EPIDEMIOLOGICAL INVE; CONGALTON RG, 1991, REMOTE SENS ENVIRON, V37, P35, DOI 10.1016/0034-4257(91)90048-B; Defra, 2005, GOV STRAT FRAM SUST; Donnelly CA, 2003, NATURE, V426, P834, DOI 10.1038/nature02192; Gibbens JC, 2001, VET REC, V149, P729, DOI 10.1136/vr.149.24.729; Gilbert M, 2004, J ANIM ECOL, V73, P459, DOI 10.1111/j.0021-8790.2004.00820.x; Hay SI, 1999, TROP MED INT HEALTH, V4, P58, DOI 10.1046/j.1365-3156.1999.00355.x; HAY SI, 2000, ADV PARASITOLOGY, V47; Haydon DT, 2003, P ROY SOC B-BIOL SCI, V270, P121, DOI 10.1098/rspb.2002.2191; Hengeveld R., 1989, DYNAMICS BIOL INVASI; Krebs J., 1997, PB3423 HMSO; Mitchell A, 2005, ANIM SCI, V80, P265, DOI 10.1079/ASC50020265; *NAO, 2003, ID TRACK LIV ENGL; Russell CA, 2004, P ROY SOC B-BIOL SCI, V271, P21, DOI 10.1098/rspb.2003.2559; Shigesada N., 1997, BIOL INVASIONS THEOR; Smith DL, 2002, P NATL ACAD SCI USA, V99, P3668, DOI [10.1073/pnas.042400799, 10.1073/pnas.132272199]; Wint GRW, 2002, TRENDS MICROBIOL, V10, P441, DOI 10.1016/S0966-842X(02)02444-7	17	270	272	0	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					491	496		10.1038/nature03548	http://dx.doi.org/10.1038/nature03548			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917808	Green Published			2022-12-28	WOS:000229337800054
J	Kepinski, S; Leyser, O				Kepinski, S; Leyser, O			The Arabidopsis F-box protein TIR1 is an auxin receptor	NATURE			English	Article							AUX/IAA PROTEINS; SCF; DEGRADATION; GENETICS; GROWTH; GENES	Despite 100 years of evidence showing a pivotal role for indole-3-acetic acid (IAA or auxin) in plant development, the mechanism of auxin perception has remained elusive. Central to auxin response are changes in gene expression, brought about by auxin-induced interaction between the Aux/IAA transcriptional repressor proteins and the ubiquitin - ligase complex SCFTIR1, thus targeting for them proteolysis. Regulated SCF-mediated protein degradation is a widely occurring signal transduction mechanism. Target specificity is conferred by the F-box protein subunit of the SCF (TIR1 in the case of Aux/IAAs) and there are multiple F-box protein genes in all eukaryotic genomes examined so far. Although SCF - target interaction is usually regulated by signal-induced modification of the target, we have previously shown that auxin signalling involves the modification of SCFTIR1. Here we show that this modification involves the direct binding of auxin to TIR1 and thus that TIR1 is an auxin receptor mediating transcriptional responses to auxin.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; SLU, Umea Plant Sci Ctr, S-90183 Umea, Sweden	University of York - UK; Swedish University of Agricultural Sciences; Umea University	Kepinski, S (corresponding author), Univ York, Dept Biol, Box 373, York YO10 5YW, N Yorkshire, England.	ssk2@york.ac.uk; hmol1@york.ac.uk	Leyser, Ottoline/AAC-5577-2019	Leyser, Ottoline/0000-0003-2161-3829	Biotechnology and Biological Sciences Research Council [BBS/B/09392] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; Berleth T, 2004, CURR OPIN PLANT BIOL, V7, P553, DOI 10.1016/j.pbi.2004.07.016; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dharmasiri N, 2003, CURR BIOL, V13, P1418, DOI 10.1016/S0960-9822(03)00536-0; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; Kepinski S, 2004, P NATL ACAD SCI USA, V101, P12381, DOI 10.1073/pnas.0402868101; Leblanc N, 1999, J BIOL CHEM, V274, P28314, DOI 10.1074/jbc.274.40.28314; Leyser O, 2002, ANNU REV PLANT BIOL, V53, P377, DOI 10.1146/annurev.arplant.53.100301.135227; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; Liscum E, 2002, PLANT MOL BIOL, V49, P387, DOI 10.1023/A:1015255030047; Moon J, 2004, PLANT CELL, V16, P3181, DOI 10.1105/tpc.104.161220; Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Ramos JA, 2001, PLANT CELL, V13, P2349, DOI 10.1105/tpc.13.10.2349; Risseeuw EP, 2003, PLANT J, V34, P753, DOI 10.1046/j.1365-313X.2003.01768.x; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Semple CAM, 2003, GENOME RES, V13, P1389, DOI 10.1101/gr.980303; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Tian Q, 2003, PLANT J, V36, P643, DOI 10.1046/j.1365-313X.2003.01909.x; Tiwari SB, 2004, PLANT CELL, V16, P533, DOI 10.1105/tpc.017384; Tiwari SB, 2001, PLANT CELL, V13, P2809, DOI 10.1105/tpc.13.12.2809; Ulmasov T, 1999, P NATL ACAD SCI USA, V96, P5844, DOI 10.1073/pnas.96.10.5844; Yang XQ, 2004, PLANT J, V40, P772, DOI 10.1111/j.1365-313X.2004.02254.x; Zenser N, 2001, P NATL ACAD SCI USA, V98, P11795, DOI 10.1073/pnas.211312798	30	1188	1329	9	261	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					446	451		10.1038/nature03542	http://dx.doi.org/10.1038/nature03542			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917798				2022-12-28	WOS:000229337800044
J	Catto, G				Catto, G			GMC and the future of revalidation - Building on the GMC's achievements	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Gen Med Council, London NW1 3JN, England		Catto, G (corresponding author), Gen Med Council, London NW1 3JN, England.	opce@gmc-uk.org						*DEP HLTH HOM OFF, 2004, SAF MAN CONTR DRUGS; Irvine D., 2003, DOCTORS TALE PROFESS; The Shipman Inquiry, SAF PAT LESS PROP FU	3	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2005	330	7501					1205	1207		10.1136/bmj.330.7501.1205	http://dx.doi.org/10.1136/bmj.330.7501.1205			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15905260	Green Published			2022-12-28	WOS:000229320500026
J	Coupland, R; Martin, S; Dutli, MT				Coupland, R; Martin, S; Dutli, MT			Protecting everybody's genetic data	LANCET			English	Editorial Material									Int Comm Red Cross, Legal Div, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Protect Div, CH-1202 Geneva, Switzerland		Coupland, R (corresponding author), Int Comm Red Cross, Legal Div, CH-1202 Geneva, Switzerland.	rcoupland@icrc.org						*GEN PROJ, NATL GEOGR; *INT, 2005, DNA PROF INT HDB DNA; *INT ORG STAND, 1999, ISOIEC170251999E INT; International Committee of the Red Cross ICRC, 2003, MISS ACT RES PROBL P; United Nations Educational Scientific and Cultural Organisation (UNESCO), 2003, INT DECL HUM GEN DAT	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1754	1756		10.1016/S0140-6736(05)66563-4	http://dx.doi.org/10.1016/S0140-6736(05)66563-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910939				2022-12-28	WOS:000229291600008
J	Essers, MAG; de Vries-Smits, LMM; Barker, N; Polderman, PE; Burgering, BMT; Korswagen, HC				Essers, MAG; de Vries-Smits, LMM; Barker, N; Polderman, PE; Burgering, BMT; Korswagen, HC			Functional interaction between beta-catenin and FOXO in oxidative stress signaling	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE; C-ELEGANS; GENE-EXPRESSION; DAF-16; ACTIVATION; PATHWAY; RAS	beta-Catenin is a multifunctional protein that mediates Writ signaling by binding to members of the T cell factor (TCF) family of transcription factors. Here, we report an evolutionarily conserved interaction of beta-catenin with FOXO transcription factors, which are regulated by insulin and oxidative stress signaling. beta-Catenin binds directly to FOXO and enhances FOXO transcriptional activity in mammalian cells. In Caenorhabditis elegans, loss of the beta-catenin BAR-1 reduces the activity of the FOXO ortholog DAF-16 in dauer formation and life span. Association of beta-catenin with FOXO was enhanced in cells exposed to oxidative stress. Furthermore, BAR-1 was required for the oxidative stress-induced expression of the DAF-16 target gene sod-3 and for resistance to oxidative damage. These results demonstrate a role for beta-catenin in regulating FOXO function that is particularly important under conditions of oxidative stress.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Univ Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Burgering, BMT (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	b.m.t.burgering@med.uu.nl; rkors@niob.knaw.nl	Barker, Nick/AAE-9833-2021; Barker, Nick/AAS-2774-2020; Barker, Nick/A-5535-2011; Essers, Marieke A.G./B-7758-2017; Korswagen, Hendrik/I-8782-2012	Barker, Nick/0000-0003-3566-4475; Essers, Marieke A.G./0000-0003-3117-1809; 				Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; ESSERS MA, UNPUB; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Korswagen HC, 2002, GENE DEV, V16, P1291, DOI 10.1101/gad.981802; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	20	583	618	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1181	1184		10.1126/science.1109083	http://dx.doi.org/10.1126/science.1109083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905404				2022-12-28	WOS:000229293400047
J	Hao, ZY; Duncan, GS; Chang, CC; Elia, A; Fang, M; Wakeham, A; Okada, H; Calzascia, T; Jang, YJ; Annick, YT; Yeh, WC; Ohashi, P; Wang, XD; Mak, TW				Hao, ZY; Duncan, GS; Chang, CC; Elia, A; Fang, M; Wakeham, A; Okada, H; Calzascia, T; Jang, YJ; Annick, YT; Yeh, WC; Ohashi, P; Wang, XD; Mak, TW			Specific ablation of the apoptotic functions of cytochrome c reveals a differential requirement for cytochrome c and apaf-1 in apoptosis	CELL			English	Article							FAMILY MEMBER BIM; CELL-DEATH; PARAVENTRICULAR NUCLEUS; CASPASE ACTIVATION; GROWTH-HORMONE; FACTOR BRN-2; FACTOR-I; MICE; DEFICIENCY; BAX	As components of the apoptosome, a caspase-activating complex, cytochrome c (Cyt c) and Apaf-1 are thought to play critical roles during apoptosis. Due to the obligate function of Cyt c in electron transport, its requirement for apoptosis in animals has been difficult to establish. We generated "knockin" mice expressing a mutant Cyt c (KA allele), which retains normal electron transfer function but fails to activate Apaf-1. Most KA/KA mice displayed embryonic or perinatal lethality caused by defects in the central nervous system, and surviving mice exhibited impaired lymphocyte homeostasis. Although fibroblasts from the KA/KA mice were resistant to apoptosis, their thymocytes were markedly more sensitive to death stimuli than Apaf-1(-/-) thymocytes. Upon treatment with gamma irradiation, procaspases were efficiently activated in apoptotic KA/KA thymocytes, but Apaf-1 oligomerization was not observed. These studies indicate the existence of a Cyt c- and apoptosome-independent but Apaf-1-dependent mechanism(s) for caspase activation.	Univ Toronto, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hao, ZY (corresponding author), Univ Toronto, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada.	zyhao@uhnres.utoronto.ca; tmak@uhnres.utoronto.ca	Duncan, Gordon/AIE-7011-2022	Ohashi, Pamela S./0000-0003-2915-9317; Wang, Xiaodong/0000-0001-9885-356X; Chang, Chia-Che/0000-0003-3509-3713; Calzascia, Thomas/0000-0001-8225-6744	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM R01 57158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Buller KM, 2003, NEUROSCIENCE, V118, P189, DOI 10.1016/S0306-4522(02)00808-4; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Dorshkind K, 2003, CLIN IMMUNOL, V109, P197, DOI 10.1016/S1521-6616(03)00181-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hefco V, 2004, BRAIN BEHAV IMMUN, V18, P158, DOI 10.1016/S0889-1591(03)00114-4; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kluck RM, 2000, J BIOL CHEM, V275, P16127, DOI 10.1074/jbc.275.21.16127; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; RATHMELL JC, 2002, CELL S, V109, P97; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wrona D, 2003, BRAIN BEHAV IMMUN, V17, P453, DOI 10.1016/S0889-1591(03)00065-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu TN, 2001, J BIOL CHEM, V276, P13034, DOI 10.1074/jbc.M009773200; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	46	208	225	3	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					579	591		10.1016/j.cell.2005.03.016	http://dx.doi.org/10.1016/j.cell.2005.03.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907471	Bronze			2022-12-28	WOS:000229331200014
J	Youngren, KK; Coveney, D; Peng, XN; Bhattacharya, C; Schmidt, LS; Nickerson, ML; Lamb, BT; Deng, JM; Behringer, RR; Capel, B; Rubin, EM; Nadeau, JH; Matin, A				Youngren, KK; Coveney, D; Peng, XN; Bhattacharya, C; Schmidt, LS; Nickerson, ML; Lamb, BT; Deng, JM; Behringer, RR; Capel, B; Rubin, EM; Nadeau, JH; Matin, A			The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours	NATURE			English	Article							RNA-BINDING PROTEIN; MESSENGER-RNA; STEM-CELLS; MOUSE CHROMOSOME-18; MICE; TERATOMAS; DEFICIENCY; CYCLOOXYGENASE-2; TRANSCRIPTION; EXPRESSION	In mice, the Ter mutation causes primordial germ cell (PGC) loss in all genetic backgrounds(1). Ter is also a potent modifier of spontaneous testicular germ cell tumour (TGCT) susceptibility in the 129 family of inbred strains, and markedly increases TGCT incidence in 129-Ter/Termales(2-4). In 129-Ter/Ter mice, some of the remaining PGCs transform into undifferentiated pluripotent embryonal carcinoma cells(2-6), and after birth differentiate into various cells and tissues that compose TGCTs. Here, we report the positional cloning of Ter, revealing a point mutation that introduces a termination codon in the mouse orthologue (Dnd1) of the zebrafish dead end (dnd) gene. PGC deficiency is corrected both with bacterial artificial chromosomes that contain Dnd1 and with a Dnd1-encoding transgene. Dnd1 is expressed in fetal gonads during the critical period when TGCTs originate. DND1 has an RNA recognition motif and is most similar to the apobec complementation factor, a component of the cytidine to uridine RNA-editing complex. These results suggest that Ter may adversely affect essential aspects of RNA biology during PGC development. DND1 is the first protein known to have an RNA recognition motif directly implicated as a heritable cause of spontaneous tumorigenesis. TGCT development in the 129-Ter mouse strain models paediatric TGCT in humans. This work will have important implications for our understanding of the genetic control of TGCT pathogenesis and PGC biology.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; SAIC Frederick Inc, Basic Res Program, Frederick, MD 21702 USA; NCI, Immunobiol Lab, Frederick, MD 21702 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; Case Western Reserve University; Case Western Reserve University; Duke University; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nadeau, JH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	jhn4@case.edu; amatin@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA093754] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093754, R01 CA075056, P30 CA016672] Funding Source: Medline; NHLBI NIH HHS [R01 HL063054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; Barbouti A, 2003, CANCER RES, V63, P1202; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Crittenden SL, 2002, NATURE, V417, P660, DOI 10.1038/nature754; Donovan PJ, 2003, CURR OPIN GENET DEV, V13, P463, DOI 10.1016/j.gde.2003.08.010; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Jinawath N, 2004, CANCER SCI, V95, P430, DOI 10.1111/j.1349-7006.2004.tb03227.x; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; Martinho RG, 2004, CURR BIOL, V14, P159, DOI 10.1016/j.cub.2003.12.036; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Menke DB, 2003, DEV BIOL, V262, P303, DOI 10.1016/S0012-1606(03)00391-9; Moore FL, 2003, P NATL ACAD SCI USA, V100, P538, DOI 10.1073/pnas.0234478100; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; NOGUCHI T, 1985, JNCI-J NATL CANCER I, V75, P385; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; SAKURAI T, 1995, DEV GROWTH DIFFER, V37, P293, DOI 10.1046/j.1440-169X.1995.t01-2-00007.x; SAKURAI T, 1994, MAMM GENOME, V5, P333, DOI 10.1007/BF00356550; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Tsuei DJ, 2004, ONCOGENE, V23, P5815, DOI 10.1038/sj.onc.1207773; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Weidinger G, 2003, CURR BIOL, V13, P1429, DOI 10.1016/S0960-9822(03)00537-2; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yao HHC, 2003, DEVELOPMENT, V130, P5895, DOI 10.1242/dev.00836	30	270	290	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					360	364		10.1038/nature03595	http://dx.doi.org/10.1038/nature03595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902260	Green Accepted			2022-12-28	WOS:000229185000048
J	Zarrin-Khameh, N; Lyon, RE				Zarrin-Khameh, N; Lyon, RE			Asphyxia due to an inhaled foreign body	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA; Forens Sci Ctr, Phoenix, AZ 85007 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Zarrin-Khameh, N (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2110	2110		10.1056/NEJMicm041055	http://dx.doi.org/10.1056/NEJMicm041055			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901864				2022-12-28	WOS:000229180100009
J	Pfander, B; Moldovan, GL; Sacher, M; Hoege, C; Jentsch, S				Pfander, B; Moldovan, GL; Sacher, M; Hoege, C; Jentsch, S			SUMO-modified PCNA recruits Srs2 to prevent recombination during S phase	NATURE			English	Article							DAMAGE-INDUCED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; POSTREPLICATION REPAIR; UBIQUITIN CONJUGATION; RAD6 PATHWAY; YEAST; REPLICATION; MUTANTS; PROTEIN	Damaged DNA, if not repaired before replication, can lead to replication fork stalling and genomic instability(1-3); however, cells can switch to different damage bypass modes that permit replication across lesions. Two main bypasses are controlled by ubiquitin modification of proliferating cell nuclear antigen ( PCNA), a homotrimeric DNA-encircling protein that functions as a polymerase processivity factor and regulator of replication-linked functions(4,5). Upon DNA damage, PCNA is modified at the conserved lysine residue 164 by either mono-ubiquitin or a lysine-63-linked multi-ubiquitin chain(5), which induce error-prone or error-free replication bypasses of the lesions(5,6). In S phase, even in the absence of exogenous DNA damage, yeast PCNA can be alternatively modified by the small ubiquitin-related modifier protein SUMO5; however the consequences of this remain controversial(5-7). Here we show by genetic analysis that SUMO-modified PCNA functionally cooperates with Srs2, a helicase that blocks recombinational repair by disrupting Rad51 nucleoprotein filaments(8,9). Moreover, Srs2 displays a preference for interacting directly with the SUMO-modified form of PCNA, owing to a specific binding site in its carboxy-terminal tail. Our finding suggests a model in which SUMO-modified PCNA recruits Srs2 in S phase in order to prevent unwanted recombination events of replicating chromosomes.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Jentsch, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	Jentsch@biochem.mpg.de	Pfander, Boris/A-8703-2013	Pfander, Boris/0000-0003-2180-5054; George-Lucian, Moldovan/0000-0003-3825-149X				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; AGUILERA A, 1988, GENETICS, V119, P779; Aylon Y, 2004, MUTAT RES-REV MUTAT, V566, P231, DOI 10.1016/j.mrrev.2003.10.001; Barbour L, 2003, MUTAT RES-FUND MOL M, V532, P137, DOI 10.1016/j.mrfmmm.2003.08.014; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Broomfield S, 2002, NUCLEIC ACIDS RES, V30, P732, DOI 10.1093/nar/30.3.732; Friedl AA, 2001, MUTAT RES-DNA REPAIR, V486, P137, DOI 10.1016/S0921-8777(01)00086-6; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; LAWRENCE CW, 1979, J BACTERIOL, V139, P866, DOI 10.1128/JB.139.3.866-876.1979; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PALLADINO F, 1992, GENETICS, V132, P23; RONG L, 1993, J BIOL CHEM, V268, P1252; Rosche WA, 2000, METHODS, V20, P4, DOI 10.1006/meth.1999.0901; SCHIESTL RH, 1990, GENETICS, V124, P817; Smirnova M, 2003, MUTAT RES-FUND MOL M, V532, P117, DOI 10.1016/j.mrfmmm.2003.08.026; Soustelle C, 2004, MOL CELL BIOL, V24, P5130, DOI 10.1128/MCB.24.12.5130-5143.2004; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Ulrich HD, 2001, NUCLEIC ACIDS RES, V29, P3487, DOI 10.1093/nar/29.17.3487; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383	28	462	478	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	2005	436	7049					428	433		10.1038/nature03665	http://dx.doi.org/10.1038/nature03665			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	947DK	15931174				2022-12-28	WOS:000230623400050
J	Bertaux, JL; Leblanc, F; Witasse, O; Quemerais, E; Lilensten, J; Stern, SA; Sandel, B; Korablev, O				Bertaux, JL; Leblanc, F; Witasse, O; Quemerais, E; Lilensten, J; Stern, SA; Sandel, B; Korablev, O			Discovery of an aurora on Mars	NATURE			English	Article							EXTREME ULTRAVIOLET OBSERVATIONS; UPPER-ATMOSPHERE; MAGNETIC-FIELD; VOYAGER-1 ENCOUNTER; IONOSPHERE; IONIZATION; EMISSIONS; NIGHTGLOW	In the high-latitude regions of Earth, aurorae are the often-spectacular visual manifestation of the interaction between electrically charged particles ( electrons, protons or ions) with the neutral upper atmosphere, as they precipitate along magnetic field lines. More generally, auroral emissions in planetary atmospheres "are those that result from the impact of particles other than photoelectrons" (ref. 1). Auroral activity has been found on all four giant planets possessing a magnetic field (Jupiter(2), Saturn(3), Uranus(4) and Neptune(5)), as well as on Venus, which has no magnetic field(6). On the nightside of Venus, atomic O emissions at 130.4 nm and 135.6 nm appear in bright patches of varying sizes and intensities(6), which are believed to be produced by electrons with energy < 300 eV ( ref. 7). Here we report the discovery of an aurora in the martian atmosphere, using the ultraviolet spectrometer SPICAM on board Mars Express. It corresponds to a distinct type of aurora not seen before in the Solar System: it is unlike aurorae at Earth and the giant planets, which lie at the foot of the intrinsic magnetic field lines near the magnetic poles, and unlike venusian auroras, which are diffuse, sometimes spreading over the entire disk. Instead, the martian aurora is a highly concentrated and localized emission controlled by magnetic field anomalies in the martian crust.	CNRS, Serv Aeron, IPSL, F-91371 Verrieres Le Buisson, France; European Space Agcy, ESTEC, NL-2200 AG Noordwijk, Netherlands; Univ Grenoble 1, CNRS, Lab Planetol Grenoble, F-38041 Grenoble, France; SW Res Inst, Boulder, CO 80302 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Space Res Inst IKI, Moscow 117810, Russia	Centre National de la Recherche Scientifique (CNRS); European Space Agency; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Arizona; Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences	Bertaux, JL (corresponding author), CNRS, Serv Aeron, IPSL, BP 3, F-91371 Verrieres Le Buisson, France.	bertaux@aerov.jussieu.fr	Korablev, Oleg/L-5083-2013; Witasse, Olivier/AGL-7805-2022; Korablev, Oleg I/K-6770-2017	Korablev, Oleg/0000-0003-1115-0656; Witasse, Olivier/0000-0003-3461-5604; Korablev, Oleg I/0000-0003-1115-0656				Acuna MH, 2001, J GEOPHYS RES-PLANET, V106, P23403, DOI 10.1029/2000JE001404; BARTH CA, 1971, J GEOPHYS RES, V76, P2213, DOI 10.1029/JA076i010p02213; Bertaux JL, 2005, ADV SPACE RES-SERIES, V35, P31, DOI 10.1016/j.asr.2003.09.055; Bertaux JL, 2005, SCIENCE, V307, P566, DOI 10.1126/science.1106957; Bertaux JL, 2000, PLANET SPACE SCI, V48, P1303, DOI 10.1016/S0032-0633(00)00111-2; BERTAUX JL, 2004, SPECIAL PUBLICATION, P95; Bhardwaj A, 2000, REV GEOPHYS, V38, P295, DOI 10.1029/1998RG000046; BLELLY PL, UNPUB J GEOPHYS RES; BROADFOOT AL, 1981, SCIENCE, V212, P206, DOI 10.1126/science.212.4491.206; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; BROADFOOT AL, 1989, SCIENCE, V246, P1459, DOI 10.1126/science.246.4936.1459; EASTES RW, 1992, PLANET SPACE SCI, V40, P481, DOI 10.1016/0032-0633(92)90168-N; Fox J.L., 1992, GEOPHYS MONOGR SER, V66, P191, DOI DOI 10.1029/GM066P0191; FOX JL, 1986, CAN J PHYS, V64, P1631, DOI 10.1139/p86-288; FOX JL, 1991, J GEOPHYS RES-SPACE, V96, P9821, DOI 10.1029/91JA00252; FOX JL, 1979, J GEOPHYS RES-SPACE, V84, P7315, DOI 10.1029/JA084iA12p07315; HAIDER SA, 1992, J GEOPHYS RES-SPACE, V97, P10637, DOI 10.1029/92JA00317; Krymskii AM, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000239; LILENSTEN J, IN PRESS J GEOPHYS R; Mitchell DL, 2001, J GEOPHYS RES-PLANET, V106, P23419, DOI 10.1029/2000JE001435; Ness NF, 2000, J GEOPHYS RES-SPACE, V105, P15991, DOI 10.1029/1999JA000212; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; PHILLIPS JL, 1986, GEOPHYS RES LETT, V13, P1047, DOI 10.1029/GL013i010p01047; Purucker M, 2000, GEOPHYS RES LETT, V27, P2449, DOI 10.1029/2000GL000072; WITASSE O, IN PRESS J GEOPHYS R	25	155	158	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					790	794		10.1038/nature03603	http://dx.doi.org/10.1038/nature03603			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944698				2022-12-28	WOS:000229638700044
J	Govindarajulu, M; Pfeffer, PE; Jin, HR; Abubaker, J; Douds, DD; Allen, JW; Bucking, H; Lammers, PJ; Shachar-Hill, Y				Govindarajulu, M; Pfeffer, PE; Jin, HR; Abubaker, J; Douds, DD; Allen, JW; Bucking, H; Lammers, PJ; Shachar-Hill, Y			Nitrogen transfer in the arbuscular mycorrhizal symbiosis	NATURE			English	Article							FUNGUS GLOMUS-INTRARADICES; IN-VITRO; GENE-EXPRESSION; TRANSPORT; CARBON; ASSIMILATION; ROOTS; METABOLISM; TRANSLOCATION; CARBOHYDRATE	Most land plants are symbiotic with arbuscular mycorrhizal fungi (AMF), which take up mineral nutrients from the soil and exchange them with plants for photosynthetically fixed carbon. This exchange is a significant factor in global nutrient cycles(1) as well as in the ecology(2), evolution(3) and physiology(4) of plants. Despite its importance as a nutrient, very little is known about how AMF take up nitrogen and transfer it to their host plants(5). Here we report the results of stable isotope labelling experiments showing that inorganic nitrogen taken up by the fungus outside the roots is incorporated into amino acids, translocated from the extraradical to the intraradical mycelium as arginine, but transferred to the plant without carbon. Consistent with this mechanism, the genes of primary nitrogen assimilation are preferentially expressed in the extraradical tissues, whereas genes associated with arginine breakdown are more highly expressed in the intraradical mycelium. Strong changes in the expression of these genes in response to nitrogen availability and form also support the operation of this novel metabolic pathway in the arbuscular mycorrhizal symbiosis.	New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA; ARS, USDA, Eastern Reg Res Ctr, Wyndmoor, PA 19038 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	New Mexico State University; United States Department of Agriculture (USDA); Michigan State University	Lammers, PJ (corresponding author), New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA.	ppfeffer@arserrc.gov; plammers@nmsu.edu	Lammers, Peter/K-6661-2018; Allen, James/AAG-6465-2019; Shachar-Hill, Yair/B-6165-2013	Lammers, Peter/0000-0002-7312-0797; Shachar-Hill, Yair/0000-0001-8793-5084; Bucking, Heike/0000-0002-4040-0944; Abubaker, Jehad/0000-0003-0681-7305				Allen MF, 2003, ANNU REV PHYTOPATHOL, V41, P271, DOI 10.1146/annurev.phyto.41.052002.095518; AMES RN, 1983, NEW PHYTOL, V95, P381, DOI 10.1111/j.1469-8137.1983.tb03506.x; Bago B, 2003, PLANT PHYSIOL, V131, P1496, DOI 10.1104/pp.102.007765; Bago B, 2002, PLANT PHYSIOL, V128, P108, DOI 10.1104/pp.010466; Bago B, 1996, NEW PHYTOL, V133, P273, DOI 10.1111/j.1469-8137.1996.tb01894.x; Bago B, 2001, NEW PHYTOL, V149, P4, DOI 10.1046/j.1469-8137.2001.00016.x; Bago B, 2000, PLANT PHYSIOL, V124, P949, DOI 10.1104/pp.124.3.949; Breuninger M, 2004, FUNGAL GENET BIOL, V41, P542, DOI 10.1016/j.fgb.2004.01.003; Bucking H, 2005, NEW PHYTOL, V165, P899, DOI 10.1111/j.1469-8137.2004.01274.x; CLIQUET JB, 1993, PLANT PHYSIOL, V101, P865, DOI 10.1104/pp.101.3.865; HARRISON MJ, 1995, NATURE, V378, P626, DOI 10.1038/378626a0; He XH, 2003, CRIT REV PLANT SCI, V22, P531, DOI 10.1080/713608315; Hildebrandt U, 2002, PHYSIOL PLANTARUM, V115, P125, DOI 10.1034/j.1399-3054.2002.1150115.x; Hodge A, 2001, NATURE, V413, P297, DOI 10.1038/35095041; Johansen A, 1996, NEW PHYTOL, V133, P705, DOI 10.1111/j.1469-8137.1996.tb01939.x; KALDORF M, 1994, MYCORRHIZA, V5, P23, DOI 10.1007/BF00204016; Lammers PJ, 2001, PLANT PHYSIOL, V127, P1287, DOI 10.1104/pp.010375; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MARTIN F, 1986, NEW PHYTOL, V102, P85, DOI 10.1111/j.1469-8137.1986.tb00800.x; MARTIN F, 1985, FEBS LETT, V182, P350, DOI 10.1016/0014-5793(85)80331-8; Nielsen JS, 2002, NEW PHYTOL, V154, P809, DOI 10.1046/j.1469-8137.2002.00412.x; Pfeffer PE, 1999, PLANT PHYSIOL, V120, P587, DOI 10.1104/pp.120.2.587; Pfeffer PE, 2004, NEW PHYTOL, V163, P617, DOI 10.1111/j.1469-8137.2004.01152.x; Read DJ, 2003, NEW PHYTOL, V157, P475, DOI 10.1046/j.1469-8137.2003.00704.x; Redecker D, 2000, SCIENCE, V289, P1920, DOI 10.1126/science.289.5486.1920; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; StArnaud M, 1996, MYCOL RES, V100, P328, DOI 10.1016/S0953-7562(96)80164-X; Toussaint JP, 2004, CAN J MICROBIOL, V50, P251, DOI 10.1139/W04-009; Vallorani L, 2002, NEW PHYTOL, V154, P779, DOI 10.1046/j.1469-8137.2002.00409.x; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085	30	605	675	19	535	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					819	823		10.1038/nature03610	http://dx.doi.org/10.1038/nature03610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944705				2022-12-28	WOS:000229638700051
J	Whalen, CC				Whalen, CC			Diagnosis of latent tuberculosis infection - Measure for measure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTERFERON-GAMMA ASSAY; MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST; BCG; SENSITIVITY		Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, TB Res Unit, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Whalen, CC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, WG-37,10900 Euclid Ave, Cleveland, OH 44106 USA.	ccw@case.edu			FIC NIH HHS [TW-00011] Funding Source: Medline; NIAID NIH HHS [AI-45244-95383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045244] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Boom WH, 2003, TUBERCULOSIS, V83, P98, DOI 10.1016/S1472-9792(02)00054-9; Brock I, 2001, INT J TUBERC LUNG D, V5, P462; Brock L, 2004, AM J RESP CRIT CARE, V170, P65, DOI 10.1164/rccm.200402-232OC; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chin DP, 2000, JAMA-J AM MED ASSOC, V283, P2968, DOI 10.1001/jama.283.22.2968; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Cole ST, 2002, MICROBIOL-SGM, V148, P2919, DOI 10.1099/00221287-148-10-2919; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; Dockrell HM, 1998, INT J TUBERC LUNG D, V2, P441; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; Fietta A, 2003, AM J INFECT CONTROL, V31, P347, DOI 10.1016/S0196-6553(02)48240-5; Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Johnson JL, 1998, AM J RESP CRIT CARE, V158, P1790, DOI 10.1164/ajrccm.158.6.9803104; Johnson PDR, 1999, CLIN DIAGN LAB IMMUN, V6, P934, DOI 10.1128/CDLI.6.6.934-937.1999; Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Nardell Edward A, 2003, Semin Respir Infect, V18, P307; Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Streeton JA, 1998, INT J TUBERC LUNG D, V2, P443; Styblo K, 1980, Adv Tuberc Res, V20, P1; Talbot EA, 2000, JAMA-J AM MED ASSOC, V284, P2894, DOI 10.1001/jama.284.22.2894; Weinbaum C., 2003, Morbidity and Mortality Weekly Report, V52; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201	29	44	46	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2785	2787		10.1001/jama.293.22.2785	http://dx.doi.org/10.1001/jama.293.22.2785			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941809				2022-12-28	WOS:000229643700028
J	de Oliveira, AM; White, KL; Leschinsky, DP; Beecham, BD; Vogt, TM; Moolenaar, RL; Perz, JF; Safranek, TJ				de Oliveira, AM; White, KL; Leschinsky, DP; Beecham, BD; Vogt, TM; Moolenaar, RL; Perz, JF; Safranek, TJ			An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; TRANSMISSION	Background: Approximately 2.7 million persons in the United States have chronic hepatitis C virus (HCV) infection. Health care-associated HCV transmission can occur if aseptic technique is not followed. The authors suspected a health care-associated HCV outbreak after the report of 4 HCV infections among patients at the same hematology/oncology clinic. Objective: To determine the extent and mechanism of HCV transmission among clinic patients. Design: Epidemiologic analysis through a cohort study. Setting: Hematology/oncology clinic in eastern Nebraska. Participants: Patients who visited the clinic from March 2000 through December 2001. Measurements: HCV infection status, relevant medical history, and clinic-associated exposures. Bivariate analysis and logistic regression were used to identify risk factors for HCV infection. Results: Of 613 clinic patients contacted, 494 (81%) underwent HCV testing. The authors documented infection in 99 patients who lacked previous evidence of HCV infection; all had begun treatment at the clinic before July 2001. Hepatitis C virus genotype 3a was present in all 95 genotyped samples and presumably originated from a patient with chronic hepatitis C who began treatment in March 2000. Infection with HCV was statistically significantly associated with receipt of saline flushes (P < 0.001). Shared saline bags were probably contaminated when syringes used to draw blood from venous catheters were reused to withdraw saline solution. The clinic corrected this procedure in July 2001. Limitation: The delay between outbreak and investigation (> 1 year) may have contributed to an underestimate of cases. Conclusions: This large health care-associated HCV outbreak was related to shared saline bags contaminated through syringe reuse. Effective infection-control programs are needed to ensure high standards of care in outpatient care facilities, such as hematology/oncology clinics.	Ctr Dis Control & Prevent, Atlanta, GA 30341 USA; Nebraska Hlth & Human Serv Syst, Lincoln, NE USA	Centers for Disease Control & Prevention - USA	de Oliveira, AM (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F-22, Atlanta, GA 30341 USA.	acq7@cdc.gov						Alter Miriam J, 2003, MMWR Recomm Rep, V52, P1; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Bruguera M, 2002, J CLIN MICROBIOL, V40, P4363, DOI 10.1128/JCM.40.11.4363-4366.2002; CHIARELLO LA, 2001, SEMIN INFECT CONTROL, V1, P44; Delarocque-Astagneau E, 2002, INFECT CONT HOSP EP, V23, P328, DOI 10.1086/502060; Desenclos JC, 2001, INFECT CONT HOSP EP, V22, P701, DOI 10.1086/501849; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Garner JS, 1996, INFECT CONT HOSP EP, V17, P54, DOI 10.1017/S0195941700006123; Herwaldt LA, 1998, INFECT CONT HOSP EP, V19, P41; Jarvis WR, 2001, EMERG INFECT DIS, V7, P170, DOI 10.3201/eid0702.010202; Krause G, 2003, INFECT CONT HOSP EP, V24, P122, DOI 10.1086/502176; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Nguyen GT, 2000, AM J INFECT CONTROL, V28, P392, DOI 10.1067/mic.2000.110298; Widell A, 1999, ANN INTERN MED, V130, P130, DOI 10.7326/0003-4819-130-2-199901190-00007; Williams IT, 2004, CLIN INFECT DIS, V38, P1592, DOI 10.1086/420935; 2001, EMERG INFECT DIS, V7, P170; 1998, MMWR MORB MORTAL REC, V47, P1; 2003, MMWR MORB MORTAL WKL, V52, P901; 1992, MMWR MORB MORAL WKLY, V41, P783	19	67	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					898	902		10.7326/0003-4819-142-11-200506070-00007	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941696				2022-12-28	WOS:000229556300003
J	Howard, RS				Howard, RS			Poliomyelitis and the postpolio syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; LATE FUNCTIONAL DETERIORATION; PARALYTIC POLIOMYELITIS; CONQUERING POLIO; POLIOVIRUSES; IDENTIFICATION; DISEASE; HEALTH		St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, Lane Fox Unit, London SE1 7EH, England; St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, Dept Neurol, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Howard, RS (corresponding author), St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, Lane Fox Unit, London SE1 7EH, England.	robin.howard@gstt.sthames.nhs.uk						Alexander LN, 2004, JAMA-J AM MED ASSOC, V292, P1696, DOI 10.1001/jama.292.14.1696; ANDERSON GW, 1954, JAMA-J AM MED ASSOC, V155, P1123, DOI 10.1001/jama.1954.03690310001001; ARMON C, 1990, NEUROLOGY, V40, P172, DOI 10.1212/WNL.40.1.172; Bouza C, 2005, HEALTH POLICY, V71, P97, DOI 10.1016/j.healthpol.2004.06.001; BRADLEY WG, 1987, MUSCLE NERVE, V10, P490, DOI 10.1002/mus.880100603; CHRONI E, 1995, POSTGRAD MED J, V71, P52, DOI 10.1136/pgmj.71.831.52; CODD MB, 1985, LATE EFFECTS POLIOMY, P121; DALAKAS M, 1991, POSTPOLIO SYNDROME, P39; DALAKAS MC, 1986, NEW ENGL J MED, V314, P959, DOI 10.1056/NEJM198604103141505; DALAKAS MC, 1995, ANN NY ACAD SCI, V753, P68, DOI 10.1111/j.1749-6632.1995.tb27532.x; DALAKAS MC, 1988, ADV CONT NEUROLOGY, P51; Fine PEM, 2004, LANCET NEUROL, V3, P703, DOI 10.1016/S1474-4422(04)00928-7; GALLAGHER HG, 1995, POSTPOLIO SYNDROME, P215; Gould Tony, 1995, SUMMER PLAGUE POLIO; GRAHAM JM, 2004, PRACT NEUROL, V4, P58; HALSTEAD LS, 1995, POST POLIO SYNDROME, P199; Heymann DL, 2004, NEW ENGL J MED, V351, P1275, DOI 10.1056/NEJMp048204; HOWARD R, 2003, PRACTICAL NEUROLOGY, V3, P66; Howard RS, 2003, J NEUROL NEUROSUR PS, V74, pIII24, DOI 10.1136/jnnp.74.suppl_3.iii24; HOWARD RS, 1988, Q J MED, V66, P219; Jubelt B, 2000, JAMA-J AM MED ASSOC, V284, P412, DOI 10.1001/jama.284.4.412; Jubelt Bruk, 2004, Curr Treat Options Neurol, V6, P87, DOI 10.1007/s11940-004-0018-3; Katz SL, 2004, NEW ENGL J MED, V351, P1485, DOI 10.1056/NEJMp048217; Kew OM, 2004, B WORLD HEALTH ORGAN, V82, P16; Kidd D, 1996, POSTGRAD MED J, V72, P641, DOI 10.1136/pgmj.72.853.641; Kidd D, 1997, QJM-MON J ASSOC PHYS, V90, P189, DOI 10.1093/qjmed/90.3.189; Kilpatrick DR, 1996, J CLIN MICROBIOL, V34, P2990, DOI 10.1128/JCM.34.12.2990-2996.1996; Lepow ML, 2004, NEW ENGL J MED, V351, P1483, DOI 10.1056/NEJMp048220; MARTYN CN, 1990, J NEUROL, V237, P336, DOI 10.1007/BF00315655; MARTYN CN, 1988, LANCET, V1, P1319, DOI 10.1016/S0140-6736(88)92129-0; Marx A, 2000, EPIDEMIOL REV, V22, P298, DOI 10.1093/oxfordjournals.epirev.a018041; MULDER DW, 1991, POSTPOLIO SYNDROME P, P1; Nollet F, 2004, ARCH NEUROL-CHICAGO, V61, P1142, DOI 10.1001/archneur.61.7.1142; Pearce JMS, 2004, J NEUROL NEUROSUR PS, V75, P1552, DOI 10.1136/jnnp.2003.028530; PLUM F, 1959, ARCH NEURO PSYCHIATR, V81, P535, DOI 10.1001/archneurpsyc.1959.02340170001001; Rosen FS, 2004, NEW ENGL J MED, V351, P1481, DOI 10.1056/NEJMp048202; RUSSELL W R, 1949, Br Med J, V1, P465; Sejvar JJ, 2004, NEUROLOGY, V63, P206, DOI 10.1212/01.WNL.0000130361.62281.69; Solomon T, 2003, CURR OPIN INFECT DIS, V16, P375, DOI 10.1097/00001432-200310000-00002; SWINGLER RJ, 1992, J NEUROL NEUROSUR PS, V55, P1116, DOI 10.1136/jnnp.55.12.1116; Trojan DA, 2005, MUSCLE NERVE, V31, P6, DOI 10.1002/mus.20259; *WHO, IN PRESS REP WHO CON; Wilson H, 2000, POSTGRAD MED J, V76, P179, DOI 10.1136/pmj.76.893.179; WINDEBANK AJ, 1991, NEUROLOGY, V41, P501, DOI 10.1212/WNL.41.4.501; WINDEBANK AJ, 1995, POST POLIO SYNDROME, P69; World Health Organization, 2004, GEN DECL ER POL; YANG CF, 1991, VIRUS RES, V20, P159; 1986, LANCET, V1, P1195; 2004, LANCET, V363, P93	49	53	60	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1314	1318		10.1136/bmj.330.7503.1314	http://dx.doi.org/10.1136/bmj.330.7503.1314			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933355	Green Published			2022-12-28	WOS:000229655700026
J	Chesebro, B; Trifilo, M; Race, R; Meade-White, K; Teng, C; LaCasse, R; Raymond, L; Favara, C; Baron, G; Priola, S; Caughey, B; Masliah, E; Oldstone, M				Chesebro, B; Trifilo, M; Race, R; Meade-White, K; Teng, C; LaCasse, R; Raymond, L; Favara, C; Baron, G; Priola, S; Caughey, B; Masliah, E; Oldstone, M			Anchorless prion protein results in infectious amyloid disease without clinical scrapie	SCIENCE			English	Article							CELL-FREE FORMATION; SPONGIFORM ENCEPHALOPATHIES; PRECURSOR PROTEIN; NEURONAL PRP; MICE; RESISTANT; BRAIN; CONVERSION; PATHOLOGY; PLAQUES	In prion and Alzheimer's diseases, the roles played by amyloid versus nonamyloid deposits in brain damage remain unresolved. In scrapie-infected transgenic mice expressing prion protein (PrP) lacking the glycosylphosphatidylinositol (GPI) membrane anchor, abnormal protease-resistant PrPres was deposited as amyloid plaques, rather than the usual nonamyloid form of PrPres. Although PrPres amyloid plaques induced brain damage reminiscent of Alzheimer's disease, clinical manifestations were minimal. In contrast, combined expression of anchorless and wild-type PrP produced accelerated clinical scrapie. Thus, the PrP GPI anchor may play a role in the pathogenesis of prion diseases.	NIAID, Rocky Mt Labs, Lab Persistent Viral Dis, Hamilton, MT 59840 USA; Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Chesebro, B (corresponding author), NIAID, Rocky Mt Labs, Lab Persistent Viral Dis, Hamilton, MT 59840 USA.	bchesebro@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000752, Z01AI000937, Z01AI000580, ZIAAI000937, Z01AI000265, Z01AI000752, ZIAAI000580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER; NIA NIH HHS [AG004342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Bruce M E, 1991, Curr Top Microbiol Immunol, V172, P125; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CHANDLER RL, 1961, LANCET, V1, P1378; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; Chesebro B, 2003, BRIT MED BULL, V66, P1, DOI 10.1093/bmb/66.1.1; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1973, LANCET, V1, P617; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Jeffrey M, 2004, ANN NEUROL, V55, P781, DOI 10.1002/ana.20093; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Masliah E, 1996, J NEUROSCI, V16, P5795; Masliah E, 2001, J NEUROPATH EXP NEUR, V60, P357, DOI 10.1093/jnen/60.4.357; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Rall GF, 1997, P NATL ACAD SCI USA, V94, P4659, DOI 10.1073/pnas.94.9.4659; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377	40	496	508	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2005	308	5727					1435	1439		10.1126/science.1110837	http://dx.doi.org/10.1126/science.1110837			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933194				2022-12-28	WOS:000229619300044
J	King-Jones, K; Charles, JP; Lam, G; Thummel, CS				King-Jones, K; Charles, JP; Lam, G; Thummel, CS			The ecdysone-induced DHR4 orphan nuclear receptor coordinates growth and maturation in Drosophila	CELL			English	Article							STEROID-HORMONE ECDYSONE; DNA-BINDING PROPERTIES; MANDUCA-SEXTA L; TOBACCO HORNWORM; GENE-EXPRESSION; INDUCIBLE GENE; BROAD-COMPLEX; BODY-SIZE; FAT-BODY; MOLECULAR ANALYSIS	A critical determinant of insect body size is the time at which the larva stops feeding and initiates wandering in preparation for metamorphosis. No genes have been identified that regulate growth by contributing to this key developmental decision to terminate feeding. We show here that mutations in the DHR4 orphan nuclear receptor result in larvae that precociously leave the food to form premature prepupae, resulting in abbreviated larval development that translates directly into smaller and lighter animals. In addition, we show that DHR4 plays a central role in the genetic cascades triggered by the steroid hormone ecdysone at the onset of metamorphosis, acting as both a repressor of the early ecdysone-induced regulatory genes and an inducer of the beta FTZ-Fl midprepupal competence factor. We propose that DHR4 coordinates growth and maturation in Drosophila by mediating endocrine responses to the attainment of critical weight during larval development.	Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Bourgogne 1, CNRS, UMR 5548, Fac Sci Gabriel, F-21000 Dijon, France	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne	Thummel, CS (corresponding author), Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, 15 N 2030 E Room 5100, Salt Lake City, UT 84112 USA.	carl.thummel@genetics.utah.edu	CHARLES, jean-philippe/Q-2427-2017	CHARLES, jean-philippe/0000-0001-7285-5532				ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BAINBRIDGE SP, 1981, J EMBRYOL EXP MORPH, V66, P57; Beadle GW, 1938, BIOL BULL-US, V75, P447, DOI 10.2307/1537573; Britton JS, 1998, DEVELOPMENT, V125, P2149; Broadus J, 1999, MOL CELL, V3, P143, DOI 10.1016/S1097-2765(00)80305-6; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARROLL SB, 1987, DNA CLONING, P89; Charles JP, 1999, EUR J BIOCHEM, V266, P181, DOI 10.1046/j.1432-1327.1999.00842.x; Chen JH, 2002, INSECT BIOCHEM MOLEC, V32, P657, DOI 10.1016/S0965-1748(01)00144-8; CLEVER U, 1964, SCIENCE, V146, P794, DOI 10.1126/science.146.3645.794; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; Davidowitz G, 2003, EVOL DEV, V5, P188, DOI 10.1046/j.1525-142X.2003.03026.x; DIBELLO PR, 1991, GENETICS, V129, P385; DOMINICK OS, 1985, J EXP BIOL, V117, P45; Hiruma K, 2001, DEV BIOL, V232, P265, DOI 10.1006/dbio.2001.0165; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; Kageyama Y, 1997, GENES CELLS, V2, P559, DOI 10.1046/j.1365-2443.1997.1460344.x; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; King-Jones K, 2005, NAT REV GENET, V6, P311, DOI 10.1038/nrg1581; KISS I, 1988, GENETICS, V118, P247; Lam G, 1999, DEV BIOL, V212, P204, DOI 10.1006/dbio.1999.9343; Lam G, 2000, CURR BIOL, V10, P957, DOI 10.1016/S0960-9822(00)00631-X; Lam GT, 1997, DEVELOPMENT, V124, P1757; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li TR, 2003, DEV CELL, V5, P59, DOI 10.1016/S1534-5807(03)00192-8; MARONI G, 1983, DROS INFORM SERV, V59, P142; Nijhout H, 2003, DEV BIOL, V261, P1, DOI 10.1016/S0012-1606(03)00276-8; NIJHOUT HF, 1974, J EXP BIOL, V61, P481; NIJHOUT HF, 1974, J EXP BIOL, V61, P493; RESTIFO LL, 1992, ROUX ARCH DEV BIOL, V201, P221, DOI 10.1007/BF00188753; Riddiford LM, 2001, VITAM HORM, V60, P1; Riddiford Lynn M., 1993, P899; ROUNTREE DB, 1986, J EXP BIOL, V120, P41; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Sokolowski MB, 2003, NEURON, V39, P6, DOI 10.1016/S0896-6273(03)00398-2; Stern D, 2003, CURR BIOL, V13, pR267, DOI 10.1016/S0960-9822(03)00197-0; Stern DL, 1999, DEVELOPMENT, V126, P1091; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; Sullivan AA, 2003, MOL ENDOCRINOL, V17, P2125, DOI 10.1210/me.2002-0430; Urness LD, 1995, EMBO J, V14, P6239, DOI 10.1002/j.1460-2075.1995.tb00314.x; Weller J, 2001, INSECT BIOCHEM MOLEC, V31, P827, DOI 10.1016/S0965-1748(00)00188-0; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; Yamada M, 2000, DEVELOPMENT, V127, P5083; Zinke I, 1999, DEVELOPMENT, V126, P5275	50	82	88	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					773	784		10.1016/j.cell.2005.03.030	http://dx.doi.org/10.1016/j.cell.2005.03.030			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935763	Bronze			2022-12-28	WOS:000229658000015
J	Smith, LC; Sheng, Y; MacDonald, GM; Hinzman, LD				Smith, LC; Sheng, Y; MacDonald, GM; Hinzman, LD			Disappearing Arctic lakes	SCIENCE			English	Article							SIBERIA		Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA; SUNY Coll Environm Sci & Forestry, Syracuse, NY 13210 USA; Univ Alaska, Water & Environm Res Ctr, Fairbanks, AK 99775 USA	University of California System; University of California Los Angeles; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; University of Alaska System; University of Alaska Fairbanks	Smith, LC (corresponding author), Univ Calif Los Angeles, Dept Geog, 1255 Bunche Hall, Los Angeles, CA 90095 USA.	lsmith@geog.ucla.edu	Hinzman, Larry/B-3309-2013; Smith, Laurence C./E-7785-2012	Hinzman, Larry/0000-0002-5878-6814; Smith, Laurence C./0000-0001-6866-5904				Frey KE, 2003, POLAR RES, V22, P287, DOI 10.1111/j.1751-8369.2003.tb00113.x; Pavlov AV, 2002, PERMAFROST PERIGLAC, V13, P43, DOI 10.1002/ppp.409; Peterson BJ, 2002, SCIENCE, V298, P2171, DOI 10.1126/science.1077445; Serreze MC, 2000, CLIMATIC CHANGE, V46, P159, DOI 10.1023/A:1005504031923; Sheng YW, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002190; Smith LC, 2004, SCIENCE, V303, P353, DOI 10.1126/science.1090553; Yoshikawa K, 2003, PERMAFROST PERIGLAC, V14, P151, DOI 10.1002/ppp.451	7	697	761	9	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2005	308	5727					1429	1429		10.1126/science.1108142	http://dx.doi.org/10.1126/science.1108142			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933192				2022-12-28	WOS:000229619300041
J	Dames, S; Tonnerre, C; Saint, S; Jones, SR				Dames, S; Tonnerre, C; Saint, S; Jones, SR			Don't know much about history	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICAL-EXAMINATION; HUMAN BRUCELLOSIS; DIAGNOSIS; ORIGIN; FEVER		Univ Utah, Med Ctr, Sch Med, Dept Med,Div Rheumatol 4B200, Salt Lake City, UT 84132 USA; Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Legacy Good Samaritan & Emanuel Hosp, Dept Med, Portland, OR USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA	Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan; Oregon Health & Science University	Dames, S (corresponding author), Univ Utah, Med Ctr, Sch Med, Dept Med,Div Rheumatol 4B200, 30 N 1900 E, Salt Lake City, UT 84132 USA.	shelby.dames@hsc.utah.edu	Saint, Sanjay/AAF-5126-2019		AHRQ HHS [P20-HS11540P20-HS115] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Chang MH, 2003, EMERG INFECT DIS, V9, P556, DOI 10.3201/eid0905.020477; Colmenero JD, 1997, MEDICINE, V76, P139; *DEP HLTH HUM SERV, 2003, GUID FED FIN ASS REC; GEORGHIOU PR, 1991, LANCET, V337, P1543, DOI 10.1016/0140-6736(91)93231-W; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; Jacobs EA, 2001, J GEN INTERN MED, V16, P468, DOI 10.1046/j.1525-1497.2001.016007468.x; KIM JH, 1990, REV INFECT DIS, V12, P583; Knockaert DC, 2003, J INTERN MED, V253, P263, DOI 10.1046/j.1365-2796.2003.01120.x; Mantur BG, 2004, J CLIN MICROBIOL, V42, P4327, DOI 10.1128/JCM.42.9.4327-4328.2004; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; PETERSON MC, 1992, WESTERN J MED, V156, P163; PLATT R, 1947, MANCHESTER U MED SCH, V27, P139; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283	13	11	11	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2338	2342		10.1056/NEJMcps041883	http://dx.doi.org/10.1056/NEJMcps041883			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930425				2022-12-28	WOS:000229446400011
J	Kessler, DP; Sage, WM; Becker, DJ				Kessler, DP; Sage, WM; Becker, DJ			Impact of malpractice reforms on the supply of physician services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIABILITY; CHOICE; LAW	Context Proponents of restrictions on malpractice lawsuits claim that tort reform will improve access to medical care. Objective To estimate the effects of changes in state malpractice law on the supply of physicians. Design Differences-in-differences regression analysis that matched data on the number of physicians in each state between 1985 and 2001 from the American Medical Association's Physician Masterfile with data on state tort laws and state demographic, political, population, and health care market characteristics. Main Outcome Measure Effect on physician supply of "direct" malpractice reforms that reduce the size of awards (eg, caps on damages). Results The adoption of "direct" malpractice reforms led to greater growth in the overall supply of physicians. Three years after adoption, direct reforms increased physician supply by 3.3%, controlling for fixed differences across states, population, states' health care market and political characteristics, and other differences in malpractice law. Direct reforms had a larger effect on the supply of nongroup vs group physicians, on the supply of most (but not all) specialties with high malpractice insurance premiums, on states with high levels of managed care, and on supply through retirements and entries than through the propensity of physicians to move between states. Direct reforms had similar effects on less experienced and more experienced physicians. Conclusion Tort reform increased physician supply. Further research is needed to determine whether reform-induced increases in physician supply benefited patients.	Stanford Univ, Grad Sch Business, Hoover Inst, Stanford, CA 94305 USA; Natl Bur Econ Res, Stanford, CA USA; Univ Calif Berkeley, Dept Econ, Berkeley, CA 94720 USA; Columbia Law Sch, New York, NY 10027 USA	Stanford University; National Bureau of Economic Research; University of California System; University of California Berkeley; Columbia University	Sage, WM (corresponding author), Columbia Law Sch, 435 W 116th St, New York, NY 10027 USA.	wsage@law.columbia.edu						*AM MED ASS, 2003, PHYS SOC STAT; CORRIGAN JM, 2002, FOSTERING RAPID ADV; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DANZON PM, 1982, RAND PUBLICATION; Dubay L, 2001, J HEALTH ECON, V20, P591, DOI 10.1016/S0167-6296(01)00082-0; Dubay L, 1999, J HEALTH ECON, V18, P491, DOI 10.1016/S0167-6296(99)00004-1; ERNST RL, 1985, PHYS LOCATION SPECIA; Escarce JJ, 2000, HEALTH SERV RES, V35, P825; HAUSMAN J, 1984, ECONOMETRICA, V52, P909, DOI 10.2307/1911191; HELLINGER FJ, 2003, IMPACT STATE LAWS LI; Kessler D, 1996, Q J ECON, V111, P353, DOI 10.2307/2946682; Kessler D, 2002, J PUBLIC ECON, V84, P175, DOI 10.1016/S0047-2727(01)00124-4; Kessler DP, 2000, Q J ECON, V115, P577, DOI 10.1162/003355300554863; Kessler DP, 2002, J HEALTH ECON, V21, P931, DOI 10.1016/S0167-6296(02)00076-0; KESSLER DP, 2002, REGULATION LITIGATIO; LANGWELL KM, 1980, MED CARE, V18, P1085, DOI 10.1097/00005650-198011000-00002; Lawrence J, 2003, MED EDUC, V37, P319, DOI 10.1046/j.1365-2923.2003.01476.x; Newton DA, 2003, JAMA-J AM MED ASSOC, V290, P1179, DOI 10.1001/jama.290.9.1179; Nuthalapaty FS, 2004, ACAD MED, V79, P417, DOI 10.1097/00001888-200405000-00010; RIZZO JA, 1994, J HEALTH ECON, V13, P433, DOI 10.1016/0167-6296(94)90012-4; RUBIN RJ, 1993, DEFENSIVE MED MED LI; Sage WM, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.4.10; SAGE WM, 2004, MED MALPRACTICE PHYS; SAGE WM, 2003, 2003 HLTH LAW HDB; SLOAN FA, 1989, J HEALTH POLIT POLIC, V14, P663, DOI 10.1215/03616878-14-4-663; SLOAN FA, 1991, INSURING MED MALPRAC; *STAT CORP, 2003, STATA US GUID REL 8; Stilwell NA, 2000, TEACH LEARN MED, V12, P14, DOI 10.1207/S15328015TLM1201_3; Studdert DM, 2004, HEALTH AFFAIR, V23, P54, DOI 10.1377/hlthaff.23.4.54; Studdert DM, 2004, NEW ENGL J MED, V350, P283, DOI 10.1056/NEJMhpr035470; Studdert DM, 2001, AM J LAW MED, V27, P225; Thornton J, 2003, HEALTH ECON, V12, P67, DOI 10.1002/hec.682; Woodworth PA, 2000, AM J SURG, V180, P570, DOI 10.1016/S0002-9610(00)00543-2	33	112	112	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2618	2625		10.1001/jama.293.21.2618	http://dx.doi.org/10.1001/jama.293.21.2618			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	930UU	15928283	Bronze			2022-12-28	WOS:000229443400020
J	Griffiths, J; Barber, VS; Morgan, L; Young, JD				Griffiths, J; Barber, VS; Morgan, L; Young, JD			Systematic review and meta-analysis of studies, of the timing of tracheostomy in adult patients undergoing artificial ventilation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTUBATION; TRACHEOTOMY	Objective To compare outcomes in critically ill patients undergoing artificial ventilation who received a tracheostomy early or late in their treatment. Data sources The Cochrane Central Register of Clinical Trials, Medline, Embase, CNAHL, the National Research Register, the NHS Trusts Clinical Trials Register, the Medical Research Council UK database, the NHS Research and Development Health Technology Assessment Programme, the British Heart Foundation database, citation review of relevant primary and review articles, and expert informants. Study selection Randomised and quasi-randomised controlled studies that compared early tracheostomy with either late tracheostomy or prolonged endotracheal intubation. From 15 950 articles screened, 12 were identified as "randomised or quasi-randomised" controlled trials, and five were included for data extraction. Data extraction Five studies with 406 participants were analysed. Descriptive and outcome data were extracted. The main outcome measure was mortality in hospital. The incidence of hospital acquired pneumonia, length of stay in a critical care unit, and duration of artificial ventilation were also recorded. Random effects meta-analyses were performed. Results Early tracheostomy did not significantly alter mortality (relative risk 0.79, 95% confidence interval 0.45 to 1.39). The risk of pneumonia was also unaltered by the timing of tracheostomy (0.90, 0.66 to 1.21). Early tracheostomy significantly reduced duration of artificial ventilation (weighted mean difference - 8.5 days, 95% confidence interval - 15.3 to - 1.7) and length of stay in intensive care (- 15.3 days, - 24.6 to - 6.1). Conclusions In critically ill adult patients who require prolonged mechanical ventilation, performing a tracheostomy at an earlier stage than is currently practised may shorten the duration of artificial ventilation and length of stay in intensive care.	John Radcliffe Hosp, Adult Intens Care Unit, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Young, JD (corresponding author), John Radcliffe Hosp, Adult Intens Care Unit, Oxford OX3 9DU, England.	duncan.young@nda.ox.ac.uk	Young, John D/M-9756-2016; Barber, Vicki/G-7383-2019	Young, John Duncan/0000-0002-6838-4835				Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Boynton JH, 2004, CRIT CARE, V8, pR261, DOI 10.1186/cc2885; DUNHAM CM, 1984, J TRAUMA, V24, P120, DOI 10.1097/00005373-198402000-00005; Freeman BD, 2000, CHEST, V118, P1412, DOI 10.1378/chest.118.5.1412; Graham JS, 1996, J TRAUMA, V41, P245, DOI 10.1097/00005373-199608000-00008; Kane T D, 1997, Respir Care Clin N Am, V3, P1; Maziak DE, 1998, CHEST, V114, P605, DOI 10.1378/chest.114.2.605; PLUMMER AL, 1989, CHEST, V96, P178, DOI 10.1378/chest.96.1.178; RODRIGUEZ JL, 1990, SURGERY, V108, P655; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Saffle JR, 2002, J BURN CARE REHABIL, V23, P431, DOI 10.1097/00004630-200211000-00009; Sellers BJ, 1997, J TRAUMA, V43, P899, DOI 10.1097/00005373-199712000-00005	12	360	382	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2005	330	7502					1243	1246		10.1136/bmj.38467.485671.E0	http://dx.doi.org/10.1136/bmj.38467.485671.E0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15901643	Green Published, Bronze			2022-12-28	WOS:000229448900018
J	Schmidt, B				Schmidt, B			Astronomy - The link between supernovae and gamma ray bursts	SCIENCE			English	Editorial Material							ERROR BOX		Australian Natl Univ, Mt Stromlo Observ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia	Australian National University	Schmidt, B (corresponding author), Australian Natl Univ, Mt Stromlo Observ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia.	brian@mso.anu.edu.au		Schmidt, Brian/0000-0001-6589-1287				Berger E, 2003, ASTROPHYS J, V599, P408, DOI 10.1086/379214; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; Mazzali PA, 2005, SCIENCE, V308, P1284, DOI 10.1126/science.1111384; MEEGAN CA, 1992, NATURE, V355, P143, DOI 10.1038/355143a0; Metzger MR, 1997, NATURE, V387, P878, DOI 10.1038/43132; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; vanParadijs J, 1997, NATURE, V386, P686, DOI 10.1038/386686a0	10	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1265	1266		10.1126/science.1112928	http://dx.doi.org/10.1126/science.1112928			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919980				2022-12-28	WOS:000229482300031
J	Imai, K; Zhang, P				Imai, K; Zhang, P			Integrating economic analysis into clinical trials	LANCET			English	Editorial Material							COST-EFFECTIVENESS		Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Imai, K (corresponding author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA.	kimai@cdc.gov						Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518; Drummond MF, 2015, METHODS EC EVALUATIO; Gold MR, 1996, COST EFFECTIVENESS H; Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007; Herman WH, 2003, DIABETES CARE, V26, P36; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; O'Sullivan AK, 2005, VALUE HEALTH, V8, P67, DOI 10.1111/j.1524-4733.2005.03065.x; OBrien B, 1996, MED CARE, V34, pDS99; Ramsey SD, 2001, ANNU REV PUBL HEALTH, V22, P129, DOI 10.1146/annurev.publhealth.22.1.129; Taylor RS, 2004, BMJ-BRIT MED J, V329, P972, DOI 10.1136/bmj.329.7472.972; *UCLA STROK VASC N, 2002, FREQ ASK QUEST	11	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2005	365	9473					1749	1750		10.1016/S0140-6736(05)66390-8	http://dx.doi.org/10.1016/S0140-6736(05)66390-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	928SI	15910936				2022-12-28	WOS:000229291600005
J	Babbitt, SE; Kiss, A; Deffenbaugh, AE; Chang, YH; Bailly, E; Erdjument-Bromage, H; Tempst, P; Buranda, T; Sklar, LA; Baumler, J; Gogol, E; Skowyra, D				Babbitt, SE; Kiss, A; Deffenbaugh, AE; Chang, YH; Bailly, E; Erdjument-Bromage, H; Tempst, P; Buranda, T; Sklar, LA; Baumler, J; Gogol, E; Skowyra, D			RETRACTED: ATP hydrolysis-dependent disassembly of the 26S proteasome is part of the catalytic cycle (Retracted article. See vol. 173, pg. 804, 2018)	CELL			English	Article; Retracted Publication							REGULATORY PARTICLE; MULTIUBIQUITIN-CHAIN; 20S PROTEASOME; CORE PARTICLE; DEGRADATION SIGNAL; PROTEIN BREAKDOWN; ACTIVE-SITES; UBIQUITIN; COMPLEX; YEAST	ATP hydrolysis is required for degradation of poly-ubiquitinated proteins by the 26S proteasome but is thought to play no role in proteasomal stability during the catalytic cycle. In contrast to this view, we report that ATP hydrolysis triggers rapid dissociation of the 19S regulatory particles from immunopurified 26S complexes in a manner coincident with release of the bulk of proteasome-interacting proteins. Strikingly, this mechanism leads to quantitative disassembly of the 19S into subcomplexes and free Rpn10, the polyubiquitin binding subunit. Biochemical reconstitution with purified Sic1, a prototype substrate of the Cdc34/ SCF ubiquitin ligase, suggests that substrate degradation is essential for triggering the ATP hydrolysis-dependent dissociation and disassembly of the 19S and that this mechanism leads to release of degradation products. This is the first demonstration that a controlled dissociation of the 19S regulatory particles from the 26S proteasome is part of the mechanism of protein degradation.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; CNRS, Lab Ingn Syst Macromol, Marseille 20, France; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	Saint Louis University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Memorial Sloan Kettering Cancer Center; University of New Mexico; University of Missouri System; University of Missouri Kansas City	Skowyra, D (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	skowyrad@slu.edu	Kiss, Alexi/AAH-6830-2021	Tempst, Paul/0000-0002-6680-3987; Kiss, Alexi/0000-0003-2330-6929	NCI NIH HHS [P30 CA 08748] Funding Source: Medline; NIAID NIH HHS [K25 AI 060036, K25 AI060036] Funding Source: Medline; NIBIB NIH HHS [EB 00264] Funding Source: Medline; NIGMS NIH HHS [GM 65267, GM 54703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K25AI060036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R24EB000264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams GM, 1998, BIOCHEMISTRY-US, V37, P12927, DOI 10.1017/S1431927600024880; ARMON T, 1990, J BIOL CHEM, V265, P20723; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Buranda T, 1999, J PHYS CHEM B, V103, P3399, DOI 10.1021/jp983842h; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GANOTH D, 1988, J BIOL CHEM, V263, P12412; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; GROLL M, 1997, ANTURE, V386, P463; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; Hoffman L, 1997, MOL BIOL REP, V24, P13, DOI 10.1023/A:1006892220996; Hutschenreiter S, 2004, EMBO J, V23, P2488, DOI 10.1038/sj.emboj.7600262; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Osmulski PA, 2002, BIOCHEMISTRY-US, V41, P7047, DOI 10.1021/bi0159130; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Schmidt M, 2005, NAT STRUCT MOL BIOL, V12, P294, DOI 10.1038/nsmb914; SIGH SK, 1999, BIOCHEMISTRY-US, V38, P14906; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	52	103	104	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					553	565		10.1016/j.cell.2005.03.028	http://dx.doi.org/10.1016/j.cell.2005.03.028			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907469				2022-12-28	WOS:000229331200012
J	Bork, P; Serrano, L				Bork, P; Serrano, L			Towards cellular systems in 4D	CELL			English	Editorial Material							YEAST		EMBL, D-67119 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Bork, P (corresponding author), EMBL, Meyerhofstr 1, D-67119 Heidelberg, Germany.	bork@embl.com; serrano@embl.cle	Bork, Peer/F-1813-2013; Serrano, Luis/B-3355-2013	Bork, Peer/0000-0002-2627-833X; Serrano, Luis/0000-0002-5276-1392				Aloy P, 2004, SCIENCE, V303, P2026, DOI 10.1126/science.1092645; ANDER M, 2005, SYST BIOL, V1, P129; de Lichtenberg U, 2005, SCIENCE, V307, P724, DOI 10.1126/science.1105103; GOERLICH D, 2003, NAT CELL BIOL S, V307, pS14; Isalan M, 2005, PLOS BIOL, V3, P488, DOI 10.1371/journal.pbio.0030064; KUMER J, 2005, SCIENCE, V307, P436; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Surrey T, 2001, SCIENCE, V292, P1167, DOI 10.1126/science.1059758	8	50	52	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					507	509		10.1016/j.cell.2005.05.001	http://dx.doi.org/10.1016/j.cell.2005.05.001			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907464	Bronze			2022-12-28	WOS:000229331200007
J	Leape, LL; Berwick, DM				Leape, LL; Berwick, DM			Five years after to err is human - What have we learned?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; SLEEP-DEPRIVATION; MEDICAL ERRORS; PATIENT SAFETY; METAANALYSIS; PERFORMANCE; QUALITY; FATIGUE; HEALTH; IMPACT	Five years ago, the Institute of Medicine (IOM) called for a national effort to make health care safe. Although progress since then has been slow, the IOM report truly "changed the conversation" to a focus on changing systems, stimulated a broad array of stakeholders to engage in patient safety, and motivated hospitals to adopt new safe practices. The pace of change is likely to accelerate, particularly in implementation of electronic health records, diffusion of safe practices, team training, and full disclosure to patients following injury. If directed toward hospitals that actually achieve high levels of safety, pay for performance could provide additional incentives. But improvement of the magnitude envisioned by the IOM requires a national commitment to strict, ambitious, quantitative, and well-tracked national goals. The Agency for Healthcare Research and Quality should bring together all stakeholders, including payers, to agree on a set of explicit and ambitious goals for patient safety to be reached by 2010.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA; Inst Healthcare Improvement, Cambridge, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Institute for Healthcare Improvement; Harvard University; Harvard Medical School	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02215 USA.	leape@hsph.harvard.edu	Hefner, Jennifer/P-5962-2014; Young, Alexander/A-1523-2009	Hefner, Jennifer/0000-0001-8083-8038; Young, Alexander/0000-0002-9367-9213				*AG HEALTHC RES QU, 2004, 2004 NAT HEALTHC QUA; *AG HEALTHC RES QU, QUAL IND; *AM BOARD MED SPEC, STAT MOC PROGR; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P149; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; Gurwitz JH, 2005, AM J MED, V118, P251, DOI 10.1016/j.amjmed.2004.09.018; Harrison Y, 2000, J EXP PSYCHOL-APPL, V6, P236, DOI 10.1037//1076-898X.6.3.236; Healey MA, 2002, ARCH SURG-CHICAGO, V137, P611, DOI 10.1001/archsurg.137.5.611; Heget Jeffrey R, 2002, Jt Comm J Qual Improv, V28, P660; Hillman K, 2001, RESUSCITATION, V48, P105, DOI 10.1016/S0300-9572(00)00334-8; *I HEALTHC IMPR, 100K LIV CAMP; *I HEALTHC IMPR, RED ADV DRUG EV; *JOINT COMM ACCR H, JOINT COMM ANN NAT P; *JOINT COMM ACCR H, SENT EV TRENDS POT C; KAZEL R, AM MED NEWS     1108; Kelly John J, 2003, Jt Comm J Qual Saf, V29, P646; KIZER KW, 2001, ADV FEDERAL SECTOR H; KOHN KT, 1999, ERR HUMAN BUILDING S; Kucukarslan SN, 2003, ARCH INTERN MED, V163, P2014, DOI 10.1001/archinte.163.17.2014; Lamb R, 2004, QUAL SAF HEALTH CARE, V13, P3, DOI 10.1136/qshc.2003.008631; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; LANDRO L, 2004, WALL STREET J; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Leatherman S, 2003, HEALTH AFFAIR, V22, P17, DOI 10.1377/hlthaff.22.2.17; LEVINSON D, 2004, REP MED GUIDEL OUTCO, V15, P5; LEVINSON D, 2004, REP MED GUIDEL OUTCO, V15, P1; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; *NAT QUAL FOR, 2004, HOSP GOV BOARDS QUAL; National Quality Forum, 2002, SER REP EV PAT SAF N; PHILLIPS DP, 1996, LANCET, V361, P643; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Rozich J., 2001, J CLIN OUTCOMES MANA, V8, P27; Rozich JD, 2003, QUAL SAF HEALTH CARE, V12, P194, DOI 10.1136/qhc.12.3.194; Rozich John D, 2004, Jt Comm J Qual Saf, V30, P5; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; Starfield B, 2000, JAMA-J AM MED ASSOC, V284, P483, DOI 10.1001/jama.284.4.483; *SURG CAR IMPR PRO, PARTN BETT CAR; the National Quality Forum, 2003, SAF PRACT BETT HLTH; Wenzel RP, 2001, EMERG INFECT DIS, V7, P174, DOI 10.3201/eid0702.010203; Whittington John, 2004, Qual Manag Health Care, V13, P53; WOLFE S, 2003, NY TIMES        0303, P25; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	47	799	810	1	87	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2384	2390		10.1001/jama.293.19.2384	http://dx.doi.org/10.1001/jama.293.19.2384			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900009				2022-12-28	WOS:000229120600026
J	Kallen, B; Finnstrom, O; Nygren, KG; Olausson, PO				Kallen, B; Finnstrom, O; Nygren, KG; Olausson, PO			Temporal trends in multiple births after in vitro fertilisation in Sweden, 1982-2001: a register study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SINGLE-EMBRYO-TRANSFER		Lund Univ, Tornblad Inst, Ctr Reprod Epidemiol, S-22362 Lund, Sweden; Linkoping Univ Hosp, Dept Paediat, S-58185 Linkoping, Sweden; Sophiahemmet, IVF Clin, S-11486 Stockholm, Sweden; Natl Board Hlth & Welf, Ctr Epidemiol, Stockholm, Sweden	Lund University; Linkoping University; National Board of Health & Welfare	Kallen, B (corresponding author), Lund Univ, Tornblad Inst, Ctr Reprod Epidemiol, Biskopsgatan 7, S-22362 Lund, Sweden.	embryol@embryol.lu.se						Andersen AN, 2004, HUM REPROD, V19, P490, DOI 10.1093/humrep/deh129; Center for Epidemiology, 2003, SWED MED BIRTH REG S; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Thurin A, 2004, NEW ENGL J MED, V351, P2392, DOI 10.1056/NEJMoa041032; Tiitinen A, 2003, HUM REPROD, V18, P1449, DOI 10.1093/humrep/deg301	5	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	2005	331	7513					382	383		10.1136/bmj.38443.595046.E0	http://dx.doi.org/10.1136/bmj.38443.595046.E0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956SK	15894553	Green Published			2022-12-28	WOS:000231319900015
J	Weisberg, JM; Johnston, S; Koribalski, B; Stanimirovic, S				Weisberg, JM; Johnston, S; Koribalski, B; Stanimirovic, S			Discovery of pulsed OH maser emission stimulated by a pulsar	SCIENCE			English	Article							NEUTRAL HYDROGEN ABSORPTION; I LINE MEASUREMENTS; ELECTRON-DENSITY; INNER GALAXY; MILKY-WAY; REGIONS	Stimulated emission of radiation has not been directly observed in astrophysical situations up to this time. Here we demonstrate that photons from pulsar B1641 -45 stimulate pulses of excess 1720-megahertz tine emission in an interstellar hydroxyl (OH) cloud. As this stimulated emission is driven by the pulsar, it varies on a few-millisecond time scale, which is orders of magnitude shorter than the quickest OH maser variations previously detected. Our 1612-megahertz spectra are inverted copies of the 1720-megahertz spectra. This "conjugate line" phenomenon enables us to constrain the properties of the interstellar OH line-producing gas. We also show that pulsar signals undergo significantly deeper OH absorption than do other background sources, which confirms earlier tentative findings that OH clouds are clumpier on small scales than are neutral hydrogen clouds.	CSIRO, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Carleton Coll, Dept Phys & Astron, Northfield, MN 55057 USA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney; University of California System; University of California Berkeley; Carleton College	Weisberg, JM (corresponding author), CSIRO, Australia Telescope Natl Facil, POB 76, Epping, NSW 1710, Australia.	jweisber@carleton.edu	Koribalski, Baerbel S/B-9987-2008; Johnston, Simon/AAW-8490-2020	Koribalski, Baerbel S/0000-0003-4351-993X; Johnston, Simon/0000-0002-7122-4963; Stanimirovic, Snezana/0000-0002-3418-7817				BEUERMANN K, 1985, ASTRON ASTROPHYS, V153, P17; Brooks KJ, 2001, MON NOT R ASTRON SOC, V320, P465, DOI 10.1046/j.1365-8711.2001.03964.x; CASWELL JL, 1987, ASTRON ASTROPHYS, V171, P261; Caswell JL, 2004, MON NOT R ASTRON SOC, V349, P99, DOI 10.1111/j.1365-2966.2004.07472.x; CERSOSIMO JC, 1990, ASTROPHYS J, V349, P67, DOI 10.1086/168294; Claussen M, 2004, SCIENCE, V306, P235, DOI 10.1126/science.1101353; CLEGG AW, 1991, ASTROPHYS J, V374, P150, DOI 10.1086/170105; Cook A. H, 1977, CELESTIAL MASERS; CORDES JM, 1993, ASTR SOC P, V47, P257; CORDES JM, 1985, ASTROPHYS J, V288, P221, DOI 10.1086/162784; DICKEY JM, 1981, ASTRON ASTROPHYS, V101, P332; Elitzur M., 1992, ASTRONOMICAL MASERS; FICH M, 1989, ASTROPHYS J, V342, P272, DOI 10.1086/167591; FRAIL DA, 1990, ASTRON J, V100, P743, DOI 10.1086/115556; HAYNES RF, 1977, MON NOT R ASTRON SOC, V178, P219, DOI 10.1093/mnras/178.2.219; Johnston S, 1998, MON NOT R ASTRON SOC, V297, P108, DOI 10.1046/j.1365-8711.1998.01461.x; Johnston S, 2001, MON NOT R ASTRON SOC, V322, P715, DOI 10.1046/j.1365-8711.2001.04152.x; KORIBALSKI B, 1995, ASTROPHYS J, V441, P756, DOI 10.1086/175397; Lockett P, 1999, ASTROPHYS J, V511, P235, DOI 10.1086/306667; MANCHESTER RN, 1977, ASTRON ASTROPHYS, V59, P401; McClure-Griffiths NM, 2005, ASTROPHYS J SUPPL S, V158, P178, DOI 10.1086/430114; PAYNE HE, 1982, ASTROPHYS J SUPPL S, V48, P199, DOI 10.1086/190775; RIEU NO, 1976, ASTRON ASTROPHYS, V46, P413; SHAVER PA, 1983, MON NOT R ASTRON SOC, V204, P53, DOI 10.1093/mnras/204.1.53; SLYSH VI, 1972, ASTRONOMICHESKII CIR, V731, P1; Stanimirovic S, 2003, ASTROPHYS J, V592, P953, DOI 10.1086/375779; TURNER BE, 1982, ASTROPHYS J, V255, pL33, DOI 10.1086/183764; VANLANGEVELDE HJ, 1995, ASTROPHYS J, V448, pL123, DOI 10.1086/309613; WEISBERG JM, 1995, ASTROPHYS J, V447, P204, DOI 10.1086/175866	29	21	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2005	309	5731					106	110		10.1126/science.1112494	http://dx.doi.org/10.1126/science.1112494			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	941KD	15919955	Green Submitted			2022-12-28	WOS:000230212800067
J	Krause, O; Rieke, GH; Birkmann, SM; Le Floc'h, E; Gordon, KD; Egami, E; Bieging, J; Hughes, JP; Young, ET; Hinz, JL; Quanz, SP; Hines, DC				Krause, O; Rieke, GH; Birkmann, SM; Le Floc'h, E; Gordon, KD; Egami, E; Bieging, J; Hughes, JP; Young, ET; Hinz, JL; Quanz, SP; Hines, DC			Infrared echoes near the supernova remnant Cassiopeia A	SCIENCE			English	Article							MULTIBAND IMAGING PHOTOMETER; RAY REPEATER SGR1900+14; GIANT FLARE; LIGHT ECHOES; SPITZER MIPS; EJECTA; DUST; SGR-1806-20; CONSTRAINTS; DISCOVERY	Two images of Cassiopeia A obtained at 24 micrometers with the Spitzer Space Telescope over a 1-year time interval show moving structures outside the shell of the supernova remnant to a distance of more than 20 arc minutes. individual features exhibit apparent motions of 10 to 20 arc seconds per year, independently confirmed by near-infrared observations. The observed tangential velocities are at roughly the speed of tight. It is likely that the moving structures are infrared echoes, in which interstellar dust is heated by the explosion and by flares from the compact object near the center of the remnant.	Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Space Sci Inst, Boulder, CO 80301 USA	University of Arizona; Max Planck Society; Rutgers State University New Brunswick	Krause, O (corresponding author), Univ Arizona, Steward Observ, 933 N Cherry Ave, Tucson, AZ 85721 USA.	krause@as.arizona.edu		Gordon, Karl/0000-0001-5340-6774; Hughes, John P./0000-0002-8816-6800				BELL AR, 1975, NATURE, V257, P463, DOI 10.1038/257463a0; Bond HE, 2003, NATURE, V422, P405, DOI 10.1038/nature01508; BRAUN R, 1987, NATURE, V327, P395, DOI 10.1038/327395a0; Chakrabarty D, 2001, ASTROPHYS J, V548, P800, DOI 10.1086/318994; CHEVALIER RA, 1988, ASTROPHYS J, V331, pL105, DOI 10.1086/185245; DWEK E, 1983, ASTROPHYS J, V274, P175, DOI 10.1086/161435; FESEN RA, 1987, ASTROPHYS J, V313, P378, DOI 10.1086/164974; Fesen RA, 2001, ASTROPHYS J SUPPL S, V133, P161, DOI 10.1086/319181; Frail DA, 1999, NATURE, V398, P127, DOI 10.1038/18163; Gaensler BM, 2005, NATURE, V434, P1104, DOI 10.1038/nature03498; GRAHAM JR, 1983, NATURE, V304, P709, DOI 10.1038/304709a0; Hines DC, 2004, ASTROPHYS J SUPPL S, V154, P290, DOI 10.1086/422583; Hurley K, 1999, NATURE, V397, P41, DOI 10.1038/16199; Krause O, 2004, NATURE, V432, P596, DOI 10.1038/nature03110; Krugel E., 2003, PHYS INTERSTELLAR DU; Mirabel IF, 1998, NATURE, V392, P673, DOI 10.1038/33603; REED JE, 1995, ASTROPHYS J, V440, P706, DOI 10.1086/175308; Rieke GH, 2004, ASTROPHYS J SUPPL S, V154, P25, DOI 10.1086/422717; Rothschild RE, 2003, ASTROPHYS J, V582, P257, DOI 10.1086/344567; TANANBAUM H, 1999, 7246 INT ASTR UN; Terasawa T, 2005, NATURE, V434, P1110, DOI 10.1038/nature03573; Thompson C, 2001, ASTROPHYS J, V561, P980, DOI 10.1086/323256; Thorstensen JR, 2001, ASTRON J, V122, P297, DOI 10.1086/321138; WOLF M, 1901, ASTRON NACHR, V156, P238; YAMAZAKI R, ASTROPH0502393	25	52	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1604	1606		10.1126/science.1112035	http://dx.doi.org/10.1126/science.1112035			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947181	Green Submitted			2022-12-28	WOS:000229827000049
J	Medoff, BD; Shepard, JO; Smith, RN; Kratz, A				Medoff, BD; Shepard, JO; Smith, RN; Kratz, A			A 22-year-old woman with back and leg pain and respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SICKLE-CELL-DISEASE; ACUTE LUNG INJURY; INHALED NITRIC-OXIDE; ACUTE CHEST SYNDROME; EXTRACORPOREAL MEMBRANE-OXYGENATION; DISTRESS-SYNDROME; PULMONARY-HYPERTENSION; RECRUITMENT MANEUVER; COMPUTED-TOMOGRAPHY; PATIENT		Massachusetts Gen Hosp, Dept Med, Ctr Immunol & Inflammatory Dis, Pulm & Crit Care Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Medoff, BD (corresponding author), Massachusetts Gen Hosp, Dept Med, Ctr Immunol & Inflammatory Dis, Pulm & Crit Care Unit, Boston, MA 02114 USA.			Medoff, Benjamin/0000-0002-2558-0449				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V42, P1301; Adhikari N, 2004, JAMA-J AM MED ASSOC, V291, P1629, DOI 10.1001/jama.291.13.1629; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2004, CRIT CARE MED, V32, P907; Bugedo G, 2003, INTENS CARE MED, V29, P218, DOI 10.1007/s00134-002-1618-6; Claster S, 2003, BRIT MED J, V327, P1151, DOI 10.1136/bmj.327.7424.1151; COLLINS FS, 1982, AM J MED, V73, P814, DOI 10.1016/0002-9343(82)90763-X; Fedullo PF, 2001, NEW ENGL J MED, V345, P1465, DOI 10.1056/NEJMra010902; FELLAHI JL, 1995, ANESTHESIOLOGY, V83, P635, DOI 10.1097/00000542-199509000-00028; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Head CA, 1997, J CLIN INVEST, V100, P1193, DOI 10.1172/JCI119631; Lim CM, 2003, CRIT CARE MED, V31, P411, DOI 10.1097/01.CCM.0000048631.88155.39; Mak V, 2003, THORAX, V58, P726, DOI 10.1136/thorax.58.8.726; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; Masiakos PT, 1999, ARCH SURG-CHICAGO, V134, P375, DOI 10.1001/archsurg.134.4.375; Medoff BD, 2000, CRIT CARE MED, V28, P1210, DOI 10.1097/00003246-200004000-00051; Moloney ED, 2004, BRIT J ANAESTH, V92, P261, DOI 10.1093/bja/aeh031; Petz LD, 1997, TRANSFUSION, V37, P382, DOI 10.1046/j.1537-2995.1997.37497265338.x; Platt OS, 2000, NEW ENGL J MED, V342, P1904, DOI 10.1056/NEJM200006223422510; PLATT OS, 2000, NEW ENGL J MED, V343, P591; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; ROTHEN HU, 1993, BRIT J ANAESTH, V71, P788, DOI 10.1093/bja/71.6.788; Schwarz MI, 2004, CHEST, V125, P1530, DOI 10.1378/chest.125.4.1530; Slutsky AS, 2001, NEW ENGL J MED, V345, P610, DOI 10.1056/NEJM200108233450811; STOWELL CP, 2002, ROSSIS PRINCIPLES TR, P483; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; Vichinsky EP, 2004, NEW ENGL J MED, V350, P857, DOI 10.1056/NEJMp038250; Vichinsky EP, 2000, NEW ENGL J MED, V343, P824; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	33	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2425	2434		10.1056/NEJMcpc059012	http://dx.doi.org/10.1056/NEJMcpc059012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944428				2022-12-28	WOS:000229638900011
J	Changeux, JP; Edelstein, SJ				Changeux, JP; Edelstein, SJ			Allosteric mechanisms of signal transduction	SCIENCE			English	Review							ACETYLCHOLINE-RECEPTOR; GLUTAMATE-RECEPTOR; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; R-STATE; T-STATE; MODEL; PROTEINS; COOPERATIVITY; HEMOGLOBIN	Forty years ago, a simple model of allosteric mechanisms (indirect interactions between distinct sites), used initially to explain feedback-inhibited enzymes, was presented by Monod, Wyman, and Changeux. We review the MWC theory and its applications for the understanding of signal transduction in biology, and also identify remaining issues that deserve theoretical and experimental substantiation.	Inst Pasteur, F-75724 Paris, France; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Geneva	Changeux, JP (corresponding author), Inst Pasteur, F-75724 Paris, France.	changeux@pasteur.fr						Ackers GK, 2000, PROTEINS, P23; Bray D, 2004, ANNU REV BIOPH BIOM, V33, P53, DOI 10.1146/annurev.biophys.33.110502.132703; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; CHANGEUX J, 1965, B SOC CHIM BIOL, V47, P281; CHANGEUX J P, 1969, Nobel Symposium, P235; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHANGEUX JP, 1961, COLD SPRING HARB SYM, V26, P313, DOI 10.1101/SQB.1961.026.01.037; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P553, DOI 10.1021/bi00842a601; CHANGEUX JP, 1967, P NATL ACAD SCI USA, V57, P335, DOI 10.1073/pnas.57.2.335; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; EDELSTEIN SJ, 1971, NATURE, V230, P224, DOI 10.1038/230224a0; EIGEN M, 1967, Nobel Symposium, V5, P333; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; Henry ER, 2002, BIOPHYS CHEM, V98, P149, DOI 10.1016/S0301-4622(02)00091-1; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; JACKSON MB, 1986, BIOPHYS J, V49, P663, DOI 10.1016/S0006-3495(86)83693-1; KOSHLAND DE, 1959, J CELL COMPAR PHYSL, V54, P245, DOI 10.1002/jcp.1030540420; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MacKinnon R, 2003, FEBS LETT, V555, P62, DOI 10.1016/S0014-5793(03)01104-9; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Shulman RG, 2001, IUBMB LIFE, V51, P351, DOI 10.1080/152165401753366104; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; Stieglitz K, 2004, J MOL BIOL, V341, P853, DOI 10.1016/j.jmb.2004.06.002; TALY A, 2005, BIOPHYS J       0401; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Viappiani C, 2004, P NATL ACAD SCI USA, V101, P14414, DOI 10.1073/pnas.0405987101; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200	37	528	541	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1424	1428		10.1126/science.1108595	http://dx.doi.org/10.1126/science.1108595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933191				2022-12-28	WOS:000229619300040
J	LaCava, J; Houseley, J; Saveanu, C; Petfalski, E; Thompson, E; Jacquier, A; Tollervey, D				LaCava, J; Houseley, J; Saveanu, C; Petfalski, E; Thompson, E; Jacquier, A; Tollervey, D			RNA degradation by the exosome is promoted by a nuclear polyade nylation complex	CELL			English	Article							CYTOPLASMIC POLY(A) POLYMERASE; YEAST NUCLEOLAR PROTEIN; 3' END FORMATION; HUMAN PM-SCL; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; ESCHERICHIA-COLI; GLOBAL ANALYSIS; POLYADENYLATION	The exosome complex of 3'-5' exonucleases participates in RNA maturation and quality control and can rapidly degrade RNA-protein complexes in vivo. However, the purified exosome showed weak in vitro activity, indicating that rapid RNA degradation requires activating cofactors. This work identifies a nuclear polyadenylation complex containing a known exosome cofactor, the RNA helicase Mtr4p; a poly(A) polymerase, Trf4p; and a zinc knuckle protein, Air2p. In vitro, the Trf4p/Air2p/Mtr4p polyadenylation complex (TRAMP) showed distributive RNA polyadenylation activity. The presence of the exosome suppressed poly(A) tail addition, while TRAMP stimulated exosome degradation through structured RNA substrates. In vivo analyses showed that TRAMP is required for polyadenylation and degradation of rRNA and snoRNA precursors that are characterized exosome substrates. Poly(A) tails stimulate RNA degradation in bacteria, suggesting that this is their ancestral function. We speculate that this function was maintained in eukaryotic nuclei, while cytoplasmic mRNA poly(A) tails acquired different roles in translation.	Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Pasteur, CNRS, Genet Interact Macromol URA 2171, F-75015 Paris, France	University of Edinburgh; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Tollervey, D (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland.	d.tollervey@ed.ac.uk	LaCava, John P/H-2840-2013; Houseley, Jon/AAF-7409-2021; Saveanu, Cosmin/K-6494-2015; Tollervey, David/AAR-6662-2020; Saveanu, Cosmin/Q-1251-2019	LaCava, John P/0000-0002-6307-7713; Saveanu, Cosmin/0000-0002-1677-7936; Tollervey, David/0000-0003-2894-2772; Saveanu, Cosmin/0000-0002-1677-7936; JACQUIER, ALAIN/0000-0001-5707-9184; Houseley, Jonathan/0000-0001-8509-1500	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Castano IB, 1996, NUCLEIC ACIDS RES, V24, P2404, DOI 10.1093/nar/24.12.2404; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inoue K, 2000, J BIOL CHEM, V275, P32793, DOI 10.1074/jbc.M004560200; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; Kuai L, 2004, P NATL ACAD SCI USA, V101, P8581, DOI 10.1073/pnas.0402888101; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Kwak JE, 2004, P NATL ACAD SCI USA, V101, P4407, DOI 10.1073/pnas.0400779101; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Li ZW, 1998, P NATL ACAD SCI USA, V95, P12158, DOI 10.1073/pnas.95.21.12158; Liang S, 1996, MOL CELL BIOL, V16, P5139; Mitchell P, 2003, MOL CELL BIOL, V23, P6982, DOI 10.1128/MCB.23.19.6982-6992.2003; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mohanty BK, 2002, MOL MICROBIOL, V45, P1315, DOI 10.1046/j.1365-2958.2002.03097.x; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Shevchenko A, 1997, J PROTEIN CHEM, V16, P481, DOI 10.1023/A:1026361427575; SYERS F, 2005, CELL, V121, P725; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; Torchet C, 2002, MOL CELL, V9, P1285, DOI 10.1016/S1097-2765(02)00544-0; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Wang LT, 2002, NATURE, V419, P312, DOI 10.1038/nature01039; Wang SW, 2000, MOL CELL BIOL, V20, P3234, DOI 10.1128/MCB.20.9.3234-3244.2000	41	698	706	4	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					713	724		10.1016/j.cell.2005.04.029	http://dx.doi.org/10.1016/j.cell.2005.04.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935758	Bronze			2022-12-28	WOS:000229658000010
J	Moore, BD; Foley, WJ				Moore, BD; Foley, WJ			Tree use by koalas in a chemically complex landscape	NATURE			English	Article							PHASCOLARCTOS-CINEREUS; FOLIAR CHEMISTRY; FOOD PREFERENCE; SNOWSHOE HARE; VARIED DIETS; EUCALYPTUS; HERBIVORY; SELECTION; POPULATIONS; NUTRIENTS	Although defence against herbivores is often argued to be the main action of plant secondary metabolites (PSMs)(1), very few examples have demonstrated that intraspecific variation in PSM concentrations influences foraging by wild vertebrate herbivores(2,3). Experiments with captive animals often indicate that PSM concentrations influence how much herbivores eat from individual plants(3-7), but these experiments do not replicate the subtle tradeoffs in diet selection faced by wild animals, which must avoid predators and extremes of weather, interact with conspecifics, and achieve a balanced, nutritious diet, while avoiding intoxication by PSMs. We characterized the foliar chemistry of every tree from two Eucalyptus species available to a population of koalas (Phascolarctos cinereus) and considered rates of tree visitation over a ten-year period. We show that visitation rate was most strongly influenced by tree size, but that koalas also visited trees less frequently if the foliage contained either high concentrations of deterrent PSMs known as formylated phloroglucinol compounds, or low concentrations of nitrogen. Consequently, plant chemistry restricts the use of trees by this herbivore, and thus limits the food available to koalas and potentially influences koala populations.	Australian Natl Univ, Sch Bot & Zool, Canberra, ACT 0200, Australia	Australian National University	Moore, BD (corresponding author), James Cook Univ N Queensland, Sch Trop Biol, Townsville, Qld 4811, Australia.	Ben.Moore@jcu.edu.au	Moore, Ben/AAE-7885-2020; Foley, William J/C-8069-2009; Moore, Ben D/C-3447-2008	Moore, Ben/0000-0002-6995-4721; Foley, William J/0000-0001-8587-1814; Moore, Ben D/0000-0002-6995-4721				BRYANT JP, 1983, SCIENCE, V222, P1023, DOI 10.1126/science.222.4627.1023; DANELL K, 1991, ECOLOGY, V72, P1350, DOI 10.2307/1941107; DEGABRIELE R, 1981, AUST J ECOL, V6, P139, DOI 10.1111/j.1442-9993.1981.tb01284.x; DEGABRIELE R, 1983, AUST J ECOL, V8, P75, DOI 10.1111/j.1442-9993.1983.tb01520.x; DUNCAN AJ, 1994, CAN J ZOOL, V72, P1715, DOI 10.1139/z94-231; Eschler BM, 2000, BIOCHEM SYST ECOL, V28, P813, DOI 10.1016/S0305-1978(99)00123-4; FARENTINOS RC, 1981, SCIENCE, V213, P1273, DOI 10.1126/science.213.4513.1273; FRAENKEL GS, 1959, SCIENCE, V129, P1466, DOI 10.1126/science.129.3361.1466; FREELAND WJ, 1974, AM NAT, V108, P269, DOI 10.1086/282907; HINDELL MA, 1985, AUST WILDLIFE RES, V12, P137; HUME ID, 1999, MARSUPIAL NUTR, pCH5; Lawler IR, 2000, ECOLOGY, V81, P1327, DOI 10.1890/0012-9658(2000)081[1327:FCOAST]2.0.CO;2; MARTIN RW, 1985, AUST WILDLIFE RES, V12, P355; MARTIN RW, 1999, KOALA NATURAL HIST C, pCH4; McIlwee AM, 2001, OECOLOGIA, V128, P539, DOI 10.1007/s004420100692; Moore BD, 2004, CONSERVATION OF AUTRALIA'S, SECOND EDITION, P549; Moore BD, 2005, BIOL LETT-UK, V1, P64, DOI 10.1098/rsbl.2004.0255; Moore BD, 2004, ECOL MONOGR, V74, P553, DOI 10.1890/03-4038; Moore BD, 2004, J CHEM ECOL, V30, P1743, DOI 10.1023/B:JOEC.0000042399.06553.c6; O'Reilly-Wapstra JM, 2002, OECOLOGIA, V130, P289, DOI 10.1007/s004420100797; Provenza FD, 2003, SMALL RUMINANT RES, V49, P257, DOI 10.1016/S0921-4488(03)00143-3; PROVENZA FD, 1995, J RANGE MANAGE, V48, P2, DOI 10.2307/4002498; SCHMITZ OJ, 1992, OIKOS, V65, P295, DOI 10.2307/3545021; Scrivener NJ, 2004, EVOL ECOL RES, V6, P77; ULLREY DE, 1981, AUST J ZOOL, V29, P839, DOI 10.1071/ZO9810839; Villalba JJ, 2002, OIKOS, V97, P282, DOI 10.1034/j.1600-0706.2002.970214.x; Vourc'h G, 2001, OECOLOGIA, V126, P84, DOI 10.1007/s004420000491; WESTOBY M, 1978, AM NAT, V112, P627, DOI 10.1086/283303; White T. C. R., 1993, INADEQUATE ENV NITRO	29	134	141	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					488	490		10.1038/nature03551	http://dx.doi.org/10.1038/nature03551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917807				2022-12-28	WOS:000229337800053
J	Aderem, A				Aderem, A			Systems biology: Its practice and challenges	CELL			English	Editorial Material									Inst Syst Biol, Seattle, WA 98103 USA	Institute for Systems Biology (ISB)	Aderem, A (corresponding author), Inst Syst Biol, 1441 N 34th St, Seattle, WA 98103 USA.	aderem@systemsbiology.org							0	266	283	0	33	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 20	2005	121	4					511	513		10.1016/j.cell.2005.04.020	http://dx.doi.org/10.1016/j.cell.2005.04.020			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907465	Bronze			2022-12-28	WOS:000229331200008
J	Maule, CF; Purucker, ME; Olsen, N; Mosegaard, K				Maule, CF; Purucker, ME; Olsen, N; Mosegaard, K			Heat flux anomalies in Antarctica revealed by satellite magnetic data	SCIENCE			English	Article							ICE-SHEET; BASAL MELT; BOREHOLE	The geothermal heat flux is an important factor in the dynamics of ice sheets; it affects the occurrence of subglacial takes, the onset of ice streams, and mass tosses from the ice sheet base. Because direct heat flux measurements in ice-covered regions are difficult to obtain, we developed a method that uses satellite magnetic data to estimate the heat flux underneath the Antarctic ice sheet We found that the heat flux underneath the ice sheet varies from 40 to 185 megawatts per square meter and that areas of high heat flux coincide with known current volcanism and some areas known to have ice streams.	Ctr Planetary Sci, DK-2100 Copenhagen, Denmark; NASA, Goddard Space Flight Ctr, Raytheon Co, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Raytheon Technologies	Maule, CF (corresponding author), Ctr Planetary Sci, Juliane Maries Vej 30, DK-2100 Copenhagen, Denmark.	foxmaule@gfy.ku.dk	Olsen, Nils/AAZ-1044-2021; Olsen, Nils/H-1822-2011	Olsen, Nils/0000-0003-1132-6113; Olsen, Nils/0000-0003-1132-6113; Mosegaard, Klaus/0000-0001-5292-5249	Natural Environment Research Council [NER/O/S/2003/00674] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Beardsmore G. R., 2001, CRUSTAL HEAT FLOW; Behrendt JC, 1999, GLOBAL PLANET CHANGE, V23, P25, DOI 10.1016/S0921-8181(99)00049-1; Bennett MR, 2003, EARTH-SCI REV, V61, P309, DOI 10.1016/S0012-8252(02)00130-7; BLANKENSHIP DD, 1993, NATURE, V361, P526, DOI 10.1038/361526a0; DahlJensen D, 2003, ANN GLACIOL-SER, V37, P207, DOI 10.3189/172756403781815492; Dyment J, 1998, J GEOPHYS RES-SOL EA, V103, P15423, DOI 10.1029/97JB03574; Dyment J, 1998, GEOPHYS RES LETT, V25, P2003, DOI 10.1029/98GL51331; Engelhardt H, 2004, J GLACIOL, V50, P251, DOI 10.3189/172756504781830105; Fahnestock M, 2001, SCIENCE, V294, P2338, DOI 10.1126/science.1065370; GOLYNSKY A, IN PRESS 9 ISAES P; LANGEL RA, 1998, MAGNETIC FIELD EARTH; Lowrie W., 1997, FUNDAMENTALS GEOPHYS; Maule CF, 2005, EARTH OBSERVATION WITH CHAMP: RESULTS FROM THREE YEARS ORBIT, P255, DOI 10.1007/3-540-26800-6_40; NASLUND JO, IN PRESS ANN GLACIOL; Nataf HC, 1996, PHYS EARTH PLANET IN, V95, P101, DOI 10.1016/0031-9201(95)03105-7; POLLACK HN, 1993, REV GEOPHYS, V31, P267, DOI 10.1029/93RG01249; Purucker M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013645; Purucker ME, 2000, GEOPHYS RES LETT, V27, P2765, DOI 10.1029/1999GL008437; Raymond CF, 2000, J GLACIOL, V46, P665, DOI 10.3189/172756500781832701; Sabaka TJ, 2004, GEOPHYS J INT, V159, P521, DOI 10.1111/j.1365-246X.2004.02421.x; Sandiford M, 2002, EARTH PLANET SC LETT, V204, P133, DOI 10.1016/S0012-821X(02)00958-5; Siegert MJ, 2000, EARTH-SCI REV, V50, P29, DOI 10.1016/S0012-8252(99)00068-9; Siegert MJ, 1996, J GLACIOL, V42, P501, DOI 10.3189/S0022143000003488; Stampolidis A, 2002, PURE APPL GEOPHYS, V159, P2659, DOI 10.1007/s00024-002-8752-5; Winberry JP, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018001	25	195	199	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	2005	309	5733					464	467		10.1126/science.1106888	http://dx.doi.org/10.1126/science.1106888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	946LY	15947138				2022-12-28	WOS:000230574900046
J	Ishii, M; Shearer, PM; Houston, H; Vidale, JE				Ishii, M; Shearer, PM; Houston, H; Vidale, JE			Extent, duration and speed of the 2004 Sumatra-Andaman earthquake imaged by the Hi-Net array	NATURE			English	Article							RUPTURE PROCESS	The disastrous Sumatra-Andaman earthquake of 26 December 2004 was one of the largest ever recorded. The damage potential of such earthquakes depends on the extent and magnitude of fault slip. The first reliable moment magnitude estimate(1) of 9.0 was obtained several hours after the Sumatra-Andaman earthquake, but more recent, longer-period, normal-mode analyses have indicated that it had a moment magnitude of 9.3, about 2.5 times larger(2). Here we introduce a method for directly imaging earthquake rupture that uses the first-arriving compressional wave and is potentially able to produce detailed images within 30 min of rupture initiation. We used the Hi-Net seismic array in Japan as an antenna to map the progression of slip by monitoring the direction of high-frequency radiation. We find that the rupture spread over the entire 1,300-km-long aftershock zone by propagating northward at roughly 2.8 km s(-1) for approximately 8 minutes. Comparisons with the aftershock areas of other great earthquakes indicate that the Sumatra-Andaman earthquake did indeed have a moment magnitude of similar to 9.3. Its rupture, in both duration and extent, is the longest ever recorded.	Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA; Univ Calif Los Angeles, IGPP, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California Los Angeles	Ishii, M (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, IGPP 0225, La Jolla, CA 92093 USA.	mishii@ucsd.edu	Vidale, John/H-4965-2011; Shearer, Peter/K-5247-2012	Vidale, John/0000-0002-3658-818X; Shearer, Peter/0000-0002-2992-7630				ALGERMISSEN ST, 1972, GREAT ALASKA EARTHQU; BECK SL, 1991, J GEOPHYS RES-SOLID, V96, P2205, DOI 10.1029/90JB02092; BRAZEE RJ, 1959, US EARTHQUAKES 1957; CHRISTENSEN DH, 1994, PURE APPL GEOPHYS, V142, P29, DOI 10.1007/BF00875967; DZIEWONSKI AM, 1983, J GEOPHYS RES, V88, P3247, DOI 10.1029/JB088iB04p03247; ELLSWORTH WL, 1992, SEISMOL RES LETT, V63, P73; HOUSTON H, 1986, B SEISMOL SOC AM, V76, P19; JOHNSON JM, 1994, PURE APPL GEOPHYS, V142, P3, DOI 10.1007/BF00875966; Kanamori H, 2004, REP PROG PHYS, V67, P1429, DOI 10.1088/0034-4885/67/8/R03; KANAMORI H, 1977, J GEOPHYS RES, V82, P2981, DOI 10.1029/JB082i020p02981; Kanamori H., 1974, Physics of the Earth and Planetary Interiors, V9, P128, DOI 10.1016/0031-9201(74)90029-6; Kennett B.L.N., 1991, IASPEI 1991 SEISMOLO; McGuire JJ, 2002, B SEISMOL SOC AM, V92, P3309, DOI 10.1785/0120010293; Ni S, 2005, NATURE, V434, P582, DOI 10.1038/434582a; Ortiz M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001941; Shearer PM, 2004, GEOPHYS J INT, V158, P1103, DOI 10.1111/j.1365-246X.2004.02378.x; SPUDICH P, 1984, B SEISMOL SOC AM, V74, P2083; Stein S, 2005, NATURE, V434, P581, DOI 10.1038/434581a; TALLEY JHC, 1962, US EARTHQUAKES 1960	19	498	518	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2005	435	7044					933	936		10.1038/nature03675	http://dx.doi.org/10.1038/nature03675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15908984				2022-12-28	WOS:000229799700044
J	Davis, CJ; Johnson, CG				Davis, CJ; Johnson, CG			Lightning-induced intensification of the ionospheric sporadic E layer	NATURE			English	Article							SUPERPOSED EPOCH; GRAVITY-WAVES; IONIZATION; VLF; THUNDERSTORM; SIGNATURES; PULSES	A connection between thunderstorms and the ionosphere has been hypothesized since the mid-1920s(1). Several mechanisms have been proposed to explain this connection(2-7), and evidence from modelling(8) as well as various types of measurements(9-14) demonstrate that lightning can interact with the lower ionosphere. It has been proposed, on the basis of a few observed events(15), that the ionospheric 'sporadic E' layer - transient, localized patches of relatively high electron density in the mid-ionosphere E layer, which significantly affect radio-wave propagation - can be modulated by thunderstorms, but a more formal statistical analysis is still needed. Here we identify a statistically significant intensification and descent in altitude of the mid-latitude sporadic E layer directly above thunderstorms. Because no ionospheric response to low-pressure systems without lightning is detected, we conclude that this localized intensification of the sporadic E layer can be attributed to lightning. We suggest that the co-location of lightning and ionospheric enhancement can be explained by either vertically propagating gravity waves that transfer energy from the site of lightning into the ionosphere, or vertical electrical discharge, or by a combination of these two mechanisms.	Rutherford Appleton Lab, Chilton OX11 0QX, Oxon, England	UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Davis, CJ (corresponding author), Rutherford Appleton Lab, Chilton OX11 0QX, Oxon, England.	C.J.Davis@rl.ac.uk	Johnson, Chris/B-3163-2012; Scott, Christopher J/H-8664-2012	Johnson, Chris/0000-0003-2192-3616; Scott, Christopher J/0000-0001-6411-5649				ARMSTRONG WC, 1987, NATURE, V327, P405, DOI 10.1038/327405a0; BAUER SJ, 1957, J GEOPHYS RES, V62, P425, DOI 10.1029/JZ062i003p00425; Bhar JN, 1937, PHILOS MAG, V23, P513; BIBL K, 1978, RADIO SCI, V13, P519, DOI 10.1029/RS013i003p00519; CHIMONAS G, 1971, J GEOPHYS RES, V76, P4578, DOI 10.1029/JA076i019p04578; Davis CJ, 1997, ANN GEOPHYS-ATM HYDR, V15, P217, DOI 10.1007/s00585-997-0217-9; INAN US, 1993, GEOPHYS RES LETT, V20, P2355, DOI 10.1029/93GL02620; Inan US, 1996, J GEOPHYS RES-SPACE, V101, P5219, DOI 10.1029/95JA03514; KELLEY MC, 1985, J GEOPHYS RES-SPACE, V90, P9815, DOI 10.1029/JA090iA10p09815; KELLEY MC, 1990, GEOPHYS RES LETT, V17, P2221, DOI 10.1029/GL017i012p02221; Larsen M.F., 2002, J GEOPHYS RES, V107, P1; LEE ACL, 1989, Q J ROY METEOR SOC, V115, P1147, DOI 10.1002/qj.49711548908; Liu JY, 1998, J ATMOS SOL-TERR PHY, V60, P1679, DOI 10.1016/S1364-6826(98)00103-5; MITRA SK, 1954, NATURE, V174, P798, DOI 10.1038/174798b0; Pasko VP, 2002, NATURE, V416, P152, DOI 10.1038/416152a; Plane JMC, 2003, ADV SPACE RES-SERIES, V32, P699, DOI 10.1016/S0273-1177(03)00401-0; RASTOGI RG, 1957, INDIAN J METEOROL GE, V1, P43; ROSS WB, 1933, NATURE, V133, P523; SAMSON JC, 1986, PLANET SPACE SCI, V34, P1133, DOI 10.1016/0032-0633(86)90025-5; SATO K, 1992, GEOPHYS RES LETT, V19, P1943, DOI 10.1029/92GL02244; SCHUNK RW, 2000, IONOSPHERES PHYS PLA, V243; Sentman DD, 2003, J ATMOS SOL-TERR PHY, V65, P537, DOI 10.1016/S1364-6826(02)00328-0; SHATKHIN KJ, 1964, GEOMAGN AERON, V4, P623; SHRESTHA KL, 1971, J ATMOS TERR PHYS, V33, P205, DOI 10.1016/0021-9169(71)90196-6; TARANENKO YN, 1993, GEOPHYS RES LETT, V20, P1539, DOI 10.1029/93GL01696; VELINOV PI, 1992, J ATMOS TERR PHYS, V54, P1347; Watson-Watt R., 1933, P ROY SOC A, V141, P715; WHITEHEAD JD, 1989, J ATMOS TERR PHYS, V51, P401, DOI 10.1016/0021-9169(89)90122-0; WILSON CTR, 1925, P PHYS SOC LOND, V37, P32, DOI DOI 10.1088/1478-7814/37/1/314; WOODMAN RF, 1984, GEOPHYS RES LETT, V11, P1165, DOI 10.1029/GL011i012p01165	30	50	52	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					799	801		10.1038/nature03638	http://dx.doi.org/10.1038/nature03638			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944700				2022-12-28	WOS:000229638700046
J	Haddad, MB; Wilson, TW; Iiaz, K; Marks, SM; Moore, M				Haddad, MB; Wilson, TW; Iiaz, K; Marks, SM; Moore, M			Tuberculosis and homelessness in the United States, 1994-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	132nd Annual Meeting of the American-Public-Health-Association	NOV 06-10, 2004	Washington, DC	Amer Public Hlth Assoc			MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; OUTBREAK; SHELTER	Context Tuberculosis (TB) rates among US homeless persons cannot be calculated because they are not included in the US Census. However, homelessness is often associated with TB. Objectives To describe homeless persons with TB and to compare risk factors and disease characteristics between homeless and nonhomeless persons with TB. Design and Setting Cross-sectional analysis of all verified TB cases reported into the National TB Surveillance System from the 50 states and the District of Columbia from 1994 through 2003. Main Outcome Measures Number and proportion of TB cases associated with homelessness, demographic characteristics, risk factors, disease characteristics, treatment, and outcomes. Results Of 185870 cases of TB disease reported between 1994 and 2003, 11369 were among persons classified as homeless during the 12 months before diagnosis. The annual proportion of cases associated with homelessness was stable (6.1%-6.7%). Regional differences occurred with a higher proportion of TB cases associated with homelessness in western and some southern states. Most homeless persons with TB were male (87%) and aged 30 to 59 years. Black individuals represented the highest proportion of TB cases among the homeless and nonhomeless. The proportion of homeless persons with TB who were born outside the United States (18%) was lower than that for nonhomeless persons with TB (44%). At the time of TB diagnosis, 9% of homeless persons were incarcerated, usually in a local jail; 3% of nonhomeless persons with TB were incarcerated. Compared with nonhomeless persons, homeless persons with TB had a higher prevalence of substance use (54% alcohol abuse, 29.5% noninjected drug use, and 14% injected drug use), and 34% of those tested had coinfection with human immunodeficiency virus. Compared with nonhomeless persons, TB disease in homeless persons was more likely to be infectious but not more likely to be drug resistant. Health departments managed 81 % of TB cases in homeless persons. Directly observed therapy, used for 86% of homeless patients, was associated with timely completion of therapy. A similar proportion in both groups (9%) died from any cause during therapy. Conclusions Individual TB risk factors often overlap with risk factors for homelessness, and the social contexts in which TB occurs are often complex and important to consider in planning TB treatment. Nevertheless, given good case management, homeless persons with TB can achieve excellent treatment outcomes.	Ctr Dis Control & Prevent, Surveillance Epidemiol & Outbreak Invest Branch, Div TB Eliminat, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Haddad, MB (corresponding author), Ctr Dis Control & Prevent, Surveillance Epidemiol & Outbreak Invest Branch, Div TB Eliminat, 1600 Clifton Rd,Mailstop E-10, Atlanta, GA 30333 USA.	maryam.haddad@cdc.hhs.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		[Anonymous], 2000, MMWR Recomm Rep, V49, P1; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 2003, MMWR RECOMM REP; Asch S, 1998, ANN EMERG MED, V32, P144, DOI 10.1016/S0196-0644(98)70128-3; Baldwin GC, 1997, AM J RESP CRIT CARE, V156, P1606, DOI 10.1164/ajrccm.156.5.9704146; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; *CDCP, 1995, CONTR TB CORR FAC; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P329; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P556; Centers for Disease Control, 2004, REP TUB US 2003; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1184; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P734; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1209; Curtis AB, 2000, INT J TUBERC LUNG D, V4, P308; *I MED, 2000, END NEGL EL TUB US; Iseman Michael D., 2000, CLIN GUIDE TUBERCULO; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; Knopf SA, 1914, J AMER MED ASSOC, V63, P1720; Lathan M, 2002, EMERG INFECT DIS, V8, P1249; Marks SM, 2000, AM J PUBLIC HEALTH, V90, P435, DOI 10.2105/AJPH.90.3.435; Mayaud C, 2001, Rev Pneumol Clin, V57, P259; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; Omidvari K, 1998, ALCOHOL CLIN EXP RES, V22, P567, DOI 10.1111/j.1530-0277.1998.tb04294.x; Perlman DC, 1997, J SUBST ABUSE TREAT, V14, P3, DOI 10.1016/S0740-5472(96)00182-1; Phelan JC, 1999, AM J PUBLIC HEALTH, V89, P1334, DOI 10.2105/AJPH.89.9.1334; Reichard AA, 2003, PUBLIC HEALTH REP, V118, P500, DOI 10.1093/phr/118.6.500; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; Thompson ML, 1998, OCCUP ENVIRON MED, V55, P272, DOI 10.1136/oem.55.4.272; *URB I, 1999, HOM PROGR PEOPL THEY; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2	31	79	82	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2762	2766		10.1001/jama.293.22.2762	http://dx.doi.org/10.1001/jama.293.22.2762			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	933OV	15941806	Green Accepted, Bronze			2022-12-28	WOS:000229643700025
J	Merriman, A; Kaur, M				Merriman, A; Kaur, M			Palliative care in Africa: an appraisal	LANCET			English	Editorial Material									Hospice Africa, Policy & Int Programmes, Kampala, Uganda		Merriman, A (corresponding author), Hospice Africa, Policy & Int Programmes, POB 7757, Kampala, Uganda.	anne@hospiceafrica.or.ug						Defilippi K, 2004, PALLIATIVE MED, V18, P583, DOI 10.1191/0269216304pm954ed; GARBUS L, 2003, HIV AIDS UGANDA; Kikule E, 2003, BRIT MED J, V327, P192, DOI 10.1136/bmj.327.7408.192; MERRIMAN A, 1991, J CHRISTIAN MED COMM; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; Sepulveda C, 2003, BRIT MED J, V327, P209, DOI 10.1136/bmj.327.7408.209; *USAID, 2005, PRES EM PLAN AIDS RE; *WHO, 2005, PALL CAR	8	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1909	1911		10.1016/S0140-6736(05)66638-X	http://dx.doi.org/10.1016/S0140-6736(05)66638-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936406				2022-12-28	WOS:000229587800007
J	Kidd, AR; Miskowski, JA; Siegfried, KR; Sawa, H; Kimble, J				Kidd, AR; Miskowski, JA; Siegfried, KR; Sawa, H; Kimble, J			A beta-catenin identified by functional rather than sequence criteria and its role in Wnt/MAPK signaling	CELL			English	Article							C-ELEGANS EMBRYOS; CANONICAL WNT PATHWAY; NEMO-LIKE-KINASE; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTORS; VULVAL DEVELOPMENT; POLARITY SIGNALS; PROTEIN-KINASE; AXIS FORMATION; CELL POLARITY	Wnt/MAPK signaling is a common variant of Wnt signaling, in C. elegans and has been implicated in vertebrates. The sys-1 gene works with Wnt/MAPK signaling to control cell fates during C. elegans development. We report that the SYS-1 amino acid sequence is novel but that SYS-1 functions as P-catenin: SYS-1 rescues a bar-1/beta-catenin null mutant, binds the POP-1/TCF beta-catenin binding domain, and coactivates POP-1-dependent transcription. Moreover, we provide genetic and molecular evidence that SYS-1 levels are crucial to POP-1 activity. Our results suggest that Wnt/MAPK signaling promotes POP-1 export from the nucleus to accommodate the limiting availability of its SYS-1/beta-catenin transcriptional coactivator. Discovery of SYS-1/beta-catenin extends our definition of beta-catenins and brings together aspects of the canonical mechanism for Wnt signaling with the noncanonical Wnt/ MAPK mechanism. We discuss the idea that a similar pathway may be employed broadly in animal development.	Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; RIKEN, Ctr Dev Biol, Lab Cell Fate Decis, Kobe, Hyogo 6500047, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; RIKEN	Kimble, J (corresponding author), Univ Wisconsin, Mol & Cellular Biol Program, 433 Babcock Dr, Madison, WI 53706 USA.	jekimble@wisc.edu		Siegfried, Kellee/0000-0002-7951-392X; Sawa, Hitoshi/0000-0001-9774-7976	NIGMS NIH HHS [T32 GM07215, T32 GM07133] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007133, T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behrens J, 2000, J CELL SCI, V113, P911; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Calvo D, 2001, EMBO J, V20, P7197, DOI 10.1093/emboj/20.24.7197; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Deshpande R, 2005, DEV BIOL, V278, P118, DOI 10.1016/j.ydbio.2004.10.020; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gleason JE, 2002, GENE DEV, V16, P1281, DOI 10.1101/gad.981602; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Herman MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1530, DOI 10.2741/1306; Herman MA, 2001, DEVELOPMENT, V128, P581; Huber F, 2000, AMA WINTER EDUC CONF, V11, P3; Inoue Takao, 2002, Gene Expression Patterns, V2, P235, DOI 10.1016/S1567-133X(02)00055-8; Inoue T, 2002, MECH DEVELOP, V119, pS203, DOI 10.1016/S0925-4773(03)00117-5; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kaplan DD, 2004, J BIOL CHEM, V279, P10829, DOI 10.1074/jbc.C400035200; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Korswagen HC, 2002, BIOESSAYS, V24, P801, DOI 10.1002/bies.10145; Korswagen HC, 2002, GENE DEV, V16, P1291, DOI 10.1101/gad.981802; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maduro MF, 2002, DEV BIOL, V248, P128, DOI 10.1006/dbio.2002.0721; Maloof JN, 1999, DEVELOPMENT, V126, P37; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miskowski J, 2001, DEV BIOL, V230, P61, DOI 10.1006/dbio.2000.9998; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Natarajan L, 2001, GENETICS, V159, P159; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Park FD, 2003, DEVELOPMENT, V130, P3547, DOI 10.1242/dev.00563; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Sawa H, 2000, MOL CELL, V6, P617, DOI 10.1016/S1097-2765(00)00060-5; Shin TH, 1999, MOL CELL, V4, P275, DOI 10.1016/S1097-2765(00)80375-5; Siegfried KR, 2004, GENETICS, V166, P171, DOI 10.1534/genetics.166.1.171; Siegfried KR, 2002, DEVELOPMENT, V129, P443; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Thorpe CJ, 2000, TRENDS CELL BIOL, V10, P10, DOI 10.1016/S0962-8924(99)01672-4; Thorpe CJ, 2004, DEVELOPMENT, V131, P2899, DOI 10.1242/dev.01171; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zeng YA, 2004, DEVELOPMENT, V131, P2911, DOI 10.1242/dev.01177	63	109	118	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					761	772		10.1016/j.cell.2005.03.029	http://dx.doi.org/10.1016/j.cell.2005.03.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935762	Bronze			2022-12-28	WOS:000229658000014
J	Rost, S; Garnero, EJ; Williams, Q; Manga, M				Rost, S; Garnero, EJ; Williams, Q; Manga, M			Seismological constraints on a possible plume root at the core-mantle boundary	NATURE			English	Article							ULTRALOW-VELOCITY ZONE; PARTIAL MELT; LAYER; BASE; SCP; TOMOGRAPHY; PRESSURES; IRON	Recent seismological discoveries have indicated that the Earth's core - mantle boundary is far more complex than a simple boundary between the molten outer core and the silicate mantle. Instead, its structural complexities probably rival those of the Earth's crust(1). Some regions of the lowermost mantle have been observed to have seismic wave speed reductions of at least 10 per cent(2-7), which appear not to be global in extent(7-9). Here we present robust evidence for an 8.5-km- thick and similar to 50-km-wide pocket of dense, partially molten material at the core - mantle boundary east of Australia. Array analyses of an anomalous precursor to the reflected seismic wave ScP reveal compressional and shear-wave velocity reductions of 8 and 25 per cent, respectively, and a 10 per cent increase in density of the partially molten aggregate. Seismological data are incompatible with a basal layer composed of pure melt, and thus require a mechanism to prevent downward percolation of dense melt within the layer. This may be possible by trapping of melt by cumulus crystal growth following melt drainage from an anomalously hot overlying region of the lowermost mantle. This magmatic evolution and the resulting cumulate structure seem to be associated with overlying thermal instabilities, and thus may mark a root zone of an upwelling plume.	Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	Arizona State University; Arizona State University-Tempe; University of California System; University of California Santa Cruz; University of California System; University of California Berkeley	Rost, S (corresponding author), Arizona State Univ, Dept Geol Sci, Box 871404, Tempe, AZ 85287 USA.	srost@asu.edu	Manga, Michael/D-3847-2013	Manga, Michael/0000-0003-3286-4682				Akins JA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020237; Berryman JG, 2000, GEOPHYS RES LETT, V27, P421, DOI 10.1029/1999GL008402; Castle JC, 2000, EARTH PLANET SC LETT, V176, P311, DOI 10.1016/S0012-821X(00)00027-3; CERVENY V, 1984, GEOPHYS J ROY ASTR S, V78, P65, DOI 10.1111/j.1365-246X.1984.tb06472.x; Dobson DP, 2005, NATURE, V434, P371, DOI 10.1038/nature03430; Garnero EJ, 1998, GEODYNAMICS-US, V28, P319; Garnero EJ, 1998, J GEOPHYS RES-SOL EA, V103, P12495, DOI 10.1029/98JB00700; Garnero EJ, 2000, ANNU REV EARTH PL SC, V28, P509, DOI 10.1146/annurev.earth.28.1.509; Garnero EJ, 1999, GEOPHYS RES LETT, V26, P377, DOI 10.1029/1998GL900319; Grand SP, 2002, PHILOS T R SOC A, V360, P2475, DOI 10.1098/rsta.2002.1077; Jellinek AM, 2002, NATURE, V418, P760, DOI 10.1038/nature00979; Karason H, 2001, J GEOPHYS RES-SOL EA, V106, P6569, DOI 10.1029/2000JB900380; Knittle E, 1998, GEODYNAMICS, V28, P119; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; MCKENZIE D, 1985, EARTH PLANET SC LETT, V74, P81, DOI 10.1016/0012-821X(85)90168-2; Montelli R, 2004, SCIENCE, V303, P338, DOI 10.1126/science.1092485; MORI J, 1995, J GEOPHYS RES-SOL EA, V100, P20359, DOI 10.1029/95JB02243; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Persh SE, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002768; Reasoner C, 2000, J GEOPHYS RES-SOL EA, V105, P28173, DOI 10.1029/2000JB900331; Rondenay S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2003JB002518; ROSCOE R, 1952, BRIT J APPL PHYS, V3, P267, DOI 10.1088/0508-3443/3/8/306; Rost S, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001627; Rost S, 2001, SCIENCE, V294, P1911, DOI 10.1126/science.1065617; SONG X, 1994, GEOPHYS RES LETT, V21, P153, DOI 10.1029/93GL03262; Steinberger B, 2000, J GEOPHYS RES-SOL EA, V105, P11127, DOI 10.1029/1999JB900398; Thorne MS, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003010; Vidale JE, 1998, NATURE, V391, P682, DOI 10.1038/35601; WALKER D, 1988, J GEOPHYS RES-SOLID, V93, P313, DOI 10.1029/JB093iB01p00313; Williams Q, 1998, SCIENCE, V281, P546, DOI 10.1126/science.281.5376.546; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528	31	139	142	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					666	669		10.1038/nature03620	http://dx.doi.org/10.1038/nature03620			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931220				2022-12-28	WOS:000229476200048
J	Chatterjee, PK				Chatterjee, PK			Pleiotropic renal actions of erythropoietin	LANCET			English	Review							ISCHEMIA-REPERFUSION; IN-VIVO; INJURY; PROTECTS; KIDNEY; DYSFUNCTION; FAILURE; RAT; ISCHEMIA/REPERFUSION; ASIALOERYTHROPOIETIN	Context Erythropoietin (EPO), which is used clinically as recombinant human EPO (rHuEPO) for anaemia associated with end-stage renal failure and cancer chemotherapy, also has pleiotropic properties. Although EPO and its receptor are primary mediators of the normal physiological response to hypoxia, rHuEPO can provide impressive protection against acute ischaemic injury in several organs and tissues. The longer-acting hyperglycosylated derivative of EPO, darbepoetin-alpha, is also used for anaemia and has pleiotropic properties. However, the ability of EPO or its analogues to act directly to reduce the severity of renal injury associated with chronic renal failure is not known. Starting point Ferdinand Bahlmann and colleagues (Circulation 2004; 110: 1006-12) investigated whether low-dose subcutaneous darbepoetin-a could protect against renal dysfunction and injury in rats with induced chronic renal failure. Given once weekly, the drug improved renal function and reduced histological evidence of renal injury. Treated rats also had greater weight gain than controls, with no change in systemic blood pressure. The drug did not increase packed-cell volume and it improved survival. Where next? Although the pleiotropic actions of rHuEPO can ameliorate ischaemic: and nephrotoxic acute renal failure, Bahlmann's work is the first evidence that darbepoetin-alpha reduces the renal dysfunction and injury of chronic renal failure. Thus rHuEPO and its analogues might have a use in patients with different types of renal failure. These pleiotropic actions, seen at lower doses, must be separated from the haemopoietic properties that occur at clinical doses and which, at the highest doses, might lead to unwanted effects. Novel analogues of EPO are devoid of haemopoietic activity but still possess protective properties. Their ability to reduce renal injury and dysfunction awaits investigation.	Univ Brighton, Sch Pharm & Biomol Sci, Dept Pharmacol & Therapeut, Brighton BN2 4GJ, E Sussex, England	University of Brighton	Chatterjee, PK (corresponding author), Univ Brighton, Sch Pharm & Biomol Sci, Dept Pharmacol & Therapeut, Brighton BN2 4GJ, E Sussex, England.	p.k.chatterjee@brighton.ac.uk						Abdelrahman M, 2004, SHOCK, V22, P63, DOI 10.1097/01.shk.00001276869.21260.9d; Acs G, 2001, CANCER RES, V61, P3561; Bagnis C, 2001, NEPHROL DIAL TRANSPL, V16, P932, DOI 10.1093/ndt/16.5.932; Bahlmann FH, 2004, CIRCULATION, V110, P1006, DOI 10.1161/01.CIR.0000139335.04152.F3; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2004, SHOCK, V22, P169, DOI 10.1097/01.shk.0000133591.47776.bd; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Fink JC, 2001, AM J KIDNEY DIS, V37, P348, DOI 10.1053/ajkd.2001.21305; GARCIA DL, 1988, P NATL ACAD SCI USA, V85, P6142, DOI 10.1073/pnas.85.16.6142; Gong H, 2004, KIDNEY INT, V66, P683, DOI 10.1111/j.1523-1755.2004.00791.x; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Nemoto T, 2001, KIDNEY INT, V59, P246, DOI 10.1046/j.1523-1755.2001.00485.x; Osterborg A, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.04.005; Patel NSA, 2004, KIDNEY INT, V66, P983, DOI 10.1111/j.1523-1755.2004.00847.x; Pillebout E, 2001, AM J PATHOL, V159, P547, DOI 10.1016/S0002-9440(10)61726-9; Schnackenberg CG, 2002, CURR OPIN PHARMACOL, V2, P121, DOI 10.1016/S1471-4892(02)00133-9; Sharples EJ, 2004, J AM SOC NEPHROL, V15, P2115, DOI 10.1097/01.ASN.0000135059.67385.5D; Shaskey DJ, 2000, SPORTS MED, V29, P27, DOI 10.2165/00007256-200029010-00003; Slowinski T, 2002, CLIN SCI, V103, p44S, DOI 10.1042/CS103S044S; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Tapolyai Mihaly, 2003, BMC Nephrol, V4, P3, DOI 10.1186/1471-2369-4-3; Vesey DA, 2004, NEPHROL DIAL TRANSPL, V19, P348, DOI 10.1093/ndt/gfg547; Wang XY, 2004, J NEUROCHEM, V91, P900, DOI 10.1111/j.1471-4159.2004.02769.x; Westenfelder C, 1999, KIDNEY INT, V55, P808, DOI 10.1046/j.1523-1755.1999.055003808.x; Yang CW, 2003, FASEB J, V17, P1754, DOI 10.1096/fj.02-1191fje	31	66	69	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1890	1892		10.1016/S0140-6736(05)66622-6	http://dx.doi.org/10.1016/S0140-6736(05)66622-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924987				2022-12-28	WOS:000229481400029
J	Boyd, J				Boyd, J			Mouse models of gynecologic pathology	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OVARIAN-CANCER		Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Boyd, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.							Connolly DC, 2003, CANCER RES, V63, P1389; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Seidman JD, 2002, BLAUSTEINS PATHOLOGY, P791; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002	5	12	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2240	2242		10.1056/NEJMcibr051024	http://dx.doi.org/10.1056/NEJMcibr051024			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917391				2022-12-28	WOS:000229333300016
J	Lou, XL; Scheuss, V; Schneggenburger, R				Lou, XL; Scheuss, V; Schneggenburger, R			Allosteric modulation of the presynaptic Ca2+ sensor for vesicle fusion	NATURE			English	Article							PROTEIN-KINASE-C; TRANSMITTER RELEASE; CALCIUM SENSITIVITY; CHROMAFFIN CELLS; MEMBRANE-FUSION; PHORBOL ESTERS; POTENTIATION; POOL; NEUROTRANSMITTER; AUGMENTATION	Neurotransmitter release is triggered by an increase in the cytosolic Ca2+ concentration ([Ca2+](i)), but it is unknown whether the Ca2+-sensitivity of vesicle fusion is modulated during synaptic plasticity. We investigated whether the potentiation of neurotransmitter release by phorbol esters(1-3), which target presynaptic protein kinase C (PKC)/munc-13 signalling cascades(4-6), exerts a direct effect on the Ca2+-sensitivity of vesicle fusion. Using direct presynaptic Ca2+-manipulation and Ca2+ uncaging at a giant presynaptic terminal, the calyx of Held, we show that phorbol esters potentiate transmitter release by increasing the apparent Ca2+-sensitivity of vesicle fusion. Phorbol esters potentiate Ca2+-evoked release as well as the spontaneous release rate. We explain both effects by an increased fusion 'willingness' in a new allosteric model of Ca2+-activation of vesicle fusion. In agreement with an allosteric mechanism, we observe that the classically high Ca2+ cooperativity in triggering vesicle fusion (similar to 4) is gradually reduced below 3 mu M [Ca2+](i), reaching a value of < 1 at basal [Ca2+](i). Our data indicate that spontaneous transmitter release close to resting [Ca2+](i) is a consequence of an intrinsic property of the molecular machinery(7,8) that mediates synaptic vesicle fusion.	Max Planck Inst Biophys Chem, AG Synapt Dynam & Modulat, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Membranbiophys, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society	Schneggenburger, R (corresponding author), Max Planck Inst Biophys Chem, AG Synapt Dynam & Modulat, Fassberg 11, D-37077 Gottingen, Germany.	rschneg@gwdg.de	Volker, Scheuss/G-7846-2015	Scheuss, Volker/0000-0002-0659-3228; Lou, Xuelin/0000-0002-0576-8575				Angleson JK, 2001, J NEUROPHYSIOL, V85, P287, DOI 10.1152/jn.2001.85.1.287; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Deitcher DL, 1998, J NEUROSCI, V18, P2028; DELANEY KR, 1994, J NEUROSCI, V14, P5885; Felmy F, 2003, NEURON, V37, P801, DOI 10.1016/S0896-6273(03)00085-0; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hori T, 1999, J NEUROSCI, V19, P7262, DOI 10.1523/JNEUROSCI.19-17-07262.1999; Ishikawa T, 2002, NEURON, V34, P613, DOI 10.1016/S0896-6273(02)00692-X; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Li J, 1997, Q REV BIOPHYS, V30, P177, DOI 10.1017/S0033583597003326; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Piedras-Renteria ES, 2004, P NATL ACAD SCI USA, V101, P3609, DOI 10.1073/pnas.0308188100; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; Schneggenburger R, 2000, NATURE, V406, P889, DOI 10.1038/35022702; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; Silinsky EM, 2003, BRIT J PHARMACOL, V138, P1191, DOI 10.1038/sj.bjp.0705213; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; Stevens CF, 1999, NEURON, V22, P139, DOI 10.1016/S0896-6273(00)80685-6; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Wu XS, 2001, J NEUROSCI, V21, P7928, DOI 10.1523/JNEUROSCI.21-20-07928.2001; Yang Y, 2002, P NATL ACAD SCI USA, V99, P17060, DOI 10.1073/pnas.242624699; Yawo H, 1999, J PHYSIOL-LONDON, V515, P169, DOI 10.1111/j.1469-7793.1999.169ad.x; Zhu HL, 2002, P NATL ACAD SCI USA, V99, P17055, DOI 10.1073/pnas.232588899	28	204	220	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2005	435	7041					497	501		10.1038/nature03568	http://dx.doi.org/10.1038/nature03568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917809				2022-12-28	WOS:000229337800055
J	Takkouche, B; Etminan, M; Montes-Martinez, A				Takkouche, B; Etminan, M; Montes-Martinez, A			Personal use of hair dyes and risk of cancer - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; MELANOTIC FRECKLE MELANOMA; BREAST-CANCER; BLADDER-CANCER; MULTIPLE-MYELOMA; COLORING PRODUCTS; UNITED-STATES; HEMATOPOIETIC NEOPLASMS; TOBACCO USE	Context Use of hair dyes has been suggested recently as a risk factor for several types of cancer in epidemiologic studies. This alarming news and controversial declarations by scientific organizations and general media have made necessary a systematic evaluation of the epidemiologic evidence. Objective To examine the association between personal use of hair dyes and relative risk of cancer. Data Sources We retrieved studies published in any language by systematically searching the MEDLINE (1966-January 2005), EMBASE, LILACS, and ISI Proceedings computerized databases and by manually examining the references of the original articles, reviews, and monographs retrieved. Study Selection We included cohort and case-control studies reporting relative risk estimates and 95% confidence intervals (CIs) (or data to calculate them) of personal hair dye use and cancer. We excluded studies that dealt with occupational exposure. We carried out separate analyses for bladder, breast, and hematopoietic cancers and cancers of other sites. Seventy-nine studies were included of 210 articles identified in the search. Data Extraction Data were extracted independently by 2 investigators. We used a standardized questionnaire to record information on study design, sample size, type of controls, year of publication, adjustment factors, and relative risks of cancer among ever users of hair dyes. When possible, we extracted association measures on use of permanent dyes and extensive use (>200 lifetime episodes of dye use). Data Synthesis Study-specific relative risks were weighted by the inverse of their variance to obtain fixed- and random-effects pooled estimates. The pooled relative risk for ever users of hair dyes was 1.06 (95% Cl, 0.95-1.18) for breast cancer (14 studies), 1.01 (95% Cl, 0.89-1.14) for bladder cancer (10 studies), and 1.15 (95% Cl, 1.05-1.27) for hematopoietic cancers (40 studies). Other cancers were examined by only 1 or 2 studies, of which the pooled or single relative risk was elevated for brain cancer, ovarian cancer, and cancer of the salivary glands. No effect was observed for use of permanent dyes or for extensive use. Conclusions We did not find strong evidence of a marked increase in the risk of cancer among personal hair dye users. Some aspects related to hematopoietic cancer and other cancers that have shown evidence of increased risk in 1 or 2 studies should be investigated further.	Univ Santiago de Compostela, Fac Med, Dept Prevent Med, Santiago De Compostela, Spain; Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; Vancouver Coastal Hlth Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada	Universidade de Santiago de Compostela; McGill University; Royal Victoria Hospital; Vancouver Coastal Health Research Institute	Takkouche, B (corresponding author), Univ Santiago de Compostela, Fac Med, Dept Prevent Med, Santiago De Compostela, Spain.	mrbahi@usc.es		Montes Martinez, Agustin/0000-0003-0474-8393				AHLBOM A, 1986, AM J EPIDEMIOL, V124, P334, DOI 10.1093/oxfordjournals.aje.a114393; Altekruse SF, 1999, CANCER CAUSE CONTROL, V10, P617, DOI 10.1023/A:1008926027805; AMES BN, 1975, P NATL ACAD SCI USA, V72, P2423, DOI 10.1073/pnas.72.6.2423; Andrew AS, 2004, INT J CANCER, V109, P581, DOI 10.1002/ijc.11729; *BBC NEWS, 2002, HAIR DYE CANC AL; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Bjork J, 2001, OCCUP ENVIRON MED, V58, P722, DOI 10.1136/oem.58.11.722; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOICE JD, 1995, JAMA-J AM MED ASSOC, V274, P394, DOI 10.1001/jama.274.5.394; BROWN LM, 1992, AM J PUBLIC HEALTH, V82, P1673, DOI 10.2105/AJPH.82.12.1673; BURCH JD, 1987, J NATL CANCER I, V78, P601; CANTOR KP, 1988, AM J PUBLIC HEALTH, V78, P570, DOI 10.2105/AJPH.78.5.570; Chiu BCH, 2004, CANCER EPIDEM BIOMAR, V13, P525; Cook LS, 1999, CANCER CAUSE CONTROL, V10, P551, DOI 10.1023/A:1008903126798; Correa A, 2000, CANCER INVEST, V18, P467, DOI 10.3109/07357900009032818; Correa A, 2000, CANCER INVEST, V18, P366, DOI 10.3109/07357900009012180; Costa-Bouzas J, 2001, COMPUT METH PROG BIO, V64, P101, DOI 10.1016/S0169-2607(00)00087-0; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gago-Dominguez M, 2001, INT J CANCER, V91, P575, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1092>3.0.CO;2-S; GREEN A, 1987, JNCI-J NATL CANCER I, V79, P253; GRODSTEIN F, 1994, J NATL CANCER I, V86, P1466, DOI 10.1093/jnci/86.19.1466; HARTGE P, 1982, CANCER RES, V42, P4784; Henley SJ, 2001, INT J CANCER, V94, P903, DOI 10.1002/ijc.1547; HENNEKENS CH, 1979, LANCET, V1, P1390; HERRINTON LJ, 1994, AM J PUBLIC HEALTH, V84, P1142, DOI 10.2105/AJPH.84.7.1142; Holly EA, 1998, AM J PUBLIC HEALTH, V88, P1767, DOI 10.2105/AJPH.88.12.1767; HOLMAN CD, 1985, BRIT J CANCER, V52, P135; HOLMAN CDJ, 1983, BRIT J CANCER, V48, P599, DOI 10.1038/bjc.1983.234; HOWE GR, 1980, JNCI-J NATL CANCER I, V64, P701; JAIN M, 1977, CAN MED ASSOC J, V117, P1131; KINLEN LJ, 1977, BRIT MED J, V2, P366, DOI 10.1136/bmj.2.6083.366; KOENIG KL, 1991, AM J EPIDEMIOL, V133, P985, DOI 10.1093/oxfordjournals.aje.a115818; LAVECCHIA C, 1995, EUR J CANCER PREV, V4, P31; LINOS A, 1994, J EPIDEMIOL, V139, pS46; MARKOVICDENIC LJ, 1995, NEOPLASMA, V42, P79; MARKOWITZ JA, 1985, AM J EPIDEMIOL, V122, P523; MEADOWS M, 2001, FDA CONSUMER     JAN; MELE A, 1994, AM J EPIDEMIOL, V139, P609, DOI 10.1093/oxfordjournals.aje.a117050; Miligi L, 1999, AM J IND MED, V36, P60, DOI 10.1002/(SICI)1097-0274(199907)36:1<60::AID-AJIM9>3.0.CO;2-Z; Miller AB, 2001, INT J CANCER, V94, P901, DOI 10.1002/ijc.1562; Nakata S, 1995, Hinyokika Kiyo, V41, P969; Nasca P C, 1992, Ann Epidemiol, V2, P577, DOI 10.1016/1047-2797(92)90002-8; NASCA PC, 1980, J NATL CANCER I, V64, P23; NEUTEL CI, 1978, CAN MED ASSOC J, V119, P307; NOMURA A, 1989, AM J EPIDEMIOL, V130, P1159, DOI 10.1093/oxfordjournals.aje.a115443; Ohno Y, 1985, Natl Cancer Inst Monogr, V69, P229; OSTERLIND A, 1988, INT J CANCER, V42, P825, DOI 10.1002/ijc.2910420604; Petro-Nustas W, 2002, J NURS SCHOLARSHIP, V34, P19, DOI 10.1111/j.1547-5069.2002.00019.x; Rauscher GH, 2004, AM J EPIDEMIOL, V160, P19, DOI 10.1093/aje/kwh166; Schroeder JC, 2002, CANCER CAUSE CONTROL, V13, P159, DOI 10.1023/A:1014397920185; *SCI COMM COSM PRO, 2004, SCCNFP079704; SHORE RE, 1979, J NATL CANCER I, V62, P277; Silverman DT, 1996, CANC EPIDEMIOLOGY PR, P1156; SONTAG JM, 1981, JNCI-J NATL CANCER I, V66, P591; SPITZ MR, 1990, ARCH OTOLARYNGOL, V116, P1163; STAVRAKY KM, 1981, BRIT J CANCER, V43, P236, DOI 10.1038/bjc.1981.35; STAVRAKY KM, 1979, J NATL CANCER I, V63, P941; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; SUTTON AJ, 2000, METHODS METAANALYSIS, P115; Takkouche B, 1999, AM J EPIDEMIOL, V150, P206; Tavani A, 2005, INT J CANCER, V113, P629, DOI 10.1002/ijc.20565; THUN MJ, 1994, JNCI-J NATL CANCER I, V86, P210, DOI 10.1093/jnci/86.3.210; TZONOU A, 1993, INT J CANCER, V55, P408, DOI 10.1002/ijc.2910550313; WYNDER EL, 1983, JNCI-J NATL CANCER I, V71, P481; ZAHM SH, 1992, AM J PUBLIC HEALTH, V82, P990, DOI 10.2105/AJPH.82.7.990; Zhang YW, 2004, AM J EPIDEMIOL, V159, P148, DOI 10.1093/aje/kwh033; Zheng T, 2002, EUR J CANCER, V38, P1647, DOI 10.1016/S0959-8049(02)00138-7; 1993, IARC MONOGR EVAL CAR, V57, P43	68	114	121	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2516	2525		10.1001/jama.293.20.2516	http://dx.doi.org/10.1001/jama.293.20.2516			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929BX	15914752				2022-12-28	WOS:000229318200026
J	Carter, NJ; Cross, RA				Carter, NJ; Cross, RA			Mechanics of the kinesin step	NATURE			English	Article							HAND-OVER-HAND; 8-NM STEP; ATP HYDROLYSIS; MYOSIN MOTOR; FORCE CLAMP; MOLECULES; CYCLE; PROCESSIVITY; MICROSCOPY; DEPENDENCE	Kinesin is a molecular walking machine that organizes cells by hauling packets of components directionally along microtubules. The physical mechanism that impels directional stepping is uncertain. We show here that, under very high backward loads, the intrinsic directional bias in kinesin stepping can be reversed such that the motor walks sustainedly backwards in a previously undescribed mode of ATP-dependent backward processivity. We find that both forward and backward 8-nm steps occur on the microsecond timescale and that both occur without mechanical substeps on this timescale. The data suggest an underlying mechanism in which, once ATP has bound to the microtubule-attached head, the other head undergoes a diffusional search for its next site, the outcome of which can be biased by an applied load.	Marie Curie Res Inst, Mol Motors Grp, Surrey RH8 0TL, England		Cross, RA (corresponding author), Marie Curie Res Inst, Mol Motors Grp, Surrey RH8 0TL, England.	r.cross@mcri.ac.uk	Cross, Robert A/F-1798-2011	Cross, Robert A/0000-0002-0004-7832				Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; Cross RA, 2004, TRENDS BIOCHEM SCI, V29, P301, DOI 10.1016/j.tibs.2004.04.010; Fisher ME, 2001, P NATL ACAD SCI USA, V98, P7748, DOI 10.1073/pnas.141080498; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Howard J., 2001, MECH MOTOR PROTEINS; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1957, PROGR BIOPHYS BIOPHY, V7, P257; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kawaguchi K, 2000, BIOCHEM BIOPH RES CO, V272, P895, DOI 10.1006/bbrc.2000.2856; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; Nishiyama M, 2002, NAT CELL BIOL, V4, P790, DOI 10.1038/ncb857; Nishiyama M, 2003, BIOSYSTEMS, V71, P145, DOI 10.1016/S0303-2647(03)00122-9; Nishiyama M, 2001, NAT CELL BIOL, V3, P425, DOI 10.1038/35070116; Okada Y, 2003, NATURE, V424, P574, DOI 10.1038/nature01804; Reconditi M, 2004, NATURE, V428, P578, DOI 10.1038/nature02380; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thomas N, 2002, P ROY SOC B-BIOL SCI, V269, P2363, DOI 10.1098/rspb.2002.2117; Tsiavaliaris G, 2004, NATURE, V427, P558, DOI 10.1038/nature02303; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753	35	557	571	2	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					308	312		10.1038/nature03528	http://dx.doi.org/10.1038/nature03528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902249				2022-12-28	WOS:000229185000037
J	Norris, JM; Barriga, K; Hoffenberg, EJ; Taki, I; Miao, DM; Haas, JE; Emery, LM; Sokol, RJ; Erlich, HA; Eisenbarth, GS; Rewers, M				Norris, JM; Barriga, K; Hoffenberg, EJ; Taki, I; Miao, DM; Haas, JE; Emery, LM; Sokol, RJ; Erlich, HA; Eisenbarth, GS; Rewers, M			Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE TRANSGLUTAMINASE; CHILDREN; OATS; AUTOANTIBODIES; ANTIBODIES; GLIADIN; MARKERS	Context While gluten ingestion is responsible for the signs and symptoms of celiac disease, it is not known what factors are associated with initial appearance of the disease. Objective To examine whether the timing of gluten exposure in the infant diet was associated with the development of celiac disease autoimmunity (CDA). Design, Setting, and Patients Prospective observational study conducted in Denver, Colo, from 1994-2004 of 1560 children at increased risk for celiac disease or type 1 diabetes, as defined by possession of either HLA-DR3 or DR4 alleles, or having a first-degree relative with type 1 diabetes. The mean follow-up was 4.8 years. Main Outcome Measure Risk of CDA defined as being positive for tissue transglutaminase (tTG) autoantibody on 2 or more consecutive visits or being positive for tTG once and having a positive small bowel biopsy for celiac disease, by timing of introduction of gluten-containing foods into the diet Results Fifty-one children developed CDA. Findings adjusted for HLA-DR3 status indicated that children exposed to foods containing wheat, barley, or rye (gluten-containing foods) in the first 3 months of life Q [6%] CDA positive vs 40 [3%] CDA negative) had a 5-fold increased risk of CDA compared with children exposed to gluten-containing foods at 4 to 6 months (12 [23%] CDA positive vs 574 [38%) CDA negative) (hazard ratio [HR], 5.17; 95% confidence interval [CI], 1.44-18.57). Children not exposed to gluten until the seventh month or later (36 [71%] CDA positive vs 895 [59%] CDA negative) had a marginally increased risk of CDA compared with those exposed at 4 to 6 months (HR, 1.87; 95% Cl, 0.97-3.60). After restricting our case group to only the 25 CDA-positive children who had biopsy-diagnosed celiac disease, initial exposure to wheat, barley, or rye in the first 3 months Q [12%] CDA positive vs 40 [3%] CDA negative) or in the seventh month or later (19 [76%] CDA positive vs 912 [59%] CDA negative) significantly increased risk of CDA compared with exposure at 4 to 6 months (3 [12%] CDA positive vs 583 [38%] CDA negative) (HR, 22.97; 95% Cl, 4,55-115.93; P=.001; and HR, 3.98; 95% Cl, 1.18-13.46; P=.04, respectively). Conclusion Timing of introduction of gluten into the infant diet is associated with the appearance of CDA in children at increased risk for the disease.	Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Colorado, Dept Pathol, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO 80262 USA; Univ Colorado, Childrens Hosp, Dept Pediat, Sect Pediat Gastroenterol Hepatol & Nutr, Denver, CO 80262 USA; Univ Colorado, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA; Roche Mol Syst Inc, Dept Human Genet, Alameda, CA USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver; Children's Hospital Colorado; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver; Roche Holding	Norris, JM (corresponding author), Univ Colorado, Dept Prevent Med & Biometr, 4200 E 9th Ave,Box B119, Denver, CO 80262 USA.	jill.norris@uchsc.edu			NCRR NIH HHS [M01RR00069] Funding Source: Medline; NIAID NIH HHS [AI 50864] Funding Source: Medline; NIDDK NIH HHS [DK49654, R01-DK32493, P30 DK 57516, DK32083, DK50979] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI050864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050979, P30DK057516, R01DK049654, R01DK032083, R01DK032493, R37DK032083] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison P. D, 1995, SURVIVAL ANAL USING; Ascher H, 1997, ARCH DIS CHILD, V76, P113, DOI 10.1136/adc.76.2.113; AURICCHIO S, 1983, J PEDIATR GASTR NUTR, V2, P428, DOI 10.1097/00005176-198302030-00006; Baldas V, 2000, GUT, V47, P628, DOI 10.1136/gut.47.5.628; Bao F, 1999, J AUTOIMMUN, V13, P143, DOI 10.1006/jaut.1999.0303; Bonamico M, 2001, AM J GASTROENTEROL, V96, P1536; Clemente MG, 2003, GUT, V52, P218, DOI 10.1136/gut.52.2.218; Collin P, 2002, ENDOCR REV, V23, P464, DOI 10.1210/er.2001-0035; Dieterich W, 1999, J INVEST DERMATOL, V113, P133, DOI 10.1046/j.1523-1747.1999.00627.x; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; FalthMagnusson K, 1996, PEDIAT ALLERG IMM-UK, V7, P1, DOI 10.1111/j.1399-3038.1996.tb00098.x; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; GRECO L, 1988, J PEDIATR GASTR NUTR, V7, P395, DOI 10.1097/00005176-198805000-00013; Hill ID, 2005, J PEDIATR GASTR NUTR, V40, P1, DOI 10.1097/00005176-200501000-00001; Hoffenberg EJ, 2000, J PEDIATR-US, V137, P356, DOI 10.1067/mpd.2000.107582; Hoffenberg EJ, 2000, J PEDIATR-US, V137, P361, DOI 10.1067/mpd.2000.109003; Hoffenberg EJ, 2003, J PEDIATR-US, V143, P308, DOI 10.1067/S0022-3476(03)00282-8; Hogberg L, 2004, GUT, V53, P649, DOI 10.1136/gut.2003.026948; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914, DOI 10.1093/ajcn/75.5.914; JANATUINEN EK, 1995, NEW ENGL J MED, V333, P1033, DOI 10.1056/NEJM199510193331602; KLEINMAN RE, 1998, PEDIAT NUTR HDB, P43; Li RW, 2003, PEDIATRICS, V111, P1198; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Peters U, 2001, ANN NUTR METAB, V45, P135, DOI 10.1159/000046720; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; Schapira M, 2003, ACTA GASTRO-ENT BELG, V66, P234; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Srinivasan U, 1996, BRIT MED J, V313, P1300, DOI 10.1136/bmj.313.7068.1300; Stern M, 2000, J PEDIATR GASTR NUTR, V31, P513, DOI 10.1097/00005176-200011000-00012; Storsrud S, 2003, EUR J CLIN NUTR, V57, P163, DOI 10.1038/sj.ejcn.1601525; Sulkanen S, 1998, GASTROENTEROLOGY, V115, P1322, DOI 10.1016/S0016-5085(98)70008-3; Ventura A, 2000, J PEDIATR-US, V137, P263, DOI 10.1067/mpd.2000.107160; Wieser H, 1998, CHANGING FEATURES OF COELIAC DISEASE, P25; Ziegler AG, 2003, JAMA-J AM MED ASSOC, V290, P1721, DOI 10.1001/jama.290.13.1721	38	305	320	1	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2343	2351		10.1001/jama.293.19.2343	http://dx.doi.org/10.1001/jama.293.19.2343			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900004				2022-12-28	WOS:000229120600021
J	Rowntree, R				Rowntree, R			Minnie made me out a liar	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Triad Hosp Inc, Plano, TX 75024 USA		Rowntree, R (corresponding author), Triad Hosp Inc, 5800 Tennyson Pkwy, Plano, TX 75024 USA.	bob.rowntree@triadhospitals.com							0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2005	142	10					869	870		10.7326/0003-4819-142-10-200505170-00016	http://dx.doi.org/10.7326/0003-4819-142-10-200505170-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926CE	15897540				2022-12-28	WOS:000229099600012
J	Harding, A				Harding, A			Katherine Austin Lathrop - Obituary	LANCET			English	Biographical-Item												anne_harding@yahoo.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 30	2005	365	9470					1536	1536		10.1016/S0140-6736(05)66444-6	http://dx.doi.org/10.1016/S0140-6736(05)66444-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	921HL	15895492				2022-12-28	WOS:000228754800015
J	Nijveldtl, R; Beekl, AM; van Gorp, JMHH; van Rossum, AC				Nijveldtl, R; Beekl, AM; van Gorp, JMHH; van Rossum, AC			Pericardial cyst	LANCET			English	Editorial Material									VU Univ Med Ctr, Dept Cardiol, NL-1081 Amsterdam, Netherlands; Diakonessen Hosp, Utrecht, Netherlands	Vrije Universiteit Amsterdam; Diakonessenhuis	Nijveldtl, R (corresponding author), VU Univ Med Ctr, Dept Cardiol, NL-1081 Amsterdam, Netherlands.	r.nijveldt@vumc.nl							0	4	4	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1960	1960		10.1016/S0140-6736(05)66664-0	http://dx.doi.org/10.1016/S0140-6736(05)66664-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936424				2022-12-28	WOS:000229587800032
J	Maziak, W				Maziak, W			Science in the Arab world: Vision of glories beyond	SCIENCE			English	Editorial Material									Syrian Ctr Tobacco Studies, Aleppo, Syria; Inst Epidemiol & Social Med, Munster, Germany		Maziak, W (corresponding author), Syrian Ctr Tobacco Studies, POB 16542, Aleppo, Syria.	maziak@net.sy	Maziak, Wasim/V-7567-2017					Al-Khader AA, 2004, SAUDI MED J, V25, P1323; Masood E, 2002, NATURE, V416, P120, DOI 10.1038/416120a; Maziak Wasim, 2003, Health Care Women Int, V24, P313; Tadmouri GO, 2003, LANCET, V362, P1766, DOI 10.1016/S0140-6736(03)14868-4	4	23	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1416	1418		10.1126/science.1114330	http://dx.doi.org/10.1126/science.1114330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933186				2022-12-28	WOS:000229619300035
J	Wilcove, DS				Wilcove, DS			Rediscovery of the ivory-billed woodpecker	SCIENCE			English	Editorial Material									Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA	Princeton University	Wilcove, DS (corresponding author), Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA.	dwilcove@princeton.edu		Wilcove, David S./0000-0002-1354-0503				*AM BIRD CONS, 2004, HAW BIRD LIK EXT GOV; Berger A. J., 1981, HAWAIIAN BIRDLIFE; BirdLife International, 2004, STAT WORLDS BIRDS IN; BirdLife International, 2000, THREAT BIRDS WORLD; Fitzpatrick JW, 2005, SCIENCE, V308, P1460, DOI 10.1126/science.1114103; FOUNTAIN H, 2005, NY TIMES        0501; Groves C.R., 2003, DRAFTING CONSERVATIO; Reynolds MH, 2001, STUD AVIAN BIOL-SER, P133; Tanner JT., 1942, 1 NAT AUD SOC; Wilcove D. S., 2000, CONDORS SHADOW LOSS; RESTORING BIG WOODS; 1990, FED REG, V55, P51112	12	5	6	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1422	1423		10.1126/science.1114507	http://dx.doi.org/10.1126/science.1114507			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933190				2022-12-28	WOS:000229619300039
J	Rauhut, OWM; Remes, K; Fechner, R; Cladera, G; Puerta, P				Rauhut, OWM; Remes, K; Fechner, R; Cladera, G; Puerta, P			Discovery of a short-necked sauropod dinosaur from the Late Jurassic period of Patagonia	NATURE			English	Article								Sauropod dinosaurs are one of the most conspicuous groups of Mesozoic terrestrial vertebrates. They show general trends towards an overall increase in size and elongation of the neck, by means of considerable elongation of the length of individual vertebrae and a cervical vertebra count that, in some cases, increases to 19 (ref. 1). The long neck is a particular hallmark of sauropod dinosaurs and is usually regarded as a key feeding adaptation(2). Here we describe a new dicraeosaurid sauropod, from the latest Jurassic period of Patagonia, that has a particularly short neck. With a neck that is about 40% shorter than in other known dicraeosaurs(3,4), this taxon demonstrates a trend opposite to that seen in most sauropods and indicates that the ecology of dicraeosaurids might have differed considerably from that of other sauropods. The new taxon indicates that there was a rapid radiation and dispersal of dicraeosaurids in the Late Jurassic of the Southern Hemisphere, after the separation of Gondwana from the northern continents by the late Middle Jurassic.	Bayer Staatssammlung Palaontol & Geol, D-80333 Munich, Germany; Museo Paleontol Egidio Feruglio, RA-9100 Trelew, Argentina		Rauhut, OWM (corresponding author), Bayer Staatssammlung Palaontol & Geol, Richard Wagner Str 10, D-80333 Munich, Germany.	o.rauhut@lrz.uni-muenchen.de	Rauhut, Oliver/AAG-1029-2020; Remes, Kristian/B-7173-2008	Rauhut, Oliver/0000-0003-3958-603X				BAKKER RT, 1978, NATURE, V274, P661, DOI 10.1038/274661a0; Barrett Paul M., 1995, P107; Bonaparte JF, 1999, AMEGHINIANA, V36, P115; Calvo Jorge O., 1994, Gaia, V10, P183; Christian Andreas, 2002, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V5, P271; Christiansen Per, 2000, Historical Biology, V14, P137; FOSTER JR, 2001, MESA SW MUSEUM B, V8, P47; Janensch W., 1929, PALAEONTOGRAPHICA S7, V2, P35; Janensch W., 1914, ARCH BIONTOLOGIE, V3, P81; Janensch WJ., 1961, PALAEONTOGRAPHICA S, P177; Maier G., 2003, AFRICAN DINOSAURS UN; MARTIN J, 1987, 4 S MES TERR EC SHOR, P150; Ouyang H., 2002, 1 MAMENCHISAURID SKE, P111; Paul Gregory S., 1997, P129; Proserpio C.A., 1987, DIRECCION NACL MINER, V201, P1; PUCHURCH P, 2000, EVOLUTION HERBIVORY, P79; REMES K, 2004, GEOBIOLOGIE, P195; SALGADO L, 1991, Ameghiniana, V28, P333; Stevens KA, 1999, SCIENCE, V284, P798, DOI 10.1126/science.284.5415.798; Upchurch P, 2004, DINOSAURIA, 2ND EDITION, P259; Weishampel DB, 2004, DINOSAURIA, 2ND EDITION, P517; Wilson JA, 1999, J VERTEBR PALEONTOL, V19, P639, DOI 10.1080/02724634.1999.10011178; Wilson JA, 2002, ZOOL J LINN SOC-LOND, V136, P217	23	115	124	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					670	672		10.1038/nature03623	http://dx.doi.org/10.1038/nature03623			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931221				2022-12-28	WOS:000229476200049
J	Springel, V; White, SDM; Jenkins, A; Frenk, CS; Yoshida, N; Gao, L; Navarro, J; Thacker, R; Croton, D; Helly, J; Peacock, JA; Cole, S; Thomas, P; Couchman, H; Evrard, A; Colberg, J; Pearce, F				Springel, V; White, SDM; Jenkins, A; Frenk, CS; Yoshida, N; Gao, L; Navarro, J; Thacker, R; Croton, D; Helly, J; Peacock, JA; Cole, S; Thomas, P; Couchman, H; Evrard, A; Colberg, J; Pearce, F			Simulations of the formation, evolution and clustering of galaxies and quasars	NATURE			English	Article							DIGITAL SKY SURVEY; PROBE WMAP OBSERVATIONS; REDSHIFT SURVEY; POWER SPECTRUM; Z-GREATER-THAN-5.7 QUASARS; MASS FUNCTION; UNIVERSE; LAMBDA; STATISTICS; DISCOVERY	The cold dark matter model has become the leading theoretical picture for the formation of structure in the Universe. This model, together with the theory of cosmic inflation, makes a clear prediction for the initial conditions for structure formation and predicts that structures grow hierarchically through gravitational instability. Testing this model requires that the precise measurements delivered by galaxy surveys can be compared to robust and equally precise theoretical calculations. Here we present a simulation of the growth of dark matter structure using 2,160 3 particles, following them from redshift z = 127 to the present in a cube-shaped region 2,230 billion lightyears on a side. In postprocessing, we also follow the formation and evolution of the galaxies and quasars. We show that baryon-induced features in the initial conditions of the Universe are reflected in distorted form in the low-redshift galaxy distribution, an effect that can be used to constrain the nature of dark energy with future generations of observational surveys of galaxies.	Max Planck Inst Astrophys, D-85740 Garching, Germany; Univ Durham, Dept Phys, Inst Computat Cosmol, Durham DH1 3LE, England; Nagoya Univ, Dept Phys, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Victoria, Dept Phys & Astron, Victoria, BC V8P 5C2, Canada; McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada; Univ Edinburgh, Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland; Univ Sussex, Dept Phys & Astron, Brighton BN1 9QH, E Sussex, England; Univ Michigan, Dept Phys & Astron, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA; Univ Nottingham, Dept Phys & Astron, Nottingham NG7 2RD, England	Max Planck Society; Durham University; Nagoya University; University of Victoria; McMaster University; University of Edinburgh; University of Sussex; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Nottingham	Springel, V (corresponding author), Max Planck Inst Astrophys, Karl Schwarzschild Str 1, D-85740 Garching, Germany.		Gao, Liang/O-6598-2014; Frenk, Carlos/Z-3084-2019; Pearce, Frazer/H-1503-2012; White, Simon/Y-2399-2019; Yoshida, Naoki/A-4305-2011; Croton, Darren/I-8636-2017	White, Simon/0000-0002-1061-6154; Croton, Darren/0000-0002-5009-512X; Springel, Volker/0000-0001-5976-4599; Peacock, John/0000-0002-1168-8299; Yoshida, Naoki/0000-0001-7925-238X; Navarro, Julio/0000-0003-3862-5076; Cole, Shaun/0000-0002-5954-7903; Pearce, Frazer/0000-0002-2383-9250; Thomas, Peter/0000-0001-6888-6483; Jenkins, Adrian/0000-0003-4389-2232; Frenk, Carlos/0000-0002-2338-716X; Evrard, August/0000-0002-4876-956X; Helly, John/0000-0002-0647-4755; Gao, Liang/0000-0002-9276-917X				Adelberger KL, 1998, ASTROPHYS J, V505, P18, DOI 10.1086/306162; BARDEEN JM, 1986, ASTROPHYS J, V304, P15, DOI 10.1086/164143; BARNES J, 1986, NATURE, V324, P446, DOI 10.1038/324446a0; Baugh CM, 1996, MON NOT R ASTRON SOC, V283, P1361, DOI 10.1093/mnras/283.4.1361; Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; Benson AJ, 2000, MON NOT R ASTRON SOC, V311, P793, DOI 10.1046/j.1365-8711.2000.03101.x; Blake C, 2003, ASTROPHYS J, V594, P665, DOI 10.1086/376983; Bond JR, 1996, NATURE, V380, P603, DOI 10.1038/380603a0; Colberg JM, 2000, MON NOT R ASTRON SOC, V319, P209, DOI 10.1046/j.1365-8711.2000.03832.x; COLE S, 1994, MON NOT R ASTRON SOC, V271, P781, DOI 10.1093/mnras/271.4.781; COLE S, UNPUB MON NOT R ASTR; Colless M, 2001, MON NOT R ASTRON SOC, V328, P1039, DOI 10.1046/j.1365-8711.2001.04902.x; DAVIS M, 1985, ASTROPHYS J, V292, P371, DOI 10.1086/163168; de Bernardis P, 2000, NATURE, V404, P955, DOI 10.1038/35010035; Eastwood J. W., 1981, COMPUTER SIMULATION; Efstathiou G., 1988, MNRAS, V230, P5, DOI [10.1093/mnras/230.1.5P, DOI 10.1093/MNRAS/230.1.5P]; EISENSTEIN DJ, UNPUB ASTROPHYS J; Evrard AE, 2002, ASTROPHYS J, V573, P7, DOI 10.1086/340551; Fan XH, 2003, ASTRON J, V125, P1649, DOI 10.1086/368246; Fan XH, 2004, ASTRON J, V128, P515, DOI 10.1086/422434; Hawkins E, 2003, MON NOT R ASTRON SOC, V346, P78, DOI 10.1046/j.1365-2966.2003.07063.x; Jenkins A, 2001, MON NOT R ASTRON SOC, V321, P372, DOI 10.1046/j.1365-8711.2001.04029.x; Jenkins A, 1998, ASTROPHYS J, V499, P20, DOI 10.1086/305615; KAUFFMANN G, 1993, MON NOT R ASTRON SOC, V264, P201, DOI 10.1093/mnras/264.1.201; Kauffmann G, 2000, MON NOT R ASTRON SOC, V311, P576, DOI 10.1046/j.1365-8711.2000.03077.x; Kauffmann G, 1999, MON NOT R ASTRON SOC, V303, P188, DOI 10.1046/j.1365-8711.1999.02202.x; Madgwick DS, 2003, MON NOT R ASTRON SOC, V344, P847, DOI 10.1046/j.1365-8711.2003.06861.x; Mauskopf PD, 2000, ASTROPHYS J, V536, pL59, DOI 10.1086/312743; Merritt D, 2001, MON NOT R ASTRON SOC, V320, pL30, DOI 10.1046/j.1365-8711.2001.04165.x; Norberg P, 2001, MON NOT R ASTRON SOC, V328, P64, DOI 10.1046/j.1365-8711.2001.04839.x; Padilla ND, 2003, MON NOT R ASTRON SOC, V343, P796, DOI 10.1046/j.1365-8711.2003.06725.x; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; PRESS WH, 1974, ASTROPHYS J, V187, P425, DOI 10.1086/152650; Reed D, 2003, MON NOT R ASTRON SOC, V346, P565, DOI 10.1046/j.1365-2966.2003.07113.x; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Seljak U, 1996, ASTROPHYS J, V469, P437, DOI 10.1086/177793; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Springel V, 2001, MON NOT R ASTRON SOC, V328, P726, DOI 10.1046/j.1365-8711.2001.04912.x; Springel V, 2001, NEW ASTRON, V6, P79, DOI 10.1016/S1384-1076(01)00042-2; Tremaine S, 2002, ASTROPHYS J, V574, P740, DOI 10.1086/341002; Wambsganss J, 2004, ASTROPHYS J, V606, pL93, DOI 10.1086/421459; Weinberg DH, 2004, ASTROPHYS J, V601, P1, DOI 10.1086/380481; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WHITE SDM, 2006, COSMOLOGY LARGE SCAL, pCH8; XU GH, 1995, ASTROPHYS J SUPPL S, V98, P355, DOI 10.1086/192166; Zehavi I, 2004, ASTROPHYS J, V608, P16, DOI 10.1086/386535; Zehavi I, 2002, ASTROPHYS J, V571, P172, DOI 10.1086/339893	50	3483	3506	1	151	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					629	636		10.1038/nature03597	http://dx.doi.org/10.1038/nature03597			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931216	Green Submitted			2022-12-28	WOS:000229476200041
J	Burnett, AL				Burnett, AL			Erectile dysfunction following radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; RETROPUBIC PROSTATECTOMY; SEXUAL FUNCTION; SILDENAFIL CITRATE; RADIATION-THERAPY; CANCER; ALPROSTADIL; RECOVERY; SATISFACTION; RADIOTHERAPY	Erectile dysfunction following radical prostatectomy for clinically localized prostate cancer is a known potential complication of the surgery. Because prostate cancer is diagnosed today more frequently than in the past and because the diagnosis is made in increasingly younger men, there is an urgent need to develop effective interventions that preserve erectile function after surgery. In this presentation, a 51-year-old man with adenocarcinoma of the prostate underwent a bilateral nerve-sparing radical prostatectomy, after which he lost natural erectile function for approximately 9 months. The case highlights the fact that following surgery in which the nerve-sparing radical prostatectomy technique is used, between 60% to 85% of men eventually recover erectile function. This constitutes a dramatic improvement over an earlier era, when postprostatectomy erectile dysfunction was the nearly universal rule. The case also emphasizes that despite expert application of the nerve-sparing prostatectomy technique, early recovery of natural erectile function is uncommon. Many patients experience erectile dysfunction for as long as 2 years after the procedure, requiring the use of erectile aids for sexual activity during this period until natural erections recover. Corrective, cause-specific advances such as neuromodulatory therapy offer valuable adjuncts to this surgery.	Johns Hopkins Univ, Sch Med, Johns Hopkins Med Inst, James Buchanan Brady Urol Inst,Dept Urol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Burnett, AL (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, 600 N Wolfe St,Marburg 407, Baltimore, MD 21287 USA.	aburnett@jhmi.edu						Burnett AL, 2002, WORLD J UROL, V20, P337, DOI 10.1007/s00345-002-0303-2; Burnett AL, 2003, UROLOGY, V61, P491, DOI 10.1016/S0090-4295(02)02271-9; Burnett AL, 1999, UROLOGY, V54, P392, DOI 10.1016/S0090-4295(99)00200-9; BUVAT J, 2004, SEXUAL MED SEXUAL DY, P605; Catalona WJ, 1999, J UROLOGY, V162, P433, DOI 10.1016/S0022-5347(05)68578-3; Chang DW, 2003, PLAST RECONSTR SURG, V111, P1174, DOI 10.1097/01.PRS.0000047606.84539.F1; Cooperberg MR, 2004, J UROLOGY, V171, P1393, DOI 10.1097/01.ju.0000107247.81471.06; Costabile RA, 1998, J UROLOGY, V160, P1325, DOI 10.1016/S0022-5347(01)62527-8; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Feng MI, 2000, J UROLOGY, V164, P1935, DOI 10.1016/S0022-5347(05)66922-4; Gilliland FD, 2001, J UROLOGY, V165, P846, DOI 10.1016/S0022-5347(05)66542-1; Gontero P, 2003, J UROLOGY, V169, P2166, DOI 10.1097/01.ju.0000064939.04658.15; Gralnek D, 2000, J UROLOGY, V163, P1166, DOI 10.1016/S0022-5347(05)67715-4; Hong EK, 1999, INT J IMPOT RES, V11, pS15, DOI 10.1038/sj.ijir.3900466; Hu JC, 2004, J UROLOGY, V171, P703, DOI 10.1097/01.ju.0000107964.61300.f6; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kendirci Muammer, 2004, Clin Prostate Cancer, V3, P87, DOI 10.3816/CGC.2004.n.017; Kim ED, 2001, UROLOGY, V58, P983, DOI 10.1016/S0090-4295(01)01403-0; Kim ED, 1999, J UROLOGY, V161, P188, DOI 10.1016/S0022-5347(01)62093-7; Kury P, 2001, CURR OPIN NEUROL, V14, P635, DOI 10.1097/00019052-200110000-00013; LAKIN MM, 1990, J UROLOGY, V143, P1138, DOI 10.1016/S0022-5347(17)40208-4; LIM AJ, 1995, J UROLOGY, V154, P1420, DOI 10.1016/S0022-5347(01)66881-2; Litwin MS, 1999, UROLOGY, V54, P503, DOI 10.1016/S0090-4295(99)00172-7; Lowentritt BH, 1999, J UROLOGY, V162, P1614, DOI 10.1016/S0022-5347(05)68179-7; Mantz CA, 1997, INT J RADIAT ONCOL, V37, P551, DOI 10.1016/S0360-3016(96)00555-X; McCammon KA, 1999, UROLOGY, V54, P509, DOI 10.1016/S0090-4295(99)00163-6; Montorsi F, 1997, J UROLOGY, V158, P1408, DOI 10.1016/S0022-5347(01)64227-7; Mulhall JP, 2002, J UROLOGY, V167, P1371, DOI 10.1016/S0022-5347(05)65303-7; Mydlo JH, 2000, EUR UROL, V38, P30, DOI 10.1159/000020248; Nehra A, 2002, INT J IMPOT RES, V14, pS38, DOI 10.1038/sj.ijir.3900795; Partin AW, 2001, UROLOGY, V58, P843, DOI 10.1016/S0090-4295(01)01441-8; Potosky AL, 2004, J NATL CANCER I, V96, P1358, DOI 10.1093/jnci/djh259; Poulter MO, 2004, NEUROSCIENCE, V128, P1, DOI 10.1016/j.neuroscience.2004.06.016; Rabbani F, 2000, J UROLOGY, V164, P1929, DOI 10.1016/S0022-5347(05)66921-2; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Sanchez-Ortiz RF, 2000, INT J IMPOT RES, V12, pS18, DOI 10.1038/sj.ijir.3900557; SIDI AA, 1990, J UROLOGY, V144, P1154, DOI 10.1016/S0022-5347(17)39679-9; User HM, 2003, J UROLOGY, V169, P1175, DOI 10.1097/01.ju.0000048974.47461.50; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Walsh PC, 2000, UROLOGY, V55, P58, DOI 10.1016/S0090-4295(99)00397-0; Walsh PC, 1998, J UROLOGY, V160, P2418, DOI 10.1016/S0022-5347(01)62202-X; Walsh PC, 2001, UROLOGY, V57, P1020, DOI 10.1016/S0090-4295(01)00987-6; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; Walsh PC., 2002, CAMPBELLS UROLOGY, V4, P3107; Zagaja GP, 2000, UROLOGY, V56, P631, DOI 10.1016/S0090-4295(00)00659-2; Zippe CD, 2000, UROLOGY, V55, P241, DOI 10.1016/S0090-4295(99)00441-0; EVALUATE EFFECTS GPI	47	56	59	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2005	293	21					2648	2653		10.1001/jama.293.21.2648	http://dx.doi.org/10.1001/jama.293.21.2648			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930UU	15928287				2022-12-28	WOS:000229443400024
J	Kohl, I; Bachmann, L; Mayer, E; Hallbrucker, A; Loerting, T				Kohl, I; Bachmann, L; Mayer, E; Hallbrucker, A; Loerting, T			Water behaviour - Glass transition in hyperquenched water?	NATURE			English	Editorial Material							LIQUID TRANSITION; TEMPERATURE; RELAXATION		Univ Innsbruck, Inst Gen Inorgan & Theoret Chem, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Phys Chem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kohl, I (corresponding author), Univ Innsbruck, Inst Gen Inorgan & Theoret Chem, A-6020 Innsbruck, Austria.	ingrid.kohl@uibk.ac.at	Loerting, Thomas/G-5274-2018	Loerting, Thomas/0000-0001-6694-3843				ANGELL CA, 1988, J NON-CRYST SOLIDS, V102, P205, DOI 10.1016/0022-3093(88)90133-0; Debenedetti P. G., 1996, METASTABLE LIQUIDS; HALLBRUCKER A, 1989, PHILOS MAG B, V60, P179, DOI 10.1080/13642818908211189; HODGE IM, 1982, MACROMOLECULES, V15, P762, DOI 10.1021/ma00231a016; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; JOHARI GP, 1987, NATURE, V330, P552, DOI 10.1038/330552a0; Kohl I, 2000, PHYS CHEM CHEM PHYS, V2, P1579, DOI 10.1039/a908688i; MOYNIHAN CT, 1976, J AM CERAM SOC, V59, P12, DOI 10.1111/j.1151-2916.1976.tb09376.x; Starr FW, 2003, PHYSICA A, V323, P51, DOI 10.1016/S0378-4371(03)00012-8; Yue YZ, 2004, NATURE, V427, P717, DOI 10.1038/nature02295	10	55	56	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					E1	E1		10.1038/nature03707	http://dx.doi.org/10.1038/nature03707			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917753	Bronze			2022-12-28	WOS:000229337800041
J	Levin, LI; Munger, KL; Rubertone, MV; Peck, CA; Lennette, ET; Spiegelman, D; Ascherio, A				Levin, LI; Munger, KL; Rubertone, MV; Peck, CA; Lennette, ET; Spiegelman, D; Ascherio, A			Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUCLEAR ANTIGEN; INFECTION; DISEASE; MONONUCLEOSIS; EXPOSURE; EBNA-2; LEVEL; RISK	Context Infection with Epstein-Barr virus (EBV) has been associated with an increased risk of multiple sclerosis (MS), but the temporal relationship remains unclear. Objective To determine whether antibodies to EBV are elevated before the onset of MS. Design, Setting, and Participants Nested case-control study conducted among more than 3 million US military personnel with blood samples collected between 1988 and 2000 and stored in the Department of Defense Serum Repository. Cases were identified as individuals granted temporary or permanent disability because of MS. For each case (n = 83), 2 controls matched by age, sex, race/ethnicity, and dates of blood sample collection were selected. Serial samples collected before the onset of symptoms were available for 69 matched case-control sets. Main Outcome Measures Antibodies including IgA against EBV viral capsid antigen (VCA), and IgG against VCA, nuclear antigens (EBNA complex, EBNA-1, and EBNA-2), diffuse and restricted early antigens, and cytomegalovirus. Results The average time between blood collection and MS onset was 4 years (range, <1-11 years). The strongest predictors of MS were serum levels of IgG antibodies to EBNA complex or EBNA-1. Among individuals who developed MS, serum antibody titers to EBNA complex were similar to those of controls before the age of 20 years (geometric mean titers: cases=245, controls=265), but 2- to 3-fold higher at age 25 years and older (cases=684, controls=282; P<.001). The risk of MS increased with these antibody titers; the relative risk (RR) in persons with EBNA complex titers of at least 1280 compared with those with titers less than 80 was 9.4 (95% confidence interval [CI], 2.5-35.4; P for trend <.001). In longitudinal analyses, a 4-fold increase in anti-EBNA complex or anti-EBNA-1 titers during the follow-up was associated with a 3-fold increase in MS risk (EBNA complex: RR,3.0; 95% Cl, 1.3-6.5; EBNA-1: RR, 3.0; 95% Cl, 1.2-7.3). No association was found between cytomegalovirus antibodies and MS. Conclusion These results suggest an age-dependent relationship between EBV infection and development of MS.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Walter Reed Army Inst Res, Div Prevent Med, Silver Spring, MD USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; USA, Army Med Surveillance Act, Ctr Hlth Promot & Prevent Med, Washington, DC 20310 USA; USA, Phys Disabil Agcy, Washington, DC 20310 USA; Virolab Inc, Berkeley, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Alberto.Ascherio@channing.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042194] Funding Source: NIH RePORTER; NINDS NIH HHS [NS42194] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alotaibi S, 2004, JAMA-J AM MED ASSOC, V291, P1875, DOI 10.1001/jama.291.15.1875; Ascherio A, 2000, EPIDEMIOLOGY, V11, P220, DOI 10.1097/00001648-200003000-00023; Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Brex PA, 1999, NEUROLOGY, V53, P1184, DOI 10.1212/WNL.53.6.1184; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; DETHE G, 1982, HERPESVIRUSES, V1, P25; Diggle P, 1994, ANAL LONGITUDINAL DA, VXI, P253; HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570; HENLE W, 1971, J INFECT DIS, V124, P58, DOI 10.1093/infdis/124.1.58; Hernan MA, 2001, EPIDEMIOLOGY, V12, P301, DOI 10.1097/00001648-200105000-00009; HORWITZ CA, 1985, J INFECT DIS, V151, P1150, DOI 10.1093/infdis/151.6.1150; James JA, 2001, ARTHRITIS RHEUM-US, V44, P1122, DOI 10.1002/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D; Kaslow, 1997, VIRAL INFECT HUMANS, P253; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; KUSUNOKI Y, 1993, MICROBIOL IMMUNOL, V37, P461, DOI 10.1111/j.1348-0421.1993.tb03237.x; LARSEN PD, 1985, NEUROLOGY, V35, P435, DOI 10.1212/WNL.35.3.435; LEIBOWITZ U, 1966, J NEUROL NEUROSUR PS, V29, P60, DOI 10.1136/jnnp.29.1.60; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; LENNETTE ET, 2000, CLIN VIROLOGY MANUAL, P140; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; Ponsonby AL, 2005, JAMA-J AM MED ASSOC, V293, P463, DOI 10.1001/jama.293.4.463; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; SHIRODARIA PV, 1987, ARCH NEUROL-CHICAGO, V44, P1237, DOI 10.1001/archneur.1987.00520240019006; Sitki-Green D, 2003, J VIROL, V77, P1840, DOI 10.1128/JVI.77.3.1840-1847.2003; Sundstrom P, 2004, NEUROLOGY, V62, P2277, DOI 10.1212/01.WNL.0000130496.51156.D7; Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820	30	291	299	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2496	2500		10.1001/jama.293.20.2496	http://dx.doi.org/10.1001/jama.293.20.2496			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929BX	15914750				2022-12-28	WOS:000229318200024
J	Liu, Y; Schiff, M; Czymmek, K; Talloczy, Z; Levine, B; Dinesh-Kumar, SP				Liu, Y; Schiff, M; Czymmek, K; Talloczy, Z; Levine, B; Dinesh-Kumar, SP			Autophagy regulates programmed cell death during the plant innate immune response	CELL			English	Article							MEDIATED RESISTANCE; PROTEINS; GENE; INHIBITION; DISEASE; MACROAUTOPHAGY; TUMORIGENESIS; DISRUPTION; SENESCENCE; SURVIVAL	The plant innate immune response includes the hypersensitive response (HR), a form of programmed cell death (PCD). PCD must be restricted to infection sites to prevent the HR from playing a pathologic rather than protective role. Here we show that plant BECLIN 1, an ortholog of the yeast and mammalian autophagy gene ATG6/VPS30/beclin 1, functions to restrict HR PCD to infection sites. Initiation of HR PCD is normal in BECLIN 1-deficient plants, but remarkably, healthy uninfected tissue adjacent to HR lesions and leaves distal to the inoculated leaf undergo unrestricted PCD. In the HR PCD response, autophagy is induced in both pathogen-infected cells and distal uninfected cells; this is reduced in BECLIN 1-deficient plants. The restriction of HR PCD also requires orthologs of other autophagy-related genes including P13K/VPS34, ATG3, and ATG7. Thus, the evolutionarily conserved autophagy pathway plays an essential role in plant innate immunity and negatively regulates PCD.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Delaware, Delaware Biotechnol Inst, Dept Biol Sci, Newark, DE 19711 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75390 USA	Yale University; University of Delaware; Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Dinesh-Kumar, SP (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	savithramma.dinesh-kumar@yale.edu	Dinesh-Kumar, Savithramma/E-1153-2011; Liu, Yule/E-5700-2010	Liu, Yule/0000-0002-4423-6045; Czymmek, Kirk/0000-0002-5471-7395	NIAID NIH HHS [AI 51367] Funding Source: Medline; NIGMS NIH HHS [GM 62625] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051367, R21AI051367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062625] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Bourett TM, 1999, PLANTA, V208, P472, DOI 10.1007/s004250050584; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Burch-Smith TM, 2004, PLANT J, V39, P734, DOI 10.1111/j.1365-313X.2004.02158.x; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Erickson FL, 1999, PLANT J, V18, P67, DOI 10.1046/j.1365-313X.1999.00426.x; Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; Lee CY, 2001, DEVELOPMENT, V128, P1443; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu YL, 2002, PLANT J, V31, P777, DOI 10.1046/j.1365-313X.2002.01394.x; Liu YL, 2004, J BIOL CHEM, V279, P2101, DOI 10.1074/jbc.M310029200; Liu YL, 2002, PLANT J, V30, P415, DOI 10.1046/j.1365-313X.2002.01297.x; Lu R, 2003, METHODS, V30, P296, DOI 10.1016/S1046-2023(03)00037-9; Marathe R, 2002, MOL PLANT PATHOL, V3, P167, DOI 10.1046/j.1364-3703.2002.00110.x; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Moriyasu Y, 2003, PLANT CELL PHYSIOL, V44, P795, DOI 10.1093/pcp/pcg100; Munafo DB, 2001, J CELL SCI, V114, P3619; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Surpin M, 2003, PLANT CELL, V15, P2885, DOI 10.1105/tpc.016121; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Yoshimoto K, 2004, PLANT CELL, V16, P2967, DOI 10.1105/tpc.104.025395; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	48	642	700	11	129	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					567	577		10.1016/j.cell.2005.03.007	http://dx.doi.org/10.1016/j.cell.2005.03.007			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907470	Bronze			2022-12-28	WOS:000229331200013
J	English, SK				English, SK			Saying good-bye	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												shamrock25@iname.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2321	2322						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15899986				2022-12-28	WOS:000229120600001
J	Nettleman, MD				Nettleman, MD			Multidrug-resistant tuberculosis - News from the front	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANCE; SURVEILLANCE; MUTATIONS; STRAINS		Michigan State Univ, Dept Med, E Lansing, MI 48823 USA	Michigan State University	Nettleman, MD (corresponding author), Michigan State Univ, Dept Med, B427 Clin Ctr, E Lansing, MI 48823 USA.	mary.nettleman@ht.msu.edu						Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753; Anonymous, 2005, Morbidity and Mortality Weekly Report, V54, P245; Cohen T, 2004, NAT MED, V10, P1117, DOI 10.1038/nm1110; Drobniewski F, 2005, JAMA-J AM MED ASSOC, V293, P2726, DOI 10.1001/jama.293.22.2726; Dubiley S, 2005, CLIN CHEM, V51, P447, DOI 10.1373/clinchem.2004.037309; Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818; Dye C, 2004, JAMA-J AM MED ASSOC, V291, P2127, DOI 10.1001/jama.291.17.2127; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Gillespie SH, 2002, ANTIMICROB AGENTS CH, V46, P267, DOI 10.1128/AAC.46.2.267-274.2002; Glynn JR, 2002, EMERG INFECT DIS, V8, P843; Granich RM, 2005, JAMA-J AM MED ASSOC, V293, P2732, DOI 10.1001/jama.293.22.2732; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; International Programme on Chemical S., 2005, 3 IPCS; Lambregts-van Weezenbeek CSB, 2003, INT J TUBERC LUNG D, V7, pS463; Munsiff SS, 2003, J INFECT DIS, V188, P356, DOI 10.1086/376837; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Pan H, 2005, NATURE, V434, P767, DOI 10.1038/nature03419; Rad ME, 2003, EMERG INFECT DIS, V9, P838, DOI 10.3201/eid0907.020803; Rajbhandary SS, 2004, INT J TUBERC LUNG D, V8, P1012; Rubin EJ, 2005, NEW ENGL J MED, V352, P933, DOI 10.1056/NEJMcibr044438; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; Webster P, 2003, LANCET, V361, P1355, DOI 10.1016/S0140-6736(03)13093-0	23	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2005	293	22					2788	2790		10.1001/jama.293.22.2788	http://dx.doi.org/10.1001/jama.293.22.2788			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933OV	15941810				2022-12-28	WOS:000229643700029
J	Castro, MR; Gharib, H				Castro, MR; Gharib, H			Continuing controversies in the management of thyroid nodules	ANNALS OF INTERNAL MEDICINE			English	Review							FINE-NEEDLE-ASPIRATION; LEVOTHYROXINE SUPPRESSIVE THERAPY; LYMPH-NODE METASTASIS; SERUM CALCITONIN; ROUTINE MEASUREMENT; BENIGN SOLITARY; DOUBLE-BLIND; PAPILLARY MICROCARCINOMA; PREOPERATIVE DIAGNOSIS; FOLLICULAR NEOPLASIA	Although thyroid nodules are common, few are malignant and require surgical treatment. A systematic approach to their evaluation is important to avoid unnecessary surgery. Fine-needle aspiration biopsy has resulted in substantial improvements in diagnostic accuracy, cost reductions, and higher malignancy yield at time of surgery. The preferred approach when repeated fine-needle aspiration biopsy fails to yield an adequate specimen remains a challenge. Management of patients with nodules "suspicious for follicular neoplasm" is difficult, since only 15% to 20% of such lesions have been shown to be malignant. Immunohistochemical markers, such as galectin-3 and human bone marrow endothelial cell (HBME-1), have shown promise in preliminary studies. Routine calcitonin measurement in patients with thyroid nodules has been advocated for early detection of medullary thyroid cancer. However, the low frequency of this cancer, coupled with the high cost associated with case detection, has resulted in a lack of general acceptance of this recommendation.	Mayo Clin, Coll Med, Rochester, MN 55902 USA	Mayo Clinic	Castro, MR (corresponding author), Mayo Clin, Coll Med, 200 1st St SW, Rochester, MN 55902 USA.	castro.regina@mayo.edu						ASP AA, 1987, AM J MED, V83, P489, DOI 10.1016/0002-9343(87)90759-5; BAKIN HJ, 2004, ENODOCR PRACT, V10, P242; Bartolazzi A, 2001, LANCET, V357, P1644, DOI 10.1016/S0140-6736(00)04817-0; Baudin E, 1998, CANCER, V83, P553, DOI 10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U; BRUNETON JN, 1994, J ULTRAS MED, V13, P87; BURCH HB, 1995, ENDOCRIN METAB CLIN, V24, P663, DOI 10.1016/S0889-8529(18)30019-7; Carmeci C, 1998, THYROID, V8, P283, DOI 10.1089/thy.1998.8.283; CARROLL BA, 1982, AM J ROENTGENOL, V138, P499, DOI 10.2214/ajr.138.3.499; Castro MR, 2002, J CLIN ENDOCR METAB, V87, P4154, DOI 10.1210/jc.2001-011762; CELANI MF, 1990, ACTA ENDOCRINOL-COP, V123, P603, DOI 10.1530/acta.0.1230603; CERSOSIMO E, 1993, MAYO CLIN PROC, V68, P343, DOI 10.1016/S0025-6196(12)60128-1; Chow SM, 2003, CLIN ONCOL-UK, V15, P329, DOI 10.1016/S0936-6555(03)00066-9; Chow SM, 2003, CANCER-AM CANCER SOC, V98, P31, DOI 10.1002/cncr.11442; Csako G, 2000, MEDICINE, V79, P9, DOI 10.1097/00005792-200001000-00002; Danese D, 1998, THYROID, V8, P15, DOI 10.1089/thy.1998.8.15; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P163, DOI 10.1210/jc.2003-030550; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; Farkas EA, 2002, AM SURGEON, V68, P678; FARKAS EA, 2002, AM SURGEON, P682; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; Gasbarri A, 1999, J CLIN ONCOL, V17, P3494, DOI 10.1200/JCO.1999.17.11.3494; GHARIB H, 1984, ANN INTERN MED, V101, P25, DOI 10.7326/0003-4819-101-1-25; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; Giles Y, 2004, ARCH SURG-CHICAGO, V139, P179, DOI 10.1001/archsurg.139.2.179; GOELLNER JR, 1987, ACTA CYTOL, V31, P587; Greaves TS, 2000, CANCER CYTOPATHOL, V90, P335, DOI 10.1002/1097-0142(20001225)90:6<335::AID-CNCR3>3.3.CO;2-C; Hahm JR, 2001, THYROID, V11, P73, DOI 10.1089/10507250150500694; HAMBURGER JI, 1989, ARCH PATHOL LAB MED, V113, P1035; HAMBURGER JI, 1986, NEW YORK STATE J MED, V86, P241; HAMBURGER JI, 1987, ARCH INTERN MED, V147, P97, DOI 10.1001/archinte.147.1.97; HAMBURGER JI, 1988, DIAGN CYTOPATHOL, V4, P14, DOI 10.1002/dc.2840040105; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hay Ian D, 2002, Trans Am Clin Climatol Assoc, V113, P241; HAY ID, 1992, SURGERY, V112, P1139; Hodak SP, 2004, J CLIN ENDOCR METAB, V89, P511, DOI 10.1210/jc.2003-031983; Ito Y, 2003, THYROID, V13, P381, DOI 10.1089/105072503321669875; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Karanikas G, 2004, J CLIN ENDOCR METAB, V89, P515, DOI 10.1210/jc.2003-030709; Kim ES, 2004, CLIN ENDOCRINOL, V61, P145, DOI 10.1111/j.1365-2265.2004.02065.x; Larijani B, 1999, Endocr Pract, V5, P251; LAROSA GL, 1995, ANN INTERN MED, V122, P1, DOI 10.7326/0003-4819-122-1-199501010-00001; Lima N, 1997, THYROID, V7, P691, DOI 10.1089/thy.1997.7.691; MacDonald L, 1996, ACTA CYTOL, V40, P423; MAENHAUT C, 1990, HORM METAB RES, V23, P51; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Miettinen M, 1996, VIRCHOWS ARCH, V429, P213; MILAZZO G, 1992, J CELL BIOCHEM, V49, P231, DOI 10.1002/jcb.240490305; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; Niccoli P, 1997, J CLIN ENDOCR METAB, V82, P338, DOI 10.1210/jc.82.2.338; Noguchi S, 1996, ARCH SURG-CHICAGO, V131, P187; Ozgen AG, 1999, THYROID, V9, P579, DOI 10.1089/thy.1999.9.579; PACINI F, 1994, J CLIN ENDOCR METAB, V78, P826, DOI 10.1210/jc.78.4.826; Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941, DOI 10.1210/jc.87.5.1941; Pellegriti G, 2004, J CLIN ENDOCR METAB, V89, P3713, DOI 10.1210/jc.2003-031982; PEPPER GM, 1989, ARCH INTERN MED, V149, P594, DOI 10.1001/archinte.149.3.594; Raber W, 2000, THYROID, V10, P709, DOI 10.1089/10507250050137806; Raphael SJ, 2002, ENDOCR PATHOL, V13, P301, DOI 10.1385/EP:13:4:301; READING CC, 1982, AM J ROENTGENOL, V139, P539, DOI 10.2214/ajr.139.3.539; RIDGWAY EC, 1992, J CLIN ENDOCR METAB, V74, P231, DOI 10.1210/jc.74.2.231; RIEU M, 1995, CLIN ENDOCRINOL, V42, P453, DOI 10.1111/j.1365-2265.1995.tb02662.x; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Scheuba C, 1999, SURGERY, V126, P1089, DOI 10.1067/msy.2099.102268; Schlinkert RT, 1997, MAYO CLIN PROC, V72, P913, DOI 10.1016/S0025-6196(11)63360-0; SHEPPARD MC, 1995, CLIN ENDOCRINOL, V42, P451, DOI 10.1111/j.1365-2265.1995.tb02661.x; SHIMAOKA K, 1974, AM J MED, V57, P576, DOI 10.1016/0002-9343(74)90009-6; TAKASHIMA S, 1994, J CLIN ULTRASOUND, V22, P535, DOI 10.1002/jcu.1870220904; Tan GH, 1997, ANN INTERN MED, V126, P226, DOI 10.7326/0003-4819-126-3-199702010-00009; Tuttle RM, 1998, THYROID, V8, P377, DOI 10.1089/thy.1998.8.377; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; Vierhapper H, 1997, J CLIN ENDOCR METAB, V82, P1589, DOI 10.1210/jc.82.5.1589; Wada N, 2003, ANN SURG, V237, P399, DOI 10.1097/00000658-200303000-00015; WELLS SA, 1982, ANN SURG, V195, P595, DOI 10.1097/00000658-198205000-00008; Wemeau JL, 2002, J CLIN ENDOCR METAB, V87, P4928, DOI 10.1210/jc.2002-020365; WERK EE, 1984, ARCH INTERN MED, V144, P474, DOI 10.1001/archinte.144.3.474; WOESTYN J, 1985, BRIT J RADIOL, V58, P1179, DOI 10.1259/0007-1285-58-696-1179; XU XC, 1995, AM J PATHOL, V147, P815; Zelmanovitz F, 1998, J CLIN ENDOCR METAB, V83, P3881, DOI 10.1210/jc.83.11.3881	80	187	202	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					926	931		10.7326/0003-4819-142-11-200506070-00011	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941700				2022-12-28	WOS:000229556300007
J	Allen, GS; Zavialov, A; Gursky, R; Ehrenberg, M; Frank, J				Allen, GS; Zavialov, A; Gursky, R; Ehrenberg, M; Frank, J			The cryo-EM structure of a translation initiation complex from Escherichia coli	CELL			English	Article							30S RIBOSOMAL-SUBUNITS; AMINOACYL-TRANSFER-RNA; FACTOR IF2; FACTOR-II; GUANOSINE TRIPHOSPHATE; CRYSTAL-STRUCTURE; GTPASE ACTIVITY; PROTEIN L7/L12; DENSITY MAPS; IN-VITRO	The 70S ribosome and its complement of factors required for initiation of translation in E. coli were purified separately and reassembled in vitro with GDPNP, producing a stable initiation complex (IC) stalled after 70S assembly. We have obtained a cryo-EM reconstruction of the IC showing IF2 center dot GDPNP at the intersubunit cleft of the 70S ribosome. IF2 center dot GDPNP contacts the 30S and 50S subunits as well as fMet-tRNA(fMet). IF2 here adopts a conformation radically different from that seen in the recent crystal structure of IF2. The C-terminal domain of IF2 binds to the singlestranded portion of fMet-tRNA(fmet), thereby forcing the tRNA into a novel orientation at the P site. The GTP binding domain of IF2 binds to the GTPase-associated center of the 50S subunit in a manner similar to EF-G and EF-Tu. Additionally, we present evidence for the localization of IF1, IF3, one C-terminal domain of L7/L12, and the N-terminal domain of IF2 in the initiation complex.	Hlth Res Inc, Wadsworth Ctr, Howard Hughes Med Inst, Albany, NY 12201 USA; Biomed Ctr, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	Health Research Inc; Howard Hughes Medical Institute; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Frank, J (corresponding author), Hlth Res Inc, Wadsworth Ctr, Howard Hughes Med Inst, Empire State Plaza, Albany, NY 12201 USA.	joachim@wadsworth.org		Zavialov, Andrey/0000-0001-6420-0368	NIGMS NIH HHS [R01 GM55440, R37 GM29169, R01 GM055440-08, R37 GM029169-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055440, R37GM029169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoun A, 2003, EMBO J, V22, P5593, DOI 10.1093/emboj/cdg525; Antoun Ayman, 2004, Biol Proced Online, V6, P35, DOI 10.1251/bpo71; BEAUDRY P, 1979, BIOCHEMISTRY-US, V18, P202, DOI 10.1021/bi00568a031; Blanchard SC, 2004, NAT STRUCT MOL BIOL, V11, P1008, DOI 10.1038/nsmb831; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; Brooijmans N, 2002, PROTEINS, V48, P645, DOI 10.1002/prot.10139; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANONACO MA, 1986, FEBS LETT, V207, P198, DOI 10.1016/0014-5793(86)81488-0; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Chen JZ, 2003, J STRUCT BIOL, V144, P144, DOI 10.1016/j.jsb.2003.09.008; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Dey D, 1998, J BIOL CHEM, V273, P1670, DOI 10.1074/jbc.273.3.1670; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gao HX, 2004, J STRUCT BIOL, V147, P283, DOI 10.1016/j.jsb.2004.02.008; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; GOSS DJ, 1982, J BIOL CHEM, V257, P119; GRIGORIADOU C, 2004, TRANSLATIONAL CONT A, P407; GRONER Y, 1973, J MOL BIOL, V74, P407, DOI 10.1016/0022-2836(73)90381-1; Grunberg-Manago M, 1975, J Mol Biol, V94, P461; GRUNBERGMANAGO M, 1972, FEBS LETT, V22, P217, DOI 10.1016/0014-5793(72)80049-8; GUALERZI C, 1971, BIOCHEM BIOPH RES CO, V45, P1312, DOI 10.1016/0006-291X(71)90162-8; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; HEIMARK RL, 1976, J BIOL CHEM, V251, P7779; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; KAY AC, 1972, BIOCHIM BIOPHYS ACTA, V277, P225, DOI 10.1016/0005-2787(72)90369-3; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; LOCKWOOD AH, 1971, P NATL ACAD SCI USA, V68, P3122, DOI 10.1073/pnas.68.12.3122; Luchin S, 1999, J BIOL CHEM, V274, P6074, DOI 10.1074/jbc.274.10.6074; Marzi S, 2003, RNA, V9, P958, DOI 10.1261/rna.2116303; Mayer C, 2003, BIOCHEMISTRY-US, V42, P4787, DOI 10.1021/bi034011r; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; Montesano-Roditis L, 2001, J BIOL CHEM, V276, P14117, DOI 10.1074/jbc.M008430200; Moreno JMP, 1998, BIOCHEM BIOPH RES CO, V252, P465, DOI 10.1006/bbrc.1998.9664; Moreno JMP, 1999, FEBS LETT, V455, P130, DOI 10.1016/S0014-5793(99)00858-3; NYENGAARD NR, 1991, BIOCHEM BIOPH RES CO, V181, P1572, DOI 10.1016/0006-291X(91)92118-4; PETERSEN HU, 1979, BIOCHEM BIOPH RES CO, V91, P1068, DOI 10.1016/0006-291X(79)91989-2; PETERSEN HU, 1981, FEBS LETT, V128, P161, DOI 10.1016/0014-5793(81)81105-2; Pieper U, 2004, NUCLEIC ACIDS RES, V32, pD217, DOI 10.1093/nar/gkh095; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; PON CL, 1986, FEBS LETT, V195, P215, DOI 10.1016/0014-5793(86)80163-6; PON CL, 1984, FEBS LETT, V175, P203, DOI 10.1016/0014-5793(84)80737-1; Rath BK, 2003, J STRUCT BIOL, V144, P95, DOI 10.1016/j.jsb.2003.09.029; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Shin BS, 2002, CELL, V111, P1015, DOI 10.1016/S0092-8674(02)01171-6; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WAKAO H, 1989, J BIOL CHEM, V264, P20363; WAKAO H, 1990, BIOCHEMISTRY-US, V29, P8144, DOI 10.1021/bi00487a023; WEIEL J, 1982, J BIOL CHEM, V257, P1215; WINTERMEYER W, 1983, BIOCHEMISTRY-US, V22, P690, DOI 10.1021/bi00272a025; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; ZUCKER FH, 1986, BIOCHEMISTRY-US, V25, P3682, DOI 10.1021/bi00360a031	64	221	227	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					703	712		10.1016/j.cell.2005.03.023	http://dx.doi.org/10.1016/j.cell.2005.03.023			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935757	Bronze			2022-12-28	WOS:000229658000009
J	Arvin, A				Arvin, A			Aging, immunity, and the varicella-zoster virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Arvin, A (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.							Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906; Hata A, 2002, NEW ENGL J MED, V347, P26, DOI 10.1056/NEJMoa013441	2	190	198	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2005	352	22					2266	2267		10.1056/NEJMp058091	http://dx.doi.org/10.1056/NEJMp058091			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930VY	15930416				2022-12-28	WOS:000229446400002
J	Mills, E				Mills, E			Environment - The specter of fuel-based lighting	SCIENCE			English	Editorial Material									US DOE, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Mills, E (corresponding author), US DOE, Lawrence Berkeley Natl Lab, MS 90-4000, Berkeley, CA 94720 USA.	emills@lbl.gov						Batliwala S., 2003, ENERGY SUSTAIN DEV, V7, P33, DOI [10.1016/S0973-0826(08)60363-4., DOI 10.1016/S0973-0826(08)60363-4]; Craine SA, 2001, P SOC PHOTO-OPT INS, V4445, P39, DOI 10.1117/12.450044; Davidson O., 2004, ENERGY SUSTAIN DEV, V8, P26, DOI DOI 10.1016/S0973-0826(08)60511-6; Dutt G.S., 1994, ENERGY SUSTAIN DEV, V1, P23, DOI [10.1016/S0973-0826(08)60010-1, DOI 10.1016/S0973-0826(08)60010-1]; FLOOR W, 2001, ESM249 UNDP ESMAP WO; Gately D., 1997, 359 WORLD BANK; GOLDEMBERG J, 1985, AMBIO, V14, P190; Goldemberg J., 2004, ENERGY SUSTAIN DEV, V8, P86, DOI [DOI 10.1016/S0973-0826(08)60515-3, 10.1016/S0973-0826(08)60515-3]; *IEA, 2002, OUTL 2002, pCH13; JIANPING D, 2005, P 6 INT C EN EFF LIG, P397; KAREKEZI S, 2004, ENERGY SUSTAIN DEV, V8, P3; Karekezi S, 2004, ENERGY SUSTAIN DEV, V8, P10, DOI DOI 10.1016/S0973-0826(08)60510-4; KOJIMA M, 2001, 237 WORLD BANK; Langenberg DN, 1996, SCIENCE, V272, P1721, DOI 10.1126/science.272.5269.1721; Laxmi V., 2003, ENERGY SUSTAIN DEV, V7, P50, DOI [10.1016/S0973-0826(08)60348-8., DOI 10.1016/S0973-0826(08)60348-8]; Liu JG, 2003, NATURE, V421, P530, DOI 10.1038/nature01359; MILLS E, 2002, P 5 EUR C EN EFF LIG, P368; Mills E., 2002, LIGHT ENG, V10; Reddy AKN, 2002, ANNU REV ENERG ENV, V27, P23, DOI 10.1146/annurev.energy.27.122001.083506; Schubert EF, 2005, SCIENCE, V308, P1274, DOI 10.1126/science.1108712; *UNDP WORLD BANK, 2001, ESM263 UNDPESMAP WOR; VANDERPLAS RJ, 1988, ENERGY SER PAP, V6	22	89	89	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1263	1264		10.1126/science.1113090	http://dx.doi.org/10.1126/science.1113090			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919979				2022-12-28	WOS:000229482300030
J	Boucrot, E; Henry, T; Borg, JP; Gorvel, JP; Meresse, S				Boucrot, E; Henry, T; Borg, JP; Gorvel, JP; Meresse, S			The intracellular fate of Salmonella depends on the recruitment of kinesin	SCIENCE			English	Article							TYPHIMURIUM; PROTEIN; SIFA; IDENTIFICATION; EFFECTOR; DOMAINS; COMPLEX	Salmonella enterica causes a variety of diseases, including gastroenteritis and typhoid fever. The success of this pathogen depends on its capacity to proliferate within host cells in a membrane-bound compartment. We found that the Salmonella-containing vacuole recruited the plus-end-directed motor kinesin. Bacterial effector proteins translocated into the host cell by a type III secretion system antagonistically regulated this event. Among these effectors, SifA targeted SKIP, a host protein that down-regulated the recruitment of kinesin on the bacterial. vacuole and, in turn, controlled vacuolar membrane dynamics.	Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, F-13288 Marseille, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; INSERM, UMR 599, Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Meresse, S (corresponding author), Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, Case 906, F-13288 Marseille, France.	meresse@ciml.univ-mrs.fr	Henry, Thomas/G-3160-2013; Borg, Jean-Paul/AAX-8096-2020; Meresse, Stephane/E-2192-2012; Gorvel, Jean-Pierre/O-1332-2018	Henry, Thomas/0000-0002-0687-8565; Borg, Jean-Paul/0000-0001-8418-3382; Meresse, Stephane/0000-0001-6578-5177; Gorvel, Jean-Pierre/0000-0002-2829-9804				Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Boucrot E, 2003, J BIOL CHEM, V278, P14196, DOI 10.1074/jbc.M207901200; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Callebaut I, 2001, TRENDS BIOCHEM SCI, V26, P79, DOI 10.1016/S0968-0004(00)01730-8; Clarke EJ, 2002, CURR BIOL, V12, pR596, DOI 10.1016/S0960-9822(02)01102-8; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Guignot J, 2004, J CELL SCI, V117, P1033, DOI 10.1242/jcs.00949; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Marsman M, 2004, MOL BIOL CELL, V15, P2954, DOI 10.1091/mbc.E03-08-0614; Miao EA, 2000, P NATL ACAD SCI USA, V97, P7539, DOI 10.1073/pnas.97.13.7539; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Sakamoto R, 2005, MOL BIOL CELL, V16, P483, DOI 10.1091/mbc.E04-07-0553; Salcedo SP, 2003, EMBO J, V22, P5003, DOI 10.1093/emboj/cdg517; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x	22	190	198	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1174	1178		10.1126/science.1110225	http://dx.doi.org/10.1126/science.1110225			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905402				2022-12-28	WOS:000229293400045
J	Kustikova, O; Fehse, B; Modlich, U; Yang, M; Dullmann, J; Kamino, K; von Neuhoff, N; Schlegelberger, B; Li, ZX; Baum, C				Kustikova, O; Fehse, B; Modlich, U; Yang, M; Dullmann, J; Kamino, K; von Neuhoff, N; Schlegelberger, B; Li, ZX; Baum, C			Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking	SCIENCE			English	Article							CANCER; PROLIFERATION; THERAPY; MOUSE	Gene marking with replication-defective retroviral vectors has been used for more than 20 years to track the in vivo fate of cell clones. We demonstrate that retroviral integrations themselves may trigger nonmalignant clonal expansion in murine long-term hematopoiesis. All 29 insertions recovered from clones dominating in serially transplanted recipients affected loci with an established or potential role in the self-renewal or survival of hematopoietic stem cells. Transcriptional dysregulation occurred in all 12 insertion sites analyzed. These findings have major implications for diagnostic gene marking and the discovery of genes regulating stem cell turnover.	Hannover Med Sch, Dept Hematol Hemostaseol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Cellular & Mol Pathol, D-30625 Hannover, Germany; Univ Hosp Eppendorf, Inst Anat Expt Morphol 2, D-20251 Hamburg, Germany; Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA	Hannover Medical School; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Li, ZX (corresponding author), Hannover Med Sch, Dept Hematol Hemostaseol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	li.zhixiong@mh-hannover.de; baum.christopher@mh-hannover.de	Fehse, Boris/A-8721-2012; Fehse, Boris/HIR-6019-2022	Fehse, Boris/0000-0001-9780-7211; Modlich, Ute/0000-0001-8018-4118				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Bonini C, 2003, NAT MED, V9, P367, DOI 10.1038/nm0403-367; Brenner MK, 2003, CYTOTHERAPY, V5, P190, DOI 10.1080/14653240310001307; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Fehse B, 2000, MOL THER, V1, P448, DOI 10.1006/mthe.2000.0068; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kohn DB, 2003, MOL THER, V8, P180, DOI 10.1016/S1525-0016(03)00212-0; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; Lemischka IR, 2001, NAT IMMUNOL, V2, P11, DOI 10.1038/83115; Li Z, 2002, LEUKEMIA, V16, P1655, DOI 10.1038/sj.leu.2402619; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Modlich U, 2005, BLOOD, V105, P4235, DOI 10.1182/blood-2004-11-4535; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Sharpe J, 1998, EMBO J, V17, P1788, DOI 10.1093/emboj/17.6.1788; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101	27	276	296	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1171	1174		10.1126/science.1105063	http://dx.doi.org/10.1126/science.1105063			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905401				2022-12-28	WOS:000229293400044
J	MacRae, IJ; Doudna, JA				MacRae, IJ; Doudna, JA			Ro's role in RNA reconnaissance	CELL			English	Editorial Material							AUTOANTIGEN; INSIGHTS; ROP-1	The Ro 60 kDa autoantigen binds misfolded RNAs and likely functions in small RNA quality control. In this issue of Cell, Stein et al. (2005) present crystal structures of Ro alone and bound to both double- and single-stranded RNA, revealing two distinct RNA binding sites that suggest how Ro may distinguish between native and misfolded small RNAs.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	MacRae, IJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.							Chen XG, 2000, GENE DEV, V14, P777; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; Chen XG, 2003, CURR BIOL, V13, P2206, DOI 10.1016/j.cub.2003.11.028; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1138, DOI 10.1128/MCB.1.12.1138; Labbe JC, 1999, GENETICS, V151, P143; Labbe JC, 1995, GENE, V167, P227, DOI 10.1016/0378-1119(95)00695-8; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; Shi H, 1996, RNA, V2, P769; Stein AJ, 2005, CELL, V121, P529, DOI 10.1016/j.cell.2005.03.009; Xue DH, 2003, P NATL ACAD SCI USA, V100, P7503, DOI 10.1073/pnas.0832411100	10	5	6	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					495	496		10.1016/j.cell.2005.05.004	http://dx.doi.org/10.1016/j.cell.2005.05.004			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907458	Bronze			2022-12-28	WOS:000229331200001
J	Park, J; Song, TRA; Tromp, J; Okal, E; Stein, S; Roult, G; Clevede, E; Laske, G; Kanamori, H; Davis, P; Berger, J; Braitenberg, C; Van Camp, M; Lei, X; Sun, HP; Xu, HZ; Rosat, S				Park, J; Song, TRA; Tromp, J; Okal, E; Stein, S; Roult, G; Clevede, E; Laske, G; Kanamori, H; Davis, P; Berger, J; Braitenberg, C; Van Camp, M; Lei, X; Sun, HP; Xu, HZ; Rosat, S			Earth's free oscillations excited by the 26 December 2004 Sumatra-Andaman earthquake	SCIENCE			English	Article							NORMAL-MODES; ATTENUATION MEASUREMENTS; EXCITATION; STRAIN; DOMAIN	At periods greater than 1000 seconds, Earth's seismic free oscillations have anomalously large amplitude when referenced to the Harvard Centroid Moment Tensor fault mechanism, which is estimated from 300- to 500-second surface waves. By using more realistic rupture models on a steeper fault derived from seismic body and surface waves, we approximated free oscillation amplitudes with a seismic moment (6.5 x 10(22) Newton-meters) that corresponds to a moment magnitude of 9.15. With a rupture duration of 600 seconds, the fault-rupture models represent seismic observations adequately but underpredict geodetic displacements that argue for slow fault motion beneath the Nicobar and Andaman islands.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA; Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Inst Phys Globe, Dept Sismol, F-75252 Paris, France; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Trieste, Dipartimento Sci Terra, I-34100 Trieste, Italy; Observ Royal Belgique, B-1180 Brussels, Belgium; Chinese Acad Sci, Inst Geodesy & Geophys, Wuhan 430077, Peoples R China; Natl Astron Observ, Mizusawa, Iwate 0230861, Japan	Yale University; California Institute of Technology; Northwestern University; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Trieste; Chinese Academy of Sciences; Institute of Geodesy & Geophysics, CAS; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ)	Park, J (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.		Van+Camp, Michel/ABE-5941-2020; Rosat, Severine/P-3438-2014; Clevede, Eric/F-7768-2017; Song, Teh-Ru Alex/I-7563-2012; Tromp, Jeroen/B-6185-2015; Van Camp, M/L-7281-2015; Braitenberg, Carla/B-5882-2013	Rosat, Severine/0000-0003-4606-2170; Clevede, Eric/0000-0001-7069-2258; Tromp, Jeroen/0000-0002-2742-8299; Van Camp, M/0000-0002-2859-3122; Braitenberg, Carla/0000-0001-7277-816X				ALSOP LE, 1961, J GEOPHYS RES, V66, P631, DOI 10.1029/JZ066i002p00631; Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; BACKUS G, 1961, P NATL ACAD SCI USA, V47, P362, DOI 10.1073/pnas.47.3.362; Bassin C., 2000, EOS T AM GEOPHYS UN, V81, pF897; BENIOFF H, 1961, J GEOPHYS RES, V66, P605, DOI 10.1029/JZ066i002p00605; BILHAM R, IN PRESS SEISM RES L; BOLT BA, 1975, GEOPHYS J ROY ASTR S, V40, P107, DOI 10.1111/j.1365-246X.1975.tb01609.x; BULAND R, 1979, NATURE, V277, P358, DOI 10.1038/277358a0; Butler R., 2004, EOS T AM GEOPHYS UN, V85, P225; Dahlen F. A, 1998, THEORETICAL GLOBAL S; DAHLEN FA, 1981, GEOPHYS J ROY ASTR S, V66, P1, DOI 10.1111/j.1365-246X.1981.tb05944.x; DAHLEN FA, 1979, GEOPHYS J ROY ASTR S, V58, P609, DOI 10.1111/j.1365-246X.1979.tb04797.x; DAVIS JP, 1985, GEOPHYS RES LETT, V12, P141, DOI 10.1029/GL012i003p00141; Deuss A, 2001, GEOPHYS J INT, V146, P833, DOI 10.1046/j.1365-246X.2001.00502.x; Ekstrom G, 2005, PHYS EARTH PLANET IN, V148, P327, DOI 10.1016/j.pepi.2004.09.006; GELLER RJ, 1979, B SEISMOL SOC AM, V69, P1671; GIARDINI D, 1987, NATURE, V325, P405, DOI 10.1038/325405a0; GILBERT F, 1975, PHILOS T R SOC A, V278, P187, DOI 10.1098/rsta.1975.0025; GOULTY NR, 1973, NATURE, V246, P470, DOI 10.1038/246470a0; HANKS TC, 1979, J GEOPHYS RES, V84, P2348, DOI 10.1029/JB084iB05p02348; Ishii M, 1999, SCIENCE, V285, P1231, DOI 10.1126/science.285.5431.1231; ISHII M, IN PRESS NATURE; Kedar S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017639; Larson KM, 2003, SCIENCE, V300, P1421, DOI 10.1126/science.1084531; Laske G, 1999, NATURE, V402, P66, DOI 10.1038/47011; Lei XG, 2002, CHINESE SCI BULL, V47, P1573, DOI 10.1360/02tb9346; LOGNONNE P, 1990, GEOPHYS J INT, V102, P365, DOI 10.1111/j.1365-246X.1990.tb04472.x; MASTERS G, 1983, J GEOPHYS RES, V88, P285, DOI 10.1029/JB088iB12p10285; Nawa K, 2000, PHYS EARTH PLANET IN, V120, P289, DOI 10.1016/S0031-9201(00)00158-8; NESS NF, 1961, J GEOPHYS RES, V66, P621, DOI 10.1029/JZ066i002p00621; Park J, 2005, SEISMOL RES LETT, V76, P331, DOI 10.1785/gssrl.76.3.331; PARK J, 1986, J GEOPHYS RES-SOLID, V91, P7241, DOI 10.1029/JB091iB07p07241; PARK J, 2005, EOS T AM GEOPHYS UN, V86, P57, DOI DOI 10.1029/2005EO060001; PILLET R, 1994, PHYS EARTH PLANET IN, V84, P161, DOI 10.1016/0031-9201(94)90039-6; Ritsema J, 2000, Sci Prog, V83 ( Pt 3), P243; RITZWOLLER M, 1988, J GEOPHYS RES-SOLID, V93, P6369, DOI 10.1029/JB093iB06p06369; Romanowicz B, 2001, SCIENCE, V293, P2000, DOI 10.1126/science.1061771; Rosat S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018304; Roult G, 1999, PHYS EARTH PLANET IN, V113, P25, DOI 10.1016/S0031-9201(99)00024-2; Roult G, 2000, PHYS EARTH PLANET IN, V121, P1, DOI 10.1016/S0031-9201(00)00155-2; SMITH SW, 1966, J GEOPHYS RES, V71, P1183, DOI 10.1029/JZ071i004p01183; Stein S, 2005, NATURE, V434, P581, DOI 10.1038/434581a; Stein S., 2003, INTRO SEISMOLOGY EAR; Van Camp M, 1999, PHYS EARTH PLANET IN, V116, P81, DOI 10.1016/S0031-9201(99)00120-X; WIDMER R, 1991, GEOPHYS J INT, V104, P541, DOI 10.1111/j.1365-246X.1991.tb05700.x; WOODHOUSE JH, 1980, GEOPHYS J ROY ASTR S, V61, P261, DOI 10.1111/j.1365-246X.1980.tb04317.x; Zadro M, 1999, EARTH-SCI REV, V47, P151, DOI 10.1016/S0012-8252(99)00028-8; Zurn W, 2000, GEOPHYS J INT, V143, P113, DOI 10.1046/j.1365-246x.2000.00220.x; Zurn W, 1995, GEOPHYS RES LETT, V22, P3537, DOI 10.1029/95GL03369	49	170	197	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1139	1144		10.1126/science.1112305	http://dx.doi.org/10.1126/science.1112305			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905394				2022-12-28	WOS:000229293400035
J	Gerstenberger, MC; Wiemer, S; Jones, LM; Reasenberg, PA				Gerstenberger, MC; Wiemer, S; Jones, LM; Reasenberg, PA			Real-time forecasts of tomorrow's earthquakes in California	NATURE			English	Article							M-W; AFTERSHOCKS; HAZARD	Despite a lack of reliable deterministic earthquake precursors, seismologists have significant predictive information about earthquake activity from an increasingly accurate understanding of the clustering properties of earthquakes(1-4). In the past 15 years, time-dependent earthquake probabilities based on a generic short-term clustering model have been made publicly available in near-real time during major earthquake sequences. These forecasts describe the probability and number of events that are, on average, likely to occur following a mainshock of a given magnitude, but are not tailored to the particular sequence at hand and contain no information about the likely locations of the aftershocks. Our model builds upon the basic principles of this generic forecast model in two ways: it recasts the forecast in terms of the probability of strong ground shaking, and it combines an existing time-independent earthquake occurrence model based on fault data and historical earthquakes(5) with increasingly complex models describing the local time-dependent earthquake clustering(1,2). The result is a time-dependent map showing the probability of strong shaking anywhere in California within the next 24 hours. The seismic hazard modelling approach we describe provides a better understanding of time-dependent earthquake hazard, and increases its usefulness for the public, emergency planners and the media.	US Geol Survey, Pasadena, CA 91106 USA; ETH, Inst Geophys, CH-8093 Zurich, Switzerland; US Geol Survey, Menlo Pk, CA 94025 USA	United States Department of the Interior; United States Geological Survey; Swiss Federal Institutes of Technology Domain; ETH Zurich; United States Department of the Interior; United States Geological Survey	Gerstenberger, MC (corresponding author), US Geol Survey, 525 S Wilson Ave, Pasadena, CA 91106 USA.	mattg@usgs.gov	Wiemer, Stefan/E-5033-2015	Wiemer, Stefan/0000-0002-4919-3283				Boore D. M., 1997, SEISMOL RES LETT, V68, P128, DOI DOI 10.1785/GSSRL.68.1.128; Burnham KP, 2002, MODEL SELECTION MULT, V2nd, DOI [DOI 10.1007/B97636, 10.1007/978-1-4757-2917-7, DOI 10.1007/978-1-4757-2917-7]; Felzer KR, 2004, B SEISMOL SOC AM, V94, P88, DOI 10.1785/0120030069; Frankel A, 1996, US GEOL SURV OPEN FI, P96, DOI DOI 10.3133/OFR96532; Geller RJ, 1997, GEOPHYS J INT, V131, P425, DOI 10.1111/j.1365-246X.1997.tb06588.x; Gutenberg B., 1954, ANN GEOF, V9, P1; Helmstetter A, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001580; REASENBERG PA, 1994, SCIENCE, V265, P1251, DOI 10.1126/science.265.5176.1251; Reasenberg PA, 1999, J GEOPHYS RES-SOL EA, V104, P4755, DOI 10.1029/1998JB900089; REASENBERG PA, 1989, SCIENCE, V243, P1173, DOI 10.1126/science.243.4895.1173; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; UTSU T, 1995, J PHYS EARTH, V43, P1, DOI 10.4294/jpe1952.43.1; Wald DJ., 1999, EARTHQ SPECTRA, V15, P537, DOI [10.1193/1.1586057, DOI 10.1193/1.1586057]; Wiemer S, 1999, J GEOPHYS RES-SOL EA, V104, P13135, DOI 10.1029/1999JB900032; Wiemer S, 2000, GEOPHYS RES LETT, V27, P3405, DOI 10.1029/2000GL011479; Wiemer S, 2002, B SEISMOL SOC AM, V92, P1227, DOI 10.1785/0120000914	16	223	234	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					328	331		10.1038/nature03622	http://dx.doi.org/10.1038/nature03622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902254				2022-12-28	WOS:000229185000042
J	Takamoto, M; Hong, FL; Higashi, R; Katori, H				Takamoto, M; Hong, FL; Higashi, R; Katori, H			An optical lattice clock	NATURE			English	Article							FREQUENCY STANDARDS; LASERS; ION; SPECTROSCOPY; ATOMS	The precision measurement of time and frequency is a prerequisite not only for fundamental science but also for technologies that support broadband communication networks and navigation with global positioning systems ( GPS). The SI second is currently realized by the microwave transition of Cs atoms with a fractional uncertainty of 10(-15) ( ref. 1). Thanks to the optical frequency comb technique(2,3), which established a coherent link between optical and radio frequencies, optical clocks(4) have attracted increasing interest as regards future atomic clocks with superior precision. To date, single trapped ions(4-6) and ultracold neutral atoms in free fall(7,8) have shown record high performance that is approaching that of the best Cs fountain clocks(1). Here we report a different approach, in which atoms trapped in an optical lattice serve as quantum references. The 'optical lattice clock'(9,10) demonstrates a linewidth one order of magnitude narrower than that observed for neutral-atom optical clocks(7,8,11), and its stability is better than that of single-ion clocks(4,5). The transition frequency for the Sr lattice clock is 429,228,004,229,952( 15) Hz, as determined by an optical frequency comb referenced to the SI second.	Univ Tokyo, Inst Engn Res, Bunkyo Ku, Tokyo 1138656, Japan; Japan Sci & Technol Agcy, Bunkyo Ku, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol NMIJ AIST, Natl Meteorol Inst Japan, Tsukuba, Ibaraki 3058563, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); National Metrology Institute of Japan	Katori, H (corresponding author), Univ Tokyo, Inst Engn Res, Bunkyo Ku, Tokyo 1138656, Japan.	katori@amo.t.u-tokyo.ac.jp	Katori, Hidetoshi/E-6633-2012; Hong, Feng-Lei/N-3098-2014	Katori, Hidetoshi/0000-0002-8500-3678; Hong, Feng-Lei/0000-0003-1318-2635; Higashi, Ryoichi/0000-0001-6125-4088				ALLAN DW, 1966, PR INST ELECTR ELECT, V54, P221, DOI 10.1109/PROC.1966.4634; Angstmann EJ, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.014102; *BIPM, 2004, 200 BIPM; Courtillot I, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.030501; Degenhardt C, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.023414; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83, DOI 10.1109/TIM.1982.6312526; DICKE RH, 1953, PHYS REV, V89, P472, DOI 10.1103/PhysRev.89.472; Diddams SA, 2001, SCIENCE, V293, P825, DOI 10.1126/science.1061171; Dos Santos FP, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233004; Gupta S, 2003, SCIENCE, V300, P1723, DOI 10.1126/science.1085335; Hong FL, 1999, IEEE T INSTRUM MEAS, V48, P532, DOI 10.1109/19.769651; Ido T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.053001; Jessen PS, 1996, ADV ATOM MOL OPT PHY, V37, P95; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; Katori H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.173005; Katori H, 1999, J PHYS SOC JPN, V68, P2479, DOI 10.1143/JPSJ.68.2479; Katori H., 2002, P 6 S FREQ STAND MET, P323; Knight JC, 2003, NATURE, V424, P847, DOI 10.1038/nature01940; MA LS, 1994, OPT LETT, V19, P1777, DOI 10.1364/OL.19.001777; Margolis HS, 2004, SCIENCE, V306, P1355, DOI 10.1126/science.1105497; Oates CW, 2000, OPT LETT, V25, P1603, DOI 10.1364/OL.25.001603; Peik E, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.170801; Porsev SG, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.021403; Rauschenbeutel A, 1998, OPT COMMUN, V148, P45, DOI 10.1016/S0030-4018(97)00669-X; Ruschewitz F, 1998, PHYS REV LETT, V80, P3173, DOI 10.1103/PhysRevLett.80.3173; Takamoto M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.223001; Udem T, 1999, PHYS REV LETT, V82, P3568, DOI 10.1103/PhysRevLett.82.3568; Wilpers G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.230801; Young BC, 1999, PHYS REV LETT, V82, P3799, DOI 10.1103/PhysRevLett.82.3799	29	600	627	8	187	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					321	324		10.1038/nature03541	http://dx.doi.org/10.1038/nature03541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902252				2022-12-28	WOS:000229185000040
J	Goldstein, LB; Simel, DL				Goldstein, LB; Simel, DL			Is this patient having a stroke?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSIENT ISCHEMIC ATTACKS; EMERGENCY-DEPARTMENT EVALUATION; CANADIAN NEUROLOGICAL SCALE; AMERICAN-HEART-ASSOCIATION; ACUTE CEREBRAL INFARCTION; SHORT-TERM PROGNOSIS; NATIONAL-INSTITUTES; INTEROBSERVER AGREEMENT; INTERRATER RELIABILITY; CLINICAL EXAMINATION	Context Patients suspected of having a stroke or transient ischemic attack require accurate assessment for appropriate acute treatment and use of secondary preventive interventions. Objective To update a 1994 systematic review of the accuracy and reliability of symptoms and findings on neurological examination for the evaluation of patients with suspected stroke or transient ischemic attack. Data Sources We identified potential articles dated between 1994 and 2005 by multiple search strategies of the MEDLINE database and review of article and textbook bibliographies along with private collections. Study Selection Selected articles provided primary data or appropriate summary statistics of the accuracy and/or reliability of the history or physical examination for diagnosis or short-term prognosis of patients with neurological signs prompting a consideration of stroke. Articles addressing accuracy also needed to provide a final diagnosis following neuroimaging and all relevant laboratory tests. Data Extraction The authors reviewed and abstracted data for estimating sensitivities, specificities, positive and negative likelihood ratios (LRs). Reliability assessment was based on reported kappa (&kappa;) statistics or intraclass correlation coefficients as appropriate. Data Synthesis The prior probability of a stroke among patients with neurologically relevant symptoms is 10%. Based on studies using modern neuroimaging, the presence of acute facial paresis, arm drift, or abnormal speech increases the likelihood of stroke (LR of &GE; 1 finding=5.5; 95% Cl, 3.3-9.1), while the absence of all 3 decreases the odds (LR of 0 findings = 0.39; 95% Cl, 0.25-0.61). The accurate determination of stroke subtype requires neuroimaging to distinguish ischemic from hemorrhagic stroke. Early mortality increases among those with any combination of impaired consciousness, hemiplegia, and conjugate gaze palsy (LR of &GE; 1 finding = 1.8; 95% Cl, 1.2-2.8 and LR of 0 findings = 0.36; 95% Cl, 0.13-1.0). Symptoms associated with high agreement for the diagnosis of stroke or transient ischemic attack vs no vascular event are a sudden change in speech, visual loss, diplopia, numbness or tingling, paralysis or weakness, and non-orthostatic dizziness (&kappa;=0.60; 95% Cl, 0.52-0.68). The reliabilities of individual neurological findings vary from slight to almost perfect, but can be improved with standardized scoring systems such as the National Institutes of Health Stroke Scale. Based on examination findings, stroke vascular distribution can be determined with moderate to good reliability (&kappa;=0.54; 95% Cl, 0.39-0.68). Conclusions The history and clinical findings provide the basis for evaluating patients with possible stroke and choosing appropriate treatments. Focusing on 3 findings (acute facial paresis, arm drift, or abnormal speech) might improve diagnostic accuracy and reliability.	Duke Univ, Med Ctr, Dept Med Neurol, Duke Ctr Cerebrovasc Dis, Durham, NC 27710 USA; Duke Univ, Ctr Clin Hlth Policy Res & Educ, Durham, NC 27710 USA; Dept Vet Affairs Med Ctr, Durham, NC USA	Duke University; Duke University	Goldstein, LB (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Duke Ctr Cerebrovasc Dis, Box 3651, Durham, NC 27710 USA.	golds004@mc.duke.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001265] Funding Source: NIH RePORTER; NINDS NIH HHS [K24-NS-01265] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Adams HP, 1996, NEUROLOGY, V47, P835; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; Albers GW, 2004, CHEST, V126, p483S, DOI 10.1378/chest.126.3_suppl.483S; ALLEN CMC, 1983, Q J MED, V52, P515; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; American Heart Association, HEART DIS STROK STAT; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Biller J, 1998, STROKE, V29, P554, DOI 10.1161/01.STR.29.2.554; BRITTON M, 1984, NEUROLOGY, V34, P1504, DOI 10.1212/WNL.34.11.1504; BRITTON M, 1980, ACTA MED SCAND, V207, P37; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Brown DL, 2004, STROKE, V35, P147, DOI 10.1161/01.STR.000010539.93273.72; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; Camilo O, 2003, STROKE, V34, P2945, DOI 10.1161/01.STR.0000103137.44496.AD; CHARI CR, 1987, NEUROLOGY, V37, P1884, DOI 10.1212/WNL.37.12.1884-a; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; Coull BM, 2002, NEUROLOGY, V59, P13, DOI 10.1212/WNL.59.1.13; Dewey HM, 1999, CEREBROVASC DIS, V9, P323, DOI 10.1159/000016006; Easton JD, 2004, NEUROLOGY, V62, pS29, DOI 10.1212/WNL.62.8_suppl_6.S29; FOSTER JW, 1987, STROKE, V18, P944, DOI 10.1161/01.STR.18.5.944; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FULLERTON KJ, 1988, Q J MED, V66, P147; GELMERS HJ, 1988, STROKE, V19, P709, DOI 10.1161/01.STR.19.6.709; Goldstein LB, 1997, STROKE, V28, P307, DOI 10.1161/01.STR.28.2.307; Goldstein LB, 2001, STROKE, V32, P1091, DOI 10.1161/01.STR.32.5.1091; Goldstein LB, 2003, STROKE, V34, P2767, DOI 10.1161/01.STR.0000097803.90702.31; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GOLDSTEIN LB, 1994, JAMA-J AM MED ASSOC, V271, P1114, DOI 10.1001/jama.271.14.1114; GROSS CR, 1986, ARCH NEUROL-CHICAGO, V43, P893, DOI 10.1001/archneur.1986.00520090031012; Hacke W, 2004, LANCET, V363, P768; HENLEY S, 1985, J NEUROL NEUROSUR PS, V48, P1, DOI 10.1136/jnnp.48.1.1; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; JENNETT B, 1975, LANCET, V1, P480; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; Karanjia PN, 1997, NEUROLOGY, V48, P346, DOI 10.1212/WNL.48.2.346; Katzan IL, 2003, STROKE, V34, P994, DOI 10.1161/01.STR.0000060870.55480.61; Kidwell CS, 2000, STROKE, V31, P71, DOI 10.1161/01.STR.31.1.71; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; Kothari R, 1997, ACAD EMERG MED, V4, P986, DOI 10.1111/j.1553-2712.1997.tb03665.x; Kothari R, 1999, ANN EMERG MED, V33, P3, DOI 10.1016/S0196-0644(99)70431-2; Kothari RU, 1999, ANN EMERG MED, V33, P373, DOI 10.1016/S0196-0644(99)70299-4; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Lacy CR, 2001, STROKE, V32, P63, DOI 10.1161/01.STR.32.1.63; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; LINDLEY RI, 1993, STROKE, V24, P1801, DOI 10.1161/01.STR.24.12.1801; MAHONEY F I, 1965, Md State Med J, V14, P61; Menon SC, 1998, NEUROLOGY, V51, P427, DOI 10.1212/WNL.51.2.427; Meyer BC, 2002, STROKE, V33, P1261, DOI 10.1161/01.STR.0000015625.87603.A7; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Morris DL, 2000, STROKE, V31, P2585, DOI 10.1161/01.STR.31.11.2585; NORRIS JW, 1982, LANCET, V1, P328; OLSEN J, 1988, J NEUROL REHABIL, V2, P59; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; PANZER RJ, 1985, ARCH INTERN MED, V145, P1800, DOI 10.1001/archinte.145.10.1800; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; ROSS RT, 1983, ARCH NEUROL-CHICAGO, V40, P633, DOI 10.1001/archneur.1983.04050090069011; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHINAR D, 1985, ARCH NEUROL-CHICAGO, V42, P557, DOI 10.1001/archneur.1985.04060060059010; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SUZUKI I, 1992, NEUROLOGY, V42, P2207, DOI 10.1212/WNL.42.11.2207; TOMASELLO F, 1982, STROKE, V13, P32, DOI 10.1161/01.STR.13.1.32; Tong DC, 1998, NEUROLOGY, V50, P864, DOI 10.1212/WNL.50.4.864; TREVES TA, 1994, STROKE, V25, P1263, DOI 10.1161/01.STR.25.6.1263; TUTHILL JE, 1969, AM HEART J, V78, P53, DOI 10.1016/0002-8703(69)90258-0; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; VOGEL HP, 1992, NEUROLOGY, V42, P2076, DOI 10.1212/WNL.42.11.2076; VONARBIN M, 1981, STROKE, V12, P288, DOI 10.1161/01.STR.12.3.288; VONARBIN M, 1980, J CHRON DIS, V33, P215, DOI 10.1016/0021-9681(80)90066-1; Wang S, 2003, STROKE, V34, pE188, DOI 10.1161/01.STR.0000091847.82140.9D; WERDELIN L, 1988, NEUROLOGY, V38, P677, DOI 10.1212/WNL.38.5.677; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523; Ziegler DK, 1973, STROKE, V4, P666, DOI 10.1161/01.STR.4.4.666	82	125	133	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2005	293	19					2391	2402		10.1001/jama.293.19.2391	http://dx.doi.org/10.1001/jama.293.19.2391			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	926JX	15900010				2022-12-28	WOS:000229120600027
J	Greffet, JJ				Greffet, JJ			Nanoantennas for light emission	SCIENCE			English	Editorial Material									Ecole Cent Paris, Lab EM2C, CNRS, UPR 288, F-92295 Chatenay Malabry, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Greffet, JJ (corresponding author), Ecole Cent Paris, Lab EM2C, CNRS, UPR 288, F-92295 Chatenay Malabry, France.	greffet@em2c.ecp.fr	Greffet, Jean-Jacques/S-3495-2019; Greffet, Jean-Jacques/Q-2427-2015	Greffet, Jean-Jacques/0000-0002-4048-2150; Greffet, Jean-Jacques/0000-0002-4048-2150				Azoulay J, 2000, EUROPHYS LETT, V51, P374, DOI 10.1209/epl/i2000-00504-y; Bian RX, 1995, PHYS REV LETT, V75, P4772, DOI 10.1103/PhysRevLett.75.4772; GOY P, 1983, PHYS REV LETT, V50, P1903, DOI 10.1103/PhysRevLett.50.1903; Greffet JJ, 2002, NATURE, V416, P61, DOI 10.1038/416061a; Hartschuh A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.095503; Hayazawa N, 2002, J CHEM PHYS, V117, P1296, DOI 10.1063/1.1485731; Lodahl P, 2004, NATURE, V430, P654, DOI 10.1038/nature02772; Muhlschlegel P, 2005, SCIENCE, V308, P1607, DOI 10.1126/science.1111886; Okamoto K, 2004, NAT MATER, V3, P601, DOI 10.1038/nmat1198; PURCELL EM, 1946, PHYS REV, V69, P681; Rigneault H, 1999, OPT LETT, V24, P148, DOI 10.1364/OL.24.000148; Schuck PJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.017402; Thomas M, 2004, APPL PHYS LETT, V85, P3863, DOI 10.1063/1.1812592; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	14	177	179	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1561	+		10.1126/science.1113355	http://dx.doi.org/10.1126/science.1113355			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947162				2022-12-28	WOS:000229827000029
J	Rocha, B				Rocha, B			Comment on "Thymic origin of intestinal alpha beta T cells revealed by fate mapping of ROR gamma t(+) cells"	SCIENCE			English	Editorial Material							GUT CRYPTOPATCHES; LYMPHOCYTES		Univ Paris 05, Inst Necker, INSERM, U591, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Rocha, B (corresponding author), Univ Paris 05, Inst Necker, INSERM, U591, 158 Rue Vaugirard, F-75015 Paris, France.							BARRETT TA, 1992, J IMMUNOL, V149, P1124; Eberl G, 2004, SCIENCE, V305, P248, DOI 10.1126/science.1096472; HULEATT JW, 1995, J IMMUNOL, V154, P5684; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Laky K, 2000, J EXP MED, V191, P1569, DOI 10.1084/jem.191.9.1569; Lambolez F, 2002, J EXP MED, V195, P437, DOI 10.1084/jem.20010798; REGNAULT A, 1994, J EXP MED, V180, P1345, DOI 10.1084/jem.180.4.1345; Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275; Suzuki K, 2000, IMMUNITY, V13, P691, DOI 10.1016/S1074-7613(00)00068-6; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294	11	9	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728								10.1126/science.1107363	http://dx.doi.org/10.1126/science.1107363			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947157				2022-12-28	WOS:000229827000022
J	He, L; Thomson, JM; Hemann, MT; Hernando-Monge, E; Mu, D; Goodson, S; Powers, S; Cordon-Cardo, C; Lowe, SW; Hannon, GJ; Hammond, SM				He, L; Thomson, JM; Hemann, MT; Hernando-Monge, E; Mu, D; Goodson, S; Powers, S; Cordon-Cardo, C; Lowe, SW; Hannon, GJ; Hammond, SM			A microRNA polycistron as a potential human oncogene	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DEVELOPMENTAL SWITCH; IN-VIVO; GENE; RNA; SUPPRESSION; EXPRESSION; LYMPHOMA; ENCODES; TARGET	To date, more than 200 microRNAs have been described in humans; however, the precise functions of these regulatory, noncoding RNAs remains largely obscure. One cluster of microRNAs, the mir-17-92 polycistron, is located in a region of DNA that is amplified in human B-cell lymphomas(1). Here we compared B-cell lymphoma samples and cell lines to normal tissues, and found that the levels of the primary or mature microRNAs derived from the mir-17-92 locus are often substantially increased in these cancers. Enforced expression of the mir-17-92 cluster acted with c-myc expression to accelerate tumour development in a mouse B-cell lymphoma model. Tumours derived from haematopoietic stem cells expressing a subset of the mir- 17 - 92 cluster and c-myc could be distinguished by an absence of apoptosis that was otherwise prevalent in c-myc-induced lymphomas. Together, these studies indicate that non-coding RNAs, specifically microRNAs, can modulate tumour formation, and implicate the mir- 17 - 92 cluster as a potential human oncogene.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA	Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Memorial Sloan Kettering Cancer Center	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.edu; hammond@med.unc.edu	Mu, David/E-8933-2011; Hannon, Gregory/AAB-3568-2019	Mu, David/0000-0002-7762-0182; Powers, Scott/0000-0003-2769-1932; Hernando, Eva/0000-0003-1023-0312	NATIONAL CANCER INSTITUTE [P01CA087497, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748, P01 CA087497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Knuutila S, 1998, AM J PATHOL, V152, P1107; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Tanzer A, 2004, J MOL BIOL, V339, P327, DOI 10.1016/j.jmb.2004.03.065; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369	28	2915	3228	4	262	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					828	833		10.1038/nature03552	http://dx.doi.org/10.1038/nature03552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944707	Green Submitted, Green Accepted			2022-12-28	WOS:000229638700053
J	Marshall, C				Marshall, C			Comment on "Abrupt and gradual extinction among late Permian land vertebrates in the Karoo basin, South Africa"	SCIENCE			English	Editorial Material									Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University	Marshall, C (corresponding author), Harvard Univ, Museum Comparat Zool, 26 Oxford St, Cambridge, MA 02138 USA.	cmarshal@oeb.harvard.edu						Marshall CR, 1996, SCIENCE, V274, P1360, DOI 10.1126/science.274.5291.1360; Marshall CR, 1998, ADEQUACY OF THE FOSSIL RECORD, P23; Schultz, 1982, GEOLOGICAL SOC AM SP, V190, P291, DOI DOI 10.1130/SPE190-P291; Wang SC, 2004, PALEOBIOLOGY, V30, P5, DOI 10.1666/0094-8373(2004)030<0005:ICIFET>2.0.CO;2; Ward PD, 2005, SCIENCE, V307, P709, DOI 10.1126/science.1107068	5	15	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2005	308	5727								10.1126/science.1110443	http://dx.doi.org/10.1126/science.1110443			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933184	Green Submitted			2022-12-28	WOS:000229619300027
J	Murphy, M; Aveyard, P				Murphy, M; Aveyard, P			New York City offensive against tobacco	LANCET			English	Editorial Material									Univ Oxford, Childhood Canc Res Grp, Oxford OX2 6HJ, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham, W Midlands, England; Univ Oxford, Dept Clin Pharmacol, Smoking Res Grp, Oxford OX2 6HJ, England	University of Oxford; University of Birmingham; University of Oxford	Murphy, M (corresponding author), Univ Oxford, Childhood Canc Res Grp, Oxford OX2 6HJ, England.	michael.murphy@ccrg.ox.ac.uk		Aveyard, Paul/0000-0002-1802-4217				Lancaster T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001292.pub2, 10.1002/14651858.CD001292.pub3]; Moher M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003440.pub2; Secker-Walker R, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd001745, DOI 10.1002/14651858.CD001745, 10.1002/14651858.CD001745]; SERRA C, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001294; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002850; TOWNSEND J, 1994, BMJ-BRIT MED J, V309, P923, DOI 10.1136/bmj.309.6959.923; *WHO, 2003, TOB FREE IN WHO FRAM	8	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1831	1832		10.1016/S0140-6736(05)66597-X	http://dx.doi.org/10.1016/S0140-6736(05)66597-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924967				2022-12-28	WOS:000229481400006
J	Nuesch, R; Gremmelmaier, D; Hirsch, HH; Marti, H; Hatz, C				Nuesch, R; Gremmelmaier, D; Hirsch, HH; Marti, H; Hatz, C			Chest pain after air travel	LANCET			English	Editorial Material									Univ Basel Hosp, Outpatient Dept Internal Med, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Infect Dis, CH-4031 Basel, Switzerland; Swiss Trop Inst, CH-4002 Basel, Switzerland	University of Basel; University of Basel; University of Basel; Swiss Tropical & Public Health Institute	Nuesch, R (corresponding author), Univ Basel Hosp, Outpatient Dept Internal Med, CH-4031 Basel, Switzerland.	nueschr@uhbs.ch		Hirsch, Hans H./0000-0003-0883-0423				CATCHPOLE BN, 1952, LANCET, V263, P711; FACEY RV, 1960, BMJ-BRIT MED J, V2, P619, DOI 10.1136/bmj.2.5199.619; Maher K, 1999, AM J TROP MED HYG, V61, P738, DOI 10.4269/ajtmh.1999.61.738; Millan JC, 2000, AM J TROP MED HYG, V63, P264, DOI 10.4269/ajtmh.2000.63.264; Mulcahy G, 1999, FASCIOLOSIS, P341	5	3	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	2005	365	9474					1902	1902		10.1016/S0140-6736(05)66625-1	http://dx.doi.org/10.1016/S0140-6736(05)66625-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924990				2022-12-28	WOS:000229481400032
J	Bingenheimer, JB; Brennan, RT; Earls, FJ				Bingenheimer, JB; Brennan, RT; Earls, FJ			Firearm violence exposure and serious violent behavior	SCIENCE			English	Article							COMMUNITY VIOLENCE; PROPENSITY SCORE; CYCLE; RISK; HOMICIDE	To estimate the cause-effect relationship between exposure to firearm violence and subsequent perpetration of serious violence, we applied the analytic method of propensity stratification to longitudinal data on adolescents residing in Chicago, Illinois. Results indicate that exposure to firearm violence approximately doubles the probability that an adolescent will perpetrate serious violence over the subsequent 2 years.	Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Dept Social Med, Cambridge, MA 02138 USA	University of Michigan System; University of Michigan; Harvard University	Bingenheimer, JB (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, 1420 Washington Hts, Ann Arbor, MI 48109 USA.	bartbing@umich.edu	Brennan, Robert T/B-8289-2013					Benjamin DJ, 2003, J PUBLIC ECON, V87, P1259, DOI 10.1016/S0047-2727(01)00167-0; Buka SL, 2001, AM J ORTHOPSYCHIAT, V71, P298, DOI 10.1037/0002-9432.71.3.298; CORNFIELD J, 1959, J NATL CANCER I, V22, P173; DODGE KA, 1990, SCIENCE, V250, P1678, DOI 10.1126/science.2270481; FARRINGTON DP, 1998, CRIME JUSTICE, V0024; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3054, DOI 10.1001/jama.267.22.3054; Gorman-Smith D, 1998, DEV PSYCHOPATHOL, V10, P101, DOI 10.1017/S0954579498001539; Halliday-Boykins CA, 2001, J ABNORM CHILD PSYCH, V29, P383, DOI 10.1023/A:1010443302344; HAWKINS JD, 1998, SERIOUS VIOLENT JUVE, pCH7; He K, 2002, JAMA-J AM MED ASSOC, V288, P3130, DOI 10.1001/jama.288.24.3130; HOLLAND PW, 1986, J AM STAT ASSOC, V81, P945, DOI 10.2307/2289064; Miller LS, 1999, J CLIN CHILD PSYCHOL, V28, P2, DOI 10.1207/s15374424jccp2801_1; Raudenbush SW, 1999, SOCIOL METHODOL, V29, P1, DOI 10.1111/0081-1750.00059; RICHTERS JE, 1993, PSYCHIATRY, V56, P7; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; SCHUBINER H, 1993, J ADOLESCENT HEALTH, V14, P214, DOI 10.1016/1054-139X(93)90008-D; SCHWABSTONE ME, 1995, J AM ACAD CHILD PSY, V34, P1343, DOI 10.1097/00004583-199510000-00020; SILVER LB, 1969, AM J PSYCHIAT, V126, P404, DOI 10.1176/ajp.126.3.404; Skeem JL, 2001, J CONSULT CLIN PSYCH, V69, P358, DOI 10.1037//0022-006X.69.3.358; Song LY, 1998, ARCH PEDIAT ADOL MED, V152, P531; SPINETTA JJ, 1972, PSYCHOL BULL, V77, P296, DOI 10.1037/h0032419; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995	28	134	134	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1323	1326		10.1126/science.1110096	http://dx.doi.org/10.1126/science.1110096			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	931JT	15919997				2022-12-28	WOS:000229482300052
J	Hannan, EL; Racz, MJ; Walford, G; Jones, RH; Ryan, TJ; Bennett, E; Culliford, AT; Isom, OW; Gold, JP; Rose, EA				Hannan, EL; Racz, MJ; Walford, G; Jones, RH; Ryan, TJ; Bennett, E; Culliford, AT; Isom, OW; Gold, JP; Rose, EA			Long-term outcomes of coronary-artery bypass grafting versus stent implantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIROLIMUS-ELUTING STENTS; RANDOMIZED-TRIAL; MULTIVESSEL DISEASE; FOLLOW-UP; PROPENSITY SCORE; CLINICAL-TRIALS; SURGERY TRIAL; ANGIOPLASTY; STENOSIS; SURVIVAL	Background Several studies have compared outcomes for coronary-artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), but most were done before the availability of stenting, which has revolutionized the latter approach. Methods We used New York's cardiac registries to identify 37,212 patients with multivessel disease who underwent CABG and 22,102 patients with multivessel disease who underwent PCI from January 1, 1997, to December 31, 2000. We determined the rates of death and subsequent revascularization within three years after the procedure in various groups of patients according to the number of diseased vessels and the presence or absence of involvement of the left anterior descending coronary artery. The rates of adverse outcomes were adjusted by means of proportional-hazards methods to account for differences in patients' severity of illness before revascularization. Results Risk-adjusted survival rates were significantly higher among patients who underwent CABG than among those who received a stent in all of the anatomical subgroups studied. For example, the adjusted hazard ratio for the long-term risk of death after CABG relative to stent implantation was 0.64 (95 percent confidence interval, 0.56 to 0.74) for patients with three-vessel disease with involvement of the proximal left anterior descending coronary artery and 0.76 (95 percent confidence interval, 0.60 to 0.96) for patients with two-vessel disease with involvement of the nonproximal left anterior descending coronary artery. Also, the three-year rates of revascularization were considerably higher in the stenting group than in the CABG group (7.8 percent vs. 0.3 percent for subsequent CABG and 27.3 percent vs. 4.6 percent for subsequent PCI). Conclusions For patients with two or more diseased coronary arteries, CABG is associated with higher adjusted rates of long-term survival than stenting.	SUNY Albany, Albany, NY 12222 USA; St Josephs Hosp, Syracuse, NY USA; Duke Univ, Med Ctr, Durham, NC USA; Boston Univ, Sch Med, Boston, MA 02118 USA; St Peters Hosp, Albany, NY USA; NYU, Med Ctr, New York, NY 10016 USA; New York Hosp, Weil Cornell Med Ctr, New York, NY 10021 USA; Montefiore Med Ctr, Bronx, NY 10467 USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Duke University; Boston University; New York University; NewYork-Presbyterian Hospital; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Columbia University; NewYork-Presbyterian Hospital	Hannan, EL (corresponding author), SUNY Albany, Albany, NY 12222 USA.		Rose, Eric/AAJ-2281-2020					Alderman EL, 1996, NEW ENGL J MED, V335, P217; Allison P. D., 1995, SURVIVAL ANAL USING; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Carrie D, 1997, CIRCULATION, V96, P1; Chaitman BR, 1997, CIRCULATION, V96, P2162; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Ghali WA, 2001, JAMA-J AM MED ASSOC, V286, P1494, DOI 10.1001/jama.286.12.1494; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; Goy JJ, 2000, MAYO CLIN PROC, V75, P1116, DOI 10.4065/75.11.1116; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; Hannan EL, 1999, J AM COLL CARDIOL, V33, P63, DOI 10.1016/S0735-1097(98)00540-3; Hoffman SN, 2003, J AM COLL CARDIOL, V41, P1293, DOI 10.1016/S0735-1097(03)00157-8; Howard G, 1997, JAMA-J AM MED ASSOC, V278, P1432; HOWARD G, 1998, JAMA-J AM MED ASSOC, V279, P580; Hueb WA, 1999, CIRCULATION, V100, P107; Jones RH, 1996, J THORAC CARDIOV SUR, V111, P1013, DOI 10.1016/S0022-5223(96)70378-1; King SB, 2000, J AM COLL CARDIOL, V35, P1116, DOI 10.1016/S0735-1097(00)00546-5; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Lauer MS, 2003, JAMA-J AM MED ASSOC, V289, P2575, DOI 10.1001/jama.289.19.2575; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Regar E, 2002, CIRCULATION, V106, P1949, DOI 10.1161/01.CIR.0000034045.36219.12; RICKARDS AF, 1995, LANCET, V346, P1179; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P51, DOI 10.1016/S0735-1097(00)01052-4; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P973; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Sigwart U, 2002, LANCET, V360, P965; Tanabe K, 2003, CIRCULATION, V107, P559, DOI 10.1161/01.CIR.0000048184.96491.8A; The Bypass Angioplasty Revascularization Investigation (BARI) Investigators, 1997, NEW ENGL J MED, V336, P147	33	472	505	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2174	2183		10.1056/NEJMoa040316	http://dx.doi.org/10.1056/NEJMoa040316			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917382				2022-12-28	WOS:000229333300005
J	Yudkin, JS; Eringa, E; Stehouwer, CDA				Yudkin, JS; Eringa, E; Stehouwer, CDA			"Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease	LANCET			English	Article							EPICARDIAL ADIPOSE-TISSUE; HUMAN SKELETAL-MUSCLE; CAPILLARY RECRUITMENT; NITRIC-OXIDE; PHYSIOLOGICAL HYPERINSULINEMIA; PROTEIN; SENSITIVITY; SYNTHASE; OBESITY; ALPHA	Adipose tissue expresses cytokines that inhibit insulin signalling pathways in liver and muscle. Obesity also results in impairment of endothelium-dependent vasodilatation in response to insulin. We propose a vasoregulatory role for local deposits of fat around the origin of arterioles supplying skeletal muscle. Isolated first-order arterioles from rat cremaster muscle are under dual regulation by insulin, which activates both endothelin-1 mediated vasoconstriction and nitric-oxide-mediated vasodilatation. In obese rat arterioles, insulin-stimulated NO synthesis is impaired, resulting in unopposed vasoconstriction. We propose that this vasoconstriction is the consequence of production of the adipocytokine tumour necrosis factor alpha from the cuff of fat seen surrounding the origin of the arteriole in obese rats-a depot to which we ascribe a specialist vasoregulatory role. We suggest that this cytokine accesses the nutritive vascular tree to inhibit insulin-mediated capillary recruitment-a mechanism we term "vasocrine" signalling. We also suggest a homology between this vasoactive periarteriolar fat and both periarterial and visceral fat, which may explain relations between visceral fat, insulin resistance, and vascular disease.	UCL Royal Free & Univ Coll Med Sch, Dept Med, Diabet & Cardiovasc Dis Acad Unit, London N19 5LW, England; Vrije Univ Amsterdam, Inst Cardiovasc Res, Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Physiol, Amsterdam, Netherlands; Univ Limburg, Acad Hosp Maastricht, Maastricht, Netherlands; Univ Maastricht, Maastricht, Netherlands	University of London; University College London; UCL Medical School; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University	Yudkin, JS (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Diabet & Cardiovasc Dis Acad Unit, Archway Campus,Holborn Union Bldg,2-10 Highgate H, London N19 5LW, England.	j.yudkin@ucl.ac.uk	Eringa, Ed/ABA-3194-2021; Yudkin, John S/C-1988-2008; Stehouwer, Coen/AAB-3435-2021	Eringa, Etto/0000-0002-9814-5149; Stehouwer, Coen/0000-0001-8752-3223				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Arner P, 2001, BIOCHEM SOC T, V29, P72, DOI 10.1042/bst0290072; BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124; Coggins M, 2001, DIABETES, V50, P2682, DOI 10.2337/diabetes.50.12.2682; DAVDA RK, 1995, HYPERTENSION, V26, P764, DOI 10.1161/01.HYP.26.5.764; Eringa EC, 2004, AM J PHYSIOL-HEART C, V287, pH2043, DOI 10.1152/ajpheart.00067.2004; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GREENE AS, 1989, AM J PHYSIOL, V256, P126; Iacobellis G, 2003, J CLIN ENDOCR METAB, V88, P5163, DOI 10.1210/jc.2003-030698; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Mazurek T, 2003, CIRCULATION, V108, P2460, DOI 10.1161/01.CIR.0000099542.57313.C5; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; Newman JMB, 1997, MICROVASC RES, V54, P49, DOI 10.1006/mvre.1997.2021; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Rattigan S, 1997, DIABETES, V46, P1381, DOI 10.2337/diabetes.46.9.1381; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Serne EH, 2002, DIABETES, V51, P1515, DOI 10.2337/diabetes.51.5.1515; Wallis MG, 2002, DIABETES, V51, P3492, DOI 10.2337/diabetes.51.12.3492; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Zhang L, 2004, DIABETES, V53, P447, DOI 10.2337/diabetes.53.2.447; Zhang L, 2003, AM J PHYSIOL-ENDOC M, V285, pE654, DOI 10.1152/ajpendo.00119.2003	22	411	431	0	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1817	1820		10.1016/S0140-6736(05)66585-3	http://dx.doi.org/10.1016/S0140-6736(05)66585-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910955				2022-12-28	WOS:000229291600027
J	Kirschner, MW				Kirschner, MW			The meaning of systems biology	CELL			English	Editorial Material									Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	marc@hms.harvard.edu							0	198	208	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					503	504		10.1016/j.cell.2005.05.005	http://dx.doi.org/10.1016/j.cell.2005.05.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907462	Bronze			2022-12-28	WOS:000229331200005
J	Okada, Y; Takeda, S; Tanaka, Y; Belmonte, JCI; Hirokawa, N				Okada, Y; Takeda, S; Tanaka, Y; Belmonte, JCI; Hirokawa, N			Mechanism of nodal flow: A conserved symmetry breaking event in left-right axis determination	CELL			English	Article							LEFT-RIGHT ASYMMETRY; ZEBRAFISH; MICE; MICROTUBULE; EXPRESSION; MONOCILIA; FLUID	The leftward flow in extraembryonic fluid is critical for the initial determination of the left-right axis of mouse embryos. It is unclear if this is a conserved mechanism among other vertebrates and how the directionality of the flow arises from the motion of cilia. In this paper, we show that rabbit and medakafish embryos also exhibit a leftward fluid flow in their ventral nodes. In all cases, primary monocilia present a clockwise rotational-like motion. Observations of defective ciliary dynamics in mutant mouse embryos support the idea that the posterior tilt of the cilia during rotational-like beating can explain the leftward fluid flow. Moreover, we show that this leftward flow may produce asymmetric distribution of exogenously introduced proteins, suggesting morphogen gradients as a subsequent mechanism of left-right axis determination. Finally, we experimentally and theoretically characterize under which conditions a morphogen gradient can arise from the flow.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	University of Tokyo; Salk Institute	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, 7-3-1 Hongo, Tokyo 1130033, Japan.	hirokawa@m.u-tokyo.ac.jp	Takeda, Sen/I-8462-2012; Okada, Yasushi/N-5067-2015	Takeda, Sen/0000-0001-7090-2139; Okada, Yasushi/0000-0003-2601-3689; Tanaka, Yosuke/0000-0001-5376-5726				Amack JD, 2004, CURR BIOL, V14, P685, DOI 10.1016/j.cub.2004.04.002; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; Bisgrove BW, 2001, AM J MED GENET, V101, P315, DOI 10.1002/ajmg.1180; BLAKE JR, 1974, BIOL REV, V49, P85, DOI 10.1111/j.1469-185X.1974.tb01299.x; BROWN NA, 1990, DEVELOPMENT, V109, P1; Cartwright JHE, 2004, P NATL ACAD SCI USA, V101, P7234, DOI 10.1073/pnas.0402001101; Essner JJ, 2002, NATURE, V418, P37, DOI 10.1038/418037a; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Mercola M, 2001, ANNU REV CELL DEV BI, V17, P779, DOI 10.1146/annurev.cellbio.17.1.779; NAKATA T, 1993, BIOPHYS J, V65, P2504, DOI 10.1016/S0006-3495(93)81304-3; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Supp DM, 1999, DEVELOPMENT, V126, P5495; Tabin CJ, 2003, GENE DEV, V17, P1, DOI 10.1101/gad.1053803; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; TAKEDA S, 1995, NEURON, V14, P1257, DOI 10.1016/0896-6273(95)90272-4; Vogan KJ, 1999, NATURE, V397, P295, DOI 10.1038/16796; Wargo MJ, 2003, P NATL ACAD SCI USA, V100, P137, DOI 10.1073/pnas.0135800100; Watanabe D, 2003, DEVELOPMENT, V130, P1725, DOI 10.1242/dev.00407; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3	25	333	344	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 20	2005	121	4					633	644		10.1016/j.cell.2005.04.008	http://dx.doi.org/10.1016/j.cell.2005.04.008			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	929GX	15907475	Bronze			2022-12-28	WOS:000229331200018
J	Wang, XQ; Lu, T; Snider, RK; Liang, L				Wang, XQ; Lu, T; Snider, RK; Liang, L			Sustained firing in auditory cortex evoked by preferred stimuli	NATURE			English	Article							COMMUNICATION SOUNDS; CORTICAL-NEURONS; RESPONSES; REPRESENTATION; CAT; NOISE; ANESTHESIA; AMPLITUDE; PRIMATES; MONKEYS	It has been well documented that neurons in the auditory cortex of anaesthetized animals generally display transient responses to acoustic stimulation, and typically respond to a brief stimulus with one or fewer action potentials(1-5). The number of action potentials evoked by each stimulus usually does not increase with increasing stimulus duration(1,5-7). Such observations have long puzzled researchers across disciplines and raised serious questions regarding the role of the auditory cortex in encoding ongoing acoustic signals. Contrary to these long-held views, here we show that single neurons in both primary ( area A1) and lateral belt areas of the auditory cortex of awake marmoset monkeys ( Callithrix jacchus) are capable of firing in a sustained manner over a prolonged period of time, especially when they are driven by their preferred stimuli. In contrast, responses become more transient or phasic when auditory cortex neurons respond to non-preferred stimuli. These findings suggest that when the auditory cortex is stimulated by a sound, a particular population of neurons fire maximally throughout the duration of the sound. Responses of other, less optimally driven neurons fade away quickly after stimulus onset. This results in a selective representation of the sound across both neuronal population and time.	Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Lab Auditory Neurophysiol, Baltimore, MD 21205 USA	Johns Hopkins University	Wang, XQ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Lab Auditory Neurophysiol, Baltimore, MD 21205 USA.	xwang@bme.jhu.edu						AITKIN LM, 1986, J COMP NEUROL, V252, P175, DOI 10.1002/cne.902520204; Bar-Yosef O, 2002, J NEUROSCI, V22, P8619; Bieser A, 1996, EXP BRAIN RES, V108, P273; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; CALFORD MB, 1995, J NEUROPHYSIOL, V73, P1876, DOI 10.1152/jn.1995.73.5.1876; Cheung SW, 2001, HEARING RES, V156, P115, DOI 10.1016/S0378-5955(01)00272-6; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; DeWeese MR, 2003, J NEUROSCI, V23, P7940; Eggermont JJ, 1997, NEUROREPORT, V8, P2709, DOI 10.1097/00001756-199708180-00014; Elhilali M, 2004, J NEUROSCI, V24, P1159, DOI 10.1523/JNEUROSCI.3825-03.2004; Gaese BH, 2001, J NEUROPHYSIOL, V86, P1062, DOI 10.1152/jn.2001.86.2.1062; Heil P, 1997, J NEUROPHYSIOL, V77, P2642, DOI 10.1152/jn.1997.77.5.2642; KANWAL JS, 1994, J ACOUST SOC AM, V96, P1229, DOI 10.1121/1.410273; Liang L, 2002, J NEUROPHYSIOL, V87, P2237, DOI 10.1152/jn.2002.87.5.2237; Lu T, 2004, J NEUROPHYSIOL, V91, P301, DOI 10.1152/jn.00022.2003; Lu T, 2001, NAT NEUROSCI, V4, P1131, DOI 10.1038/nn737; Malone BJ, 2002, J NEUROSCI, V22, P4625, DOI 10.1523/JNEUROSCI.22-11-04625.2002; Mickey BJ, 2003, J NEUROSCI, V23, P8649; PFINGST BE, 1981, J NEUROPHYSIOL, V45, P16, DOI 10.1152/jn.1981.45.1.16; PHILLIPS DP, 1985, HEARING RES, V19, P253, DOI 10.1016/0378-5955(85)90145-5; PHILLIPS DP, 1993, ANN NY ACAD SCI, V682, P104, DOI 10.1111/j.1749-6632.1993.tb22963.x; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; Recanzone GH, 2000, HEARING RES, V150, P104, DOI 10.1016/S0378-5955(00)00194-5; RHODE WS, 1986, J NEUROPHYSIOL, V56, P261, DOI 10.1152/jn.1986.56.2.261; Schnupp JWH, 2001, NATURE, V414, P200, DOI 10.1038/35102568; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SUGA N, 1989, J EXP BIOL, V146, P277; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685; Wang XQ, 2000, P NATL ACAD SCI USA, V97, P11843, DOI 10.1073/pnas.97.22.11843; ZURITA P, 1994, NEUROSCI RES, V19, P303, DOI 10.1016/0168-0102(94)90043-4	30	276	280	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					341	346		10.1038/nature03565	http://dx.doi.org/10.1038/nature03565			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902257				2022-12-28	WOS:000229185000045
J	Oransky, I				Oransky, I			Wilfred Gordon Bigelow - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						BIGELOW WG, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 7	2005	365	9471					1616	1616		10.1016/S0140-6736(05)66498-7	http://dx.doi.org/10.1016/S0140-6736(05)66498-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923UB	15898141				2022-12-28	WOS:000228933700014
J	Borrero, JC				Borrero, JC			Field data and satellite imagery of tsunami effects in Banda Aceh	SCIENCE			English	Article									Univ So Calif, Dept Civil Engn, Tsunami Res Ctr, Los Angeles, CA 90089 USA	University of Southern California	Borrero, JC (corresponding author), Univ So Calif, Dept Civil Engn, Tsunami Res Ctr, Los Angeles, CA 90089 USA.	jborrero@usc.edu						Okal EA, 2004, GEOPHYS J INT, V158, P899, DOI 10.1111/j.1365-246x.2004.02347.x; Synolakis CE, 2002, P ROY SOC A-MATH PHY, V458, P763, DOI 10.1098/rspa.2001.0915; Tadepalli S, 1996, PHYS REV LETT, V77, P2141, DOI 10.1103/PhysRevLett.77.2141; Titov VV, 2005, NAT HAZARDS, V35, P41, DOI 10.1007/s11069-004-2403-3	4	94	97	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1596	1596		10.1126/science.1110957	http://dx.doi.org/10.1126/science.1110957			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947180				2022-12-28	WOS:000229827000047
J	Achlioptas, D; Naor, A; Peres, Y				Achlioptas, D; Naor, A; Peres, Y			Rigorous location of phase transitions in hard optimization problems	NATURE			English	Article							STATISTICAL-MECHANICS; K-SAT; SATISFIABILITY; THRESHOLD	It is widely believed that for many optimization problems, no algorithm is substantially more efficient than exhaustive search. This means that finding optimal solutions for many practical problems is completely beyond any current or projected computational capacity. To understand the origin of this extreme 'hardness', computer scientists, mathematicians and physicists have been investigating for two decades a connection between computational complexity and phase transitions in random instances of constraint satisfaction problems. Here we present a mathematically rigorous method for locating such phase transitions. Our method works by analysing the distribution of distances between pairs of solutions as constraints are added. By identifying critical behaviour in the evolution of this distribution, we can pinpoint the threshold location for a number of problems, including the two most-studied ones: random k-SAT and random graph colouring. Our results prove that the heuristic predictions of statistical physics in this context are essentially correct. Moreover, we establish that random instances of constraint satisfaction problems have solutions well beyond the reach of any analysed algorithm.	Microsoft Res, Redmond, WA 98052 USA; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA	Microsoft; University of California System; University of California Berkeley	Achlioptas, D (corresponding author), Microsoft Res, 1 Microsoft Way, Redmond, WA 98052 USA.	optas@microsoft.com	Achlioptas, Dimitris/AAJ-6358-2020					Achlioptas D, 2004, J AM MATH SOC, V17, P947, DOI 10.1090/S0894-0347-04-00464-3; Achlioptas D, 2002, ANN IEEE SYMP FOUND, P779, DOI 10.1109/SFCS.2002.1182003; Achlioptas D, 2003, ANN IEEE SYMP FOUND, P362, DOI 10.1109/SFCS.2003.1238210; Achlioptas D., 2004, P 36 ANN ACM S THEOR, P587; Anderson PW, 1999, NATURE, V400, P115, DOI 10.1038/22001; Appel Kenneth, 1989, CONT MATH, V98; Bollobas B., 2001, RANDOM GRAPHS, V73; CHEESEMAN P, 1991, P 12 INT JOINT C ART, P331; COOK SA, 1971, STOC 71, P151, DOI DOI 10.1145/800157.805047; Coppersmith D, 2004, RANDOM STRUCT ALGOR, V24, P502, DOI 10.1002/rsa.20015; Dubois O, 2000, PROCEEDINGS OF THE ELEVENTH ANNUAL ACM-SIAM SYMPOSIUM ON DISCRETE ALGORITHMS, P126; Friedgut E, 1999, J AM MATH SOC, V12, P1017, DOI 10.1090/S0894-0347-99-00305-7; Frieze A, 1996, J ALGORITHM, V20, P312, DOI 10.1006/jagm.1996.0016; FU YT, 1986, J PHYS A-MATH GEN, V19, P1605, DOI 10.1088/0305-4470/19/9/033; Gomes CP, 2002, SCIENCE, V297, P784, DOI 10.1126/science.1074599; KAPORIS AC, 2002, P 10 ANN EUR S ALG, P574; Kirousis LM, 1998, RANDOM STRUCT ALGOR, V12, P253, DOI 10.1002/(SICI)1098-2418(199805)12:3<253::AID-RSA3>3.0.CO;2-U; Krzakala F, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.046705; MERTENS S, 2003, IN PRESS RANDOM STRU; Mezard M, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056126; Mezard M, 2002, SCIENCE, V297, P812, DOI 10.1126/science.1073287; Monasson R, 1997, PHYS REV E, V56, P1357, DOI 10.1103/PhysRevE.56.1357; Selman B., 1992, P 10 NAT C ART INT, P459	25	144	148	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					759	764		10.1038/nature03602	http://dx.doi.org/10.1038/nature03602			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944693				2022-12-28	WOS:000229638700039
J	Nelson, R; Sawaya, MR; Balbirnie, M; Madsen, AO; Riekel, C; Grothe, R; Eisenberg, D				Nelson, R; Sawaya, MR; Balbirnie, M; Madsen, AO; Riekel, C; Grothe, R; Eisenberg, D			Structure of the cross-beta spine of amyloid-like fibrils	NATURE			English	Article							X-RAY-DIFFRACTION; MOLECULAR-BASIS; PROTEIN MODELS; CORE STRUCTURE; SHEET; PEPTIDE; TRANSTHYRETIN; CONFORMATION; CONVERSION; REVEALS	Numerous soluble proteins convert to insoluble amyloid-like fibrils that have common properties. Amyloid fibrils are associated with fatal diseases such as Alzheimer's, and amyloid-like fibrils can be formed in vitro. For the yeast protein Sup35, conversion to amyloid-like fibrils is associated with a transmissible infection akin to that caused by mammalian prions. A seven-residue peptide segment from Sup35 forms amyloid-like fibrils and closely related microcrystals, from which we have determined the atomic structure of the cross-beta spine. It is a double beta-sheet, with each sheet formed from parallel segments stacked in register. Side chains protruding from the two sheets form a dry, tightly self-complementing steric zipper, bonding the sheets. Within each sheet, every segment is bound to its two neighbouring segments through stacks of both backbone and side-chain hydrogen bonds. The structure illuminates the stability of amyloid fibrils, their self-seeding characteristic and their tendency to form polymorphic structures.	Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Proteom, Los Angeles, CA 90095 USA; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Copenhagen, Ctr Crystallog Studies, Dept Chem, DK-2100 KBH, Denmark	Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles; European Synchrotron Radiation Facility (ESRF); University of Copenhagen	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, UCLA DOE Inst Genom & Proteom, Box 951570, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu	Madsen, Anders Østergaard/B-4760-2015	Madsen, Anders Østergaard/0000-0001-5422-8076; Sawaya, Michael/0000-0003-0874-9043	NIGMS NIH HHS [T32 GM007185, P01 GM031299] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, P01GM031299] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; COHEN AS, 1959, NATURE, V183, P1202, DOI 10.1038/1831202a0; COULSON CA, 1966, PROC R SOC LON SER-A, V291, P445, DOI 10.1098/rspa.1966.0105; de la Paz ML, 2004, P NATL ACAD SCI USA, V101, P87, DOI 10.1073/pnas.2634884100; DeLano WL, 2002, PYMOL USERS MANUAL; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Diaz-Avalos R, 2003, J MOL BIOL, V330, P1165, DOI 10.1016/S0022-2836(03)00659-4; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Jaroniec CP, 2002, P NATL ACAD SCI USA, V99, P16748, DOI 10.1073/pnas.252625999; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Makin OS, 2005, P NATL ACAD SCI USA, V102, P315, DOI 10.1073/pnas.0406847102; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Pickersgill RW, 2003, STRUCTURE, V11, P137, DOI 10.1016/S0969-2126(03)00009-1; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Riekel C, 2004, J SYNCHROTRON RADIAT, V11, P4, DOI 10.1107/S090904950302541X; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Sivaraman T, 1998, J BIOL CHEM, V273, P10181, DOI 10.1074/jbc.273.17.10181; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tjernberg L, 2002, J BIOL CHEM, V277, P43243, DOI 10.1074/jbc.M205570200; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008	50	1736	1772	4	420	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					773	778		10.1038/nature03680	http://dx.doi.org/10.1038/nature03680			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944695	Green Accepted			2022-12-28	WOS:000229638700041
J	Sotin, C; Jaumann, R; Buratti, BJ; Brown, RH; Clark, RN; Soderblom, LA; Baines, KH; Bellucci, G; Bibring, JP; Capaccioni, F; Cerroni, P; Combes, M; Coradini, A; Cruikshank, DP; Drossart, P; Formisano, V; Langevin, Y; Matson, DL; McCord, TB; Nelson, RM; Nicholson, PD; Sicardy, B; LeMouelic, S; Rodriguez, S; Stephan, K; Scholz, CK				Sotin, C; Jaumann, R; Buratti, BJ; Brown, RH; Clark, RN; Soderblom, LA; Baines, KH; Bellucci, G; Bibring, JP; Capaccioni, F; Cerroni, P; Combes, M; Coradini, A; Cruikshank, DP; Drossart, P; Formisano, V; Langevin, Y; Matson, DL; McCord, TB; Nelson, RM; Nicholson, PD; Sicardy, B; LeMouelic, S; Rodriguez, S; Stephan, K; Scholz, CK			Release of volatiles from a possible cryovolcano from near-infrared imaging of Titan	NATURE			English	Article							OCEAN	Titan is the only satellite in our Solar System with a dense atmosphere. The surface pressure is 1.5 bar ( ref. 1) and, similar to the Earth, N-2 is the main component of the atmosphere. Methane is the second most important component(2), but it is photodissociated on a timescale of 10(7) years ( ref. 3). This short timescale has led to the suggestion that Titan may possess a surface or subsurface reservoir of hydrocarbons(4,5) to replenish the atmosphere. Here we report near-infrared images of Titan obtained on 26 October 2004 by the Cassini spacecraft. The images show that a widespread methane ocean does not exist; subtle albedo variations instead suggest topographical variations, as would be expected for a more solid ( perhaps icy) surface. We also find a circular structure similar to 30 km in diameter that does not resemble any features seen on other icy satellites. We propose that the structure is a dome formed by upwelling icy plumes that release methane into Titan's atmosphere.	Univ Nantes, CNRS, UMR 6112, Lab Planetol & Geodynam, F-44100 Nantes, France; DLR, Inst Planetary Explorat, D-12489 Berlin, Germany; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Arizona, Stewart Observ, Tucson, AZ 85721 USA; US Geol Survey, Denver, CO 80225 USA; US Geol Survey, Flagstaff, AZ 86011 USA; CNR, Ist Fis Spazio Interplanetario, I-00133 Rome, Italy; Univ Paris 11, Inst Astrophys Spatiale, F-91405 Orsay, France; CNR, Ist Astrofis Spaziale & Fis Cosmica, I-00133 Rome, Italy; Observ Paris, F-92195 Meudon, France; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Nantes Universite; Helmholtz Association; German Aerospace Centre (DLR); California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona; University of Arizona; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Washington; University of Washington Seattle; Cornell University	Sotin, C (corresponding author), Univ Nantes, CNRS, UMR 6112, Lab Planetol & Geodynam, F-44100 Nantes, France.	Christophe.Sotin@univ-nantes.fr	Bellucci, Giancarlo/ABA-9201-2020; Rodriguez, Sebastien/H-5902-2016; Drossart, Pierre/H-8670-2013; Jaumann, Ralf/N-1001-2018; Stephan, Katrin/U-2524-2018	Bellucci, Giancarlo/0000-0003-0867-8679; Rodriguez, Sebastien/0000-0003-1219-0641; Jaumann, Ralf/0000-0002-9759-6597; Capaccioni, Fabrizio/0000-0003-1631-4314; Cerroni, Priscilla/0000-0003-0239-2741; Le Mouelic, Stephane/0000-0001-5260-1367				Brown RH, 2003, ICARUS, V164, P461, DOI 10.1016/S0019-1035(03)00134-9; Gibbard SG, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019803; KUIPER GP, 1944, ASTORPHYS J, V100, P329; LELLOUCH E, 1990, ANN GEOPHYS-ATM HYDR, V8, P653; LUCCHITTA BK, 1980, ICARUS, V44, P481, DOI 10.1016/0019-1035(80)90039-1; LUNINE JI, 1993, REV GEOPHYS, V31, P133, DOI 10.1029/92RG02794; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Meier R, 2000, ICARUS, V145, P462, DOI 10.1006/icar.2000.6360; Sotin C, 2004, CR PHYS, V5, P769, DOI 10.1016/j.crhy.2004.08.001; Sotin C, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013844; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	11	149	152	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2005	435	7043					786	789		10.1038/nature03596	http://dx.doi.org/10.1038/nature03596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944697	Green Submitted			2022-12-28	WOS:000229638700043
J	Choudhry, NK; Avorn, J				Choudhry, NK; Avorn, J			Over-the-counter statins	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN-CHOLESTEROL; CONSUMER USE; PREVENTION; THERAPY; PERSISTENCE; PRAVASTATIN; LOVASTATIN; AVERAGE; EVENTS	In late 2004, the British government decided to allow a lipid-lowering agent to be sold as an over-the-counter medication. In contrast, the U.S. Food and Drug Administration recently decided not to do so. The United States and other countries will soon face similar decisions for other statins. Although statins have infrequent side effects and have been shown to be effective in moderate-risk primary prevention populations, many questions remain unanswered about their effectiveness at lower doses in over-the-counter use, the ability of patients to self-select themselves for appropriate therapy, and the social and economic implications associated with this method of distribution for preventive medications. A rational policy decision concerning over-the-counter statin use will require an effectiveness trial to provide data on how such drugs would be used in this context, as well as on the clinical outcomes that could be expected from this novel "route of administration".	Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Choudhry, NK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St, Boston, MA 02120 USA.							Alter DA, 2004, JAMA-J AM MED ASSOC, V291, P1100, DOI 10.1001/jama.291.9.1100; ALVAREZ L, 2004, NY TIMES        1015, pA10; [Anonymous], 2004, LANCET, V363, P1659; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Avorn J, 2004, POWERFUL MED BENEFIT; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Brass EP, 2004, AM J CARDIOL, V94, p22F, DOI 10.1016/j.amjcard.2004.07.051; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; *CTR DRUG EV RES, OV THE COUNT DRUG PR; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Dyer Owen, 2005, BMJ, V330, P164, DOI 10.1136/bmj.330.7484.164-d; Ford ES, 2004, J AM COLL CARDIOL, V43, P1791, DOI 10.1016/j.jacc.2003.11.061; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; JOHNSON LA, OTC STATUS SOUGHT ST; Kopjar B, 2003, AM J CARDIOL, V92, P1106, DOI 10.1016/j.amjcard.2003.07.008; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; *MED HLTH PROD REG, 2003, RECL SUMM SIMV POM P; Melin JM, 2004, AM J CARDIOL, V94, P1243, DOI 10.1016/j.amjcard.2004.08.007; Mitka M, 2004, JAMA-J AM MED ASSOC, V292, P317, DOI 10.1001/jama.292.3.317; PARKS MH, NONPR MEV 20 MG JOIN; Pearson TA, 2000, ARCH INTERN MED, V160, P459, DOI 10.1001/archinte.160.4.459; Schneeweiss S, 2004, BRIT MED J, V328, P560, DOI 10.1136/bmj.38020.698194.F6; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHETTY D, MEVACOR DAILY 20 MG; United States Preventive Services Task Force, 2018, ANN INTERN MED; *US FDA, CONS BEH SAF DAT NON; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419	31	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					910	913		10.7326/0003-4819-142-11-200506070-00009	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941698				2022-12-28	WOS:000229556300005
J	Eisen, SA; Kang, HK; Murphy, FM; Blanchard, MS; Reda, DJ; Henderson, WG; Toomey, R; Jackson, LW; Alpem, R; Parks, BJ; Klimas, N; Hall, C; Pak, HS; Hunter, J; Karlinsky, J; Battistone, MJ; Lyons, MJ				Eisen, SA; Kang, HK; Murphy, FM; Blanchard, MS; Reda, DJ; Henderson, WG; Toomey, R; Jackson, LW; Alpem, R; Parks, BJ; Klimas, N; Hall, C; Pak, HS; Hunter, J; Karlinsky, J; Battistone, MJ; Lyons, MJ		Gulf War Study Participating Inves	Gulf war veterans' health: Medical evaluation of a US cohort	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC-FATIGUE-SYNDROME; POPULATION-BASED SURVEY; OPERATION-DESERT-STORM; AL ESKAN DISEASE; VISCERAL INFECTION; LEISHMANIA-TROPICA; ILLNESS; FIBROMYALGIA; PREVALENCE; ACTIVATION	Background: United States military personnel reported various symptoms after deployment to the Persian Gulf during the 1991 Gulf War. However, the symptoms' long-term prevalence and association with deployment remain controversial. Objective: To assess and compare the prevalence of selected medical conditions in a national cohort of deployed and nondeployed Gulf War veterans who were evaluated by direct medical and teledermatologic examinations. Design: A cross-sectional prevalence study performed 10 years after the 1991 Gulf War. Setting: Veterans were examined at 1 of 16 Veterans Affairs medical centers. Participants: Deployed (n = 1061) and nondeployed (n = 1128) veterans of the 1991 Gulf War. Measurements: Primary outcome measures included fibromyalgia, the chronic fatigue syndrome, dermatologic conditions, dyspepsia, physical health-related quality of life (Short Form-36 [SF36]), hypertension, obstructive lung disease, arthralgias, and peripheral neuropathy. Results: Of 12 conditions, only 4 conditions were more prevalent among deployed than nondeployed veterans: fibromyalgia (deployed, 2.0%; nondeployed, 1.2%; odds ratio, 2.32 [95% Cl, 1.02 to 5.27]); the chronic fatigue syndrome (deployed, 1.6%; nondeployed 0.1%; odds ratio, 40.6 [Cl, 10.2 to 161]); dermatologic conditions (deployed, 34.6%; nondeployed, 26.8%; odds ratio, 1.38 [Cl, 1.06 to 1.80]), and dyspepsia (deployed, 9.1%; nondeployed, 6.0%; odds ratio, 1.87 [Cl, 1.16 to 2.99]). The mean physical component summary score of the SF-36 for deployed and nondeployed veterans was 49.3 and 50.8, respectively. Limitations: Relatively low participation rates introduce potential participation bias, and deployment-related illnesses that resolved before the research examination could not, by design, be detected. Conclusions: Ten years after the Gulf War, the physical health of deployed and nondeployed veterans is similar. However, Gulf War deployment is associated with an increased risk for fibromyalgia, the chronic fatigue syndrome, skin conditions, dyspepsia, and a clinically insignificant decrease in the SF-36 physical component score.	Washington Univ, Sch Med, Med Affairs Med Ctr 151 JC, St Louis, MO 63103 USA; St Louis Univ, St Louis, MO 63103 USA; US Dept Vet Affairs, Vet Hlth Adm, Environm Epidemiol Serv, Washington, DC USA; Uniformed Serv Univ Hlth Sci, Washington, DC USA; Hines Vet Affairs Hosp, Cooperat Studies Program, Coodinating Ctr, Hines, IL USA; Harvard Univ, Vet Affairs Med Ctr, Brockton, MA 02401 USA; Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr,Vet Affairs Med Ctr, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA; Boston Univ, Sch Med, Boston, MA 02215 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA; Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA	Washington University (WUSTL); Saint Louis University; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Antonio Military Medical Center; United States Department of Defense; United States Army; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah	Eisen, SA (corresponding author), Washington Univ, Sch Med, Med Affairs Med Ctr 151 JC, 915 N Grand Ave, St Louis, MO 63103 USA.	seth.eisen@med.va.gov	Lyons, Michael J./B-6119-2011	Eisen, Seth/0000-0001-7746-6624; , Domenic/0000-0003-1831-4270; Lyons, Michael/0000-0001-6516-9219				Andrews G, 1998, SOC PSYCH PSYCH EPID, V33, P80, DOI 10.1007/s001270050026; [Anonymous], 1996, FIN REP; Buchwald D, 2001, PSYCHOSOM MED, V63, P936, DOI 10.1097/00006842-200111000-00012; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; Coker WJ, 1999, BMJ-BRIT MED J, V318, P290, DOI 10.1136/bmj.318.7179.290; Cook DB, 2003, MED SCI SPORT EXER, V35, P569, DOI 10.1249/01.MSS.0000058438.25278.33; Davis LE, 2004, NEUROLOGY, V63, P1070, DOI 10.1212/01.WNL.0000138426.88460.CB; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; Endresen GKM, 2003, RHEUMATOL INT, V23, P211, DOI 10.1007/s00296-003-0355-7; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Hickie I B, 2001, Twin Res, V4, P94, DOI 10.1375/twin.4.2.94; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kang HK, 2001, AM J EPIDEMIOL, V154, P399, DOI 10.1093/aje/154.5.399; Kang HK, 2000, J OCCUP ENVIRON MED, V42, P491, DOI 10.1097/00043764-200005000-00006; Karlinsky JB, 2004, ARCH INTERN MED, V164, P2488, DOI 10.1001/archinte.164.22.2488; KELLER RH, 1994, CLIN INFECT DIS, V18, pS154, DOI 10.1093/clinids/18.Supplement_1.S154; Kennedy G, 2004, ANN EPIDEMIOL, V14, P95, DOI 10.1016/j.annepidem.2003.10.004; Khan F, 2004, CLIN SCI, V106, P183, DOI 10.1042/CS20030246; Kipen HM, 1999, ARCH ENVIRON HEALTH, V54, P313, DOI 10.1080/00039899909602493; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; KORENYIBOTH AL, 1992, MIL MED, V157, P452, DOI 10.1093/milmed/157.9.452; KorenyiBoth AL, 1997, MIL MED, V162, P1; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MAGILL AJ, 1994, CLIN INFECT DIS, V19, P805, DOI 10.1093/clinids/19.4.805; Murphy FM, 1999, MIL MED, V164, P327, DOI 10.1093/milmed/164.5.327; MURRAYLEISURE KA, 1994, 34 INT C ANT AG CHEM; Naschitz JE, 2001, SEMIN ARTHRITIS RHEU, V31, P199, DOI 10.1053/sarh.2001.27738; Natelson BH, 2001, JAMA-J AM MED ASSOC, V285, P2557, DOI 10.1001/jama.285.20.2557; NICHOLSON G, 1996, INT J OCCUPAT MED IM, V5, P69; OSTER CN, 1992, HOSP PRACT, V27, P145; Oumeish OY, 2002, CLIN DERMATOL, V20, P401, DOI 10.1016/S0738-081X(02)00241-9; Patarca-Montero R, 2001, Appl Neuropsychol, V8, P51, DOI 10.1207/S15324826AN0801_7; PRICE RK, 1992, PUBLIC HEALTH REP, V107, P514; Proctor SP, 1998, INT J EPIDEMIOL, V27, P1000, DOI 10.1093/ije/27.6.1000; ROBINSON A, 1995, CAN MED ASSOC J, V152, P944; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; STRAUS SE, 1993, CIBA F SYMP, V173, P132; STRAUS SE, 1993, J CLIN IMMUNOL, V13, P30, DOI 10.1007/BF00920633; STRAUS SE, 1993, CIBA FOUND S, V173, P139; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; Visser J, 2001, J NEUROIMMUNOL, V119, P343, DOI 10.1016/S0165-5728(01)00400-3; Ware JE, 1993, SF36 HLTH SURVEY MAN; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2; 1995, MMWR MORB MORTAL WKL, V44, P443	48	95	97	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					881	890		10.7326/0003-4819-142-11-200506070-00005	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	932LX	15941694				2022-12-28	WOS:000229556300001
J	Haas, JS; Phillips, KA; Gerstenberger, EP; Seger, AC				Haas, JS; Phillips, KA; Gerstenberger, EP; Seger, AC			Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING-ENZYME-INHIBITORS; PHARMACY BENEFITS; PHYSICIAN; COMPANIES	Background: Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution. Objective: To estimate the potential savings associated with broad substitution of generic drugs. Design: Cross-sectional, nationally representative survey of noninstitutionalized adults. Setting: United States. Participants: Adults included in the Medical Expenditure Panel Survey Household Component, 1997-2000. Measurements: Use of a multisource drug (that is, a drug available in a brand-name and >= 1 generic formulation) or a generic drug and the potential cost savings associated with broad generic substitution for all multisource products. Results: Fifty-six percent of all outpatient drugs were multisource products, accounting for 41% of total outpatient drug expenditures. Of these multisource drugs, 61% were dispensed as a generic. If a generic had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual savings in drug expenditures per person would have been $45.89 (interquartile range, $10.35 to 158.06) for adults younger than 65 years of age and $78.05 (interquartile range, $19.94 to $241.72) for adults at least 65 years of age. in these age groups, the national savings would have been $5.9 billion (95% Cl, $5.5 billion to $6.2 billion) and $2.9 billion (Cl, $2.6 billion to $3.1 billion), respectively, representing approximately 11% of drug expenditures. Limitations: Specific information about an individual's formulary was not available, so the authors could not estimate how much of the potential savings would benefit an individual or his or her health plan. Conclusion: Although broad substitution of generic drugs would affect only a modest percentage of drug expenditures, it could result in substantial absolute savings.	Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco	Haas, JS (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.	jhaas@partners.org		HAAS, JENNIFER/0000-0001-7227-851X				ANDERSON GF, 2004, HLTH AFF MILLWOOD, V4, P396; Bae JP, 1997, HEALTH SERV RES, V32, P87; Banahan BF, 1997, ARCH INTERN MED, V157, P2080, DOI 10.1001/archinte.157.18.2080; Brennan TA, 2004, ANN INTERN MED, V141, P126, DOI 10.7326/0003-4819-141-2-200407200-00011; Cohen JW, 1996, INQUIRY-J HEALTH CAR, V33, P373; COHEN SB, AHCRP PUB; CRUICKSHANK JM, 1988, BRIT MED J, V297, P1597, DOI 10.1136/bmj.297.6663.1597; CUBANSKI J, 2004, HLTH AFF W, V4, P198; DeCara JM, 1998, CHEST, V113, P261, DOI 10.1378/chest.113.2.261; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; Fischer MA, 2003, HEALTH SERV RES, V38, P1051, DOI 10.1111/1475-6773.00162; Gaither CA, 2001, J AM PHARM ASS, V41, P729, DOI [10.1016/S1086-5802(16)31308-0, DOI 10.1016/S1086-5802(16)31308-0]; Ganther J M, 2000, J Am Pharm Assoc (Wash), V40, P378; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; HARRIS G, 2003, NY TIMES        1005, P1; Hellerstein JK, 1998, RAND J ECON, V29, P108, DOI 10.2307/2555818; HENRY J, 2003, FAMILY FDN; *HJ KAIS FAM FDN, 2001, KAIS COMM MED UN; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; *MEDC HLTH SOL INC, ANT 1 TIM GEN 2004 2; MOELLER JF, 1996, AHRQ PUB; MOON N, 2004, BENEFICIARIES FARE N; Mott DA, 2002, MED CARE, V40, P662, DOI 10.1097/00005650-200208000-00006; Murphy JE, 1999, ARCH INTERN MED, V159, P429, DOI 10.1001/archinte.159.5.429; Nightingale SL, 1998, JAMA-J AM MED ASSOC, V279, P645, DOI 10.1001/jama.279.9.645-b; *NIH CAR MAN FDN, 2002, PRIM GEN DRUGS PAT P; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Robinson AR, 2004, ARCH INTERN MED, V164, P427, DOI 10.1001/archinte.164.4.427; Schneeweiss S, 2004, MED CARE, V42, P653, DOI 10.1097/01.mlr.0000129497.10930.a2; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Suh DC, 1999, PHARM WORLD SCI, V21, P260, DOI 10.1023/A:1008781619011; *US FOOD DRUG ADM, NEW FDA IN IMPR; 2002, FORMULARY, V38, P499; 2001, PRESCRIPTION DRUG TR	34	185	192	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2005	142	11					891	897		10.7326/0003-4819-142-11-200506070-00006	http://dx.doi.org/10.7326/0003-4819-142-11-200506070-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932LX	15941695				2022-12-28	WOS:000229556300002
J	Mignogna, MD; Fedele, S				Mignogna, MD; Fedele, S			Oral cancer screening: 5 minutes to save a life	LANCET			English	Editorial Material							PHARYNGEAL CANCER; CARE		Univ Naples Federico II, Dept Odontostomatol & Maxillofacial Sci, Div Oral Med, I-80129 Naples, Italy	University of Naples Federico II	Mignogna, MD (corresponding author), Univ Naples Federico II, Dept Odontostomatol & Maxillofacial Sci, Div Oral Med, I-80129 Naples, Italy.	mdmig@tin.it		Fedele, Stefano/0000-0001-9006-9412				[Anonymous], 2004, IARC CANC BASE; Duxbury AJ, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD004150, 10.1002/14651858.CD004150]; Mashberg A, 2000, ORAL ONCOL, V36, P253, DOI 10.1016/S1368-8375(00)00006-3; Mignogna MA, 2002, J ORAL PATHOL MED, V31, P246, DOI 10.1034/j.1600-0714.2002.310411.x; Mignogna MD, 2002, EUR J CANCER PREV, V11, P205, DOI 10.1097/00008469-200206000-00002; Mignogna MD, 2001, EUR J CANCER PREV, V10, P381, DOI 10.1097/00008469-200108000-00014; SMART CR, 1993, CANCER, V72, P1061, DOI 10.1002/1097-0142(19930801)72:3+<1061::AID-CNCR2820721320>3.0.CO;2-1; Warnakulasuriya KAAS, 1999, BRIT DENT J, V187, P319, DOI 10.1038/sj.bdj.4800269a; *WHO, 2005, CRET DECL OR CANC PR	9	32	33	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1905	1906		10.1016/S0140-6736(05)66635-4	http://dx.doi.org/10.1016/S0140-6736(05)66635-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936403				2022-12-28	WOS:000229587800004
J	Anway, MD; Cupp, AS; Uzumcu, M; Skinner, MK				Anway, MD; Cupp, AS; Uzumcu, M; Skinner, MK			Epigenetic transgenerational actions of endocrine disruptors and mate fertility	SCIENCE			English	Article							POSTNATAL TESTIS DEVELOPMENT; ANDROGEN RECEPTOR; METHOXYCHLOR; CELLS; VINCLOZOLIN; EXPOSURE; RAT; IMMUNOLOCALIZATION; DIFFERENTIATION; INHERITANCE	Transgenerational effects of environmental toxins require either a chromosomal or epigenetic alteration in the germ line. Transient exposure of a gestating female rat during the period of gonadal sex determination to the endocrine disruptors vinclozolin (an antiandrogenic compound) or methoxychlor (an estrogenic compound) induced an adult phenotype in the F-1 generation of decreased spermatogenic capacity (cell number and viability) and increased incidence of mate infertility. These effects were transferred through the mate germ line to nearly all mates of ail subsequent generations examined (that is F-1 to F-4). The effects on reproduction correlate with altered DNA methylation patterns in the germ line. The ability of an environmental factor (for example, endocrine disruptor) to reprogram the germ line and to promote a transgenerational disease state has significant implications for evolutionary biology and disease etiology.	Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA	Washington State University	Skinner, MK (corresponding author), Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA.	skinner@mail.wsu.edu	Anway, Matthew D/B-1480-2008; Reis-Silva, Thiago M./E-6318-2013					Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; BUEHR M, 1993, DEVELOPMENT, V117, P273; Chapin RE, 1997, FUND APPL TOXICOL, V40, P138, DOI 10.1006/faat.1997.2381; Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899; Cupp AS, 2003, J ANDROL, V24, P736; DeRosa C, 1998, J TOXICOL ENV HEAL B, V1, P3, DOI 10.1080/10937409809524541; Dong H, 2004, BIOCHEMISTRY-US, V43, P15922, DOI 10.1021/bi0482194; Durcova-Hills G, 2001, DIFFERENTIATION, V68, P220, DOI 10.1046/j.1432-0436.2001.680409.x; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; Foran CM, 2002, TOXICOL SCI, V68, P389, DOI 10.1093/toxsci/68.2.389; Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746; Goyal HO, 1997, ANAT REC, V249, P54, DOI 10.1002/(SICI)1097-0185(199709)249:1<54::AID-AR7>3.0.CO;2-F; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; JOST A, 1981, HUM GENET, V58, P59, DOI 10.1007/BF00284150; KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117; Kelce WR, 1997, TOXICOL APPL PHARM, V142, P192, DOI 10.1006/taap.1996.7966; MAJDIC G, 1995, J ENDOCRINOL, V147, P285, DOI 10.1677/joe.0.1470285; Morris ID, 2002, INT J ANDROL, V25, P255, DOI 10.1046/j.1365-2605.2002.00372.x; Rakyan V, 2003, CURR BIOL, V13, pR6, DOI 10.1016/S0960-9822(02)01377-5; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Shi BS, 2004, MUTAT RES-FUND MOL M, V556, P1, DOI 10.1016/j.mrfmmm.2004.05.014; Tokumura A, 2004, J CELL BIOCHEM, V92, P869, DOI 10.1002/jcb.20147; Uzumcu M, 2004, REPROD TOXICOL, V18, P765, DOI 10.1016/j.reprotox.2004.05.008	24	1776	1858	4	390	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1466	1469		10.1126/science.1108190	http://dx.doi.org/10.1126/science.1108190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933200	Green Published			2022-12-28	WOS:000229619300053
J	Jensen, TH; Moore, C				Jensen, TH; Moore, C			Reviving the exosome	CELL			English	Editorial Material							RIBOSOMAL-RNA; COMPLEX	In the nucleus of eukaryotic cells, RNA decay in the 3'-5' direction is carried out by a complex of exonucleases called the exosome. Surprisingly, the purified exosome shows only weak activity in vitro. Two papers in this issue of Cell, by LaCava et al. (2005) and Wyers et al. (2005), and a third report by Vanacova et al. (2005) help to solve this riddle by characterizing a new RNA decay-activating complex containing a poly(A) polymerase. In addition, they identify new unconventional RNA polymerase 11 transcription units.	Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus, Denmark; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Aarhus University; Tufts University	Jensen, TH (corresponding author), Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus, Denmark.		Jensen, Torben H/G-2954-2017	Jensen, Torben Heick/0000-0001-5127-1239				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; Kuai L, 2004, P NATL ACAD SCI USA, V101, P8581, DOI 10.1073/pnas.0402888101; LaCava J, 2005, CELL, V121, P713, DOI 10.1016/j.cell.2005.04.029; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Vanacova S, 2005, PLOS BIOL, V3, P986, DOI 10.1371/journal.pbio.0030189; Wyers F, 2005, CELL, V121, P725, DOI 10.1016/j.cell.2005.04.030	11	15	17	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					660	662		10.1016/j.cell.2005.05.018	http://dx.doi.org/10.1016/j.cell.2005.05.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935750	Bronze			2022-12-28	WOS:000229658000002
J	Barnett, R				Barnett, R			Obesity	LANCET			English	Editorial Material									Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Barnett, R (corresponding author), Wellcome Trust Ctr Hist Med, London, England.								0	15	15	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1843	1843		10.1016/S0140-6736(05)66604-4	http://dx.doi.org/10.1016/S0140-6736(05)66604-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924972				2022-12-28	WOS:000229481400011
J	McGavin, CR; Gaber, K; Davies, MG				McGavin, CR; Gaber, K; Davies, MG			Sarcoidosis in a gecko	LANCET			English	Editorial Material									Derriford Hosp, Dept Resp Med, Plymouth PL6 8DH, Devon, England	Derriford Hospital	McGavin, CR (corresponding author), Derriford Hosp, Dept Resp Med, Plymouth PL6 8DH, Devon, England.	clive.mcgavin@phnt.swest.nhs.uk							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 28	2005	365	9474					1876	1876		10.1016/S0140-6736(05)66620-2	http://dx.doi.org/10.1016/S0140-6736(05)66620-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	931JK	15924985				2022-12-28	WOS:000229481400027
J	Foster, KR				Foster, KR			Biomedicine - Hamiltonian medicine: Why the social lives of pathogens matter	SCIENCE			English	Editorial Material							PARASITE VIRULENCE; COMPETITION; BIOFILMS; BACTERIA		Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77005 USA	Rice University	Foster, KR (corresponding author), Wissensch Kolleg Berlin, Inst Adv Study, Wallotstr 19, D-14193 Berlin, Germany.	krfoster@rice.edu		Foster, Kevin/0000-0003-4687-6633				Brown SP, 2002, TRENDS MICROBIOL, V10, P401, DOI 10.1016/S0966-842X(02)02413-7; Ewald PW, 1994, EVOLUTION INFECT DIS; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; Fux CA, 2005, TRENDS MICROBIOL, V13, P34, DOI 10.1016/j.tim.2004.11.010; Gardner A, 2004, P ROY SOC B-BIOL SCI, V271, P1529, DOI 10.1098/rspb.2004.2756; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; Kreft JU, 2005, MICROBIOL-SGM, V151, P637, DOI 10.1099/mic.0.27415-0; Kreft JU, 2004, MICROBIOL-SGM, V150, P2751, DOI 10.1099/mic.0.26829-0; Massey RC, 2004, P ROY SOC B-BIOL SCI, V271, P785, DOI 10.1098/rspb.2004.2676; Read AF, 2001, SCIENCE, V292, P1099, DOI 10.1126/science.1059410; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; [No title captured]	12	52	52	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2005	308	5726					1269	1270		10.1126/science.1108158	http://dx.doi.org/10.1126/science.1108158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919984				2022-12-28	WOS:000229482300035
J	Schubert, EF; Kim, JK				Schubert, EF; Kim, JK			Solid-state light sources getting smart	SCIENCE			English	Review							GANGLION-CELLS	More than a century after the introduction of incandescent lighting and half a century after the introduction of fluorescent lighting, solid-state light sources are revolutionizing an increasing number of applications. Whereas the efficiency of conventional incandescent and fluorescent lights is limited by fundamental factors that cannot be overcome, the efficiency of solid-state sources is limited only by human creativity and imagination. The high efficiency of solid-state sources already provides energy savings and environmental benefits in a number of applications. However, solid-state sources also offer controllability of their spectral power distribution, spatial distribution, color temperature, temporal modulation, and polarization properties. Such "smart" light sources can adjust to specific environments and requirements, a property that could result in tremendous benefits in lighting, automobiles, transportation, communication, imaging, agriculture, and medicine.	Rensselaer Polytech Inst, Dept Elect Comp & Syst Engn, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Phys Appl Phys & Astron, Troy, NY 12180 USA	Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	Schubert, EF (corresponding author), Rensselaer Polytech Inst, Dept Elect Comp & Syst Engn, Troy, NY 12180 USA.							Bergh A, 2001, PHYS TODAY, V54, P42, DOI 10.1063/1.1445547; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Blask DE, 2003, BREAST CANCER RES TR, V79, P313, DOI 10.1023/A:1024030518065; Bowers Brian, 1998, LENGTHENING DAY; Brainard GC, 2001, J NEUROSCI, V21, P6405; Chhajed S, 2005, J APPL PHYS, V97, DOI 10.1063/1.1852073; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; KELSO J, 2005, BUILDINGS ENERGY DAT; MACADAM DL, 1993, SPIE MILESTONE SERIE, V77; Rohwer L. S., 2003, Electrochemical Society Interface, V12, P36; Sun XY, 2004, J APPL PHYS, V95, P1450, DOI 10.1063/1.1639952; Tsao JY, 2004, IEEE CIRCUITS DEVICE, V20, P28, DOI 10.1109/MCD.2004.1304539; Zubia D, 1999, J APPL PHYS, V85, P6492, DOI 10.1063/1.370153	13	2970	3090	37	692	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1274	1278		10.1126/science.1108712	http://dx.doi.org/10.1126/science.1108712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15919985				2022-12-28	WOS:000229482300036
J	Kohane, DS; Ingelfinger, JR; Nimkin, K; Wu, CL; Harris; Daouk, GH				Kohane, DS; Ingelfinger, JR; Nimkin, K; Wu, CL; Harris; Daouk, GH			A nine-year-old girl with headaches and hypertension - Pheochromocytoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RENAL-ARTERY STENOSIS; BENIGN		Massachusetts Gen Hosp, Dept Pediat Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat Nephrol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kohane, DS (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care, Boston, MA 02114 USA.							Camberos A, 2000, J PEDIATR SURG, V35, P714, DOI 10.1053/jpsu.2000.6032; Conlin PR, 2001, NEW ENGL J MED, V344, P1314, DOI 10.1056/NEJM200104263441708; Dluhy RG, 2002, NEW ENGL J MED, V346, P1486, DOI 10.1056/NEJM200205093461911; Feldmann R, 2003, NEUROLOGY, V61, P1725, DOI 10.1212/01.WNL.0000098881.95854.5F; GALVEZ OG, 1977, J CLIN INVEST, V59, P609, DOI 10.1172/JCI108678; Gill IS, 2000, J UROLOGY, V164, P296, DOI 10.1016/S0022-5347(05)67344-2; Guyton A.C., 2011, HALL TXB MED PHYSL; HARRISON JH, 1958, J UROLOGY, V79, P173, DOI 10.1016/S0022-5347(17)66254-2; Ilias I, 2004, J CLIN ENDOCR METAB, V89, P479, DOI 10.1210/jc.2003-031091; Kohane Daniel S., 1996, P1247; Lenders JWM, 2002, JAMA-J AM MED ASSOC, V287, P1427, DOI 10.1001/jama.287.11.1427; LINNOILA RI, 1990, HUM PATHOL, V21, P1168; LONDE S, 1978, PEDIATR CLIN N AM, V25, P55; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; PICKARD JL, 1995, J PEDIATR SURG, V30, P1613, DOI 10.1016/0022-3468(95)90172-8; Reddy VS, 2000, AM SURGEON, V66, P1085; REED G, 1985, AM J MED SCI, V289, P37, DOI 10.1097/00000441-198501000-00007; SLOAND EM, 1984, ARCH INTERN MED, V144, P173, DOI 10.1001/archinte.144.1.173; Stackpole RH, 1963, J PEDIATR, V63, P314; Thompson LDR, 2002, AM J SURG PATHOL, V26, P551, DOI 10.1097/00000478-200205000-00002; van der Harst E, 2001, J CLIN ENDOCR METAB, V86, P685, DOI 10.1210/jc.86.2.685; WEST ML, 1986, MINER ELECTROL METAB, V12, P234; Williams DT, 2003, EUR J SURG ONCOL, V29, P933, DOI 10.1016/j.ejso.2003.09.011	23	11	11	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2223	2231		10.1056/NEJMcpc059011	http://dx.doi.org/10.1056/NEJMcpc059011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917388				2022-12-28	WOS:000229333300012
J	Chadban, SJ; Atkins, RC				Chadban, SJ; Atkins, RC			Glomerulonephritis	LANCET			English	Review							MONOCYTE CHEMOATTRACTANT PROTEIN-1; LOCAL MACROPHAGE PROLIFERATION; MEMBRANE ATTACK COMPLEX; CHRONIC-RENAL-FAILURE; GLOMERULAR INJURY; CRESCENTIC GLOMERULONEPHRITIS; CHEMOKINE RECEPTOR; CONTROLLED-TRIAL; KIDNEY-DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS	The term glomerulonephritis encompasses a range of immune-mediated disorders that cause inflammation within the glomerulus and other compartments of the kidney. Studies with animal models have shown the crucial interaction between bone-marrow-derived inflammatory cells and cells intrinsic to the kidney that is both fundamental and unique to the pathogenesis of glomerulonephritis. The mechanisms of interaction between these cells and the mediators of their coordinated response to inflammation are being elucidated. Despite these pathophysiological advances, treatments for glomerulonephritis remain non-specific, hazardous, and only partly successful. Glomerulonephritis therefore remains a common cause of end-stage kidney failure worldwide. Molecule-specific approaches offer hope for more effective and safer treatments in the future.	Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia; Monash Med Ctr, Dept Nephrol, Clayton, Vic 3168, Australia; Univ Sydney, Camperdown, NSW, Australia	University of Sydney; Monash University; University of Sydney	Chadban, SJ (corresponding author), Royal Prince Alfred Hosp, Level E9, Camperdown, NSW 2050, Australia.	Steve.Chadban@cs.nsw.gov.au						BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; BAKER PJ, 1989, AM J PATHOL, V135, P185; Bargman JM, 1999, KIDNEY INT, V55, pS3, DOI 10.1046/j.1523-1755.1999.07002.x; Barratt J, 2004, SEMIN NEPHROL, V24, P197, DOI 10.1016/j.semnephrol.2004.01.002; BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; BOLTON WK, 1988, KIDNEY INT, V34, P598, DOI 10.1038/ki.1988.224; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BOYCE NW, 1989, KIDNEY INT, V35, P778, DOI 10.1038/ki.1989.52; Boyle JJ, 2004, CLIN EXP IMMUNOL, V137, P529, DOI 10.1111/j.1365-2249.2004.02565.x; Bremer V, 1997, J AM SOC NEPHROL, V8, P1712; BRENCHLEY PE, 1992, KIDNEY INT, V41, P933, DOI 10.1038/ki.1992.143; Briganti EM, 2002, NEW ENGL J MED, V347, P103, DOI 10.1056/NEJMoa013036; Briganti EM, 2001, NEPHROL DIAL TRANSPL, V16, P1364, DOI 10.1093/ndt/16.7.1364; Burgess E, 1999, KIDNEY INT, V55, pS26, DOI 10.1046/j.1523-1755.1999.07004.x; Chadban SJ, 1997, KIDNEY INT, V51, P1809, DOI 10.1038/ki.1997.248; Chadban SJ, 2003, J AM SOC NEPHROL, V14, pS131, DOI 10.1097/01.ASN.0000070152.11927.4A; Chadban SJ, 2001, J AM SOC NEPHROL, V12, P394, DOI 10.1681/ASN.V122394; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; *COCHR REN GROUP, 2003, REN HLTH LIB EV BAS; Collins AJ, 2003, AM J KIDNEY DIS, V41, pV, DOI 10.1016/S0272-6386(03)80001-X; Contreras G, 2004, NEW ENGL J MED, V350, P971, DOI 10.1056/NEJMoa031855; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; COUSER WG, 1988, AM J KIDNEY DIS, V11, P449, DOI 10.1016/S0272-6386(88)80079-9; COUSER WG, 1995, J AM SOC NEPHROL, V5, P1888; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; CYBULSKY AV, 1986, J IMMUNOL, V137, P1511; DAMICO G, 1995, AM J KIDNEY DIS, V26, P124, DOI 10.1016/0272-6386(95)90165-5; De Lema GP, 2001, J AM SOC NEPHROL, V12, P1369, DOI 10.1681/ASN.V1271369; Erlich JH, 1996, J CLIN INVEST, V98, P325, DOI 10.1172/JCI118796; Fervenza FC, 2004, NEPHROL DIAL TRANSPL, V19, P1288, DOI 10.1093/ndt/gfh079; Flanc RS, 2004, AM J KIDNEY DIS, V43, P197, DOI 10.1053/j.ajkd.2003.10.012; FLOEGE J, 1993, KIDNEY INT, V43, pS47; FLOEGE J, 2001, IMMUNOLOGIC RENAL DI, P415; Gilbert RE, 2001, KIDNEY INT, V59, P1324, DOI 10.1046/j.1523-1755.2001.0590041324.x; Groux H, 2003, TRANSPLANTATION, V75, p8S, DOI 10.1097/01.TP.0000067944.90241.BD; HEWITSON TD, 1995, AM J NEPHROL, V15, P111, DOI 10.1159/000168813; HOOKE DH, 1987, KIDNEY INT, V31, P964, DOI 10.1038/ki.1987.93; Houssiau FA, 2004, ARTHRITIS RHEUM-US, V50, P3934, DOI 10.1002/art.20666; Hsu SIH, 2003, J AM SOC NEPHROL, V14, pS186, DOI 10.1097/01.ASN.0000070032.58017.20; Hughes J, 2000, AM J PHYSIOL-RENAL, V278, pF747, DOI 10.1152/ajprenal.2000.278.5.F747; Ikezumi Y, 2003, KIDNEY INT, V63, P83, DOI 10.1046/j.1523-1755.2003.00717.x; Isbel NM, 2001, NEPHROL DIAL TRANSPL, V16, P1638, DOI 10.1093/ndt/16.8.1638; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JOHNSON RJ, 1992, J AM SOC NEPHROL, V2, pS190; Kaneko Y, 2003, J IMMUNOL, V170, P3377, DOI 10.4049/jimmunol.170.6.3377; KERR PG, 2001, DIS KIDNEY, P1665; Kim YG, 2000, KIDNEY INT, V58, P2390, DOI 10.1046/j.1523-1755.2000.00422.x; King K, 2002, HUM GENET, V111, P548, DOI 10.1007/s00439-002-0830-3; Kitching AR, 1997, KIDNEY INT, V52, P52, DOI 10.1038/ki.1997.303; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LAN HY, 1995, KIDNEY INT, V48, P753, DOI 10.1038/ki.1995.347; Lan HY, 2003, CURR OPIN NEPHROL HY, V12, P25, DOI 10.1097/00041552-200301000-00005; Le Meur Y, 2002, J LEUKOCYTE BIOL, V72, P530; Leinonen A, 1999, KIDNEY INT, V55, P926, DOI 10.1046/j.1523-1755.1999.055003926.x; Levin A, 1999, KIDNEY INT, V55, pS41, DOI 10.1046/j.1523-1755.1999.07006.x; Levin ML, 2002, KIDNEY INT, V62, P1475, DOI 10.1046/j.1523-1755.2002.00595.x; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; Liu WM, 2004, ARTHRITIS RHEUM-US, V50, P1884, DOI 10.1002/art.20290; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; Longo I, 2002, KIDNEY INT, V61, P1947, DOI 10.1046/j.1523-1755.2002.00379.x; MCDONALD S, NEW PATIENTS COMMENC; MONTSENY JJ, 1995, MEDICINE, V74, P63, DOI 10.1097/00005792-199503000-00001; Morita Y, 2000, J AM SOC NEPHROL, V11, P700, DOI 10.1681/ASN.V114700; Morrissey JJ, 1998, AM J PHYSIOL-RENAL, V274, pF580, DOI 10.1152/ajprenal.1998.274.3.F580; Muirhead N, 1999, KIDNEY INT, V55, pS47, DOI 10.1046/j.1523-1755.1999.07007.x; Nachman PH, 1996, J AM SOC NEPHROL, V7, P33; Nakao N, 2003, LANCET, V361, P117, DOI 10.1016/S0140-6736(03)12229-5; Nangaku M, 1999, J AM SOC NEPHROL, V10, P2323; Nangaku M, 1998, KIDNEY INT, V54, P1419, DOI 10.1046/j.1523-1755.1998.00130.x; NICOLICPATERSON, 2001, IMMUNOLOGIC RENAL DI, P609; NIKOLICPATERSON DJ, 1994, J AM SOC NEPHROL, V4, P1695; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Penny MJ, 1998, J EXP MED, V188, P1775, DOI 10.1084/jem.188.10.1775; PONTICELLI C, 1993, NEPHROL DIAL TRANSPL, V8, P1326; PONTICELLI C, 1992, NEW ENGL J MED, V327, P599, DOI 10.1056/NEJM199208273270904; Pozzi C, 1999, LANCET, V353, P883, DOI 10.1016/S0140-6736(98)03563-6; QUIZA CG, 1992, INT IMMUNOL, V4, P423, DOI 10.1093/intimm/4.4.423; Remuzzi G, 2002, LANCET, V360, P923, DOI 10.1016/S0140-6736(02)11042-7; RISDON RA, 1968, LANCET, V2, P363; Roccatello D, 2004, NEPHROL DIAL TRANSPL, V19, P3054, DOI 10.1093/ndt/gfh469; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; RYDEL JJ, 1995, AM J KIDNEY DIS, V25, P534, DOI 10.1016/0272-6386(95)90120-5; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Savige J, 1999, AM J CLIN PATHOL, V111, P507; SAVIN VJ, 1994, KIDNEY INT, V46, P382, DOI 10.1038/ki.1994.285; Segerer S, 2000, J AM SOC NEPHROL, V11, P2231, DOI 10.1681/ASN.V11122231; Sibelius U, 1998, J EXP MED, V187, P497, DOI 10.1084/jem.187.4.497; Simon P, 2004, KIDNEY INT, V66, P905, DOI 10.1111/j.1523-1755.2004.00834.x; Stambe C, 2003, J AM SOC NEPHROL, V14, P338, DOI 10.1097/01.ASN.0000048715.12315.FD; STREETON CL, 1995, J PAEDIATR CHILD H, V31, P245, DOI 10.1111/j.1440-1754.1995.tb00795.x; Suto TS, 1997, J IMMUNOL, V159, P2476; Tang WW, 1996, KIDNEY INT, V50, P665, DOI 10.1038/ki.1996.363; TARSHISH P, 1992, PEDIATR NEPHROL, V6, P123, DOI 10.1007/BF00866289; Tesch GH, 1997, NEPHROL DIAL TRANSPL, V12, P1109, DOI 10.1093/ndt/12.6.1109; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; TIPPING PG, 1985, KIDNEY INT, V27, P530, DOI 10.1038/ki.1985.43; Tomita N, 2000, GENE THER, V7, P1326, DOI 10.1038/sj.gt.3301243; Topham PS, 1999, J CLIN INVEST, V104, P1549, DOI 10.1172/JCI7707; Trivedi HS, 2002, AM J KIDNEY DIS, V39, P721, DOI 10.1053/ajkd.2002.31990; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; Wheeler DC, 2004, AM J KIDNEY DIS, V44, P917, DOI 10.1053/j.ajkd.2004.08.016; Winston JA, 1999, KIDNEY INT, V55, P1036, DOI 10.1046/j.1523-1755.1999.0550031036.x; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yang NS, 1998, KIDNEY INT, V54, P143, DOI 10.1046/j.1523-1755.1998.00978.x; Zernecke A, 2001, J IMMUNOL, V166, P5755, DOI 10.4049/jimmunol.166.9.5755; Zhou WD, 2001, KIDNEY INT, V59, P1227, DOI 10.1046/j.1523-1755.2001.0590041227.x	110	101	110	3	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2005	365	9473					1797	1806		10.1016/S0140-6736(05)66583-X	http://dx.doi.org/10.1016/S0140-6736(05)66583-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910953				2022-12-28	WOS:000229291600025
J	van Heel, DA; Ghosh, S; Butler, M; Hunt, KA; Lundberg, AMC; Ahmad, T; McGovern, DPB; Onnie, C; Negoro, K; Goldthorpe, S; Foxwell, BMJ; Mathew, CG; Forbes, A; Jewell, DP; Playford, RJ				van Heel, DA; Ghosh, S; Butler, M; Hunt, KA; Lundberg, AMC; Ahmad, T; McGovern, DPB; Onnie, C; Negoro, K; Goldthorpe, S; Foxwell, BMJ; Mathew, CG; Forbes, A; Jewell, DP; Playford, RJ			Murarnyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease	LANCET			English	Article							NOD2; SUSCEPTIBILITY	Both NOD2 (CARD15) alleles are mutated in roughly 15% of patients with Crohn's disease, but functional effects are unclear. We analysed the cytokine response of peripheral blood mononuclear cells to muramyl dipeptide (MDP), the ligand for NOD2. MDP induced little TNF alpha or interleukin 1 beta, but strong interleukin-8 secretion. MDP also substantially upregulated secretion of TNF alpha and interleukin 1 beta induced by toll-like receptor ligands. These effects were abolished by the most common Crohn's NOD2 double mutant genotypes at low nanomolar MDP concentrations, and provide the basis to develop a test of NOD2 functional deficiency. In Crohn's disease, there are defects in neutrophil recruitment driven by NOD2 and interleukin 8 and in cross talk between the NOD2 and toll-like receptor pathways, which suggests that the immune system fails to receive an early priming signal.	Univ London Imperial Coll Sci & Technol, Dept Gastroenterol, Intestinal Inflammat & Repair Grp, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Kennedy Inst Rheumatol, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, St Marks Hosp, London W12 0NN, England; Univ Oxford, Radcliffe Infirm, Gibson Labs, Gastroenterol Unit, Oxford OX2 6HE, England; Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, London, England; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Gastroenterol, Sendai, Miyagi 980, Japan	Imperial College London; Imperial College London; University of Oxford; Imperial College London; Radcliffe Infirmary; University of Oxford; University of London; King's College London; Tohoku University	van Heel, DA (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Gastroenterol, Intestinal Inflammat & Repair Grp, Hammersmith Campus, London W12 0NN, England.	d.vanheel@imperial.ac.uk	Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Playford, Raymond/0000-0003-1235-8504; van Heel, David/0000-0002-0637-2265; Forbes, Alastair/0000-0001-7416-9843				Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Traub S, 2004, J BIOL CHEM, V279, P8694, DOI 10.1074/jbc.M310556200; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092	8	262	267	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 21	2005	365	9473					1794	1796		10.1016/S0140-6736(05)66582-8	http://dx.doi.org/10.1016/S0140-6736(05)66582-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	928SI	15910952				2022-12-28	WOS:000229291600024
J	Mery, F; Kawecki, TJ				Mery, F; Kawecki, TJ			A cost of long-term memory in Drosophila	SCIENCE			English	Article							CONSOLIDATED MEMORY		Univ Fribourg, Dept Biol, Sect Ecol & Evolut, CH-1700 Fribourg, Switzerland	University of Fribourg	Mery, F (corresponding author), Univ Fribourg, Dept Biol, Sect Ecol & Evolut, Chemin Musee 10, CH-1700 Fribourg, Switzerland.	frederic.mery@unifr.ch	Kawecki, Tadeusz/K-5466-2015	Kawecki, Tadeusz/0000-0002-9244-1991				Isabel G, 2004, SCIENCE, V304, P1024, DOI 10.1126/science.1094932; Karan D, 1998, EVOLUTION, V52, P825, DOI 10.1111/j.1558-5646.1998.tb03706.x; Mery F, 2002, P NATL ACAD SCI USA, V99, P14274, DOI 10.1073/pnas.222371199; Nevo E, 1998, HEREDITY, V80, P9, DOI 10.1046/j.1365-2540.1998.00274.x; Niven JE, 2003, P ROY SOC B-BIOL SCI, V270, pS58, DOI 10.1098/rsbl.2003.0010; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0	6	184	187	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1148	1148		10.1126/science.1111331	http://dx.doi.org/10.1126/science.1111331			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15905396	Green Submitted			2022-12-28	WOS:000229293400037
J	Peters, K				Peters, K			Saunders Mac Lane (1909-2005) - Obituary	NATURE			English	Biographical-Item									AK Peters Ltd, Wellesley, MA 02482 USA		Peters, K (corresponding author), AK Peters Ltd, 888 Worcester St,Suite 230, Wellesley, MA 02482 USA.	klaus@akpeters.com						LANE SM, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2005	435	7040					292	292		10.1038/435292a	http://dx.doi.org/10.1038/435292a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902245	Bronze			2022-12-28	WOS:000229185000033
J	Dubben, HH; Beck-Bornholdt, HP				Dubben, HH; Beck-Bornholdt, HP			Systematic review of publication bias in studies on publication bias	BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS		Univ Hamburg, Hosp Eppendorf, Inst Allgemeinmed, D-20246 Hamburg, Germany	University of Hamburg	Dubben, HH (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Allgemeinmed, Martinistr 52, D-20246 Hamburg, Germany.	dubben@uke.uni-hamburg.de						CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Scherer RW, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000005.pub3, 10.1002/14651858.MR000005.pub4]	5	93	95	2	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 20	2005	331	7514					433	434		10.1136/bmj.38478.497164.F7	http://dx.doi.org/10.1136/bmj.38478.497164.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	958WB	15937056	Green Published, Bronze			2022-12-28	WOS:000231477800016
J	Magnus, D; Cho, MK				Magnus, D; Cho, MK			Issues in oocyte donation for stem cell research	SCIENCE			English	Editorial Material							INFORMED-CONSENT; GUIDELINES; DONORS; EMBRYO		Stanford Univ, Stanford Ctr Biomed Eth, Palo Alto, CA 94304 USA; Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Cho, MK (corresponding author), Stanford Univ, Stanford Ctr Biomed Eth, Palo Alto, CA 94304 USA.	micho@stanford.edu						Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Adams PL, 2002, TRANSPLANTATION, V74, P582, DOI 10.1097/00007890-200208270-00030; *AM SOC TRANSPL SU, 2005, STAT SOL DON ORG; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; Biller-Andorno N, 2001, THEOR MED BIOETH, V22, P351, DOI 10.1023/A:1011842211016; Delmonico FL, 2003, TRANSPLANTATION, V76, P1257, DOI 10.1097/01.TP.0000089674.07433.DA; Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351; Golan A, 1989, Obstet Gynecol Surv, V44, P430, DOI 10.1097/00006254-198906000-00004; Henderson GE, 2004, MOL THER, V10, P225, DOI 10.1016/j.ymthe.2004.05.013; Hwang WS, 2005, SCIENCE, V308, P1777, DOI 10.1126/science.1112286; Institute of Medicine and National Research Council, 2007, GUID HUM EMBR STEM C, DOI [10.17226/11870, DOI 10.17226/11153]; King NMP, 1999, HUM GENE THER, V10, P133, DOI 10.1089/10430349950019264; Lo B, 2004, FERTIL STERIL, V82, P559, DOI 10.1016/j.fertnstert.2004.01.040; Lo B, 2003, SCIENCE, V301, P921, DOI 10.1126/science.1087038; Macklin R, 2001, KENNEDY INST ETHIC J, V11, P17, DOI 10.1353/ken.2001.0005; Rimington M R, 2003, Reprod Biomed Online, V6, P277; SCHENKER JG, 1978, FERTIL STERIL, V30, P255; White MT, 1999, J LAW MED ETHICS, V27, P87, DOI 10.1111/j.1748-720X.1999.tb01440.x; Zink S, 2005, AM J BIOETHICS, V5, P6, DOI 10.1080/15265160590953085	19	78	78	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2005	308	5729					1747	1748		10.1126/science.1114454	http://dx.doi.org/10.1126/science.1114454			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	937LY	15905363				2022-12-28	WOS:000229926800039
J	Shattuck, TM; Westra, WH; Ladenson, PW; Arnold, A				Shattuck, TM; Westra, WH; Ladenson, PW; Arnold, A			Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAF MUTATIONS; INTRAGLANDULAR DISSEMINATION; RET PROTOONCOGENE; REARRANGEMENTS; RET/PTC; ACTIVATION; CANCER; GENE; CLASSIFICATION; HETEROGENEITY	BACKGROUND: Papillary thyroid carcinoma is frequently multifocal. We investigated whether noncontiguous tumor foci arise from intraglandular metastases from a single primary tumor or originate as unrelated clones derived from independent precursors. METHODS: Using a polymerase-chain-reaction assay involving the human androgen receptor gene (HUMARA), we analyzed the patterns of X-chromosome inactivation of multiple distinct foci of well-differentiated multifocal papillary thyroid cancer from 17 women. RESULTS: Multiple thyroid tumor foci from 10 of 17 patients yielded DNA of adequate quality and were heterozygous for the HUMARA polymorphism and hence suitable for analysis. A single X chromosome was inactivated in each focus, consistent with its monoclonality. When the specific monoclonal configurations of each patient's discrete tumor foci were compared, discordant patterns indicative of independent origins were observed among the tumors from five patients; results in the remaining five were consistent with either a shared or independent clonal origin. CONCLUSIONS: Individual tumor foci in patients with multifocal papillary thyroid cancer often arise as independent tumors.	Univ Connecticut, Sch Med, Ctr Mol Med, Farmington, CT 06030 USA; Univ Connecticut, Sch Med, Div Endocrinol & Metab, Farmington, CT 06030 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Baltimore, MD USA	University of Connecticut; University of Connecticut; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Arnold, A (corresponding author), Univ Connecticut, Sch Med, Ctr Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	molecularmedicine@uchc.edu			NIGMS NIH HHS [T32 GM008607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; BONGARZONE I, 1994, CANCER RES, V54, P2979; Carcangiu M L, 1985, Pathol Annu, V20 Pt 1, P1; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Fagin JA, 2004, J CLIN ENDOCR METAB, V89, P4264, DOI 10.1210/jc.2004-1426; Fey MF, 1996, ANN ONCOL, V7, P121; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Grebe S K, 1997, Cancer Treat Res, V89, P91; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARA H, 1994, SURGERY, V116, P1010; HAWK WA, 1976, CLEVELAND CLIN Q, V43, P207, DOI 10.3949/ccjm.43.4.207; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; IIDA F, 1969, CANCER, V24, P764, DOI 10.1002/1097-0142(196910)24:4<764::AID-CNCR2820240416>3.0.CO;2-S; Jovanovic L, 2003, J CLIN ENDOCR METAB, V88, P3284, DOI 10.1210/jc.2002-021552; KATOH R, 1992, CANCER-AM CANCER SOC, V70, P1585, DOI 10.1002/1097-0142(19920915)70:6<1585::AID-CNCR2820700623>3.0.CO;2-Z; Kim H, 1998, BRIT J SURG, V85, P1125; Kimura ET, 2003, CANCER RES, V63, P1454; MAZZAFERRI, 1995, AM J MED, V98, P215; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Moniz S, 2002, EUR J ENDOCRINOL, V146, P27, DOI 10.1530/eje.0.1460027; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; PACINI F, THYROID ITS DIS; Pierotti MA, 1998, RECENT RES CANCER, V154, P237; PIEROTTI MA, 1995, J ENDOCRINOL INVEST, V18, P130, DOI 10.1007/BF03349721; Rienhoff WF, 1931, ARCH SURG-CHICAGO, V23, P783, DOI 10.1001/archsurg.1931.01160110070003; Ringel MD, 2004, ENDOCR-RELAT CANCER, V11, P97, DOI 10.1677/erc.0.0110097; RUSSELL WO, 1963, CANCER, V16, P1425, DOI 10.1002/1097-0142(196311)16:11<1425::AID-CNCR2820161106>3.0.CO;2-E; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHNEIDER AB, 1990, ENDOCRIN METAB CLIN, V19, P495, DOI 10.1016/S0889-8529(18)30307-4; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SOZZI G, 1994, GENE CHROMOSOME CANC, V9, P244, DOI 10.1002/gcc.2870090404; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; TSCHOLLDUCOMMUN J, 1982, VIRCHOWS ARCH A, V396, P19, DOI 10.1007/BF00428498; Uchida T, 2000, LEUKEMIA, V14, P207, DOI 10.1038/sj.leu.2401631; Unger K, 2004, J CLIN ENDOCR METAB, V89, P4272, DOI 10.1210/jc.2003-031870; WILLIAMS GT, 1994, HISTOPATHOLOGY, V24, P287, DOI 10.1111/j.1365-2559.1994.tb00526.x	41	188	202	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2406	2412		10.1056/NEJMoa044190	http://dx.doi.org/10.1056/NEJMoa044190			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15944425	Bronze			2022-12-28	WOS:000229638900007
J	Sankaranarayanan, R; Ramadas, K; Thomas, G; Muwonge, R; Thara, S; Mathew, B; Rajan, B				Sankaranarayanan, R; Ramadas, K; Thomas, G; Muwonge, R; Thara, S; Mathew, B; Rajan, B		Trivandrum Oral Canc Screening Stu	Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial	LANCET			English	Article							VISUAL INSPECTION; HEALTH-WORKERS; SRI-LANKA; PRECANCER; REPRODUCIBILITY; PROGRAM; CUBA	Background Oral cancer is common in men from developing countries, and is increased by tobacco and alcohol use. We aimed to assess the effect of visual screening on oral cancer mortality in a cluster-randomised controlled trial in India. Methods Of the 13 clusters chosen for the study, seven were randomised to three rounds of oral visual inspection by trained health workers at 3-year intervals and six to a control group during 1996-2004, in Trivandrum district, Kerala, India. Healthy participants aged 35 years and older were eligible for the study. Screen-positive people were referred for clinical examination by doctors, biopsy, and treatment. Outcome measures were survival, case fatality, and oral cancer mortality. Oral cancer mortality in the study groups was analysed and compared by use of cluster analysis. Analysis was by intention to treat. Findings Of the 96 517 eligible participants in the intervention group, 87 655 (91%) were screened at least once, 53 312 (55%) twice, and 29 102 (30%) three times. Of the 5145 individuals who screened positive, 3218 (63%) complied with referral. 95 356 eligible participants in the control group received standard care. 205 oral cancer cases and 77 oral cancer deaths were recorded in the intervention group compared with 158 cases and 87 deaths in the control group (mortality rate ratio 0.79 [95% Cl 0.51-1.22]). 70 oral cancer deaths took place in users of tobacco or alcohol, or both, in the intervention group, compared with 85 in controls (0.66 [0.45-0.95]). The mortality rate ratio was 0.57 (0.35-0.93) in male tobacco or alcohol users and 0.78 (0.43-1.42) in female users. Interpretation: Oral visual screening can reduce mortality in high-risk individuals and has the potential of preventing at least 37 000 oral cancer deaths worldwide.	Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France; Reg Canc Ctr, Div Radiotherapy, Trivandrum 695011, Kerala, India; Reg Canc Ctr, Div Prevent Oncol, Trivandrum 695011, Kerala, India; Reg Canc Ctr, Div Cytopathol, Trivandrum 695011, Kerala, India	World Health Organization; International Agency for Research on Cancer (IARC)	Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	Sankar@iarc.fr	Muwonge, Richard/P-6375-2015					Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839; Ferlay J, 2004, GLOBOCAN 2002 CANC I; GARROTE LF, 1995, EPIDEMIOLOGY, V6, P428, DOI 10.1097/00001648-199507000-00019; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Hermanek P., 1987, TNM CLASSIFICATION M, V4, P13; International Agency for Research on Cancer (IARC), 2004, IARC MONOGRAPHS EVAL; KAPLAN E, 1958, J AM STAT ASSOC, V53, P407; La Vecchia C, 2004, ORAL ONCOL, V40, P433, DOI 10.1016/j.oraloncology.2003.09.013; MASHBERG A, 1984, CA-CANCER J CLIN, V34, P262, DOI 10.3322/canjclin.34.5.262; Mathew B, 1996, World Health Forum, V17, P377; MATHEW B, 1995, BRIT J CANCER, V71, P397, DOI 10.1038/bjc.1995.81; Mathew B, 1997, BRIT J CANCER, V76, P390, DOI 10.1038/bjc.1997.396; MATHEW B, 1988, GUIDE HLTH WORKERS E; MEHTA FS, 1986, CANCER DETECT PREV, V9, P219; Mehta FS, 1993, TOBACCO RELATED ORAL; Pandey M, 2001, ORAL ONCOL, V37, P103, DOI 10.1016/S1368-8375(00)00070-1; Parkin DM, 2002, CANC INCIDENCE 5 CON; Ramadas K, 2003, ORAL ONCOL, V39, P580, DOI 10.1016/S1368-8375(03)00041-1; RIES LAG, 1997, SEER CANC STAT REV 1; SANKARANARAYANA.R, 1998, CANC SURVIVAL DEV CO; Sankaranarayanan R, 2000, CANCER, V88, P664, DOI 10.1002/(SICI)1097-0142(20000201)88:3&lt;664::AID-CNCR25&gt;3.0.CO;2-V; Sankaranarayanan R, 2002, ORAL ONCOL, V38, P131, DOI 10.1016/S1368-8375(01)00033-1; Sankaranarayanan R, 1997, ORAL ONCOL, V33, P149, DOI 10.1016/S0964-1955(97)00013-4; WARNAKULASURIYA KAAS, 1991, CANCER DETECT PREV, V15, P331; WARNAKULASURIYA KAAS, 1984, B WORLD HEALTH ORGAN, V62, P243; Yeole BB, 2000, CANCER, V89, P437, DOI 10.1002/1097-0142(20000715)89:2&lt;437::AID-CNCR32&gt;3.0.CO;2-R	26	440	451	3	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2005	365	9475					1927	1933		10.1016/S0140-6736(05)66658-5	http://dx.doi.org/10.1016/S0140-6736(05)66658-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936419				2022-12-28	WOS:000229587800026
J	Feldmann, M; Steinman, L				Feldmann, M; Steinman, L			Design of effective immunotherapy for human autoimmunity	NATURE			English	Review							ANTITUMOR NECROSIS FACTOR; FACTOR MONOCLONAL-ANTIBODY; T-CELL-ACTIVATION; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; MULTIPLE-SCLEROSIS; ANIMAL-MODELS; FACTOR-ALPHA; THERAPY; METHOTREXATE	A better understanding of the molecules involved in immune responses has identified many potential targets for the treatment of autoimmune diseases. But although successful therapies have been found for immune disorders in animal studies, few have passed the much harder test of treating human diseases. So far, non-antigen-specific approaches, such as the blocking of tumour-necrosis factor, are achieving some success but the same is not true for antigen-specific approaches. Future therapies will probably include both non-antigen-specific strategies that target cytokines ( cell - cell signalling molecules) or block the molecules that stimulate immune responses, and antigen-specific therapies that induce tolerance to self antigens.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, London W6 8LH, England; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Imperial College London; University of Oxford; Stanford University	Feldmann, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, ARC Bldg,1 Aspenlea Rd, London W6 8LH, England.	m.feldmann@imperial.ac.uk; Steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250				Adams G, 2003, NAT BIOTECHNOL, V21, P1314, DOI 10.1038/nbt888; Bach JF, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar554; Baecklund E, 2004, CURR OPIN RHEUMATOL, V16, P254, DOI 10.1097/00002281-200405000-00014; Baggiolini M, 2000, IMMUNOL REV, V177, P5, DOI 10.1034/j.1600-065X.2000.17722.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bluestone JA, 2004, P NATL ACAD SCI USA, V101, P14622, DOI 10.1073/pnas.0405234101; BOTTAZZO GF, 1983, LANCET, V2, P1115; Breedveld FC, 1998, RHEUM DIS CLIN N AM, V24, P567, DOI 10.1016/S0889-857X(05)70026-0; Brennan FM, 2002, ARTHRITIS RHEUM, V46, P31, DOI 10.1002/1529-0131(200201)46:1<31::AID-ART10029>3.0.CO;2-5; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4; CHARPENTIER B, 1992, TRANSPLANTATION, V54, P997, DOI 10.1097/00007890-199212000-00011; Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHILLER JM, 1970, P NATL ACAD SCI USA, V65, P551, DOI 10.1073/pnas.65.3.551; COPE AP, 1994, J CLIN INVEST, V94, P749, DOI 10.1172/JCI117394; Czura CJ, 2004, ADV IMMUNOL, V84, P181, DOI 10.1016/S0065-2776(04)84005-7; Dalbeth N, 2005, RHEUMATOLOGY, V44, P24, DOI 10.1093/rheumatology/keh398; Day R, 2002, LANCET, V359, P540, DOI 10.1016/S0140-6736(02)07718-8; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FELDMANN M, 2001, CYTOKINE REFERENCE, V1, P35; Garren H, 2001, IMMUNITY, V15, P15, DOI 10.1016/S1074-7613(01)00171-6; Genovese MC, 2004, ARTHRITIS RHEUM-US, V50, P1412, DOI 10.1002/art.20221; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gladwell M., 2006, TIPPING POINT LITTLE; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Humphreys IR, 2003, J EXP MED, V198, P1237, DOI 10.1084/jem.20030351; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kazkaz H, 2004, CURR OPIN PHARMACOL, V4, P398, DOI 10.1016/j.coph.2004.03.006; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LINDSEY JW, 1994, ANN NEUROL, V36, P183; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Lovett-Racke AE, 2004, J IMMUNOL, V172, P5790, DOI 10.4049/jimmunol.172.9.5790; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Malfait AM, 2001, ARTHRITIS RHEUM, V44, P1215, DOI 10.1002/1529-0131(200105)44:5<1215::AID-ANR206>3.3.CO;2-R; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; MCDEVITT HO, 1987, CIBA F SYMP, V129, P184; McInnes IB, 2004, CURR OPIN PHARMACOL, V4, P392, DOI 10.1016/j.coph.2004.04.003; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Nishimoto N, 2004, CURR OPIN PHARMACOL, V4, P386, DOI 10.1016/j.coph.2004.03.005; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; OPPENHEIM JJ, 2001, CYTOKINE REFERENCE, P3; Pisetsky DS, 2001, JAMA-J AM MED ASSOC, V286, P2787, DOI 10.1001/jama.286.22.2787; Quinn MA, 2005, ARTHRITIS RHEUM-US, V52, P27, DOI 10.1002/art.20712; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Revel M, 2003, PHARMACOL THERAPEUT, V100, P49, DOI 10.1016/S0163-7258(03)00085-8; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Roep BO, 2004, NAT REV IMMUNOL, V4, P989, DOI 10.1038/nri1502; Ruiz PJ, 1999, J IMMUNOL, V162, P3336; Sayegh MH, 2004, NEW ENGL J MED, V351, P2761, DOI 10.1056/NEJMon043418; Sela M, 1999, Int Rev Immunol, V18, P201, DOI 10.3109/08830189909043025; Shevach EM, 2004, ARTHRITIS RHEUM, V50, P2721, DOI 10.1002/art.20500; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Steinman L, 2004, SCIENCE, V305, P212, DOI 10.1126/science.1099896; Steinman L, 2003, NAT BIOTECHNOL, V21, P1293, DOI 10.1038/nbt1103-1293; Toussirot Eric A., 2002, Current Drug Targets - Inflammation and Allergy, V1, P45, DOI 10.2174/1568010023344850; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	80	210	249	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					612	619		10.1038/nature03727	http://dx.doi.org/10.1038/nature03727			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15931214				2022-12-28	WOS:000229476200039
J	McHugh, PR				McHugh, PR			Striving for coherence - Psychiatry's efforts over classification	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIAGNOSIS		Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21287 USA	Johns Hopkins University	McHugh, PR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, 600 N Wolfe St,Meyer Bldg,Room 127, Baltimore, MD 21287 USA.	pmchugh1@jhmi.edu						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P10; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; ANTHONY JC, 1985, ARCH GEN PSYCHIAT, V42, P667; COOPER JE, 1969, AM J PSYCHIAT, V125, P21, DOI 10.1176/ajp.125.10S.21; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; LEAHY CW, 2004, BIRDWATCHERS COMPANI, P786; McHugh PR, 1998, PERSPECTIVES PSYCHIA; Parker G, 2005, PSYCHOL MED, V35, P467, DOI 10.1017/S0033291704004210; Peterson R.T., 1947, FIELD GUIDE BIRDS	9	70	70	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2005	293	20					2526	2528		10.1001/jama.293.20.2526	http://dx.doi.org/10.1001/jama.293.20.2526			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929BX	15914753				2022-12-28	WOS:000229318200027
J	Annas, GJ				Annas, GJ			Unspeakably cruel - Torture, medical ethics, and the law	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-RIGHTS; DOCTORS		Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Annas G. J., 2005, AM BIOETHICS CROSSIN; Annas George J., 1992, NAZI DOCTORS NUREMBE; Bloche MG, 2005, NEW ENGL J MED, V352, P3, DOI 10.1056/NEJMp048346; CURRAN WJ, 1981, NEW ENGL J MED, V304, P1342, DOI 10.1056/NEJM198105283042207; Dershowitz Alan., 2004, TORTURE COLLECTION, P257; DERSHOWITZ AM, 2002, TERRORISM WORKS, P144; Golden Tim, 2004, NY TIMES        1024, pN1; Gonzales Alberto R., 2005, TORTURE PAPERS ROAD, V1st, P118; Greenberg Karen J., 2005, TORTURE PAPERS ROAD; Greenberg Karen J., 2005, THE TORTURE PAPERS, P81; HERSH SM, 2004, CHAIN COMMAND ROAD 9, P30; JEHL D, 2005, NY TIMES        0218, pA1; Lewis Neil A, 2004, N Y Times Web, pA14; Lifton RJ, 2004, NEW ENGL J MED, V351, P415, DOI 10.1056/NEJMp048065; Miles SH, 2004, LANCET, V364, P725, DOI 10.1016/S0140-6736(04)16902-X; SAGAN LA, 1976, NEW ENGL J MED, V294, P1427, DOI 10.1056/NEJM197606242942605; SARTRE JP, 1958, QUESTION, P23; Schlesinger J. R., 2004, FINAL REPORT INDEPEN; Weisman S., 2005, NEW YORK TIMES  0130, pA1; Wiesel E, 2005, NEW ENGL J MED, V352, P1511, DOI 10.1056/NEJMp058069	20	22	22	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2127	2132		10.1056/NEJMlim044131	http://dx.doi.org/10.1056/NEJMlim044131			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901869	Green Published, Green Submitted			2022-12-28	WOS:000229180100015
J	Dember, LM; Shepard, JO; Nesta, F; Harris, NL; Judge, DC; Januzzi, JL; Stone, JR				Dember, LM; Shepard, JO; Nesta, F; Harris, NL; Judge, DC; Januzzi, JL; Stone, JR			An 80-year-old man with shortness of breath, edema, and proteinuria - Systemic amyloidosis involving the heart and colon, in the setting of a monoclonal gammopathy; probably AL amyloidosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STEM-CELL TRANSPLANTATION; IMMUNOGLOBULIN LIGHT-CHAIN; HEREDITARY AMYLOIDOSIS; CLINICAL-FEATURES; BIOPSY SPECIMENS; INVOLVEMENT; DISEASE; DEPOSITION; DIAGNOSIS; MELPHALAN		Boston Univ, Sch Med, Boston Med Ctr, Dept Med,Renal Sect, Boston, MA 02118 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cardiol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Boston Medical Center; Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Dember, LM (corresponding author), Boston Univ, Sch Med, Boston Med Ctr, Dept Med,Renal Sect, Boston, MA 02118 USA.		Januzzi, James/Y-2436-2019					Anesi E, 2001, AM J MED, V111, P243, DOI 10.1016/S0002-9343(01)00774-4; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; Berk JL, 2003, CHEST, V124, P969, DOI 10.1378/chest.124.3.969; Buxbaum J, 1999, HEMATOL ONCOL CLIN N, V13, P1235, DOI 10.1016/S0889-8588(05)70123-4; CELLI BR, 1978, CHEST, V74, P543, DOI 10.1378/chest.74.5.543; CROTTY TB, 1995, CARDIOVASC PATHOL, V4, P39, DOI 10.1016/1054-8807(94)00023-K; Dember LM, 2001, ANN INTERN MED, V134, P746, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00011; Dubrey SW, 1998, QJM-MON J ASSOC PHYS, V91, P141, DOI 10.1093/qjmed/91.2.141; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; Gertz MA, 2002, AM J MED, V113, P549, DOI 10.1016/S0002-9343(02)01208-1; GERTZ MA, 1988, ARCH INTERN MED, V148, P929, DOI 10.1001/archinte.148.4.929; Jacobson DR, 1997, NEW ENGL J MED, V336, P466, DOI 10.1056/NEJM199702133360703; Lachmann HJ, 2002, NEW ENGL J MED, V346, P1786, DOI 10.1056/NEJMoa013354; LIBBEY CA, 1983, ARCH INTERN MED, V143, P1549, DOI 10.1001/archinte.143.8.1549; MASSON RG, 1992, NEW ENGL J MED, V326, P36, DOI 10.1056/NEJM199201023260106; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Murphy CL, 2001, AM J CLIN PATHOL, V116, P135; Park MA, 2003, MEDICINE, V82, P291, DOI 10.1097/01.md.0000091183.93122.c7; Pozzi C, 2002, SEMIN NEPHROL, V22, P319, DOI 10.1053/snep.2002.33673; Rocken C, 1996, HISTOPATHOLOGY, V29, P325, DOI 10.1111/j.1365-2559.1996.tb01416.x; Rocken C, 2003, VIRCHOWS ARCH, V443, P3, DOI 10.1007/s00428-003-0834-y; Skinner M, 2004, ANN INTERN MED, V140, P85, DOI 10.7326/0003-4819-140-2-200401200-00008; Swan N, 2003, AM J CLIN PATHOL, V120, P610, DOI 10.1309/PFUGHBX0TY20E08U; Wallner M, 1996, NEPHROL DIAL TRANSPL, V11, P1619	24	5	6	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2111	2119		10.1056/NEJMcpc059009	http://dx.doi.org/10.1056/NEJMcpc059009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GJ	15901865				2022-12-28	WOS:000229180100011
J	Dietz, WH; Robinson, TN				Dietz, WH; Robinson, TN			Overweight children and adolescents.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; BARIATRIC SURGERY; CHILDHOOD OBESITY; WEIGHT-LOSS; HEALTH; AMERICAN; DISEASE; PROFESSIONALS; ENVIRONMENT; PREVALENCE	A seven-year-old girl is 130 cm tall (51 in., the 90th percentile for girls ofthe same age) and weighs 34.6 kg (76 lb, above the 95th percentile), with a body-mass index (defined as the weight in kilograms divided by the square of the height in meters) of 20.5 (above the 95th percentile). Physical examination reveals no abnormalities aside from her excess weight. Her family eats at a quick-service restaurant once a week, and she drinks approximately 16 oz (450 ml) of soft drinks and 8 oz (225 ml) of whole milk per day. Her physical activity is limited to 30 minutes of physical education twice per week and 20-minute recesses three days per week in school. She has approximately 4.5 hours of screen time per day, which is divided among the television sets in her bedroom and in the family room and the family computer. What should you advise?	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA; Stanford Univ, Sch Med, Div Gen Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA	Centers for Disease Control & Prevention - USA; Stanford University; Stanford University	Dietz, WH (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, 4770 Buford Hwy NE,MS K-24, Atlanta, GA 30341 USA.	wcd4@cdc.gov						[Anonymous], 2000, Pediatrics, V105, P671; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; Berkowitz RI, 2003, JAMA-J AM MED ASSOC, V289, P1805, DOI 10.1001/jama.289.14.1805; Birch LL, 1998, PEDIATRICS, V101, P539; Butte Nancy F, 2003, Science, V301, P598; Campbell K, 2002, COCHRANE DB SYST REV, V2; Dewey Kathryn G, 2003, J Hum Lact, V19, P9; Dietz WH, 1999, AM J CLIN NUTR, V70, p123S; DIETZ WH, 1982, J PEDIATR-US, V101, P735, DOI 10.1016/S0022-3476(82)80305-3; DIETZ WH, 1982, J PEDIATR-US, V100, P638, DOI 10.1016/S0022-3476(82)80776-2; DWYER T, 1983, INT J EPIDEMIOL, V12, P308, DOI 10.1093/ije/12.3.308; Epstein LH, 2000, ARCH PEDIAT ADOL MED, V154, P220, DOI 10.1001/archpedi.154.3.220; EPSTEIN LH, 1994, HEALTH PSYCHOL, V13, P373, DOI 10.1037/0278-6133.13.5.373; Epstein LH, 2001, OBES RES, V9, P171, DOI 10.1038/oby.2001.18; Epstein LH, 1998, PEDIATRICS, V101, P554; Erler Thomas, 2004, Treat Respir Med, V3, P107, DOI 10.2165/00151829-200403020-00005; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; FLORES R, 1995, PUBLIC HEALTH REP, V110, P189; FRANKS S, 1995, NEW ENGL J MED, V333, P1435; Freedman DS, 2005, INT J OBESITY, V29, P1, DOI 10.1038/sj.ijo.0802735; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Freedman DS, 2001, PEDIATRICS, V108, P712, DOI 10.1542/peds.108.3.712; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; Gutin B, 2002, AM J CLIN NUTR, V75, P818, DOI 10.1093/ajcn/75.5.818; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; Holm V.A, 1981, PRADER WILLI SYNDROM; Inge TH, 2004, PEDIATRICS, V114, P217, DOI 10.1542/peds.114.1.217; Institute of Medicine Committee on Prevention of Obesity in Children and Youth, 2005, PREV CHILDH OB HLTH; KELSEY JL, 1972, AM J DIS CHILD, V124, P276, DOI 10.1001/archpedi.1972.02110140126018; KILLEN JD, 1994, INT J EAT DISORDER, V16, P227, DOI 10.1002/1098-108X(199411)16:3&lt;227::AID-EAT2260160303&gt;3.0.CO;2-L; Lavine Joel E, 2004, Clin Liver Dis, V8, P549, DOI 10.1016/j.cld.2004.04.010; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; MALLORY GB, 1989, J PEDIATR-US, V115, P892, DOI 10.1016/S0022-3476(89)80738-3; MCKENNA TJ, 1988, NEW ENGL J MED, V318, P558, DOI 10.1056/NEJM198803033180906; Mei ZG, 2004, PEDIATRICS, V113, pE617, DOI 10.1542/peds.113.6.e617; Oude Luttikhuis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001872.pub2; Robinson TN, 1999, INT J OBESITY, V23, pS52, DOI 10.1038/sj.ijo.0800860; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Rodgers BM, 2004, PEDIATRICS, V114, P255, DOI 10.1542/peds.114.1.255; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Strauss RS, 2000, J PEDIATR-US, V136, P727, DOI 10.1016/S0022-3476(00)24645-3; Wadden T. A., 1999, The management of eating disorders and obesity., P173; Wang GJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.5.e81; WEISBERG LA, 1977, AM J DIS CHILD, V131, P1243, DOI 10.1001/archpedi.1977.02120240061012; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Whitaker RC, 1998, J PEDIATR-US, V132, P768, DOI 10.1016/S0022-3476(98)70302-6; Williams, 2002, CIRCULATION, V106, P1178, DOI 10.1161/01.CIR.0000032311.84663.5B; Williams CL, 2002, CIRCULATION, V106, P143, DOI 10.1161/01.CIR.0000019555.61092.9E; Wing R. R., 2002, Handbook of obesity treatment, P301	55	343	359	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2005	352	20					2100	2109		10.1056/NEJMcp043052	http://dx.doi.org/10.1056/NEJMcp043052			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	927GJ	15901863	Green Published			2022-12-28	WOS:000229180100008
J	Smirnakis, SM; Brewer, AA; Schmid, MC; Tolias, AS; Schuz, A; Augath, M; Inhoffen, W; Wandell, BA; Logothetis, NK				Smirnakis, SM; Brewer, AA; Schmid, MC; Tolias, AS; Schuz, A; Augath, M; Inhoffen, W; Wandell, BA; Logothetis, NK			Lack of long-term cortical reorganization after macaque retinal lesions	NATURE			English	Article							PRIMARY VISUAL-CORTEX; PRIMATE STRIATE CORTEX; CROSS-MODAL PLASTICITY; RECEPTIVE-FIELD; ADULT CAT; SENSORY DEAFFERENTATION; TOPOGRAPHIC PLASTICITY; MACULAR DEGENERATION; FUNCTIONAL MRI; BLIND HUMANS	Several aspects of cortical organization are thought to remain plastic into adulthood, allowing cortical sensorimotor maps to be modified continuously by experience. This dynamic nature of cortical circuitry is important for learning, as well as for repair after injury to the nervous system. Electrophysiology studies suggest that adult macaque primary visual cortex (V1) undergoes large-scale reorganization within a few months after retinal lesioning, but this issue has not been conclusively settled. Here we applied the technique of functional magnetic resonance imaging ( fMRI) to detect changes in the cortical topography of macaque area V1 after binocular retinal lesions. fMRI allows non-invasive, in vivo, long-term monitoring of cortical activity with a wide field of view, sampling signals from multiple neurons per unit cortical area. We show that, in contrast with previous studies, adult macaque V1 does not approach normal responsivity during 7.5 months of follow-up after retinal lesions, and its topography does not change. Electrophysiology experiments corroborated the fMRI results. This indicates that adult macaque V1 has limited potential for reorganization in the months following retinal injury.	Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Univ Tubingen, Dept Ophthalmol 1, D-72076 Tubingen, Germany	Max Planck Society; Harvard University; Massachusetts General Hospital; Stanford University; Stanford University; Eberhard Karls University of Tubingen	Smirnakis, SM (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.	smsmirnakis@partners.org	Schmid, Michael C./G-1867-2010; Logothetis, Nikos/U-9282-2019; Schmid, Michael Christoph/AAH-4835-2020	Schmid, Michael C./0000-0003-1424-130X; Schmid, Michael Christoph/0000-0003-1424-130X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS044759] Funding Source: NIH RePORTER; NINDS NIH HHS [F30 NS044759] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angelucci A, 2002, PROG BRAIN RES, V136, P373; Angelucci A, 2002, J NEUROSCI, V22, P8633; Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Brewer AA, 2002, J NEUROSCI, V22, P10416; Calford MB, 1999, P ROY SOC B-BIOL SCI, V266, P499, DOI 10.1098/rspb.1999.0665; Cavanaugh JR, 2002, J NEUROPHYSIOL, V88, P2530, DOI 10.1152/jn.00692.2001; CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DEANGELIS GC, 1995, P NATL ACAD SCI USA, V92, P9682, DOI 10.1073/pnas.92.21.9682; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; Fenrich K, 2004, CAN J NEUROL SCI, V31, P142, DOI 10.1017/S0317167100053798; FIORANI M, 1992, P NATL ACAD SCI USA, V89, P8547, DOI 10.1073/pnas.89.18.8547; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; HENDRY SHC, 1986, NATURE, V320, P750, DOI 10.1038/320750a0; Horton JC, 1998, J NEUROSCI, V18, P5433, DOI 10.1523/JNEUROSCI.18-14-05433.1998; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Koeberle PD, 2004, J NEUROBIOL, V59, P162, DOI 10.1002/neu.10345; Lee TS, 1998, VISION RES, V38, P2429, DOI 10.1016/S0042-6989(97)00464-1; Levitt JB, 2002, VISUAL NEUROSCI, V19, P439, DOI 10.1017/S0952523802194065; Li W, 2001, EXP BRAIN RES, V139, P359, DOI 10.1007/s002210100757; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; Murakami I, 1997, VISUAL NEUROSCI, V14, P89, DOI 10.1017/S0952523800008798; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; PONS TP, 1988, P NATL ACAD SCI USA, V85, P5279, DOI 10.1073/pnas.85.14.5279; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; ROSA MGP, 1995, J PHYSIOL-LONDON, V482, P589, DOI 10.1113/jphysiol.1995.sp020543; ROSIER AM, 1995, J COMP NEUROL, V359, P476, DOI 10.1002/cne.903590309; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; Rossi AF, 2001, J NEUROSCI, V21, P1698, DOI 10.1523/JNEUROSCI.21-05-01698.2001; Sadato N, 2002, NEUROIMAGE, V16, P389, DOI 10.1006/nimg.2002.1111; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; SCHMID LM, 1995, NEUROREPORT, V6, P1349, DOI 10.1097/00001756-199506090-00030; Schmid LM, 1996, CEREB CORTEX, V6, P388, DOI 10.1093/cercor/6.3.388; SCLAR G, 1990, VISION RES, V30, P1, DOI 10.1016/0042-6989(90)90123-3; Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050; Tolias AS, 2001, J NEUROSCI, V21, P8594, DOI 10.1523/JNEUROSCI.21-21-08594.2001; VOLCHAN E, 1995, VISION RES, V35, P1, DOI 10.1016/0042-6989(94)E0083-W; Wandell BA, 1999, ANNU REV NEUROSCI, V22, P145, DOI 10.1146/annurev.neuro.22.1.145; Wandell BA, 2000, J COGNITIVE NEUROSCI, V12, P739, DOI 10.1162/089892900562561	47	150	157	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2005	435	7040					300	307		10.1038/nature03495	http://dx.doi.org/10.1038/nature03495			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927HM	15902248				2022-12-28	WOS:000229185000036
J	Noonan, JP; Hofreiter, M; Smith, D; Priest, JR; Rohland, N; Rabeder, G; Krause, J; Detter, JC; Paabo, S; Rubin, EM				Noonan, JP; Hofreiter, M; Smith, D; Priest, JR; Rohland, N; Rabeder, G; Krause, J; Detter, JC; Paabo, S; Rubin, EM			Genomic sequencing of Pleistocene cave bears	SCIENCE			English	Article							ANCIENT DNA; URSUS-SPELAEUS; MODERN HUMANS; DIVERSITY; EVOLUTION; MAIZE; BLAST	Despite the greater information content of genomic DNA, ancient DNA studies have largely been limited to the amplification of mitochondrial sequences. Here we describe metagenomic libraries constructed with unamplified DNA extracted from skeletal remains of two 40,000-year-old extinct cave bears. Analysis of similar to 1 megabase of sequence from each library showed that despite significant microbial contamination, 5.8 and 1.1% of clones contained cave bear inserts, yielding 26,861 base pairs of cave bear genome sequence. Comparison of cave bear and modern bear sequences revealed the evolutionary relationship of these lineages. The metagenomic approach used here establishes the feasibility of ancient DNA genome sequencing programs.	US Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genom Div, Berkeley, CA 94720 USA; Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Univ Vienna, Inst Paleontol, A-1010 Vienna, Austria; Lawrence Livermore Natl Lab, Biosci Directorate, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Max Planck Society; University of Vienna; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Rubin, EM (corresponding author), US Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA.	emrubin@lbl.gov	Krause, Johannes/E-6640-2015; Noonan, James/ABF-1320-2021; Krause, Johannes/AFP-2642-2022; Hofreiter, Michael/A-3996-2017	Krause, Johannes/0000-0001-5475-4690; Krause, Johannes/0000-0001-9144-3920; Hofreiter, Michael/0000-0003-0441-4705	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007279, U01HL066681] Funding Source: NIH RePORTER; NHLBI NIH HHS [U1 HL66681B, T32 HL07279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Cooper GM, 2004, GENOME RES, V14, P539, DOI 10.1101/gr.2034704; GOLOUBINOFF P, 1993, P NATL ACAD SCI USA, V90, P1997, DOI 10.1073/pnas.90.5.1997; Greenwood AD, 1999, MOL BIOL EVOL, V16, P1466, DOI 10.1093/oxfordjournals.molbev.a026058; HANNI C, 1994, P NATL ACAD SCI USA, V91, P12336, DOI 10.1073/pnas.91.25.12336; Hofreiter M, 2004, P NATL ACAD SCI USA, V101, P12963, DOI 10.1073/pnas.0403618101; Hofreiter M, 2002, MOL BIOL EVOL, V19, P1244, DOI 10.1093/oxfordjournals.molbev.a004185; Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071; Hofreiter M, 2001, NUCLEIC ACIDS RES, V29, P4793, DOI 10.1093/nar/29.23.4793; Jaenicke-Despres V, 2003, SCIENCE, V302, P1206, DOI 10.1126/science.1089056; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Krings M, 1999, P NATL ACAD SCI USA, V96, P5581, DOI 10.1073/pnas.96.10.5581; Loreille O, 2001, CURR BIOL, V11, P200, DOI 10.1016/S0960-9822(01)00046-X; Paabo S, 2004, ANNU REV GENET, V38, P645, DOI 10.1146/annurev.genet.37.110801.143214; Poinar H, 2003, CURR BIOL, V13, P1150, DOI 10.1016/S0960-9822(03)00450-0; Serre D, 2004, PLOS BIOL, V2, P313, DOI 10.1371/journal.pbio.0020057; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851	18	172	181	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 22	2005	309	5734					597	600		10.1126/science.1113485	http://dx.doi.org/10.1126/science.1113485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SE	15933159	Green Submitted			2022-12-28	WOS:000230735200044
J	Viner, RM; Cole, TJ				Viner, RM; Cole, TJ			Adult socioeconomic, educational, social, and psychological outcomes of childhood obesity: a national birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; SELF-REPORTED HEIGHT; YOUNG ADULTHOOD; OVERWEIGHT; WEIGHT; HEALTH; CONSEQUENCES; ADOLESCENCE; DEPRESSION; VALIDITY	Objectives To assess adult socioeconomic, educational, social, and psychological outcomes of childhood obesity by using nationally representative data. Design 1970 British birth cohort. Participants 16 567 babies born in Great Britain 5-11 April 1970 and followed up at 5, 10, and 29-30 years. Main outcome measures Obesity at age 10 and 30 years. Self reported socioeconomic, educational, psychological, and social outcomes at 30 years. Odds ratios were calculated for the risk of each adult outcome associated with obesity in childhood only, obesity in adulthood only, and persistent child and adult obesity, compared with those obese at neither period. Results Of the 8490 participants with data on body mass index at 10 and 30 years, 4.3% were obese at 10 years and 16.3% at 30 years. Obesity in childhood only was not associated with adult social class, income, years of schooling, educational attainment, relationships, or psychological morbidity in either sex after adjustment for confounding factors. Persistent obesity was not associated with any adverse adult outcomes in men, though it was associated among women with a higher risk of never having been gainfully employed (odds ratio 1.9, 95% confidence interval 1.1 to 3.3) and not having a current partner (2.0, 1.3 to 3.3). Conclusions Obesity limited to childhood has little impact on adult outcomes. Persistent obesity in women is associated with poorer employment and relationship outcomes. Efforts to reduce the socioeconomic and psychosocial burden of obesity in adult life should focus on prevention of the persistence of obesity from childhood into adulthood.	UCL, Dept Paediat, Royal Free & Univ Coll Med Sch, London NW3 2PF, England; UCL, Ctr Paediat Edpidemiol & Biostat, Inst Child Hlth, London WC1N 1EH, England	University of London; University College London; University of London; University College London	Viner, RM (corresponding author), UCL, Dept Paediat, Royal Free & Univ Coll Med Sch, London NW3 2PF, England.	R.Viner@ich.ucl.ac.uk	Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821, G9827821(62595)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Butler NR, 2000, 1970 BRIT BIRTH COHO; BYNNER J, 2002, 1 CLS I ED; Chinn S, 2001, BRIT MED J, V322, P24, DOI 10.1136/bmj.322.7277.24; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; CRAWLEY HF, 1995, INT J OBESITY, V19, P579; Elliot C. D., 1983, BRIT ABILITY SCALES; Ferraro KF, 2003, J GERONTOL B-PSYCHOL, V58, pS110, DOI 10.1093/geronb/58.2.S110; Goodman E, 2002, PEDIATRICS, V110, P497, DOI 10.1542/peds.110.3.497; Goodman E, 2003, J ADOLESCENT HEALTH, V33, P140, DOI 10.1016/S1054-139X(03)00247-7; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; Laitinen J, 2002, INT J OBESITY, V26, P1329, DOI 10.1038/sj.ijo.0802134; Lake JK, 1997, ARCH DIS CHILD, V77, P376, DOI 10.1136/adc.77.5.376; MAXWELL SE, 1993, PSYCHOL BULL, V113, P181, DOI 10.1037/0033-2909.113.1.181; Mustillo S, 2003, PEDIATRICS, V111, P851, DOI 10.1542/peds.111.4.851; Onyike CU, 2003, AM J EPIDEMIOL, V158, P1139, DOI 10.1093/aje/kwg275; Power C, 2003, INT J OBESITY, V27, P1081, DOI 10.1038/sj.ijo.0802323; Reilly JJ, 2003, ARCH DIS CHILD, V88, P748, DOI 10.1136/adc.88.9.748; Rodgers B, 1999, SOC PSYCH PSYCH EPID, V34, P333, DOI 10.1007/s001270050153; SARGENT JD, 1994, ARCH PEDIAT ADOL MED, V148, P681, DOI 10.1001/archpedi.1994.02170070019003; Spencer EA, 2002, PUBLIC HEALTH NUTR, V5, P561, DOI 10.1079/PHN2001322; Srinivasan SR, 2002, DIABETES, V51, P204, DOI 10.2337/diabetes.51.1.204; Wright CM, 2001, BMJ-BRIT MED J, V323, P1280, DOI 10.1136/bmj.323.7324.1280	23	130	133	1	24	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 11	2005	330	7504					1354	1357		10.1136/bmj.38453.422049.E0	http://dx.doi.org/10.1136/bmj.38453.422049.E0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	936FE	15901644	Green Published, Green Submitted			2022-12-28	WOS:000229840100016
J	Blaauw, M; Christen, JA				Blaauw, M; Christen, JA			The problems of radiocarbon dating	SCIENCE			English	Letter									Ctr Invest Matemat, Guanajuato, Mexico	CIMAT - Centro de Investigacion en Matematicas	Blaauw, M (corresponding author), Ctr Invest Matemat, AP 402, Guanajuato, Mexico.	blaauwm@cimat.mx	Blaauw, Maarten/N-9576-2019; Blaauw, Maarten/E-4539-2011	Blaauw, Maarten/0000-0002-5680-1515; Blaauw, Maarten/0000-0002-5680-1515; Brown, Tom/0000-0001-9984-7647; Christen, J Andres/0000-0002-5795-4345				BLAAUW M, IN PRESS APPL STAT; Broecker W, 2004, SCIENCE, V306, P1169, DOI 10.1126/science.1102293; BUCK CE, 1996, BAYESIAN APPROACH IN; James, 1999, INTERNET ARCHAEOL, V7; Scott EM, 2003, RADIOCARBON, V45, P135, DOI DOI 10.1017/S0033822200032574; [No title captured]	6	12	12	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1551	1551		10.1126/science.308.5728.1551	http://dx.doi.org/10.1126/science.308.5728.1551			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947156	Green Submitted			2022-12-28	WOS:000229827000020
J	Mendelsohn, ME; Karas, RH				Mendelsohn, ME; Karas, RH			Molecular and cellular basis of cardiovascular gender differences	SCIENCE			English	Review							ESTROGEN-RECEPTOR-ALPHA; CORONARY-ARTERY-DISEASE; ADVANCED HEART-FAILURE; E-DEFICIENT MICE; HORMONE-THERAPY; POSTMENOPAUSAL WOMEN; ANDROGEN RECEPTOR; SEX-HORMONES; ATHEROSCLEROSIS; TESTOSTERONE	Cardiovascular diseases (CVDs), the major cause of morbidity and mortality for both men and women, occur uncommonly in premenopausal women, but their incidence rises sharply after the menopausal transition. Cardiovascular gender differences are apparent long before CVDs appear in men and women, and improved understanding of the biology underlying these differences has the potential to advance the diagnosis and treatment of CVDs in both sexes. This review considers gender differences in the molecular and cellular physiology of the heart and blood vessels in health and disease, highlighting understudied areas that can help resolve the current controversy regarding hormone replacement therapy and improve cardiovascular health in women.	Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Tufts New England Med Ctr Hosp, Mol Cardiol Res Inst,Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Tufts New England Med Ctr Hosp, Mol Cardiol Res Inst,Div Cardiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	mmendelsohn@tufts-nemc.org			NHLBI NIH HHS [R01 HL50569, P50 HL63494-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams KF, 1999, CIRCULATION, V99, P1816, DOI 10.1161/01.CIR.99.14.1816; Barish GD, 2004, TRENDS ENDOCRIN MET, V15, P158, DOI 10.1016/j.tem.2004.03.003; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Braunstein JB, 2002, CHEST, V121, P906, DOI 10.1378/chest.121.3.906; Brouchet L, 2001, CIRCULATION, V103, P423; Cavasin MA, 2003, AM J PHYSIOL-HEART C, V284, pH1560, DOI 10.1152/ajpheart.01087.2002; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Clarkson TB, 2005, MATURITAS, V51, P64, DOI 10.1016/j.maturitas.2005.02.016; Davis SR, 2003, BEST PRACT RES CL EN, V17, P165, DOI 10.1016/S1521-690X(02)00078-7; Douglas PS, 1998, J AM COLL CARDIOL, V32, P1118, DOI 10.1016/S0735-1097(98)00347-7; Dubey RK, 2002, CARDIOVASC RES, V53, P688, DOI 10.1016/S0008-6363(01)00527-2; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Forster C, 2004, P NATL ACAD SCI USA, V101, P14234, DOI 10.1073/pnas.0405571101; Gabel Scott A, 2005, J Mol Cell Cardiol, V38, P289, DOI 10.1016/j.yjmcc.2004.11.013; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Ghali JK, 2003, J AM COLL CARDIOL, V42, P2128, DOI 10.1016/j.jacc.2003.05.012; Golden KL, 2004, HORM METAB RES, V36, P197; Gorodeski GI, 2002, BEST PRACT RES CL OB, V16, P329, DOI 10.1053/beog.2002.0282; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Grohe C, 1998, J ENDOCRINOL, V156, pR1, DOI 10.1677/joe.0.156R001; Grumbach MM, 1999, J CLIN ENDOCR METAB, V84, P4677, DOI 10.1210/jc.84.12.4677; Haarbo J, 1996, ATHEROSCLEROSIS, V123, P139, DOI 10.1016/0021-9150(96)05798-X; Hanke H, 1999, ATHEROSCLEROSIS, V147, P123, DOI 10.1016/S0021-9150(99)00182-3; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Herrington DM, 2003, CURR OPIN LIPIDOL, V14, P145, DOI 10.1097/00041433-200304000-00005; Hodgin JB, 2002, ENDOCRINOLOGY, V143, P4495, DOI 10.1210/en.2002-220844; Huhtaniemi I, 1995, REPROD FERT DEVELOP, V7, P1025, DOI 10.1071/RD9951025; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Jayachandran M, 2004, J APPL PHYSIOL, V97, P1445, DOI 10.1152/japplphysiol.01074.2003; Khetawat G, 2000, BLOOD, V95, P2289, DOI 10.1182/blood.V95.7.2289.007k03_2289_2296; KLEIN KO, 1994, J CLIN INVEST, V94, P2475, DOI 10.1172/JCI117616; Larsen JA, 1998, J CARDIOVASC ELECTR, V9, P655, DOI 10.1111/j.1540-8167.1998.tb00950.x; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mendelsohn ME, 2001, CIRCULATION, V104, P2256, DOI 10.1161/circ.104.19.2256; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mendelsohn ME, 2003, CIRC RES, V93, P1142, DOI 10.1161/01.RES.0000108694.68635.1C; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Merz CNB, 1996, AM HEART J, V131, P704; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naftolin F, 2004, FERTIL STERIL, V81, P1498, DOI 10.1016/j.fertnstert.2004.02.095; Nathan L, 2001, P NATL ACAD SCI USA, V98, P3589, DOI 10.1073/pnas.051003698; OLIVETTI G, 1995, J AM COLL CARDIOL, V26, P1068, DOI 10.1016/0735-1097(95)00282-8; Olsson MC, 2001, AM J PHYSIOL-HEART C, V280, pH1136, DOI 10.1152/ajpheart.2001.280.3.H1136; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Reckelhoff JF, 2001, HYPERTENSION, V37, P1199, DOI 10.1161/01.HYP.37.5.1199; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Rosano GMC, 1999, CIRCULATION, V99, P1666, DOI 10.1161/01.CIR.99.13.1666; Rosenfeld ME, 2002, ATHEROSCLEROSIS, V164, P251, DOI 10.1016/S0021-9150(02)00178-8; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sader MA, 2002, CARDIOVASC RES, V53, P597, DOI 10.1016/S0008-6363(01)00473-4; Seed M, 2004, CURR OPIN LIPIDOL, V15, P459, DOI 10.1097/01.mol.0000137231.84772.80; Shearman AM, 2003, JAMA-J AM MED ASSOC, V290, P2263, DOI 10.1001/jama.290.17.2263; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stefanelli CB, 2004, MOL GENET METAB, V83, P188, DOI 10.1016/j.ymgme.2004.04.013; Sudhir K, 1999, J CLIN ENDOCR METAB, V84, P3411, DOI 10.1210/jc.84.10.3411; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; Wu FCW, 2003, ENDOCR REV, V24, P183, DOI 10.1210/er.2001-0025; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Yan L, 2004, J MOL CELL CARDIOL, V37, P921, DOI 10.1016/j.yjmcc.2004.06.012; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	68	795	816	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1583	1587		10.1126/science.1112062	http://dx.doi.org/10.1126/science.1112062			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15947175				2022-12-28	WOS:000229827000042
J	Lu, J; Getz, G; Miska, EA; Alvarez-Saavedra, E; Lamb, J; Peck, D; Sweet-Cordero, A; Ebet, BL; Mak, RH; Ferrando, AA; Downing, JR; Jacks, T; Horvitz, HR; Golub, TR				Lu, J; Getz, G; Miska, EA; Alvarez-Saavedra, E; Lamb, J; Peck, D; Sweet-Cordero, A; Ebet, BL; Mak, RH; Ferrando, AA; Downing, JR; Jacks, T; Horvitz, HR; Golub, TR			MicroRNA expression profiles classify human cancers	NATURE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION; CAENORHABDITIS-ELEGANS; STEM-CELLS; SIGNATURES; RNA; DIFFERENTIATION; IDENTIFICATION; ACCUMULATION; MICROARRAYS	Recent work has revealed the existence of a class of small non-coding RNA species, known as microRNAs ( miRNAs), which have critical functions across various biological processes(1,2). Here we use a new, bead-based flow cytometric miRNA expression profiling method to present a systematic expression analysis of 217 mammalian miRNAs from 334 samples, including multiple human cancers. The miRNA profiles are surprisingly informative, reflecting the developmental lineage and differentiation state of the tumours. We observe a general downregulation of miRNAs in tumours compared with normal tissues. Furthermore, we were able to successfully classify poorly differentiated tumours using miRNA expression profiles, whereas messenger RNA profiles were highly inaccurate when applied to the same samples. These findings highlight the potential of miRNA profiling in cancer diagnosis.	MIT, Broad Inst, Cambridge, MA 02141 USA; Harvard Univ, Broad Inst, Cambridge, MA 02141 USA; MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; St Jude Children's Research Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Golub, TR (corresponding author), MIT, Broad Inst, Cambridge, MA 02141 USA.	golub@broad.mit.edu	Downing, James R./N-8102-2018; Ferrando, Adolfo A/Q-7026-2016	Mak, Raymond/0000-0002-8754-0565; Miska, Eric/0000-0002-4450-576X				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Michael MZ, 2003, MOL CANCER RES, V1, P882; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Nelson PT, 2004, NAT METHODS, V1, P155, DOI 10.1038/NMETH717; Pavlidis N, 2003, EUR J CANCER, V39, P1990, DOI 10.1016/S0959-8049(03)00547-1; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Sun YQ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh186; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	30	7640	8290	19	1486	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2005	435	7043					834	838		10.1038/nature03702	http://dx.doi.org/10.1038/nature03702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933NK	15944708				2022-12-28	WOS:000229638700054
J	Shamdasani, S				Shamdasani, S			Historical keywords - Unconscious	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Shamdasani, S (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London, England.	s.shamdasani@ucl.ac.uk							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 4	2005	365	9475					1921	1921		10.1016/S0140-6736(05)66647-0	http://dx.doi.org/10.1016/S0140-6736(05)66647-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932XJ	15936411	Bronze			2022-12-28	WOS:000229587800015
J	Watts, G				Watts, G			Science commentary: Power to confuse	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							POLLUTANT AEROSOLS; INCREASED EXPOSURE				Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Draper G, 2005, BRIT MED J, V330, P1290, DOI 10.1136/bmj.330.7503.1290; Fews AP, 1999, INT J RADIAT BIOL, V75, P1505, DOI 10.1080/095530099139115; Fews AP, 1999, INT J RADIAT BIOL, V75, P1523, DOI 10.1080/095530099139124; *NAT RAD PROT BOAR, 2004, DOCUMENTS NRPB, V15	4	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2005	330	7503					1293	1293		10.1136/bmj.330.7503.1293	http://dx.doi.org/10.1136/bmj.330.7503.1293			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TL	15933352	Bronze, Green Published			2022-12-28	WOS:000229655700015
J	Green, DR				Green, DR			Apoptotic pathways: Ten minutes to dead	CELL			English	Review							CELL-SURVIVAL; CYTOCHROME-C; PROTEINS; APAF-1	For more than a decade, it has been apparent that apoptosis and other forms of cell death are often controlled at one or more crucial steps involving the mitochondria. Recent findings, including an elegant investigation in a recent issue of Cell (Hao et al., 2005), have helped to elucidate fundamental aspects of this involvement while raising puzzling new questions about mitochondrial routes to cellular demise. The emerging, if preliminary, perspective these new studies provide may represent either a refinement of our views of how cells die or, perhaps, the beginnings of what amounts to a reformulation of our ideas.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	doug@liai.org	Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				Abdullaev ZK, 2002, BIOCHEM J, V362, P749, DOI 10.1042/0264-6021:3620749; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Riedl SJ, 2005, NATURE, V434, P926, DOI 10.1038/nature03465; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022	15	619	654	1	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	2005	121	5					671	674		10.1016/j.cell.2005.05.019	http://dx.doi.org/10.1016/j.cell.2005.05.019			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935754	Bronze			2022-12-28	WOS:000229658000006
J	Hegde, SS; Vetting, MW; Roderick, SL; Mitchenall, LA; Maxwell, A; Takiff, HE; Blanchard, JS				Hegde, SS; Vetting, MW; Roderick, SL; Mitchenall, LA; Maxwell, A; Takiff, HE; Blanchard, JS			A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA	SCIENCE			English	Article							MEDIATED QUINOLONE RESISTANCE; ESCHERICHIA-COLI; MICROCIN B17; CRYSTAL-STRUCTURE; GYRASE; PLASMID; INHIBITOR; MOXIFLOXACIN; MUTATIONS; SEQUENCE	Fluoroquinolones are gaining increasing importance in the treatment of tuberculosis. The expression of MfpA, a member of the pentapeptide repeat family of proteins from Mycobacterium tuberculosis, causes resistance to ciprofloxacin and sparfloxacin. This protein binds to DNA gyrase and inhibits its activity. Its three-dimensional structure reveals a fold, which we have named the right-handed quadrilateral beta helix, that exhibits size, shape, and electrostatic similarity to B-form DNA. This represents a form of DNA mimicry and explains both its inhibitory effect on DNA gyrase and fluoroquinolone resistance resulting from the protein's expression in vivo.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Inst Venezolano Invest Cient, Ctr Microbiol & Biol Celular, Mol Genet Lab, Caracas 1020A, Venezuela	Yeshiva University; Albert Einstein College of Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Venezuelan Institute Science Research	Blanchard, JS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	btanchar@aecom.yu.edu		Mitchenall, Lesley/0000-0002-0063-1991; Maxwell, Anthony/0000-0002-5756-6430	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696, T32AI007501, R01AI060899] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BBS/E/J/00000201] Funding Source: Medline; NIAID NIH HHS [AI60899, AI33696, T32 AI07501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aubry A, 2004, ANTIMICROB AGENTS CH, V48, P1281, DOI 10.1128/AAC.48.4.1281-1288.2004; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bateman A, 1998, PROTEIN SCI, V7, P1477, DOI 10.1002/pro.5560070625; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CAMBAU E, 1994, J INFECT DIS, V170, P479, DOI 10.1093/infdis/170.2.479; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Crofton J., 1997, GUIDELINES MANAGEMEN; Drlica K, 2003, CURR TOP MED CHEM, V3, P249, DOI 10.2174/1568026033452537; Fisher MA, 2002, J BACTERIOL, V184, P4025, DOI 10.1128/JB.184.14.4025-4032.2002; GARRIDO MD, 1988, EMBO J, V7, P1853, DOI 10.1002/j.1460-2075.1988.tb03018.x; Guillemin I, 1998, ANTIMICROB AGENTS CH, V42, P2084, DOI 10.1128/AAC.42.8.2084; Hata M, 2005, ANTIMICROB AGENTS CH, V49, P801, DOI 10.1128/AAC.49.2.801-803.2005; Heddle JG, 2001, J MOL BIOL, V307, P1223, DOI 10.1006/jmbi.2001.4562; HEGDE S, UNPUB; Jacoby GA, 2003, ANTIMICROB AGENTS CH, V47, P559, DOI 10.1128/AAC.47.2.559-562.2003; Ji BH, 1998, ANTIMICROB AGENTS CH, V42, P2066, DOI 10.1128/AAC.42.8.2066; Jonas D, 2005, ANTIMICROB AGENTS CH, V49, P773, DOI 10.1128/AAC.49.2.773-775.2005; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Montero C, 2001, ANTIMICROB AGENTS CH, V45, P3387, DOI 10.1128/AAC.45.12.3387-3392.2001; Nakanishi A, 2002, J BIOL CHEM, V277, P8949, DOI 10.1074/jbc.M111278200; Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885OC; Parsons LX, 2004, PROTEINS, V54, P375, DOI 10.1002/prot.10607; Pierrat OA, 2003, J BIOL CHEM, V278, P35016, DOI 10.1074/jbc.M304516200; Romanowski MJ, 2002, PROTEINS, V47, P403, DOI 10.1002/prot.10102; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SULLIVAN EA, 1995, LANCET, V345, P1148, DOI 10.1016/S0140-6736(95)90980-X; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; Tran JH, 2002, P NATL ACAD SCI USA, V99, P5638, DOI 10.1073/pnas.082092899; Tran JH, 2005, ANTIMICROB AGENTS CH, V49, P118, DOI 10.1128/AAC.49.1.118-125.2005; Walkinshaw MD, 2002, MOL CELL, V9, P187, DOI 10.1016/S1097-2765(02)00435-5; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; Xu C, 1996, J INFECT DIS, V174, P1127, DOI 10.1093/infdis/174.5.1127	32	200	217	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1480	1483		10.1126/science.1110699	http://dx.doi.org/10.1126/science.1110699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933203				2022-12-28	WOS:000229619300057
J	Kresse, G; Schmid, M; Napetschnig, E; Shishkin, M; Kohler, L; Varga, P				Kresse, G; Schmid, M; Napetschnig, E; Shishkin, M; Kohler, L; Varga, P			Structure of the ultrathin aluminum oxide film on NiAl(110)	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; SURFACE; INTERFACE; DEFECTS	The well-ordered aluminum oxide film formed by oxidation of the NiA[(110) surface is the most intensely studied metal surface oxide, but its structure was previously unknown. We determined the structure by extensive ab initio modeling and scanning tunneling microscopy experiments. Because the topmost aluminum atoms are pyramidally and tetrahedrally coordinated, the surface is different from all Al2O3 bulk phases. The film is a wide-gap insulator, although the overall stoichiometry of the film is not Al2O3 but Al10O13. We propose that the same building blocks can be found on the surfaces of bulk oxides, such as the reduced corundum (0001) surface.	Univ Vienna, Inst Mat Phys, A-1090 Vienna, Austria; Univ Vienna, Ctr Computat Mat Sci, A-1090 Vienna, Austria; Vienna Univ Technol, Inst Allgemeine Phys, A-1040 Vienna, Austria	University of Vienna; University of Vienna; Technische Universitat Wien	Kresse, G (corresponding author), Univ Vienna, Inst Mat Phys, Waehringer Guertel 18, A-1090 Vienna, Austria.	Georg.Kresse@univie.ac.at	Shishkin, Maxim/I-3308-2013; Kresse, Georg/X-2531-2018; Varga, Peter/K-6377-2013	Kresse, Georg/0000-0001-9102-4259; Schmid, Michael/0000-0003-3373-9357				Barth C, 2001, NATURE, V414, P54, DOI 10.1038/35102031; Carlisle CI, 2000, PHYS REV LETT, V84, P3899, DOI 10.1103/PhysRevLett.84.3899; Frank M, 2001, SURF SCI, V492, P270, DOI 10.1016/S0039-6028(01)01475-3; Gustafson J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.126102; Hagen M, 1998, PHILOS MAG A, V77, P447, DOI 10.1080/01418619808223764; Hendriksen BLM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.046101; JAEGER RM, 1991, SURF SCI, V259, P235, DOI 10.1016/0039-6028(91)90555-7; Jennison DR, 2000, SURF SCI, V464, P108, DOI 10.1016/S0039-6028(00)00578-1; Kulawik M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.256101; Li WX, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.146104; LIBUDA J, 1994, SURF SCI, V318, P61, DOI 10.1016/0039-6028(94)90341-7; Lundgren E, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.046101; Lundgren E, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.246103; Nilius N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.046808; Over H, 2000, SCIENCE, V287, P1474, DOI 10.1126/science.287.5457.1474; Qiu XH, 2003, SCIENCE, V299, P542, DOI 10.1126/science.1078675; RENAUD G, 1994, PHYS REV LETT, V73, P1825, DOI 10.1103/PhysRevLett.73.1825; Reuter K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.035406; SCHMID M, 1993, PHYS REV LETT, V70, P1441, DOI 10.1103/PhysRevLett.70.1441; Stierle A, 2004, SCIENCE, V303, P1652, DOI 10.1126/science.1094060; Torrelles X, 2001, SURF SCI, V487, P97, DOI 10.1016/S0039-6028(01)01078-0; Wang XG, 2000, PHYS REV LETT, V84, P3650, DOI 10.1103/PhysRevLett.84.3650; WINKELMANN F, 1994, SURF SCI, V307, P1148, DOI 10.1016/0039-6028(94)91556-3	23	317	318	5	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2005	308	5727					1440	1442		10.1126/science.1107783	http://dx.doi.org/10.1126/science.1107783			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933195				2022-12-28	WOS:000229619300045
J	Rickert, M; Wang, XQ; Boulanger, MJ; Goriatcheva, N; Garcia, KC				Rickert, M; Wang, XQ; Boulanger, MJ; Goriatcheva, N; Garcia, KC			The structure of interleukin-2 complexed with its alpha receptor	SCIENCE			English	Article							CRYSTAL-STRUCTURE; IL-2 RECEPTOR; BINDING; IDENTIFICATION; LOCALIZATION; COMPONENT; ANTIBODY; CHAIN; P55	Interleukin-2 (IL-2) is an immunoregulatory cytokine that binds sequentially to the alpha (IL-2R alpha), beta (IL-2R beta), and common gamma chain (gamma(c)) receptor subunits. Here we present the 2.8 angstrom crystal structure of a complex between human IL-2 and IL-2R alpha, which-interact in a docking mode distinct from that of other cytokine receptor complexes. IL-2R alpha is composed of strand-swapped "sushi-like" domains, unlike the classical cytokine receptor fold. As a result of this domain swap, IL-2R alpha uses a composite surface to dock into a groove on IL-2 that also serves as a binding site for antagonist drugs. With this complex, we now have representative structures for each class of hematopoietic cytokine receptor-docking modules.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University; Stanford University	Garcia, KC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, 299 Campus Dr,Fairchild D319, Stanford, CA 94305 USA.	kcgarcia@stanford.edu			NIAID NIH HHS [AI51321] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051321] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arkin MR, 2003, P NATL ACAD SCI USA, V100, P1603, DOI 10.1073/pnas.252756299; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; Church AC, 2003, QJM-INT J MED, V96, P91, DOI 10.1093/qjmed/hcg014; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Eklund JW, 2004, CURR OPIN ONCOL, V16, P542, DOI 10.1097/01.cco.0000142070.45097.68; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; Liparoto SF, 1999, J MOL RECOGNIT, V12, P316, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<316::AID-JMR468>3.0.CO;2-1; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Rickert M, 2004, J MOL BIOL, V339, P1115, DOI 10.1016/j.jmb.2004.04.038; ROBB RJ, 1988, P NATL ACAD SCI USA, V85, P5654, DOI 10.1073/pnas.85.15.5654; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; SHACKELFORD DA, 1986, EMBO J, V5, P3275, DOI 10.1002/j.1460-2075.1986.tb04639.x; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Stroud Robert M, 2004, Sci STKE, V2004, pre7, DOI 10.1126/stke.2312004re7; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; Tilley JW, 1997, J AM CHEM SOC, V119, P7589, DOI 10.1021/ja970702x; Tsytsikov VN, 1996, J BIOL CHEM, V271, P23055, DOI 10.1074/jbc.271.38.23055; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; Waldmann TA, 1998, CURR OPIN IMMUNOL, V10, P507, DOI 10.1016/S0952-7915(98)80215-X; WU ZN, 1995, J BIOL CHEM, V270, P16039, DOI 10.1074/jbc.270.27.16039; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	31	162	177	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1477	1480		10.1126/science.1109745	http://dx.doi.org/10.1126/science.1109745			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15933202				2022-12-28	WOS:000229619300056
J	Tonks, NK				Tonks, NK			Redox redux: Revisiting PTPs and the control of cell signaling	CELL			English	Review							PROTEIN-TYROSINE PHOSPHATASES; OXIDATIVE STRESS; REACTIVE OXYGEN; DISULFIDE BOND; H2O2; ENZYMES; PTEN; 1B	The architecture of the active site of members of the protein tyrosine phosphatase (PTP) superfamily renders these enzymes sensitive to reversible oxidation and inactivation. The importance of reversible oxidation of PTP superfamily members in controlling the signal output following an extracellular stimulus is discussed.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buhrman G, 2005, BIOCHEMISTRY-US, V44, P5307, DOI 10.1021/bi047449f; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Groen A, 2005, J BIOL CHEM, V280, P10298, DOI 10.1074/jbc.M412424200; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; MARTYN KD, 2005, IN PRESS CELL SIGNAL; Meng TC, 2004, J BIOL CHEM, V279, P37716, DOI 10.1074/jbc.M404606200; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Singh DK, 2005, CELL, V121, P281, DOI 10.1016/j.cell.2005.02.036; van der Wijk T, 2004, J BIOL CHEM, V279, P44355, DOI 10.1074/jbc.M407483200; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681	17	583	601	3	37	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 3	2005	121	5					667	670		10.1016/j.cell.2005.05.016	http://dx.doi.org/10.1016/j.cell.2005.05.016			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	933UI	15935753	Bronze			2022-12-28	WOS:000229658000005
J	Kumar, S; Regan, F				Kumar, S; Regan, F			Management of pregnancies with RhD alloimmunisation	BRITISH MEDICAL JOURNAL			English	Review							RED-CELL ALLOIMMUNIZATION; RHESUS HEMOLYTIC-DISEASE; INTRAUTERINE TRANSFUSIONS; FETAL TRANSFUSION; LATE ANEMIA; BLOOD; ISOIMMUNIZATION; ERYTHROPOIESIS; PREDICTION; HYDROPS		Univ London Imperial Coll Sci Technol & Med, Queen Charlottes Hosp, Hammersmith Hosp NHS Trust, Ctr Fetal Care, London W12 0HS, England; Univ London Imperial Coll Sci Technol & Med, Queen Charlottes Hosp, Hammersmith Hosp NHS Trust, Dept Haematol, London W12 0HS, England	Imperial College London; Imperial College London	Kumar, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Queen Charlottes Hosp, Hammersmith Hosp NHS Trust, Ctr Fetal Care, London W12 0HS, England.	sailesh.kumar@imperial.ac.uk	Kumar, Sailesh/M-3207-2014; Kumar, Sailesh/A-9203-2011	Kumar, Sailesh/0000-0003-0832-4811; 				BERGER HM, 1990, LANCET, V335, P933, DOI 10.1016/0140-6736(90)90997-J; Bowman J M, 1988, Transfus Med Rev, V2, P129, DOI 10.1016/S0887-7963(88)70039-5; BOWMAN JM, 1986, VOX SANG, V51, P117, DOI 10.1111/j.1423-0410.1986.tb00226.x; Bullock R, 2005, ULTRASOUND OBST GYN, V25, P331, DOI 10.1002/uog.1886; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; De Groot CJM, 2000, EARLY HUM DEV, V57, P205, DOI 10.1016/S0378-3782(99)00063-8; Finning KM, 2002, TRANSFUSION, V42, P1079, DOI 10.1046/j.1537-2995.2002.00165.x; Grab D, 1999, OBSTET GYNECOL, V93, P165, DOI 10.1016/S0029-7844(98)00421-9; Hudon L, 1998, AM J OBSTET GYNECOL, V179, P858, DOI 10.1016/S0002-9378(98)70178-4; Klumper FJ, 2000, EUR J OBSTET GYN R B, V92, P91, DOI 10.1016/S0301-2115(00)00430-9; LANDSTEINER KARL, 1940, PROC SOC EXP BIOL AND MED, V43, P223; LILEY AW, 1961, AM J OBSTET GYNECOL, V82, P1359; LO YMD, 1994, ANN NY ACAD SCI, V731, P229, DOI 10.1111/j.1749-6632.1994.tb55774.x; Mari G, 2000, NEW ENGL J MED, V342, P9, DOI 10.1056/NEJM200001063420102; MAXWELL DJ, 1991, BRIT J OBSTET GYNAEC, V98, P892, DOI 10.1111/j.1471-0528.1991.tb13511.x; MILLARD DD, 1990, J PEDIATR-US, V117, P447, DOI 10.1016/S0022-3476(05)81096-0; *NAT I CLIN EXC, 2002, GUID PREGN ROUT ANT; NICOLAIDES KH, 1992, BRIT MED J, V304, P1155, DOI 10.1136/bmj.304.6835.1155; Ovali F, 1996, PEDIATR RES, V39, P831, DOI 10.1203/00006450-199605000-00015; PATTISON NS, 1992, ULTRASOUND OBST GYN, V2, P329, DOI 10.1046/j.1469-0705.1992.02050329.x; PETEREC SM, 1995, CLIN PERINATOL, V22, P561; *ROYAL COLL OBST G, 2002, GREEN TOP GUID ANT I; SAADE GR, 1993, FETAL DIAGN THER, V8, P161, DOI 10.1159/000263816; SCARADAVOU A, 1993, J PEDIATR-US, V123, P279, DOI 10.1016/S0022-3476(05)81704-4; Schumacher B, 1996, OBSTET GYNECOL, V88, P137, DOI 10.1016/0029-7844(96)00113-5; TRONCEK DF, 2001, IMMUNOHEMATOLOGY, V17, P37; van Kamp IL, 2001, AM J OBSTET GYNECOL, V185, P668, DOI 10.1067/mob.2001.116690; Voto LS, 1997, J PERINAT MED, V25, P85, DOI 10.1515/jpme.1997.25.1.85; Whitecar PW, 2002, AM J OBSTET GYNECOL, V187, P977, DOI 10.1067/mob.2002.126960	29	44	44	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 28	2005	330	7502					1255	1258		10.1136/bmj.330.7502.1255	http://dx.doi.org/10.1136/bmj.330.7502.1255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15920129	Green Published			2022-12-28	WOS:000229448900023
J	Rivero-Arias, O; Campbell, H; Gray, A; Fairbank, J; Frost, H; Wilson-MacDonald, J				Rivero-Arias, O; Campbell, H; Gray, A; Fairbank, J; Frost, H; Wilson-MacDonald, J		Spine Stabilisation Trial Grp	Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SWEDISH-LUMBAR-SPINE; NONSURGICAL TREATMENT; FUSION; SPONDYLOLISTHESIS; MULTICENTER	Objective To determine whether from a health provider and patient perspective, surgical stabilisation of the spine is cost effective when compared with an intensive programme of rehabilitation in patients with chronic low back pain. Design Economic evaluation alongside a pragmatic randomised controlled trial. Setting Secondary care. Participants 349 patients randomised to surgery (n =176) or to an intensive rehabilitation programme (n = 173) from 15 centres across the United Kingdom between June 1996 and February 2002. Main outcome measures Costs related to back pain and incurred by the NHS and patients up to 24 months after randomisation. Return to paid employment and total hours worked. Patient utility as estimated by using the EuroQol EQ-5D questionnaire at several time points and used to calculate quality adjusted life years (QALYs). Cost effectiveness was expressed as an incremental cost per QALY. Results At two years, 38 patients randomised to rehabilitation had received rehabilitation and surgery whereas just seven surgery patients received had both treatments. The mean total cost per patient was estimated to be 7830 pound (SD 5202) pound in the surgery group and 4526 pound (SD 4155) pound in the intensive rehabilitation arm, a significant difference of 3304 pound (95% confidence interval 2317 pound to 4291) pound. Mean QALYs over the trial period were 1.004 (SD 0.405) in the surgery group and 0.936 (SD 0.43 1) in the intensive rehabilitation group, giving a non-significant difference of 0.068 (- 0.020 to 0.156). The incremental cost effectiveness ratio was estimated to be A:48 588 per QALY gained (- 279 pound 883 to 372 pound 406). Conclusion Two year follow-up data show that surgical stabilisation of the spine may not be a cost effective use of scarce healthcare resources. However, sensitivity analyses show that this could change-for example, if the proportion of rehabilitation patients requiring subsequent surgery continues to increase.	Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England; Nuffield Orthopaed Ctr, Oxford OX3 7LD, England; Univ Warwick, Div Hlth Community, Coventry CV4 7AL, W Midlands, England	University of Oxford; Nuffield Orthopaedic Centre; University of Warwick	Campbell, H (corresponding author), Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England.	helen.campbell@dphpc.ox.ac.uk	Fairbank, Jeremy/AAA-3411-2019	Rivero-Arias, Oliver/0000-0003-2233-6544; Frost, Helen/0000-0001-9241-8970				Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; Brox JI, 2003, SPINE, V28, P1913; BROX JI, 2005, IN PRESS BMJ, V330; BULMAN J, 2003, LABOUR MARKET TRENDS, P601; *BUPA, HLTH INF ABC HLTH BA; *CHART I PUBL FIN, 2000, HLTH SERV FIN DAT CO; Curtis, 2003, UNIT COSTS HLTH SOCI; *DEP HLTH, 2004, NHS REF COSTS 2003; DION P, 1992, CAN J ANAESTH, V39, P633, DOI 10.1007/BF03008331; Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N; Fairbank J, 2005, BMJ-BRIT MED J, V330, P1233, DOI 10.1136/bmj.38441.620417.8F; Fairbank J C, 1980, Physiotherapy, V66, P271; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Fritzell P, 2001, SPINE, V26, P2521, DOI 10.1097/00007632-200112010-00002; Fritzell P, 2004, SPINE, V29, P421, DOI 10.1097/01.BRS.0000102681.61791.12; *GREAT BRIT HM TRE, 2003, GREEN BOOK APPR EV C; *INF SERV DIV NHS, COST BOOK 2003; Kuntz KM, 2000, SPINE, V25, P1132, DOI 10.1097/00007632-200005010-00015; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; *MHA, 1998, NAT AV SPEC TREATM H; Moller H, 2000, SPINE, V25, P1711, DOI 10.1097/00007632-200007010-00016; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Skouen JS, 2002, SPINE, V27, P901, DOI 10.1097/00007632-200205010-00002; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	27	107	109	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2005	330	7502					1239	1243		10.1136/bmj.38441.429618.8F	http://dx.doi.org/10.1136/bmj.38441.429618.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930WX	15911536	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000229448900017
J	Ribeiro, RC; Pui, C				Ribeiro, RC; Pui, C			Saving the children - Improving childhood cancer treatment in developing countrie.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA		St Jude Childrens Res Hosp, Int Outreach Program, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Leukemia Lymphoma Div, Memphis, TN 38105 USA; Amer Canc Soc, Atlanta, GA 30329 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; American Cancer Society	Ribeiro, RC (corresponding author), St Jude Childrens Res Hosp, Int Outreach Program, 332 N Lauderdale St, Memphis, TN 38105 USA.		Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658				Howard SC, 2004, JAMA-J AM MED ASSOC, V291, P2471, DOI 10.1001/jama.291.20.2471; Kazembe P, 2003, MED PEDIATR ONCOL, V40, P23, DOI 10.1002/mpo.10190; Pui C-H, 2004, Leukemia, V18, P1043, DOI 10.1038/sj.leu.2403365; Pui CH, 2003, NEW ENGL J MED, V349, P1299; Pui CH, 2003, NEW ENGL J MED, V349, P640, DOI 10.1056/NEJMoa035091; Pui CH, 2003, INT J HEMATOL, V78, P383, DOI 10.1007/BF02983810	6	115	120	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2005	352	21					2158	2160		10.1056/NEJMp048313	http://dx.doi.org/10.1056/NEJMp048313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929HS	15917380				2022-12-28	WOS:000229333300002
J	Webster, R; Hulse, D				Webster, R; Hulse, D			Controlling avian flu at the source	NATURE			English	Editorial Material							INFLUENZA-VIRUS; H5N1 INFLUENZA		St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, R (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, 332 N Lauderdale St, Memphis, TN 38105 USA.							deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; Kuiken T, 2004, SCIENCE, V306, P241, DOI 10.1126/science.1102287; Lee CW, 2004, J VIROL, V78, P8372, DOI [10.1128/JVI.78.15.8372-8381.2004, 10.1128/jvi.78.15.8372-8381.2004]; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746	4	34	37	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2005	435	7041					415	416		10.1038/435415a	http://dx.doi.org/10.1038/435415a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929IF	15917777	Bronze, Green Published			2022-12-28	WOS:000229337800023
J	Reijman, M; Hazes, JMW; Pols, HAP; Bernsen, RMD; Koes, BW; Bierma-Zeinstra, SMA				Reijman, M; Hazes, JMW; Pols, HAP; Bernsen, RMD; Koes, BW; Bierma-Zeinstra, SMA			Role of radiography in predicting progression of osteoarthritis of the hip: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISABILITY; DISEASE; KNEE; DETERMINANTS; JOINT	Objectives To investigate which variables identify people at high risk of progression of osteoarthritis of the hip. Design Population based cohort study. Setting Ommoord district in Rotterdam, Netherlands. Participants 1904 men and women aged 55 years and older from the Rotterdam study were selected on the basis of the presence of osteoarthritic signs on radiography at baseline, as defined by a Kellgren and Lawrence score >= grade 1. Main outcome measures Radiological progression of osteoarthritis of the hip, defined as a decrease of joint space width (>= 1.0 mm) at follow-up or the presence of a total hip replacement. Methods Potential determinants of progression of hip osteoarthritis were collected at baseline. x Ray films of the hip at baseline and follow-up (mean follow-up time 6.6 years) were evaluated. Multivariate logistic regression models were used to assess the association between potential risk factors and progression of hip osteoarthritis. Results In 13.1% (1904 subjects) of the study population (mean age 66.2 years), progression of hip osteoarthritis was evident on the radiograph. Starting with a simple model of only directly obtainable variables, the Kellgren and Lawrence score at baseline, when added to the model, was a strong predictor (odds ratio 5.8, 95% confidence interval 4.0 to 8.4), increasing to 24.3 (11.3 to 52.1) in subjects with hip pain at baseline. Conclusions The Kellgren and Lawrence score at baseline was by far the strongest predictor for progression of hip osteoarthritis, especially in patients with existing hip pain at baseline. In patients with hip pain, a radiograph has strong additional value in identifying those at high risk of progression of hip osteoarthritis.	Erasmus MC, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Reijman, M (corresponding author), Erasmus MC, POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.reijman@erasmusmc.nl	Koes, Bart w/K-4614-2016; Bierma-Zeinstra, Sita/AAF-2122-2019; Reijman, Max/AFO-6451-2022	Koes, Bart w/0000-0002-0450-9969; 				Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Altman RD, 2004, OSTEOARTHR CARTILAGE, V12, P515, DOI 10.1016/j.joca.2004.04.004; ALUNAN RD, 1996, OSTEOARTHR CARTILAGE, V4, P217; [Anonymous], 1985, TECHN REP SER WHO; Auleley GR, 2000, ANN RHEUM DIS, V59, P422, DOI 10.1136/ard.59.6.422; Bergink AP, 2003, ARTHRITIS RHEUM, V48, P1913, DOI 10.1002/art.11046; Birrell F, 2003, BRIT J GEN PRACT, V53, P26; *CENTR BUR STAT, 1985, STAND BER; Chalmers J, 1999, J HYPERTENS, V17, P151; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; Dahaghin S, 2005, ANN RHEUM DIS, V64, P99, DOI 10.1136/ard.2003.017087; Dougados M, 1999, J RHEUMATOL, V26, P855; Dougados M, 1996, ANN RHEUM DIS, V55, P356, DOI 10.1136/ard.55.6.356; Dougados M, 1996, ANN RHEUM DIS, V55, P552; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kellgren JH, 1963, EPIDEMIOLOGY CHRONIC; Lievense AM, 2002, ARTHRIT RHEUM-ARTHR, V47, P556, DOI 10.1002/art.10660; Odding E, 1998, ANN RHEUM DIS, V57, P203, DOI 10.1136/ard.57.4.203; Reijman M, 2004, ANN RHEUM DIS, V63, P1427, DOI 10.1136/ard.2003.016477; Reijman M, 2004, ARTHRITIS RHEUM-US, V50, P2471, DOI 10.1002/art.20332; Weel AEAM, 1999, J CLIN ENDOCR METAB, V84, P3146, DOI 10.1210/jc.84.9.3146; Zhang YQ, 1996, J RHEUMATOL, V23, P1130	25	47	49	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2005	330	7501					1183	1185		10.1136/bmj.38442.457488.8F	http://dx.doi.org/10.1136/bmj.38442.457488.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15894555	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000229320500018
J	Powell, K				Powell, K			Hothouse high	NATURE			English	News Item																			0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 16	2005	435	7044					874	875		10.1038/435874a	http://dx.doi.org/10.1038/435874a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	935RN	15944712	Bronze			2022-12-28	WOS:000229799700014
